PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MANGIONE, S; NIEMAN, LZ; GRACELY, E; KAYE, D				MANGIONE, S; NIEMAN, LZ; GRACELY, E; KAYE, D			THE TEACHING AND PRACTICE OF CARDIAC AUSCULTATION DURING INTERNAL-MEDICINE AND CARDIOLOGY TRAINING - A NATIONWIDE SURVEY	ANNALS OF INTERNAL MEDICINE			English	Article						HEART AUSCULTATION; CLINICAL COMPETENCE; INTERNSHIP AND RESIDENCY; TEACHING; STUDENTS, MEDICAL	DIAGNOSIS; SKILLS	Objectives: To assess the time and importance given to cardiac auscultation during internal medicine and cardiology training and to evaluate the auscultatory proficiency of medical students and physicians-in-training. Study Design: A nationwide survey of internal medicine and cardiology program directors and a multi-center cross-sectional assessment of students' and housestaff's auscultatory proficiency. Setting: All accredited U.S. internal medicine and cardiology programs and nine university-affiliated internal medicine and cardiology programs. Participants: Four hundred ninety-eight (75.6%) of all 659 directors surveyed; 203 physicians-in-training and 49 third-year medical students. Interventions: Directors completed a 23-item questionnaire, and students and trainees were tested on 12 prerecorded cardiac events. Main Outcome Measures: The teaching and proficiency of cardiac auscultation at all levels of training. Results: Directors attributed great importance to cardiac auscultation and thought that more time should be spent teaching it. However, only 27.1% of internal medicine and 37.1% of cardiology programs offered any structured teaching of auscultation (P = 0.02). Programs without teaching were more likely to be large, university affiliated, and located in the northeast. The trainees' accuracy ranged from 0 to 56.2% for cardiology fellows (median, 21.9%) and from 2% to 36.8% for medical residents (median, 19.3%). Residents improved little with year of training and were never better than third-year medical students. Conclusions: A low emphasis on cardiac auscultation appears to have affected the proficiency of medical trainees. Our study raises concern about the future of this time-honored art and, possibly, other bedside diagnostic skills.			MANGIONE, S (corresponding author), MED COLL PENN, DEPT MED, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA.		Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223				BROWN RS, 1970, J MED EDUC, V45, P156; BUTTERWORTH JS, 1960, JAMA-J AM MED ASSOC, V174, P32, DOI 10.1001/jama.1960.03030010034009; COLLINS GF, 1978, J MED EDUC, V53, P429; CRAIGE E, 1988, NEW ENGL J MED, V318, P1611, DOI 10.1056/NEJM198806163182409; GOETZL EJ, 1973, ANN INTERN MED, V78, P481, DOI 10.7326/0003-4819-78-4-481; HURST JW, 1984, ANN INTERN MED, V101, P546, DOI 10.7326/0003-4819-101-4-546; KERN DC, 1985, JAMA-J AM MED ASSOC, V254, P70, DOI 10.1001/jama.254.1.70; LEMBO NJ, 1988, NEW ENGL J MED, V318, P1572, DOI 10.1056/NEJM198806163182404; LINFORS EW, 1980, NEW ENGL J MED, V303, P1230, DOI 10.1056/NEJM198011203032110; MANDEL JH, 1988, ARCH INTERN MED, V148, P853, DOI 10.1001/archinte.148.4.853; RUBIN EH, 1961, THORACIC DISEASES; SOX HC, 1984, J MED ED 2, V59, P139; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; WOOD P, 1950, DISEASES HEART CIRCU, pR8; WRAY NP, 1983, JAMA-J AM MED ASSOC, V249, P1035, DOI 10.1001/jama.249.8.1035	15	183	190	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					47	54		10.7326/0003-4819-119-1-199307010-00009	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498764				2022-12-28	WOS:A1993LJ26600009
J	WOLFE, MW; EDELMAN, ER				WOLFE, MW; EDELMAN, ER			TRANSIENT SYSTOLIC DYSFUNCTION AFTER RELIEF OF CARDIAC-TAMPONADE	ANNALS OF INTERNAL MEDICINE			English	Note						CARDIAC TAMPONADE; VENTRICULAR FUNCTION, LEFT; PERICARDIAL EFFUSION; SYSTOLE		Cardiac tamponade is known to directly affect the diastolic function of the myocardium, but no cases have been reported in which systolic function was affected. We describe two patients with malignant pericardial effusions and previously normal left ventricular function in whom marked reductions in left ventricular systolic function developed after the relief of tamponade by pericardiocentesis. The patients received serial follow-up with transthoracic echocardiography, which documented a progressive return to normal systolic function in the absence of further intervening therapy. These two cases suggest that cardiac tamponade may transiently affect systolic function. Potential pathophysiologic mechanisms include changes in coronary blood flow and sympathetic tone induced by tamponade.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	WOLFE, MW (corresponding author), BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA.							FRANK MJ, 1971, AM J PHYSIOL, V220, P179, DOI 10.1152/ajplegacy.1971.220.1.179; FRIEDMAN HS, 1977, AM J PHYSIOL, V232, pH5, DOI 10.1152/ajpheart.1977.232.1.H5; GROSE R, 1982, CIRCULATION, V66, P149, DOI 10.1161/01.CIR.66.1.149; JANICKI JS, 1990, CIRCULATION, V81, P15; MANYARI DE, 1983, AM J CARDIOL, V52, P159, DOI 10.1016/0002-9149(83)90088-7; MARTINS JB, 1980, AM J CARDIOL, V46, P59, DOI 10.1016/0002-9149(80)90606-2; SHABETAI R, 1978, AM J CARDIOL, V42, P1036, DOI 10.1016/0002-9149(78)90692-6; VONHOFF DD, 1982, SEMIN ONCOL, V9, P23; WECHSLER AS, 1974, J THORAC CARDIOV SUR, V68, P847	9	35	38	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					42	44		10.7326/0003-4819-119-1-199307010-00007	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498762				2022-12-28	WOS:A1993LJ26600007
J	GERBERDING, J				GERBERDING, J			IS ANTIRETROVIRAL TREATMENT AFTER PERCUTANEOUS HIV EXPOSURE JUSTIFIED	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						HUMAN IMMUNODEFICIENCY VIRUS; OCCUPATIONAL EXPOSURE; ZIDOVUDINE; HEALTH PERSONNEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS	HUMAN-IMMUNODEFICIENCY-VIRUS	The practice of treating health care providers occupationally exposed to human immunodeficiency virus with zidovudine has become widespread, despite the absence of data showing treatment efficacy. We need to encourage basic and clinical research relevant to occupational exposure so that a scientific basis for postexposure use can be established. In the interim, Provision of zidovudine or other antiviral agents should be regarded as an experimental treatment option, not as a standard of care.			GERBERDING, J (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, MED SERV 5H22, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.							BEEKMANN S, 1992, OCT ANN M INF DIS SO; FAHRNER R, 1992, 8 INT C AIDS AMST; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; LAFON SW, 1988, J INFECT DIS, V158, P503, DOI 10.1093/infdis/158.2.503; LAFON SW, 1990, 30TH INT C ANT AG CH; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381	8	16	16	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					979	980		10.7326/0003-4819-118-12-199306150-00012	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489114				2022-12-28	WOS:A1993LF93700012
J	WOLFF, SN; FAY, JW; HERZIG, RH; GREER, JP; DUMMER, S; BROWN, RA; COLLINS, RH; STEVENS, DA; HERZIG, GP				WOLFF, SN; FAY, JW; HERZIG, RH; GREER, JP; DUMMER, S; BROWN, RA; COLLINS, RH; STEVENS, DA; HERZIG, GP			HIGH-DOSE WEEKLY INTRAVENOUS IMMUNOGLOBULIN TO PREVENT INFECTIONS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION OR SEVERE MYELOSUPPRESSIVE THERAPY - A STUDY OF THE AMERICAN-BONE-MARROW-TRANSPLANT-GROUP	ANNALS OF INTERNAL MEDICINE			English	Article						IMMUNOGLOBULINS, INTRAVENOUS; TRANSPLANTATION, AUTOLOGOUS; BONE MARROW TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; NEUTROPENIA	RELAPSED HODGKINS-DISEASE; IMMUNE GLOBULIN; IGG ANTIBODY; RECIPIENTS; CYCLOPHOSPHAMIDE; ETOPOSIDE; CHEMOTHERAPY; CARMUSTINE; LEUKEMIA	Objective: To determine whether intravenous immunoglobulin (IVIG) prevents severe infections during autologous bone marrow transplantation or equivalent high-dose myelosuppressive therapy. Design: Randomized, stratified, nonblinded study. Setting: Three tertiary care university hospitals. Patients: One hundred seventy patients entered the study; 82 received IVIG and 88 were untreated controls. The study groups were similar for parameters capable of influencing the likelihood of infection. Interventions: Intravenous immunoglobulin was given weekly at a dose of 500 mg/kg body weight from the initiation of cytotoxic therapy to the resolution of neutropenia. Measurements: The development of bloodstream or other clinically proven infection, platelet use, and the development of alloimmunity to platelet transfusion. Results: Clinical infection, bacteremia, and fungemia occurred in 43%, 35%, and 6% of the IVIG-treated patients and in 44%, 34%, and 9% of the control patients. Gram-positive bacteremia and gram-negative bacteremia occurred in 28% and 11% of the IVIG group and in 23% and 13% of the control group. Death due to infection occurred in 4.9% of IVIG recipients and in 2.3% of controls. None of these observations was statistically significant (P > 0.2). Survival to hospital discharge was achieved in 86.6% of the IVIG group and in 96.6% of the control group. The survival difference (10%; 95% CI, 1.7% to 18.3%; P = 0.02) was due to a higher incidence of regimen-related toxic death in the IVIG-treated group. Conclusions: The use of IVIG did not prevent infection. Fewer deaths occurred among controls due to a higher incidence of fatal hepatic veno-occlusive disease in patients receiving IVIG.	BAYLOR UNIV, MED CTR, DALLAS, TX 75246 USA; UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA; WASHINGTON UNIV, SCH MED, DIV HEME ONCOL, ST LOUIS, MO 63110 USA	Baylor University; Baylor University Medical Center; University of Louisville; Washington University (WUSTL)	WOLFF, SN (corresponding author), VANDERBILT UNIV, BONE MARROW TRANSPLANT PROGRAM, 913 OXFORD HOUSE, NASHVILLE, TN 37232 USA.							ANTHONY BF, 1986, PEDIATR INFECT DIS J, V5, pS164; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BROWN RA, 1990, BLOOD, V76, P473; BUCKNER CD, 1978, ANN INTERN MED, V89, P893, DOI 10.7326/0003-4819-89-6-893; BUNCH C, 1988, NEW ENGL J MED, V319, P902; CAFIERO F, 1990, 1990 P C INT LOND, P125; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CALLUM JL, 1991, BONE MARROW TRANSPL, V8, P245; CHEHIMI J, 1987, BONE MARROW TRANSPL, V2, P395; COHEN J, 1988, J HOSP INFECT, V12, P47, DOI 10.1016/0195-6701(88)90029-1; COTTLERFOX M, 1991, BONE MARROW TRANSPL, V8, P27; DOMINIONI L, 1990, 1990 P C INT LOND, P141; DWYER JM, 1992, NEW ENGL J MED, V326, P107; EINSELE H, 1988, BONE MARROW TRANSPL, V3, P607; FAY J, 1990, P AN M AM SOC CLIN, V9, pA1006; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GOODRICH JM, 1991, J INFECT DIS, V164, P731, DOI 10.1093/infdis/164.4.731; GRAHAMPOLE J, 1988, BONE MARROW TRANSPL, V3, P559; KESSINGER A, 1991, BLOOD, V77, P2322; MEYERS JD, 1988, BONE MARROW TRANSPL, V3, P95; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MORIO S, 1991, BONE MARROW TRANSPL, V8, P147; PETERSEN F, 1988, INFECTION, V16, P199, DOI 10.1007/BF01650752; PETERSEN FB, 1987, BONE MARROW TRANSPL, V2, P141; PIROFSKY B, 1984, AM J MED, V76, P53, DOI 10.1016/0002-9343(84)90320-6; RAND KH, 1989, BONE MARROW TRANSPL, V4, P679; REECE DE, 1991, J CLIN ONCOL, V9, P1871, DOI 10.1200/JCO.1991.9.10.1871; RUBIN M, 1989, RES STAFF PHYSICIAN, V35, P25; RUBIN M, 1988, 28TH INT C ANT AG CH; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; STIEHM ER, 1987, ANN INTERN MED, V107, P367, DOI 10.7326/0003-4819-107-2-367; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; WOLFF SN, 1989, J CLIN ONCOL, V7, P1260, DOI 10.1200/JCO.1989.7.9.1260; YAP PL, 1987, J INFECTION, V15, P21, DOI 10.1016/S0163-4453(87)92436-4	35	69	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					937	942		10.7326/0003-4819-118-12-199306150-00004	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489107				2022-12-28	WOS:A1993LF93700004
J	DANISHEFSKY, SJ; MCCLURE, KF; RANDOLPH, JT; RUGGERI, RB				DANISHEFSKY, SJ; MCCLURE, KF; RANDOLPH, JT; RUGGERI, RB			A STRATEGY FOR THE SOLID-PHASE SYNTHESIS OF OLIGOSACCHARIDES	SCIENCE			English	Article							GLYCALS; CORROBORATION; REARRANGEMENT	Repeating glycosidic linkages of oligosaccharides can be synthesized by solid-phase methods. Glycals were attached to a polystyrene copolymer with a silyl ether bond and were activated to function as glycosyl donors with 3,3-dimethyldioxirane. Glycosidation was performed by reactions with a solution-based acceptor (itself a glycal). Excess ar-ceptor and promoter were removed by rinsing after each coupling, and the desired oligosaccharides were then easily obtained from the polymer by the addition of tetra-n-butylammonium fluoride. By this method, glycosidations are stereospecific and interior deletions are avoided.			DANISHEFSKY, SJ (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025848] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM W, 1987, J ORG CHEM, V52, P2800, DOI 10.1021/jo00389a029; BOLITT V, 1990, J ORG CHEM, V55, P5812, DOI 10.1021/jo00310a006; CARUTHERS MH, 1982, GENETIC ENG, V4, pCH1; CHAN TH, 1985, J CHEM SOC CHEM COMM, P909, DOI 10.1039/c39850000909; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8329, DOI 10.1021/ja00047a077; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8331, DOI 10.1021/ja00047a078; DOUGLAS SP, 1991, J AM CHEM SOC, V113, P5095, DOI 10.1021/ja00013a075; FARRALL MJ, 1976, J ORG CHEM, V41, P3877, DOI 10.1021/jo00886a023; FRECHET JM, 1972, CARBOHYD RES, V22, P399, DOI 10.1016/S0008-6215(00)81291-4; FRECHET JMJ, 1980, POLYM SUPPORTED REAC, pCH8; FRIESEN RW, 1989, J AM CHEM SOC, V111, P6656, DOI 10.1021/ja00199a027; GRIFFITH DA, 1990, J AM CHEM SOC, V112, P5811, DOI 10.1021/ja00171a021; GUTHRIE RD, 1971, J CHEM SOC C, P2690, DOI 10.1039/j39710002690; GUTHRIE RD, 1973, J CHEM SOC PERK T 1, P2414, DOI 10.1039/p19730002414; HALCOMB RL, 1991, J AM CHEM SOC, V113, P5080, DOI 10.1021/ja00013a065; HALCOMB RL, 1989, J AM CHEM SOC, V111, P6661, DOI 10.1021/ja00199a028; LEMIEUX RU, 1965, CAN J CHEMISTRY, V43, P2190, DOI 10.1139/v65-296; MCDONALD FE, 1992, J ORG CHEM, V57, P7001, DOI 10.1021/jo00052a001; MERRIFIELD RB, 1988, ANAL BIOCHEM, V174, P399, DOI 10.1016/0003-2697(88)90039-5; MURRAY RW, 1985, J ORG CHEM, V50, P2847, DOI 10.1021/jo00216a007; RAMESH S, 1990, J ORG CHEM, V55, P5, DOI 10.1021/jo00288a003; SINAY P, 1991, PURE APPL CHEM, V63, P519, DOI 10.1351/pac199163040519; SUZUKI K, 1990, J AM CHEM SOC, V112, P8895, DOI 10.1021/ja00180a037; THIEM J, 1978, SYNTHESIS-STUTTGART, P696; VEENEMAN GH, 1987, TETRAHEDRON LETT, V28, P6695, DOI 10.1016/S0040-4039(00)96948-X	25	298	308	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1307	1309		10.1126/science.8493573	http://dx.doi.org/10.1126/science.8493573			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493573				2022-12-28	WOS:A1993LE02500037
J	AYANIAN, JZ; UDVARHELYI, IS; GATSONIS, CA; PASHOS, CL; EPSTEIN, AM				AYANIAN, JZ; UDVARHELYI, IS; GATSONIS, CA; PASHOS, CL; EPSTEIN, AM			RACIAL-DIFFERENCES IN THE USE OF REVASCULARIZATION PROCEDURES AFTER CORONARY ANGIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; HEART-DISEASE; BLACKS; REGISTRY	Objective.-To assess whether rates of coronary revascularization procedures differ between blacks and whites after coronary angiography is performed and to assess the relationship of these rates to hospital characteristics. Design.-A retrospective cohort study using 1987 and 1988 data on hospital claims and characteristics from the Health Care Financing Administration. Setting.-One thousand four hundred twenty-nine acute care hospitals that provide coronary angiography in the United States. Patients.-A national sample of 27 485 Medicare Part A enrollees, aged 65 to 74 years, who underwent inpatient angiography for coronary heart disease in 1987. Main Outcome Measure.-The adjusted odds of revascularization with either coronary angioplasty or bypass graft surgery within 90 days of angiography for whites relative to blacks, controlling for age, sex, region, Medicaid eligibility, principal diagnosis, comorbid diagnoses, and hospital characteristics of ownership, teaching status, urban/suburban or rural location, and availability of revascularization procedures. Results.-White men and women were significantly more likely than black men and women, respectively, to receive a revascularization procedure after coronary angiography (57% and 50% vs 40% and 34%, both P<.001). The adjusted odds of receiving a revascularization procedure after coronary angiography were 78% higher for whites than blacks (95% confidence interval for odds ratio, 1.56 to 2.03). Statistically significant racial differences in the adjusted odds of receiving a revascularization procedure were present in all types of hospitals except rural hospitals, and these differences did not vary significantly by any of the four hospital characteristics (all P>.20 for interaction terms). Conclusions.-Among Medicare enrollees, whites are more likely than blacks to receive revascularization procedures after coronary angiography. Racial differences of similar magnitude occur in all types of hospitals. These differences may reflect overuse in whites or underuse in blacks, but they are unlikely to reflect access to cardiologists or hospitals that perform revascularization procedures. Potential explanations include unmeasured clinical or socioeconomic factors, differing patient preferences, and racial bias at the hospitals performing angiography.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,HLTH SERV & POLICY RES SECT,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1986, CIRCULATION, V74, P64, DOI 10.1161/01.CIR.74.1.64; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; SIMMONS BE, 1988, AM HEART J, V116, P90, DOI 10.1016/0002-8703(88)90254-2; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; 1990, 03301 HLTH CAR FIN A; 1983, CIRCULATION, V68, P951; 1983, CIRCULATION, V68, P939; 1991, PHS911232 US DEP HLT	18	357	357	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2642	2646		10.1001/jama.269.20.2642	http://dx.doi.org/10.1001/jama.269.20.2642			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC865	8487447				2022-12-28	WOS:A1993LC86500028
J	CASCONE, PJ; HAYDAR, TF; SIMON, AE				CASCONE, PJ; HAYDAR, TF; SIMON, AE			SEQUENCES AND STRUCTURES REQUIRED FOR RECOMBINATION BETWEEN VIRUS-ASSOCIATED RNAS	SCIENCE			English	Article							TURNIP CRINKLE VIRUS; VIRULENT SATELLITE RNA; BROME MOSAIC-VIRUS; MESSENGER-RNA; SPECIFICALLY INTERACTS; BINDING PROTEIN; POLIOVIRUS; GENOME; INVIVO; ENCODES	RNA recombination has been described for a number of viruses in the plant and animal kingdoms, but the mechanisms of selection of recombination sites are poorly understood. The nonrandom recombination between two subviral RNAs associated with turnip crinkle virus was used to study the requirement for specific sequences and structures in the generation of recombinant molecules. Single-base mutations that disrupted either the stem or the loop of one of the two computer-predicted stem-loop structures eliminated detectable recombinant molecules. However, recombinants were detected if compensatory mutations were generated that re-formed a stable hairpin structure. These results provide evidence for the necessity of specific structures in the formation of recombinant molecules in this system.	UNIV MASSACHUSETTS, PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, DEPT BIOCHEM & MOLEC BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Simon, Anne E/B-8713-2014	Simon, Anne E/0000-0001-6121-0704; Haydar, Tarik/0000-0001-6772-3076				ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; ANGENENT GC, 1986, NUCLEIC ACIDS RES, V14, P4673, DOI 10.1093/nar/14.11.4673; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BUJARSKI JJ, 1991, J VIROL, V65, P4153, DOI 10.1128/JVI.65.8.4153-4159.1991; BUJARSKI JJ, 1986, NATURE, V321, P528, DOI 10.1038/321528a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CARPENTER CD, 1991, VIROLOGY, V183, P586, DOI 10.1016/0042-6822(91)90987-M; CARPENTER CD, 1990, BIOTECHNIQUES, V8, P26; CARPENTER CD, 1991, VIROLOGY, V183, P595, DOI 10.1016/0042-6822(91)90988-N; CASCONE PJ, 1990, EMBO J, V9, P1709, DOI 10.1002/j.1460-2075.1990.tb08294.x; CASCONE PJ, 1992, THESIS U MASSACHUSET; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; EDWARDS MC, 1992, VIROLOGY, V189, P389, DOI 10.1016/0042-6822(92)90722-2; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KING AMQ, 1988, NUCLEIC ACIDS RES, V16, P11705, DOI 10.1093/nar/16.24.11705; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1; LI XH, 1991, J VIROL, V65, P4582, DOI 10.1128/JVI.65.9.4582-4590.1991; LI XH, 1990, PHYTOPATHOLOGY, V80, P238, DOI 10.1094/Phyto-80-238; LI XH, 1989, P NATL ACAD SCI USA, V86, P9173, DOI 10.1073/pnas.86.23.9173; NAGY PD, 1992, J VIROL, V66, P6824, DOI 10.1128/JVI.66.11.6824-6828.1992; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PRINGLE CR, 1965, VIROLOGY, V25, P48, DOI 10.1016/0042-6822(65)90250-3; QIAN ZW, 1991, MOL CELL BIOL, V11, P5312, DOI 10.1128/MCB.11.10.5312; RAO ALN, 1990, J VIROL, V64, P2437, DOI 10.1128/JVI.64.5.2437-2441.1990; ROMANIUK RJ, 1987, BIOCHEMISTRY-US, V26, P1567; SIMON AE, 1988, EMBO J, V7, P2645, DOI 10.1002/j.1460-2075.1988.tb03117.x; SIMON AE, 1986, EMBO J, V5, P3423, DOI 10.1002/j.1460-2075.1986.tb04664.x; SIMON AE, 1987, VIROLOGY, V156, P146, DOI 10.1016/0042-6822(87)90445-4; SOUTHERN JA, 1990, VIROLOGY, V177, P388, DOI 10.1016/0042-6822(90)90497-F; TOLSKAYA EA, 1983, VIROLOGY, V124, P121, DOI 10.1016/0042-6822(83)90295-7; TOLSKAYA EA, 1987, VIROLOGY, V161, P54, DOI 10.1016/0042-6822(87)90170-X; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; ZHANG CX, 1991, VIROLOGY, V184, P791, DOI 10.1016/0042-6822(91)90454-J; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	103	104	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1993	260	5109					801	805		10.1126/science.8484119	http://dx.doi.org/10.1126/science.8484119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484119				2022-12-28	WOS:A1993LA74400028
J	LEFEBVRE, PP; MALGRANGE, B; STAECKER, H; MOONEN, G; VANDEWATER, TR				LEFEBVRE, PP; MALGRANGE, B; STAECKER, H; MOONEN, G; VANDEWATER, TR			RETINOIC ACID STIMULATES REGENERATION OF MAMMALIAN AUDITORY HAIR-CELLS	SCIENCE			English	Article							INNER-EAR; CHICKEN COCHLEA; ACOUSTIC TRAUMA; STEREOCILIA; EXPRESSION; TOXICITY; GROWTH	Sensorineural hearing loss resulting from the loss of auditory hair cells is thought to be irreversible in mammals. This study provides evidence that retinoic acid can stimulate the regeneration in vitro of mammalian auditory hair cells in ototoxic-poisoned organ of Corti explants in the rat. In contrast, treatment with retinoic acid does not stimulate the formation of extra hair cells in control cultures of Corti's organ. Retinoic acid-stimulated hair cell regeneration can be blocked by cytosine arabinoside, which suggests that a period of mitosis is required for the regeneration of auditory hair cells in this system. These results provide hope for a recovery of hearing function in mammals after auditory hair cell damage.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT OTOLARYNGOL,1410 PELHAM PKWY S,KENNEDY CTR, ROOM 302, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROSCI, BRONX, NY 10461 USA; UNIV LIEGE, DEPT HUMAN PHYSIOL & PATHOPHYSIOL, B-4020 LIEGE, BELGIUM	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Liege			Malgrange, Brigitte/A-4887-2019	Malgrange, Brigitte/0000-0002-8957-2528; Staecker, Hinrich/0000-0002-0348-3015	NIDCD NIH HHS [DC00088] Funding Source: Medline; NINDS NIH HHS [NS07098] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007098] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER HJ, 1992, ASS RES OTOLARYNGOL, V15, P160; ANNIKO M, 1983, ANAT EMBRYOL, V166, P355, DOI 10.1007/BF00305923; BALAK KJ, 1990, J NEUROSCI, V10, P2502; CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1983, J COMP NEUROL, V217, P345, DOI 10.1002/cne.902170309; CORWIN JT, 1985, P NATL ACAD SCI USA, V82, P3911, DOI 10.1073/pnas.82.11.3911; COTANCHE DA, 1987, HEARING RES, V30, P181, DOI 10.1016/0378-5955(87)90135-3; CROWLEY DE, 1966, J COMP PHYSIOL PSYCH, V62, P427, DOI 10.1037/h0023953; CRUZ RM, 1987, ARCH OTOLARYNGOL, V113, P1058; DOLLE P, 1990, DEVELOPMENT, V110, P1133; JORGENSEN JM, 1981, ACTA ZOOL-STOCKHOLM, V62, P171, DOI 10.1111/j.1463-6395.1981.tb00626.x; KATAYAMA A, 1989, J COMP NEUROL, V281, P129, DOI 10.1002/cne.902810110; KELLEY MW, 1992, ASS RES OTOLARYNGOL, V15, P145; KESSEL M, 1992, DEVELOPMENT, V115, P487; LAVIGNEREBILLARD M, 1986, ANAT EMBRYOL, V174, P369, DOI 10.1007/BF00698787; LEFEBVRE PP, 1992, HEARING RES, V58, P185, DOI 10.1016/0378-5955(92)90127-9; LEFEBVRE PP, 1991, BRAIN RES, V567, P306, DOI 10.1016/0006-8993(91)90809-A; LEFEBVRE PP, 1992, ACTA OTO-LARYNGOL, V112, P288, DOI 10.1080/00016489.1992.11665420; LEFEBVRE PP, 1991, NEUROREPORT, V2, P305, DOI 10.1097/00001756-199106000-00001; LENOIR M, 1987, ANAT EMBRYOL, V175, P477, DOI 10.1007/BF00309683; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; LIPPE WR, 1991, HEARING RES, V56, P203, DOI 10.1016/0378-5955(91)90171-5; MCFADDEN EA, 1989, HEARING RES, V41, P205, DOI 10.1016/0378-5955(89)90012-9; POPPER AN, 1990, HEARING RES, V45, P33, DOI 10.1016/0378-5955(90)90180-W; PUGLIANO FA, 1992, ASS RES OTOLARYNGOL, V15, P160; RAPHAEL Y, 1992, J NEUROCYTOL, V21, P663, DOI 10.1007/BF01191727; REPRESA J, 1990, DEVELOPMENT, V110, P1081; RUBEL EW, 1991, CIBA F SYMP, V160, P77; RUBEN RJ, 1987, ACTA OTO-LARYNGOL, V220, P1; SOBKOWICZ HM, 1992, EXP NEUROL, V115, P44, DOI 10.1016/0014-4886(92)90219-G; SPOENDLIN H, 1971, ARCH KLIN EXP OHR, V200, P275, DOI 10.1007/BF00373310; TILNEY LG, 1986, DEV BIOL, V116, P100, DOI 10.1016/0012-1606(86)90047-3; TUCCI DL, 1990, OTOLARYNG HEAD NECK, V103, P443, DOI 10.1177/019459989010300317; Wada T., 1923, American Anatomical Memoir, Vno. 10, P1; YAN HY, 1992, ASS RES OTOLARYNGOL, V15, P161	37	122	135	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					692	695		10.1126/science.8480180	http://dx.doi.org/10.1126/science.8480180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480180				2022-12-28	WOS:A1993KZ64100038
J	LOPEZ, GP; BIEBUYCK, HA; FRISBIE, CD; WHITESIDES, GM				LOPEZ, GP; BIEBUYCK, HA; FRISBIE, CD; WHITESIDES, GM			IMAGING OF FEATURES ON SURFACES BY CONDENSATION FIGURES	SCIENCE			English	Article							BREATH FIGURES; GROWTH; MONOLAYERS; DROPLETS; SIMULATION	Condensation of a vapor to a liquid on a cold surface that is not wet completely by this liquid leads to the formation of an array of droplets. If the surface is heterogeneous in its physical properties (especially its interfacial free energy), the patterns of these arrays reflect this heterogeneity. The distribution of droplets of water (condensation figures or CFs) observed by optical microscopy on a surface can be correlated with the molecular structure of that surface. The substrates used to investigate the formation and morphology of the CFs were patterned, self-assembled monolayers of different alkanethiolates on gold and of alkyl siloxanes on glass. Analysis of CFs is a valuable nondestructive technique for characterizing heterogeneities in surfaces.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University			Frisbie, C Daniel/F-3995-2011					Aitkek J, 1911, NATURE, V86, P516, DOI DOI 10.1038/086516A0; BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040; BEYSENS D, 1986, PHYS REV LETT, V57, P1433, DOI 10.1103/PhysRevLett.57.1433; BIEBUYCK HA, UNPUB; BRISCOE BJ, 1991, COLLOID SURFACE, V56, P263, DOI 10.1016/0166-6622(91)80126-9; BRISCOE BJ, 1990, J PHYS D APPL PHYS, V23, P422, DOI 10.1088/0022-3727/23/4/005; BUBECK C, 1989, THIN SOLID FILMS, V178, P483, DOI 10.1016/0040-6090(89)90342-8; DERRIDA B, 1990, EUROPHYS LETT, V12, P385, DOI 10.1209/0295-5075/12/5/001; ELWING H, 1980, FEBS LETT, V111, P365, DOI 10.1016/0014-5793(80)80828-3; FAMILY F, 1989, PHYS REV A, V40, P3836, DOI 10.1103/PhysRevA.40.3836; FRISBIE CD, 1992, J AM CHEM SOC, V114, P7142, DOI 10.1021/ja00044a028; FRITTER D, 1991, PHYS REV A, V43, P2858, DOI 10.1103/PhysRevA.43.2858; KNOBLER CM, 1986, PHYSICA A, V140, P198, DOI 10.1016/0378-4371(86)90221-9; KUMAR A, IN PRESS J AM CHEM S; LAIBINIS PE, 1991, SCIENCE, V254, P981, DOI 10.1126/science.254.5034.981; Lopez G., UNPUB; MEAKIN P, 1989, J PHYS A-MATH GEN, V22, pL225, DOI 10.1088/0305-4470/22/6/007; Merigoux R, 1937, REV OPT, V9, P281; PERROT F, 1987, REV SCI INSTRUM, V58, P183, DOI 10.1063/1.1139303; Rayleigh L, 1912, NATURE, V90, P436; Rayleigh L, 1911, NATURE, V86, P416; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; STEYER A, 1990, EUROPHYS LETT, V12, P211, DOI 10.1209/0295-5075/12/3/004; STEYER A, 1991, PHYS REV A, V44, P8271, DOI 10.1103/PhysRevA.44.8271; TARLOV MJ, 1992, LANGMUIR, V8, P80, DOI 10.1021/la00037a017; VIOVY JL, 1988, PHYS REV A, V37, P4965, DOI 10.1103/PhysRevA.37.4965; VROMAN L, 1963, THROMB DIATH HAEMO, V10, P455; WASSERMAN SR, 1989, LANGMUIR, V5, P1074, DOI 10.1021/la00088a035; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013	29	233	251	10	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 30	1993	260	5108					647	649		10.1126/science.8480175	http://dx.doi.org/10.1126/science.8480175			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480175				2022-12-28	WOS:A1993KZ64100023
J	DRIVER, HS; SHAPIRO, CM				DRIVER, HS; SHAPIRO, CM			ABC OF SLEEP DISORDERS - PARASOMNIAS	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	DRIVER, HS (corresponding author), UNIV WITWATERSRAND,DEPT PHYSIOL,EDBLO SLEEP LAB,JOHANNESBURG 2001,SOUTH AFRICA.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					921	924		10.1136/bmj.306.6882.921	http://dx.doi.org/10.1136/bmj.306.6882.921			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490425	Green Published, Bronze			2022-12-28	WOS:A1993KW38700034
J	BALDWIN, LN; HENDERSON, A; THOMAS, P; WRIGHT, M				BALDWIN, LN; HENDERSON, A; THOMAS, P; WRIGHT, M			LESSON OF THE WEEK - ACUTE BACTERIAL-MENINGITIS IN YOUNG-ADULTS MISTAKEN FOR SUBSTANCE-ABUSE	BRITISH MEDICAL JOURNAL			English	Article							ENCEPHALITIS; PSYCHOSIS		PRINCESS ALEXANDRA HOSP,INTENS CARE UNIT,WOOLLOONGABBA,QLD 4102,AUSTRALIA; PRINCESS ALEXANDRA HOSP,DEPT EMERGENCY MED,WOOLLOONGABBA,QLD 4102,AUSTRALIA				Thomas, Peter P/I-7748-2014; Henderson, Alan/K-2846-2012; Wright, Malcolm/D-9837-2012					Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; Greenlee J E, 1990, Infect Dis Clin North Am, V4, P583; JOHANNESSEN DJ, 1988, J CLIN PSYCHIAT, V49, P200; MISRA PC, 1971, BMJ-BRIT MED J, V1, P532, DOI 10.1136/bmj.1.5748.532; OOMMEN KJ, 1982, AM J MED, V73, P445, DOI 10.1016/0002-9343(82)90751-3; Rischbieth R H, 1987, Clin Exp Neurol, V23, P191; SCHLITT M, 1985, SOUTHERN MED J, V78, P1347, DOI 10.1097/00007611-198511000-00021; THIENHAUS OJ, 1984, AM J PSYCHIAT, V141, P1459, DOI 10.1176/ajp.141.11.1459	8	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					775	776		10.1136/bmj.306.6880.775	http://dx.doi.org/10.1136/bmj.306.6880.775			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490343	Bronze, Green Published			2022-12-28	WOS:A1993KU17300032
J	BADESCH, DB; WYNNE, KM; BONVALLET, S; VOELKEL, NF; RIDGWAY, C; GROVES, BM				BADESCH, DB; WYNNE, KM; BONVALLET, S; VOELKEL, NF; RIDGWAY, C; GROVES, BM			HYPOTHYROIDISM AND PRIMARY PULMONARY-HYPERTENSION - AN AUTOIMMUNE PATHOGENETIC LINK	ANNALS OF INTERNAL MEDICINE			English	Note						HYPOTHYROIDISM; HYPERTENSION, PULMONARY; AUTOIMMUNE DISEASES; ANTIBODIES, ANTINUCLEAR; THYROID FUNCTION TESTS	DISEASE; THYROIDITIS	Primary pulmonary hypertension (PPH), an often fatal disease of unknown cause that primarily affects young women, is a diagnosis of exclusion. The relative roles of genetic predisposition, autoimmunity, viral infection, hormonal influences, and environmental and drug exposures am not known. Among seven patients enrolled by our center in a multicenter trial of continuous prostacyclin in severe PPH, four of the five women had hypothyroidism. Although a causal relationship cannot be established based on this small case series, the possibility of an autoimmune pathogenetic link between PPH and hypothyroidism should be investigated further.			BADESCH, DB (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV PULM SCI & CRIT CARE MED, BOX B-133, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043180] Funding Source: NIH RePORTER; NCRR NIH HHS [M501RR00051] Funding Source: Medline; NHLBI NIH HHS [HL 43180-01A3, HL 02408-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIKUSA B, 1984, AM J CLIN PATHOL, V81, P260, DOI 10.1093/ajcp/81.2.260; GRAZIANO FM, 1983, CLIN EXP RHEUMATOL, V1, P251; HANSEN BU, 1991, CLIN EXP RHEUMATOL, V9, P137; ISERN RA, 1992, AM J MED, V93, P307, DOI 10.1016/0002-9343(92)90238-7; KANEMOTO N, 1975, JPN HEART J, V16, P354; KATAKURA M, 1987, J CLIN ENDOCR METAB, V64, P405, DOI 10.1210/jcem-64-3-405; KITAMURA S, 1968, ACTA PATHOL JAPON, V18, P508; LATEIWISH AM, 1992, J ENDOCRINOL INVEST, V15, P49, DOI 10.1007/BF03348657; MARTOS VJ, 1992, ATEN PRIM, V9, P163; MILLER FW, 1987, ARTHRITIS RHEUM-US, V30, P1124, DOI 10.1002/art.1780301006; OHAR JM, 1986, AM J MED, V81, P361, DOI 10.1016/0002-9343(86)90280-9; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; SALERNI R, 1977, ANN INTERN MED, V86, P394, DOI 10.7326/0003-4819-86-4-394; SHAGAN BP, 1980, ARCH INTERN MED, V140, P832, DOI 10.1001/archinte.140.6.832; SHAGAN BP, 1976, ANGIOLOGY, V27, P19, DOI 10.1177/000331977602700104; TAJIRI J, 1986, ARCH INTERN MED, V146, P1623, DOI 10.1001/archinte.146.8.1623	17	55	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					44	46		10.7326/0003-4819-119-1-199307010-00008	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498763				2022-12-28	WOS:A1993LJ26600008
J	BROWN, P				BROWN, P			EEG FINDINGS IN CREUTZFELDT-JAKOB-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BROWN, P (corresponding author), NINCDS,BETHESDA,MD 20892, USA.								0	14	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3168	3168		10.1001/jama.269.24.3168	http://dx.doi.org/10.1001/jama.269.24.3168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505822				2022-12-28	WOS:A1993LH14500038
J	GRIMES, DA				GRIMES, DA			TECHNOLOGY FOLLIES - THE UNCRITICAL ACCEPTANCE OF MEDICAL INNOVATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; QUALITY; SCIENCE				GRIMES, DA (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94110 USA.							ANDERSON GM, 1990, PREVENTING DISEASE R, P19; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BAGGISH MS, 1992, J GYNECOL SURG, V8, P57, DOI 10.1089/gyn.1992.8.57; BANTA HD, 1990, JAMA-J AM MED ASSOC, V264, P235, DOI 10.1001/jama.264.2.235; BARONDESS JA, 1981, J MED EDUC, V56, P381; BASSETT CAL, 1984, ORTHOP CLIN N AM, V15, P61; BEECHER HK, 1953, JAMA-J AM MED ASSOC, V151, P44; BISHOP JM, 1984, J MED EDUC, V59, P91; BLONDEL B, 1992, AM J OBSTET GYNECOL, V167, P424, DOI 10.1016/S0002-9378(11)91423-9; BUNKER JP, 1982, NEW ENGL J MED, V306, P620, DOI 10.1056/NEJM198203113061029; BURNES BA, 1977, COSTS RISKS BENEFITS, P109; CHALMERS I, 1986, BIRTH-ISS PERINAT C, V13, P155, DOI 10.1111/j.1523-536X.1986.tb01037.x; CHALMERS I, 1991, BIRTH-ISS PERINAT C, V18, P137, DOI 10.1111/j.1523-536X.1991.tb00083.x; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; DAWBER TR, 1978, NEW ENGL J MED, V299, P452, DOI 10.1056/NEJM197808312990905; DUENHOELTER JH, 1976, AM J OBSTET GYNECOL, V125, P889, DOI 10.1016/0002-9378(76)90484-1; DYSON DC, 1991, AM J OBSTET GYNECOL, V164, P756, DOI 10.1016/0002-9378(91)90510-X; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; GRIMES DA, 1986, BIRTH-ISS PERINAT C, V13, P83, DOI 10.1111/j.1523-536X.1986.tb01013.x; GRIMES DA, 1992, OBSTET GYNECOL, V79, P137; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Klein MC., 1992, ONLINE J CURR CLIN T, V1, P25, DOI [10.1097/00006254-199404000-00008, DOI 10.1097/00006254-199404000-00008]; LINTON AL, 1990, NEW ENGL J MED, V323, P1463, DOI 10.1056/NEJM199011223232106; MAO C, 1988, AM J OBSTET GYNECOL, V159, P279, DOI 10.1016/S0002-9378(88)80068-1; MOU SM, 1991, AM J OBSTET GYNECOL, V165, P858, DOI 10.1016/0002-9378(91)90429-U; PICKERING G, 1971, BMJ-BRIT MED J, V1, P191, DOI 10.1136/bmj.1.5742.191; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P2929; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1978, PHAROS           JAN, P18; SACKETT DL, 1981, CAN MED ASSOC J, V124, P1156; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; SHY KK, 1990, NEW ENGL J MED, V322, P588, DOI 10.1056/NEJM199003013220904; SIDDALL AC, 1980, B HIST MED, V54, P101; SPODICK DH, 1979, ANN THORAC SURG, V27, P284, DOI 10.1016/S0003-4975(10)63292-4; SPODICK DH, 1975, JAMA-J AM MED ASSOC, V232, P35; SUMMITT RL, 1992, OBSTET GYNECOL, V80, P895; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THACKER SB, 1987, AM J OBSTET GYNECOL, V156, P24, DOI 10.1016/0002-9378(87)90197-9; TODD JW, 1970, LANCET, V1, P665; TYSON JE, 1983, OBSTET GYNECOL, V62, P99; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; WENNBERG JE, 1980, ANNU REV PUBL HEALTH, V1, P277, DOI 10.1146/annurev.pu.01.050180.001425; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; 1990, JAMA-J AM MED ASSOC, V263, P881; 1989, ACOG TECHNICAL B, V132, P1; 1988, JAMA-J AM MED ASSOC, V260, P264; 1981, OBSTET GYNECOL SURV, V36, P30	50	130	130	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3030	3033		10.1001/jama.269.23.3030	http://dx.doi.org/10.1001/jama.269.23.3030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501846				2022-12-28	WOS:A1993LF94100033
J	MARIK, PE; SIBBALD, WJ				MARIK, PE; SIBBALD, WJ			EFFECT OF STORED-BLOOD TRANSFUSION ON OXYGEN DELIVERY IN PATIENTS WITH SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ADULT RESPIRATORY-DISTRESS; INTRAMURAL PH; GASTRIC TONOMETRY; CONSUMPTION; ENDOTOXEMIA; VALIDATION; FAILURE; SURGERY; SYSTEM	Background.-Red blood cell transfusion is commonly used to augment systemic oxygen delivery to supranormal levels in patients with sepsis. However, clinical studies have not consistently demonstrated that this therapeutic maneuver is accompanied by an increase in oxygen utilization at either the whole-body level or within individual organs. Study Objectives.-To determine the effect of red blood cell transfusion on gastrointestinal and whole-body oxygen uptake. Design.-Prospective, controlled, interventional study. Setting.-Multidisciplinary intensive care unit of a tertiary care teaching hospital. Patients.-Twenty-three critically ill patients with sepsis undergoing mechanical ventilation. Measurements and Main Results.-Systemic oxygen uptake was measured by indirect calorimetry and calculated by the Fick method. Gastric intramucosal pH as measured by tonometry was used to assess changes in splanchnic oxygen availability. Measurements were made prior to transfusion of 3 U of packed red blood cells. These were then repeated immediately following transfusion, as well as 3 and 6 hours later. There was no increase in systemic oxygen uptake measured by indirect calorimetry in any of the patients studied for up to 6 hours posttransfusion (including those patients with an elevated arterial lactate concentration). However, the calculated systemic oxygen uptake increased in parallel with the oxygen delivery in all the patients. More importantly, we found an inverse association between the change in gastric intramucosal pH and the age of the transfused blood (r=-.71; P<.001). In those patients receiving blood that had been stored for more than 15 days, the gastric intramucosal pH consistently decreased following the red blood cell transfusion. Conclusion.-We failed to demonstrate a beneficial effect of red blood cell transfusion on measured systemic oxygen uptake in patients with sepsis. Patients receiving old transfused red blood cells developed evidence of splanchnic ischemia. We postulate that the poorly deformable transfused red blood cells cause microcirculatory occlusion in some organs, which may lead to tissue ischemia in some organs.	VICTORIA HOSP, RES INST,AC BURTON VASC BIOL LAB,ROOM 482 4 NW, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, PROGRAM CRIT CARE, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT SURG, LONDON N6A 3K7, ONTARIO, CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Marik, Paul E/U-9733-2019					ALEXANDER JW, 1990, ANN SURG, V212, P496, DOI 10.1097/00000658-199010000-00012; ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; APSTEIN CS, 1985, AM J PHYSIOL, V248, pH508, DOI 10.1152/ajpheart.1985.248.4.H508; ARGWAL JB, 1970, J APPL PHYSIOL, V29, P866; BAKER CH, 1984, CIRC SHOCK, V12, P165; BARTLETT RH, 1990, J CRIT CARE, V5, P77, DOI 10.1016/0883-9441(90)90051-A; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; DOYLE MP, 1990, J APPL PHYSIOL, V69, P1270, DOI 10.1152/jappl.1990.69.4.1270; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; GANZ W, 1971, AM J CARDIOL, V27, P392, DOI 10.1016/0002-9149(71)90436-X; GREENWALT TJ, 1984, VOX SANG, V47, P261, DOI 10.1111/j.1423-0410.1984.tb01596.x; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HERSCH M, 1990, SURGERY, V107, P397; Jodal M, 1984, PHYSL INTESTINAL CIR, P83; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAM C, 1991, MICROVASC RES, V66, P501; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; LKUNDGREN O, 1973, ACTA PHYSL SCAND, V88, P551; MAETANI S, 1986, ANN SURG, V203, P275, DOI 10.1097/00000658-198603000-00010; Mollison P. L., 1987, BLOOD TRANSFUSION CL, P95; MOORE GL, 1983, DIAGN MED, V6, P33; MORISAKI H, 1992, CRIT CARE MED S1, V20, pS101; MURRAY JF, 1963, J CLIN INVEST, V42, P1150, DOI 10.1172/JCI104800; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; PARKER MM, 1990, CHEST, V97, P126, DOI 10.1378/chest.97.1.126; PEEK CC, 1981, CRIT REV CLIN LAB SC, V13, P173; RASHKIN MC, 1985, CHEST, V87, P580, DOI 10.1378/chest.87.5.580; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; SAADIA R, 1990, BRIT J SURG, V77, P487, DOI 10.1002/bjs.1800770505; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1991, CHEST, V100, pS155, DOI 10.1378/chest.100.3.155S; SIGURDSSON GH, 1992, CRIT CARE MED, V20, P458, DOI 10.1097/00003246-199204000-00005; SILVERMAN HJ, 1992, CHEST, V102, P184, DOI 10.1378/chest.102.1.184; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; STUART J, 1990, BLOOD REV, V4, P141, DOI 10.1016/0268-960X(90)90041-P; SUGERMAN HJ, 1970, SURG GYNECOL OBSTETR, V131, P733; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WEG JG, 1991, CRIT CARE MED, V19, P650, DOI 10.1097/00003246-199105000-00011	44	571	586	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3024	3029		10.1001/jama.269.23.3024	http://dx.doi.org/10.1001/jama.269.23.3024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501845				2022-12-28	WOS:A1993LF94100032
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSED CALL FOR SCIENTIFIC-DATA ON INFLATABLE PENILE IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REG         0428	1	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2964	2964						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501827				2022-12-28	WOS:A1993LF94100006
J	NATHAN, DM				NATHAN, DM			LONG-TERM COMPLICATIONS OF DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INSULIN-DEPENDENT DIABETICS; CORONARY HEART-DISEASE; METABOLIC CONTROL; NATURAL-HISTORY; KIDNEY-FUNCTION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; RISK-FACTORS; MICROVASCULAR COMPLICATIONS; ANTIHYPERTENSIVE TREATMENT		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	NATHAN, DM (corresponding author), MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02114 USA.		Hramiak, Irene/G-3305-2011		AHRQ HHS [1-R01 HSO6665] Funding Source: Medline; NIDDK NIH HHS [5UO1 DK30643] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK030643] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT RD, 1987, JAMA-J AM MED ASSOC, V257, P949, DOI 10.1001/jama.257.7.949; ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1985, Arch Ophthalmol, V103, P1644; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BAUDOIN C, 1989, DIABETES, V38, P491; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; CIAVARELLA A, 1987, DIABETES CARE, V10, P407, DOI 10.2337/diacare.10.4.407; COHEN AJ, 1987, DIABETES, V36, P944, DOI 10.2337/diabetes.36.8.944; COHEN D, 1987, BRIT MED J, V294, P795, DOI 10.1136/bmj.294.6575.795; COLWELL JA, 1983, DIABETES, V32, P14, DOI 10.2337/diab.32.2.S14; COOK J, 1990, J PEDIATR-US, V117, P39, DOI 10.1016/S0022-3476(05)82441-2; COONROD BA, 1989, DIABETES CARE, V12, P389, DOI 10.2337/diacare.12.6.389; CRYER PE, 1981, DIABETES, V30, P261, DOI 10.2337/diab.30.3.261; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; DCCT Res Grp, 1988, DIABETES, V37, P476; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; DILLS DG, 1990, DIABETES, V39, P191, DOI 10.2337/diabetes.39.2.191; DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225; ELLENBERG M, 1968, NEW YORK STATE J MED, V68, P2653; ELLENBERG M, 1974, DIABETES, V23, P418, DOI 10.2337/diab.23.5.418; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; FEDORAK RN, 1985, ANN INTERN MED, V102, P197, DOI 10.7326/0003-4819-102-2-197; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, SCAND J CLIN LAB INV, V51, P31, DOI 10.1080/00365513.1991.11978686; FIRTH RG, 1986, NEW ENGL J MED, V314, P1280, DOI 10.1056/NEJM198605153142003; FRANK RN, 1982, DIABETES, V31, P874, DOI 10.2337/diabetes.31.10.874; GASSER TC, 1987, J UROLOGY, V137, P678, DOI 10.1016/S0022-5347(17)44172-3; GORDON T, 1977, ANN INTERN MED, V87, P393, DOI 10.7326/0003-4819-87-4-393; GREENE DA, 1987, NEW ENGL J MED, V316, P599; GUNDERSEN T, 1983, DIABETES CARE, V6, P285, DOI 10.2337/diacare.6.3.285; HADDEN DR, 1986, Q J MED, V59, P579; HARRIS M, 1979, DIABETES, V28, P1039; HASSLACHER C, 1985, HYPERTENSION, V7, P74; HOLMAN RR, 1983, LANCET, V1, P204; HOMMEL E, 1986, BMJ-BRIT MED J, V293, P467, DOI 10.1136/bmj.293.6545.467; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KAPLAN NM, 1987, ARCH INTERN MED, V147, P1160, DOI 10.1001/archinte.147.6.1160; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN R, 1985, DIABETES CARE, V8, P311, DOI 10.2337/diacare.8.4.311; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KOSTRABA JN, 1989, DIABETES CARE, V12, P686, DOI 10.2337/diacare.12.10.686; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KULLER LH, 1985, NIH851468 PUBL; KUSSMAN MJ, 1976, JAMA-J AM MED ASSOC, V236, P1861, DOI 10.1001/jama.236.16.1861; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; LEWIN IG, 1984, DIABETOLOGIA, V26, P445; LITZELMAN DK, 1991, CLIN RES, V39, pA581; LORENZI M, 1991, DIABETES, V40, P653, DOI 10.2337/diabetes.40.6.653; MARGOLIS JR, 1973, AM J CARDIOL, V32, P1, DOI 10.1016/S0002-9149(73)80079-7; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1987, BMJ-BRIT MED J, V294, P1448, DOI 10.1136/bmj.294.6585.1448; MASER RE, 1989, DIABETES CARE, V12, P270, DOI 10.2337/diacare.12.4.270; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1986, SCAND J CLIN LAB INV, V46, P201, DOI 10.3109/00365518609083660; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NATHAN DM, 1987, DIABETES CARE, V10, P414, DOI 10.2337/diacare.10.4.414; NATHAN DM, 1986, AM J MED, V81, P837, DOI 10.1016/0002-9343(86)90355-4; NATHAN DM, 1988, ANN INTERN MED, V108, P334, DOI 10.7326/0003-4819-108-3-334; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NATHAN DM, 1986, DIABETES, V35, P797, DOI 10.2337/diabetes.35.7.797; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; OSTERBY R, 1987, DIABETES, V36, P612, DOI 10.2337/diabetes.36.5.612; OSTERBY R, 1985, ACTA MED SCAND, V574, P3; PALMBERG P, 1981, OPHTHALMOLOGY, V88, P613; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; PERLMUTER LC, 1984, AM J MED, V77, P1043, DOI 10.1016/0002-9343(84)90186-4; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; Pugh JA, 1990, DIABETES S1, V39, p170A; QUINN M, 1992, DIABETES S1, V41, pA121; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; REICHARD P, 1989, J INTERN MED, V226, P81, DOI 10.1111/j.1365-2796.1989.tb01359.x; RULL JA, 1969, DIABETOLOGIA, V5, P215, DOI 10.1007/BF01212087; RYTTER L, 1985, DIABETES CARE, V8, P230, DOI 10.2337/diacare.8.3.230; SAID G, 1992, NEW ENGL J MED, V326, P1257, DOI 10.1056/NEJM199205073261905; SCOTT FB, 1980, ANN INTERN MED, V92, P340, DOI 10.7326/0003-4819-92-2-340; SELBY JV, 1990, JAMA-J AM MED ASSOC, V263, P1954, DOI 10.1001/jama.263.14.1954; SERVICE FJ, 1985, DIABETOLOGIA, V28, P722; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SINGER DE, 1989, DIABETES, V38, P350, DOI 10.2337/diabetes.38.3.350; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SNAPE WJ, 1982, ANN INTERN MED, V96, P444, DOI 10.7326/0003-4819-96-4-444; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Sundkvist Goran, 1992, Journal of Diabetes and its Complications, V6, P123, DOI 10.1016/1056-8727(92)90023-E; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; TAMBORLANE WV, 1982, DIABETES CARE, V5, P58; VIBERTI G, 1984, DIABETES, V33, P686, DOI 10.2337/diab.33.7.686; VIBERTI GC, 1983, BRIT MED J, V286, P598, DOI 10.1136/bmj.286.6365.598; VIBERTI GC, 1983, AM J MED, V74, P256, DOI 10.1016/0002-9343(83)90624-1; VIBERTI GC, 1982, LANCET, V1, P1430; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187; WIEGMANN TB, 1992, DIABETES, V41, P62, DOI 10.2337/diabetes.41.1.62; WIEGMANN TB, 1990, DIABETES CARE, V13, P864, DOI 10.2337/diacare.13.8.864; WINGARD DL, 1983, AM J EPIDEMIOL, V117, P19, DOI 10.1093/oxfordjournals.aje.a113510; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202; 1970, DIABETES S2, V19, P787; 1985, NIH851468 PUBL	126	1365	1445	3	90	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1676	1685		10.1056/NEJM199306103282306	http://dx.doi.org/10.1056/NEJM199306103282306			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8487827				2022-12-28	WOS:A1993LF05400006
J	EISENHANDLER, J; DRUCKER, E				EISENHANDLER, J; DRUCKER, E			OPIATE DEPENDENCY AMONG THE SUBSCRIBERS OF A NEW-YORK AREA PRIVATE INSURANCE PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IMMUNODEFICIENCY VIRUS-INFECTION; INTRAVENOUS DRUG-USERS; CITY	Objective.-To estimate the prevalence of opiate use among the subscribers of a large private insurance plan, Empire Blue Cross and Blue Shield (EBCBS). Design.-Six and a half million hospital inpatient claims for the period January 1, 1982, through June 30, 1992, were reviewed. Thirty-one thousand eight hundred ten different individuals who had a total of 55 143 hospital admissions with a primary diagnosis of opiate dependency (International Classification of Diseases, Ninth Revision, Clinical Modification 304.0 and 304.7) were identified. In the same period, 17 493 EBCBS subscribers (15 191 male and 2302 female) were identified from hospital admissions data as having acquired immunodeficiency syndrome. These data were cross-matched with the opiate dependency data to estimate the ''capture'' of opiate users in the EBCBS subscribers with acquired immunodeficiency syndrome and to model the size of the opiate using population in EBCBS. Results.-It is estimated that between 1982 and 1992 EBCBS insured approximately 141 000 opiate users, 85 000 of whom are currently insured by EBCBS. Conclusion.-There is a large population of insured opiate users who may be excluded from the estimates of the overall number of opiate users as insured opiate users are less likely to be counted via contact with government agencies. This suggests that current estimates of the number of opiate users and their social characteristics should be reconsidered.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	EISENHANDLER, J (corresponding author), EMPIRE BLUE CROSS & BLUE SHIELD,622 3RD AVE,NEW YORK,NY 10017, USA.							[Anonymous], 1992, INT CLASSIFICATION D; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BUTYNSKI W, 1990, STATE RESOURCES SERV; COHEN P, 1991, NONDEVIANT COCAINE U; COURTWRIGHT D, 1990, ADDICTS WHO SURVIVED; DESJARLAIS D, 1988, AIDS S1, V2, P565; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DRUCKER E, 1989, AM J EPIDEMIOL, V130, P133, DOI 10.1093/oxfordjournals.aje.a115304; DRUCKER E, 1986, AM J DRUG ALCOHOL AB, V12, P165, DOI 10.3109/00952998609083750; DRUCKER E, 1990, AIDS SOCIAL SCI, P45; EISENHANDLER J, 1992, APR SOC ACT SPRING M; GERSTEIN DR, 1991, TREATING DRUG PROBLE, V1; KANDEL DB, 1992, MILBANK Q, V69, P365; MANDELL J, 1989, 1ST INT C HARM RED L; MUSTO DF, 1987, AM DISEASE ORIGINS N; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; WALDORF D, 1984, PATHWAYS ADDICTION; WINICK C, 1991, MILBANK Q, V69, P437, DOI 10.2307/3350104; Zinberg Norman., 1984, DRUG SET SETTING BAS; 1992, NATIONAL HOUSEHOLD S; 1990, AIDS SEXUAL BEHAVIOR; 1992, AIDS SURVEILLANCE RE	22	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2890	2891		10.1001/jama.269.22.2890	http://dx.doi.org/10.1001/jama.269.22.2890			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497094				2022-12-28	WOS:A1993LE93600027
J	GANN, P; MELVILLE, SK; LUCKMANN, R				GANN, P; MELVILLE, SK; LUCKMANN, R			CHARACTERISTICS OF PRIMARY-CARE OFFICE SYSTEMS AS PREDICTORS OF MAMMOGRAPHY UTILIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						MAMMOGRAPHY; KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH MAINTENANCE; ORGANIZATIONS PHYSICIANS, FAMILY; REMINDER SYSTEMS	BREAST-CANCER; PHYSICIANS; REMINDERS	Objective: To evaluate the association between primary care office systems and mammography utilization by women older than 50 years. Design: Cross-sectional. Setting: An independent-practice association health maintenance organization (HMO) in Massachusetts. Participants: One hundred thirty-two primary care practices, representing 321 physicians and 4378 women with at least 12 months of recent, continuous assignment to a practice participating in the HMO. Measurements: Practice characteristics and procedures for mammography referral and follow-up were ascertained by interviews of office managers. For each practice, the proportion of women older than 50 years who received a mammogram during their most recent 12-month period of assignment to the practice was calculated. Main Results: Forty-five percent of eligible women received a mammogram during their most recent year of assignment to an HMO practice. In a regression model, use of one particular urban mammography center, group practice, and low percentage of Medicaid patients in the practice were each associated with 9% to 12% higher mammography utilization; use of flow-sheets and the scheduling of mammograms by the patients themselves were associated with 7% to 9% higher utilization. Smaller, nonsignificant increases were associated with the use of reminders to patients (5%) and the presence of only internists on staff (5%). The model accounted for 51% of the variation in mammography utilization among practices. Conclusions: Mammography utilization among women older than 50 years, in a population in which cost was not a barrier, was related to specific office characteristics. Features of the mammography center, the process for scheduling mammograms, the use of flowsheets to prompt physicians, and the use of reminders to patients are important.	UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	GANN, P (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, 680 N LAKE SHORE DR, SUITE 1102, CHICAGO, IL 60611 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				ANDA RF, 1990, AM J PREV MED, V6, P123, DOI 10.1016/S0749-3797(18)31016-X; BATTISTA RN, 1986, MED CARE, V24, P216, DOI 10.1097/00005650-198603000-00004; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; HARRIS RP, 1990, AM J PREV MED, V6, P145, DOI 10.1016/S0749-3797(18)31019-5; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; POMMERENKE FA, 1992, J FAM PRACTICE, V34, P86; Slenker S E, 1988, Ohio Med, V84, P476; THOMPSON GB, 1989, AM J PUBLIC HEALTH, V79, P1541, DOI 10.2105/AJPH.79.11.1541; WOLOSIN RJ, 1990, J FAM PRACTICE, V30, P542; 1990, CA, V40, P77; 1988, MMWR, V37, P357; 1990, MMWR, V39, P621; 1986, NATL CANCER I MONOGR, V2, P27	16	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					893	898		10.7326/0003-4819-118-11-199306010-00011	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480964				2022-12-28	WOS:A1993LD25200011
J	DRATZ, EA; FURSTENAU, JE; LAMBERT, CG; THIREAULT, DL; RARICK, H; SCHEPERS, T; PAKHLEVANIANTS, S; HAMM, HE				DRATZ, EA; FURSTENAU, JE; LAMBERT, CG; THIREAULT, DL; RARICK, H; SCHEPERS, T; PAKHLEVANIANTS, S; HAMM, HE			NMR STRUCTURE OF A RECEPTOR-BOUND G-PROTEIN PEPTIDE	NATURE			English	Article							SIGNAL TRANSDUCTION; PERTUSSIS TOXIN; ALPHA-SUBUNIT; BINDING; DETERMINANTS; MUTATION	HETEROTRIMERIC GTP-binding proteins (G proteins) regulate cellular activity by coupling to hormone or sensory receptors. Stimulated receptors catalyse the release of GDP from G protein alpha-subunits1-4 and GTP bound to the empty alpha-subunits provides signals that control effectors such as adenylyl cyclases, phosphodiesterases, phospholipases and ion channels4. Three cytoplasmic loops of the activated receptor are thought to interact with three sites on the heterotrimeric G protein to provide high-affinity interaction and catalyse G-protein activation5-8. The carboxyl terminus of the alpha-subunit is particularly important for interaction with the receptor9-14. Here we study the structure of part of the active interface between the photon receptor rhodopsin and the G protein transducin, or G(t), using nuclear magnetic resonance. An 11-amino-acid peptide from the C terminus of the alpha-subunit of G(t) (alpha(t) (340-350)) binds to rhodopsin and mimics the G protein in stabilizing its active form, metarhodopsin II. The peptide alpha(t) (340-350) binds to both excited and unexcited rhodopsin and conformational differences between the two bound forms suggest a mechanism for activation of G proteins by agonist-stimulated receptors. Insight into receptor-catalysed GDP release will have broad application because the GTP/GDP exchange and the intrinsic GTPase activity of GTP-binding proteins constitute a widespread regulatory mechanism15.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; UNIV ILLINOIS, COLL MED, DEPT OPHTHALMOL, CHICAGO, IL 60680 USA; UNIV SASSARI, IST FISIOL GEN & CHIM BIOL, I-07100 SASSARI, ITALY	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari	DRATZ, EA (corresponding author), MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA.		Hamm, Heidi E/G-2374-2014; Lambert, Christophe/AAH-4448-2021	Lambert, Christophe/0000-0003-1994-2893				AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN MF, 1982, METHOD ENZYMOL, V81, P709; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DERETIC D, 1987, J BIOL CHEM, V262, P10839; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HARGRAVE PA, 1993, BIOESSAYS, V15, P1; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HUBBARD R, 1971, P615; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1983, J BIOL CHEM, V258, P4870; OSTHEIMER GJ, 1992, J BIOL CHEM, V267, P25120; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479	33	160	163	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					276	281		10.1038/363276a0	http://dx.doi.org/10.1038/363276a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8487866				2022-12-28	WOS:A1993LC86600057
J	JACOBS, WR; BARLETTA, RG; UDANI, R; CHAN, J; KALKUT, G; SOSNE, G; KIESER, T; SARKIS, GJ; HATFULL, GF; BLOOM, BR				JACOBS, WR; BARLETTA, RG; UDANI, R; CHAN, J; KALKUT, G; SOSNE, G; KIESER, T; SARKIS, GJ; HATFULL, GF; BLOOM, BR			RAPID ASSESSMENT OF DRUG SUSCEPTIBILITIES OF MYCOBACTERIUM-TUBERCULOSIS BY MEANS OF LUCIFERASE REPORTER PHAGES	SCIENCE			English	Article							MEASURING GENE-EXPRESSION; FIREFLY LUCIFERASE; STABLE EXPRESSION; BACTERIA; TRANSFORMATION; SMEGMATIS; CELLS	Effective chemotherapy of tuberculosis requires rapid assessment of drug sensitivity because of the emergence of multidrug-resistant Mycobacterium tuberculosis. Drug susceptibility was assessed by a simple method based on the efficient production of photons by viable mycobacteria infected with specific reporter phages expressing the firefly luciferase gene. Light production was dependent on phage infection, expression of the luciferase gene, and the level of cellular adenosine triphosphate. Signals could be detected within minutes after infection of virulent M. tuberculosis with reporter phages. Culture of conventional strains with antituberculosis drugs, including isoniazid or rifampicin, resulted in extinction of light production. In contrast, light signals after luciferase reporter phage infection of drug-resistant strains continued to be produced. Luciferase reporter phages may help to reduce the time required for establishing antibiotic sensitivity of M. tuberculosis strains from weeks to days and to accelerate screening for new antituberculosis drugs.	JOHN INNES INST, NORWICH NR4 7UH, NORFOLK, ENGLAND; AFRC, INST PLANT SCI RES, NORWICH NR4 7UH, ENGLAND; UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15230 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	JACOBS, WR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA.		Barletta, Raul G./V-9053-2019	Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI27235, AI28927, UO1AI30189] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027235, R29AI028927, U01AI030189, R01AI028927] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; BARLETTA RG, UNPUB; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARMI OA, 1987, J BACTERIOL, V169, P2165, DOI 10.1128/jb.169.5.2165-2170.1987; DeLuca M. A., 1981, BIOLUMINESCENCE CHEM; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILELLA AG, 1988, NUCLEIC ACIDS RES, V16, P4159, DOI 10.1093/nar/16.9.4159; DONNELLYWU MK, 1993, MOL MICROBIOL, V7, P407, DOI 10.1111/j.1365-2958.1993.tb01132.x; ENGEBRECHT J, 1985, SCIENCE, V227, P1345, DOI 10.1126/science.2983423; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HEIFETS LB, 1991, DRUG SUSCEPTIBILITY, P89; Iseman M D, 1992, Curr Clin Top Infect Dis, V12, P188; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JACOBS WW, UNPUB; KODIKARA CP, 1991, FEMS MICROBIOL LETT, V83, P261, DOI [10.1111/j.1574-6968.1991.tb04474.x, 10.1016/0378-1097(91)90486-T]; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MURRAY C, IN PRESS DISEASE CON; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; PALOMARES AJ, 1989, GENE, V81, P55, DOI 10.1016/0378-1119(89)90336-3; SANLEY PE, 1989, J BIOLUMIN CHEMILUMI, V3, P131; SCHMETTERER G, 1986, J BACTERIOL, V167, P411, DOI 10.1128/jb.167.1.411-414.1986; SHAW JJ, 1986, BIO-TECHNOL, V4, P560, DOI 10.1038/nbt0686-560; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; THORPE GHG, 1984, CLIN CHEM, V30, P806; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P463; WOOD KV, 1990, J BIOLUM CHEMILUM, V5, P107, DOI 10.1002/bio.1170050206; 1992, MORBID MORTAL WEEKLY, V41, P507; IN PRESS MORBID MORT	40	354	388	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1993	260	5109					819	822		10.1126/science.8484123	http://dx.doi.org/10.1126/science.8484123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484123	Green Published			2022-12-28	WOS:A1993LA74400034
J	PELHAM, HRB				PELHAM, HRB			IS EPIMORPHIN INVOLVED IN VESICULAR TRANSPORT	CELL			English	Note											PELHAM, HRB (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.							BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	6	36	36	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					425	426		10.1016/0092-8674(93)90128-D	http://dx.doi.org/10.1016/0092-8674(93)90128-D			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490959				2022-12-28	WOS:A1993LA74300003
J	SACKEY, AH; BROADHEAD, RL				SACKEY, AH; BROADHEAD, RL			HEMIPLEGIA AFTER MEASLES, MUMPS, AND RUBELLA VACCINATION	BRITISH MEDICAL JOURNAL			English	Letter											SACKEY, AH (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP,LIVERPOOL L12 2AP,ENGLAND.							GRIFFIN MR, 1991, PEDIATRICS, V88, P881; ISAACS D, 1990, LANCET, V335, P1384, DOI 10.1016/0140-6736(90)91255-9; Norman RM, 1962, ACUTE HEMIPLEGIA CHI; REYNOLDS JES, 1989, EXTRA PHARMACOPEIA M; TAVANGER J, 1987, LAKARTIDRINGER, V84, P948; 1991, DRUG THER B, V29, P61	6	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1169	1169		10.1136/bmj.306.6886.1169-a	http://dx.doi.org/10.1136/bmj.306.6886.1169-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499819	Green Published, Bronze			2022-12-28	WOS:A1993LA68500024
J	JARMAN, B				JARMAN, B			IS LONDON OVERBEDDED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine whether there are too many hospital beds in London. Design-Analysis of data from the Hospital In-Patient Enquiry, Mental Health Enquiry, health service indicators, and Emergency Bed Service. Setting-England, London, and inner London. Results-Hospital admission rates for acute plus geriatric services for London residents were very similar to the national values in all age groups. In the special case considered in the Tomlinson report-acute services in inner London-the admission rate was 22% above the value for England. However, the admission rate of inner deprived Londoners was 9% below that of comparable areas outside London. For psychiatry, admission rates in London roughly equalled those in comparable areas. When special health authorities were excluded, in 1990-1 there were 4% more acute plus geriatric beds available per resident in London than in England. Bed provision has been reduced more rapidly in London than nationally. Extrapolating the trend of bed closures forward indicates that beds (all and acute) per resident in London are now at about the national average. Data from the Emergency Bed Service indicate that the pressure on available hospital beds in London has been increasing since 1985. Conclusions-Data regarding bed provision and utilisation for all specialties by London residents do not provide a case for reducing the total hospital bed stock in London at a rate faster than elsewhere. Bed closures should take account of London's relatively poorer social and primary health care circumstances, longer hospital waiting lists, poorer provision of residential homes, and evidence from the Emergency Bed Service of increasing pressure on beds. Higher average costs in London, some unavoidable, are forcing hospital beds to be closed at a faster rate in London than nationally.			JARMAN, B (corresponding author), ST MARYS HOSP,LISSON GROVE HLTH CTR,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND.							Boyle S, 1992, ACUTE HLTH SERVICES; BOYLE S, IN PRESS PRIMARY HLT; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; JARMAN B, 1992, BRIT MED J, V304, P1146, DOI 10.1136/bmj.304.6835.1146; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1993, MAKING LONDON BETTER; 1992, HLTH PERSONAL SOCIAL; 1992, CASELOAD REPORT; 1985, HOSPITAL PATIENT ENQ; 1992, SUMMARY AVAILABLE BE; 1992, RA86912H GOV STAT SE; 1986, PATIENT STATISTICS M; 1992, LONDON HLTH CARE 201	13	17	17	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					979	982		10.1136/bmj.306.6883.979	http://dx.doi.org/10.1136/bmj.306.6883.979			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490480	Bronze, Green Published			2022-12-28	WOS:A1993KX43600025
J	CLARKE, M; MASON, ES; MACVICAR, J; CLAYTON, DG				CLARKE, M; MASON, ES; MACVICAR, J; CLAYTON, DG			EVALUATING PERINATAL-MORTALITY RATES - EFFECTS OF REFERRAL AND CASE MIX	BRITISH MEDICAL JOURNAL			English	Article							PLACE	Objective-To evaluate perinatal mortality rates as a method of auditing obstetric and neonatal care after account had been taken of transfer between hospitals during pregnancy and case mix. Design-Case-control study of perinatal deaths. Setting-Leicestershire health district. Subjects-1179 singleton perinatal deaths and their selected live born controls among 114 362 singleton births to women whose place of residence was Leicestershire during 1978-87. Main outcome measure-Crude perinatal mortality rates and rates adjusted for case mix. Results-An estimated 11 701 of the 28 750 women booked for delivery in general practitioner maternity units were transferred to consultant units during their pregnancy. These 11 701 women had a high perinatal mortality rate (16.8/1000 deliveries). Perinatal mortality rates by place of booking showed little difference between general practitioner units (8.8/1000) and consultant units (9.3-11.7/1000). Perinatal mortality rates by place of delivery, however, showed substantial differences between general practitioner units (3.3/1000) and consultant units (9.4-12.6/1000) because of the selective referral of high risk women from general practitioner units to consultant units. Adjustment for risk factors made little difference to the rates except when the subset of deaths due to immaturity was adjusted for birth weight. Conclusion-Perinatal mortality rates should be adjusted for case mix and referral patterns to get a meaningful result. Even when this is done it is difficult to compare the effectiveness of hospital units with perinatal mortality rates because of the increasingly small subset of perinatal deaths that are amenable to medical intervention.	UNIV LEICESTER,DEPT OBSTET & GYNAECOL,LEICESTER LE1 7RH,ENGLAND	University of Leicester	CLARKE, M (corresponding author), UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,POB 65,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							CAIN KC, 1988, AM J EPIDEMIOL, V128, P1198, DOI 10.1093/oxfordjournals.aje.a115074; CAMPBELL R, 1984, BRIT MED J, V289, P721, DOI 10.1136/bmj.289.6447.721; CAMPLING EA, 1992, REPORT NATIONAL CONF; CLARKE M, 1988, BMJ-BRIT MED J, V297, P384, DOI 10.1136/bmj.297.6645.384; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; Nightingale F., 1871, INTRO NOTES LYING; TEW M, 1985, J ROY COLL GEN PRACT, V35, P390; WIGGLESWORTH JS, 1980, LANCET, V2, P684; 1986, 29 DEPT HLTH SOC SEC; 1988, 1ST HOUS COMM SOC SE; 1990, REPORT WORKING GROUP	11	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					824	827		10.1136/bmj.306.6881.824	http://dx.doi.org/10.1136/bmj.306.6881.824			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490374	Green Published, Bronze			2022-12-28	WOS:A1993KV34800020
J	RANDOLPH, AG; WASHINGTON, AE; PROBER, CG				RANDOLPH, AG; WASHINGTON, AE; PROBER, CG			CESAREAN DELIVERY FOR WOMEN PRESENTING WITH GENITAL HERPES LESIONS - EFFICACY, RISKS, AND COSTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SIMPLEX VIRUS-INFECTION; NEONATAL HERPES; DECISION-ANALYSIS; PREGNANT-WOMEN; INFANTS; MORBIDITY; ACYCLOVIR; CULTURES; TIME	Objective.-To assess the effect of cesarean delivery on neonatal and maternal morbidity and mortality and their associated costs for two populations of women presenting with genital herpes lesions at delivery: those with and those without a history of genital herpes. Data Sources.-MEDLINE (search for herpes simplex virus and neonatal, cesarean, and mortality) and recognized experts. Data Extraction.-The quality of the overall data used for baseline values was graded using a predetermined scale. Results.-The practice of cesarean delivery for women with a history of genital herpes lesions that recur at delivery results in more than 1580 excess cesarean deliveries performed for every poor neonatal outcome prevented, a cost per neonatal herpes case averted of $2.5 million and a cost per quality-adjusted life-year gained of $203 000. For these women, lowering the efficacy of cesarean delivery or the herpes simplex virus vertical transmission rate could result in maternal deaths outnumbering neonatal deaths prevented. In contrast, cesarean delivery for women with no history of genital herpes simplex virus who have lesions at delivery has low maternal costs per neonatal benefit and saves money. Conclusions.-Women who present with their first clinical episode of genital herpes at delivery should have a cesarean section performed. However, the current practice of cesarean delivery for women with a history of genital herpes lesions that recur at delivery results in high maternal morbidity and mortality at substantial financial expense, underscoring the urgency of examining alternative management strategies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GYNECOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,MEDTEP RES CTR MINOR POPULAT,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	RANDOLPH, AG (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.			Randolph, Adrienne/0000-0002-3084-3071	AHRQ HHS [HS07373-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARNOLD CB, 1988, STAT B METROP INSUR, V69, P18; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BALDWIN S, 1989, TERATOLOGY, V39, P1, DOI 10.1002/tera.1420390102; BASHORE RA, 1990, AM J OBSTET GYNECOL, V162, P1428, DOI 10.1016/0002-9378(90)90902-J; BINKIN NJ, 1989, MED DECIS MAKING, V9, P225, DOI 10.1177/0272989X8900900401; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; Bujko M, 1989, Clin Exp Obstet Gynecol, V16, P6; CATALANO PM, 1991, AM J OBSTET GYNECOL, V164, P1303, DOI 10.1016/0002-9378(91)90704-U; CHANG TW, 1977, NEW ENGL J MED, V296, P573; CHANG TW, 1977, JAMA-J AM MED ASSOC, V296, P573; CHUANG TY, 1983, MAYO CLIN PROC, V58, P436; CHUANG TY, 1988, AM J PREV MED, V4, P47, DOI 10.1016/S0749-3797(18)31219-4; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; GIBBS RS, 1988, OBSTET GYNECOL, V71, P779; LAYDE PM, 1979, JAMA-J AM MED ASSOC, V241, P2290, DOI 10.1001/jama.241.21.2290; LIBMAN MD, 1991, REV INFECT DIS, V13, P1093; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; NAHMIAS AJ, 1983, INFECT DIS, P636; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PETITTI DB, 1982, OBSTET GYNECOL, V59, P6; Prober C G, 1989, Curr Clin Top Infect Dis, V10, P1; SHANKARAN S, 1988, PEDIATRICS, V81, P372; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAYPEDERSEN B, 1990, LANCET, V336, P756, DOI 10.1016/0140-6736(90)92255-G; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; 1986, HOSPITAL FACT BOOK C; 1987, BLESSED EVENTS BOTTO, P18; 1981, NIH822067 DEP HLTH H; 1991, STATISTICAL ABSTRACT	37	89	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					77	82		10.1001/jama.270.1.77	http://dx.doi.org/10.1001/jama.270.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510301				2022-12-28	WOS:A1993LK36600028
J	MOODIE, SA; WILLUMSEN, BM; WEBER, MJ; WOLFMAN, A				MOODIE, SA; WILLUMSEN, BM; WEBER, MJ; WOLFMAN, A			COMPLEXES OF RAS.GTP WITH RAF-1 AND MITOGEN-ACTIVATED PROTEIN-KINASE KINASE	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CASCADE; RAS	The guanosine triphosphate (GTP)-binding protein Ras functions in regulating growth and differentiation; however, little is known about the protein interactions that bring about its biological activity. Wild-type Ras or mutant forms of Ras were covalently attached to an insoluble matrix and then used to examine the interaction of signaling proteins with Ras. Forms of Ras activated either by mutation (Gly12Val) or by binding of the GTP analog, guanylyl-imidodiphosphate (GMP-PNP) interacted specifically with Raf-1 whereas an effector domain mutant, Ile36Ala, failed to interact with Raf-1. Mitogen-activated protein kinase (MAP kinase) activity was only associated with activated forms of Ras. The specific interaction of activated Ras with active MAP kinase kinase (MAPK) was confirmed by direct assays. Thus the forming of complexes containing MAPKK activity and Raf-1 protein are dependent upon the activity of Ras.	UNIV COPENHAGER,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia	MOODIE, SA (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44106, USA.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999	NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39076, CA 40042] Funding Source: Medline; NIGMS NIH HHS [GM 41220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ANDERSON NG, 1992, CELL SIGNAL, V4, P239, DOI 10.1016/0898-6568(92)90063-E; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIBATTISTE D, 1993, ONCOGENE, V8, P637; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, UNPUB; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SMITH MR, 1986, NATURE, V320, P5400; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	37	914	956	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1658	1661		10.1126/science.8503013	http://dx.doi.org/10.1126/science.8503013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503013				2022-12-28	WOS:A1993LG17600033
J	BREO, DL				BREO, DL			THE UNITED-STATES RACE TO CURE AIDS - AT 4 ON A SCALE OF 10, SAYS FAUCI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		FAUCI, 1993, NEW ENGLAND J M 0204; FAUCI, 1993, NATURE          0325	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2898	2900		10.1001/jama.269.22.2898	http://dx.doi.org/10.1001/jama.269.22.2898			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497096				2022-12-28	WOS:A1993LE93600030
J	CHARDIN, P; CAMONIS, JH; GALE, NW; VANAELST, L; SCHLESSINGER, J; WIGLER, MH; BARSAGI, D				CHARDIN, P; CAMONIS, JH; GALE, NW; VANAELST, L; SCHLESSINGER, J; WIGLER, MH; BARSAGI, D			HUMAN SOS1 - A GUANINE-NUCLEOTIDE EXCHANGE FACTOR FOR RAS THAT BINDS TO GRB2	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; CDC25 GENE; MUTATION; GROWTH; CELLS; REQUIREMENT; CLONING; P21RAS; SYSTEM	A human complementary DNA was isolated that encodes a widely expressed protein, hSos1, that is closely related to Sos, the product of the Drosophila son of sevenless gene. The hSos1 protein contains a region of significant sequence similarity to CDC25, a guanine nucleotide exchange factor for Ras from yeast. A fragment of hSos1 encoding the CDC25-related domain complemented loss of CDC25 function in yeast. This hSos1 domain specifically stimulated guanine nucleotide exchange on mammalian Ras proteins in vitro. Mammalian cells overexpressing full-length hSos1 had increased guanine nucleotide exchange activity. Thus hSos1 is a guanine nucleotide exchange factor for Ras. The hSos1 interacted with growth factor receptor-bound protein 2 (GRB2) in vivo and in vitro. This interaction was mediated by the carboxyl-terminal domain of hSos1 and the Src homology 3 (SH3) domains of GRB2. These results suggest that the coupling of receptor tyrosine kinases to Ras signaling is mediated by a molecular complex consisting of GRB2 and hSos1.	COLD SPRING HARBOR LAB,1 BUNGTOWN RD,BOX 100,COLD SPRING HARBOR,NY 11724; CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Cold Spring Harbor Laboratory; Centre National de la Recherche Scientifique (CNRS); New York University				Wigler, Michael/0000-0003-4396-1971; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360, CA46370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R56CA055360, R01CA055360, P01CA046370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pringle JR, 1981, SACCHAROMYCES CEREVI; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STEIN MJ, 1993, UNPUB; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WIGLER M, UNPUB; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; [No title captured]	45	728	758	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1338	1343		10.1126/science.8493579	http://dx.doi.org/10.1126/science.8493579			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493579				2022-12-28	WOS:A1993LE02500047
J	ESCARY, JL; PERREAU, J; DUMENIL, D; EZINE, S; BRULET, P				ESCARY, JL; PERREAU, J; DUMENIL, D; EZINE, S; BRULET, P			LEUKEMIA INHIBITORY FACTOR IS NECESSARY FOR MAINTENANCE OF HEMATOPOIETIC STEM-CELLS AND THYMOCYTE STIMULATION	NATURE			English	Article							PRIMORDIAL GERM-CELLS; MURINE; DIFFERENTIATION; SURVIVAL; INVITRO	LEUKAEMIA inhibitory factor (LIF) has a variety of effects on different cell types in vitro1, inhibiting the differentiation of embryonic stem cells2,3 and promoting the survival and/or proliferation of primitive haematopoietic precursors4,5 and primordial germ cells6,7. Here we show that LIF-deficient mice derived by gene targeting techniques have dramatically decreased numbers of stem cells in spleen and bone marrow. Injection of spleen and marrow cells from these mice promotes long-term survival of lethally irradiated wild-type animals, however, showing that the LIF- stem cells remain pluripotent. The numbers of committed progenitors are also reduced in the spleen but not the bone marrow, suggesting that stem cells interact differently with the splenic and medullary microenvironment. Heterozygous animals are intermediate in phenotype, implying that LIF has a dosage effect, and defects in stem cell number can be compensated by exogenous LIF. LIF thus appears to be required for the survival of the normal pool of stem cells, but not their terminal differentiation.	INST PASTEUR,UNITE EMBRYOL MOLEC,CNRS,URA 1148,F-75724 PARIS 15,FRANCE; INST GUSTAVE ROUSSY,INSERM,U362,F-94800 VILLEJUIF,FRANCE; CHU NECKER,INSERM,U345,F-75015 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								CONQUET F, 1992, P NATL ACAD SCI USA, V89, P8195, DOI 10.1073/pnas.89.17.8195; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; DEFELICI M, 1991, DEV BIOL, V147, P281, DOI 10.1016/S0012-1606(05)80025-9; FLETCHER FA, 1991, J EXP MED, V174, P837, DOI 10.1084/jem.174.4.837; GEARING DP, 1988, NUCLEIC ACIDS RES, V16, P9857, DOI 10.1093/nar/16.20.9857; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; KOLA I, 1990, GROWTH FACTORS, V2, P325; LE PT, 1990, J IMMUNOL, V145, P3310; LEARY AG, 1990, BLOOD, V75, P1960; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1990, BLOOD, V76, P50; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; RATJEN PD, 1990, CELL, V62, P1105; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; STAHL J, 1990, J BIOL CHEM, V265, P8833; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WORTON RG, 1969, J CELL PHYSIOL, V74, P171, DOI 10.1002/jcp.1040740209	24	337	350	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					361	364		10.1038/363361a0	http://dx.doi.org/10.1038/363361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497320				2022-12-28	WOS:A1993LD91700057
J	PASSADOR, L; COOK, JM; GAMBELLO, MJ; RUST, L; IGLEWSKI, BH				PASSADOR, L; COOK, JM; GAMBELLO, MJ; RUST, L; IGLEWSKI, BH			EXPRESSION OF PSEUDOMONAS-AERUGINOSA VIRULENCE GENES REQUIRES CELL-TO-CELL COMMUNICATION	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ELASTASE; AUTOINDUCER; PROTEIN; IDENTIFICATION; INACTIVATION; INHIBITION; LUCIFERASE; TOXIN	Pseudomonas aeruginosa is an opportunistic human pathogen that causes a variety of infections in immunocompromised hosts and individuals with cystic fibrosis. Expression of elastase, one of the virulence factors produced by this organism, requires the transcriptional activator LasR. Experiments with gene fusions show that gene lasI is essential for high expression of elastase. The lasI gene is involved in the synthesis of a diffusible molecule termed Pseudomonas autoinducer (PAI). PAI provides P. aeruginosa with a means of cell-to-cell communication that is required for the expression of virulence genes and may provide a target for therapeutic approaches.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14620 USA	University of Rochester					NIAID NIH HHS [AI33713, T32AI07362] Funding Source: Medline; NIGMS NIH HHS [T32GM07356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033713, T32AI007362, R37AI033713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEPPU T, 1992, GENE, V115, P159, DOI 10.1016/0378-1119(92)90554-3; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; COOK JPD, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING G, 1981, ZBL BAKT-INT J MED M, V249, P89, DOI 10.1016/S0174-3031(81)80045-5; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; GAMBELLO MJ, 1993, INFECT IMMUN, V61, P1180, DOI 10.1128/IAI.61.4.1180-1184.1993; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; GAMBELLO MJ, 1991, THESIS U ROCHESTER; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HECK LW, 1990, J IMMUNOL, V144, P2253; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Miller J.H., 1972, EXPT MOL GENETICS; MORIHARA K, 1979, INFECT IMMUN, V24, P188, DOI 10.1128/IAI.24.1.188-193.1979; MORIHARA K, 1985, BACTERIAL ENZYMES VI, P49; PASSADOR L, UNPUB; RALLING G, 1985, MOL GEN GENET, V201, P379, DOI 10.1007/BF00331327; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOCK J, 1990, J BACTERIOL, V172, P3974; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SINAI A, UNPUB; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TODER DS, 1991, MOL MICROBIOL, V5, P2003, DOI 10.1111/j.1365-2958.1991.tb00822.x; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; 1984, FOCUS, V6, P4	32	680	727	3	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1993	260	5111					1127	1130		10.1126/science.8493556	http://dx.doi.org/10.1126/science.8493556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493556				2022-12-28	WOS:A1993LC94200030
J	LANGER, R; VACANTI, JP				LANGER, R; VACANTI, JP			TISSUE ENGINEERING	SCIENCE			English	Article							MICROCARRIER-ATTACHED HEPATOCYTES; PERIPHERAL-NERVE REGENERATION; ENDOTHELIAL-CELLS; VASCULAR GRAFTS; TRANSPLANTATION; GROWTH; ISLETS; LIVER; MYOBLASTS; INVITRO	The loss or failure of an organ or tissue is one of the most frequent, devastating, and costly problems in human health care. A new field, tissue engineering, applies the principles of biology and engineering to the development of functional substitutes for damaged tissue. This article discusses the foundations and challenges of this interdisciplinary field and its attempts to provide solutions to tissue creation and repair.	MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA; CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	LANGER, R (corresponding author), MIT, DEPT CHEM ENGN, E25-342, CAMBRIDGE, MA 02139 USA.							ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; AEBISCHER P, 1991, EXP NEUROL, V111, P269, DOI 10.1016/0014-4886(91)90093-R; AEBISCHER P, 1989, J NEUROSCI RES, V23, P282, DOI 10.1002/jnr.490230306; ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5; BALDASSARE JJ, 1985, J CLIN INVEST, V75, P35, DOI 10.1172/JCI111693; BARRERA D, 1992, NOV ANN M AM I CHEM; BEATY CE, IN PRESS J CONTROLLE; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Borel Rinkes IH, 1992, CELL TRANSPLANT, V1, P281, DOI DOI 10.1177/096368979200100405; BUSCHMANN MD, 1992, J ORTHOPAED RES, V10, P745, DOI 10.1002/jor.1100100602; CAI ZH, 1989, HEPATOLOGY, V10, P855, DOI 10.1002/hep.1840100518; CHANG AS, 1992, NEUROSCIENCE YEAR, P125; CHANG TMS, 1989, BLOOD SUBSTITUTES, P11; Christenson L., 1993, FUNDAMENTALS ANIMAL, P7; CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228; CLOWES AW, 1991, J VASC SURG, V13, P734; COHEN S, 1990, J AM CHEM SOC, V112, P7832, DOI 10.1021/ja00177a074; COMPTON CC, 1989, LAB INVEST, V60, P600; DEMETRIOU AA, 1988, HEPATOLOGY, V8, P1006, DOI 10.1002/hep.1840080505; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DEVENUTO F, 1988, BIOMATER ARTIF CELL, V16, P77, DOI 10.3109/10731198809132557; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104; FREED LE, 1993, J CELL BIOCHEM, V51, P257, DOI 10.1002/jcb.240510304; GALLETTI PM, 1988, SURGERY, V103, P231; GEYER RP, 1989, BLOOD SUBSTITUTES, P31; GOLDEN MA, 1990, J VASC SURG, V11, P838, DOI 10.1067/mva.1990.18047; GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P274; GRANDE DA, 1989, J ORTHOP RES, V7, P208, DOI 10.1002/jor.1100070208; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREISLER HP, 1989, J VASC SURG, V9, P588, DOI 10.1067/mva.1989.vs0090588; GROWER MF, 1989, BIOMATER ARTIF CELL, V17, P291, DOI 10.3109/10731198909118286; GUENARD V, 1992, J NEUROSCI, V12, P3310; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HAGER JC, 1978, T AM SOC ART INT ORG, V24, P250; HANSBROUGH JF, 1992, SURGERY, V111, P438; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008; HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151-2916.1991.tb07132.x; HSIEH HE, 1983, J CELL PHYSL, V154, P143; HU WS, 1991, CAN J CHEM ENG, V69, P409, DOI 10.1002/cjce.5450690203; HUBBELL JA, 1992, ANN NY ACAD SCI, V665, P253, DOI 10.1111/j.1749-6632.1992.tb42589.x; HUBBELL JA, 1991, BIO-TECHNOL, V9, P568, DOI 10.1038/nbt0691-568; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JARRELL BE, 1991, J VASC SURG, V13, P733; KAHN RA, 1985, BLOOD, V66, P1; KOBAYASHI H, 1991, J APPL BIOMATER, V2, P261, DOI 10.1002/jab.770020407; Kolff WJ, 1944, ACTA MED SCAND, V117, P121; KOLLER MR, 1992, BLOOD, V80, P403; KUSAMA K, 1989, DIS COLON RECTUM, V32, P694, DOI 10.1007/BF02555776; LACY PE, 1991, SCIENCE, V254, P1782, DOI 10.1126/science.1763328; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANZA RP, 1992, DIABETES, V41, P1503, DOI 10.2337/diabetes.41.12.1503; LAUFFENBURGER DA, 1991, ANNU REV BIOPHYS BIO, V20, P387, DOI 10.1146/annurev.biophys.20.1.387; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEVESQUE L, 1992, ENDOCRINOLOGY, V130, P644, DOI 10.1210/en.130.2.644; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; LIN HB, 1992, BIOMATERIALS, V13, P905, DOI 10.1016/0142-9612(92)90113-3; LINDVALL O, 1990, PROG BRAIN RES, V82, P729; LUM ZP, 1992, TRANSPLANTATION, V53, P1180, DOI 10.1097/00007890-199206000-00002; MADISON R, 1985, EXP NEUROL, V88, P767, DOI 10.1016/0014-4886(85)90087-1; MANNING LR, 1991, P NATL ACAD SCI USA, V88, P3329, DOI 10.1073/pnas.88.8.3329; Marelli D, 1992, Cell Transplant, V1, P383; MARK DE, 1990, PLAST RECONSTR SURG, V86, P623, DOI 10.1097/00006534-199010000-00001; Merrill John P, 1955, SURG FORUM, V6, P432; MICHAELI D, 1990, Journal of Burn Care and Rehabilitation, V11, P21, DOI 10.1097/00004630-199001000-00005; MIKOS AG, 1993, J BIOMED MATER RES, V27, P183, DOI 10.1002/jbm.820270207; MIKOS AG, IN PRESS BIOTECHNOL; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOW VC, 1992, BIOMATERIALS, V13, P67, DOI 10.1016/0142-9612(92)90001-5; MURPHY GF, 1990, LAB INVEST, V62, P305; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NAUGHTON BA, 1991, J BIOMECH ENG-T ASME, V113, P171, DOI 10.1115/1.2891230; NAVE M, 1992, J BURN CARE REHABIL, V13, P130; NEREM RM, 1991, ANN BIOMED ENG, V19, P529, DOI 10.1007/BF02367396; NEREM RM, 1990, TOXICOL PATHOL, V18, P572; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OSHEA GM, 1984, BIOCHIM BIOPHYS ACTA, V804, P133, DOI 10.1016/0167-4889(84)90107-1; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARKHURST MR, 1992, BIOPHYS J, V61, P306, DOI 10.1016/S0006-3495(92)81838-6; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755; RICORDI C, 1988, TRANSPLANTATION, V45, P994, DOI 10.1097/00007890-198805000-00035; ROTEM A, 1992, BIOTECHNOL BIOENG, V40, P1286, DOI 10.1002/bit.260401020; Sagen J, 1992, ASAIO J, V38, P24, DOI 10.1097/00002480-199201000-00007; SAWHNEY AS, 1992, BIOMATERIALS, V13, P863, DOI 10.1016/0142-9612(92)90180-V; SCHWARTZ RM, 1991, BLOOD, V78, P3155; SCHWARTZ RM, 1991, P NATL ACAD SCI USA, V88, P6760, DOI 10.1073/pnas.88.15.6760; SEFTON MV, 1992, J CONTROL RELEASE, V19, P289, DOI 10.1016/0168-3659(92)90084-5; SIE P, 1980, BIOCHEM BIOPH RES CO, V97, P133, DOI 10.1016/S0006-291X(80)80145-8; SIPEHIA R, 1990, BIOMATER ARTIF CELL, V18, P643, DOI 10.3109/10731199009117333; SKALAK R, 1988, TISSUE ENG; SPECTOR M, 1988, NONCEMENTED TOTAL HI, P69; STERN R, 1990, Journal of Burn Care and Rehabilitation, V11, P7, DOI 10.1097/00004630-199001000-00003; Stoker AW, 1990, CURR OPIN CELL BIOL, V2, P864, DOI 10.1016/0955-0674(90)90085-S; STONE KR, 1990, CLIN ORTHOP RELAT R, P129; SUGAMORI ME, 1989, T AM SOC ART INT ORG, V35, P791; SULLIVAN FP, 1987, TRANSPLANTATION, V44, P465, DOI 10.1097/00007890-198710000-00001; SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124; Sun AM, 1992, MICROCAPSULES NANOPA, P315; SUTHERLAND DER, 1977, SURGERY, V82, P124; SYKES M, 1993, TRANSPLANTATION, V55, P197, DOI 10.1097/00007890-199301000-00037; TACHIBANA M, 1985, J UROLOGY, V133, P866, DOI 10.1016/S0022-5347(17)49268-8; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1990, P NATL ACAD SCI USA, V87, P1625; Thompson K P, 1991, Refract Corneal Surg, V7, P240; TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101; TRINKAUSRANDALL V, 1988, INVEST OPHTH VIS SCI, V29, P393; ULUDAG H, 1990, INT J ARTIF ORGANS, V13, P93, DOI 10.1177/039139889001300207; ULUDAG H, 1992, BIOTECHNOL BIOENG, V39, P672, DOI 10.1002/bit.260390612; UYAMA S, IN PRESS TRANSPLANTA; VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001; VACANTI JP, 1988, J PEDIATR SURG, V23, P3, DOI 10.1016/S0022-3468(88)80529-3; VALENTINI RF, 1992, BIOMATERIALS, V13, P183, DOI 10.1016/0142-9612(92)90069-Z; VONSCHROEDER HP, 1991, J BIOMED MATER RES, V25, P329, DOI 10.1002/jbm.820250305; WATKITANI S, 1989, J BONE JT SURG B, V71, P74; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; WELLS GDM, IN PRESS BIOMATERIAL; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; YANNAS IV, 1990, ANGEW CHEM INT EDIT, V29, P20, DOI 10.1002/anie.199000201; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899; Yarmush M L, 1992, Cell Transplant, V1, P323; YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; 1990, ANN REPORT US SCI RE; 1988, VITAL STATISTICS U A, V2	129	8104	8799	112	3611	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					920	926		10.1126/science.8493529	http://dx.doi.org/10.1126/science.8493529			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493529				2022-12-28	WOS:A1993LB79100031
J	LIN, WC; DESIDERIO, S				LIN, WC; DESIDERIO, S			REGULATION OF V(D)J RECOMBINATION ACTIVATOR PROTEIN RAG-2 BY PHOSPHORYLATION	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; SIGNAL SEQUENCES; RECEPTOR GENES; B-CELLS; KINASE; DEFECT; EXPRESSION; MUTATION	Antigen receptor genes are assembled by site-specific DNA rearrangement. The recombination activator genes RAG-1 and RAG-2 are essential for this process, termed V(D)J rearrangement. The activity and stability of the RAG-2 protein have now been shown to be regulated by phosphorylation. In fibroblasts RAG-2 was phosphorylated predominantly at two serine residues, one of which affected RAG-2 activity in vivo. The threonine at residue 490 was phosphorylated by p34cdcs kinase in vitro; phosphorylation at this site in vivo was associated with rapid degradation of RAG-2. Instability was transferred to chimeric proteins by a 90-residue portion of RAG-2. Mutation of the p34cdc2 phosphorylation site of the tumor suppressor protein p53 conferred a similar phenotype, suggesting that this association between phosphorylation and degradation is a general mechanism.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	LIN, WC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARTER P, 1987, METHOD ENZYMOL, V154, P382; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; ERICKSON A, 1992, J BIOL CHEM, V265, P19728; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOBAYASHI Y, 1991, J IMMUNOL, V147, P3201; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBER MR, 1987, GENES DEV, V751; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lin W. A., UNPUB; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MELCHERS F, 1989, COLD SH Q B, V54, P183; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORIHARA K, 1968, BIOCHEM BIOPH RES CO, V30, P625, DOI 10.1016/0006-291X(68)90558-5; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	45	194	196	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					953	959		10.1126/science.8493533	http://dx.doi.org/10.1126/science.8493533			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493533				2022-12-28	WOS:A1993LB79100035
J	MCDONALD, NQ; HENDRICKSON, WA				MCDONALD, NQ; HENDRICKSON, WA			A STRUCTURAL SUPERFAMILY OF GROWTH-FACTORS CONTAINING A CYSTINE KNOT MOTIF	CELL			English	Review							RESOLUTION; RECEPTOR		COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	MCDONALD, NQ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BANNER DW, 1993, CELL, V73; BRADSHAW RA, 1993, TRENDS BIOCHEM SCI, V18, P48, DOI 10.1016/0968-0004(93)90052-O; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DAOPIN S, 1992, SCIENCE, V258, P1161, DOI 10.1126/science.258.5085.1161; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1993, IN PRESS EMBO J, V12; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; REES DC, 1980, P NATL ACAD SCI-BIOL, V77, P4633, DOI 10.1073/pnas.77.8.4633; RICHARDSON JS, 1981, ADV PROTEIN CHEM, V37, P167; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Server A C, 1977, Adv Protein Chem, V31, P339, DOI 10.1016/S0065-3233(08)60221-1; SWINDELLS MB, 1992, SCIENCE, V258, P1160, DOI 10.1126/science.1439827; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	30	464	532	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					421	424		10.1016/0092-8674(93)90127-C	http://dx.doi.org/10.1016/0092-8674(93)90127-C			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490958	hybrid			2022-12-28	WOS:A1993LA74300002
J	PARVIN, JD; SHARP, PA				PARVIN, JD; SHARP, PA			DNA TOPOLOGY AND A MINIMAL SET OF BASAL FACTORS FOR TRANSCRIPTION BY RNA POLYMERASE-II	CELL			English	Article							MAJOR LATE PROMOTER; SIMIAN VIRUS 40; PREINITIATION COMPLEX; TATA BOX; ACCURATE TRANSCRIPTION; FUNCTIONAL-PROPERTIES; INITIATION; GENE; PURIFICATION; CHROMATIN	Immunoglobulin heavy chain (IgH) gene transcription in vitro can be reconstituted with a minimal reaction containing only TATA-binding protein (TBP), TFIIB, and RNA polymerase II (pol II) when the template is negatively supercoiled. Transcription from linear DNA templates containing either the IgH or the adenovirus major late promoters (MLPs) requires in addition TFIIF, TFIIE, TFIIH, and a fraction containing TFIIA and TFIIJ. Promoters vary in their activities in the minimal reaction. Initiation at the adenovirus MLP site was not observed in this reaction, even with templates containing negative superhelical density. When only TBP, TFIIB, and pol II were present in the reaction, the more negatively supercoiled the IgH template DNA was, the more active the transcription. It is suggested that the free energy of supercoiling promotes the formation of an open complex for initiation of transcription by the minimal set of transcription factors.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	PARVIN, JD (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA-14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTCHAN P, 1973, P NATL ACAD SCI USA, V70, P3077, DOI 10.1073/pnas.70.11.3077; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRADKIN LG, 1985, P NATL ACAD SCI USA, V82, P7979, DOI 10.1073/pnas.82.23.7979; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLAND RM, 1983, NATURE, V302, P38, DOI 10.1038/302038a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUCHNIK AN, 1982, EMBO J, V1, P1353, DOI 10.1002/j.1460-2075.1982.tb01322.x; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; OHBA R, 1992, BIOCHEM BIOPH RES CO, V186, P963, DOI 10.1016/0006-291X(92)90840-H; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1992, CELL, V68, P1153; PETERSON MG, 1991, NATURE, V354, P369; PROBST E, 1979, J MOL BIOL, V135, P709, DOI 10.1016/0022-2836(79)90173-6; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716	49	331	336	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					533	540		10.1016/0092-8674(93)90140-L	http://dx.doi.org/10.1016/0092-8674(93)90140-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490964				2022-12-28	WOS:A1993LA74300014
J	MORRISS, R; SHARPE, M; SHARPLEY, AL; COWEN, PJ; HAWTON, K; MORRIS, J				MORRISS, R; SHARPE, M; SHARPLEY, AL; COWEN, PJ; HAWTON, K; MORRIS, J			ABNORMALITIES OF SLEEP IN PATIENTS WITH THE CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							FIBROSITIS SYNDROME; DEPRESSION; INTENSITY; EXERCISE; ANXIETY	Objective-To determine whether patients with the chronic fatigue syndrome have abnormalities of sleep which may contribute to daytime fatigue. Design-A case-control study of the sleep of patients with the chronic fatigue syndrome and that of healthy volunteers. Setting-An infectious disease outpatient clinic and subjects' homes. Subjects-12 patients who met research criteria for the chronic fatigue syndrome but not for major depressive disorder and 12 healthy controls matched for age, sex, and weight. Main outcome measures-Subjective reports of sleep from patients' diaries and measurement of sleep patterns by polysomnography. Subjects' anxiety, depression, and functional impairment were assessed by interview. Results-Patients with the chronic fatigue syndrome spent more time in bed than controls (544 min v 465 min, p < 0.001) but slept less efficiently (90% v 96%, p < 0.05) and spent more time awake after initially going to sleep (31.9 min v 16.6 min, p < 0.05). Seven patients with the chronic fatigue syndrome had a sleep disorder (four had difficulty maintaining sleep, one had difficulty getting to sleep, one had difficulty in both initiating and maintaining sleep, and one had hypersomnia) compared with none of the controls (p = 0.003). Those with sleep disorders showed greater functional impairment than the remaining five patients (score on general health survey 50.4% v 70.4%, p < 0.05), but their psychiatric scores were not significantly different. Conclusions-Most patients with the chronic fatigue syndrome had sleep disorders, which are likely to contribute to daytime fatigue. Sleep disorders may be important in the aetiology of the syndrome.	LITTLEMORE HOSP,MRC,CLIN PHARMACOL UNIT,OXFORD OX4 4XN,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND; UNIV HOSP S MANCHESTER,DEPT MED STAT,MANCHESTER M20 8LR,LANCS,ENGLAND	University of Oxford; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				sharpe, michael/0000-0002-6474-9980; Sharpley, Ann L/0000-0002-0623-1067; Morriss, Richard/0000-0003-2910-4121				ABBEY SE, 1990, CAN J PSYCHIAT, V35, P625, DOI 10.1177/070674379003500714; ARRIAGA F, 1990, BIOL PSYCHIAT, V27, P649, DOI 10.1016/0006-3223(90)90533-8; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; GARDNER MJ, 1989, STATISTICS CONFIDENC, P9; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; Horne J.A., 1991, SLEEP SLEEPINESS PER, P169; KENDELL RE, 1991, LANCET, V337, P160; KRUPP LB, 1991, J CLIN PSYCHIAT, V52, P403; KUPFER DJ, 1992, BRIT J PSYCHIAT, V161, P309, DOI 10.1192/bjp.161.3.309; Mackie R.R., 1977, VIGILANCE THEORY OPE; MCMURRAY RG, 1984, AVIAT SPACE ENVIR MD, V55, P1031; MOLDOFSKY H, 1989, Journal of Rheumatology, V16, P150; MOLDOFSKY H, 1975, PSYCHOSOM MED, V37, P341, DOI 10.1097/00006842-197507000-00008; MYLES WS, 1985, MED SCI SPORT EXER, V17, P580; NEYTA N, 1990, HUM PSYCHOPHARMACOL, V6, P173; REYNOLDS CF, 1987, SLEEP, V10, P199, DOI 10.1093/sleep/10.3.199; REYNOLDS CF, 1983, PSYCHIAT RES, V8, P81, DOI 10.1016/0165-1781(83)90094-X; SASKIN P, 1986, PSYCHOSOM MED, V48, P319, DOI 10.1097/00006842-198605000-00002; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SHARPLEY AL, 1988, SLEEP, V11, P273, DOI 10.1093/sleep/11.3.273; Spitzer RL, 1990, STRUCTURED CLIN INTE; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WHELTON CL, 1988, SLEEP RES, V17, P309; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1987, DIAGNOSTIC STATISTIC	26	87	89	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1161	1164		10.1136/bmj.306.6886.1161	http://dx.doi.org/10.1136/bmj.306.6886.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LA685	8499816	Green Published, Bronze			2022-12-28	WOS:A1993LA68500019
J	PFENNIG, DW; COLLINS, JP				PFENNIG, DW; COLLINS, JP			KINSHIP AFFECTS MORPHOGENESIS IN CANNIBALISTIC SALAMANDERS	NATURE			English	Article							AMBYSTOMA-TIGRINUM-NEBULOSUM; TIGER SALAMANDERS; COMPETITION	INCLUSIVE fitness theory predicts that organisms can often increase their fitness by helping relatives1. Indeed, many animals modify their behaviour towards kin in a fashion consistent with theory2-4. Morphogenesis may also be sensitive to kinship environment, especially in species that facultatively produce distinct morphs that differ in their ability to harm relatives, such as those that produce alternative cannibalistic and non-cannibalistic phenotypes5-9. We tested this hypothesis by examining whether consanguinity affected the probability that structurally distinctive cannibal morphs5,10 would develop in larval Arizona tiger salamanders (Ambystoma tigrinum nebulosum). We report here that when tiger salamander larvae are reared in mixed-brood groups they are significantly more likely to develop the cannibal morphology and at an earlier age than siblings reared in pure-sibship groups. In general, morphogenesis may be responsive to kinship in any species that facultatively develops structures that can be used against conspecifics as weaponry.	ARIZONA STATE UNIV,DEPT ZOOL,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe	PFENNIG, DW (corresponding author), CORNELL UNIV,NEUROBIOL & BEHAV SECT,MUDD HALL,ITHACA,NY 14853, USA.							ARMSTRONG JT, 1964, ECOLOGY, V45, P361, DOI 10.2307/1933849; COLLINS JP, 1983, AM ZOOL, V23, P77; COLLINS JP, 1984, CAN J ZOOL, V62, P168, DOI 10.1139/z84-027; CONOVER W. J, 1980, PRACTICAL NONPARAMET; CRESPI BJ, 1988, BEHAV ECOL SOCIOBIOL, V23, P93, DOI 10.1007/BF00299892; EMLEN ST, 1989, BEHAV ECOL SOCIOBIOL, V25, P303, DOI 10.1007/BF00302988; GILBERT JJ, 1973, SCIENCE, V181, P63, DOI 10.1126/science.181.4094.63; GODFRAY HCJ, 1987, AM NAT, V129, P221, DOI 10.1086/284632; GRBIC M, 1992, NATURE, V360, P254, DOI 10.1038/360254a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hepper PG., 1991, KIN RECOGNITION; JASIENSKI M, 1988, OECOLOGIA, V77, P407, DOI 10.1007/BF00378052; PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0; PARKER GA, 1989, AM NAT, V133, P846, DOI 10.1086/284956; PEDERSEN S C, 1991, Amphibia-Reptilia, V12, P1, DOI 10.1163/156853891X00275; PFENNIG DW, 1992, EVOLUTION, V46, P1408, DOI 10.1111/j.1558-5646.1992.tb01133.x; PFENNIG DW, 1991, OECOLOGIA, V88, P161, DOI 10.1007/BF00320806; POWERS JH, 1907, STUD U NEBRASKA, V7, P197; REILLY SM, 1992, COPEIA, P672, DOI 10.2307/1446142; ROSE FL, 1976, J ANIM ECOL, V45, P713, DOI 10.2307/3577; SHERMAN PW, 1981, BEHAV ECOL SOCIOBIOL, V8, P251, DOI 10.1007/BF00299523; Shvarts SS, 1970, SOV J ECOL, V1, P58; SMITH DC, 1990, EVOLUTION, V44, P1529, DOI 10.1111/j.1558-5646.1990.tb03844.x; TRAVIS J, 1980, EVOLUTION, V34, P40, DOI 10.1111/j.1558-5646.1980.tb04787.x; Waddell David R., 1992, P85; Waldman B., 1991, P162; WESTEBERHARD MJ, 1989, ANNU REV ECOL SYST, V20, P249, DOI 10.1146/annurev.es.20.110189.001341	27	93	97	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					836	838		10.1038/362836a0	http://dx.doi.org/10.1038/362836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479520				2022-12-28	WOS:A1993KZ56300055
J	KAMISAKO, T; ADACHI, Y; CHIHARA, J; YAMAMOTO, T				KAMISAKO, T; ADACHI, Y; CHIHARA, J; YAMAMOTO, T			INTERSTITIAL PNEUMONITIS AND INTERFERON-ALFA	BRITISH MEDICAL JOURNAL			English	Letter							HEPATITIS-C				KAMISAKO, T (corresponding author), KINKI UNIV,SCH MED,SAYAMA,OSAKA 589,JAPAN.							BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; GEDDES DM, 1976, BRIT MED J, V1, P1444, DOI 10.1136/bmj.1.6023.1444; KANAI K, 1990, LANCET, V336, P245, DOI 10.1016/0140-6736(90)91768-6	4	36	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					896	896		10.1136/bmj.306.6882.896-c	http://dx.doi.org/10.1136/bmj.306.6882.896-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490417	Bronze, Green Published			2022-12-28	WOS:A1993KW38700024
J	WALKER, J; YATHAM, LN				WALKER, J; YATHAM, LN			BENYLIN (DEXTROMETHORPHAN) ABUSE AND MANIA	BRITISH MEDICAL JOURNAL			English	Letter							HYDROBROMIDE; DEPENDENCE				WALKER, J (corresponding author), NOVA SCOTIA HOSP,DARTMOUTH,NS,CANADA.							DODDS A, 1967, MED J AUSTRALIA, V2, P231; FLEMING PM, 1986, BRIT MED J, V293, P597, DOI 10.1136/bmj.293.6547.597; GILLMAN AG, 1990, PHARMACOL BASIS THER, P518; LAMBERT MT, 1987, BRIT J PSYCHIAT, V151, P548, DOI 10.1192/bjp.151.4.548; LEIGHTON KM, 1982, BRIT MED J, V284, P789, DOI 10.1136/bmj.284.6318.789-a; MCCARTHY JP, 1971, MED J AUSTRALIA, V2, P1078, DOI 10.5694/j.1326-5377.1971.tb92714.x; ORRELL MW, 1986, BRIT MED J, V293, P1242, DOI 10.1136/bmj.293.6556.1242-d	7	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					896	896		10.1136/bmj.306.6882.896	http://dx.doi.org/10.1136/bmj.306.6882.896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KW387	8490415	Bronze, Green Published			2022-12-28	WOS:A1993KW38700021
J	PAPPAS, G; QUEEN, S; HADDEN, W; FISHER, G				PAPPAS, G; QUEEN, S; HADDEN, W; FISHER, G			THE INCREASING DISPARITY IN MORTALITY BETWEEN SOCIOECONOMIC GROUPS IN THE UNITED-STATES, 1960 AND 1986	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; EXCESS MORTALITY; SOCIAL-CLASS; DIFFERENTIALS; HEALTH; TRENDS; INEQUALITIES	Background. There is an inverse relation between socioeconomic status and mortality. Over the past several decades death rates in the United States have declined, but it is unclear whether all socioeconomic groups have benefited equally. Methods. Using records from the 1986 National Mortality Followback Survey (n = 13,491) and the 1986 National Health Interview Survey (n = 30,725), we replicated the analysis by Kitagawa and Hauser of differential mortality in 1960. We calculated direct standardized mortality rates and indirect standardized mortality ratios for persons 25 to 64 years of age according to race, sex, income, and family status. Results. The inverse relation between mortality and socioeconomic status persisted in 1986 and was stronger than in 1960. The disparity in mortality rates according to income and education increased for men and women, whites and blacks, and family members and unrelated persons. Over the 26-year period, the inequalities according to educational level increased for whites and blacks by over 20 percent in women and by over 1 00 percent in men. In whites, absolute death rates declined in persons of all educational levels, but the reduction was greater for men and women with more education than for those with less. Conclusions. Despite an overall decline in death rates in the United States since 1960, poor and poorly educated people still die at higher rates than those with higher incomes or better educations, and this disparity increased between 1960 and 1986.			PAPPAS, G (corresponding author), NATL CTR HLTH STAT,OFF PLANNING & EXTRAMURAL PROGRAMS,RM 1100,6525 BELCREST RD,HYATTSVILLE,MD 20782, USA.							[Anonymous], 1988, FUTURE PUBLIC HLTH; ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; Black D., 1982, BLACK REPORT; Davis K, 1978, HLTH WAR POVERTY 10; DULEEP HO, 1989, DEMOGRAPHY, V26, P345, DOI 10.2307/2061531; ENSTROM JE, 1983, BRIT MED J, V286, P1101, DOI 10.1136/bmj.286.6371.1101; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; HAAN MN, 1985, REPORT SECRETARYS TA, V2, P69; JENKINS CD, 1977, NEW ENGL J MED, V296, P1354, DOI 10.1056/NEJM197706092962315; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; Kleinman J C, 1990, Paediatr Perinat Epidemiol, V4, P373, DOI 10.1111/j.1365-3016.1990.tb00660.x; KOLONEL LN, 1977, AM J EPIDEMIOL, V106, P476, DOI 10.1093/oxfordjournals.aje.a112494; LAHELMA E, 1990, SOC SCI MED, V31, P257, DOI 10.1016/0277-9536(90)90272-T; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARSHALL J, 1980, AM J EPIDEMIOL, V112, P675, DOI 10.1093/oxfordjournals.aje.a113040; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; MISHEL L, 1991, STATE WORKING AM; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; Phillips Kevin P, 1990, POLITICS RICH POOR W; ROGERS RG, 1992, DEMOGRAPHY, V29, P287, DOI 10.2307/2061732; STAMLER J, 1981, AM J CARDIOL, V47, P722; STAMLER J, 1985, CARDIOLOGY, V72, P11, DOI 10.1159/000173836; Starfield B, 1985, EFFECTIVENESS MED CA; Susser MW, 1985, SOCIOLOGY MED; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; Townsend P, 1990, INEQUALITIES HLTH; VALKONEN T, 1987, EUROPEAN POPULATION; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; Whitehead, 1988, HLTH DIVIDE; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; Wilkinson RG, 1986, CLASS HLTH RES LONGI; WILLIAMS DR, 1990, SOC PSYCHOL QUART, V53, P81, DOI 10.2307/2786672; 1981, NIH822035 PUBL, V2, P265; 1991, DHHS PHS911101 NAT C, V2; 1985, VITAL HLTH STATIST 1, V18; 1990, MON VITAL STAT RE S2, V40; 1979, STAT B METROPOL LIFE, V60, P2	40	1018	1030	1	67	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					103	109		10.1056/NEJM199307083290207	http://dx.doi.org/10.1056/NEJM199307083290207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL196	8510686				2022-12-28	WOS:A1993LL19600007
J	YODER, MD; KEEN, NT; JURNAK, F				YODER, MD; KEEN, NT; JURNAK, F			NEW DOMAIN MOTIF - THE STRUCTURE OF PECTATE LYASE-C, A SECRETED PLANT VIRULENCE FACTOR	SCIENCE			English	Article							ERWINIA-CHRYSANTHEMI EC16; SOFT-ROT ERWINIAS; ESCHERICHIA-COLI; MOLECULAR-CLONING; GENES; PATHOGENESIS; EXPRESSION; RESOLUTION; REFINEMENT; ENZYMES	Pectate lyases are secreted by pathogens and initiate soft-rot diseases in plants by cleaving polygalacturonate, a major component of the plant cell wall. The three-dimensional structure of pectate lyase C from Erwinia chrysanthemi has been solved and refined to a resolution of 2.2 angstroms. The enzyme folds into a unique motif of parallel beta strands coiled into a large helix. Within the core, the amino acids form linear stacks and include a novel asparagine ladder. The sequence similarities that pectate lyases share with pectin lyases, pollen and style proteins, and tubulins suggest that the parallel beta helix motif may occur in a broad spectrum of proteins.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								BARRAS F, 1987, MOL GEN GENET, V209, P319, DOI 10.1007/BF00329660; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BUDELIER KA, 1990, MOL GEN GENET, V224, P183, DOI 10.1007/BF00271551; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CONDEMINE G, 1992, MOL MICROBIOL, V6, P3199, DOI 10.1111/j.1365-2958.1992.tb01775.x; CRAWFORD MS, 1987, ARCH BIOCHEM BIOPHYS, V258, P196, DOI 10.1016/0003-9861(87)90336-5; EVANS CH, 1990, BIOCH ELEMENTS, V8, P11; FARRELL K, UNPUB; GYSLER C, 1990, GENE, V89, P101, DOI 10.1016/0378-1119(90)90211-9; He S. Y., 1993, Biotechnology in plant disease control., P39; HE SY, 1990, J BACTERIOL, V172, P4988, DOI 10.1128/jb.172.9.4988-4995.1990; HE SY, 1991, P NATL ACAD SCI USA, V88, P1079, DOI 10.1073/pnas.88.3.1079; HE SY, 1991, J BACTERIOL, V173, P4310, DOI 10.1128/JB.173.14.4310-4317.1991; HINTON JCD, 1989, MOL MICROBIOL, V3, P1785, DOI 10.1111/j.1365-2958.1989.tb00164.x; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN NT, 1986, J BACTERIOL, V168, P595, DOI 10.1128/jb.168.2.595-606.1986; KEEN NT, 1984, J BACTERIOL, V159, P825, DOI 10.1128/JB.159.3.825-831.1984; KOTOUJANSKY A, 1987, ANNU REV PHYTOPATHOL, V25, P405, DOI 10.1146/annurev.py.25.090187.002201; KUSTERVANSOMERE.M, 1991, THESIS; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MANDELKOW EM, 1989, GUANINE NUCLEOTIDE B, V165, P385; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; PEROMBELON MCM, 1980, ANNU REV PHYTOPATHOL, V18, P361, DOI 10.1146/annurev.py.18.090180.002045; PRESTON JF, 1992, J BACTERIOL, V174, P2039, DOI 10.1128/jb.174.6.2039-2042.1992; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROGERS HJ, 1992, PLANT MOL BIOL, V20, P493, DOI 10.1007/BF00040608; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651; YODER MD, 1990, J BIOL CHEM, V265, P11429	39	383	400	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1503	1507		10.1126/science.8502994	http://dx.doi.org/10.1126/science.8502994			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502994				2022-12-28	WOS:A1993LF05800036
J	CHELAZZI, L; MILLER, EK; DUNCAN, J; DESIMONE, R				CHELAZZI, L; MILLER, EK; DUNCAN, J; DESIMONE, R			A NEURAL BASIS FOR VISUAL-SEARCH IN INFERIOR TEMPORAL CORTEX	NATURE			English	Article							SUPERIOR COLLICULUS; SINGLE UNITS; ATTENTION; FEATURES; NEURONS; MONKEY	WE often search for a face in a crowd or for a particular object in a cluttered environment. In this type of visual search, memory interacts with attention: the mediating neural mechanisms should include a stored representation of the object and a means for selecting that object from among others in the scene1-4. Here we test whether neurons in inferior temporal cortex, an area known to be important for high-level visual processing, might provide these components. Monkeys were presented with a complex picture (the cue) to hold in memory during a delay period. The cue initiated activity that persisted through the delay among the neurons that were tuned to its features. The monkeys were then given 2-5 choice pictures and were required to make an eye movement to the one (the target) that matched the cue. About 90-120 milliseconds before the onset of the eye movement to the target, responses to non-targets were suppressed and the neuronal response was dominated by the target. The results suggest that inferior temporal cortex is involved in selecting the objects to which we attend and foveate.	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND	University of Cambridge	CHELAZZI, L (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1E104,BETHESDA,MD 20892, USA.		Chelazzi, Leonardo/B-6084-2011; Miller, Earl K./AAE-8187-2019; Desimone, Robert/G-1121-2018	Chelazzi, Leonardo/0000-0001-8566-0611; Miller, Earl K./0000-0002-0582-6958; Duncan, John/0000-0002-9695-2764; Desimone, Robert/0000-0002-5938-4227				BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GIMCHER PW, 1992, NATURE, V355, P542; MILLER EK, 1993, J NEUROSCI, V13, P1460; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; NEISSER U, 1963, AM J PSYCHIAT, V76, P316; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P132, DOI 10.1152/jn.1987.57.1.132; SATO T, 1988, J NEUROPHYSIOL, V60, P344, DOI 10.1152/jn.1988.60.1.344; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	13	813	834	3	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					345	347		10.1038/363345a0	http://dx.doi.org/10.1038/363345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497317				2022-12-28	WOS:A1993LD91700051
J	FORD, AM; RIDGE, SA; CABRERA, ME; MAHMOUD, H; STEEL, CM; CHAN, LC; GREAVES, M				FORD, AM; RIDGE, SA; CABRERA, ME; MAHMOUD, H; STEEL, CM; CHAN, LC; GREAVES, M			INUTERO REARRANGEMENTS IN THE TRITHORAX-RELATED ONCOGENE IN INFANT LEUKEMIAS	NATURE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL; TWINS; GENE; TRANSLOCATIONS; ABNORMALITIES; EXPRESSION; CHILDREN	THE majority (approximately 75%) of infant acute leukaemias have a reciprocal translocation between chromosome 11q23 and one of several partner chromosomes1. The gene at 11q23 (named MLL, ALL-1, HRX or HTRX-1; refs 2-6) has been cloned and shares homology with the Drosophila developmental gene trithorax3-5. Rearrangements of this gene (called HRX here) occur in introns and cluster in a region of approximately 10 kb; individual patients have different breakpoints3-10. Here we describe three pairs of infant twins with concordant leukaemia who each share unique (clonal) but non-constitutive HRX rearrangements in their leukaemic cells, providing evidence that the leukaemogenic event originates in utero and unequivocal support for the intra-placental 'metastasis' hypothesis for leukaemia concordance in twins11.	UNIV CHILE, HAEMATOL SECT, SANTIAGO, CHILE; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, MEMPHIS COLL MED, MEMPHIS, TN 38101 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UNIV HONG KONG, QUEEN MARY HOSP COMPOUND, DEPT PATHOL, HONG KONG, HONG KONG	Universidad de Chile; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Edinburgh; University of Hong Kong	FORD, AM (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CTR LEUKAEMIA RES FUND, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND.							BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; CARTER M, 1991, LEUKEMIA, V5, P668; CHAGANTI RSK, 1979, NEW ENGL J MED, V300, P1032, DOI 10.1056/NEJM197905033001807; CHEN CS, IN PRESS BLOOD; CIMINO G, 1991, CANCER RES, V51, P6712; CLARKSON BD, 1971, LANCET, V1, P699; DEOLIVEIRA MSP, 1986, LANCET, V2, P969; DJABALI M, 1992, NAT GENET, V2, P112; DRAPER GJ, 1977, J MED GENET, V14, P81, DOI 10.1136/jmg.14.2.81; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARTLEY SE, 1981, HUM GENET, V58, P408, DOI 10.1007/BF00282824; HILTON HB, 1970, BLOOD-J HEMATOL, V35, P222, DOI 10.1182/blood.V35.2.222.222; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; Linet MS, 1985, LEUKEMIAS EPIDEMIOLO; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MILLER RW, 1971, J NATL CANCER I, V46, P203; MILLER RW, 1968, NEW ENGL J MED, V279, P122, DOI 10.1056/NEJM196807182790302; MORGAN GJ, 1992, BLOOD, V80, P2172; PRIGOGINA EL, 1979, HUM GENET, V53, P5, DOI 10.1007/BF00289443; PUI CH, 1992, LEUKEMIA LYMPHOMA, V7, P173, DOI 10.3109/10428199209053620; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; RUBIN CM, 1991, BLOOD, V78, P2982; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Strong S.J, 1967, PLACENTA TWIN PREGNA; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDENBERGHE H, 1979, HUM GENET, V46, P173, DOI 10.1007/BF00291919; YAMAMOTO K, 1993, ONCOGENE, V8, P479; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; ZUELZER WW, 1969, SEMIN HEMATOL, V228, P228	36	344	349	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					358	360		10.1038/363358a0	http://dx.doi.org/10.1038/363358a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497319				2022-12-28	WOS:A1993LD91700056
J	KRUPA, DJ; THOMPSON, JK; THOMPSON, RF				KRUPA, DJ; THOMPSON, JK; THOMPSON, RF			LOCALIZATION OF A MEMORY TRACE IN THE MAMMALIAN BRAIN	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; RED NUCLEUS; NEURONAL RESPONSES; CEREBELLAR NUCLEI; UNCONDITIONED STIMULUS; EYELID RESPONSE; LESIONS; RABBIT; ACQUISITION; STIMULATION	The localization of sites of memory formation within the brain has proven to be a formidable task even for simple forms of learning and memory. In order to localize a particular site of memory formation within the brain, the rabbit eyeblink response was classically conditioned while regions of the cerebellum or red nucleus were temporarily inactivated by microinfusions of the gamma-aminobutyric acid agonist muscimol. Cerebellar inactivation completely blocked learning but had no effect on subsequent learning after inactivation, whereas red nucleus inactivation did not prevent learning but did block the expression of conditioned responses. The site of memory formation for this learned response thus appears to be localized within the cerebellum.			KRUPA, DJ (corresponding author), UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089, USA.				NIA NIH HHS [AG05142] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005142] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CHAPMAN PF, 1988, BRAIN RES, V442, P97, DOI 10.1016/0006-8993(88)91436-9; CHAPMAN PF, 1990, BRAIN RES, V537, P149, DOI 10.1016/0006-8993(90)90351-B; CLARK GA, 1984, BRAIN RES, V291, P125, DOI 10.1016/0006-8993(84)90658-9; CLARK RE, 1993, BEHAV NEUROSCI, V107, P264, DOI 10.1037/0735-7044.107.2.264; CLARK RE, 1992, BEHAV NEUROSCI, V106, P879, DOI 10.1037/0735-7044.106.6.879; DISTERHOFT JF, 1985, J NEUROSCI, V5, P941; DONEGAN NH, 1983, SOC NEUR ABSTR, V9, P331; ECCLES JC, 1977, BRAIN RES, V127, P327, DOI 10.1016/0006-8993(77)90550-9; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; Ito M, 1984, CEREBELLUM NEURAL CO; KEATING J G, 1991, Society for Neuroscience Abstracts, V17, P1381; LAVOND DG, IN PRESS ANN REV PSY; LEWIS JL, 1987, BEHAV NEUROSCI, V101, P151, DOI 10.1037/0735-7044.101.2.151; LYE RH, 1988, J PHYSIOL-LONDON, V403, pP58; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARTIN JH, 1988, BEHAV BRAIN RES, V28, P217, DOI 10.1016/0166-4328(88)90099-X; MATSUMOTO RR, 1989, BRAIN RES REV, V14, P203, DOI 10.1016/0165-0173(89)90001-5; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; MCCORMICK DA, 1984, J NEUROSCI, V4, P2811; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MCCORMICK DA, 1985, BRAIN RES, V359, P120, DOI 10.1016/0006-8993(85)91419-2; MCCORMICK DA, 1982, BRAIN RES, V245, P347; MINK JW, 1991, J NEUROPHYSIOL, V65, P330, DOI 10.1152/jn.1991.65.2.330; NORDHOLM AF, IN PRESS BEHAV NEURO; ROSENFIELD ME, 1985, BEHAV BRAIN RES, V17, P77, DOI 10.1016/0166-4328(85)90010-5; ROSENFIELD ME, 1983, BEHAV BRAIN RES, V10, P393, DOI 10.1016/0166-4328(83)90043-8; ROSENFIELD ME, 1983, PHYSIOL BEHAV, V34, P751; Squire L. R., 1987, MEMORY BRAIN; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; STEINMETZ JE, 1987, P NATL ACAD SCI USA, V84, P3531, DOI 10.1073/pnas.84.10.3531; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; VANNEERVEN J, 1989, ARCH ITAL BIOL, V127, P243; VONEIDA T J, 1990, Society for Neuroscience Abstracts, V16, P270; WELSH JP, 1991, J PHYSIOL-LONDON, V444, P459, DOI 10.1113/jphysiol.1991.sp018888; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022	38	354	359	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					989	991		10.1126/science.8493536	http://dx.doi.org/10.1126/science.8493536			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493536				2022-12-28	WOS:A1993LB79100045
J	LANE, HA; FERNANDEZ, A; LAMB, NJC; THOMAS, G				LANE, HA; FERNANDEZ, A; LAMB, NJC; THOMAS, G			P70(S6K) FUNCTION IS ESSENTIAL FOR G1-PROGRESSION	NATURE			English	Article							PROTEIN-KINASE; RIBOSOMAL PROTEIN-S6; DEPENDENT PROTEIN; DNA-SYNTHESIS; MAP2 KINASE; S6 KINASE; RAT-LIVER; PHOSPHORYLATION; FIBROBLASTS; SERUM	AN essential step in the pathway by which growth factors trigger cellular proliferation is the induction of high levels of protein synthesis1-3. This appears in part to be controlled by multiple phosphorylation of the ribosomal protein S6 (refs 4, 5). The main kinase responsible, p70s6k (refs 6-8), is activated through the phosphorylation of four sites clustered in a putative autoinhibitory domain9, which is mediated by a signalling pathway distinct from those used by other well characterized mitogen-activated serine/threonine kinases (such as p42/p44mapk or p90rsk; refs 10, 11). Here we investigate the role of p70s6k in the mitogenic response. Microinjection of quiescent rat embryo fibroblasts with any of three distinct polyclonal antibodies to p70s6k abolishes serum-induced entry into S phase of the cell cycle. This effect is preceded by almost complete abrogation of the activation of protein synthesis and the expression of an essential immediate early gene product, c-fos. The inhibitory effect on DNA synthesis is also elicited by microinjection of the antibodies late in G1 phase, consistent with the finding that p70s6k activity remains high throughout G1.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND; CNRS, INSERM, F-34033 MONTPELLIER, FRANCE	Friedrich Miescher Institute for Biomedical Research; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERAMISCO JR, MICROINJECTION ORGAN, P39; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HARLOW E, 1988, ANTIBODIES LABORATOR; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1991, METHOD ENZYMOL, V200, P268; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	29	345	347	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1993	363	6425					170	172		10.1038/363170a0	http://dx.doi.org/10.1038/363170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483501				2022-12-28	WOS:A1993LB80100050
J	EGAN, SE; GIDDINGS, BW; BROOKS, MW; BUDAY, L; SIZELAND, AM; WEINBERG, RA				EGAN, SE; GIDDINGS, BW; BROOKS, MW; BUDAY, L; SIZELAND, AM; WEINBERG, RA			ASSOCIATION OF SOS RAS EXCHANGE PROTEIN WITH GRB2 IS IMPLICATED IN TYROSINE KINASE SIGNAL TRANSDUCTION AND TRANSFORMATION	NATURE			English	Article							ELEGANS VULVAR INDUCTION; GENE-TRANSFER; ONCOGENE; RECEPTOR; SEVENLESS; ENCODES; DROSOPHILA; PATHWAY; DOMAIN; LET-60	The proteins Grb2-Sem-5, Shc and Sos have been implicated in the signalling pathway from tyrosine kinase receptors to Ras. Grb2-Sem-5 binds directly to murine Sos1, a Ras exchange factor, through two SH3 domains. Sos is also associated with ligand-activated tyrosine kinase receptors which bind Grb2-Sem-5, and with the Grb2-Sem-5 binding protein, Shc. Ectopic expression of Drosophila Sos stimulates morphological transformation of rodent fibroblasts. These data define a pathway by which tyrosine kinases act through Ras to control cell growth and differentiation.	MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Cancer Research UK			Franzeck, Fabian C/B-5055-2011					AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARLAT I, 1993, ONCOGENE, V8, P215; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, IN PRESS CELL; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARLOW E, 1988, ANTIBODIES LABORATOR; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513	46	1185	1221	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					45	51		10.1038/363045a0	http://dx.doi.org/10.1038/363045a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479536				2022-12-28	WOS:A1993LA68200051
J	KINLEN, LJ; CLARKE, K; BALKWILL, A				KINLEN, LJ; CLARKE, K; BALKWILL, A			PATERNAL PRECONCEPTIONAL RADIATION EXPOSURE IN THE NUCLEAR INDUSTRY AND LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN YOUNG-PEOPLE IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD LEUKEMIA	Objective-To determine if a relation exists between paternal exposure to relatively high levels of radiation in the Scottish nuclear industry and the risk of leukaemia and non-Hodgkin's lymphoma in subsequently conceived children. Design-Matched case-control study with three controls for each case. Setting-The whole of Scotland. Subjects-The fathers of 1024 children with leukaemia and 237 children with non-Hodgkin's lymphoma diagnosed in Scotland below the age of 25 among those born in Scotland since nuclear operations began (in 1958) and the fathers of 3783 randomly chosen controls. The fathers of 80 children with leukaemia and 16 with non-Hodgkin's lymphoma in north Cumbria were also covered since some workers at one Scottish nuclear site live over the border in that area. Details of all fathers were then matched against records of the nuclear industry. Main outcome measures-Paternal preconceptional radiation exposures, particularly relatively high levels, both lifetime and in the six and three months before conception. Results-No significant excess was observed in any subgroup and there was no significant trend: fathers of three controls but no cases were exposed to lifetime preconceptional levels of 100 mSv or greater (Fisher's exact p value 0.84). In the six months before conception, fathers of two cases and three controls received 10 mSv or more, odds ratio 2.3 (95% confidence interval 0.31 to 17.24). In the three months before conception the fathers of one case and two controls received 5 mSv or more, odds ratio 1.7 (0.10 to 30.76). The results for leukaemia and non-Hodgkin's lymphoma combined were similar. Conclusion-No significant excess of leukaemia or of leukaemia and non-Hodgkin's lymphoma was found at any radiation level in any preconceptional period.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,EPIDEMIOL,OXFORD OX2 6HE,ENGLAND.			Balkwill, Angela/0000-0002-6327-6245				Breslow N, 1980, STATISTICAL METHODS, V32; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; DRAPER GJ, 1992, RADIOLOGICAL PROTECT, V129, P10; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KENDALL GM, 1988, NRPBR219; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1990, BRIT MED J, V300, P677, DOI 10.1136/bmj.300.6725.677-a; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1993, IN PRESS BMJ; MCLAUGHLIN JR, 1992, INFO0424 RES REP; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; 1991, ICRP60 INT COMM RAD; 1991, EGRET	18	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1153	1158		10.1136/bmj.306.6886.1153	http://dx.doi.org/10.1136/bmj.306.6886.1153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499814	Bronze, Green Published			2022-12-28	WOS:A1993LA68500017
J	RAYNOR, DK; BOOTH, TG; BLENKINSOPP, A				RAYNOR, DK; BOOTH, TG; BLENKINSOPP, A			EFFECTS OF COMPUTER-GENERATED REMINDER CHARTS ON PATIENTS COMPLIANCE WITH DRUG REGIMENS	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; DISCHARGE	Objective To investigate whether a reminder chart improved patients' compliance with their drug regimen after discharge from hospital. Design-Patients were randomly allocated to one of four groups. Two groups received the reminder chart: one also received routine counselling from a nurse and the other received structured counselling from a pharmacist, which included an explanation of the reminder chart. The other two groups received only counselling, either from a nurse or from a pharmacist. Patients were visited about 10 days later: they were questioned about their drug regimen, and their compliance was measured by tablet counting. Setting-The pharmacy in a district general hospital and patients' homes. Patients-197 patients being discharged from hospital who were regularly taking two or more drugs. Intervention-An individualised reminder chart, which listed each person's medicines and when they were to be taken and was automatically generated by a medicine labelling computer. Main outcome measures-Patient's compliance with and knowledge of their drug regimen. Main results-Of the patients who received the reminder chart, 83% (95% confidence interval 74% to 90%) correctly described their dose regimen compared with 47% (37% to 58%) of those without the chart (p < 0.001). The mean compliance score was 86% (81% to 91%) in both groups not given the reminder chart; 91% (87% to 94%) in the group given the chart without an explanation; and 95% (93% to 98%) in the group given the chart and an explanation. A mean compliance score of > 85% was achieved by 63% (53% to 73%) of patients without a reminder chart and by 86% (78% to 93%) of those receiving the chart (p < 0.001). Conclusions-An automatically generated reminder chart is a practical and cost effective aid to compliance.	KILLINGBECK HOSP,LEEDS LS14 6UH,ENGLAND; UNIV BRADFORD,PHARM PRACTICE RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND; UNIV MANCHESTER,CTR PHARM POSTGRAD EDUC,MANCHESTER M60 7LP,ENGLAND	University of Bradford; University of Manchester	RAYNOR, DK (corresponding author), SEACROFT HOSP,DEPT PHARM,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				ELLIS DA, 1979, BRIT MED J, V1, P456, DOI 10.1136/bmj.1.6161.456; GARDNER MJ, 1989, CONFIDENCE INTERVAL; HALLWORTH RB, 1984, BR J PHARM PRACT, V6, P42; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Raynor DK, 1992, INT J PHARM PRACT, V1, P126; RAYNOR DK, 1991, THESIS U BRADFORD; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; SANDLER DA, 1989, BRIT MED J, V299, P1511, DOI 10.1136/bmj.299.6714.1511; Sweeney SJ, 1989, PHARM J, V242; 1989, DISCHARGE PATIENTS H; 1988, PHARM J, V240, P252	13	83	85	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1158	1161		10.1136/bmj.306.6886.1158	http://dx.doi.org/10.1136/bmj.306.6886.1158			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499815	Green Published, Bronze			2022-12-28	WOS:A1993LA68500018
J	MCELVANNEY, AM; FIELDER, AR				MCELVANNEY, AM; FIELDER, AR			LESSON OF THE WEEK - INTRAOCULAR FOREIGN-BODY MISSED BY RADIOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article							OCULAR INJURIES; BODIES				MCELVANNEY, AM (corresponding author), BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,ENGLAND.							BENSON WE, 1991, DUANES CLIN OPHTHALM, V5, P1; BRAY L C, 1991, Eye (London), V5, P751; BRYDEN FM, 1990, EYE, V4, P727, DOI 10.1038/eye.1990.103; DELACEY G, 1985, BRIT J RADIOL, V58, P27, DOI 10.1259/0007-1285-58-685-27; MIELER WF, 1990, OPHTHALMOLOGY, V97, P1532; PERCIVAL SP, 1972, BRIT J OPHTHALMOL, V56, P454, DOI 10.1136/bjo.56.6.454; SHOCK JP, 1985, AM J OPHTHALMOL, V100, P714, DOI 10.1016/0002-9394(85)90628-2; WILLIAMS DF, 1988, OPHTHALMOLOGY, V95, P911; WILLIAMS DF, 1990, RETINA-J RET VIT DIS, V10, pS45, DOI 10.1097/00006982-199010001-00007; ZINREICH SJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P1477	10	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1060	1061		10.1136/bmj.306.6884.1060	http://dx.doi.org/10.1136/bmj.306.6884.1060			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490508	Green Published, Bronze			2022-12-28	WOS:A1993KY44800033
J	KEIL, JE; SUTHERLAND, SE; KNAPP, RG; LACKLAND, DT; GAZES, PC; TYROLER, HA				KEIL, JE; SUTHERLAND, SE; KNAPP, RG; LACKLAND, DT; GAZES, PC; TYROLER, HA			MORTALITY-RATES AND RISK-FACTORS FOR CORONARY-DISEASE IN BLACK AS COMPARED WITH WHITE MEN AND WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; POPULATIONS	Background. Currently recognized risk factors for coronary artery disease have been identified primarily from investigations of white populations. In this investigation, we estimated mortality rates for coronary disease and for any cause and identified risk factors for death from coronary disease among whites and blacks. Methods. Data collected over a 30-year period in the Charleston Heart Study were used to estimate mortality rates and quantify associations with risk factors assessed at the base-line examination in 1960 and 1961 of 653 white men, 333 black men, 741 white women, and 454 black women. Results. There were no significant racial differences in the rate ratios for death from coronary disease; however, women had significantly lower death rates than men. Over the 30-year period, the mortality rates for coronary disease per 1000 person-years were 5.2 for white men (95 percent confidence interval, 4.1 to 6.3), 4.6 for black men (3.0 to 6.2), 2:1 for white women (1.6 to 2.6), and 3.2 for black women (2.3 to 4.0). Significant, or nearly significant, predictors of mortality due to coronary disease were systolic blood pressure in all four groups; serum cholesterol level among white men, white women, and black women; and smoking among white men, white women, and black men. Although the difference was not statistically significant, the risk of death from coronary disease was consistently increased among diabetics in all four groups. A higher level of education was predictive of lower rates of death due to coronary disease among white men and black women. For all causes of death taken together, the rates for blacks were higher than the rates for whites. The presence of hypertension, a history of smoking, and a history of diabetes were significant or nearly significant predictors of mortality from any cause in all four groups. Conclusions. Although the rates of death from coronary disease were somewhat lower among black men than white men and higher among black women than white women, the black:white mortality rate ratios were not statistically significant, and the major risk factors for mortality from coronary disease were similar in blacks and whites in the 30-year follow-up of the Charleston Heart Study.	UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	KEIL, JE (corresponding author), MED UNIV S CAROLINA,CHARLESTON HEART STUDY,RM 908,HARBORVIEW OFF TOWERS,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031397] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL31397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGSTRALH EJ, 1986, 11TH P ANN SAS US GR, P868; BOYLE EDWIN, 1967, P193; CASSEL J, 1971, ARCH INTERN MED, V128, P901, DOI 10.1001/archinte.128.6.901; COMSTOCK GW, 1957, AM J HYG, V65, P271, DOI 10.1093/oxfordjournals.aje.a119870; Cooper R S, 1991, Cardiovasc Clin, V21, P205; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; Gillum R F, 1991, Cardiovasc Clin, V21, P3; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEIL JE, 1984, AM HEART J, V108, P779, DOI 10.1016/0002-8703(84)90671-9; KNAPP RG, 1992, J CLIN EPIDEMIOL, V45, P1119, DOI 10.1016/0895-4356(92)90152-D; MCDONOUGH JR, 1965, J CHRON DIS, V18, P443, DOI 10.1016/0021-9681(65)90027-5; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; Peery TM, 1939, ARCH INTERN MED, V64, P971, DOI 10.1001/archinte.1939.00190050077006; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; SO Y, 1991, 1991 P SAS US GROUP, P1; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486	21	217	225	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					73	78		10.1056/NEJM199307083290201	http://dx.doi.org/10.1056/NEJM199307083290201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510705				2022-12-28	WOS:A1993LL19600001
J	ROA, BB; GARCIA, CA; SUTER, U; KULPA, DA; WISE, CA; MUELLER, J; WELCHER, AA; SNIPES, GJ; SHOOTER, EM; PATEL, PI; LUPSKI, JR				ROA, BB; GARCIA, CA; SUTER, U; KULPA, DA; WISE, CA; MUELLER, J; WELCHER, AA; SNIPES, GJ; SHOOTER, EM; PATEL, PI; LUPSKI, JR			CHARCOT-MARIE-TOOTH DISEASE TYPE-1A - ASSOCIATION WITH A SPONTANEOUS POINT MUTATION IN THE PMP22 GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERKALEMIC PERIODIC PARALYSIS	Background. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy. CMT type 1A is associated with a 1.5-megabase (Mb) DNA duplication in region p11.2-p12 of chromosome 17 in most patients. An increased dosage of a gene within the duplicated segment appears to cause the disease. The PMP22 gene, which encodes a myelin protein, has been mapped within the duplication and proposed as a candidate gene for CMT type 1A. Methods. We analyzed DNA samples from a cohort of 32 unrelated patients with CMT type 1 who did not have the 1.5-Mb tandem duplication in 17p11.2-p12 for mutations within the PMP22 coding region. Molecular techniques included the polymerase chain reaction (PCR), heteroduplex analysis to detect point mutations, and direct nucleotide-sequence determination of amplified PCR products. Results. A 10-year-old boy was identified with a point mutation in PMP22, which resulted in the substitution of cysteine for serine in a putative transmembrane domain of PMP22. Analysis of family members revealed that the PMP22 point mutation arose spontaneously and segregated with the CMT type 1 phenotype in an autosomal dominant pattern. The patients with the PMP22 point mutation had clinical and electrophysiologic phenotypes that were similar to those of patients with the 1.5-Mb duplication. Conclusions. The PMP22 gene has a causative role in CMT type 1. Either a point mutation in PMP22 or a duplication of the region including the PMP22 gene can result in the disease phenotype.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT NEUROL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; SWISS FED INST TECHNOL,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Louisiana State University System; Louisiana State University System; Stanford University; Stanford University; Swiss Federal Institutes of Technology Domain; ETH Zurich			Kulpa, Deanna A/O-5016-2019; Suter, Ueli/A-1624-2010; Kulpa, Deanna/ABE-2035-2020; Patel, Pragna/H-9129-2017	Kulpa, Deanna A/0000-0002-0411-7295; Patel, Pragna/0000-0003-3584-1072; Wise, Carol/0000-0002-6790-2194				BELLONE E, 1992, J MED GENET, V29, P492; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; Charcot JM, 1886, REV MED-PARIS, V6, P97; DYCK PJ, 1992, PERIPHERAL NEUROPATH, V2, P1094; HALLAM PJ, 1992, ANN NEUROL, V31, P570, DOI 10.1002/ana.410310518; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; KAKU DA, IN PRESS NEUROLOGY; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LUPSKI JR, 1993, AM J MED GENET, V45, P92, DOI 10.1002/ajmg.1320450122; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1992, CLIN RES, V40, P645; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1992, BRAIN PATHOL, V2, P337, DOI 10.1111/j.1750-3639.1992.tb00710.x; LUPSKI JR, 1991, CURRENT NEUROLOGY, V11, P1; MACMILLAN JC, 1992, J MED GENET, V29, P12, DOI 10.1136/jmg.29.1.12; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P769; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P211; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, IN PRESS PHENOTYPIC; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SKRE H, 1974, CLIN GENET, V6, P98; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; Tooth HH, 1886, PERONEAL TYPE PROGRE; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	44	309	321	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					96	101		10.1056/NEJM199307083290205	http://dx.doi.org/10.1056/NEJM199307083290205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510709				2022-12-28	WOS:A1993LL19600005
J	MCLACHLAN, EM; JANIG, W; DEVOR, M; MICHAELIS, M				MCLACHLAN, EM; JANIG, W; DEVOR, M; MICHAELIS, M			PERIPHERAL-NERVE INJURY TRIGGERS NORADRENERGIC SPROUTING WITHIN DORSAL-ROOT GANGLIA	NATURE			English	Article							SENSORY NEURONS; RAT; NORADRENALINE; MODES; CAT	IN humans, trauma to a peripheral nerve may be followed by chronic pain syndromes which are only relieved by blockade of the effects of sympathetic impulse traffic1-4. It is presumed that, after the lesion, noradrenaline released by activity of sympathetic postganglionic axons excites primary afferent neurons by activating alpha-adrenoceptors2,5, generating signals that enter the 'pain pathways' of the central nervous system. The site of coupling is unclear. In some patients local anaesthesia of the relevant peripheral nerve6 does not alleviate pain, implying that ectopic impulses arise either within the central nervous system, or in proximal parts of the primary afferent neurons. In experimentally lesioned rats, activity can originate within the dorsal root ganglia7,8. Here we report that, after sciatic nerve ligation, noradrenergic perivascular axons in rats sprout into dorsal root ganglia and form basket-like structures around large-diameter axotomized sensory neurons; sympathetic stimulation can activate such neurons repetitively. These unusual connections provide a possible origin for abnormal discharge following peripheral nerve damage. Further, in contrast to the sprouting of intact nerve terminals into nearby denervated effector tissues in skin9,10, muscle11, sympathetic ganglia12 and sweat glands13, the axons sprout into a target which has not been-partially denervated.	CHRISTIAN ALBRECHTS UNIV KIEL,INST PHYSIOL,W-2300 KIEL 1,GERMANY; HEBREW UNIV JERUSALEM,INST ORAL HLTH RES,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL	University of Kiel; Hebrew University of Jerusalem	MCLACHLAN, EM (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		McLachlan, Elspeth M/A-1844-2013	McLachlan, Elspeth M/0000-0003-0755-8747				AKASU T, 1985, J PHYSIOL-LONDON, V361, P165, DOI 10.1113/jphysiol.1985.sp015639; Bonica J.J., 1990, MANAGEMENT PAIN, P220; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CRUTCHER KA, 1982, BRAIN RES BULL, V9, P501, DOI 10.1016/0361-9230(82)90158-7; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DEVOR M, 1990, J NEUROPHYSIOL, V64, P1733, DOI 10.1152/jn.1990.64.6.1733; DEVOR M, 1979, J COMP NEUROL, V185, P211, DOI 10.1002/cne.901850113; DIAMOND J, 1992, J NEUROSCI, V12, P1454; FUKUDA A, 1987, J PHYSIOL-LONDON, V393, P213, DOI 10.1113/jphysiol.1987.sp016820; GOLDSTEIN RS, 1988, NEUROSCI LETT, V94, P58, DOI 10.1016/0304-3940(88)90270-4; JANIG W, 1984, J COMP NEUROL, V225, P302, DOI 10.1002/cne.902250213; JANIG W, 1992, REFLEX SYMPATHETIC D; Janig W, 1990, PAIN SYMPATHETIC NER, P17; JOBLING P, 1992, J PHYSIOL-LONDON, V454, P107, DOI 10.1113/jphysiol.1992.sp019256; KENNEDY WR, 1984, ANN NEUROL, V15, P73, DOI 10.1002/ana.410150114; KOLSTON J, 1991, NEUROSCI LETT, V130, P187, DOI 10.1016/0304-3940(91)90393-8; KUMMER W, 1990, CELL TISSUE RES, V261, P595, DOI 10.1007/BF00313540; MAEHLEN J, 1981, J PHYSIOL-LONDON, V319, P555, DOI 10.1113/jphysiol.1981.sp013926; MORRIS JL, 1989, INT J DEV NEUROSCI, V7, P521, DOI 10.1016/0736-5748(89)90011-7; ROTSHENKER S, 1988, TRENDS NEUROSCI, V11, P363, DOI 10.1016/0166-2236(88)90059-8; SCHMALBRUCH H, 1987, ANAT REC, V219, P323, DOI 10.1002/ar.1092190314; SHIR Y, 1991, PAIN, V45, P309, DOI 10.1016/0304-3959(91)90056-4; SMALL JR, 1990, J NEUROL SCI, V100, P98, DOI 10.1016/0022-510X(90)90019-J; Sunderland S., 1978, NERVES NERVE INJURIE; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WALL PD, 1983, PAIN, V17, P321, DOI 10.1016/0304-3959(83)90164-1; WILLIS WJD, 1992, HYPERALGESIA ALLODYN; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; YOSHIMURA M, 1987, BRAIN RES, V414, P138, DOI 10.1016/0006-8993(87)91334-5; [No title captured]	30	581	608	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					543	546		10.1038/363543a0	http://dx.doi.org/10.1038/363543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505981				2022-12-28	WOS:A1993LF93900050
J	FINNEY, RE; BISHOP, JM				FINNEY, RE; BISHOP, JM			PREDISPOSITION TO NEOPLASTIC TRANSFORMATION CAUSED BY GENE REPLACEMENT OF H-RAS1	SCIENCE			English	Article							BLADDER-CARCINOMA ONCOGENE; EMBRYONIC STEM-CELLS; HA-RAS ONCOGENE; MALIGNANT ACTIVATION; POINT MUTATIONS; LUNG-CARCINOMA; EXPRESSION; HARVEY; CARCINOGENESIS; TUMORIGENICITY	Homologous recombination was used to introduce a nominally transforming mutation into an endogenous H-ras1 gene in Rat1 fibroblasts. Although both the mutant and the remaining normal allele were expressed equally, the heterozygous cells were not neoplastically transformed. Instead, spontaneously transformed cells arose from the heterozygotes at a low frequency, and the majority of these cells had amplified the mutant allele. Thus, the activated H-ras1 allele was not by itself dominant over the normal allele but predisposed cells to transformation by independent events, such as amplification of the mutant allele.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FINNEY, RE (corresponding author), UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,BOX 0552,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA 44338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CUNHA GR, 1991, DEVELOPMENT, V111, P145; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; FINNEY RE, UNPUB; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; Luria SE, 1943, GENETICS, V28, P491; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PICARD D, 1985, EMBO J, V4, P2831, DOI 10.1002/j.1460-2075.1985.tb04011.x; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	32	119	123	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1524	1527		10.1126/science.8502998	http://dx.doi.org/10.1126/science.8502998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502998				2022-12-28	WOS:A1993LF05800043
J	KAISER, D; LOSICK, R				KAISER, D; LOSICK, R			HOW AND WHY BACTERIA TALK TO EACH OTHER	CELL			English	Review							FRUITING BODY MORPHOGENESIS; CELL-CELL-INTERACTIONS; FISCHERI LUXR PROTEIN; BLUE-GREEN-ALGA; BACILLUS-SUBTILIS; VIBRIO-FISCHERI; ENTEROCOCCUS-FAECALIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; SEX-PHEROMONE		HARVARD UNIV,BIOL LABS,CAMBRIDGE,MA 02138	Harvard University	KAISER, D (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							BAINTON NJ, 1992, GENE, V116, P87, DOI 10.1016/0378-1119(92)90633-Z; BEPPU T, 1992, GENE, V115, P159, DOI 10.1016/0378-1119(92)90554-3; BIRO S, 1980, EUR J BIOCHEM, V103, P359, DOI 10.1111/j.1432-1033.1980.tb04322.x; BOYLAN M, 1989, J BIOL CHEM, V264, P1915; BROTMAN H, 1983, NYT MAG         0515, P106; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; BUIKEMA WJ, 1991, GENE DEV, V5, P321, DOI 10.1101/gad.5.2.321; BUIKEMA WJ, 1993, INPRESS ANN REV PLAN, V44; BYERS D, 1984, J BIOL CHEM, V259, P7109; CAO JG, 1989, J BIOL CHEM, V264, P21670; CHATER KF, 1993, IN PRESS ANN REV MIC; CLEWELL DB, 1989, PLASMID, V21, P175, DOI 10.1016/0147-619X(89)90041-3; CLEWELL DB, 1982, MICROBIOLOGY 1982, P97; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DEVINE JH, 1988, BIOCHEMISTRY-US, V27, P837, DOI 10.1021/bi00402a052; DUNNY GM, 1990, MOL MICROBIOL, V4, P689, DOI 10.1111/j.1365-2958.1990.tb00639.x; DUNNY GM, 1978, P NATL ACAD SCI USA, V75, P3479, DOI 10.1073/pnas.75.7.3479; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455; EHRENFELD EE, 1986, J BACTERIOL, V168, P6, DOI 10.1128/jb.168.1.6-12.1986; ELHAI J, 1990, EMBO J, V9, P3379, DOI 10.1002/j.1460-2075.1990.tb07539.x; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Engebrecht J, 1986, GENET ENG, V8, P31; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GALLI D, 1992, MOL MICROBIOL, V6, P1297, DOI 10.1111/j.1365-2958.1992.tb00851.x; GALLI D, 1989, ARCH MICROBIOL, V151, P486, DOI 10.1007/BF00454863; GALLI D, 1990, MOL MICROBIOL, V4, P895, DOI 10.1111/j.1365-2958.1990.tb00662.x; GOLDEN JW, 1985, NATURE, V314, P419, DOI 10.1038/314419a0; GOLDEN JW, 1988, J BACTERIOL, V170, P5034, DOI 10.1128/jb.170.11.5034-5041.1988; GROSSMAN AD, 1988, P NATL ACAD SCI USA, V85, P4369, DOI 10.1073/pnas.85.12.4369; GUIJARRO J, 1988, J BACTERIOL, V170, P1895, DOI 10.1128/jb.170.4.1895-1901.1988; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAGEN TJ, 1990, J BACTERIOL, V172, P15, DOI 10.1128/JB.172.1.15-23.1990; HOLLAND D, 1990, J BACTERIOL, V172, P3131, DOI 10.1128/jb.172.6.3131-3137.1990; HORINOUCHI S, 1992, GENE, V115, P167, DOI 10.1016/0378-1119(92)90555-4; HORINOUCHI S, 1990, CRIT REV BIOTECHNOL, V10, P191, DOI 10.3109/07388559009038207; JONAS RM, 1989, J BACTERIOL, V171, P5226, DOI 10.1128/jb.171.9.5226-5228.1989; KAPLAN HB, 1987, P NATL ACAD SCI USA, V84, P6639, DOI 10.1073/pnas.84.19.6639; KHOKHLOV AS, 1973, Z ALLG MIKROBIOL, V13, P647, DOI 10.1002/jobm.3630130803; KHOKHLOV AS, 1985, 6TH P INT S ACT BIOL, P791; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; KIM SK, 1990, SCIENCE, V249, P926, DOI 10.1126/science.2118274; KIM SK, 1990, GENE DEV, V4, P896, DOI 10.1101/gad.4.6.896; KROOS L, 1987, GENE DEV, V1, P840, DOI 10.1101/gad.1.8.840; KUNER JM, 1982, J BACTERIOL, V151, P458, DOI 10.1128/JB.151.1.458-461.1982; KUSPA A, 1992, J BACTERIOL, V174, P7360, DOI 10.1128/jb.174.22.7360-7369.1992; KUSPA A, 1992, J BACTERIOL, V174, P3319, DOI 10.1128/jb.174.10.3319-3326.1992; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LIANG J, 1992, P NATL ACAD SCI USA, V89, P5655, DOI 10.1073/pnas.89.12.5655; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MCCANN PA, 1979, J ANTIBIOT, V32, P673, DOI 10.7164/antibiotics.32.673; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MINTZ B, 1974, ANNU REV GENET, V8, P411, DOI 10.1146/annurev.ge.08.120174.002211; MORI M, 1988, J BIOL CHEM, V263, P14574; NEALSON KH, 1979, MICROBIOL REV, V43, P496, DOI 10.1128/MMBR.43.4.496-518.1979; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PETTERS RM, 1980, J HERED, V71, P70; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; PLAMANN L, 1992, J BACTERIOL, V174, P3311, DOI 10.1128/jb.174.10.3311-3318.1992; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; RUBY EG, 1992, J BACTERIOL, V174, P4865, DOI 10.1128/JB.174.15.4865-4870.1992; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SAGER B, 1993, P NATL ACAD SCI USA, V90, P3690, DOI 10.1073/pnas.90.8.3690; Saxen L., 1976, CELL SURFACE ANIMAL, P331; SHADEL GS, 1992, J BIOL CHEM, V267, P7696; SHADEL GS, 1991, J BACTERIOL, V173, P568, DOI 10.1128/jb.173.2.568-574.1991; SHADEL GS, 1990, J BIOLUM CHEMILUM, V5, P99, DOI 10.1002/bio.1170050205; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SHAPIRO JA, 1989, J BACTERIOL, V171, P5975, DOI 10.1128/jb.171.11.5975-5986.1989; SHAPIRO JA, 1989, J BACTERIOL, V171, P5963, DOI 10.1128/jb.171.11.5963-5974.1989; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STRAGIER P, 1992, PROKARYOTIC STRUCTUR, P297; TROTTER KM, 1990, PLASMID, V24, P57, DOI 10.1016/0147-619X(90)90025-8; WEAVER KE, 1990, J BACTERIOL, V172, P2633, DOI 10.1128/jb.172.5.2633-2641.1990; WILCOX M, 1973, J CELL SCI, V13, P637; WILCOX M, 1973, J CELL SCI, V12, P707; WILLEY J, 1993, GENE DEV, V7, P895, DOI 10.1101/gad.7.5.895; WILLEY J, 1991, CELL, V65, P641, DOI 10.1016/0092-8674(91)90096-H; Wolk CP, 1991, CURR OPIN GENET DEV, V1, P336; WOLK CP, 1993, MOL MICROBIOL, V7, P441, DOI 10.1111/j.1365-2958.1993.tb01135.x; WOLK CP, 1989, PLANT SYST EVOL, V164, P27, DOI 10.1007/BF00940427; WOLK CP, 1967, P NATL ACAD SCI USA, V57, P1246, DOI 10.1073/pnas.57.5.1246	94	199	205	2	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					873	885		10.1016/0092-8674(93)90268-U	http://dx.doi.org/10.1016/0092-8674(93)90268-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500179	Bronze			2022-12-28	WOS:A1993LF06100006
J	NICCHITTA, CV; BLOBEL, G				NICCHITTA, CV; BLOBEL, G			LUMENAL PROTEINS OF THE MAMMALIAN ENDOPLASMIC-RETICULUM ARE REQUIRED TO COMPLETE PROTEIN TRANSLOCATION	CELL			English	Article							DISULFIDE-ISOMERASE; SECRETORY PROTEINS; ROUGH MICROSOMES; DOCKING PROTEIN; DOG PANCREAS; BINDING-PROTEIN; ALPHA-FACTOR; MEMBRANES; YEAST; ATP	The role of the lumenal contents (reticuloplasm) of the endoplasmic reticulum (ER) in protein translocation was determined by in vitro analysis. Depletion of the reticuloplasm from mammalian rough microsomes revealed two distinct stages of the translocation reaction. The first stage, translocation up to and including signal peptide cleavage, was insensitive to the loss of the reticuloplasm, whereas the second stage, net transfer of the nascent chain into the ER lumen, was reticuloplasm dependent. In reticuloplasm-depleted membranes, signal-cleaved and glycosylated translocation intermediates were observed to transit free from the translocation channel to the cis, or cytoplasmic, side of the membrane. This translocation defect was complemented by reconstitution of lumenal proteins into depleted membranes. We propose that lumenal proteins are necessary for unidirectional protein translocation in mammalian ER.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANG D, 1991, J BIOL CHEM, V266, P24233; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FEYNMAN RP, 1963, FEYNMAN LECTURES PHY; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOCH GLE, 1987, J CELL SCI, V87, P491; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STADDON JM, 1992, J BIOL CHEM, V267, P25239; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931; ZIMMERMAN DL, 1990, J BIOL CHEM, V265, P4048	52	161	161	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					989	998		10.1016/0092-8674(93)90276-V	http://dx.doi.org/10.1016/0092-8674(93)90276-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500184	Bronze			2022-12-28	WOS:A1993LF06100014
J	VONAHSEN, U; NOLLER, HF				VONAHSEN, U; NOLLER, HF			FOOTPRINTING THE SITES OF INTERACTION OF ANTIBIOTICS WITH CATALYTIC GROUP-I INTRON RNA	SCIENCE			English	Article							16S RIBOSOMAL-RNA; BINDING-SITE; TETRAHYMENA RIBOZYME; CHEMICAL PROBES; SEQUENCE; STREPTOMYCIN; NUCLEOTIDES; SUBSTRATE	Aminoglycoside inhibitors of translation have been shown previously to inhibit in vitro self-splicing by group I introns. Chemical probing of the phage T4-derived sunY intron shows that neomycin, streptomycin, and elated antibiotics protected the N-7 position of G96, a universally conserved guanine in the binding site for the guanosine cofactor in the splicing reaction. The antibiotics also disrupted structural contacts that have been proposed to bring the 5' cleavage site of the intron into proximity to the catalytic core. In contrast, the strictly competitive inhibitors deoxyguanosine and arginine protected only the N-7 position of G96. Parallels between these results and previously observed protection of 16S ribosomal RNA by aminoglycosides raise the possibility that group I intron splicing and transfer RNA selection by ribosomes involve similar RNA structural motifs.			VONAHSEN, U (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NIGMS NIH HHS [GM17129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; DAVIES J, IN PRESS RNA WORLD; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; STERN S, 1988, METHOD ENZYMOL, V164, P481; VONAHSEN U, 1990, NATURE, V346, P801; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; VONAHSEN U, UNPUB; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; XU MQ, 1989, GENE, V82, P77; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	30	97	102	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1993	260	5113					1500	1503		10.1126/science.8502993	http://dx.doi.org/10.1126/science.8502993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502993				2022-12-28	WOS:A1993LF05800035
J	VONITZSTEIN, M; WU, WY; KOK, GB; PEGG, MS; DYASON, JC; JIN, B; PHAN, TV; SMYTHE, ML; WHITE, HF; OLIVER, SW; COLMAN, PM; VARGHESE, JN; RYAN, DM; WOODS, JM; BETHELL, RC; HOTHAM, VJ; CAMERON, JM; PENN, CR				VONITZSTEIN, M; WU, WY; KOK, GB; PEGG, MS; DYASON, JC; JIN, B; PHAN, TV; SMYTHE, ML; WHITE, HF; OLIVER, SW; COLMAN, PM; VARGHESE, JN; RYAN, DM; WOODS, JM; BETHELL, RC; HOTHAM, VJ; CAMERON, JM; PENN, CR			RATIONAL DESIGN OF POTENT SIALIDASE-BASED INHIBITORS OF INFLUENZA-VIRUS REPLICATION	NATURE			English	Article							2-DEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID; BINDING-SITES; NEURAMINIDASE; RESOLUTION; HEMAGGLUTININ; GLYCOPROTEIN; ASSAY	Two potent inhibitors based on the crystal structure of influenza virus sialidase have been designed. These compounds are effective inhibitors not only of the enzyme, but also of the virus In cell culture and in animal models. The results provide an example of the power of rational, computer-assisted drug design, as well as indicating significant progress in the development of a new therapeutic or prophylactic treatment for influenza infection.	CSIRO,DIV BIOMOLEC ENGN,PARKVILLE,VIC 3052,AUSTRALIA; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	Commonwealth Scientific & Industrial Research Organisation (CSIRO); GlaxoSmithKline	VONITZSTEIN, M (corresponding author), MONASH UNIV,VICTORIAN COLL PHARM,DEPT PHARMACEUT CHEM,381 ROYAL PARADE,PARKVILLE,VIC 3052,AUSTRALIA.		von Itzstein, Mark/E-4823-2010; Dyason, Jeffrey C/L-5534-2014; Phan, Tien/GRN-9075-2022; Varghese, Joseph N/A-8191-2012	Smythe, Mark/0000-0001-7840-1021				BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; BURNET FM, 1948, AUST J EXP BIOL MED, V26, P381, DOI 10.1038/icb.1948.39; CARROLL SM, 1982, ARCH VIROL, V71, P273, DOI 10.1007/BF01314879; CHONG AKJ, 1992, EUR J BIOCHEM, V207, P335, DOI 10.1111/j.1432-1033.1992.tb17055.x; CHONG AKJ, 1991, BIOCHEM INT, V24, P165; CHONG AKJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P65, DOI 10.1016/0167-4838(91)90526-6; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; COLMAN PM, 1985, CURR TOP MICROBIOL I, V114, P117; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; DIMMOCK NJ, 1971, J GEN VIROL, V13, P481, DOI 10.1099/0022-1317-13-3-481; Drzeniek R, 1972, Curr Top Microbiol Immunol, V59, P35; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOTTSCHALK A, 1957, BIOCHIM BIOPHYS ACTA, V23, P645, DOI 10.1016/0006-3002(57)90389-X; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V17, P865, DOI 10.1128/AAC.17.5.865; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hirst GK, 1942, J EXP MED, V76, P195, DOI 10.1084/jem.76.2.195; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; KLENK E, 1955, H-S Z PHYSIOL CHEM, V301, P235, DOI 10.1515/bchm2.1955.301.1-2.235; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; LANGMUIR AD, 1985, NEW ENGL J MED, V313, P1027, DOI 10.1056/NEJM198510173131618; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; NOHLE U, 1982, EUR J BIOCHEM, V126, P543, DOI 10.1111/j.1432-1033.1982.tb06815.x; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; Palese P., 1977, CHEMOPROPHYLAXIS VIR, P189; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHAUER R, 1983, STRUCTURAL CARBOHYDR, P83; STOFF JC, 1992, EUR J PHARMACOL, V213, P439; TINTELNOT M, 1989, J COMPUT AID MOL DES, V3, P67, DOI 10.1007/BF01590996; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VONITZSTEIN M, IN PRESS CARBOHYDR R; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	41	1525	1629	9	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					418	423		10.1038/363418a0	http://dx.doi.org/10.1038/363418a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502295				2022-12-28	WOS:A1993LE93800048
J	MATTHEWS, DJ; WELLS, JA				MATTHEWS, DJ; WELLS, JA			SUBSTRATE PHAGE - SELECTION OF PROTEASE SUBSTRATES BY MONOVALENT PHAGE DISPLAY	SCIENCE			English	Article							SITE-SPECIFIC PROTEOLYSIS; HUMAN GROWTH-HORMONE; ESCHERICHIA-COLI; ASSISTED CATALYSIS; SERINE PROTEASES; SUBTILISIN BPN'; PROTEINS; MECHANISM; SECRETION; SEQUENCE	A method is described here for identifying good protease substrates among approximately 10(7) possible sequences. A library of fusion proteins was constructed containing an amino-terminal domain used to bind to an affinity support, followed by a randomized protease substrate sequence and the carboxyl-terminal domain of M13 gene III. Each fusion protein was displayed as a single copy on filamentous phagemid particles (substrate phage). Phage were then bound to an affinity support and treated with the protease of interest. Phage with good protease substrates were released, whereas phage with substrates that resisted proteolysis remained bound. After several rounds of binding, proteolysis, and phagemid propagation, sensitive and resistant substrate sequences were identified for two different proteases, a variant of subtilisin and factor X(a). The technique may also be useful for studying the sequence specificity of a variety of posttranslational modifications.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; CARTER P, 1990, ACS SYM SER, V427, P181; CARTER P, 1989, PROTEINS, V6, P240, DOI 10.1002/prot.340060306; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FUH G, 1990, J BIOL CHEM, V265, P3111; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS DC, UNPUB; MITSUI Y, 1979, J MOL BIOL, V131, P697, DOI 10.1016/0022-2836(79)90198-0; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	29	292	347	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1993	260	5111					1113	1117		10.1126/science.8493554	http://dx.doi.org/10.1126/science.8493554			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493554				2022-12-28	WOS:A1993LC94200026
J	VARLEY, P; GRONENBORN, AM; CHRISTENSEN, H; WINGFIELD, PT; PAIN, RH; CLORE, GM				VARLEY, P; GRONENBORN, AM; CHRISTENSEN, H; WINGFIELD, PT; PAIN, RH; CLORE, GM			KINETICS OF FOLDING OF THE ALL BETA-SHEET PROTEIN INTERLEUKIN-1-BETA	SCIENCE			English	Article							NMR-SPECTROSCOPY; SECONDARY STRUCTURE; INTERMEDIATE; RESOLUTION; RESONANCE; ASSIGNMENT; FRAMEWORK; STABILITY; H-1	The folding of the all-beta sheet protein, interleukin-1beta, was studied with nuclear magnetic resonance (NMR) spectroscopy, circular dichroism, and fluorescence. Ninety percent of the beta structure present in the native protein, as monitored by far-ultraviolet circular dichroism, was attained within 25 milliseconds, correlating with the first kinetic phase determined by tryptophan and 1-anilinonaphthalene-8-sulfonate fluorescence. In contrast, formation of stable native secondary structure, as measured by quenched-flow deuterium-hydrogen exchange experiments, began after only 1 second. Results from the NMR experiments indicated the formation of at least two intermediates with half-lives of 0.7 to 1.5 and 15 to 25 seconds. The final stabilization of the secondary structure, however, occurs on a time scale much greater than 25 seconds. These results differ from previous results on mixed alpha helix-beta sheet proteins in which both the alpha helices and beta sheets were stabilized very rapidly (less than 10 to 20 milliseconds).	NIDDKD,CHEM PHYS LAB,BLDG 5,ROOM 132,BETHESDA,MD 20892; UNIV NEWCASTLE UPON TYNE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND; NIH,PROT EXPRESS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Newcastle University - UK; National Institutes of Health (NIH) - USA			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Wingfield, Paul/0000-0002-9515-4752				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FINKELSTEIN AV, 1991, PROTEINS, V9, P23, DOI 10.1002/prot.340090104; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, UNPUB; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103	24	165	166	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1110	1113		10.1126/science.8493553	http://dx.doi.org/10.1126/science.8493553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493553				2022-12-28	WOS:A1993LC94200025
J	MOXHAM, CM; HOD, Y; MALBON, CC				MOXHAM, CM; HOD, Y; MALBON, CC			INDUCTION OF G-ALPHA(I2)-SPECIFIC ANTISENSE RNA INVIVO INHIBITS NEONATAL GROWTH	SCIENCE			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HUMAN PITUITARY-TUMORS; ADENYLYL CYCLASE; TRANSGENIC MICE; MESSENGER-RNA; HORMONE GENE; G-PROTEINS; EXPRESSION; GI2	Guanosine triphosphate-binding regulatory proteins (G proteins) are key elements in transmembrane signaling and have been implicated as regulators of more complex biological processes such as differentiation and development. The G protein Galpha(i2) is capable of mediating the inhibitory control of adenylylcyclase and regulates stem cell differentiation to primitive endoderm. Here an antisense RNA to Galpha(i2) was expressed in a hybrid RNA construct whose expression was both tissue-specific and induced at birth. Transgenic mice in which the antisense construct was expressed displayed a lack of normal development in targeted organs that correlated with the absence of Galpha(i2). The loss of Galpha(i2) expression in adipose tissue of the transgenic mice was correlated with a rise in basal levels of adenosine 3',5'-monophosphate (cAMP) and the loss of receptor-mediated inhibition of adenylylcyclase. These data expand our understanding of G protein function in vivo and demonstrate the necessity for Galpha(i2) in the development of liver and fat.	SUNY, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College	MOXHAM, CM (corresponding author), SUNY, HLTH SCI CTR, DEPT MOLEC PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020					BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BEALE EG, 1985, J BIOL CHEM, V260, P748; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CLEMENTI E, 1990, ONCOGENE, V5, P1059; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOGAN B, 1986, MANIPULATING MOUSE E, P174; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MOXHAM CM, IN PRESS DEV GENET; MOXHAM CM, UNPUB; RICHARDS W, UNPUB; RUIZ J P G, 1978, Proceedings of the National Academy of Sciences of the United States of America, V75, P4189, DOI 10.1073/pnas.75.9.4189; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	24	125	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					991	995		10.1126/science.8493537	http://dx.doi.org/10.1126/science.8493537			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493537				2022-12-28	WOS:A1993LB79100046
J	YIP, J				YIP, J			RISK-FACTORS FOR DEVELOPMENT OF MICROALBUMINURIA IN INSULIN-DEPENDENT DIABETIC-PATIENTS - A COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; INCIPIENT NEPHROPATHY; METABOLIC CONTROL; SMOKING	Objective-To investigate the risk factors for the development of persistent microalbuminuria in insulin dependent diabetic patients. Design-Four year follow up of a cohort of diabetic patients. Setting-Outpatient departments of teaching and district general hospitals in England. Subjects-148 non-microalbuminuric, non-hypertensive insulin dependent diabetic patients. Main outcome measures-Urinary albumin excretion rate and arterial blood pressure. Results-137 patients completed four year follow up, of whom 11 developed persistent microalbuminuria (albumin excretion rate greater-than-or-equal-to 30 mug/min on at least two consecutive occasions), giving a cumulative frequency of 8%. 103 remained normoalbuminuric and 23 exhibited intermittent microalbuminuria. At baseline the persistent microalbuminuric group had had significantly raised blood pressure (mean 137.9 (SD 14.9)/82.3 (7.6) v 123.5 (13.2)/72.8 (9.1) mm Hg), glycated haemoglobin concentration 10.4% (2.0%) v 8-9% (2.0%), and albumin excretion rate (median (interquartile range) 17.5 (13.0-22.3) v 4.8 (3.7-6.7) mug/min) (p < 0.05 for all) compared with the normoalbuminuric group. Blood pressure and glycated haemoglobin remained significantly higher in the persistent microalbuminuric group throughout the study (p < 0.05). Multiple regression analysis showed initial albumin excretion rate, blood pressure, and smoking to be significant determinants of persistent microalbuminuria (p < 0.02). Conclusion-In insulin dependent diabetic patients with poor glucose control, which may initially increase albumin excretion rate, an early rise of arterial pressure and smoking are implicated in the development of persistent microalbuminuria.			YIP, J (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,LONDON SE1 9RT,ENGLAND.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; ARMITAGE P, 1987, STATISTICAL METHODS, P408; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CHAVERS BM, 1989, NEW ENGL J MED, V320, P966, DOI 10.1056/NEJM198904133201503; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; GATLING W, 1985, DIABETIC MED, V2, P451, DOI 10.1111/j.1464-5491.1985.tb00681.x; Jarrett R J, 1979, Diabetes Care, V2, P175, DOI 10.2337/diacare.2.2.175; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1986, UREMIA INVEST, V9, P85; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P500; REID DD, 1976, LANCET, V2, P979; RUDBERG S, 1992, KIDNEY INT, V41, P822, DOI 10.1038/ki.1992.126; VIBERTI GC, 1982, LANCET, V1, P1430; VIGSTRUP J, 1985, ACTA OPHTHALMOL, V63, P530; WISEMAN MJ, 1984, DIABETOLOGIA, V26, P402; 1985, SAS USERS GUIDE STAT; 1984, NEW ENGL J MED, V6, P2365; 1992, DIABETES CARE, V4, P495	24	168	168	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1235	1239						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499853				2022-12-28	WOS:A1993LB80400015
J	CHAN, MK; KIM, JS; REES, DC				CHAN, MK; KIM, JS; REES, DC			THE NITROGENASE FEMO-COFACTOR AND P-CLUSTER PAIR - 2.2-ANGSTROM RESOLUTION STRUCTURES	SCIENCE			English	Article							IRON SULFUR CENTERS; COORDINATION; REFINEMENT	Structures recently proposed for the FeMo-cofactor and P-cluster pair of the nitrogenase molybdenum-iron (MoFe)-protein from Azotobacter vinelandii have been crystallographically verified at 2.2 angstrom resolution. Significantly, no hexacoordinate sulfur atoms are observed in either type of metal center. Consequently, the six bridged iron atoms in the FeMo-cofactor are trigonally coordinated by nonprotein ligands, although there may be some iron-iron bonding interactions that could provide a fourth coordination interaction for these sites. Two of the cluster sulfurs in the P-cluster pair are very close together (approximately 2.1 angstroms), indicating that they form a disulfide bond. These findings indicate that a cavity exists in the interior of the FeMo-cofactor that could be involved in substrate binding and suggest that redox reactions at the P-cluster pair may be linked to transitions of two cluster-bound sulfurs between disulfide and sulfide oxidation states.	CALTECH, DIV CHEM & CHEM ENGN 14775CH, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015006] Funding Source: NIH RePORTER; NIGMS NIH HHS [1F32 GM15006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIKIE PE, 1967, J CHEM SOC CHEM COMM, P1228; BLONK HL, 1992, INORG CHEM, V31, P962, DOI 10.1021/ic00032a008; BOSE KS, 1984, ORGANOMETALLICS, V3, P1126, DOI 10.1021/om00085a032; BRICE MD, 1972, INORG CHEM, V11, P1381, DOI 10.1021/ic50112a044; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; CHAN MY, UNPUB; CHU CTW, 1982, J AM CHEM SOC, V104, P737, DOI 10.1021/ja00367a017; COTTON FA, 1977, J AM CHEM SOC, V99, P3293, DOI 10.1021/ja00452a016; HOLM RH, 1985, MOLYBDENUM ENZYMES, pCH2; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; MOFFAT AS, 1992, SCIENCE, V257, P1624, DOI 10.1126/science.1529349; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1992, SCIENCE, V257, P1639, DOI 10.1126/science.1529351; SELLMANN D, 1978, Z NATURFORSCH B, V33, P1341; SELLMANN D, 1989, ANGEW CHEM INT EDIT, V28, P1271, DOI 10.1002/anie.198912711; SEYFERTH D, 1985, J ORGANOMET CHEM, V281, P111, DOI 10.1016/0022-328X(85)87094-7; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; STIEFEL EI, 1988, ACS SYM SER, V372, P372; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILLIAMS GD, 1985, J AM CHEM SOC, V107, P729, DOI 10.1021/ja00289a049; SERC4 DAR LAB COLL C	25	480	500	5	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1993	260	5109					792	794		10.1126/science.8484118	http://dx.doi.org/10.1126/science.8484118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484118				2022-12-28	WOS:A1993LA74400025
J	VANWIJNGAARDEN, WJ; DUNCAN, ID				VANWIJNGAARDEN, WJ; DUNCAN, ID			RATIONALE FOR STOPPING CERVICAL SCREENING IN WOMEN OVER 50	BRITISH MEDICAL JOURNAL			English	Article							CANCER	Objective-To investigate whether the currently recommended age at which to stop cervical screening (64) can be lowered and what criteria should be used for safely doing so. Design-Retrospective case analysis study. Setting-Dundee and Angus districts of Scotland. Subjects-Women diagnosed as having cervical intraepithelial neoplasia and microinvasive or invasive cancer of the cervix in 1989 and 1990 (798 cases). Main outcome measure-History of cervical cytology results according to age (age groups of five years) and screening interval (three years and five years). Results-Cervical intraepithelial neoplasia was most common in women under 45 (711 cases in women of 45 and under v 38 cases in those of 46 and over). Cervical intraepithelial neoplasia occurring de novo was not seen in women over 50 who had been screened every three years. Microinvasive or invasive cancer of the cervix was diagnosed in 26 women over 50. None of these women had participated adequately in the cervical screening programme. Conclusion-Cervical intraepithelial neoplasia typically occurs in younger women. All women over 50 with an adequate history of negative results on smear testing every three years may be safely discharged from further screening if these findings are confirmed in other populations.			VANWIJNGAARDEN, WJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND.							DUGUID HLD, 1985, LANCET, V2, P1053; DUNCAN I, 1992, GUIDELINES CLIN PRAC; FLETCHER A, 1990, LANCET, V335, P97, DOI 10.1016/0140-6736(90)90552-G; 1986, BMJ, V293, P659; 1987, REPORT INTERCOLLEGIA; 1987, REPORT CERVICAL CYTO; 1990, CANCER CERVIX UTERI; 1988, DHSSHC881HCFP882 DEP; 1985, CERVICAL CYTOLOGY SC	9	70	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					967	971		10.1136/bmj.306.6883.967	http://dx.doi.org/10.1136/bmj.306.6883.967			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490472	Green Published, Bronze			2022-12-28	WOS:A1993KX43600017
J	COLLIGHAN, G; MACDONALD, A; HERZBERG, J; PHILPOT, M; LINDESAY, J				COLLIGHAN, G; MACDONALD, A; HERZBERG, J; PHILPOT, M; LINDESAY, J			AN EVALUATION OF THE MULTIDISCIPLINARY APPROACH TO PSYCHIATRIC-DIAGNOSIS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the accuracy of psychiatric diagnoses made by two community psychogeriatric teams operating a multidisciplinary assessment procedure. Design-Comparison of team diagnosis with independent formal assessment and consensus diagnosis by research psychiatrists. Setting-Two community psychogeriatric teams with similar operational policies in an inner London health district. Subjects-100 people aged 65-90 (70 women) newly referred to the teams. Main outcome measures-Concordance between team and research diagnoses. Results-Agreement between team and research diagnoses ranged from 90% to 99% for the specific psychiatric disorders studied. There was no significant difference between medical and non-medical team members in their diagnostic performance compared with the research psychiatrists. Increased diagnostic accuracy by team members was associated with longer experience of team working, regardless of the team members' professional background. Conclusions-The multidisciplinary approach to the assessment of referrals to these community teams for the elderly is not associated with misdiagnosis of psychiatric disorder.	LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,LONDON SE1 9RT,ENGLAND; HITHER GREEN HOSP,LONDON SE13 6RU,ENGLAND; GUYS HOSP,LONDON SE1 9RT,ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								ARIE T, 1982, PSYCHIATRY LATE LIFE; BREARLEY S, 1992, BRIT MED J, V304, P832, DOI 10.1136/bmj.304.6830.832; COLES RJ, 1991, INT J GERIATR PSYCH, V6, P31, DOI 10.1002/gps.930060106; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; GELHAAR E, 1988, PSYCHIATRIC B, V12, P428; Jolley D., 1992, RECENT ADV PSYCHOGER, V2; LINDESAY J, 1991, WORKING OUT SETTING; McGrath M., 1991, MULTIDISCIPLINARY TE; MURPHY E, 1991, WORKING OUT SETTING; Ovretveit J., 1988, ESSENTIALS MULTIDISC; SPITZNAGEL EL, 1985, ARCH GEN PSYCHIAT, V42, P725; 1986, SPSS PCPLUS STATISTI; 1991, BRIANS 1ST CASE MULT	13	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					821	824		10.1136/bmj.306.6881.821	http://dx.doi.org/10.1136/bmj.306.6881.821			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV348	8490373	Bronze, Green Published			2022-12-28	WOS:A1993KV34800019
J	SALISBURY, C				SALISBURY, C			VISITING THROUGH THE NIGHT	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HOURS WORKLOAD; RATES; CALLS; CARE	Objective-To describe the time distribution of visits at night and to evaluate trends in night visits from 1982 to 1992. Design-Analysis of a sample of one in 12 claim forms for night visits submitted over one year beginning 1 July 1991, and estimation of the number of night visits in previous years from data on payment. Further information was obtained from performance indicators from the Department of Health. Setting-General practices responsible to Berkshire family health services authority. Main outcome measures-Times of night visits, proportion performed by deputies, and trend in number of night visits after adjusting for the increased hours during which visits are claimed. Results-The change in the hours for which payment may be claimed accounted for 33.8% (536/1584) of all night visits in the sample. After visits during these extra two hours were excluded, claims increased by 38.7% from 1989 to 1992 and more than doubled in the past 10 years. Use of deputies both in Berkshire and in England and Wales dropped by more than half since 1989. General practitioners in Berkshire claimed 31.5 night visits per 1000 population in 1992. Conclusions-The increase in the number of night visits is only partly due to the change in hours during which visits may be claimed. It is also due to a long term and possibly accelerating rise in demand. This is despite a major reduction in the proportion of calls performed by deputising services, the use of which had been said to be the main factor increasing the numbers of night visits.			SALISBURY, C (corresponding author), GROVELANDS MED CTR,READING RG3 1HG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; COFFEY B, 1984, J ROY COLL GEN PRACT, V34, P386; FRY J, 1977, TRENDS GENERAL PRACT; HOBDAY PJ, 1984, BRIT MED J, V289, P663, DOI 10.1136/bmj.289.6446.663; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; 1990, STATEMENT FEES ALLOW; 1989, GENERAL PRACTICE NAT; 1992, 1990 91 HLTH SERVICE	14	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					762	764		10.1136/bmj.306.6880.762	http://dx.doi.org/10.1136/bmj.306.6880.762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490340	Green Published, Bronze			2022-12-28	WOS:A1993KU17300026
J	CHELLURI, L; PINSKY, MR; DONAHOE, MP; GRENVIK, A				CHELLURI, L; PINSKY, MR; DONAHOE, MP; GRENVIK, A			LONG-TERM OUTCOME OF CRITICALLY ILL ELDERLY PATIENTS REQUIRING INTENSIVE-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; UPDATE 1983; AGE; RESOURCES; MORTALITY; SEVERITY; SURVIVAL; SYSTEM; UNIT	Objective.-To evaluate the long-term mortality and morbidity of critically ill elderly patients requiring intensive care. Design.-Prospective comparison of outcome of critically ill patients aged 75 years and older with patients aged 65 to 74 years. Patients.-Critically ill patients aged 65 years and older who required intensive care and who were recruited during a 3-month period. Main Outcome Measures.-Duration of hospitalization, hospital charges, procedures used in the intensive care unit, mortality in the hospital and during the follow-up period, and quality of life of survivors during the follow-up period. Results.-Ninety-seven patients were included in the study; 54 were 75 years or older and 43 were aged 65 to 74 years. No significant difference was noted between the two groups for length of stay in the hospital, hospital charges, or mortality at 1 year. Severity of illness, as assessed by Acute Physiology and Chronic Health Evaluation score at the time of intensive care unit admission, was a better predictor of survival than age. Quality of life, as assessed by activities of daily living, perceived quality of life, and Center for Epidemiologic Studies-Depression score, were not significantly different in either group at 1, 6, and 12 months after discharge from the hospital. Most patients in both groups described their quality of life as adequate and were willing to receive intensive care again, if necessary. Conclusion.-Age alone is not an adequate predictor of long-term survival and quality of life in critically ill elderly patients.	UNIV PITTSBURGH,MED CTR,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT SURG,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	CHELLURI, L (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT ANESTHESIOL CRIT CARE MED,SCAIFE HALL,ROOM 608,PITTSBURGH,PA 15213, USA.							BYRICK RJ, 1980, CRIT CARE MED, V8, P332, DOI 10.1097/00003246-198006000-00003; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CULLEN DJ, 1984, CRIT CARE MED, V12, P102, DOI 10.1097/00003246-198402000-00004; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1982, CRIT CARE MED, V10, P575; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; MARTIN L, 1987, NEW ENGL J MED, V316, P1425; MAYEROAKES SA, 1991, J AM GERIATR SOC, V39, P862, DOI 10.1111/j.1532-5415.1991.tb04452.x; MCCLISH DK, 1987, J AM GERIATR SOC, V35, P983, DOI 10.1111/j.1532-5415.1987.tb04000.x; MUNDT DJ, 1989, ARCH INTERN MED, V149, P68, DOI 10.1001/archinte.149.1.68; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; RILEY SA, 1991, INTENSIVE CRIT CARE, V10, P62; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; SLAYTER MA, 1986, ANAESTH INTENSIVE CA, V14, P381; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x	27	214	223	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3119	3123		10.1001/jama.269.24.3119	http://dx.doi.org/10.1001/jama.269.24.3119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LH145	8505814				2022-12-28	WOS:A1993LH14500025
J	HARDIE, RC; PERETZ, A; SUSSTOBY, E; ROMGLAS, A; BISHOP, SA; SELINGER, Z; MINKE, B				HARDIE, RC; PERETZ, A; SUSSTOBY, E; ROMGLAS, A; BISHOP, SA; SELINGER, Z; MINKE, B			PROTEIN-KINASE-C IS REQUIRED FOR LIGHT ADAPTATION IN DROSOPHILA PHOTORECEPTORS	NATURE			English	Article							LIMULUS PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; INOSITOL TRISPHOSPHATE; VENTRAL PHOTORECEPTORS; FLY PHOTORECEPTORS; MUTANT; PHOTOTRANSDUCTION; EXCITATION; POLYPHOSPHATE; DEACTIVATION	PROTEIN kinase C (PKC) is a key enzyme for many cellular processes1,2 but its physiological roles are poorly understood. An excellent opportunity to investigate the function of PKC has been provided by the identification of an eye-specific PKC in Drosophila3-5 and a null PKC mutant, inaC(P209) (refs 5,6). Bright conditioning lights delivered to inaC photoreceptors lead to an abnormal loss of sensitivity in whole cell recordings from dissociated ommatidia; this has been interpreted as 'hyperadaptation' and PKC's role has been suggested to be distinct from light adaptation5. A presumably related finding is that during intense light, the response of inaC declines to baseline6. Invertebrate photoreceptors use the phosphoinositide signalling cascade7-12, responding to single photons with so-called quantum bumps13 which sum to form the macroscopic response to light14-16. Light adaptation allows photoreceptors to adjust their sensitivity over the enormous range of ambient intensities14,17. Although the molecular mechanism of light adaptation remains obscure, it is a negative-feedback process12 mediated by a rise in cytosolic calcium12,18 and a decrease in bump size12,14-16. We now show that under physiological conditions light adaptation is severely reduced in inaC, suggesting that eye-specific PKC, itself activated by a rise in cytosolic calcium4,5 and diacylglycerol, is required for adaptation. Furthermore, we show that in the absence of PKC individual bumps fail to terminate normally, an effect that can account for the pleiotropic manifestations of the inaC phenotype.	HEBREW UNIV JERUSALEM,MINERVA CTR STUDIES VISUAL TRANSDUCT,DEPT PHYSIOL,IL-91010 JERUSALEM,ISRAEL; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND; HEBREW UNIV JERUSALEM,MINERVA CTR STUDIES VISUAL TRANSDUCT,DEPT BIOL CHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; University of Cambridge; Hebrew University of Jerusalem			Bishop, Sheila/AAE-8387-2020	Hardie, Roger/0000-0001-5531-3264				BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROWN JE, 1975, NATURE, V258, P252, DOI 10.1038/258252a0; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DODGE FA, 1968, SCIENCE, V160, P88, DOI 10.1126/science.160.3823.88; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HOWARD J, 1984, J EXP BIOL, V113, P471; KLEINSCHMIDT J, 1975, J GEN PHYSIOL, V66, P617, DOI 10.1085/jgp.66.5.617; LAUGHLIN SB, 1978, J COMP PHYSIOL, V128, P319, DOI 10.1007/BF00657606; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; MINKE B, 1991, J NEUROSCI, V11, P900; MINKE B, 1982, J GEN PHYSIOL, V79, P361, DOI 10.1085/jgp.79.3.361; MINKE B, 1992, PROGR RETINAL RES, V11, P99; MINKE B, 1986, PHOTOCHEM PHOTOBIOL, V32, P553; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NASI E, 1991, J GEN PHYSIOL, V97, P55, DOI 10.1085/jgp.97.1.55; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pak W.L., 1979, P67; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; PAYNE R, 1988, PHILOS T ROY SOC B, V320, P359, DOI 10.1098/rstb.1988.0082; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; Shapley R.M., 1984, PROG RETIN RES, V3, P263, DOI [DOI 10.1016/0278-4327(84)90011-7, 10.1016/0278-4327(84)90011-7]; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STIEVE H, 1986, MOL MECHANISM PHOTOR, P199; WONG F, 1978, NATURE, V276, P76, DOI 10.1038/276076a0; Yeandle S., 1958, AM J OPHTHALMOL, V46, P82	34	131	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					634	637		10.1038/363634a0	http://dx.doi.org/10.1038/363634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510756				2022-12-28	WOS:A1993LH13900058
J	GREENBERG, AE; HINDIN, R; NICHOLAS, AG; BRYAN, EL; THOMAS, PA				GREENBERG, AE; HINDIN, R; NICHOLAS, AG; BRYAN, EL; THOMAS, PA			THE COMPLETENESS OF AIDS CASE REPORTING IN NEW-YORK-CITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVEILLANCE	Objective.-To assess the completeness of acquired immunodeficiency syndrome (AIDS) case reporting in New York City (NYC), and to determine whether the completeness of reporting differs in various populations. Design.-Retrospective record review of hospital laboratory logs, death certificates, hospital discharge records, and patient registries at private physicians' offices and hospital outpatient clinics. Setting.-Public and private hospitals, and private physicians' offices in NYC. Patients.-Adults and adolescents with AIDS or with illnesses suggestive of AIDS were identified using both population-based and nonrandom sampling techniques. These persons were matched with the NYC AIDS case registry, and the medical records of nonmatching persons were reviewed to determine whether they met the 1987 Centers for Disease Control and Prevention surveillance case definition for AIDS. Main Outcome Measures.-The completeness of reporting was calculated for the five individual projects and for the aggregate database by gender, race/ethnicity, risk, borough of residence, age, first AIDS diagnosis, and year of diagnosis. Results.-Of 7015 persons with AIDS identified in the five projects, 5912 (84%) had been previously reported (range, 77% to 89%). The completeness of reporting ranged from 81% to 87% in all major gender, race/ethnicity, risk, borough of residence, and age subgroups. In a multivariate analysis, the odds of being unreported were significantly higher among outpatients in hospital clinics, out-of-state residents, persons with diagnoses other than Pneumocystis carinii pneumonia, and persons recently diagnosed with AIDS. Conclusions.-This study indicates that the NYC AIDS surveillance system functioned effectively during the first decade of the AIDS epidemic. Completeness-of-reporting studies are an integral part of AIDS surveillance, providing data that are critical for assessing the validity of the AIDS surveillance database.	CTR DIS CONTROL & PREVENT,DIV HIV AIDS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	GREENBERG, AE (corresponding author), NEW YORK CITY DEPT HLTH,OFF AIDS SURVEILLANCE,BOX 44,125 WORTH ST,NEW YORK,NY 10013, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; CALZAVARA LM, 1990, CAN MED ASSOC J, V142, P36; CARR E, 1990, 6TH INT C AIDS SAN F; CHAMBERLAND ME, 1985, JAMA-J AM MED ASSOC, V254, P383, DOI 10.1001/jama.254.3.383; CONWAY GA, 1989, JAMA-J AM MED ASSOC, V262, P2859, DOI 10.1001/jama.262.20.2859; EVANS BG, 1991, AIDS, V5, P1261, DOI 10.1097/00002030-199110000-00018; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; GREENBERG AE, 1992, AIDS, V6, P849, DOI 10.1097/00002030-199208000-00014; GREENBERG AE, 1990, 6TH INT C AIDS SAN F; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HINDIN RH, 1989, 5 INT C AIDS MONTR; LIEB L, 1990, 6TH INT C AIDS SAN F; MODESITT SK, 1993, J ACQ IMMUN DEF SYND, V6, P91; RAUCH KJ, 1986, JAMA-J AM MED ASSOC, V256, P863, DOI 10.1001/jama.1986.03380070069013; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; THOMAS PA, 1993, AM J EPIDEMIOL, V137, P121, DOI 10.1093/oxfordjournals.aje.a116652; 1989, GAOPEMD8913  US GEN, P37; 1992, AIDS SURVEILLANCE UP; 1986, AM J EPIDEMIOL, V123, P1013; 1991, INT CLASSIFICATION D; 1987, AIDS SURVEILLANCE UP; 1987, MMWR MORB MORTAL WKL, V36, pS3; 1992, HIV AIDS SURVEILLANC	24	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2995	3001		10.1001/jama.269.23.2995	http://dx.doi.org/10.1001/jama.269.23.2995			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501841				2022-12-28	WOS:A1993LF94100028
J	SELIK, RM; CHU, SY; BUEHLER, JW				SELIK, RM; CHU, SY; BUEHLER, JW			HIV-INFECTION AS LEADING CAUSE OF DEATH AMONG YOUNG-ADULTS IN UNITED-STATES CITIES AND STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe the extent to which human immunodeficiency virus (HIV) infection has become the leading cause of death among young adults (25 to 44 years of age) in US states and cities of at least 100 000 population. Design.-Analysis of underlying causes of death using national vital statistics for 1990 by state and city. Deaths caused by HIV were defined as those with underlying cause assigned a code number of 042, 043, or 044, as established by the National Center for Health Statistics. Results.-Infection with HIV was the leading cause of death among young men in five states, causing 29% of their deaths in New York, 28% in New Jersey, 24% in California and Florida, and 16% in Massachusetts. Among young women, HIV was not the leading cause of death in any state. Among young men, HIV infection was the leading cause of death in 64 cities, with the proportion of deaths due to HIV ranging from 16% in Bridgeport, Conn, to 61% in San Francisco, Calif. Among young women, HIV infection was the leading cause of death in nine cities, with the proportion of deaths due to HIV ranging from 15% in Baltimore, Md, to 43% in Newark, NJ. Conclusion.-In many US communities, HIV infection is the leading cause of death among young men and women, causing a large proportion of deaths in this age group.			SELIK, RM (corresponding author), US PHS,CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,MAILSTOP E47,ATLANTA,GA 30333, USA.		Buehler, James/B-8419-2014					BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; MICHAELS D, 1992, JAMA-J AM MED ASSOC, V268, P3456, DOI 10.1001/jama.268.24.3456; 1989, MMWR MORB MORTAL WKL, V38, P165; 1992, MMWR MORB MORTAL WKL, V41, P121; 1993, EMPLOY EARN, V40, P174; 1992, CATALOG ELECTRONIC D; 1993, MONTHLY VITAL STA S7, V41, P1; 1992, MMWR MORB MORTAL WKL, V41, P4; 1992, MMWR MORB MORTAL WKL, V41, P708; 1992, HIV AIDS SURVEILLANC, P10; [No title captured]; 1992, MMWR MORB MORTAL WKL, V40, P6; 1992, MMWR MORB MORTAL WKL, V41, P463; 1987, MMWR MORB MORTAL  S7, V36, P1; 1991, MMWR MORB MORTAL WKL, V40, P41	18	97	97	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2991	2994		10.1001/jama.269.23.2991	http://dx.doi.org/10.1001/jama.269.23.2991			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501840				2022-12-28	WOS:A1993LF94100027
J	BLABER, M; ZHANG, XJ; MATTHEWS, BW				BLABER, M; ZHANG, XJ; MATTHEWS, BW			STRUCTURAL BASIS OF AMINO-ACID ALPHA-HELIX PROPENSITY	SCIENCE			English	Article							T4 LYSOZYME; FORMING TENDENCIES; DIRECTED MUTATIONS; STABILITY; AREA; THERMOSTABILITY; PREDICTIONS; PROTEINS	The propensity of an amino acid to form an alpha helix in a protein was determined by multiple amino substitutions at positions 44 and 131 in T4 lysozyme. These positions are solvent-exposed sites within the alpha helices that comprise, respectively, residues 39 to 50 and 126 to 134. Except for two acidic substitutions that may be involved in salt bridges, the changes in stability at the two sites agree well. The stability values also agree with those observed for corresponding amino acid substitutions in some model peptides. Thus, helix propensity values derived from model peptides can be applicable to proteins. Among the 20 naturally occurring amino acids, proline, glycine, and alanine each have a structurally unique feature that helps to explain their low or high helix propensities. For the remaining 17 amino acids, it appears that the side chain hydrophobic surface buried against the side of the helix contributes substantially to a helix propensity.	UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon			Blaber, Michael/E-7478-2011; Blaber, Michael/ABA-5031-2021; Blaber, Michael/N-1083-2019	Blaber, Michael/0000-0002-6856-1643; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, METHOD ENZYMOL, V154, P511; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1972, BIOCHEMISTRY-US, V11, P3028, DOI 10.1021/bi00766a015; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HERMANN RB, 1977, P NATL ACAD SCI USA, V74, P4144, DOI 10.1073/pnas.74.10.4144; HERMANS J, 1992, BIOCHEMISTRY-US, V31, P5646, DOI 10.1021/bi00139a031; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; NICHOLSON H, 1992, BIOPOLYMERS, V32, P1431, DOI 10.1002/bip.360321103; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; PTITSYN O B, 1972, Pure and Applied Chemistry, V31, P227, DOI 10.1351/pac197231010227; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; SHORTLE D, 1992, PROTEIN SCI, V1, P201; TANFORD C, 1980, HYDROPHOBIC EFFECT; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; [No title captured]	37	440	443	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1637	1640		10.1126/science.8503008	http://dx.doi.org/10.1126/science.8503008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503008				2022-12-28	WOS:A1993LG17600026
J	BOYINGTON, JC; GAFFNEY, BJ; AMZEL, LM				BOYINGTON, JC; GAFFNEY, BJ; AMZEL, LM			THE 3-DIMENSIONAL STRUCTURE OF AN ARACHIDONIC-ACID 15-LIPOXYGENASE	SCIENCE			English	Article							SATIVUM SEED LIPOXYGENASE; SOYBEAN LIPOXYGENASE-1; HUMAN 5-LIPOXYGENASE; MOLECULAR-CLONING; MACROMOLECULAR CRYSTALLOGRAPHY; SUPEROXIDE-DISMUTASE; IRON ENVIRONMENT; SEQUENCE; CDNA; CRYSTALLIZATION	In mammals, the hydroperoxidation of arachidonic acid by lipoxygenases leads to the formation of leukotrienes and lipoxins, compounds that mediate inflammatory responses. Lipoxygenases are dioxygenases that contain a nonheme iron and are present in many animal cells. Soybean lipoxygenase-1 is a single-chain, 839-residue protein closely related to mammalian lipoxygenases. The structure of soybean lipoxygenase-1 solved to 2.6 angstrom resolution shows that the enzyme has two domains: a 146-residue beta barrel and a 693-residue helical bundle. The iron atom is in the center of the larger domain and is coordinated by three histidines and the COO- of the carboxyl terminus. The coordination geometry is nonregular and appears to be a distorted octahedron in which two adjacent positions are not occupied by ligands. Two cavities, in the shapes of a bent cylinder and a frustum, connect the unoccupied positions to the surface of the enzyme The iron, with two adjacent and unoccupied positions, is poised to interact with the 1 4-diene system of the substrate and with molecular oxygen during catalysis.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT CHEM,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Gaffney, Betty J/C-9666-2015	Amzel, L. Mario/0000-0002-0129-9572	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BOYINGTON JC, 1990, J BIOL CHEM, V265, P12771; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; CHEESBROUGH TM, 1983, BIOCHEMISTRY-US, V22, P3837, DOI 10.1021/bi00285a019; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COREY EJ, 1987, J AM CHEM SOC, V109, P8108, DOI 10.1021/ja00260a039; COREY EJ, 1987, J AM CHEM SOC, V109, P8701; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; DEGROOT JJM, 1973, BIOCHIM BIOPHYS ACTA, V326, P279, DOI 10.1016/0005-2760(73)90254-3; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; EALING PM, 1989, BIOCHEM J, V264, P929, DOI 10.1042/bj2640929; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FINNEN DC, 1991, INORG CHEM, V30, P3960, DOI 10.1021/ic00020a034; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GAFFNEY BJ, 1993, BIOPHYS J, V64, P773, DOI 10.1016/S0006-3495(93)81438-3; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P211; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVRATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70; NELSON MJ, 1990, BIOCHEMISTRY-US, V29, P6897, DOI 10.1021/bi00481a020; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; SHIBATA D, 1991, PLANT MOL BIOL, V16, P353, DOI 10.1007/BF00020569; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SLOANE DL, 1990, BIOCHEM BIOPH RES CO, V173, P507, DOI 10.1016/S0006-291X(05)80063-4; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STALLINGS WC, 1990, J MOL BIOL, V211, P685, DOI 10.1016/0022-2836(90)90067-V; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STECZKO J, 1990, J BIOL CHEM, V265, P11362; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; VANDERHEIJDT LM, 1992, EUR J BIOCHEM, V207, P793, DOI 10.1111/j.1432-1033.1992.tb17110.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITTAKER JW, 1988, J AM CHEM SOC, V110, P5329, DOI 10.1021/ja00224a017; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	51	457	464	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1482	1486		10.1126/science.8502991	http://dx.doi.org/10.1126/science.8502991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502991				2022-12-28	WOS:A1993LF05800030
J	SCHROEDER, R; STREICHER, B; WANK, H				SCHROEDER, R; STREICHER, B; WANK, H			SPLICE-SITE SELECTION AND DECODING - ARE THEY RELATED	SCIENCE			English	Editorial Material							RIBOZYME; RNA				SCHROEDER, R (corresponding author), VIENNA BIOCTR,INST MICROBIOL & GENET,DR BOHRGASSE 9,A-1030 VIENNA,AUSTRIA.							CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUNDLIFFE E, 1990, RIBOSOME, P470; DAVIES J, IN PRESS RNA WORLD; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; NOLLER HF, 1993, FASEB J, V7, P86; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	18	26	29	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1443	1444		10.1126/science.8502988	http://dx.doi.org/10.1126/science.8502988			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502988				2022-12-28	WOS:A1993LF05800023
J	FALK, RH				FALK, RH			COGNOCARDIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2601	2601		10.1001/jama.269.20.2601	http://dx.doi.org/10.1001/jama.269.20.2601			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487428				2022-12-28	WOS:A1993LC86500001
J	BLENDON, RJ; HYAMS, TS; BENSON, JM				BLENDON, RJ; HYAMS, TS; BENSON, JM			BRIDGING THE GAP BETWEEN EXPERT AND PUBLIC VIEWS ON HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									FORTIS HOLDINGS INC,NEW YORK,NY		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P2587; BLENDON RJ, 1990, NEW ENGL J MED, V323, P211; BLENDON RJ, 1991, SYSTEM CRISIS CASE H, P93; Burner S T, 1992, Health Care Financ Rev, V14, P1; DAVIS JA, 1991, GENERAL SOCIAL SURVE, P105; IMMERWAHR J, 1992, FAULTY DIAGNOSIS PUB; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; SPRINGER MD, 1991, CARING UNINSURED UND; YANKELOVICH D, 1991, HLTH MANAGE Q, V13, P14; 1992, PD HART RES ASS PEPP; 1990, CONTROLLING HLTH CAR; 1992, C BOARD POLL; 1993, PRINCETON SURVEY RES; 1992, EC IMPLICATIONS RISI, P49; 1991, ABC NEWS WASHINGTON; 1991, YANKELOVICH CLANCY S; 1993, BATTLEGROUND 94 POLL; 1991, GALLUP EMPLOYEE BENE; 1993, NBC NEWS WALL STREET; 1992, L HARRIS ASS HJ KAIS; 1991, GALLUP POLL; 1993, L HARRIS ASS HJ KAIS; 1991, DYG INC AM ASS RETIR; 1993, CBS NEWS NY TIMES PO; 1993, FACT FINDERS NOVALIS; 1992, ROPER ORG HLTH INSUR; 1991, L HARRIS ASS POLL; 1990, LOS ANGELES TIMES PO; 1992, MELLMAN LAZARUS PUBL; 1992, GALLUP EMPLOYEE BENE; 1992, CBS NEWS NY TIMES PO; 1993, L HARRIS ASS POLL; 1993, GALLUP USA TODAY CNN	33	46	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2573	2578		10.1001/jama.269.19.2573	http://dx.doi.org/10.1001/jama.269.19.2573			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487426				2022-12-28	WOS:A1993LB45000042
J	BLUESTONE, N				BLUESTONE, N			THE BOTTOM LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BLUESTONE, N (corresponding author), CTR BARNSTEAD,BARNSTEAD,NH 03218, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2580	2580		10.1001/jama.269.19.2580	http://dx.doi.org/10.1001/jama.269.19.2580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487427				2022-12-28	WOS:A1993LB45000043
J	HOSOI, J; MURPHY, GF; EGAN, CL; LERNER, EA; GRABBE, S; ASAHINA, A; GRANSTEIN, RD				HOSOI, J; MURPHY, GF; EGAN, CL; LERNER, EA; GRABBE, S; ASAHINA, A; GRANSTEIN, RD			REGULATION OF LANGERHANS CELL-FUNCTION BY NERVES CONTAINING CALCITONIN GENE-RELATED PEPTIDE	NATURE			English	Article							HUMAN-SKIN; FIBERS ASSOCIATE; IMMUNE-SYSTEM; NEUROPEPTIDES; INNERVATION; RATS; CGRP; IMMUNOREACTIVITY; COMPARTMENTS; LYMPHOCYTES	SEVERAL observations suggest interactions between the immune and nervous systems1,2. Psoriasis and atopic dermatitis may worsen with anxiety and have been associated with anomalous neuropeptide regulation2. Neurotransmitters affect lymphocyte function1-4 and lymphoid organs are innervated5-9. Calcitonin gene-related peptide (CGRP) is a neuropeptide and vasodilator10 that modulates some macrophage functions, including antigen presentation in vitro11. CGRP is associated with Langerhans cells (LC) in oesophageal mucosa, particularly during inflammation12, is present in epidermal nerves and is associated with Merkel cells10,13-15. We examined the ability of CGRP to modulate LC antigen-presenting function16 and asked if CGRP-containing nerve impinge on LC. We report here that CGRP-containing nerve fibers are intimately associated with LC in human epidermis and CGRP is found at the surface of some LC. In three functional assay, CGRP inhibited LC antigen presentation. These findings indicate that CGRP may have immunomodulatory effects in vivo and suggest a locus of interaction between the nervous system and immunological function.	MASSACHUSETTS GEN HOSP E, MGH HARVARD CUTANEOUS BIOL RES CTR, BLDG 149, 13TH ST, BOSTON, MA 02129 USA; UNIV PENN, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Grabe, Stephan/AAJ-4578-2021	Grabe, Stephan/0000-0002-6863-8719				ABERER W, 1982, J INVEST DERMATOL, V79, P129, DOI 10.1111/1523-1747.ep12500040; BULLOCH K, 1985, NEURAL MODULATION IM; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V91, P35, DOI 10.1007/BF00501907; FELTEN DL, 1987, J NEUROSCI RES, V18, P28, DOI 10.1002/jnr.490180107; GARCIACABALLERO T, 1989, HISTOCHEMISTRY, V92, P127, DOI 10.1007/BF00490231; GRABBE S, 1992, J LEUKOCYTE BIOL, V52, P209, DOI 10.1002/jlb.52.2.209; HARRIST TJ, 1983, J INVEST DERMATOL, V80, P100, DOI 10.1111/1523-1747.ep12531695; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; HUGHES SR, 1991, BRIT J PHARMACOL, V104, P738, DOI 10.1111/j.1476-5381.1991.tb12497.x; KAPSENBERG M, 1990, SKIN IMMUNE SYSTEM, P109; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; KRUGER L, 1985, SOMATOSENS RES, V2, P335, DOI 10.3109/07367228509144573; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; LORTON D, 1991, BRAIN BEHAV IMMUN, V5, P29, DOI 10.1016/0889-1591(91)90005-U; MASLIAH E, 1992, AM J PATHOL, V140, P263; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MIROWSKI G, 1990, LAB INVEST, V63, P52; NONG YH, 1989, J IMMUNOL, V143, P45; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; SHIMADA S, 1987, J IMMUNOL, V139, P2551; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; SINGARAM C, 1991, GASTROENTEROLOGY, V100, P560, DOI 10.1016/0016-5085(91)90231-9; SIRINEK LP, 1991, ACTA ONCOL, V30, P509, DOI 10.3109/02841869109092410; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; WALKER RF, 1985, J NEUROIMMUNOL, V10, P41, DOI 10.1016/0165-5728(85)90033-5; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185; XU D, 1989, PEPTIDES, V10, P309, DOI 10.1016/0196-9781(89)90035-1; ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900	28	492	511	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1993	363	6425					159	163		10.1038/363159a0	http://dx.doi.org/10.1038/363159a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483499				2022-12-28	WOS:A1993LB80100047
J	FRIEDMAN, E				FRIEDMAN, E			CHANGING THE SYSTEM - IMPLICATIONS FOR PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; FRIEDMAN E, 1993, HOSPITALS, V67, P18; FRIEDMAN EA, 1993, ALOHA WAY HLTH CARE; FRIEDMAN EA, 1992, HLTH BUSINESS, V7, pT1; GINZBERG E, 1984, NEW ENGL J MED, V310, P1162, DOI 10.1056/NEJM198405033101806; HAVLICEK PL, 1992, HLTH BUSINESS, V7, pT1; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V267, P2521; 1990, CALL ACTION; 1992, 1991 SURVEY HUMAN RE; 1992, HLTH BENEFITS 1992; 1991, PHYSICIAN MARKETPLAC, V2, P3	11	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2437	+		10.1001/jama.269.18.2437	http://dx.doi.org/10.1001/jama.269.18.2437			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479072				2022-12-28	WOS:A1993LA67500041
J	DESAI, DM; SAP, J; SCHLESSINGER, J; WEISS, A				DESAI, DM; SAP, J; SCHLESSINGER, J; WEISS, A			LIGAND-MEDIATED NEGATIVE REGULATION OF A CHIMERIC TRANSMEMBRANE RECEPTOR TYROSINE PHOSPHATASE	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; PHOSPHOLIPASE-C ACTIVATION; CD45 ISOFORM EXPRESSION; T-CELLS; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PROTEIN-KINASE; EGF-RECEPTOR	CD45, a transmembrane protein tyrosine phosphatase (PTPase), is required for TCR signaling. Multiple CD45 isoforms, differing in the extracellular domain, are expressed in a tissue- and activation-specific manner, suggesting an important function for this domain. We report that a chimeric protein in which the extracellular and transmembrane domains of CD45 are replaced with those of the EGF receptor (EGFR) is able to restore TCR signaling in a CD45-deficient cell. Thus, the cytoplasmic domain of CD45 is necessary and sufficient for TCR signal transduction. Moreover, EGFR ligands functionally inactivate the EGFR-CD45 chimera in a manner that is dependent on dimerization of the chimeric protein. Inactivation of EGFR-CD45 chimera function results in the loss of TCR signaling, indicating that CD45 function is continuously required for TCR-mediated proximal signaling events. These results suggest that ligand-mediated regulation of receptor-PTPases may have mechanistic similarities with receptor tyrosine kinases.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Howard Hughes Medical Institute; University of California System; University of California San Francisco; New York University	DESAI, DM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEANS JP, 1992, J IMMUNOL, V148, P1898; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDMAN SJ, 1992, J BIOL CHEM, V267, P6197; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HATHCOCK KS, 1992, J IMMUNOL, V148, P19; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING AC, 1982, J BIOL CHEM, V257, P3053; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MARVEL J, 1989, EUR J IMMUNOL, V19, P2005, DOI 10.1002/eji.1830191106; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHRAVEN B, 1989, EUR J IMMUNOL, V19, P397, DOI 10.1002/eji.1830190226; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SHIVNAN E, 1992, EUR J IMMUNOL, V22, P1055, DOI 10.1002/eji.1830220427; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1988, FUNDAMENTAL IMMUNOLO, P359	80	261	268	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					541	554		10.1016/0092-8674(93)90141-C	http://dx.doi.org/10.1016/0092-8674(93)90141-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490965				2022-12-28	WOS:A1993LA74300015
J	BIANCHI, DW; BERNFIELD, M; NATHAN, DG				BIANCHI, DW; BERNFIELD, M; NATHAN, DG			A REVIVED OPPORTUNITY FOR FETAL RESEARCH	NATURE			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	BIANCHI, DW (corresponding author), TUFTS UNIV,SCH MED,DEPT PEDIAT OBSTET & GYNECOL,BOSTON,MA 02111, USA.							CROMBLEHOLME TM, 1991, AM J OBSTET GYNECOL, V164, P218, DOI 10.1016/0002-9378(91)90656-C; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; LEDBETTER DH, 1992, PRENATAL DIAG, V12, P317, DOI 10.1002/pd.1970120503; LIM B, 1989, P NATL ACAD SCI USA, V86, P8892, DOI 10.1073/pnas.86.22.8892; PURVISSMITH SG, 1992, AM J HUM GENET, V50, P1348; RAUDRANT D, 1992, BONE MARROW TRANSPL, V9, P98; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; TOURAINE JL, 1991, J INHERIT METAB DIS, V14, P610; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; WAPNER RJ, 1992, PRENATAL DIAG, V12, P347, DOI 10.1002/pd.1970120504; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203	12	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					12	12		10.1038/363012a0	http://dx.doi.org/10.1038/363012a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479528	Bronze			2022-12-28	WOS:A1993LA68200024
J	GARFIELD, J				GARFIELD, J			LET THE HEALTH AUTHORITY TAKE THE RESPONSIBILITY	BRITISH MEDICAL JOURNAL			English	Article											GARFIELD, J (corresponding author), SOUTHAMPTON GEN HOSP,WESSEX NEUROL CTR,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1050	1050		10.1136/bmj.306.6884.1050	http://dx.doi.org/10.1136/bmj.306.6884.1050			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490504	Green Published, Bronze			2022-12-28	WOS:A1993KY44800028
J	MAW, R; BAWDEN, R				MAW, R; BAWDEN, R			SPONTANEOUS RESOLUTION OF SEVERE CHRONIC GLUE EAR IN CHILDREN AND THE EFFECT OF ADENOIDECTOMY, TONSILLECTOMY, AND INSERTION OF VENTILATION TUBES (GROMMETS)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; EFFUSION; SURGERY; SIZE; AGE	Objective-To measure the time to spontaneous resolution of severe chronic otitis media with effusion (glue ear) in children and study the effects of adenoidectomy, adenotonsillectomy, and ventilation tubes (grommets). Design-Randomised controlled study over 12 years. Setting-Paediatric otorhinolaryngology clinics and in-patient unit. Subjects-228 children aged 2-9 years with pronounced hearing loss from glue ear and persistent bilateral middle ear effusions confirmed on three occasions over three months. Interventions-Children were randomly allocated to adenotonsillectomy, adenoidectomy, or neither procedure. In all groups a Shepard type ventilation tube was inserted in one randomly chosen ear. Follow up was annually for five years and then less often for up to seven years four months. For analysis the two operated groups were combined. Main outcome measures-Otoscopic clearance of fluid, change in tympanogram, and improvement in mean audiometric hearing threshold. Results-Survival analysis showed appreciable otoscopic and tympanometric resolution of fluid with ventilation tubes alone and adenoidectomy alone compared with no surgery. Further improvement was seen after combination of both treatments. Mean audiometric hearing thresholds improved with fluid resolution. Resolution was delayed in younger children and in those whose parents smoked, irrespective of treatment. Whereas a single insertion of a Shepard tube resolved the glue for a mean (SD) period of 9.5 (5.2) months, the effect of adenoidectomy was sustained throughout follow up. Conclusions-Treatment of glue ear considerably shortened the time to fluid resolution, combined adenoidectomy and tube insertion being better than either procedure alone. Resolution was longer in younger children and those whose parent(s) smoked, irrespective of treatment.	UNIV BRISTOL, BRISTOL BS8 1TH, AVON, ENGLAND	University of Bristol	MAW, R (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP, DEPT OTOLARYNGOL, BRISTOL BS2 8HW, AVON, ENGLAND.							BLACK N, 1985, J ROY SOC MED, V78, P641, DOI 10.1177/014107688507800809; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; BUCKLEY G, 1991, CLIN OTOLARYNGOL, V16, P354, DOI 10.1111/j.1365-2273.1991.tb00947.x; DEMPSTER JH, IN PRESS J LARYNGOL; LEIBERMAN A, 1986, J LARYNGOL OTOL, V100, P875, DOI 10.1017/S0022215100100258; MAW AR, 1979, CLIN OTOLARYNGOL, V4, P149; MAW AR, 1986, LANCET, V1, P1399; MAW AR, 1988, ACTA OTO-LARYNGOL, P202; MAW AR, 1983, BRIT MED J, V287, P1586, DOI 10.1136/bmj.287.6405.1586; MAW AR, 1985, AM J OTOLARYNG, V6, P245; MAW AR, 1991, J LARYNGOL OTOL, V105, P71, DOI 10.1017/S0022215100114999; PARKER AJ, 1989, J LARYNGOL OTOL, V103, P66, DOI 10.1017/S0022215100108059; STEPHENSON H, 1992, CLIN OTOLARYNGOL, V17, P67, DOI 10.1111/j.1365-2273.1992.tb00991.x; 1985, SAS USERS GUIDE STAT	14	78	79	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	1993	306	6880					756	760		10.1136/bmj.306.6880.756	http://dx.doi.org/10.1136/bmj.306.6880.756			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490338	Bronze, Green Published			2022-12-28	WOS:A1993KU17300022
J	CERHAN, JR; WALLACE, RB; FOLSOM, AR; POTTER, JD; MUNGER, RG; PRINEAS, RJ				CERHAN, JR; WALLACE, RB; FOLSOM, AR; POTTER, JD; MUNGER, RG; PRINEAS, RJ			TRANSFUSION HISTORY AND CANCER RISK IN OLDER WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD TRANSFUSION; NEOPLASMS; REGISTRIES; KIDNEY NEOPLASMS; LYMPHOMA, NON-HODGKINS	PERIOPERATIVE BLOOD-TRANSFUSION; ADVERSELY AFFECTS PROGNOSIS; CELL LUNG-CANCER; COLORECTAL-CANCER; BREAST-CANCER; TRANSPLANT PATIENTS; SURVIVAL; RECURRENCE; COLON; CARCINOMA	Objective: To test the hypothesis that history of blood transfusion is associated with an increased incidence of cancer in older women. Design: Prospective cohort study. Setting: General community in the state of Iowa. Participants: Random sample of 37 337 cancer-free Iowa women ages 55 to 69 years. Measurements: Transfusion history was assessed with a mailed questionnaire completed in January 1986. Cancer incidence in 5 years was ascertained by a population-based cancer registry. Results: Women who had ever received a blood transfusion were at an increased risk for non-Hodgkin lymphoma (relative risk (RR) = 2.20; 95% CI, 1.35 to 3.58) and kidney cancer (RR = 2.53; CI, 1.34 to 4.78). The relative risks for these cancers were greater with decreasing time from first transfusion. No increased risk occurred for cancers of the breast, lung, uterine corpus, ovary, pancreas, colon, rectum, skin (melanoma), or for all cancers considered together. Conclusion: These findings suggest that previous blood transfusion may be a risk factor for non-Hodgkin lymphoma and kidney cancer but is not associated with the most common neoplasms.	UNIV MIAMI, SCH MED, MIAMI, FL 33152 USA; UNIV MINNESOTA, SCH PUBL HLTH, MINNEAPOLIS, MN 55455 USA	University of Miami; University of Minnesota System; University of Minnesota Twin Cities	CERHAN, JR (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, 2800 STEINDLER BLDG, IOWA CITY, IA 52242 USA.			Potter, John/0000-0001-5439-1500; Cerhan, James/0000-0002-7482-178X	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA099607, R01-CA 39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK I, 1981, AM J REPROD IMMUNOL, V1, P224, DOI 10.1111/j.1600-0897.1981.tb00043.x; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BIRKELAND SA, 1983, SURGERY, V93, P504; BIRKELAND SA, 1983, TRANSPLANT P, V15, P1071; BLUMBERG N, 1985, BRIT MED J, V290, P1037, DOI 10.1136/bmj.290.6474.1037; Breslow N. E., 1987, STATISTICAL METHODS, VII; BURKITT DP, 1969, JNCI-J NATL CANCER I, V42, P19; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; BURROWS L, 1982, LANCET, V2, P662; BURROWS L, 1983, TRANSFUSION, V23, P419; COHEN E, 1986, P INT SOC BLOOD TRAN, P490; CORMAN J, 1986, CAN J SURG, V29, P325; DAWSON DA, 1989, VITAL HLTH STATISTIC, V176; FISCHER E, 1980, HUM IMMUNOL, V1, P187, DOI 10.1016/0198-8859(80)90013-0; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOSTER RS, 1985, CANCER, V55, P1195, DOI 10.1002/1097-0142(19850315)55:6<1195::AID-CNCR2820550610>3.0.CO;2-H; FOSTER RS, 1984, ARCH SURG-CHICAGO, V119, P1138; FRANCIS DMA, 1987, BRIT J SURG, V74, P26, DOI 10.1002/bjs.1800740110; FRANKISH PD, 1985, BRIT MED J, V290, P1827, DOI 10.1136/bmj.290.6484.1827-b; Fraumeni J F Jr, 1977, Natl Cancer Inst Monogr, V47, P121; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GASCON P, 1984, ANN INTERN MED, V100, P173, DOI 10.7326/0003-4819-100-2-173; GRZELAK I, 1984, EUR SURG RES, V16, P105, DOI 10.1159/000128395; HAMID J, 1984, CLIN EXP IMMUNOL, V56, P49; HARDY AM, 1989, VITAL HLTH STATISTIC, V179; HYMAN NH, 1985, AM J SURG, V149, P502, DOI 10.1016/S0002-9610(85)80047-7; JOHNSON JT, 1987, ARCH OTOLARYNGOL, V113, P307; KANEDA M, 1987, TRANSFUSION, V27, P375, DOI 10.1046/j.1537-2995.1987.27587320526.x; KAPLAN J, 1984, BLOOD, V64, P308; KELLER SM, 1988, CANCER, V62, P606, DOI 10.1002/1097-0142(19880801)62:3<606::AID-CNCR2820620327>3.0.CO;2-Q; KINLEN L, 1983, TRANSPLANT P, V15, P1039; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1981, BRIT MED J, V282, P474, DOI 10.1136/bmj.282.6262.474-b; LITTLE AG, 1990, AM J SURG, V160, P630, DOI 10.1016/S0002-9610(05)80762-7; MANYONDA IT, 1986, BRIT MED J, V293, P537, DOI 10.1136/bmj.293.6546.537-a; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MG VL, 1989, 4TH INT C AIDS MONTR, P688; MIKULIN T, 1986, BRIT J SURG, V73, P1036; MOFFAT LEF, 1987, BRIT J UROL, V60, P316, DOI 10.1111/j.1464-410X.1987.tb04975.x; MOORES DWO, 1989, ANN THORAC SURG, V47, P346, DOI 10.1016/0003-4975(89)90371-8; NATHANSON SD, 1985, ARCH SURG-CHICAGO, V120, P734; NOWAK MM, 1984, J SURG ONCOL, V27, P124, DOI 10.1002/jso.2930270214; OPELZ G, 1981, LANCET, V2, P1057; OPELZ G, 1980, TRANSPLANTATION, V29, P153, DOI 10.1097/00007890-198002000-00013; OTA D, 1985, TRANSFUSION, V25, P392, DOI 10.1046/j.1537-2995.1985.25485273825.x; PARROT NR, 1986, BRIT J SURG, V73, P970, DOI 10.1002/bjs.1800731208; PASTORINO U, 1986, EUR J CANCER CLIN ON, V22, P1375, DOI 10.1016/0277-5379(86)90148-3; PENN I, 1986, PROG ALLERGY, V37, P259; PERSIJN GG, 1979, TRANSPLANTATION, V28, P396, DOI 10.1097/00007890-197911000-00010; RAPAPORT FT, 1984, ANN SURG, V199, P79, DOI 10.1097/00000658-198401000-00014; REYNOLDS T, 1991, J NATL CANCER I, V83, P232, DOI 10.1093/jnci/83.4.232; RIES LAG, 1989, NCI NIH902789 PUBL; ROSENBERG SA, 1985, J CLIN ONCOL, V3, P698, DOI 10.1200/JCO.1985.3.5.698; SINGAL DP, 1983, TRANSPLANT P, V15, P1005; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P697; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1985, NIH852028 PUBL; TARTTER PI, 1989, AM J CLIN ONCOL-CANC, V12, P169, DOI 10.1097/00000421-198904000-00016; TARTTER PI, 1988, TRANSFUSION, V28, P593, DOI 10.1046/j.1537-2995.1988.28689059039.x; TARTTER PI, 1984, J THORAC CARDIOV SUR, V88, P659; TARTTER PI, 1985, SURGERY, V97, P225; TARTTER PI, 1989, VOX SANG, V56, P80, DOI 10.1111/j.1423-0410.1989.tb04954.x; TARTTER PI, 1989, TRANSFUSION, V29, P456, DOI 10.1046/j.1537-2995.1989.29589284149.x; Thomas L, 1959, CELLULAR HUMORAL ASP, P529; VANES AA, 1977, LANCET, V1, P506; VOOGT PJ, 1987, CANCER, V59, P836, DOI 10.1002/1097-0142(19870215)59:4<836::AID-CNCR2820590430>3.0.CO;2-S; WAHMAN A, 1991, EPIDEMIOL REV, V13, P178, DOI 10.1093/oxfordjournals.epirev.a036068; WAYMACK JP, 1987, ARCH SURG-CHICAGO, V122, P935; WEIDEN PL, 1987, CANCER-AM CANCER SOC, V60, P870, DOI 10.1002/1097-0142(19870815)60:4<870::AID-CNCR2820600425>3.0.CO;2-0; Woolson R. F, 1987, STATISTICAL METHODS; 1984, NCI NIH851837 PUBL; 1984, IOWA POPULATION PROJ; 1985, BRIT MED J, V290, P1516; 1992, IOWA HLTH Q	74	62	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					8	15		10.7326/0003-4819-119-1-199307010-00002	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498768				2022-12-28	WOS:A1993LJ26600002
J	ZANGWILL, KM; HAMILTON, DH; PERKINS, BA; REGNERY, RL; PLIKAYTIS, BD; HADLER, JL; CARTTER, ML; WENGER, JD				ZANGWILL, KM; HAMILTON, DH; PERKINS, BA; REGNERY, RL; PLIKAYTIS, BD; HADLER, JL; CARTTER, ML; WENGER, JD			CAT-SCRATCH DISEASE IN CONNECTICUT - EPIDEMIOLOGY, RISK-FACTORS, AND EVALUATION OF A NEW DIAGNOSTIC-TEST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AGENT	Background. Although cat scratch disease is commonly diagnosed in patients who have unexplained regional lymphadenopathy after encounters with cats, its epidemiology and the risk factors for disease are not clearly defined, and there is no generally accepted diagnostic test Methods. We conducted a physician survey to identify cases of cat scratch disease occurring over a 13-month period in cat owners in Connecticut. We interviewed both the patients (or their parents) and controls matched for age who owned cats. Serum from the patients was tested for antibodies to Rochalimaea henselae with a new, indirect fluorescent-antibody test. Results. We identified 60 patients with cat scratch disease and 56 age-matched, cat-owning control subjects. Patients were more likely than controls to have at least one pet kitten 12 months old or younger (odds ratio, 15), to have been scratched or kitten by a kitten (odds ratio, 27), and to have had at least one kitten with fleas (odds ratio, 29). A conditional logistic-regression analysis found that in kitten-owning households, patients were more likely than controls to have been scratched or bitten by a cat or kitten (odds ratio, 12.4; 95 percent confidence interval, 1.0 to 150). Of 45 patients, 38 had serum samples with titers of 1:64 or higher for antibody to R. henselae, as compared with 4 of 112 samples from controls (P<0.001). The positive predictive value of the serologic test was 91 percent. Of 48 serum samples from patients' cats, 39 were positive for antibodies to R. henselae, as compared with positive samples from 11 of 29 control cats (P<0.001). Conclusions. Cat scratch disease is strongly associated with owning a kitten, and fleas may be involved in its transmission. The serologic test for rochalimaea may be useful diagnostically, and our results suggest an etiologic role for this genus.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,HARTFORD,CT; CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD SERV,HARTFORD,CT; CONNECTICUT DEPT HLTH SERV,BUR HLTH PROMOT,EPIDEMIOL SECT,HARTFORD,CT; CTR DIS CONTROL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	ZANGWILL, KM (corresponding author), CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.							BOYD GL, 1961, J PEDIATR-US, V59, P313, DOI 10.1016/S0022-3476(61)80282-5; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; DANIELS WB, 1954, JAMA-J AM MED ASSOC, V154, P1247, DOI 10.1001/jama.1954.02940490011003; DEBRE R., 1950, BuL Mem. Soc. Med. Hop., V66, P76; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; GERBER MA, 1985, LANCET, V1, P1236; GROVES R, 1988, TELEPHONE SURVEY MET; Harwood RF, 1979, ENTOMOLOGY HUMAN ANI, V7th; JACKSON LA, IN PRESS AM J PUBLIC; KALTER SS, 1969, NATURE, V224, P190, DOI 10.1038/224190a0; KWOCHKA KW, 1987, VET CLIN N AM-SMALL, V17, P1235, DOI 10.1016/S0195-5616(87)50001-8; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MARGILETH AM, 1968, PEDIATRICS, V42, P803; MARGILETH AM, 1987, VET CLIN N AM-SMALL, V17, P91, DOI 10.1016/S0195-5616(87)50607-6; MARGILETH AM, 1971, CLIN P CHILDRENS HOS, V27, P213; MARGILETH AM, 1990, CONT PEDIATR, V7, P25; Moriarty R A, 1987, Infect Dis Clin North Am, V1, P575; PERKINS BA, 1992, NEW ENGL J MED, V327, P1599, DOI 10.1056/NEJM199211263272215; REGNERY R, 1992, LANCET, V340, P557, DOI 10.1016/0140-6736(92)91760-6; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SHINALL EA, 1990, PEDIATR DERMATOL, V7, P11, DOI 10.1111/j.1525-1470.1990.tb01066.x; Shinall EA, 1990, PEDIAT DERMATOL, V7, P165; SPAULDING WB, 1960, AM J MED, V28, P504, DOI 10.1016/0002-9343(60)90144-3; TROUTMAN CM, 1988, J AM VET MED ASSOC, V193, P1217; TURNER W, 1960, J BACTERIOL, V80, P430, DOI 10.1128/JB.80.4.430-435.1960; Warwick W J, 1967, Prog Med Virol, V9, P256; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZITELLI BJ, 1990, CONT PEDIATR, V7, P90; 1988, SAS USERS GUIDE VERS	31	411	422	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					8	13		10.1056/NEJM199307013290102	http://dx.doi.org/10.1056/NEJM199307013290102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505963				2022-12-28	WOS:A1993LJ33800002
J	DOWNS, JR; OSTER, G; SANTANELLO, NC				DOWNS, JR; OSTER, G; SANTANELLO, NC			HMG COA REDUCTASE INHIBITORS AND QUALITY-OF-LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VALIDITY		POLICY ANAL INC,BROOKLINE,MA; MERCK SHARP & DOHME LTD,W POINT,PA 19486	Policy Analysis Inc; Merck & Company	DOWNS, JR (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.							CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007	5	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3107	3108		10.1001/jama.269.24.3107	http://dx.doi.org/10.1001/jama.269.24.3107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505809				2022-12-28	WOS:A1993LH14500018
J	DEBONDT, HL; ROSENBLATT, J; JANCARIK, J; JONES, HD; MORGAN, DO; KIM, SH				DEBONDT, HL; ROSENBLATT, J; JANCARIK, J; JONES, HD; MORGAN, DO; KIM, SH			CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2	NATURE			English	Article							P34CDC2 PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REGULATORY PHOSPHORYLATION; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MUTANT ALLELES; GENE CDC28; IDENTIFICATION	Cyclin-dependent kinase 2 (CDK2) is a member of a highly conserved family of protein kinases that regulate the eukaryotic cell cycle. The crystal structures of the human CDK2 apoenzyme and its Mg2+ ATP complex have been determined to 2.4angstrom resolution. The structure is bi-lobate, like that of the cyclic AMP-dependent protein kinase, but contains a unique helix-loop segment that interferes with ATP and protein substrate binding and probably plays a key part in the regulation of all cyclin-dependent kinases.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco			Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868; Morgan, David/0000-0001-8753-4416				ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FUREY W, 1992, PHASES MANUAL; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P286; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETSKO GA, 1985, METHOD ENZYMOL, V114, P147; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHENG J, 1993, ACTA CRYSTALLOG RD, V49, P363; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	50	830	854	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					595	602		10.1038/363595a0	http://dx.doi.org/10.1038/363595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510751				2022-12-28	WOS:A1993LH13900045
J	CHILMONCZYK, BA; SALMUN, LM; MEGATHLIN, KN; NEVEUX, LM; PALOMAKI, GE; KNIGHT, GJ; PULKKINEN, AJ; HADDOW, JE				CHILMONCZYK, BA; SALMUN, LM; MEGATHLIN, KN; NEVEUX, LM; PALOMAKI, GE; KNIGHT, GJ; PULKKINEN, AJ; HADDOW, JE			ASSOCIATION BETWEEN EXPOSURE TO ENVIRONMENTAL TOBACCO-SMOKE AND EXACERBATIONS OF ASTHMA IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY COTININE CONCENTRATIONS; PASSIVE SMOKING; RESPIRATORY ILLNESS; MATERNAL SMOKING; PULMONARY-FUNCTION; CIGARETTE-SMOKING; BRONCHIAL RESPONSIVENESS; PARENTAL SMOKING; EARLY-CHILDHOOD; LUNG-FUNCTION	Background. Exposure to environmental tobacco smoke, as reported by parents, has been linked to diminished pulmonary function and more frequent exacerbations of asthma in children with the disease. Further insight into this association might be gained by using urine cotinine levels to measure actual exposure. Methods. We measured urine cotinine levels in 199 children with asthma; 145 also underwent pulmonary-function studies. A parent answered questions about each child's exposure to environmental tobacco smoke. Acute exacerbations of asthma during the preceding year were documented through blinded review of medical records. Possible confounding factors were accounted for by the use of multivariate analysis and by comparisons of serum theophylline levels in exposed and unexposed children. Results. The median urine cotinine levels were 5.6 ng per milliliter in the 116 children reported not to have been exposed to tobacco smoke, 13.1 ng per milliliter in the 53 children exposed to cigarette smoking by the mother or other persons, and 55.8 ng per milliliter in the 30 children exposed to cigarette smoking by the mother and other persons. Acute exacerbations of asthma increased with exposure, whether such exposure was reported by a parent or identified on the basis of the cotinine level; the relative risks for the highest as compared with the lowest exposure category were 1.8 (95 percent confidence interval, 1.4 to 2.2) for reported exposure and 1.7 (95 percent confidence interval, 1.4 to 2.1) for exposure indicated by cotinine levels. The forced expiratory volume in one second (FEV1), the forced expiratory flow between 25 and 75 percent of vital capacity, and the ratio of FEV1 to forced vital capacity also decreased with increases in both measures of exposure. Conclusions. Measurement of urine cotinine levels provides further evidence of an association between exposure to environmental tobacco smoke and pulmonary morbidity in children with asthma. These data emphasize the need for systematic, persistent efforts to stop the exposure of children with asthma to environmental tobacco smoke.	FDN BLOOD RES,POB 190,SCARBOROUGH,ME 04070; MAINE MED CTR,PORTLAND,OR	Foundation for Blood Research (FBR)								CHEN Y, 1986, BRIT MED J, V293, P303, DOI 10.1136/bmj.293.6542.303; CHEN Y, 1986, AM J PUBLIC HEALTH, V76, P515, DOI 10.2105/AJPH.76.5.515; CHILMONCZYK BA, 1990, AM J PUBLIC HEALTH, V80, P1205, DOI 10.2105/AJPH.80.10.1205; COLLEY JRT, 1974, LANCET, V2, P1031; Dixon W. J., 1990, BMDP STATISTICAL SOF; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; FERRIS BG, 1985, ENVIRON HEALTH PERSP, V62, P289, DOI 10.2307/3430127; FRISCHER T, 1992, J PEDIATR-US, V121, P17, DOI 10.1016/S0022-3476(05)82534-X; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; KNIGHT A, 1985, MED J AUSTRALIA, V142, P194, DOI 10.5694/j.1326-5377.1985.tb133098.x; KNIGHT GJ, 1989, CLIN CHEM, V35, P1036; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1989, PEDIATRICS, V84, P451; RANTAKALLIO P, 1978, ACTA PAEDIATR SCAND, V67, P621, DOI 10.1111/j.1651-2227.1978.tb17813.x; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; THOMPSON SG, 1990, CLIN CHIM ACTA, V187, P289, DOI 10.1016/0009-8981(90)90114-8; THOMPSON SG, 1990, THORAX, V45, P356, DOI 10.1136/thx.45.5.356; WALD NJ, 1984, LANCET, V1, P230; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; WEITZMAN M, 1990, PEDIATRICS, V85, P505; YARNELL JWG, 1979, BRIT J DIS CHEST, V73, P230, DOI 10.1016/0007-0971(79)90045-7; 1991, J ALLERGY CLIN IMM S, V88, P427; 1986, CAN MED ASSOC J, V135, P321	27	387	396	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1665	1669		10.1056/NEJM199306103282303	http://dx.doi.org/10.1056/NEJM199306103282303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8487825				2022-12-28	WOS:A1993LF05400003
J	JORDAN, G; MOLLON, JD				JORDAN, G; MOLLON, JD			THE NAGEL ANOMALOSCOPE AND SEASONAL-VARIATION OF COLOR-VISION	NATURE			English	Article								IN 1948 the German physicist, Manfred Richter, reported that colour vision has a seasonal variation1,2. For four colour-normal subjects, he found a sinusoidal variation in the proportion of red and green required to match a monochromatic yellow, the equation known as the 'Rayleigh match'3. In summer, subjects required more red in their mixture. The measurements were made with the Nagel anomaloscope, an instrument introduced in 1907(4,5) and which today, essentially unchanged, remains the definitive clinical instrument for classifying the many phenotypic variations in colour vision. The variation that Richter recorded in the red-green ratio was large (three Nagel units), and it now takes on fresh interest because it is comparable in size to the difference in Nagel settings later reported between normal observers of different genetic type6,7. We have been able to replicate Richter's result, but report here that it is almost certainly instrumental: the Nagel anomaloscope proves to be very sensitive to ambient temperature.			JORDAN, G (corresponding author), UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, DOWNING ST, CAMBRIDGE CB2 3EB, ENGLAND.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X; Jordan, Gabriele/0000-0002-3994-6675				HEINSIUS E, 1973, FARBSINNSTORUNGEN IH; JORDAN G, 1992, POLYM NORMAL COLOUR; KNOWLES A, 1980, VISION RES, V20, P475, DOI 10.1016/0042-6989(80)90122-4; KOLLNER H, 1915, ARCH AUGENHEILKD, V78, P302; KUNLIN J, 1948, CR HEBD ACAD SCI, V226, P357, DOI 10.1007/BF00369741; Merton TR, 1927, P R SOC LOND A-CONTA, V113, P704, DOI 10.1098/rspa.1927.0018; MORELAND JD, 1974, COLOUR VISION DEFICI, V2, P14; NAGEL W, 1909, HDB PHYSL METHODIK; NAGEL WA, 1907, Z AUGENHEILKD, V18, P201; POKORNY J., 1979, CONGENITAL ACQUIRED; Rayleigh L., 1881, NATURE, V25, P64, DOI [10.1038/025064a0, DOI 10.1038/025064A0]; RICHTER M, 1951, Klin Monbl Augenheilkd Augenarztl Fortbild, V119, P561; RICHTER M, 1948, Z WISS PHOTOGR PHOTO, V43, P209; Waaler G. H. M., 1967, AVHANDL DET NORSKE V, V9, P1; WAALER GHM, 1967, NATURE, V215, P406, DOI 10.1038/215406a0; WINDERICKX J, 1992, NAT GENET, V1, P251, DOI 10.1038/ng0792-251	16	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					546	549		10.1038/363546a0	http://dx.doi.org/10.1038/363546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505982				2022-12-28	WOS:A1993LF93900051
J	KIRKWOOD, A; DUDEK, SM; GOLD, JT; AIZENMAN, CD; BEAR, MF				KIRKWOOD, A; DUDEK, SM; GOLD, JT; AIZENMAN, CD; BEAR, MF			COMMON FORMS OF SYNAPTIC PLASTICITY IN THE HIPPOCAMPUS AND NEOCORTEX INVITRO	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT VISUAL-CORTEX; D-ASPARTATE RECEPTORS; NMDA RECEPTORS; INDUCTION; STIMULATION; SLICES; TRANSMISSION; DEPRESSION; BLOCKADE	Activity-dependent synaptic plasticity in the superficial layers of juvenile cat and adult rat visual neocortex was compared with that in adult rat hippocampal field CA1. Stimulation of neocortical layer IV reliably induced synaptic long-term potentiation (LTP) and long-term depression (LTD) in layer III with precisely the same types of stimulation protocols that were effective in CA1. Neocortical LTP and LTD were specific to the conditioned pathway and, as in the hippocampus, were dependent on activation of N-methyl-D-aspartate receptors. These results provide strong support for the view that common principles may govern experience-dependent synaptic plasticity in CA1 and throughout the superficial layers of the mammalian neocortex.			KIRKWOOD, A (corresponding author), BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912, USA.		Dudek, Serena/C-6561-2009	Dudek, Serena/0000-0003-4094-8368; Bear, Mark/0000-0002-9903-2541				ALGER BE, 1976, BRAIN RES, V110, P463, DOI 10.1016/0006-8993(76)90858-1; ARONIADOU VA, 1992, BRAIN RES, V584, P169, DOI 10.1016/0006-8993(92)90891-C; ARTOLA A, 1990, EUR J NEUROSCI, V2, P254, DOI 10.1111/j.1460-9568.1990.tb00417.x; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, IN PRESS  CURR OPINI; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BERRY RL, 1989, BRAIN RES, V481, P221, DOI 10.1016/0006-8993(89)90797-X; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BODEGREUEL KM, 1987, EXP BRAIN RES, V69, P213; BURKHALTER A, 1989, J COMP NEUROL, V279, P171, DOI 10.1002/cne.902790202; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GOLDMAN RS, 1990, P NATL ACAD SCI USA, V87, P7165, DOI 10.1073/pnas.87.18.7165; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HIRSCH JC, 1991, EXP BRAIN RES, V85, P621; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KIMURA F, 1989, J PHYSIOL-LONDON, V414, P125, DOI 10.1113/jphysiol.1989.sp017680; KOMATSU Y, 1991, J NEUROPHYSIOL, V65, P20, DOI 10.1152/jn.1991.65.1.20; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; PERKINS AT, 1988, BRAIN RES, V439, P222; STEVENS CF, 1993, NEURON S, V10, P55; TSUMOTO T, 1992, PROG NEUROBIOL, V39, P209, DOI 10.1016/0301-0082(92)90011-3	28	395	399	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1518	1521		10.1126/science.8502997	http://dx.doi.org/10.1126/science.8502997			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502997				2022-12-28	WOS:A1993LF05800041
J	ANSCHER, MS; PETERS, WP; REISENBICHLER, H; PETROS, WP; JIRTLE, RL				ANSCHER, MS; PETERS, WP; REISENBICHLER, H; PETROS, WP; JIRTLE, RL			TRANSFORMING GROWTH-FACTOR-BETA AS A PREDICTOR OF LIVER AND LUNG FIBROSIS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADVANCED BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDUCED PULMONARY FIBROSIS; VENO-OCCLUSIVE DISEASE; RNA ENCODING PROCOLLAGENS; VENOOCCLUSIVE DISEASE; GENE-EXPRESSION; FACTOR-BETA-1 EXPRESSION; CARBON-TETRACHLORIDE; COLLAGEN-SYNTHESIS; RISK-FACTORS; CYCLOPHOSPHAMIDE	Background. Hepatic veno-occlusive disease and idiopathic interstitial pneumonitis are major causes of morbidity and mortality after bone marrow transplantation. Fibrosis is a characteristic of both conditions, and transforming growth factor beta (TGFbeta) has been implicated in the pathogenesis of fibrosis. Methods. Using acid-ethanol extraction to remove TGFbeta from human plasma and a mink-lung epithelial-cell growth-inhibition assay to measure TGFbeta activity, we quantified plasma TGFbeta in 10 normal subjects and 41 patients before and after they underwent high-dose chemotherapy and autologous bone marrow transplantation for advanced breast cancer. Results. There was no difference in pretransplantation TGFbeta levels between the controls and the patients who did not have hepatic veno-occlusive disease or idiopathic interstitial pneumonitis after transplantation. In contrast, pretransplantation TGFbeta levels were significantly higher in patients in whom hepatic veno-occlusive disease or idiopathic interstitial pneumonitis developed than in the controls or the patients without these conditions. The predictive value for the development of either condition was 90 percent or more when pretransplantation plasma TGFbeta levels were more than 2 SD above the mean established in the controls. Conclusions. The plasma TGFbeta concentration measured after induction chemotherapy but before high-dose chemotherapy and autologous bone marrow transplantation strongly correlates with the risk of hepatic veno-occlusive disease and idiopathic interstitial pneumonitis after these treatments.	DUKE UNIV, SCH MED, DEPT RADIAT ONCOL, DURHAM, NC 27706 USA; DUKE UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, DURHAM, NC 27706 USA	Duke University; Duke University				Anscher, Mitchell/0000-0003-4480-111X	NATIONAL CANCER INSTITUTE [R01CA025951, R01CA040172] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40172, CA-25951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMENTO EP, 1991, CIBA FDN S, V157, P115; ANSCHER MS, 1990, RADIAT RES, V122, P77, DOI 10.2307/3577586; ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRODSKY R, 1990, AM J CLIN ONCOL-CANC, V13, P221, DOI 10.1097/00000421-199006000-00009; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; ETTINGER NA, 1991, AM REV RESPIR DIS, V144, P213, DOI 10.1164/ajrccm/144.1.213; FREUND JE, 1967, MODERN ELEMENTARY ST; GANEM G, 1988, INT J RADIAT ONCOL, V14, P879, DOI 10.1016/0360-3016(88)90009-0; GLUCKMAN E, 1990, NOUV REV FR HEMATOL, V32, P1; HACKMAN RC, 1989, TRANSPLANTATION, V47, P989, DOI 10.1097/00007890-198906000-00014; HARRISON NK, 1991, CHEST, V99, pS71, DOI 10.1378/chest.99.3_Supplement.71S; HOYT DG, 1989, J PHARMACOL EXP THER, V249, P38; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; JIRTLE RL, 1991, J BIOL CHEM, V266, P24860; JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011; Kahaleh M.B., 1989, CLIN ASPECTS AUTOIMM, V3, P19; KELLEY J, 1991, CHEST, V99, pS85, DOI 10.1378/chest.99.3_Supplement.85S; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LIE TS, 1991, SURGERY, V110, P847; LIMPER AH, 1991, CHEST, V99, pS55, DOI 10.1378/chest.99.3_Supplement.55S; LUCAS C, 1990, J IMMUNOL, V145, P1415; LYNCH SE, 1989, J CLIN INVEST, V84, P640, DOI 10.1172/JCI114210; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCDONALD GB, 1986, GASTROENTEROLOGY, V90, P770, DOI 10.1016/0016-5085(86)91137-6; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578; MILANI S, 1991, AM J PATHOL, V139, P1221; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; NOBLE PW, 1989, WESTERN J MED, V150, P443; OZKAYNAK MF, 1991, BONE MARROW TRANSPL, V7, P467; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PHAN SH, 1991, J CLIN INVEST, V87, P148, DOI 10.1172/JCI114964; Piedbois P, 1990, Radiother Oncol, V18 Suppl 1, P125, DOI 10.1016/0167-8140(90)90191-X; PROPER JA, 1982, J CELL PHYSIOL, V110, P169, DOI 10.1002/jcp.1041100210; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; SCROBOHACI ML, 1991, THROMB RES, V63, P509, DOI 10.1016/0049-3848(91)90176-W; SHULMAN HM, 1987, AM J PATHOL, V127, P549; VARGA J, 1991, JAMA-J AM MED ASSOC, V265, P3292, DOI 10.1001/jama.265.24.3292; WEINER RS, 1989, BRIT J HAEMATOL, V71, P535, DOI 10.1111/j.1365-2141.1989.tb06314.x; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685; YAMAUCHI K, 1988, AM REV RESPIR DIS, V137, P1360, DOI 10.1164/ajrccm/137.6.1360	52	288	294	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1592	1598		10.1056/NEJM199306033282203	http://dx.doi.org/10.1056/NEJM199306033282203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8487801				2022-12-28	WOS:A1993LE28900003
J	WELLSTONE, PD; SHAFFER, ER				WELLSTONE, PD; SHAFFER, ER			THE AMERICAN HEALTH SECURITY ACT - A SINGLE-PAYER PROPOSAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MARINER WK, 1992, NEW ENGL J MED, V327, P1682, DOI 10.1056/NEJM199212033272312; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805	5	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1489	1493		10.1056/NEJM199305203282013	http://dx.doi.org/10.1056/NEJM199305203282013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479471	Bronze, Green Published			2022-12-28	WOS:A1993LB78300013
J	SARY, G; VOGELS, R; ORBAN, GA				SARY, G; VOGELS, R; ORBAN, GA			CUE-INVARIANT SHAPE SELECTIVITY OF MACAQUE INFERIOR TEMPORAL NEURONS	SCIENCE			English	Article							INFEROTEMPORAL CORTEX; CORTICAL CONNECTIONS; MONKEY; DISCRIMINATION; CONTRAST; SULCUS	The perception of shape is independent of the size and position of the shape and also of the visual cue that defines it. The same shape can be recognized whether defined by a difference in luminance, by motion, or by texture. Experiments showed that the shape selectivity of individual cells in the macaque inferior temporal cortex did not vary with the size and position of a shape and also did not vary with the visual cue used to define the shape. This cue invariance was true for static luminance and texture cues as well as for relative motion cues-that is, for cues that are processed in ventral and dorsal visual pathways. The properties of these inferior temporal cells meet the demands of cue-invariant shape coding.	CATHOLIC UNIV LEUVEN,FAC GENEESKUNDE,NEURO & PSYCHOFYSIOL LAB,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM	KU Leuven				Orban, Guy/0000-0002-8179-9584				ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; BAIZER JS, 1991, J NEUROSCI, V11, P168; BRITTEN KH, 1992, EXP BRAIN RES, V88, P292, DOI 10.1007/BF02259104; DEAN P, 1976, PSYCHOL BULL, V83, P41, DOI 10.1037/0033-2909.83.1.41; DESIMONE R, 1984, J NEUROSCI, V4, P2051; DESIMONE R, 1980, BRAIN RES, V184, P41, DOI 10.1016/0006-8993(80)90586-7; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; LOGOTHETIS NK, 1990, INVEST OPHTH VIS SCI, V31, P444; MARCAR V L, 1991, Society for Neuroscience Abstracts, V17, P525; Marcar V. L., 1992, Society for Neuroscience Abstracts, V18, P1275; MARCAR VL, 1992, EUR J NEUROSCI, V4, P1228, DOI 10.1111/j.1460-9568.1992.tb00148.x; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; OLAVARRIA JF, 1992, J NEUROPHYSIOL, V68, P164, DOI 10.1152/jn.1992.68.1.164; REGAN D, 1991, PERCEPTION, V20, P315, DOI 10.1068/p200315; ROLLS ET, 1986, EXP BRAIN RES, V65, P38; SATO T, 1980, EXP BRAIN RES, V38, P313; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204	23	247	249	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					995	997		10.1126/science.8493538	http://dx.doi.org/10.1126/science.8493538			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493538	Green Accepted			2022-12-28	WOS:A1993LB79100047
J	SILAGY, C				SILAGY, C			DEVELOPING A REGISTER OF RANDOMIZED CONTROLLED TRIALS IN PRIMARY CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINATAL TRIALS; DATABASE	Objective-To determine the number, nature, site of publication, and feasibility of identifying randomised controlled trials relevant to primary care. Design-Review of literature using three strategies: approaching journal editors, Medline search, and manual search of individual journals. Setting-Journals containing publications of studies based in primary care. Main outcome measures-The number, site of publication, and subject of trials identified. Results-No journal had a system which enabled identification of all the randomised controlled trials it published. 266 trials relevant to primary care were identified from 110 different journals during 1987-91 by Medline. Of these, only 62 trials were published in primary care journals. Hand searching of seven major primary care research journals showed that between 13% and 38% of the trials had been missed by the Medline search. Of the trials identified, 47 (18%) were concerned with mental disease (including neuroses, tobacco misuse and alcohol misuse) and 43 (16%) were concerned with hypertension. Conclusion-Given the diversity of publication sources and topics, this supports the need for a centrally based register of randomised controlled trials that may be relevant to primary care overviews in the future.			SILAGY, C (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHALMERS I, 1986, CONTROL CLIN TRIALS, V7, P306, DOI 10.1016/0197-2456(86)90038-3; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS I, 1985, EFFECTIVE CARE PREGN; CHALMES I, 1991, OXFORD DATABASE PERI; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; DICKERSIN K, 1985, CONTROL CLIN TRIALS, V6, P306, DOI 10.1016/0197-2456(85)90106-0; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; Lock Stephen P., 1991, FUTURE MED J, P127; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; VERSTRAETE M, 1984, THROMB HAEMOSTASIS, V51, P283; 1980, FAMLI FAMILY MED LIT; [No title captured]; 1983, ICHPC2 WORLD ORG NAT; 1982, LANCET, V1, P293; 1990, SERIALS DIRECTORY, V2	17	48	48	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					897	900		10.1136/bmj.306.6882.897	http://dx.doi.org/10.1136/bmj.306.6882.897			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490419	Bronze, Green Published			2022-12-28	WOS:A1993KW38700025
J	CAMPBELL, P				CAMPBELL, P			COUNTDOWN TO COMMUNITY CARE - MENTAL-HEALTH-SERVICES - THE USERS VIEW	BRITISH MEDICAL JOURNAL			English	Article								The needs of people with serious mental illnesses have dominated much of the debate on reforming community care. In this article Peter Campbell, who has used mental health services many times in the past, explains how the reforms could affect people like him. He welcomes the thinking behind the changes, particularly the idea that people who use community care should take part in planning services, but he warns that implementing the new philosophy might prove very difficult. Mr Campbell is secretary of a voluntary organisation for users of mental health services called Survivors Speak Out. The views he expresses here are his own, and do not necessarily reflect those of Survivors Speak Out.										BEWLEY C, 1992, U MANCHESTER SOCIAL, V27; BLUGLASS R, 1993, BRIT MED J, V306, P159, DOI 10.1136/bmj.306.6871.159; GROVES T, 1993, BRIT MED J, V306, P475; SONE K, 1992, COMMUNITY CARE  0130, P18; THORNICROFT G, 1992, BRIT MED J, V305, P996, DOI 10.1136/bmj.305.6860.996; WALLACE M, 1993, DAILY MAIL      0102; 1993, BMJ, V306, P604	7	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					848	850		10.1136/bmj.306.6881.848	http://dx.doi.org/10.1136/bmj.306.6881.848			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV348	8490382	Green Published, Bronze			2022-12-28	WOS:A1993KV34800029
J	SMITH, AP; THOMAS, M; BROCKMAN, P; KENT, J; NICHOLSON, KG				SMITH, AP; THOMAS, M; BROCKMAN, P; KENT, J; NICHOLSON, KG			EFFECT OF INFLUENZA B-VIRUS INFECTION ON HUMAN-PERFORMANCE	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 7RH,ENGLAND	University of Leicester	SMITH, AP (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,HLTH PSYCHOL RES UNIT,CARDIFF CF1 3YG,WALES.		Smith, Andrew P/B-2192-2010	Smith, Andrew/0000-0001-8805-8028; Thomas, Marie/0000-0003-2360-255X				CARPENTER JA, 1959, J COMP PHYSIOL PSYCH, V52, P491, DOI 10.1037/h0048652; GLUE P, 1991, Journal of Psychopharmacology, V5, P377, DOI [10.1177/026988119200600306, 10.1177/026988119100500432]; Smith A.P., 1992, HDB HUMAN PERFORMANC, V2, P197; SMITH AP, 1990, PHILOS T ROY SOC B, V327, P519, DOI 10.1098/rstb.1990.0095; SMITH AP, 1985, CONT ERGONOMICS 1985, P33	5	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					760	761		10.1136/bmj.306.6880.760	http://dx.doi.org/10.1136/bmj.306.6880.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490339	Bronze, Green Published			2022-12-28	WOS:A1993KU17300023
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .6. TEACHING THE TEACHERS	BRITISH MEDICAL JOURNAL			English	Article																		COLES C, IN PRESS LEARNING ME; COLES C, IN PRESS POSTGRAD ME; ELTON L., 1991, TEACHING STANDARDS E; Harden R M, 1984, Med Educ, V18, P284; IRBY D, 1981, J MED EDUC, V56, P181; IRBY DM, 1978, J MED EDUC, V53, P808; IRBY DM, 1983, J MED EDUC, V58, P844; MARRIN M, 1991, PEDAGOGUE, V3, P1; TOWLE A, 1991, CRITICAL THINKING FU; WATSON N, 1992, SURGERY ABIGDON 2, V10, pA36; WILSON DH, IN PRESS BMJ; 1992, TEACHING HOSPITAL DO; 1990, HC9016 DEP HLTH HLTH; 1991, UNDERGRADUATE MED ED	14	37	37	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					127	130		10.1136/bmj.306.6870.127	http://dx.doi.org/10.1136/bmj.306.6870.127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG465	8507235	Bronze, Green Published			2022-12-28	WOS:A1993KG46500030
J	PACKER, M; GHEORGHIADE, M; YOUNG, JB; COSTANTINI, PJ; ADAMS, KF; CODY, RJ; SMITH, LK; VANVOORHEES, L; GOURLEY, LA; JOLLY, MK				PACKER, M; GHEORGHIADE, M; YOUNG, JB; COSTANTINI, PJ; ADAMS, KF; CODY, RJ; SMITH, LK; VANVOORHEES, L; GOURLEY, LA; JOLLY, MK			WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART-FAILURE TREATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINUS RHYTHM; MAINTENANCE DIGOXIN; ENALAPRIL; EXERCISE; THERAPY; COMBINATION; MULTICENTER; CROSSOVER; DISEASE; TRIAL	Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is often the case in current practice. Methods. We studied 178 patients with New York Heart Association class 11 or Ill heart failure and left ventricular ejection fractions of 35 percent or less in normal sinus rhythm who were clinically stable while receiving digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor (captopril or enalapril). The patients were randomly assigned in a double-blind fashion either to continue receiving digoxin (85 patients) or to be switched to placebo (93 patients) for 12 weeks. Otherwise, their medical therapy for heart failure was not changed. Results. Worsening heart failure necessitating withdrawal from the study developed in 23 patients switched to placebo, but in only 4 patients who continued to receive digoxin (P<0.001). The relative risk of worsening heart failure in the placebo group as compared with the digoxin group was 5.9 (95 percent confidence interval, 2.1 to 17.2). All measures of functional capacity deteriorated in the patients receiving placebo as compared with those continuing to receive digoxin (P = 0.033 for maximal exercise tolerance, P = 0.01 for submaximal exercise endurance, and P = 0.019 for New York Heart Association class). In addition, the patients switched from digoxin to placebo had lower quality-of-life scores (P = 0.04), decreased ejection fractions (P = 0.001), and increases in heart rate (P = 0.001) and body weight (P<0.001). Conclusions. These findings indicate that the withdrawal of digoxin carries considerable risks for patients with chronic heart failure and impaired systolic function who have remained clinically stable while receiving digoxin and angiotensin-converting-enzyme inhibitors.	UNIV MED & DENT NEW JERSEY, CAMDEN, NJ USA; ARIZONA HEART INST, TUCSON, AZ USA; GH BESSELAAR ASSOCIATES, PRINCETON, NJ USA; OHIO STATE UNIV, SCH MED, COLUMBUS, OH 43210 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; HENRY FORD HOSP, DETROIT, MI 48202 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Arizona Heart Institute; University System of Ohio; Ohio State University; MedStar Washington Hospital Center; Burroughs Wellcome Fund; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Baylor College of Medicine; Henry Ford Health System; Henry Ford Hospital; University of North Carolina; University of North Carolina Chapel Hill								ALICANDRI C, 1987, J CARDIOVASC PHARM, V9, pS61, DOI 10.1097/00005344-198700002-00013; BEAUNE J, 1989, AM J CARDIOL, V63, pD22, DOI 10.1016/0002-9149(89)90413-X; BERRY DA, 1990, STATISTICAL METHODOL, P389; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; CHURCHILL PC, 1979, J PHYSIOL-LONDON, V294, P123, DOI 10.1113/jphysiol.1979.sp012919; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COVIT AB, 1983, AM J MED, V75, P445, DOI 10.1016/0002-9343(83)90346-7; CREAGER MA, 1985, J AM COLL CARDIOL, V6, P163, DOI 10.1016/S0735-1097(85)80269-2; DALL JLC, 1970, BRIT MED J, V2, P705, DOI 10.1136/bmj.2.5711.705; DAVIES RF, 1991, J AM COLL CARDIOL, V18, P1602, DOI 10.1016/0735-1097(91)90491-Q; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; FERGUSON DW, 1989, CIRCULATION, V80, P65, DOI 10.1161/01.CIR.80.1.65; FLEG JL, 1991, J AM COLL CARDIOL, V17, P743, DOI 10.1016/S0735-1097(10)80194-9; FLEG JL, 1982, AM J MED, V73, P244, DOI 10.1016/0002-9343(82)90186-3; GHEORGHIADE M, 1983, AM J CARDIOL, V51, P1243, DOI 10.1016/0002-9149(83)90293-X; GHEORGHIADE M, 1989, J AM COLL CARDIOL, V13, P134, DOI 10.1016/0735-1097(89)90561-5; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; GUYATT GH, 1988, AM J CARDIOL, V61, P371, DOI 10.1016/0002-9149(88)90947-2; HULL SM, 1977, LANCET, V2, P1054; KROMER EP, 1990, J CARDIOVASC PHARM, V16, P9, DOI 10.1097/00005344-199007000-00002; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; LEE ET, 1980, STATISTICAL METHODS, P129; Naughton JHR, 1973, EXERCISE TESTING EXE, P79; PACKER M, 1990, CIRCULATION, V82, P323; PUGH SE, 1989, BRIT HEART J, V61, P529; Rector TS, 1987, HEART FAIL, V3, P198; RIBNER HS, 1985, AM J CARDIOL, V56, P896, DOI 10.1016/0002-9149(85)90778-7; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAGGART AJ, 1983, J CARDIOVASC PHARM, V5, P229, DOI 10.1097/00005344-198303000-00011; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3	32	609	629	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					1	7		10.1056/NEJM199307013290101	http://dx.doi.org/10.1056/NEJM199307013290101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505940				2022-12-28	WOS:A1993LJ33800001
J	BUCHSCHACHER, GL				BUCHSCHACHER, GL			MOLECULAR TARGETS OF GENE-TRANSFER THERAPY FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; REVERSE TRANSCRIPTION; MUTATIONAL ANALYSIS; MESSENGER-RNA; TAT PROTEIN; REV PROTEIN; CELLS; EXPRESSION; REPLICATION		UNIV WISCONSIN,MD PHD INTEGRATED DEGREE PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	BUCHSCHACHER, GL (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,1400 UNIV AVE,MADISON,WI 53706, USA.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BUCHSCHACHER GL, 1992, HUM GENE THER, V3, P391, DOI 10.1089/hum.1992.3.4-391; BUCHSCHACHER GL, 1992, J VIROL, V66, P2731, DOI 10.1128/JVI.66.5.2731-2739.1992; CARUSO M, 1992, P NATL ACAD SCI USA, V89, P182, DOI 10.1073/pnas.89.1.182; CHATTERJEE S, 1992, SCIENCE, V258, P1485, DOI 10.1126/science.1359646; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DROPULIC B, 1992, J VIROL, V66, P1432; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1992, AIDS RES HUM RETROV, V8, P1013, DOI 10.1089/aid.1992.8.1013; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; HARRISON GS, 1991, HUM GENE THER, V2, P53, DOI 10.1089/hum.1991.2.1-53; HARRISON GS, 1992, HUM GENE THER, V3, P461, DOI 10.1089/hum.1992.3.5-461; HARRISON GS, 1992, AIDS RES HUM RETROV, V8, P39, DOI 10.1089/aid.1992.8.39; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOSHI S, 1991, J VIROL, V65, P5524, DOI 10.1128/JVI.65.10.5524-5530.1991; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KOBOTA S, 1992, J VIROL, V66, P2510; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE TC, 1992, NEW BIOL, V4, P66; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LISZIEWICZ J, 1991, NEW BIOL, V3, P82; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MILLER AD, 1990, BLOOD, V76, P271; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PANGANIBAN AT, 1990, SEMIN VIROL, V1, P187; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEARSON L, 1990, P NATL ACAD SCI USA, V87, P5079, DOI 10.1073/pnas.87.13.5079; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; RHODES A, 1990, J GEN VIROL, V71, P1965, DOI 10.1099/0022-1317-71-9-1965; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; ROSENBERG SA, 1992, JAMA-J AM MED ASSOC, V268, P2416, DOI 10.1001/jama.268.17.2416; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCZAKIEL G, 1992, J VIROL, V66, P5576, DOI 10.1128/JVI.66.9.5576-5581.1992; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TERWILLIGER EF, 1992, AIDS RES REV, V2, P3; THOMPSON L, 1992, SCIENCE, V258, P744, DOI 10.1126/science.1472258; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VENKATESH LK, 1990, P NATL ACAD SCI USA, V87, P8746, DOI 10.1073/pnas.87.22.8746; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARNER JF, 1991, AIDS RES HUM RETROV, V7, P645, DOI 10.1089/aid.1991.7.645; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	74	23	25	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2880	2886		10.1001/jama.269.22.2880	http://dx.doi.org/10.1001/jama.269.22.2880			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497092				2022-12-28	WOS:A1993LE93600025
J	SHAPIRO, L; KAISER, D; LOSICK, R				SHAPIRO, L; KAISER, D; LOSICK, R			DEVELOPMENT AND BEHAVIOR IN BACTERIA	CELL			English	Review									HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	SHAPIRO, L (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S	6	14	14	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					835	836		10.1016/0092-8674(93)90264-Q	http://dx.doi.org/10.1016/0092-8674(93)90264-Q			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500176	Bronze			2022-12-28	WOS:A1993LF06100002
J	MARX, PA; COMPANS, RW; GETTIE, A; STAAS, JK; GILLEY, RM; MULLIGAN, MJ; YAMSHCHIKOV, GV; CHEN, DX; ELDRIDGE, JH				MARX, PA; COMPANS, RW; GETTIE, A; STAAS, JK; GILLEY, RM; MULLIGAN, MJ; YAMSHCHIKOV, GV; CHEN, DX; ELDRIDGE, JH			PROTECTION AGAINST VAGINAL SIV TRANSMISSION WITH MICROENCAPSULATED VACCINE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; HUMAN CERVICOVAGINAL SECRETIONS; SECRETORY IMMUNE-RESPONSES; FEMALE GENITAL-TRACT; BIODEGRADABLE MICROSPHERES; IMMUNOGLOBULIN-A; CONFERS PROTECTION; ORAL IMMUNIZATION; RHESUS MACAQUES; DELIVERY SYSTEM	Although protection in animal models against intravenous challenges with simian immunodeficiency virus (SIV) has been reported, no previous vaccines have protected against a heterosexual route of infection. In this study, five of six macaques were protected against vaginal challenge when immunized with formalin-treated SIV in biodegradable microspheres by the intramuscular plus oral or plus intratracheal route. Oral immunization alone did not protect. After a second vaginal challenge, three of four intramuscularly primed and mucosally boosted macaques remained protected. The data suggest that protection against human immunodeficiency virus vaginal transmission could be provided by microsphere-based booster vaccines when used to immunize women who are systemically primed.	SO RES INST, DIV CONTROLLED RELEASE, BIRMINGHAM, AL 35255 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; NEW MEXICO STATE UNIV, DEPT BIOL, HOLLOMAN AFB, NM 88330 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA	Emory University; New Mexico State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	MARX, PA (corresponding author), NEW MEXICO STATE UNIV, NEW MEXICO REG PRIMATE RES LAB, HOLLOMAN AFB, NM 88330 USA.		Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI028147, U19AI028147] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; CURTISS R, 1989, CURR TOP MICROBIOL, V146, P35; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; ELDRIDGE JH, 1989, CURR TOP MICROBIOL, V146, P59; ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978, DOI 10.1128/IAI.59.9.2978-2986.1991; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V; ELDRIDGE JH, 1992, RES IMMUNOL, V143, P557, DOI 10.1016/0923-2494(92)80069-W; ELDRIDGE JH, IN PRESS RETROVIRUSE; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOLARZ MN, 1975, RHESUS MONKEY ANATOM, P251; HEREMANS JF, 1974, ANTIGENS, V2, P365; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; HOLMES KK, 1990, WEEKLY EPIDEMIOL REC, V6, P33; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; JACKSON S, 1990, INFECT IMMUN, V58, P1932, DOI 10.1128/IAI.58.6.1932-1936.1990; JALANTI R, 1977, INT ARCH ALLER A IMM, V53, P402, DOI 10.1159/000231778; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; MARX PA, UNPUB; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; McGhee J R, 1990, Infect Dis Clin North Am, V4, P315; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MICHALEK SM, 1989, CURR TOP MICROBIOL, V146, P51; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MOLDOVEANU Z, 1989, CURR TOP MICROBIOL, V146, P91; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Ogra P L, 1976, Dev Biol Stand, V33, P19; OGRA PL, 1973, J IMMUNOL, V110, P1307; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; OHAGAN DT, 1989, VACCINE, V7, P213, DOI 10.1016/0264-410X(89)90231-4; OHAGAN DT, 1991, VACCINE, V9, P768, DOI 10.1016/0264-410X(91)90295-H; OHAGAN DT, 1989, VACCINE, V7, P421, DOI 10.1016/0264-410X(89)90156-4; PARR MB, 1985, J REPROD FERTIL, V74, P361, DOI 10.1530/jrf.0.0740361; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PREVEC L, 1990, J INFECT DIS, V161, P27, DOI 10.1093/infdis/161.1.27; PREVEC L, 1991, J ACQ IMMUN DEF SYND, V4, P568; QUINN TC, 1990, AIDS, V4, P709, DOI 10.1097/00002030-199008000-00001; SCHODEL F, 1990, J IMMUNOL, V145, P4317; Schumacher, 1980, IMMUNOLOGICAL ASPECT, P93; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990; THAPAR MA, 1990, IMMUNOLOGY, V70, P121; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; WALDMAN RH, 1972, CLIN EXP IMMUNOL, V10, P427; WILKIE BN, 1972, J REPROD FERTIL, V31, P359, DOI 10.1530/jrf.0.0310359; WIRA CR, 1987, J IMMUNOL, V138, P4159; YANG SL, 1983, FERTIL STERIL, V39, P359; 1992, MORBID MORTAL WEEKLY, V41, P899; 1991, MORBID MORTAL WEEKLY, V40, P358	58	260	273	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1323	1327		10.1126/science.8493576	http://dx.doi.org/10.1126/science.8493576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493576				2022-12-28	WOS:A1993LE02500043
J	HOLTZMAN, EJ; HARRIS, HW; KOLAKOWSKI, LF; GUAYWOODFORD, LM; BOTELHO, B; AUSIELLO, DA				HOLTZMAN, EJ; HARRIS, HW; KOLAKOWSKI, LF; GUAYWOODFORD, LM; BOTELHO, B; AUSIELLO, DA			A MOLECULAR DEFECT IN THE VASOPRESSIN V2-RECEPTOR GENE CAUSING NEPHROGENIC DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POINT MUTATION; LINKAGE		HARVARD UNIV,SCH MED,DEPT PEDIAT,300 LONGWOOD AVE,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV NEPHROL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019406, R37DK019406, R01DK038874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38874, DK-19406] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BODE HH, 1969, NEW ENGL J MED, V280, P750, DOI 10.1056/NEJM196904032801404; BODE HH, 1970, AM J HUM GENET, V22, P221; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; FORSSMAN H, 1945, ACTA MED SCAND     S, V159, P9; KAMBOURIS M, 1988, AM J MED GENET, V29, P239, DOI 10.1002/ajmg.1320290138; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KNOERS N, 1988, HUM GENET, V80, P31, DOI 10.1007/BF00451451; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MCCLATCHEY AI, 1992, AM J HUM GENET, V50, P896; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OTT J, 1974, AM J HUM GENET, V26, P588; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; REEVES WB, 1989, METABOLIC BASIS INHE, V2, P1985; ROBINSON MG, 1960, AMA J DIS CHILD, V99, P164, DOI 10.1001/archpedi.1960.02070030166004; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Sambrook J, 1989, MOL CLONING LABORATO; SKORECKI KL, 1992, HDB PHYSL, P1185; TROFATTER JA, 1986, AM J HUM GENET, V39, P147	21	65	66	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1534	1537		10.1056/NEJM199305273282105	http://dx.doi.org/10.1056/NEJM199305273282105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479490				2022-12-28	WOS:A1993LC94100005
J	LUYAO, GL; MCLERRAN, D; WASSON, J; WENNBERG, JE				LUYAO, GL; MCLERRAN, D; WASSON, J; WENNBERG, JE			AN ASSESSMENT OF RADICAL PROSTATECTOMY - TIME TRENDS, GEOGRAPHIC-VARIATION, AND OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSTATIC-CANCER; CARCINOMA	Objectives.-To examine temporal trends and geographic variation in radical prostatectomy rates and short-term outcomes. Design.-Population-based study of radical prostatectomy for the years 1984 through 1990. Poisson regression was used to estimate temporal and regional effects. Setting.-The 50 states and the District of Columbia. Participants.-A 20% national sample of male Medicare beneficiaries aged 65 years or older. Main Outcome Measures.-Rate of radical prostatectomy; 30-day mortality; and major cardiopulmonary complications, vascular complications, or surgical repairs within 30 days of radical prostatectomy. Results.-A total of 10 598 radical prostatectomies were identified. The adjusted rate of radical prostatectomy in 1990 was 5.75 times that in 1984. The relative increase was similar in all age groups. Substantial geographic variation existed in rates from 1988 through 1990: all states in the New England and Mid-Atlantic regions had rates equal to or below 60 per 100 000 male Medicare beneficiaries, while all states in the Pacific and Mountain regions had rates equal to or above 130 per 100 000. The mortality and morbidity after radical prostatectomy are not trivial for older men (aged 75 years and older)-almost 2% died and nearly 8% suffered major cardiopulmonary complications within 30 days of the operation. Conclusion.-The sharp increase and wide geographic variation in radical prostatectomy rates make the evaluation of this surgical procedure a pressing issue. The rising rate of radical prostatectomy among men aged 75 years and older merits special attention.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756	Dartmouth College				Lu-Yao, Grace/0000-0002-6017-9175	AHRQ HHS [HS06336-03, HS05745-05] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BECKNER M, 1985, J CHRON DIS, V38, P225, DOI 10.1016/0021-9681(85)90065-7; BORING CC, 1993, CA-CANCER J CLIN, V43, P18; Fleming C, 1993, JAMA, V269, P2650; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P200; HOLLEB AI, 1991, TXB CLIN ONCOLOGY, P280; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P503; LANGE PH, 1989, UROLOGY, V33, P13, DOI 10.1016/S0090-4295(89)80003-2; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; RIES LAG, 1991, NIG912789 PUBL; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHMIDT JD, 1986, J UROLOGY, V136, P416, DOI 10.1016/S0022-5347(17)44889-0; THOMPSON IM, 1989, SOUTHERN MED J, V82, P335, DOI 10.1097/00007611-198903000-00014; WALSH P, 1991, J UROLOGY, V145, P126; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; 1989, INT CLASSIFICATION D	16	405	410	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2633	2636		10.1001/jama.269.20.2633	http://dx.doi.org/10.1001/jama.269.20.2633			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487445				2022-12-28	WOS:A1993LC86500026
J	LIN, LFH; DOHERTY, DH; LILE, JD; BEKTESH, S; COLLINS, F				LIN, LFH; DOHERTY, DH; LILE, JD; BEKTESH, S; COLLINS, F			GDNF - A GLIAL-CELL LINE DERIVED NEUROTROPHIC FACTOR FOR MIDBRAIN DOPAMINERGIC-NEURONS	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; MESENCEPHALIC GLIA; SURVIVAL; INVITRO; CULTURE; DIFFERENTIATION; INHIBIN; SIGNAL	A potent neurotrophic factor that enhances survival of midbrain dopaminergic neurons was purified and cloned. Glial cell line-derived neurotrophic factor (GDNF) is a glycosylated, disulfide-bonded homodimer that is a distantly related member of the transforming growth factor-beta superfamily. In embryonic midbrain cultures, recombinant human GDNF promoted the survival and morphological differentiation of dopaminergic neurons and increased their high-affinity dopamine uptake. These effects were relatively specific; GDNF did not increase total neuron or astrocyte numbers nor did it increase transmitter uptake by gamma-aminobutyric-containing and serotonergic neurons. GDNF may have utility in the treatment of Parkinson's disease, which is marked by progressive degeneration of midbrain dopaminergic neurons.	SYNERGEN INC,1885 33RD ST,BOULDER,CO 80301									BURT DW, 1992, BIOCHEM BIOPH RES CO, V184, P590, DOI 10.1016/0006-291X(92)90630-4; CASPER D, 1991, J NEUROSCI RES, V30, P372, DOI 10.1002/jnr.490300213; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, P13; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; ENGELE J, 1991, J NEUROSCI, V11, P3070; ENGELE J, 1991, J NEUROSCI RES, V30, P359, DOI 10.1002/jnr.490300212; FERRARI G, 1991, J NEUROSCI RES, V30, P493, DOI 10.1002/jnr.490300306; FERRARI G, 1989, DEV BIOL, V133, P140, DOI 10.1016/0012-1606(89)90305-9; FRIEDMAN L, 1987, NEUROSCI LETT, V79, P65, DOI 10.1016/0304-3940(87)90673-2; GAUL G, 1992, P ROY SOC B-BIOL SCI, V249, P57, DOI 10.1098/rspb.1992.0083; GERMAN DC, 1992, ANN NY ACAD SCI, V648, P42, DOI 10.1111/j.1749-6632.1992.tb24523.x; HETEY L, 1986, BIOMED BIOCHIM ACTA, V45, P1203; HOFFER BJ, UNPUB; Hornykiewicz O, 1986, ADV NEUROL, V45, P19; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HYMAN C, 1991, Society for Neuroscience Abstracts, V17, P908; KNUSEL B, 1990, J NEUROSCI, V10, P558; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LIN LFH, 1990, J BIOL CHEM, V265, P8942; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MCDONALD JR, 1991, BIOCHIM BIOPHYS ACTA, V1090, P70, DOI 10.1016/0167-4781(91)90038-N; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; OMALLEY EK, 1992, BRAIN RES, V582, P65, DOI 10.1016/0006-8993(92)90317-3; PROCHIANTZ A, 1979, P NATL ACAD SCI USA, V76, P5387, DOI 10.1073/pnas.76.10.5387; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220	30	2717	3069	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1130	1132		10.1126/science.8493557	http://dx.doi.org/10.1126/science.8493557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493557				2022-12-28	WOS:A1993LC94200031
J	SPIEGELMAN, BM; HOTAMISLIGIL, GS				SPIEGELMAN, BM; HOTAMISLIGIL, GS			THROUGH THICK AND THIN - WASTING, OBESITY, AND TNF-ALPHA	CELL			English	Review							TUMOR-NECROSIS-FACTOR; INSULIN RESISTANCE; CACHECTIN; MICE; ENDOTOXIN; CACHEXIA; EXPRESSION; RECEPTORS		HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	SPIEGELMAN, BM (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BJONTORP P, 1991, DIABETES CARE, V14, P1132; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CERAMI A, 1985, IMMUNOL LETT, V11, P173, DOI 10.1016/0165-2478(85)90165-8; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; CHOY LN, 1992, J BIOL CHEM, V267, P12736; DEZUBE BJ, 1992, J ACQ IMMUN DEF SYND, V5, P1099; ELLAURIE M, 1992, AIDS, V6, P1265, DOI 10.1097/00002030-199211000-00004; FAUST IM, 1977, SCIENCE, V197, P391, DOI 10.1126/science.877563; FRAKER DL, 1989, AM J PHYSIOL, V256, pE725, DOI 10.1152/ajpendo.1989.256.6.E725; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIBERT C, 1991, J IMMUNOTHER, V10, P227, DOI 10.1097/00002371-199108000-00001; MICHIE HR, 1989, ANN SURG, V209, P19, DOI 10.1097/00000658-198901000-00002; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; ROSEN BS, 1990, UCLA SYM BI, V132, P273; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; VANDERPOLL T, 1991, AM J PHYSIOL, V261, pE457, DOI 10.1152/ajpendo.1991.261.4.E457	30	195	207	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					625	627		10.1016/0092-8674(93)90243-J	http://dx.doi.org/10.1016/0092-8674(93)90243-J			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500160				2022-12-28	WOS:A1993LD83000002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			HAEMOPHILUS-B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487398				2022-12-28	WOS:A1993LB45000007
J	PATTERSON, BK; TILL, M; OTTO, P; GOOLSBY, C; FURTADO, MR; MCBRIDE, LJ; WOLINSKY, SM				PATTERSON, BK; TILL, M; OTTO, P; GOOLSBY, C; FURTADO, MR; MCBRIDE, LJ; WOLINSKY, SM			DETECTION OF HIV-1 DNA AND MESSENGER-RNA IN INDIVIDUAL CELLS BY PCR-DRIVEN INSITU HYBRIDIZATION AND FLOW-CYTOMETRY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD; T-CELL; LYMPHOCYTES; AMPLIFICATION; RESERVOIR; INFECTION	Human immunodeficiency virus type-1 (HIV-1) DNA and messenger RNA sequences in both cell lines and blood obtained directly from HIV-1-infected patients were amplified by polymerase chain reaction and hybridized to fluorescein-labeled probes in situ, and the individually labeled cells were analyzed by flow cytometry. After flow cytometric analysis, heterogeneous cell populations were reproducibly resolved into HIV-1-positive and -negative distributions. Fluorescence microscopy showed that the cellular morphology was preserved and intracellular localization of amplified product DNA was maintained. Retention of nonspecific probe was not observed. Analysis of proviral DNA and viral messenger RNA in cells in the blood of HIV-1-infected patients showed that the HIV-1 genome persists in a large reservoir of latently infected cells. With the use of this technique it is now possible to detect single-copy DNA or low-abundance messenger RNA rapidly and reproducibly in a minor subpopulation of cells in suspension at single-cell resolution and to sort those cells for further characterization.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; APPL BIOSYST INC,DEPT DNA ANAL,FOSTER CITY,CA 94404; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Thermo Fisher Scientific; Applied Biosystems; Northwestern University			Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Furtado, Manohar/0000-0001-6016-1357	NIAID NIH HHS [AI-32535] Funding Source: Medline; NICHD NIH HHS [HD-26619-01] Funding Source: Medline; PHS HHS [P01-25569] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI032535] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADORI A, 1992, J IMMUNOL, V148, P2709; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BAUMAN JGJ, 1988, CYTOMETRY, V9, P517, DOI 10.1002/cyto.990090602; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; DUDIN G, 1987, HUM GENET, V76, P290; EMBLETON MJ, 1992, NUCLEIC ACIDS RES, V20, P3831, DOI 10.1093/nar/20.15.3831; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MACDONELL K, 1990, AM J MED, V89, P708; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PATTERSON B, UNPUB; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TIMM EA, 1992, BIOTECHNIQUES, V12, P363; VANDEKKEN H, 1990, CYTOMETRY, V11, P153, DOI 10.1002/cyto.990110118; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	236	276	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					976	979		10.1126/science.8493534	http://dx.doi.org/10.1126/science.8493534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493534				2022-12-28	WOS:A1993LB79100041
J	VIDAL, SM; MALO, D; VOGAN, K; SKAMENE, E; GROS, P				VIDAL, SM; MALO, D; VOGAN, K; SKAMENE, E; GROS, P			NATURAL-RESISTANCE TO INFECTION WITH INTRACELLULAR PARASITES - ISOLATION OF A CANDIDATE FOR BCG	CELL			English	Article							MYCOBACTERIUM-BOVIS BCG; DEPENDENT TRANSPORT-SYSTEMS; PROTEIN-KINASE-C; BINDING PROTEIN; HOST-RESISTANCE; GENETIC-CONTROL; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC-EXPRESSION; MOUSE CHROMOSOME-1; COMPLEMENTARY-DNA	Natural resistance to infection with intracellular parasites is controlled by a dominant gene on mouse chromosome 1, called Bcg, Lsh, or Ity. Bcg affects the capacity of macrophages to destroy ingested intracellular parasites early during infection. We have assembled a 400 kb bacteriophage and cosmid contig within the genomic interval containing Bcg. A search for transcription units by exon amplification identified six novel genes in this contig. RNA expression studies showed that one of them, designated Nramp, was expressed exclusively in macrophage populations from reticuloendothelial organs and in the macrophage line J774A. Nramp encodes an integral membrane protein that has structural homology with known prokaryotic and eukaryotic transport systems, suggesting a macrophage-specific membrane transport function. Susceptibility to infection (Bcg(s)) in 13 Bcg(r) and Bcg(s) strains tested is associated with a nonconservative Gly-105 to Asp-105 substitution within predicted transmembrane domain 2 of Nramp.	MCGILL UNIV, CTR STUDY HOST RESISTANCE, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University	VIDAL, SM (corresponding author), MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA.			Malo, Danielle/0000-0003-3980-6610; Vogan, Kyle/0000-0001-9565-9665				ABEL L, 1988, AM J HUM GENET, V42, P256; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1990, RES MICROBIOL, V141, P341; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL JM, 1991, IMMUNOL LETT, V30, P241, DOI 10.1016/0165-2478(91)90032-6; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; BRETT S, 1992, IMMUNOLOGY, V76, P129; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUSCHMAN E, 1989, RES IMMUNOL, V140, P793, DOI 10.1016/0923-2494(89)90035-7; BUSCHMAN E, 1993, IN PRESS P GLYCOPROT, V3; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLSTON MJ, 1991, NATURE, V351, P442, DOI 10.1038/351442d0; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; CROWLE AJ, 1990, INFECT IMMUN, V58, P632, DOI 10.1128/IAI.58.3.632-638.1990; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DENIS M, 1990, J LEUKOCYTE BIOL, V47, P25, DOI 10.1002/jlb.47.1.25; DEVEREUX J, 1991, GCG SEQUENCE ANAL SO; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FORGET A, 1981, INFECT IMMUN, V32, P42, DOI 10.1128/IAI.32.1.42-47.1981; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GOTO Y, 1989, IMMUNOGENETICS, V30, P218, DOI 10.1007/BF02421210; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GROS P, 1983, J IMMUNOL, V131, P1966; GROS P, 1981, J IMMUNOL, V127, P2417; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HORMAECHE CE, 1985, J INFECT DIS, V152, P1050, DOI 10.1093/infdis/152.5.1050; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LISSNER CR, 1983, J IMMUNOL, V131, P3006; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MALO D, 1991, GENOMICS, V10, P356, DOI 10.1016/0888-7543(91)90320-E; MALO D, 1993, IN PRESS GENOMICS; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; O'BRIEN S J, 1991, Current Biology, V1, P209, DOI 10.1016/0960-9822(91)90058-5; OTTENHOFF THM, 1987, INT J LEPROSY, V55, P521; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PELLETIER M, 1982, J IMMUNOL, V129, P2179; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; PTACEK LJ, 1991, CELL, V67, P1021; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSSI JM, 1992, P NATL ACAD SCI USA, V89, P2456, DOI 10.1073/pnas.89.6.2456; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHURR E, 1991, AM J TROP MED HYG, V44, P4, DOI 10.4269/ajtmh.1991.44.4; SCHURR E, 1990, GENOMICS, V8, P477, DOI 10.1016/0888-7543(90)90034-R; SCHURR E, 1989, CYTOGENET CELL GENET, V52, P65, DOI 10.1159/000132841; SCHURR E, 1989, J IMMUNOL, V142, P4507; SERJEANTSON SW, 1983, IMMUNOL REV, V70, P89, DOI 10.1111/j.1600-065X.1983.tb00711.x; SHEETS MD, 1990, NUCLEIC ACIDS RES, V13, P1905; SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKAMENE E, 1991, CURR OPIN IMMUNOL, V3, P511, DOI 10.1016/0952-7915(91)90013-Q; SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; SKAMENE E, 1985, PROG LEUKOC BIOL, V3, P111; STACH JL, 1984, J IMMUNOL, V132, P888; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANEDEN W, 1984, LEPROSY REV, V55, P89; VIDAL SM, 1992, GENOMICS, V14, P32, DOI 10.1016/S0888-7543(05)80279-4; WILKES D, 1991, GENOMICS, V9, P90, DOI 10.1016/0888-7543(91)90224-3; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	90	987	1031	3	47	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					469	485		10.1016/0092-8674(93)90135-D	http://dx.doi.org/10.1016/0092-8674(93)90135-D			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490962				2022-12-28	WOS:A1993LA74300009
J	BARTSCH, P; MERKI, B; HOFSTETTER, D; MAGGIORINI, M; KAYSER, B; OELZ, O				BARTSCH, P; MERKI, B; HOFSTETTER, D; MAGGIORINI, M; KAYSER, B; OELZ, O			TREATMENT OF ACUTE MOUNTAIN-SICKNESS BY SIMULATED DESCENT - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							PORTABLE HYPERBARIC CHAMBER; HIGH-ALTITUDE; EXERCISE; EVEREST; ALDOSTERONE; BALANCE; ILLNESS; BAG	Objective-To evaluate the therapeutic efficacy of a portable hyperbaric chamber for treatment of acute mountain sickness. Design-Controlled randomised trial over two mountaineering seasons. Setting-High altitude research laboratory at 4559 m above sea level. Subjects-64 climbers with acute mountain sickness randomly allocated to different treatments. Interventions-One hour of treatment in the hyperbaric chamber at a pressure of 193 mbar or 20 mbar as control or bed rest. Main outcome measures-Symptoms of acute mountain sickness before, immediately after, and 12 hours after treatment. Permitted intake of analgesic and antiemetic drugs in the follow up period. Results-Treatment with 193 mbar caused greater relief of symptoms than did control treatment or bed rest. During the 12 hour follow up period intake of analgesics was similar (58-80% of subjects in each group). Symptom scores had improved in all subjects after 12 hours with no significant differences between groups. Conclusions-One hour of treatment with 193 mbar in a portable hyperbaric chamber, corresponding to a descent of 2250 m, leads to a short term improvement in symptoms of acute mountain sickness but has no beneficial long term effects attributable to pressurisation.	UNIV HOSP ZURICH,DEPT MED,CH-8091 ZURICH,SWITZERLAND; UNIV GENEVA,DEPT PHYSIOL,CH-1211 GENEVA,SWITZERLAND; UNIV HEIDELBERG,MED CLIN,DEPT SPORTS MED,W-6900 HEIDELBERG,GERMANY	University of Zurich; University Zurich Hospital; University of Geneva; Ruprecht Karls University Heidelberg			Kayser, Bengt/M-8643-2013	Kayser, Bengt/0000-0002-9776-7501; Maggiorini, Marco/0000-0001-8180-2117				BARTSCH P, 1991, J APPL PHYSIOL, V71, P136; BARTSCH P, 1990, LANCET, V336, P772, DOI 10.1016/0140-6736(90)93240-P; Bartsch P., 1990, HYPOXIA ADAPTATIONS, P241; GAMOW RI, 1990, J WILDERNESS MED, V1, P165, DOI 10.1580/0953-9859-1.3.165; GROVER RF, 1982, OXYGEN TRANSPORT HUM, P223; HACKETT PH, 1981, RESP PHYSIOL, V46, P383, DOI 10.1016/0034-5687(81)90133-X; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1990, HYPOXIA ADAPTATIONS, P291; HERRY JP, 1992, INT J SPORTS MED, V13, P83; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KING SJ, 1990, J WILDERNESS MED, V1, P193, DOI 10.1580/0953-9859-1.3.193; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; MILLEDGE JS, 1982, CLIN SCI, V62, P595, DOI 10.1042/cs0620595; REEVES JT, 1987, J APPL PHYSIOL, V63, P531, DOI 10.1152/jappl.1987.63.2.531; ROBERTSON JA, 1991, J WILDERNESS MED, V2, P268, DOI 10.1580/0953-9859-2.4.268; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; SCHOENE RB, 1984, J APPL PHYSIOL, V56, P1478, DOI 10.1152/jappl.1984.56.6.1478; SUTTON JR, 1979, B EUR PHYSIOPATH RES, V15, P1045; TABER RL, 1990, J WILDERNESS MED, V1, P181, DOI 10.1580/0953-9859-1.3.181; 1987, SAS STAT GUIDE PERSO; 1981, LANCET, V1, P180	21	45	47	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1098	1101		10.1136/bmj.306.6885.1098	http://dx.doi.org/10.1136/bmj.306.6885.1098			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495155	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500021
J	MAHMOUDI, A; ISEMAN, MD				MAHMOUDI, A; ISEMAN, MD			PITFALLS IN THE CARE OF PATIENTS WITH TUBERCULOSIS - COMMON ERRORS AND THEIR ASSOCIATION WITH THE ACQUISITION OF DRUG-RESISTANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RADIOMETRIC METHOD; INFECTION; SUSCEPTIBILITY; DISEASE	Objective.-To determine, among a group of patients with multidrug-resistant pulmonary tuberculosis, whether there had been management practices that deviated from established guidelines, and whether these decisions were associated with the acquisition of multidrug resistance and adverse medical sequelae. Design.-Case series. Setting.-Referral center. Patients.-All patients with pulmonary tuberculosis admitted to the National Jewish Center for Immunology and Respiratory Medicine in 1989 through 1990. Interventions.-The records of all patients referred to this institution for the treatment of tuberculosis in 1989 through 1990 were reviewed to ascertain the nature of management decisions that might have been associated with the acquisition of drug resistance. Main Outcome Measures.-Standards of practice as defined by the American Thoracic Society, the Centers for Disease Control and Prevention, and the American College of Chest Physicians were compared with these management decisions to determine whether ''errors'' had been made, resulting in treatment failure and the development of acquired drug resistance. Results.-Among the 35 study patients, errors were detected in the management decisions in 28; there was an average of 3.93 errors per patient. The most common errors were the addition of a single drug to a failing regimen, failure to identify preexisting or acquired drug resistance, initiation of an inadequate primary regimen, failure to identify and address noncompliance, and inappropriate isoniazid preventive therapy. The multidrug resistance acquired through the errors resulted in prolonged hospitalizations, treatment with more toxic drugs, and high-risk resectional surgery. The costs for this ''salvage therapy'' were extraordinary, averaging $180 000 per patient. Conclusions.-Aggressive professional education, tighter control on the provisions of care for tuberculosis patients, and the committing of additional resources to tuberculosis control programs are vital in improving the care of tuberculosis patients and limiting the development of acquired drug resistance.	NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,ROOM J201,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007085] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07085] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDINGTON WW, 1979, CHEST, V76, pS741; [Anonymous], 1991, Am Rev Respir Dis, V143, P707; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BYRD RB, 1977, ANN INTERN MED, V86, P799, DOI 10.7326/0003-4819-86-6-799; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GOODMAN PC, 1990, J THORAC IMAG, V5, P38, DOI 10.1097/00005382-199004000-00007; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; HEIFETS L, 1988, AM REV RESPIR DIS, V137, P1217, DOI 10.1164/ajrccm/137.5.1217; Heifets L B, 1986, Semin Respir Infect, V1, P242; HEIFETS LB, 1985, J CLIN MICROBIOL, V21, P200, DOI 10.1128/JCM.21.2.200-204.1985; ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MANALO F, 1990, AM REV RESPIR DIS, V142, P1301, DOI 10.1164/ajrccm/142.6_Pt_1.1301; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; MCDERMOT.W, 1970, AM REV RESPIR DIS, V102, P857; MITCHISON DA, 1950, THORAX, V5, P144, DOI 10.1136/thx.5.2.144; MURRAY CJL, 1990, LANCET, V335, P1043, DOI 10.1016/0140-6736(90)91114-P; MURRAY JF, 1989, AM REV RESPIR DIS, V140, P1788, DOI 10.1164/ajrccm/140.6.1788; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; REICHMAN LB, 1989, ANN INTERN MED, V111, P197, DOI 10.7326/0003-4819-111-3-197; ROBERTS GD, 1983, J CLIN MICROBIOL, V18, P689, DOI 10.1128/JCM.18.3.689-696.1983; SATHE SS, 1989, CLIN CHEST MED, V10, P445; SBARBARO JA, 1979, CHEST, V76, pS750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Slutkin G, 1988, Bull Int Union Tuberc Lung Dis, V63, P21; Styblo K, 1988, Bull Int Union Tuberc Lung Dis, V63, P25; WATSON JM, 1990, BMJ-BRIT MED J, V300, P63, DOI 10.1136/bmj.300.6717.63; 1986, AM REV RESPIR DIS, V134, P335; 1985, CHEST S, V87, pS115; 1990, LANCET, V335, P1249; 1992, MMWR MORB MORTAL WKL, V41, P507; 1989, MMWR MORB MORTAL S3, V38, P1; 1990, AM REV RESPIR DIS, V142, P725; 1990, MMWR MORB MORTAL REP, V39, P718; 1981, AM REV RESPIR DIS, V123, P343; 1983, AM REV RESPIR DIS, V128, P336; 1991, MMWR MORB MORTAL REP, V40, P585; [No title captured]; 1990, MMWR MORB MORTAL WKL, V39, P3	49	231	241	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					65	68		10.1001/jama.270.1.65	http://dx.doi.org/10.1001/jama.270.1.65			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510299				2022-12-28	WOS:A1993LK36600025
J	BARRON, SA; ROGOVSKI, Z; HEMLI, Y				BARRON, SA; ROGOVSKI, Z; HEMLI, Y			VAGAL CARDIOVASCULAR REFLEXES IN YOUNG PERSONS WITH SYNCOPE	ANNALS OF INTERNAL MEDICINE			English	Article						SYNCOPE; EMOTIONS; HEART RATE; AUTONOMIC NERVOUS SYSTEM; VAGUS NERVE	UNKNOWN ORIGIN; ISOPROTERENOL; MANAGEMENT; HEART	Objective: To study the neurocardiologic reflexes in young persons who have fainted under conditions of emotional stress. Design: Case-control study. Setting: Clinical neurophysiology laboratory in Haifa, Israel. Patients: Sixty persons (41 women and 19 men), 15 to 17 years old, who were referred for study because of syncope related to an emotionally distressing event. Forty aged-matched, healthy volunteers drawn from the same population served as controls. Measurements: Resting electrocardiogram, inspiratory-expiratory difference in heart rate during deep breathing, heart rate response to the Valsalva maneuver, and blood pressure during motionless standing for 5 minutes. Results: Although individual results were within widely accepted limits of normal, patients with syncope as a group had higher vagal autonomic tone than did controls. This manifested as a slower heart rate at rest (mean, 67.8 beats/min compared with 73.2 beats/min; P = 0.005), a higher inspiratory-expiratory difference in heart rate (mean, 44.1 beats/min compared with 37.9 beats/min; P = 0.001), and a higher Valsalva ratio (1.91 compared with 1.72; P < 0.0001). No significant difference was found in the PR and QT(c) (QT interval corrected for rate) intervals of the electrocardiogram or in the blood pressure response to standing. Conclusion: Many young persons who faint under conditions of emotional distress do so because a relatively high vagal tone predisposes them to the cardioinhibitory component of the syncope. Age-related physiologic reduction in vagal cardiac responses may explain the lower incidence of this type of syncope with increasing age.	RAMBAM MED CTR, HAIFA, ISRAEL	Rambam Health Care Campus; Technion Israel Institute of Technology	BARRON, SA (corresponding author), TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, CLIN NEUROPHYSIOL LAB, EFRON ST, POB 9649, IL-31096 HAIFA, ISRAEL.							ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; ARNOLD RW, 1991, MAYO CLIN PROC, V66, P797, DOI 10.1016/S0025-6196(12)61197-5; BALDWA VS, 1977, BRIT HEART J, V39, P641; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; JOHNSON RH, 1984, NEUROCARDIOLOGY INTE, P3; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; LEVIN AB, 1966, AM J CARDIOL, V18, P90, DOI 10.1016/0002-9149(66)90200-1; LINZER M, 1991, AM J MED, V90, P1, DOI 10.1016/0002-9343(91)90498-M; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MUSTONEN J, 1989, CLIN PHYSIOL, V9, P249, DOI 10.1111/j.1475-097X.1989.tb00977.x; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; WEISSLER AM, 1986, HEART, P507; WIELING W, 1982, DIABETOLOGIA, V22, P163, DOI 10.1007/BF00283745	17	19	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					943	946		10.7326/0003-4819-118-12-199306150-00005	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489108				2022-12-28	WOS:A1993LF93700005
J	ADHYA, S				ADHYA, S			ECHOLS,HARRISON (1933-1993) - OBITUARY	CELL			English	Item About an Individual											ADHYA, S (corresponding author), NCI,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ECHOLS H, PUBLICATION LIST	1	2	2	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					833	834		10.1016/0092-8674(93)90263-P	http://dx.doi.org/10.1016/0092-8674(93)90263-P			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500175	Bronze			2022-12-28	WOS:A1993LF06100001
J	LANDEFELD, CS				LANDEFELD, CS			THE SPRING MEETINGS - ARE THEY DYING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LANDEFELD, CS (corresponding author), UNIV HOSP CLEVELAND,CLEVELAND,OH 44106, USA.							MINOT GR, 1938, T ASSOC AM PHYSICIAN, V53, P1; SMITH LH, 1976, T ASSOC AM PHYSICIAN, V89, P1	2	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1645	1647		10.1056/NEJM199306033282221	http://dx.doi.org/10.1056/NEJM199306033282221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8487822				2022-12-28	WOS:A1993LE28900039
J	STOSSEL, TP				STOSSEL, TP			ON THE CRAWLING OF ANIMAL-CELLS	SCIENCE			English	Article							ACTIN-BINDING PROTEIN; LEADING-EDGE; POLYMORPHONUCLEAR LEUKOCYTES; FIBROBLAST LOCOMOTION; HUMAN PLATELET; GROWTH CONES; FILAMENTS; PROFILIN; DYNAMICS; CYTOSKELETON	Cells crawl in response to external stimuli by extending and remodeling peripheral elastic lamellae in the direction of locomotion. The remodeling requires vectorial assembly of actin subunits into linear polymers at the lamella's leading edge and the crosslinking of the filaments by bifunctional gelation proteins. The disassembly of the crosslinked filaments into short fragments or monomeric subunits away from the leading edge supplies components for the actin assembly reactions that drive protrusion. Cellular proteins that respond to lipid and ionic signals elicited by sensory cues escort actin through this cycle in which filaments are assembled, crosslinked, and disassembled. One class of myosin molecules may contribute to crawling by guiding sensory receptors to the cell surface, and another class may contribute by imposing contractile forces on actin networks in the lamellae.			STOSSEL, TP (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT INTERNAL MED, DIV EXPTL MED, BOSTON, MA 02115 USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; BEDLACK RS, 1992, NEURON, V9, P393, DOI 10.1016/0896-6273(92)90178-G; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BRAY D, 1991, J CELL SCI, V98, P507; Bray D., 1992, CELL MOVEMENTS; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BURN P, 1988, J CELL BIOCHEM, V36, P15, DOI 10.1002/jcb.240360103; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARSON MR, 1992, AM J PHYSIOL, V263, pL664, DOI 10.1152/ajplung.1992.263.6.L664; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHIA CP, 1993, J CELL BIOL, V120, P909, DOI 10.1083/jcb.120.4.909; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; CONDEELIS JS, IN PRESS ANN REV CEL; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; CORTESE JD, 1989, P NATL ACAD SCI USA, V86, P5773, DOI 10.1073/pnas.86.15.5773; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; CYPHER C, 1992, Current Opinion in Cell Biology, V4, P4, DOI 10.1016/0955-0674(92)90051-D; DABADAY CY, 1991, J CELL BIOL, V112, P1151; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DEMBO M, 1981, J CELL BIOL, V91, P528, DOI 10.1083/jcb.91.2.528; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DREWES G, 1991, J BIOL CHEM, V266, P5508; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; EUTENEUER U, 1991, J CELL BIOL, V113, P155; Evans E. A., 1978, CURR TOP MEMBR TRANS, P1; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FINLAY BB, 1991, J CELL SCI, V99, P283; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FURUHASHI K, 1992, J BIOL CHEM, V267, P9326; GALLIN EK, 1982, INFLAMMATION BASIC P, P441; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; GINELL D, 1992, J CELL SCI, V101, P255; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOLDSCHMIDTCLERMONT P, 1992, CIRCULATION, V86, P178; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; HEWITT JA, 1979, J THEOR BIOL, V80, P115, DOI 10.1016/0022-5193(79)90183-8; HOFMANN A, 1992, CELL MOTIL CYTOSKEL, V23, P133, DOI 10.1002/cm.970230206; Hoglund A S, 1980, J Muscle Res Cell Motil, V1, P127, DOI 10.1007/BF00711795; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG G, 1992, J MUSCLE RES CELL M, V13, P587, DOI 10.1007/BF01738248; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATAKAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1122, P123, DOI 10.1016/0167-4838(92)90314-4; KOLEGA J, 1991, J CELL BIOL, V114, P993, DOI 10.1083/jcb.114.5.993; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; LAHAM LE, IN PRESS J BIOL CHEM; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; LEW DP, 1993, CURR OPIN HEMATOL, V1, P106; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; MALAWISTA SE, 1982, J CELL BIOL, V95, P960, DOI 10.1083/jcb.95.3.960; MANNHERZ HG, 1992, J BIOL CHEM, V267, P11661; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; MITCHISON TJ, 1992, MOL BIOL CELL, V3, P1309, DOI 10.1091/mbc.3.12.1309; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MULLER O, 1991, MACROMOLECULES, V24, P3111; MURPHY P, 1993, CELL, V72, P21; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKABE S, 1991, J NEUROSCI, V11, P1918; OLIVER JM, 1982, PHILOS T ROY SOC B, V299, P215, DOI 10.1098/rstb.1982.0128; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; OSTER G, IN PRESS FORNTIERS M; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P363, DOI 10.1021/bi00052a045; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PESKIN C, IN PRESS BIOPHYS J; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; QIAN H, 1992, BIOPHYS J, V63, P1000, DOI 10.1016/S0006-3495(92)81686-7; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RINNERTHALER G, 1991, J STRUCT BIOL, V106, P1, DOI 10.1016/1047-8477(91)90058-5; ROULIER EM, 1992, J CELL BIOL, V116, P911, DOI 10.1083/jcb.116.4.911; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SATO N, 1992, J CELL SCI, V103, P131; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SOBUE K, 1991, J BIOL CHEM, V266, P12115; STICKEL SK, 1988, J CELL BIOL, V107, P1231, DOI 10.1083/jcb.107.3.1231; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; THERIOT JA, 1992, J CELL BIOL, V119, P367, DOI 10.1083/jcb.119.2.367; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; Trinkaus J.P., 1984, CELLS ORGANS; USAMI S, 1992, BIOPHYS J, V63, P1663, DOI 10.1016/S0006-3495(92)81745-9; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANDEKERCKHOVE J, 1992, Current Opinion in Cell Biology, V4, P36, DOI 10.1016/0955-0674(92)90056-I; VASILIEV JM, 1991, J CELL SCI, V98, P1; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304; WEEDS AG, 1991, BIOCHEM SOC T, V19, P1016, DOI 10.1042/bst0191016; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YU FX, 1992, J BIOL CHEM, V267, P14616; ZIGMOND SH, 1992, J CELL BIOL, V119, P559, DOI 10.1083/jcb.119.3.559; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	154	926	938	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1993	260	5111					1086	1094		10.1126/science.8493552	http://dx.doi.org/10.1126/science.8493552			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493552				2022-12-28	WOS:A1993LC94200019
J	WRIGHT, RA				WRIGHT, RA			COMMUNITY-ORIENTED PRIMARY CARE - THE CORNERSTONE OF HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICINE; SERVICES; ACCESS	The current high-cost health care delivery system, which places greater emphasis on acute hospital care than on community-based primary and preventive care, is no longer viewed by policymakers, politicians, and the American public as the ideal model for organizing and providing health care services. Americans want change; however, politicians are responding with a barrage of disjointed finance and cost-containment proposals that fail to address the organization and provision of health care services. Nevertheless, to adequately address problems of cost, access, and quality, reform proposals will need to consider delivery models that create a balance between medical care and health care, between public health and personal health services, and between curative and preventive care. The community-oriented primary care model and the discipline of community and socially responsive medicine is a process for making a health care system more rational, accountable, appropriate, and socially relevant to the public. Consequently, this model, which is now at a pivotal point in its evolution, may serve as a paradigm for reforming the organization and provision of health care services in America.	UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WRIGHT, RA (corresponding author), DENVER HLTH & HOSP,COMMUNITY HLTH SERV,777 BANNOCK ST,DENVER,CO 80204, USA.							Berwick D M, 1992, Healthc Forum J, V35, P22; Brown E R, 1989, Med Care Rev, V46, P349, DOI 10.1177/107755878904600402; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DAVIS K, 1983, MILBANK FUND Q, V61, P149, DOI 10.2307/3349903; Enthoven AC, 1980, HLTH PLAN ONLY PRACT; Fisher C R, 1980, Health Care Financ Rev, V1, P65; FREEMAN HE, 1987, AM REPORT THEIR ACCE; FREYMANN JG, 1989, J GEN INTERN MED, V4, P313, DOI 10.1007/BF02597404; FRUELUND MS, 1984, HLTH CARE FINANC REV, V5, P1; FULMER HS, 1992, J HLTH ED, V23, P167; GINZBERG E, 1985, J HLTH POLIT POLICY, V10, P238; KARK SL, 1983, ISRAEL J MED SCI, V19, P707; LAMM RD, 1991, EXCESS ENEMY ACCESS; LUFT HS, 1980, MED CARE, V18, P1, DOI 10.1097/00005650-198001000-00001; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MULLAN F, 1982, NEW ENGL J MED, V307, P1076, DOI 10.1056/NEJM198210213071710; NEWHOUSE JP, 1985, MED CARE, V23, P960, DOI 10.1097/00005650-198508000-00003; OMRAN AR, 1979, HLTH ILLNESS MED; PENCHANSKY R, 1981, MED CARE, V19, P127, DOI 10.1097/00005650-198102000-00001; ROOS NP, 1990, MILBANK Q, V68, P347; Sardell A., 1989, US EXPT SOCIAL MED C; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; Shugars DA, 1991, HLTH AM PRACTITIONER; SMITH DR, 1991, AM J MED SCI, V302, P313, DOI 10.1097/00000441-199111000-00010; WHITE KL, 1988, MED CULTURE; WOOLHANDLER S, 1989, J GEN INTERN MED, V4, P54, DOI 10.1007/BF02596493; 1984, COMMUNITY ORIENTED P; 1991, SOURCE BOOK HLTH INS; 1983, COMMUNITY ORIENTED P	29	38	38	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2544	2547		10.1001/jama.269.19.2544	http://dx.doi.org/10.1001/jama.269.19.2544			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487420				2022-12-28	WOS:A1993LB45000036
J	HAN, M; GOLDEN, A; HAN, YM; STERNBERG, PW				HAN, M; GOLDEN, A; HAN, YM; STERNBERG, PW			C-ELEGANS LIN-45 RAF GENE PARTICIPATES IN LET-60 RAS-STIMULATED VULVAR DIFFERENTIATION	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EMBRYONIC CELL LINEAGES; PROTEIN-KINASE-C; TYROSINE KINASE; INDUCTION; SEQUENCE; MUTATIONS; BINDING; FATES; IDENTIFICATION	Vulval differentiation in Caenorhabditis elegans is controlled by intercellular signalling mediated by a receptor tyrosine kinase and a ras gene product. The lin-45 gene encodes a homologue of the raf family of serine/threonine kinases and is necessary for vulval differentiation. The lin-45 raf gene product appears to act downstream of the ras protein in this pathway. A proto-oncogene-mediated signalling pathway may be a common feature of metazoan development.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL 15629,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute	HAN, M (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.			Sternberg, Paul/0000-0002-7699-0173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047869] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047869] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRENNER S, 1974, GENETICS, V77, P71; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CLARK DV, 1988, GENETICS, V119, P345; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON AR, 1988, NEMATODE CAENORHABDI, P47; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HERMAN RK, 1978, GENETICS, V88, P49; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; HOSONO R, 1982, J EXP ZOOL, V235, P409; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARK EC, 1986, GENETICS, V113, P821; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; Sambrook J, 1989, MOL CLONING LABORATO; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9	48	222	244	3	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					133	140		10.1038/363133a0	http://dx.doi.org/10.1038/363133a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483497				2022-12-28	WOS:A1993LB80100038
J	SMITH, MS				SMITH, MS			BABU	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2447	2447		10.1001/jama.269.18.2447	http://dx.doi.org/10.1001/jama.269.18.2447			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479073				2022-12-28	WOS:A1993LA67500043
J	AMOS, B; SCHLOTTERER, C; TAUTZ, D				AMOS, B; SCHLOTTERER, C; TAUTZ, D			SOCIAL-STRUCTURE OF PILOT WHALES REVEALED BY ANALYTICAL DNA PROFILING	SCIENCE			English	Article							MATING SYSTEMS; SELECTION; MAMMALS	Long-finned pilot whales swim in large, extremely cohesive social groups known as pods. Molecular typing revealed that pod members form a single extended family. Mature males neither disperse from nor mate within their natal pods, a situation unusual for mammals. Such behavior could be explained in terms of inclusive fitness benefits gained by adult males helping the large number of female relatives with which they swim.	UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich	AMOS, B (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 2EH,ENGLAND.		Tautz, Diethard/H-8436-2014; Schlötterer, Christian/G-6326-2010; Schlötterer, Christian/Q-5264-2019; Tautz, Diethard/D-4304-2011; Peng, Bo/A-6920-2009	Tautz, Diethard/0000-0002-0460-5344; Schlötterer, Christian/0000-0003-4710-6526; Schlötterer, Christian/0000-0003-4710-6526; Peng, Bo/0000-0001-8225-2284				AMOS B, 1991, HEREDITY, V67, P49, DOI 10.1038/hdy.1991.64; AMOS W, IN PRESS S ZOOL SOC; Bigg M.A., 1990, REP INT WHALING COMM, V12, P384; BROWNELL RL, 1990, REP INT WHALING COMM, V8, P383; CHARNOV EL, 1981, ANIM BEHAV, V29, P631, DOI 10.1016/S0003-3472(81)80130-3; CLUTTONBROCK TH, 1989, NATURE, V337, P70, DOI 10.1038/337070a0; CLUTTONBROCK TH, 1989, PROC R SOC SER B-BIO, V236, P339, DOI 10.1098/rspb.1989.0027; EDWARDS AWF, 1972, LIKELIHOOD; EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; JOENSEN JP, 1976, ETHNOLOGIA SCANDINAV, P5; SCHLOTTERER C, 1991, NATURE, V354, P63, DOI 10.1038/354063a0; Sergeant DE, 1962, B FISH RES BD CANADA, V132, P1; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; Wittenberger J. F., 1979, SOCIAL BEHAV COMMUNI, P271, DOI [10.1007/978-1-4615-9116-0_6, DOI 10.1007/978-1-4615-9116-0_6]	15	258	273	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 30	1993	260	5108					670	672		10.1126/science.8480176	http://dx.doi.org/10.1126/science.8480176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480176				2022-12-28	WOS:A1993KZ64100031
J	FREESTONE, DS; MITCHELL, H				FREESTONE, DS; MITCHELL, H			INAPPROPRIATE PUBLICATION OF TRIAL RESULTS AND POTENTIAL FOR ALLEGATIONS OF ILLEGAL SHARE DEALING	BRITISH MEDICAL JOURNAL			English	Article							INGELFINGER RULE	There is increasing evidence of fraud in clinical research, and one aspect concerns trading in pharmaceutical company shares by people who may have confidential information about the results of clinical trials. Plainly this has implications for honest investigators, who may find themselves exposed to such allegations. In this paper Dr D S Freestone and Mr H Mitchell, QC, identify three interlinked issues which they think underlie the potential for these allegations. They are pressure for premature or inappropriate communication of research results; trading in pharmaceutical company shares by academic clinical investigators; and the possibility that clinical investigators might succumb to temptation. Dr Freestone and Mr Mitchell suggest that whenever possible results of clinical studies should be published in appropriate medical journals without prior public disclosure. This conflicts with Stock Exchange rules, which require that price sensitive information should be published at the earliest opportunity and preclude priority of publication in medical journals. Freestone and Mitchell believe that rarely rapid public disclosure is acceptable if it is to protect patients' interests but that it must not prejudice publication in the medical or scientific press. When rapid public disclosure is needed, they say, every attempt should be made to inform prescribers before patients. Dr Freestone and Mr Mitchell warn that academic clinical investigators who have access to unpublished price sensitive information about pharmaceutical companies whose shares they trade in will almost certainly be in breach of the Company Securities (Insider Dealing) Act 1985. Furthermore, disclosing such information to third parties, they say, exposes those people also to potential criminal liability. Freestone and Mitchell advise that when potential for allegations of conflict of interest exists clinical investigators should consider declaring their position to ethics committees and any sponsoring organisations.	WELLCOME FDN LTD,DIV MED SCI,LONDON,ENGLAND	GlaxoSmithKline								ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; LOCK S, 1990, BRIT MED J, V301, P1348; LOCK S, 1988, BRIT MED J, V297, P1531, DOI 10.1136/bmj.297.6662.1531; LUNDBERG GD, 1989, JAMA-J AM MED ASSOC, V262, P2003, DOI 10.1001/jama.262.14.2003; RELMAN AS, 1988, NEW ENGL J MED, V318, P1125, DOI 10.1056/NEJM198804283181709; RELMAN AS, 1981, NEW ENGL J MED, V305, P824, DOI 10.1056/NEJM198110013051408; Sibbison J B, 1989, Lancet, V2, P1094; SMITH J, 1989, BRIT MED J, V298, P1601; 1990, SCRIP, P18; 1989, SCRIP, P5; 1991, FRAUD MISCONDUCT MED; 1988, WPEMP111397688 WORK; 1989, SCRIP, P20; 1992, FRAUD MALPRACTICE CO; 1989, SCRIP, P19; 1989, SCRIP, P18; 1990, SCRIP, P22; 1988, GUIDELINES GOOD CLIN; 1989, SCRIP, P2; 1990, SCRIP, P13	21	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1112	1114		10.1136/bmj.306.6885.1112	http://dx.doi.org/10.1136/bmj.306.6885.1112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495159	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500027
J	WARD, L; SHEPHERD, JP; EMOND, AM				WARD, L; SHEPHERD, JP; EMOND, AM			RELATIONSHIP BETWEEN ADULT VICTIMS OF ASSAULT AND CHILDREN AT RISK OF ABUSE	BRITISH MEDICAL JOURNAL			English	Article									UNITED BRISTOL HEALTHCARE TRUST,DEPT COMMUNITY CHILD HLTH,BRISTOL BS8 1QB,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT ORAL SURG MED & PATHOL,CARDIFF CF4 4XY,WALES	Cardiff University								Borland Marie, 1976, VIOLENCE FAMILY; BROWNE K, 1988, EARLY PREDICTION PRE, P57; HOUGH M, 1985, HOME OFFICE RES STUD, V76; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; 1991, WORKING TOGETHER GUI	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1101	1102		10.1136/bmj.306.6885.1101	http://dx.doi.org/10.1136/bmj.306.6885.1101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ565	8495156	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500022
J	LAVELLEJONES, C; BYRNE, DJ; RICE, P; CUSCHIERI, A				LAVELLEJONES, C; BYRNE, DJ; RICE, P; CUSCHIERI, A			FACTORS AFFECTING QUALITY OF INFORMED CONSENT	BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION	Objective-To examine the factors influencing quality of informed consent. Design-Prospective study comprising interviews with patients and patients' completing standard questionnaires. Setting-Academic surgical unit of large teaching hospital. Patients-265 patients undergoing intrathoracic, intraperitoneal, and vascular surgical procedures. Of these patients, 192 have been followed up for six months. Main outcome measures-Patients' recall of information at various points in the study; this score was compared by age, provision of written information, cognitive function, intelligence quotient (IQ), mood state and personality traits, and health locus of control. Results-The patients were best informed immediately after signing the consent form and from then on recall of information deteriorated. A total of 172/250 (69%) patients admitted to not reading the consent form before signing it. Old age adversely affected recall of information at all assessment points. Impaired cognitive function reduced information recall only during the stay in hospital. Patients with above average lQs handled information better than those with a lower IQ except immediately after the signing of consent forms. Patients with an internal locus of health control (that is, those who believed their health to be in their own control) were better informed than those with an external locus of health control. Operation information cards improved recall only on the day of discharge. Conclusion-Elderly patients and patients with below average IQ, impaired cognitive functions, and an external locus of control have poor information recall. Written information may be more useful if given before admission to hospital.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT SURG,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PSYCHIAT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee			Cuschieri, Alfred/A-7634-2013; Cuschieri, Alfred/O-4092-2019	Cuschieri, Alfred/0000-0003-0764-5947				Askew G, 1990, J R Coll Surg Edinb, V35, P308; BYRNE DJ, 1988, BRIT MED J, V296, P839, DOI 10.1136/bmj.296.6625.839; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; EDWARDS MH, 1990, BRIT J SURG, V77, P463, DOI 10.1002/bjs.1800770431; LEY P, 1976, PSYCHOL MED, V6, P599, DOI 10.1017/S0033291700018237; REYNOLDS M, 1978, BRIT MED J, V1, P1673, DOI 10.1136/bmj.1.6128.1673; RICHARDS J, 1985, J ROY SOC MED, V78, P922, DOI 10.1177/014107688507801109; VILLAR RN, 1984, J MED DEFENCE UNION, V4, P32	8	234	235	2	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					885	890		10.1136/bmj.306.6882.885	http://dx.doi.org/10.1136/bmj.306.6882.885			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490411	Green Published, Bronze			2022-12-28	WOS:A1993KW38700017
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			ACCIDENTAL DURAL PUNCTURE IN OBSTETRIC PATIENTS AND LONG-TERM SYMPTOMS	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS; ANESTHESIA; MANAGEMENT; BLOCK	Objective-To examine the association between accidental dural puncture and long term headache and related symptoms. Design-Postal questionnaire survey to elucidate new symptoms occurring after childbirth, and linking of these to data in obstetric and anaesthetic case notes. Women were surveyed between 13 months and nine years after delivery. Setting-Birmingham Maternity Hospital. Subjects-4700 women who had delivered their most recent baby under epidural anaesthesia, 74 of whom had suffered an accidental dural puncture. Main outcome measures-Frequencies of new headache or migraine or neck ache starting within three months after childbirth and lasting over six weeks. Results-Among the 74 women who had had an accidental dural puncture there were 17 (23%) who reported one or more of the above symptoms. By comparison, among those who had had an epidural anaesthetic but no recorded puncture, only 329 (7.1%) reported these symptoms. The duration of the headache or migraine or neck ache in the dural tap group ranged from nine weeks to over eight years. Ten of these women reported still unresolved symptoms. Conclusions-Conclusions on causality were tentative. Most women would remember a dural tap, and this might influence their reporting of subsequent symptoms attributable to the event. In addition, detailed characterisation of the symptoms was not available. Nevertheless, the findings provide a clear indication of the need for further study of the possible long term sequelae of accidental dural puncture.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				ABOULEISH E, 1978, ANESTHESIOLOGY, V49, P291, DOI 10.1097/00000542-197810000-00016; Bromage PR, 1978, EPIDURAL ANALGESIA, V1st; BROWNRIDGE P, 1982, ANAESTH INTENS CARE, V10, P298, DOI 10.1177/0310057X8201000401; BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CAST W, 1974, JAMA-J AM MED ASSOC, V227, P786; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P1277, DOI 10.1093/bja/44.12.1277; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; KALAS DB, 1972, ANESTH ANAL CURR RES, V51, P192; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1992, BRIT MED J, V304, P1279, DOI 10.1136/bmj.304.6837.1279; MACARTHUR C, 1991, HLTH CHILDBIRTH; OKELL RW, 1987, ANAESTHESIA, V42, P1110, DOI 10.1111/j.1365-2044.1987.tb05181.x; ONG B, 1987, CAN J ANAESTH, V34, P294, DOI 10.1007/BF03015169; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; STRIDE PC, 1993, ANAESTHESIA, V48, P247, DOI 10.1111/j.1365-2044.1993.tb06913.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	17	70	71	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					883	885		10.1136/bmj.306.6882.883	http://dx.doi.org/10.1136/bmj.306.6882.883			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490410	Bronze, Green Published			2022-12-28	WOS:A1993KW38700016
J	AHMED, T; GARRIGO, J; DANTA, I				AHMED, T; GARRIGO, J; DANTA, I			PREVENTING BRONCHOCONSTRICTION IN EXERCISE-INDUCED ASTHMA WITH INHALED HEPARIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; MAST-CELLS; INOSITOL TRISPHOSPHATE; CROMOLYN SODIUM; CALCIUM RELEASE; RECEPTOR; SULFATE; BINDING; INTERNALIZATION; INHIBITION	Background. We have previously reported that inhaled heparin prevents allergic bronchoconstriction in sheep and inhibits the anti-IgE-mediated release of histamine from mast cells in vitro. Since the release of such mediators has been implicated in exercise-induced asthma, we investigated whether inhaled heparin could also attenuate the bronchoconstrictor response in this disease. Methods. On five days we studied 12 subjects with a history of exercise-induced asthma. On day 1 they underwent a standardized exercise challenge on a treadmill to document the presence of exercise-induced asthma. Minute ventilation was estimated with a calibrated respiratory inductive plethysmograph. The workload was increased until the heart rate reached 85 percent of the predicted maximal value, and was sustained for 10 minutes. The magnitude of bronchoconstriction was assessed by measuring specific airway conductance before and after the exercise. On day 2 the partial-thromboplastin time was measured in plasma obtained before and after the subjects inhaled a nebulized solution of heparin (1000 U per kilogram of body weight). On days 3 through 5 the subjects were pretreated with 4 ml of inhaled heparin (1000 U per kilogram), cromolyn sodium (20 mg), or placebo according to a single-blind, randomized, crossover design and underwent exercise challenge 45 minutes later. To exclude the possibility that heparin had any direct effect on airway smooth muscle, bronchial provocation with histamine was induced in five subjects on two further days after pretreatment with either heparin or placebo. Results. Inhaled heparin and cromolyn sodium had no effect on specific airway conductance at base line, but did attenuate the exercise-induced decreases in this variable: the mean (+/-SE) maximal decrease five minutes after exercise was 9+/-5 percent after pretreatment with heparin, as compared with 22+/-5 percent after pretreatment with cromolyn and 35+/-2 percent after pretreatment with placebo. Heparin did not change the partial-thromboplastin time and did not modify the bronchoconstrictor response to histamine. Conclusions. Inhaled heparin prevents exercise-induced asthma without influencing histamine-induced bronchoconstriction. This non-anticoagulant action of heparin is more likely to be related to a modulation of mediator release than to a direct effect on smooth muscle.	UNIV MIAMI,SCH MED,DIV PULM DIS,MIAMI,FL 33152	University of Miami	AHMED, T (corresponding author), MT SINAI MED CTR,DIV PULM DIS,4300 ALTON RD,MIAMI BEACH,FL 33140, USA.							AHMED T, 1992, AM REV RESPIR DIS, V145, P566, DOI 10.1164/ajrccm/145.3.566; AHMED T, 1988, J ALLERGY CLIN IMMUN, V81, P852, DOI 10.1016/0091-6749(88)90942-6; AHMED T, 1991, American Review of Respiratory Disease, V143, pA360; AHMED T, 1993, J APPL PHYSIOL, V74, P1492, DOI 10.1152/jappl.1993.74.4.1492; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIANCO S, 1988, LANCET, V2, P252; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160, DOI 10.1164/ajrccm/147.1.160; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; CHADHA TS, 1983, MODELLING CONTROL BR, P258; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DOLOWITZ D A, 1960, Laryngoscope, V70, P873; Dragstedt CA, 1942, P SOC EXP BIOL MED, V51, P191; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FINE NL, 1968, AM REV RESPIR DIS, V98, P886; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; HIEBERT LM, 1990, ARTERY, V17, P107; HIGGINBOTHAM RD, 1956, P SOC EXP BIOL MED, V92, P493; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jaques LB, 1980, PHARMACOL REV, V31, P99; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LUCIO J, 1992, J APPL PHYSIOL, V73, P1093, DOI 10.1152/jappl.1992.73.3.1093; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; RUMYANTSEVA AG, 1991, B EXP BIOL MED+, V112, P1612, DOI 10.1007/BF00840427; SACKNER JD, 1980, AM REV RESPIR DIS, V122, P867; SACKNER JD, 1980, AM REV RESPIR DIS, V122, P933; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; TAMAOKI J, 1990, AM J PHYSIOL, V258, pL355, DOI 10.1152/ajplung.1990.258.6.L355; TASAKA K, 1987, AGENTS ACTIONS, V20, P157, DOI 10.1007/BF02074656; TONES MA, 1989, FEBS LETT, V252, P105, DOI 10.1016/0014-5793(89)80898-1; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Zar JH, 1974, BIOSTATISTICAL ANAL	44	183	190	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					90	95		10.1056/NEJM199307083290204	http://dx.doi.org/10.1056/NEJM199307083290204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510708				2022-12-28	WOS:A1993LL19600004
J	FOX, LA				FOX, LA			IMAGES IN CLINICAL MEDICINE - 3-DIMENSIONAL CT DIAGNOSIS OF MAXILLOFACIAL TRAUMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FOX, LA (corresponding author), EDWARD MALLINCKRODT INST RADIOL,ST LOUIS,MO 63110, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					102	102						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510685				2022-12-28	WOS:A1993LL19600006
J	LINDBERG, DAB; SIEGEL, ER; RAPP, BA; WALLINGFORD, KT; WILSON, SR				LINDBERG, DAB; SIEGEL, ER; RAPP, BA; WALLINGFORD, KT; WILSON, SR			USE OF MEDLINE BY PHYSICIANS FOR CLINICAL PROBLEM-SOLVING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMATION	Objective.-To understand the Ways in which computer-mediated searching of the biomedical literature affects patient care and other professional activities. Undertaken to determine the ways in which on-line access to the biomedical literature via the National Library of Medicine's MEDLINE database ''makes a difference'' in what physicians do when confronted with a medical problem requiring new or additional information. Design.-An adaptation of the Critical Incident Technique used to gather detailed reports of MEDLINE search results that were especially helpful (or not helpful) in carrying out the individual's professional activities. The individual physician was the source of the patient care incident reports. One thousand one hundred fifty-eight reports were systematically analyzed from three different perspectives: (1) why the information was sought; (2) the effect of having (or not having) the needed information on professional decisions and actions; and (3) the outcome of the search. Participants and Setting.-Telephone interviews were carried out with a purposive sample of 552 physicians, scientists, and other professionals working in a variety of clinical care and other settings. Of these, 65% were direct users of MEDLINE throughout the United States, and 35% had MEDLINE searches conducted for them either at a major health sciences center or in community hospitals. Results.-Three comprehensive and detailed inventories that describe the motivation for the searches, how search results affected the actions and decisions of the individual who initiated the search, and how they affected the outcome of the situation that motivated the search. Conclusions.-MEDLINE searches are being carried out by and for physicians to meet a wide diversity of clinical information needs. Physicians report that in situations involving individual patients, rapid access to the biomedical literature via MEDLINE is at times critical to sound patient care and favorably influences patient outcomes.	NATL LIB MED,8600 ROCKVILLE PIKE,BETHESDA,MD 20894; AMER INST RES,PALO ALTO,CA 94302	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); American Institutes for Research								BLUM JM, 1965, CRITICAL PERFORMANCE; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; DEBAKEY ME, 1991, JAMA-J AM MED ASSOC, V266, P1252, DOI 10.1001/jama.266.9.1252; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; FLANAGAN JC, 1948, 1 ARM AIR FORC AV PS; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HUBBARD JP, 1965, NEW ENGL J MED, V272, P1321, DOI 10.1056/NEJM196506242722505; JACOBS AM, 1978, CRITICAL REQUIREMENT; McClatchey W M, 1985, J Med Assoc Ga, V74, P290; MCDERMOTT JF, 1977, J AM ACAD CHILD PSY, V16, P517, DOI 10.1016/S0002-7138(09)61604-6; MURRAY KM, 1987, CRIT CARE MED, V15, P797, DOI 10.1097/00003246-198708000-00020; SANAZARO PJ, 1968, MED CARE, V6, P123, DOI 10.1097/00005650-196803000-00004; SOHN N, 1985, NEW ENGL J MED, V312, P924; TARICO V, 1984, RADIOLOGY, V152, P327, DOI 10.1148/radiology.152.2.6739793; WALLINGFORD KT, 1990, M D COMPUT, V7, P166; WILSON SR, 1989, USE CRITICAL INCIDEN; 1990, MED STUDENT GRADUATI	17	139	139	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3124	3129		10.1001/jama.269.24.3124	http://dx.doi.org/10.1001/jama.269.24.3124			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LH145	8505815				2022-12-28	WOS:A1993LH14500026
J	MISHU, B; ILYAS, AA; KOSKI, CL; VRIESENDORP, F; COOK, SD; MITHEN, FA; BLASER, MJ				MISHU, B; ILYAS, AA; KOSKI, CL; VRIESENDORP, F; COOK, SD; MITHEN, FA; BLASER, MJ			SEROLOGIC EVIDENCE OF PREVIOUS CAMPYLOBACTER-JEJUNI INFECTION IN PATIENTS WITH THE GUILLAIN-BARRE-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						CAMPYLOBACTER-JEJUNI; CAMPYLOBACTER INFECTIONS; POLYRADICULONEURITIS; NEUROLOGIC MANIFESTATIONS	ENTERITIS; CHILDREN; DIARRHEA; FETUS; COLI	Objective: To determine if patients with the Guillain-Barre syndrome are likely to have had Campylobacter jejuni infection before onset of neurologic symptoms. Design: A case-control study. Setting: Several university medical centers. Patients: Case patients met clinical criteria for the Guillain-Barre syndrome between 1983 and 1990 and had a serum sample collected and frozen within 3 weeks after onset of neurologic symptoms (n = 118). Disease controls were patients with other neurologic illnesses (n = 56); healthy controls were hospital employees or healthy family members of patients (n = 47). Measurements: Serum IgA, IgG, and IgM antibodies to C. jejuni were determined by enzyme-linked immunosorbent assays. Assays were done in a blinded manner. Results: Optical density ratios greater-than-or-equal-to 2 in two or more immunoglobulin classes were seen in 43 (36%) of patients with the Guillain-Barre syndrome and in 10 (10%) of controls (odds ratio, 5.3; 95% CI, 2.4 to 12.5; P < 0.001). Increasing the optical density ratio or the number of immunoglobulin classes necessary to yield a positive result increased the strength of the association. The number of patients with the Guillain-Barre syndrome who had positive serologic responses was greatest from September to November (P = 0.02). Male patients were three times more likely to have serologic evidence of C. jejuni infection (P = 0.009); the proportion of patients with the syndrome who had a positive serologic response increased with age. Conclusions: Patients with the Guillain-Barre syndrome are more likely than controls to have serologic evidence of C. jejuni infection in the weeks before onset of neurologic symptoms. Campylobacter jejuni may play a role in the initiation of the Guillain-Barre syndrome in many patients.	UNIV MED & DENT NEW JERSEY, DEPT NEUROSCI, NEWARK, NJ 07103 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; VET AFFAIRS MED CTR, NASHVILLE, TN USA; ST LOUIS UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Saint Louis University	MISHU, B (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DIV INFECT DIS, A3310 MED CTR N, NASHVILLE, TN 37232 USA.							[Anonymous], 1978, Ann Neurol, V3, P565; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; BLASER MJ, 1981, NEW ENGL J MED, V305, P1444, DOI 10.1056/NEJM198112103052404; BLASER MJ, 1991, LANCET, V338, P308, DOI 10.1016/0140-6736(91)90447-W; BRISCOE DM, 1987, ARCH DIS CHILD, V62, P733, DOI 10.1136/adc.62.7.733; CARPO M, 1991, CLIN NEUROPATHOL, V10, P46; CONSTANT OC, 1983, J INFECTION, V6, P89, DOI 10.1016/S0163-4453(83)95881-4; FUJIMOTO S, 1990, LANCET, V335, P1350, DOI 10.1016/0140-6736(90)91234-2; FUJIMOTO S, 1992, J INFECT DIS, V165, P183, DOI 10.1093/infdis/165.1.183; GRUENEWALD R, 1991, ARCH NEUROL-CHICAGO, V48, P1080, DOI 10.1001/archneur.1991.00530220102027; HUGHES RAC, 1990, GUILLAINBARRE SYNDRO; Ismael S, 1990, Paediatr Indones, V30, P79; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; KENNEDY RH, 1978, MAYO CLIN PROC, V53, P93; KUROKI S, 1991, PEDIATR INFECT DIS J, V10, P149, DOI 10.1097/00006454-199102000-00014; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; LATOVITZKI N, 1979, NEUROLOGY, V29, P743, DOI 10.1212/WNL.29.5.743; LENEMAN F, 1966, ARCH INTERN MED, V118, P139, DOI 10.1001/archinte.118.2.139; LIOR H, 1983, CAMPYLOBACTER, V2, P72; MCCOY EC, 1975, INFECT IMMUN, V11, P517, DOI 10.1128/IAI.11.3.517-525.1975; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MOLNAR GK, 1982, BRIT MED J, V285, P652, DOI 10.1136/bmj.285.6342.652; PANDEY JP, 1986, EXP CLIN IMMUNOGENET, V3, P49; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PEI ZH, 1991, J BIOL CHEM, V266, P16363; PITKANEN T, 1983, ARCH INTERN MED, V143, P215, DOI 10.1001/archinte.143.2.215; PRYOR WM, 1984, AUST NZ J MED, V14, P687, DOI 10.1111/j.1445-5994.1984.tb05033.x; RAUTELIN H, 1983, J CLIN MICROBIOL, V17, P700, DOI 10.1128/JCM.17.4.700-701.1983; RHODES KM, 1982, BRIT MED J, V285, P173, DOI 10.1136/bmj.285.6336.173; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; ROPPER AH, 1988, ARCH NEUROL-CHICAGO, V45, P655, DOI 10.1001/archneur.1988.00520300075022; SPEED BR, 1987, MED J AUSTRALIA, V147, P13, DOI 10.5694/j.1326-5377.1987.tb133228.x; SVEDHEM A, 1980, J INFECT DIS, V142, P353, DOI 10.1093/infdis/142.3.353; Tauxe R V, 1988, MMWR CDC Surveill Summ, V37, P1; TRABELSI M, 1989, PEDIATRIE, V44, P413; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; YUKI N, 1991, NEUROLOGY, V41, P1561, DOI 10.1212/WNL.41.10.1561	37	149	152	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					947	953		10.7326/0003-4819-118-12-199306150-00006	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489109				2022-12-28	WOS:A1993LF93700006
J	CHANG, SYP; BOWMAN, BH; WEISS, JB; GARCIA, RE; WHITE, TJ				CHANG, SYP; BOWMAN, BH; WEISS, JB; GARCIA, RE; WHITE, TJ			THE ORIGIN OF HIV-1 ISOLATE HTLV-IIIB	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AIDS VIRUS; NUCLEOTIDE-SEQUENCE; RETROVIRUS; EVOLUTION; RISK; LAV; DNA	THE striking similarity between the first two human immunodeficiency virus type 1 (HIV-1) isolates Lai/LAV (formerly LAV, isolated at the Pasteur Institute1,2) and Lai/IIIB (formerly HTLV-IIIB, reported to be isolated from a pooled culture at the Laboratory of Tumor Cell Biology (LTCB) of the National Cancer Institute3,4) provoked considerable controversy in light of the high level of variability found among subsequent HIV-1 isolates5. In November 1990, the Office of Scientific Integrity at the National Institutes of Health commissioned our group to analyse archival samples established at the Pasteur Institute and LTCB between 1983 and 1985. Retrospective analyses6,7 have shown that contamination of a culture derived from patient BRU by one from patient LAI was responsible for the provenance of HIV-1 Lai/LAV; the contaminated culture (M2T-/B) was sent to LTCB in September 1983(6,7). Our goals were to determine which HIV-1 variants were present in the samples and the sequence diversity among HIV-1 isolates from the earliest stages of the AIDS epidemic. We examined archival specimens and report here the detection of six novel HIV-1 sequences in the cultures used to establish the pool: none is closely related to HIV-1 Lai/IIIB. A sample derived from patient LAI contained variants of both HIV-1 Lai/IIIB and HIV-1 Lai/LAV, and a sequence identical to a variant of HIV-1 Lai/IIIB was detected in the contaminated M2T-/B culture. We conclude that the pool, and probably another LTCB culture, MoV, were contaminated between October 1983 and early 1984 by variants of HIV-1 Lai from the M2T-/B culture. Therefore, the origin of the HIV-1 Lai/IIIB isolate also was patient LAI.	ROCHE MOLEC SYST INC,1145 ATLANTIC AVE,ALAMEDA,CA 94501									ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BURGER H, 1991, P NATL ACAD SCI USA, V88, P11236, DOI 10.1073/pnas.88.24.11236; CHANG SY, IN PRESS MOL EVOLUTI; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GUO HG, 1991, NATURE, V349, P745, DOI 10.1038/349745a0; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; Kwok S, 1990, PCR PROTOCOLS GUIDE, P142; LI WH, 1988, MOL BIOL EVOL, V5, P313; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MYERS G, 1991, HUMAN RETROVIRUSES A; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316	27	35	37	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					466	469		10.1038/363466a0	http://dx.doi.org/10.1038/363466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502298				2022-12-28	WOS:A1993LE93800064
J	CARR, CM; KIM, PS				CARR, CM; KIM, PS			A SPRING-LOADED MECHANISM FOR THE CONFORMATIONAL CHANGE OF INFLUENZA HEMAGGLUTININ	CELL			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; COILED-COIL; LEUCINE ZIPPER; INTRACELLULAR-TRANSPORT; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION; HEPTAD REPEAT; PROTEINS; PH	Influenza hemagglutinin (HA) undergoes a conformational change that induces viral fusion with the cellular membrane. The structure of HA in the fusogenic state is unknown. We have identified a sequence in HA that has a high propensity for forming a coiled coil. Surprisingly, this sequence corresponds to a loop region in the X-ray structure of native HA: the loop is followed by a three-stranded, coiled-coil stem. We find that a 36 residue peptide (LOOP-36), comprising the loop region and the first part of the stem, forms a three-stranded coiled coil. This coiled coll is extended and stabilized in a longer peptide, corresponding to LOOP-36 plus the residues of a preceding, short alpha helix. These findings lead to a model for the fusogenic conformation of HA: the coiled-coil stem of the native state extends, relocating the hydrophobic fusion peptide, by 100 angstrom, toward the target membrane.			CARR, CM (corresponding author), MIT,DEPT BIOL,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142, USA.				NIAID NIH HHS [AI07348] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS C G, 1991, Peptide Research, V4, P95; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GLICK GD, 1991, J BIOL CHEM, V266, P23660; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HODGES RS, 1981, J BIOL CHEM, V256, P1217; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PEREZ LG, 1992, J VIROL, V66, P4134, DOI 10.1128/JVI.66.7.4134-4143.1992; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2; SAUTER NK, 1992, P NATL ACAD SCI USA, V89, P324, DOI 10.1073/pnas.89.1.324; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WARD CW, 1980, AUST J BIOL SCI, V33, P441; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1982, NATURE, V300, P658, DOI 10.1038/300658a0; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001	65	796	837	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					823	832		10.1016/0092-8674(93)90260-W	http://dx.doi.org/10.1016/0092-8674(93)90260-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500173				2022-12-28	WOS:A1993LD83000019
J	FUTTERER, J; KISSLASZLO, Z; HOHN, T				FUTTERER, J; KISSLASZLO, Z; HOHN, T			NONLINEAR RIBOSOME MIGRATION ON CAULIFLOWER MOSAIC VIRUS-35S RNA	CELL			English	Article							MESSENGER-RNA; TRANSLATIONAL CONTROL; CHLORAMPHENICOL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC RIBOSOMES; INITIATION; SEQUENCE; REGION; EXPRESSION; LEADER	Cauliflower mosaic virus 35S RNA contains a 600 nt leader with several small open reading frames that by themselves inhibit translation of downstream coding regions. In the context of the whole leader and in certain plant cells, however, translation of downstream coding regions is allowed. This translation is dependent on the RNA 5' terminus and other elements of the leader. However, its central portion is dispensable or can be modified by insertion of an energy-rich stem-loop structure or long coding region with many internal AUG codons. We conclude that this region can be by-passed (shunted) by the scanning complex. Shunting was also observed in trans between two separate RNA molecules.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABASTADO JP, 1991, NEW BIOL, V3, P511; ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; AGOL VI, 1991, ADV VIRUS RES, V40, P103; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BAUGHMAN G, 1988, VIROLOGY, V167, P125, DOI 10.1016/0042-6822(88)90061-X; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BONNEVILLE JM, 1988, RNA GENETICS, P23; BOROVJAGIN AV, 1991, NUCLEIC ACIDS RES, V19, P4999, DOI 10.1093/nar/19.18.4999; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHANG LJ, 1990, P NATL ACAD SCI USA, V87, P5158, DOI 10.1073/pnas.87.13.5158; CHEVRIER D, 1988, J BIOL CHEM, V263, P902; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DARLIX JL, 1982, NUCLEIC ACIDS RES, V10, P5183, DOI 10.1093/nar/10.17.5183; DONZE O, 1992, EMBO J, V11, P3747, DOI 10.1002/j.1460-2075.1992.tb05460.x; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FUTTERER J, 1988, NUCLEIC ACIDS RES, V16, P8377, DOI 10.1093/nar/16.17.8377; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; Futterer J, 1989, Virus Genes, V3, P45, DOI 10.1007/BF00301986; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1990, NATO ASI SERIES H, V49, P349; GALILI G, 1988, J BIOL CHEM, V263, P5764; GALILIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631; GALILIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257; GIBBS MR, 1990, BIOCHEMISTRY-US, V29, P11261, DOI 10.1021/bi00503a015; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOWDA S, 1989, P NATL ACAD SCI USA, V86, P9203, DOI 10.1073/pnas.86.23.9203; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HACKETT PB, 1991, NUCLEIC ACIDS RES, V19, P6929, DOI 10.1093/nar/19.24.6929; HAY JM, 1991, NUCLEIC ACIDS RES, V19, P2615, DOI 10.1093/nar/19.10.2615; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; HULL R, 1984, PLANT MOL BIOL, V3, P121, DOI 10.1007/BF00016059; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JEFFERSON RA, 1987, EMBO J, V6, P3901; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE S, 1989, J VIROL, V63, P1069, DOI 10.1128/JVI.63.3.1069-1075.1989; KUHN R, 1990, J VIROL, V64, P4625; LEVINE F, 1991, GENE, V108, P167, DOI 10.1016/0378-1119(91)90431-A; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Maniatis T., 1982, MOL CLONING; MASON WS, 1987, ADV VIRUS RES, V32, P35, DOI 10.1016/S0065-3527(08)60474-1; NASSAL M, 1990, CELL, V63, P1357, DOI 10.1016/0092-8674(90)90431-D; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OU JH, 1990, J VIROL, V64, P4578, DOI 10.1128/JVI.64.9.4578-4581.1990; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PUCHTA H, 1991, NUCLEIC ACIDS RES, V19, P2693, DOI 10.1093/nar/19.10.2693; SANFACON H, 1992, VIROLOGY, V190, P30, DOI 10.1016/0042-6822(92)91189-2; SANFACON H, 1990, NATURE, V346, P81, DOI 10.1038/346081a0; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; SCHOLTHOF HB, 1992, J VIROL, V66, P3131, DOI 10.1128/JVI.66.5.3131-3139.1992; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; THOMAS AAM, 1992, NEW BIOL, V4, P404; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; ZIJLSTRA C, 1992, PLANT CELL, V4, P1471, DOI 10.1105/tpc.4.12.1471; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	71	183	185	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					789	802		10.1016/0092-8674(93)90257-Q	http://dx.doi.org/10.1016/0092-8674(93)90257-Q			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500171				2022-12-28	WOS:A1993LD83000016
J	DASILVA, AMT; KAULBACH, HC; CHUIDIAN, FS; LAMBERT, DR; SUFFREDINI, AF; DANNER, RL				DASILVA, AMT; KAULBACH, HC; CHUIDIAN, FS; LAMBERT, DR; SUFFREDINI, AF; DANNER, RL			SHOCK AND MULTIPLE-ORGAN DYSFUNCTION AFTER SELF-ADMINISTRATION OF SALMONELLA ENDOTOXIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							TUMOR-NECROSIS-FACTOR; HUMAN SEPTIC SHOCK; CARDIOVASCULAR DYSFUNCTION; INTRAVENOUS ENDOTOXIN; ESCHERICHIA-COLI; CANINE MODEL; MORTALITY; INTERLEUKIN-1; SERUM		GEORGETOWN UNIV,DIV PULM & CRIT CARE MED,WASHINGTON,DC 20057; GEORGETOWN UNIV,DEPT MED,WASHINGTON,DC 20057; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT CRIT CARE MED,BETHESDA,MD 20892	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA								BOUJOUKOS AJ, IN PRESS J APPL PHYS; BRAUDE AI, 1955, J CLIN INVEST, V34, P858, DOI 10.1172/JCI103141; Brues AM, 1944, J NATL CANCER I, V5, P195; Danner R, 1989, MULTIPLE ORGAN FAILU, P151; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DANNER RL, 1990, CHEST, V98, P1480, DOI 10.1378/chest.98.6.1480; DONOVAN MA, 1992, J CELL BIOCH SC, V16, P170; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GREISMAN SE, 1969, J CLIN INVEST, V48, P613, DOI 10.1172/JCI106020; HERRING WB, 1963, J CLIN INVEST, V42, P79, DOI 10.1172/JCI104698; HESS ML, 1981, PROG CARDIOVASC DIS, V23, P279, DOI 10.1016/0033-0620(81)90017-7; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MARKS JD, 1990, AM REV RESPIR DIS, V141, P94, DOI 10.1164/ajrccm/141.1.94; MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021; MCCABE WR, 1981, CURRENT CLIN TOPICS, V2, P121; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; STEVENS AR, 1953, ANN INTERN MED, V39, P1228, DOI 10.7326/0003-4819-39-6-1228; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WEBSTER CJ, 1980, J CLIN MICROBIOL, V12, P644, DOI 10.1128/JCM.12.5.644-650.1980; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; 1986, CARDIAC CATHETERIZAT, P545	26	206	211	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1457	1460		10.1056/NEJM199305203282005	http://dx.doi.org/10.1056/NEJM199305203282005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479465				2022-12-28	WOS:A1993LB78300005
J	LOZANO, F; RADA, C; JARVIS, JM; MILSTEIN, C				LOZANO, F; RADA, C; JARVIS, JM; MILSTEIN, C			AFFINITY MATURATION LEADS TO DIFFERENTIAL EXPRESSION OF MULTIPLE COPIES OF A KAPPA-LIGHT-CHAIN TRANSGENE	NATURE			English	Article							SOMATIC HYPERMUTATION; IMMUNOGLOBULIN-KAPPA; MUTATION	TRANSGENIC animals containing rearranged heavy or light chains are used to study the process of hypermutation, which characterizes the maturation of the antibody response1-3. LK6 mice contain five copies of a transgene coding for a light chain produced in response to the hapten 2-phenyloxazolone4. We have selected hybridomas from secondary responses that express the transgene as the only light chain2. Some of these hybridomas contain transgene copies carrying mutations known to improve antibody affinity5. We have analysed the expression of the five transgene copies in those hybridomas. We report here that the somatic hypermutation process can affect the successful expression of antibody light-chain transgenes. When mutations that improve the antibody affinity appear in one transgene copy, antigenic selection favours cells that downregulate the other copies at multiple levels of gene expression, including examples where nonsense mutations correlate with a drop in messenger RNA level.			LOZANO, F (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		LOZANO, FRANCISCO/AAB-7888-2019; Lozano-Soto, Francisco/AAB-7930-2019	LOZANO, FRANCISCO/0000-0003-1119-4368; Lozano-Soto, Francisco/0000-0003-3714-2304				BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; HACKETT J, 1990, J EXP MED, V172, P131, DOI 10.1084/jem.172.1.131; HARLOW E, 1988, ANTIBODIES LABORATOR; Kabat EA, 1991, SEQUENCES PROTEINS I; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MILSTEIN C, 1992, EUR J IMMUNOL, V22, P1627, DOI 10.1002/eji.1830220642; NESPOLO A, 1989, ELECTROPHORESIS, V10, P34, DOI 10.1002/elps.1150100109; OANCEA A, 1992, NATURE, V359, P371, DOI 10.1038/359371a0; Pettersson S, 1989, Int Immunol, V1, P509, DOI 10.1093/intimm/1.5.509; RAJEWSKY K, 1992, NATURE, V359, P171; ROGERSON B, 1991, EMBO J, V10, P4331, DOI 10.1002/j.1460-2075.1991.tb05011.x; Sambrook J, 1989, MOL CLONING LABORATO; SHARPE MJ, 1990, EUR J IMMUNOL, V20, P1379, DOI 10.1002/eji.1830200625; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SOHN J, 1993, J EXP MED, V177, P493, DOI 10.1084/jem.177.2.493; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WABL M, 1992, NATURE, V359, P370, DOI 10.1038/359370c0	20	42	42	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					271	273		10.1038/363271a0	http://dx.doi.org/10.1038/363271a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8487865				2022-12-28	WOS:A1993LC86600055
J	BREO, DL				BREO, DL			THE BIGGEST ROADBLOCK TO REFORM - THIS CONGRESS IS INDEPENDENT OF CLINTON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		CALIFANO, TRIUMPH TRAGEDY L JO	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2498	2499		10.1001/jama.269.19.2498	http://dx.doi.org/10.1001/jama.269.19.2498			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487401				2022-12-28	WOS:A1993LB45000012
J	LOVE, SM				LOVE, SM			BREAST-CANCER - WHAT THE DEPARTMENT-OF-DEFENSE SHOULD DO WITH ITS 210-MILLION-DOLLAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LOVE, SM (corresponding author), UNIV CALIF LOS ANGELES, CTR BREAST, 200 UCLA MED PLAZA, SUITE 510, LOS ANGELES, CA 90024 USA.							FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; MARSHALL E, 1993, SCIENCE, V259, P616, DOI 10.1126/science.8430307; MARSHALL E, 1992, SCIENCE, V258, P732, DOI 10.1126/science.1439774; WESTIN JB, 1990, ANN NY ACAD SCI, V609, P269, DOI 10.1111/j.1749-6632.1990.tb32074.x; 1992, LANCET, V340, P904	5	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2417	2417		10.1001/jama.269.18.2417	http://dx.doi.org/10.1001/jama.269.18.2417			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479069				2022-12-28	WOS:A1993LA67500038
J	ALVAREZDARDET, C; RUIZ, MT				ALVAREZDARDET, C; RUIZ, MT			MCKEOWN,THOMAS AND COCHRANE,ARCHIBALD - A JOURNEY THROUGH THE DIFFUSION OF THEIR IDEAS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								In the 1970s Thomas McKeown and Archibald L Cochrane were two of the most influential voices in criticising the dominance of medical thinking. A bibliometric study of the citations to McKeown's The Role of Medicine: Dream, Mirage or Nemesis and Cochrane's Effectiveness and Efficiency: Random Reflections on Health Services was performed from the publication of each book until 1988 to study how their ideas have been disseminated. During the study period 430 papers in the Science Citation Index or the Social Sciences Citation Index cited Cochrane's book, 133 cited McKeown's, and 166 cited both. The citations came mainly from original papers published in journals of internal medicine or public health and epidemiology (35%) and written by authors from the United States or the United Kingdom. Cochrane's book was cited most frequently in medical journals, suggesting a higher degree of penetration of his ideas among medical scientists. Although the dominance of original papers among the citations suggests that these books have been important in stimulating new knowledge, the main problems that McKeown and Cochrane identified-namely, the relatively small impact of clinical medicine on health outcomes and the poor use of scientific methods in clinical practice-are still with us.			ALVAREZDARDET, C (corresponding author), UNIV ALICANTE, DEPT PUBL HLTH, CAMPUS SANT JOAN, APDO 374, E-03080 ALICANTE, SPAIN.			Alvarez-Dardet, Carlos/0000-0003-3530-7451				[Anonymous], 1988, NEW PUBLIC HLTH; ASHTON J, 1991, BRIT MED J, V302, P189, DOI 10.1136/bmj.302.6770.189; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; HADLEY J, 1982, MORE MED CARE BETTER; ILLICH I, 1974, LANCET, V1, P918; KENNEDY I, 1985, UNMASKING MED; KOLATA G, 1982, SCIENCE, V218, P31, DOI 10.1126/science.7123213; MAHLER H, 1975, LANCET, V2, P829; MCKEOWN T, 1976, ROLE MED; MILIO N, 1992, J NURS ADMIN, V22, P24, DOI 10.1097/00005110-199202000-00021; MILIO N, 1981, PROMOTING HLTH PUBLI, P215; MILIO N, 1990, NUTRITION POLICY FOO; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; Starfield B, 1985, EFFECTIVENESS MED CA; Szreter Simon, 1988, SOCIAL SCI MED, V1, P1, DOI DOI 10.1145/1073943.1073950; WARREN M, 1987, RECALLING MED OFFICE; 1991, WHO HLTH POLICY REV; 1976, PREVENTION HLTH EVER; 1978, ALMA ATA 1977 PRIMAR	21	22	22	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1993	306	6887					1252	1255		10.1136/bmj.306.6887.1252	http://dx.doi.org/10.1136/bmj.306.6887.1252			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499857	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1993LB80400021
J	DAVIES, HA; LENNARD, L; LILLEYMAN, JS				DAVIES, HA; LENNARD, L; LILLEYMAN, JS			VARIABLE MERCAPTOPURINE METABOLISM IN CHILDREN WITH LEUKEMIA - A PROBLEM OF NONCOMPLIANCE	BRITISH MEDICAL JOURNAL			English	Article							CANCER		UNIV SHEFFIELD,CHILDRENS HOSP,DEPT PAEDIAT,PAEDIAT HAEMATOL SECT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield			Lennard, Lynne/E-1131-2011					LENNARD L, 1992, J CHROMATOGR-BIOMED, V583, P83, DOI 10.1016/0378-4347(92)80347-S; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, J CLIN ONCOL, V7, P816; SMITH SD, 1979, CANCER, V43, P169, DOI 10.1002/1097-0142(197901)43:1<169::AID-CNCR2820430125>3.0.CO;2-F; TEBBI CK, 1986, CANCER, V58, P1179, DOI 10.1002/1097-0142(19860901)58:5<1179::AID-CNCR2820580534>3.0.CO;2-E	5	58	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1239	1240		10.1136/bmj.306.6887.1239	http://dx.doi.org/10.1136/bmj.306.6887.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499854	Green Published, Bronze			2022-12-28	WOS:A1993LB80400016
J	CULLEN, BR				CULLEN, BR			DOES HIV-1 TAT INDUCE A CHANGE IN VIRAL INITIATION RIGHTS	CELL			English	Review							LONG TERMINAL REPEAT; TRANSCRIPTIONAL ELONGATION; PROTEIN; RNA		DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	Duke University	CULLEN, BR (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710, USA.							CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; WHALEN W A, 1990, New Biologist, V2, P975	16	177	180	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					417	420		10.1016/0092-8674(93)90126-B	http://dx.doi.org/10.1016/0092-8674(93)90126-B			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490957				2022-12-28	WOS:A1993LA74300001
J	HAMED, M; MITCHELL, H; CLOW, DJ				HAMED, M; MITCHELL, H; CLOW, DJ			HYPONATREMIC CONVULSION ASSOCIATED WITH DESMOPRESSIN AND IMIPRAMINE TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter							HYPONATREMIA; MEASLES; RUBELLA; MUMPS				HAMED, M (corresponding author), DUMFRIES & GALLOWAY ROYAL INFIRM,DUMFRIES DG1 4AP,SCOTLAND.							BAMFORD MFM, 1989, EXTRA PHARMACOPOEIA; BLANCHARD P, 1991, ARCH FR PEDIATR, V48, P589; GRIFFIN MR, 1991, PEDIATRICS, V88, P881; ISAACS D, 1990, LANCET, V335, P1384, DOI 10.1016/0140-6736(90)91255-9; MITCH RA, 1986, DRUG INTELLIGENCE CL, V20, P787; MOSES AM, 1974, NEW ENGL J MED, V291, P1234, DOI 10.1056/NEJM197412052912307; Norman RM, 1962, ACUTE HEMIPLEGIA CHI; TAVANGER J, 1987, LAKARTIDRINGER, V84, P948; 1991, DRUG THER B, V29, P61	9	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1169	1169		10.1136/bmj.306.6886.1169	http://dx.doi.org/10.1136/bmj.306.6886.1169			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499820	Green Published, Bronze			2022-12-28	WOS:A1993LA68500023
J	PRINS, JB; TODD, JA; RODRIGUES, NR; GHOSH, S; HOGARTH, PM; WICKER, LS; GAFFNEY, E; PODOLIN, PL; FISCHER, PA; SIROTINA, A; PETERSON, LB				PRINS, JB; TODD, JA; RODRIGUES, NR; GHOSH, S; HOGARTH, PM; WICKER, LS; GAFFNEY, E; PODOLIN, PL; FISCHER, PA; SIROTINA, A; PETERSON, LB			LINKAGE ON CHROMOSOME-3 OF AUTOIMMUNE DIABETES AND DEFECTIVE FC RECEPTOR FOR IGG IN NOD MICE	SCIENCE			English	Article							TUMOR NECROSIS FACTOR; MOUSE GENOME; GENETIC-CONTROL; CYTO-TOXICITY; GAMMA-RI; INSULITIS; RAT; INTERLEUKIN-1; ACTIVATION; MACROPHAGE	A congenic, non-obese diabetic (NOD) mouse strain that contains a segment of chromosome 3 from the diabetes-resistant mouse strain B6.PL-Thy-1a was less susceptible to diabetes than NOD mice. A fully penetrant immunological defect also mapped to this segment, which encodes the high-affinity Fc receptor for immunoglobulin G (IgG), FcgammaRI. The NOD Fcgr1 allele, which results in a deletion of the cytoplasmic tail, caused a 73 percent reduction in the turnover of cell surface receptor-antibody complexes. The development of congenic strains and the characterization of Mendelian traits that are specific to the disease phenotype demonstrate the feasibility of dissecting the pathophysiology of complex, non-Mendelian diseases.	AUSTIN HOSP, AUSTIN RES INST, HEIDELBERG, VIC 3084, AUSTRALIA; MERCK SHARP & DOHME LTD, AUTOIMMUNE DIS RES, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, IMMUNOL RES, RAHWAY, NJ 07065 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Merck & Company; Merck & Company; Merck & Company	PRINS, JB (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT SURG, OXFORD OX3 9DU, ENGLAND.		Todd, John A/A-3542-2010; Wicker, Linda S/F-7384-2010	Todd, John A/0000-0003-2740-8148; Hogarth, Mark/0000-0002-0360-7890; Prins, Jan-Bas/0000-0002-1831-8522	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; BAKER D, 1990, J NEUROIMMUNOL, V28, P261, DOI 10.1016/0165-5728(90)90019-J; BIOZZI G, 1984, ADV IMMUNOL, V36, P189, DOI 10.1016/S0065-2776(08)60902-5; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; CORNALL RJ, 1992, MAMM GENOME, V3, P620, DOI 10.1007/BF00352478; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; DIETRICH W, 1992, GENETICS, V131, P423; Ghosh S. K., UNPUB; HATAMORI N, 1990, DIABETES, V39, P1070, DOI 10.2337/diabetes.39.9.1070; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KATAOKA S, 1983, DIABETES, V32, P247, DOI 10.2337/diabetes.32.3.247; KIKUTANI H, 1992, ADV IMMUNOL, V51, P285, DOI 10.1016/S0065-2776(08)60490-3; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; LEE KU, 1988, DIABETES, V37, P989, DOI 10.2337/diabetes.37.7.989; LI S, 1986, J IMMUNOL, V137, P3378; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; Lyon M., 1989, GENETIC VARIANTS STR; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MANDRUPPOULSEN T, 1987, J IMMUNOL, V139, P4077; MCALEER MA, 1992, MAMM GENOME, V3, P457, DOI 10.1007/BF00356156; MCALEER MA, UNPUB; Meisler M H, 1991, Mamm Genome, V1 Spec No, pS42, DOI 10.1007/BF00656485; NAKAJIMA H, 1986, IMMUNOL LETT, V12, P91, DOI 10.1016/0165-2478(86)90088-X; OAKEY RJ, 1992, IMMUNOGENETICS, V35, P279, DOI 10.1007/BF00166834; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OSMAN N, 1992, J IMMUNOL, V148, P1570; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RISCH N, 1992, SCIENCE, V255, P803, DOI 10.1126/science.1536004; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; Seldin M F, 1991, Mamm Genome, V1 Spec No, pS1, DOI 10.1007/BF00656483; SENSI M, 1981, DIABETOLOGIA, V20, P106, DOI 10.1007/BF00262010; SERREZE DV, 1988, J IMMUNOL, V140, P3801; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1992, J EXP MED, V176, P67, DOI 10.1084/jem.176.1.67; WICKER LS, 1989, J IMMUNOL, V142, P781; WICKER LS, UNPUB	46	91	91	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					695	698		10.1126/science.8480181	http://dx.doi.org/10.1126/science.8480181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480181				2022-12-28	WOS:A1993KZ64100039
J	JACOBS, I; DAVIES, AP; BRIDGES, J; STABILE, I; FAY, T; LOWER, A; GRUDZINSKAS, JG; ORAM, D				JACOBS, I; DAVIES, AP; BRIDGES, J; STABILE, I; FAY, T; LOWER, A; GRUDZINSKAS, JG; ORAM, D			PREVALENCE SCREENING FOR OVARIAN-CANCER IN POSTMENOPAUSAL WOMEN BY CA 125 MEASUREMENT AND ULTRASONOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article							SERUM CA-125 LEVELS; CARCINOMA; MARKERS; BENIGN	Objective-To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer. Design-The serum CA 125 concentration of each subject was determined and those with a concentration greater-than-or-equal-to 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire. Setting-General practice, occupational health departments, ovarian cancer screening clinic. Subjects-22 000 women volunteers who were postmenopausal and aged over 45 years. Main outcome measures-Apparent sensitivity, specificity, positive predictive value, years of cancer detected. Results-41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 1.4 years. Conclusions-This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion of cases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.	ROYAL LONDON HOSP, ACAD UNIT OBSTET & GYNAECOL, LONDON E1 1BB, ENGLAND; ROYAL LONDON HOSP, GYNAECOL ONCOL UNIT, LONDON E1 1BB, ENGLAND	Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital			Jacobs, Ian J/F-1743-2013	Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672				ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; BAST RC, 1991, CANCER-AM CANCER SOC, V68, P1758, DOI 10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO;2-#; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BAST RC, 1983, NEW ENGL J MED, V309, P169; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; CAMPBELL S, 1982, LANCET, V1, P425; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; COLE LA, 1990, GYNECOL ONCOL, V36, P391, DOI 10.1016/0090-8258(90)90149-F; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1989, HUM REPROD, V4, P1; JACOBS IJ, 1992, OBSTET GYNECOL, V80, P396; KACINSKI BM, 1990, PROG LEUC B, V10, P393; NAROD SA, 1991, LANCET, V338, P82; SCHWARTZ PE, 1987, CANCER, V60, P353, DOI 10.1002/1097-0142(19870801)60:3<353::AID-CNCR2820600312>3.0.CO;2-V; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; WARD BG, 1987, BRIT J OBSTET GYNAEC, V94, P696, DOI 10.1111/j.1471-0528.1987.tb03178.x; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; ZURAWSKI VR, 1990, GYNECOL ONCOL, V36, P299, DOI 10.1016/0090-8258(90)90130-D; 1983, CANCER STATISTICS RE, P26	21	284	316	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1030	1034		10.1136/bmj.306.6884.1030	http://dx.doi.org/10.1136/bmj.306.6884.1030			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490497	Green Published, Bronze			2022-12-28	WOS:A1993KY44800018
J	THORNICROFT, G; WARD, P; JAMES, S				THORNICROFT, G; WARD, P; JAMES, S			COUNTDOWN TO COMMUNITY CARE - CARE MANAGEMENT AND MENTAL-HEALTH	BRITISH MEDICAL JOURNAL			English	Article								The community care reforms will produce a new kind of key worker who will organise and budget for packages of care: the care manager. Care management goes live in April 1993 but is still poorly rehearsed and its performance may yet disappoint. This overview sets out the origins of case management, its transformation into care management, and the principles guiding its practice. To spell out how the concept works, plans for care management in Southwark's mental health services are described.	S E LONDON COMMISS AGCY,LONDON SE1 9RY,ENGLAND; LONDON BOROUGH SOUTHWARK,LONDON SE1,ENGLAND		THORNICROFT, G (corresponding author), INST PSYCHIAT,PRISM,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ANTHONY WA, 1988, COMMUNITY MENT HLT J, V24, P219, DOI 10.1007/BF00757139; BLOMCOOPER L, 1991, PSYCHIATRIC B, V15, P665; BRAUN P, 1981, AM J PSYCHIAT, V138, P736; Challis D, 1986, CASE MANAGEMENT COMM; INTAGLIATA J, 1982, SCHIZOPHRENIA BULL, V8, P655, DOI 10.1093/schbul/8.4.655; KIESLER C, 1982, AM PSYCHOL, V4, P354; LAMING H, 1992, IMPLEMENTING CARING; ONYETT S, 1992, CASE MANAGEMENT MENT; PATMORE C, 1991, COMMUNITY MENTAL HLT; RENSHAW J, 1988, CARE COMMUNITY 1ST S; Tessler R, 1982, CHRONICALLY MENTALLY; THORNICROFT G, 1991, International Review of Psychiatry, V3, P125, DOI 10.3109/09540269109067527; TORREY EF, 1986, HOSP COMMUNITY PSYCH, V37, P1243; 1990, CARE PROGRAMME APPRO; 1991, CARE MANAGEMENT ASSE; 1990, NATIONAL HLTH SERVIC; 1985, 2ND HOUS COMM SOC SE; 1992, PRIORITIES COMMUNITY; 1989, CM849, P21	19	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					768	771		10.1136/bmj.306.6880.768	http://dx.doi.org/10.1136/bmj.306.6880.768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KU173	8490341	Green Published, Bronze			2022-12-28	WOS:A1993KU17300029
J	CURRY, BH				CURRY, BH			TRIBUTE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; KNOWLEDGE, ATTITUDES, PRACTICE; GRIEF		A physician has an encounter with a patient who has recently suffered a tremendous personal loss. The physician treats the patient and in so doing explores the rationale for and consequences of empathetic participation in the grieving process.	DEACONESS MED CTR, BILLINGS, MT 59107 USA	Harvard University; Beth Israel Deaconess Medical Center									0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					86	86		10.7326/0003-4819-119-1-199307010-00014	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498769				2022-12-28	WOS:A1993LJ26600014
J	ROMANOWSKI, B; TALBOT, H; STADNYK, M; KOWALCHUK, P; BOWIE, WR				ROMANOWSKI, B; TALBOT, H; STADNYK, M; KOWALCHUK, P; BOWIE, WR			MINOCYCLINE COMPARED WITH DOXYCYCLINE IN THE TREATMENT OF NONGONOCOCCAL URETHRITIS AND MUCOPURULENT CERVICITIS	ANNALS OF INTERNAL MEDICINE			English	Article						MINOCYCLINE; DOXYCYCLINE; URETHRITIS; CERVICITIS; CHLAMYDIA TRACHOMATIS	NON-GONOCOCCAL URETHRITIS; CHLAMYDIA-TRACHOMATIS; INFECTION; WOMEN	Objective:To compare the efficacy and tolerability of minocycline versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Design: Randomized, double-blind trial. Setting: Sexually transmitted disease clinics. Patients: 151 men and 102 women with nongonococcal urethritis, mucopurulent cervicitis or whose sexual partner had either condition or a positive culture for Chlamydia trachomatis. Interventions: Minocycline, 100 mg nightly, or doxycycline, 100 mg twice daily, each administered for 7 days. Measurements: At each visit (days 14 +/- 3, 28 +/- 5, and 49 +/- 7) patients were questioned regarding symptoms, signs, drug compliance, and sexual contact. Cultures for C. trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis were obtained at each visit. Results: 253 patients were enrolled (133, doxycycline; 120, minocycline). Chlamydia trachomatis was initially isolated from 31% of men and 39% of women. Men with a positive smear had a higher symptom/sign score (P < 0.001) and were more likely to have chlamydia (P = 0.004). Positive endocervical smears were not associated with symptoms or signs (P > 0.2) but correlated with isolation of chlamydia (P < 0.001). One hundred sixty-two patients (64%) completed the study. The proportion with urethritis or cervicitis did not differ by treatment group at any follow-up visit (P > 0.08). Unprotected sexual contact did not affect clinical or microbiological cure rates. Adverse effects occurred more frequently in the doxycycline group (men: 43% versus 26%; P = 0.05; women: 62% versus 35%; P = 0.009). Although the proportion with dizziness did not differ by drug administered (P = 0.1), dizziness was reported more often by women (11% versus 3%). Conclusions: Minocycline, 100 mg nightly, was as effective as doxycycline, 100 mg twice daily, each given for 7 days in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Vomiting and gastrointestinal upset occurred more frequently in the doxycycline group.	VANCOUVER SEXUALLY TRANSMITTED DIS SERV, VANCOUVER, BC, CANADA		ROMANOWSKI, B (corresponding author), ALBERTA HLTH, SEXUALLY TRANSMITTED DIS SERV, 4TH FLOOR, 10105-109 ST, EDMONTON T5J 1M8, AB, CANADA.							BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; BOWIE WR, 1993, IN PRESS CAN J INFEC; BRUNHAM RC, 1984, NEW ENGL J MED, V311, P1, DOI 10.1056/NEJM198407053110101; JESKANEN L, 1990, 3RD INT S NEW QUIN V; KITCHEN VS, 1990, J ANTIMICROB CHEMOTH, V26, P99, DOI 10.1093/jac/26.suppl_D.99; KOVACS GT, 1989, MED J AUSTRALIA, V150, P483, DOI 10.5694/j.1326-5377.1989.tb136591.x; MARTIN DH, 1990, 3RD INT S NEW QUIN V; MCCARTHY J, 1990, 3RD INT S NEW QUIN V; MOSCICKI B, 1987, AM J OBSTET GYNECOL, V157, P65, DOI 10.1016/S0002-9378(87)80347-2; ORIEL J D, 1975, Journal of the American Venereal Disease Association, V2, P17; ORIEL JD, 1983, BRIT J VENER DIS, V59, P245; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; ROBERTSON JA, 1978, J CLIN MICROBIOL, V7, P127; SANDERS LL, 1986, JAMA-J AM MED ASSOC, V255, P1750, DOI 10.1001/jama.255.13.1750; TOOMEY KE, 1990, REV INFECT DIS, V12, pS645	15	26	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					16	22		10.7326/0003-4819-119-1-199307010-00003	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498758				2022-12-28	WOS:A1993LJ26600003
J	SHULKIN, DJ; HILLMAN, AL; COOPER, WM				SHULKIN, DJ; HILLMAN, AL; COOPER, WM			REASONS FOR INCREASING ADMINISTRATIVE COSTS IN HOSPITALS	ANNALS OF INTERNAL MEDICINE			English	Article						HOSPITAL ADMINISTRATION; COSTS AND COST ANALYSIS; COST-BENEFIT ANALYSIS; BUDGETS; QUALITY OF HEALTH CARE	STATES HEALTH-CARE; MORTALITY; SYSTEM	Objective: To evaluate trends in administrative expenditures by examining changes in administrative costs compared with other areas of the hospital budget, changes in expenditures for patient care departments compared with nonpatient care departments, and departments with a greater number of regulatory requirements compared with those with fewer regulatory requirements. Design: Annual hospital operating budgets submitted to Blue Cross were examined for an 8-year period from 1983 to 1990. Participants: Seventy hospitals in Western Pennsylvania. Measurements: Annual operating expenditures. Results: Total administrative expenditures showed a larger growth rate (90%) than service departments (29%), ancillary services (30%), professional care (52%), miscellaneous expenses (70%), and the total hospital budget (45%). Administrative costs increased from 10.6% as a proportion of the total hospital budget in 1983 to 13.9% in 1990. These increases were seen regardless of hospital size. Departments with a greater number of regulatory obligations had a greater increase in expenditures (84%) than did departments with fewer regulatory requirements (5%). However, overall expenditures in departments with direct patient care responsibilities did not increase appreciably faster (44%) than in departments not providing clinical services (46%), possibly reflecting the fact that administrative costs may be increasing equally in both areas. Conclusions: Administrative costs were found to be one of the fastest growing components of hospital budgets. Future research should determine the effect of these increases on the quality of patient care.	UNIV PENN, MED CTR, OFF CLIN OUTCOME ASSESSMENT & QUAL MANAGEMENT, PHILADELPHIA, PA 19104 USA; UNIV PENN, MED CTR, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; SHADYSIDE HOSP, PITTSBURGH, PA 15232 USA	University of Pennsylvania; University of Pennsylvania								HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; LINDBERG GL, 1989, AM J PUBLIC HEALTH, V79, P1481, DOI 10.2105/AJPH.79.11.1481; MCCARTHY CM, 1978, REPORT TASK FORCE RE; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1990, AM HOSPITAL ASS MEMB; 1985, NEW ENGL J MED, V311, P447; 1990, PENNSYLVANIA HLTH CA	9	18	19	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					74	78		10.7326/0003-4819-119-1-199307010-00012	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498766				2022-12-28	WOS:A1993LJ26600012
J	BRISKIN, MJ; MCEVOY, LM; BUTCHER, EC				BRISKIN, MJ; MCEVOY, LM; BUTCHER, EC			MADCAM-1 HAS HOMOLOGY TO IMMUNOGLOBULIN AND MUCIN-LIKE ADHESION RECEPTORS AND TO IGA1	NATURE			English	Article							VASCULAR ADDRESSIN; ENDOTHELIAL-CELLS; LYMPH-NODE; BINDING; GENE; LYMPHOCYTES; SUPERFAMILY; RECOGNITION; ANTIBODIES; MOLECULE	TISSUE-SPECIFIC homing of lymphocytes is regulated by interactions with the endothelium of specialized venules, such as the high endothelial venules (HEV) in lymph nodes and mucosal lymphoid tissues1-3. The mucosal vascular addressin, a 58-66K glycoprotein adhesion receptor for lymphocytes, is selectively expressed on HEV of mucosal lymphoid organ and on lamina propria venules and helps direct lymphocyte traffic to these mucosal tissues4,5. We now report the isolation of a complementary DNA that, on transfection into COS cells, encodes immunoreactive addressin that specifically binds the mucosal HEV-binding T-cell lymphoma TK1. The predicted amino-acid sequence defines the mucosal addressin as a novel immunoglobulin family member, MAdCAM-1, with two amino-terminal domains that display strong homology to previously described vascular adhesion receptors for leukocytes, ICAM-1 (ref. 6) and VCAM-1 (ref. 7). The membrane proximal domain is homologous to the third domain (Calpha2) of another mucosa-associated immunoglobulin family member, IgA1 (refs 8, 9). In addition to the immunoglobulin domains, there is a serine/threonine-rich region which may serve as a backbone to present carbohydrate ligands to lymphocytes. MAdCAM-1 is thus a complex multidomain receptor displaying several structural motifs that may participate in lymphocyte homing interactions.	STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BRISKIN, MJ (corresponding author), STANFORD UNIV, DEPT PATHOL, IMMUNOL & VASC BIOL LAB, STANFORD, CA 94305 USA.							BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V133, P2961; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HOLTZMANN B, 1989, CELL, V56, P37; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAWAMURA S, 1989, NUCLEIC ACIDS RES, V17, P6732, DOI 10.1093/nar/17.16.6732; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1990, MOL CLONING; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIMONETMARTIN MT, 1986, CR SOC BIOL, V180, P229; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	28	366	392	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					461	464		10.1038/363461a0	http://dx.doi.org/10.1038/363461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502297				2022-12-28	WOS:A1993LE93800062
J	FRANK, S; LAUTERBUR, PC				FRANK, S; LAUTERBUR, PC			VOLTAGE-SENSITIVE MAGNETIC GELS AS MAGNETIC-RESONANCE MONITORING AGENTS	NATURE			English	Article							PHASE-TRANSITION; ELECTRIC-FIELD; SYSTEMS	MANY polymer gels undergo a volume phase transition in electric fields1-5. We report here the synthesis of a Polyelectrolyte gel that incorporates magnetic particles of iron oxide into the polymer network; these particles couple the gel volume transition to the NMR relaxation times of the surrounding water. We find that the water proton relaxation rates (T2(-1)) in aqueous suspensions of particles of the magnetic gel increase significantly in an electric field. Such changes can also be induced by the hyperpolarization of red blood cells in the suspension, presumably as a result of the electric fields at the cell membrane surfaces. These gels may play a part in magnetic resonance imaging analogous to that of voltage-sensitive dyes in optical imaging6-9.	UNIV ILLINOIS,BIOMED MAGNET RESONANCE LAB,1307 W PK ST,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								COHEN L, 1988, NATURE, V331, P112, DOI 10.1038/331112a0; CORTI M, 1991, PHYS REV A, V43, P6887, DOI 10.1103/PhysRevA.43.6887; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; HIROSE Y, 1987, MACROMOLECULES, V20, P1342, DOI 10.1021/ma00172a029; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; KAJIWARA K, 1992, NATURE, V355, P208, DOI 10.1038/355208a0; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KISHI R, 1989, J CHEM SOC FARAD T 1, V85, P655, DOI 10.1039/f19898500655; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MATSUO ES, 1988, J CHEM PHYS, V89, P1695, DOI 10.1063/1.455115; MULLER RN, 1991, MAGNET RESON MED, V22, P178, DOI 10.1002/mrm.1910220203; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; OHGUSHI M, 1978, J MAGN RESON, V29, P599, DOI 10.1016/0022-2364(78)90018-5; OSADA Y, 1987, ADV POLYM SCI, V82, P1; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; RINK TJ, 1982, RED CELL MEMBRANES M, P321; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Shaw D. J., 1969, ELECTROPHORESIS; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA J, 1992, ACS SYM SER, V480, P1; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; 1977, Patent No. 4064080	23	67	70	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					334	336		10.1038/363334a0	http://dx.doi.org/10.1038/363334a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497316				2022-12-28	WOS:A1993LD91700047
J	MERENDINO, JJ; SPIEGEL, AM; CRAWFORD, JD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ				MERENDINO, JJ; SPIEGEL, AM; CRAWFORD, JD; OCARROLL, AM; BROWNSTEIN, MJ; LOLAIT, SJ			A MUTATION IN THE VASOPRESSIN V2-RECEPTOR GENE IN A KINDRED WITH X-LINKED NEPHROGENIC DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							RECEPTORS; DNA		NIMH,CELL BIOL LAB,BETHESDA,MD 20892; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Massachusetts General Hospital	MERENDINO, JJ (corresponding author), NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,RM 8C-101,BETHESDA,MD 20892, USA.		Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009					BELL NH, 1974, PEDIATR RES, V8, P223, DOI 10.1203/00006450-197404000-00002; Bichet D G, 1991, Adv Nephrol Necker Hosp, V20, P175; BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BICHET DG, 1991, KIDNEY INT, V39, P693, DOI 10.1038/ki.1991.83; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; DAVISON JM, 1984, AM J PHYSIOL, V246, pF105, DOI 10.1152/ajprenal.1984.246.1.F105; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HUGHES MR, 1991, J RECEPTOR RES, V11, P699, DOI 10.3109/10799899109066437; JANS DA, 1990, J BIOL CHEM, V265, P15379; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JEANPIERRE M, 1987, NUCLEIC ACIDS RES, V15, P9611, DOI 10.1093/nar/15.22.9611; KAMBOURIS M, 1988, AM J MED GENET, V29, P239, DOI 10.1002/ajmg.1320290138; KNOERS N, 1988, HUM GENET, V80, P31, DOI 10.1007/BF00451451; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MOSES AM, 1982, J CLIN ENDOCR METAB, V55, P699, DOI 10.1210/jcem-55-4-699; Niaudet P, 1984, Adv Nephrol Necker Hosp, V13, P247; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; ROBERTSON GL, 1981, CLIN RES, V29, pA555; ROBERTSON GL, 1973, J CLIN INVEST, V52, P2340, DOI 10.1172/JCI107423; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P712, DOI 10.1210/jc.74.4.712; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99	26	55	55	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1538	1541		10.1056/NEJM199305273282106	http://dx.doi.org/10.1056/NEJM199305273282106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479491				2022-12-28	WOS:A1993LC94100006
J	WALWORTH, N; DAVEY, S; BEACH, D				WALWORTH, N; DAVEY, S; BEACH, D			FISSION YEAST CHK1-PROTEIN KINASE LINKS THE RAD CHECKPOINT PATHWAY TO CDC2	NATURE			English	Article							TYROSINE PHOSPHATASE; GENE	THE dependence of cell-cycle progression on the integrity of the genome has been described as checkpoint control1,2. A number of mutants of the fission yeast Schizosaccharomyces pombe, selected for their sensitivity to DNA damage caused by radiation (rad mutants) or to the DNA synthesis inhibitor hydroxyurea (hus mutants) have been classified as checkpoint mutants because they fail to arrest the cell cycle in response to DNA damage or incompletely replicated DNA3-6. Coupling of the checkpoint pathways that monitor DNA repair and replication to control of the cell cycle is essential. In a search for components that interact with the cell-cycle regulatory kinase p34cdc2, we have identified a novel fission yeast protein kinase homologue which is involved in cell-cycle arrest when DNA damage has occurred or when unligated DNA is present. We have called the gene encoding this protein chk1 for checkpoint kinase. Multiple copies of chk1 partially rescue the ultraviolet sensitivity of rad1-1, a mutant deficient in checkpoint control3-5. Identification of a gene involved in checkpoint control as a rescue of a cdc2 mutant links the rad1-dependent DNA-damage-sensing pathway and p34cdc2 activity.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute								ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; COTTAREL G, IN PRESS GENE; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2	19	412	435	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1993	363	6427					368	371		10.1038/363368a0	http://dx.doi.org/10.1038/363368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497322				2022-12-28	WOS:A1993LD91700059
J	FEIL, EC; WELCH, HG; FISHER, ES				FEIL, EC; WELCH, HG; FISHER, ES			WHY ESTIMATES OF PHYSICIAN SUPPLY AND REQUIREMENTS DISAGREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HEALTH-CARE; CANADA; COST; WILL	Objective.-To review the major forecasts of physician supply and physician requirements. Data Sources.-English-language medical literature on physician manpower published between 1980 and 1990, identified from journal articles selected through searches of the MEDLINE and Health Planning and Administration databases using the search formulations physician supply, health manpower-physicians, and physician manpower. Study Selection.-Sources were selected if they were repeatedly cited and provided quantitative projections. Data Extraction.-Each study was reviewed for its quantitative projections and to identify its methodological assumptions. Data Synthesis.-All forecasts point to a steadily increasing physician supply and, with one exception, suggest that supply will exceed requirements in the year 2000. The estimates of physician supply across studies varied primarily because of differing assumptions about entrance rates into the profession and the size and clinical work load of specific categories of physicians: researchers, teachers, administrators, residents, and women. The estimates of physician requirements were more volatile because of differences in the basic approach and assumptions about future growth and market structure. Conclusions.-Even though the measurement of entrance and exit rates from the profession is a generally accepted approach to forecasting supply, apparently minor disagreements on assumptions create large discrepancies between forecasts over time. There is no accepted approach to forecasting physician requirements.	DEPT VET AFFAIRS MED CTR,111B,WHITE RIVER JCT,VT 05009; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756	Dartmouth College; Dartmouth College								DAVIES NE, 1990, JAMA-J AM MED ASSOC, V263, P73, DOI 10.1001/jama.263.1.73; EVANS RG, 1985, J HEALTH POLIT POLIC, V10, P439, DOI 10.1215/03616878-10-3-439; EVANS RG, 1991, ANNU REV PUBL HEALTH, V12, P481, DOI 10.1146/annurev.pu.12.050191.002405; Fruen M A, 1982, Inquiry, V19, P44; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; JACOBSEN SJ, 1987, HEALTH AFFAIR, V6, P48, DOI 10.1377/hlthaff.6.2.48; KNICKMAN JR, 1990, HLTH CARE DELIVERY U, P240; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; SINGER AM, 1989, ACAD MED, V64, P235, DOI 10.1097/00001888-198905000-00003; SLOAN FA, 1983, JAMA-J AM MED ASSOC, V249, P766, DOI 10.1001/jama.249.6.766; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; [No title captured]; 1990, 7TH BUR HLTH PROF RE; 1980, REPORT GRADUATE MED, V1; 1990, HLTH CARE FINANC REV, V11, P1; 1988, 6TH BUR HLTH PROF RE; 1988, 1ST COUNC GRAD MED E, V1	19	71	71	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2659	2663		10.1001/jama.269.20.2659	http://dx.doi.org/10.1001/jama.269.20.2659			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC865	8487450				2022-12-28	WOS:A1993LC86500031
J	HENDERSON, CE; CAMU, W; METTLING, C; GOUIN, A; POULSEN, K; KARIHALOO, M; RULLAMAS, J; EVANS, T; MCMAHON, SB; ARMANINI, MP; BERKEMEIER, L; PHILLIPS, HS; ROSENTHAL, A				HENDERSON, CE; CAMU, W; METTLING, C; GOUIN, A; POULSEN, K; KARIHALOO, M; RULLAMAS, J; EVANS, T; MCMAHON, SB; ARMANINI, MP; BERKEMEIER, L; PHILLIPS, HS; ROSENTHAL, A			NEUROTROPHINS PROMOTE MOTOR-NEURON SURVIVAL AND ARE PRESENT IN EMBRYONIC LIMB BUD	NATURE			English	Article							TYROSINE KINASE RECEPTOR; NERVE GROWTH-FACTOR; EXPRESSION; TRKB; MOTONEURONS; BDNF; CULTURE; SYSTEM; GENE	Embryonic spinal motor neurons are thought to depend for survival on unidentified factors secreted both by their peripheral targets and by cells within the central nervous system1. The neurotrophins are a family of polypeptides required for survival of discrete central and peripheral neuronal populations in vivo and in vitro2,3. In spite of their ability to reduce motor neuron death in vivo4-6, the known neurotrophins have been thought to be without direct effect on motor neurons7-10. Here we show that picomolar concentrations of three of them, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-5, can prevent the death of cultured embryonic rat spinal motor neurons. Furthermore, messenger RNA coding for neurotrophins is present at appropriate stages in spinal cord and limb bud, and mRNA for their receptors is found in motor neurons. These neurotrophins may therefore be physiological motor neuron growth factors.	GENENTECH INC,DEPT CELL ANAL,S SAN FRANCISCO,CA 94080; UMDS,DEPT PHYSIOL,LONDON SE1 7EH,ENGLAND; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; University of London; King's College London; Roche Holding; Genentech	HENDERSON, CE (corresponding author), CTR RECH BIOCHIM MACROMOLEC,CNRS,UPR 9008,INSERM,U249,BP 5051,F-34033 MONTPELLIER,FRANCE.		camu, william/AAB-4727-2020	McMahon, Stephen/0000-0003-4656-5536; Mettling, Clement/0000-0002-4963-2928; Henderson, Christopher/0000-0002-9936-3279				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARANOWSKI AP, 1992, NEUROSCI LETT, V141, P53, DOI 10.1016/0304-3940(92)90332-2; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; HYNES MA, 1990, J NEUROSCI, V10, P1004; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINOU JC, 1990, DEV BRAIN RES, V52, P175, DOI 10.1016/0165-3806(90)90233-O; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RASSENDREN FA, 1992, P NATL ACAD SCI USA, V89, P7194, DOI 10.1073/pnas.89.15.7194; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	32	570	600	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					266	270		10.1038/363266a0	http://dx.doi.org/10.1038/363266a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8487864				2022-12-28	WOS:A1993LC86600054
J	MIYAZAKI, K; HASEGAWA, M; FUNAHASHI, K; UMEDA, M				MIYAZAKI, K; HASEGAWA, M; FUNAHASHI, K; UMEDA, M			A METALLOPROTEINASE INHIBITOR DOMAIN IN ALZHEIMER AMYLOID PROTEIN-PRECURSOR	NATURE			English	Article							BASEMENT-MEMBRANE COLLAGEN; NEXIN-II; DISEASE; CELLS; CLEAVAGE	EXTRACELLULAR deposition of amyloid beta-protein (beta-AP), or A4 protein (M(r) 4,000), is associated with Alzheimer's disease and with Down's syndrome (trisomy for chromosome 21)1-3. The large membrane-bound precursor protein (APP) of beta-AP is normally cleaved within the beta-AP region by a putative proteinase (APP secretase) to release its extracellular portion; beta-AP is produced by an alternative proteolytic processing4-6. Here we demonstrate that APP contains a proteinase inhibitor domain for the matrix metalloproteinase gelatinase A, which is located in the C-terminal glycosylated region of the secretory forms of APP. In addition, we show that the gelatinase has an APP secretase-like activity, which hydrolyses the Lys16-Leu17 bond in the beta-AP sequence. Our results indicate that the proteinase inhibitor domain of APP and gelatinase A may be involved in the formation of beta-AP.			MIYAZAKI, K (corresponding author), YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,DIV CELL BIOL,2-120-3 NAKAMURA CHO,MINAMI KU,YOKOHAMA,KANAGAWA 232,JAPAN.							ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HERRON GS, 1986, J BIOL CHEM, V261, P2814; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOLKENBROCK H, 1991, EUR J BIOCHEM, V198, P775, DOI 10.1111/j.1432-1033.1991.tb16080.x; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; ZUCKER S, 1990, INT J CANCER, V45, P1137, DOI 10.1002/ijc.2910450625	25	165	168	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					839	841		10.1038/362839a0	http://dx.doi.org/10.1038/362839a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479521				2022-12-28	WOS:A1993KZ56300056
J	JOHNSON, AG				JOHNSON, AG			FOR DEBATE - GALL-STONES - THE REAL ISSUES	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, AG (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SURG UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							JORGENSEN T, 1989, HEPATOLOGY, V9, P856, DOI 10.1002/hep.1840090611; SCOTT EA, 1992, ANN ROY COLL SURG, V74, P97	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1114	1115		10.1136/bmj.306.6885.1114	http://dx.doi.org/10.1136/bmj.306.6885.1114			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495160	Bronze, Green Published			2022-12-28	WOS:A1993KZ56500028
J	HAAS, JS; UDVARHELYI, S; EPSTEIN, AM				HAAS, JS; UDVARHELYI, S; EPSTEIN, AM			THE EFFECT OF HEALTH COVERAGE FOR UNINSURED PREGNANT-WOMEN ON MATERNAL HEALTH AND THE USE OF CESAREAN-SECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MORTALITY; CARE; MASSACHUSETTS; ECLAMPSIA	Objectives.-Although there has been substantial policy interest in interventions to improve the neonatal outcomes of disadvantaged women, little attention has been paid to the health status of pregnant women themselves. We therefore examined whether the provision of health coverage to uninsured low-income pregnant women affects maternal health status or the use of cesarean section. Design.-Natural experiment in Massachusetts. Patients.-All in-hospital, single-gestation births in 1984 (N=57 257) and 1987 (N=64 346). Intervention.-Healthy Start is a statewide health coverage program for uninsured pregnant women. In 1985, it covered women with incomes below 185% of the federal poverty level. Main Outcome Measures.-Rates of adverse maternal outcome (severe pregnancy-related hypertension, placental abruption, and a length of stay at least 1 day longer than infants' stay) and cesarean section for uninsured women, and for two concurrent control groups, women with Medicaid and women with private insurance. We calculated the difference in rates between the uninsured and each concurrent control. We then examined the change in these interpayer differences in rates between 1984 and 1987 to measure the effect of Healthy Start. Main Results.-In 1984, uninsured women had higher rates of adverse maternal health outcome than privately insured women (5.5% vs 5.1%, respectively; interpayer difference, 0.4%) and received fewer cesarean sections (1 7.2% vs 23.0%; interpayer difference, -5.8%). Between 1984 and 1987 there was no statistically significant change in the interpayer difference in adverse outcome relative to women with private insurance. However, the interpayer difference in cesarean sections between the uninsured and the privately insured was reduced by 2.3% (95% confidence interval [CI], +0.4% to +4.2%), although the uninsured continued to undergo fewer cesarean sections (22.4% vs 25.9%). Similar results were observed when the uninsured women were compared with women with Medicaid. Conclusions.-The provision of health insurance alone to low-income pregnant women may not be associated with an improvement in maternal health. Expanded coverage was associated, however, with an increase in the rate of cesarean section.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; PRUDENTIAL INSURANCE CO AMER,ROSELAND,NJ	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health				HAAS, JENNIFER/0000-0001-7227-851X	AHRQ HHS [5-F32-HS00025-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AZZARA CV, 1988, HLTY START PROGRAM E; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; EVANS S, 1983, NEW ENGL J MED, V309, P1644, DOI 10.1056/NEJM198312293092612; GABBE SG, 1986, OBSTETRICS NORMAL PR; GOLDFARB MG, 1984, 843345 US DEP HLTH H; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HERNANDEZ C, 1990, CLIN OBSTET GYNECOL, V33, P460, DOI 10.1097/00003081-199009000-00011; HIBBARD BM, 1966, OBSTET GYNECOL, V27, P155; Kessner DM, 1973, CONTRASTS HLTH STATU; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; PRITCHARD JA, 1970, AM J OBSTET GYNECOL, V108, P22, DOI 10.1016/0002-9378(70)90199-7; ROSTOW VP, 1989, NEW ENGL J MED, V321, P1057, DOI 10.1056/NEJM198910123211526; RUTKOW IM, 1986, OBSTET GYNECOL, V67, P755, DOI 10.1097/00006250-198606000-00001; SACHS BP, 1988, AM J PUBLIC HEALTH, V78, P671, DOI 10.2105/AJPH.78.6.671; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; TAFFEL SM, 1990, NEW ENGL J MED, V323, P199; TORRES A, 1989, FAM PLANN PERSPECT, V21, P19, DOI 10.2307/2135414; 1980, OBJECTIVES NATION; 1987, BLESSED EVENTS BOTTO; 1986, HLTH US 1986; 1980, US PHS801260 US DEP	24	78	78	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					61	64		10.1001/jama.270.1.61	http://dx.doi.org/10.1001/jama.270.1.61			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510298				2022-12-28	WOS:A1993LK36600024
J	GIAID, A; YANAGISAWA, M; LANGLEBEN, D; MICHEL, RP; LEVY, R; SHENNIB, H; KIMURA, S; MASAKI, T; DUGUID, WP; STEWART, DJ				GIAID, A; YANAGISAWA, M; LANGLEBEN, D; MICHEL, RP; LEVY, R; SHENNIB, H; KIMURA, S; MASAKI, T; DUGUID, WP; STEWART, DJ			EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; RELAXING FACTOR; MESSENGER-RNA; C-FOS; POTENT; VASOCONSTRICTOR; MITOGENESIS; FIBROBLASTS; SCLERODERMA; RELEASE	Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin-1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1-like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1-like immunoreactivity. There was a strong correlation between the intensity of endothelin-1-like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75230 USA; MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT SURG, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT PATHOL, MONTREAL H3A 2T5, QUEBEC, CANADA; KYOTO UNIV, KYOTO 606, JAPAN; CHIBA UNIV, FAC MED, CHIBA, JAPAN; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75230 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University; McGill University; McGill University; Kyoto University; Chiba University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Langleben, David/AAJ-9152-2020	Kimura, Sadao/0000-0001-6768-7474				CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Dubin D, 1989, J VASC MED BIOL, V1, P150; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; KANSE SM, 1991, J CARDIOVASC PHARM, V17, pS113, DOI 10.1097/00005344-199100177-00029; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOMURO I, 1989, FEBS LETT, V244, P509; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MICHEL RP, 1991, J APPL PHYSIOL, V71, P601, DOI 10.1152/jappl.1991.71.2.601; MONCADA S, 1978, PHARMACOL REV, V30, P293; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; SCHARFFETTER K, 1988, EUR J CLIN INVEST, V18, P9, DOI 10.1111/j.1365-2362.1988.tb01158.x; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SNEDECOR GW, 1980, STATISTICAL METHODS, P135; STELZNER TJ, 1992, AM J PHYSIOL, V262, pL614, DOI 10.1152/ajplung.1992.262.5.L614; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WAGENVOORT CA, 1981, HISTOPATHOLOGY, V5, P595, DOI 10.1111/j.1365-2559.1981.tb01826.x; WOOD P, 1958, BRIT HEART J, V20, P557; YAMANE K, 1991, ARTHRITIS RHEUM, V34, P243, DOI 10.1002/art.1780340220; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	36	1420	1485	2	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1732	1739		10.1056/NEJM199306173282402	http://dx.doi.org/10.1056/NEJM199306173282402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8497283				2022-12-28	WOS:A1993LG03800002
J	JOHNSON, CL; RIFKIND, BM; SEMPOS, CT; CARROLL, MD; BACHORIK, PS; BRIEFEL, RR; GORDON, DJ; BURT, VL; BROWN, CD; LIPPEL, K; CLEEMAN, JI				JOHNSON, CL; RIFKIND, BM; SEMPOS, CT; CARROLL, MD; BACHORIK, PS; BRIEFEL, RR; GORDON, DJ; BURT, VL; BROWN, CD; LIPPEL, K; CLEEMAN, JI			DECLINING SERUM TOTAL CHOLESTEROL LEVELS AMONG UNITED-STATES ADULTS - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; LIPID RESEARCH CLINICS; MINNESOTA-HEART-SURVEY; EDUCATION-PROGRAM; DISEASE; TRENDS; MORTALITY; PLASMA; RISK	Objective.-To examine the secular trend in serum total cholesterol levels of the US adult population. Design.-Nationally representative cross-sectional surveys with both an in-person interview and a medical examination that included the measurement of blood lipid levels. Setting/Participants.-Between 6000 and 13 000 adults aged 20 through 74 years examined in each of four separate national surveys during 1960 through 1962, 1971 through 1974, 1976 through 1980, and 1988 through 1991. Results.-Mean serum total cholesterol levels in US adults aged 20 through 74 years have consistently declined over the time period 1960 through 1991. More than half of the decline occurred during the time period 1976 through 1991. This decline occurred across the entire distribution of serum cholesterol levels and in all age-sex groups. High-density lipoprotein cholesterol and very low-density lipoprotein cholesterol levels have not changed, suggesting that the decline in total cholesterol levels is due to a decline in low-density lipoprotein cholesterol levels. Conclusions.-These results document a continuing and substantial decline in serum cholesterol levels among US adults. They suggest that public health programs, designed to reduce cholesterol levels, are proving successful. The observed downward trend in serum cholesterol levels has coincided with a continuing decline in coronary heart disease mortality. These observations suggest that the Healthy People 2000 goal of reducing the mean serum cholesterol level of US adults to no more than 200 mg/dL (5.17 mmol/L) is attainable.	NHLBI,NATL CHOLESTEROL EDUC PROGRAM,BLDG 31,ROOM 4A-05,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ABELL LL, 1952, J BIOL CHEM, V195, P357; ABRAHAM S, 1978, VITAL HLTH STAT 11, V205; AHMED S, 1979, CLIN CHEM, V25, P880; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BACHORIK PS, 1979, CLIN CHIM ACTA, V96, P145, DOI 10.1016/0009-8981(79)90064-0; BACHORIK PS, 1984, CLIN CHEM, V30, P839; BRIEFEL RR, 1986, PREV MED, V15, P352; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; CARROLL MD, 1990, VITAL HLTH STATIS 11, V240; CARROLL MD, 1993, VITAL HLTH STATIS 11, V242; CLEEMAN JI, 1989, CLIN LAB MED, V9, P7, DOI 10.1016/S0272-2712(18)30638-3; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; ELLERBE P, 1990, CLIN CHEM, V36, P370; EZZATI T, 1992, IN PRESS 1992 P SURV; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRANK E, 1992, JAMA-J AM MED ASSOC, V268, P1566, DOI 10.1001/jama.268.12.1566; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULWOOD R, 1987, JAMA-J AM MED ASSOC, V257, P937; FULWOOD R, 1986, VITAL HLTH STAT 11, V236; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HAINLINE A, 1986, CLIN CHEM, V32, P611; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIPPEL K, 1978, CLIN CHEM, V24, P1477; MILLER H, 1969, VITAL HLTH STAT 6, V6; MOORE FE, 1967, VITAL HLTH STAT 11, V22; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; PIETINEN P, 1987, AM HEART J, V113, P620, DOI 10.1016/0002-8703(87)90643-0; RIZEK RL, 1980, CURRENT FOOD CONSUMP; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; WOTEKI CE, 1990, J NUTR, V120, P1440, DOI 10.1093/jn/120.suppl_11.1440; WRIGHT J, 1992, NUTRITION MONITERING; 1975, HANES STUDY FINAL RE; 1982, DHEW NIH75628 PUBL; 1990, NUTRITION YOUR HLTH; 1965, VITAL HLTH STAT 1, V4; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1991, HLTH PEOPLE 2000 NAT; 1988, ARCH INTERN MED, V148, P36; 1988, PHS8950210 US DEP HL; 1985, VITAL HLTH STAT 1, V19; 1974, USDHEW HSM11073371 P; 1989, PHS891255 US DEP AGR; 1987, AM J CLIN NUTR, V45, P1060; 1984, JAMA-J AM MED ASSOC, V251, P351; 1981, VITAL HLTH STAT 1, V15; 1991, CIRCULATION, V83, P2154; 1993, JAMA-J AM MED ASSOC, V269, P3015; 1973, VITAL HLTH STAT 1 A, V10	52	415	428	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3002	3008		10.1001/jama.269.23.3002	http://dx.doi.org/10.1001/jama.269.23.3002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501842				2022-12-28	WOS:A1993LF94100029
J	GRAINGER, DJ; KIRSCHENLOHR, HL; METCALFE, JC; WEISSBERG, PL; WADE, DP; LAWN, RM				GRAINGER, DJ; KIRSCHENLOHR, HL; METCALFE, JC; WEISSBERG, PL; WADE, DP; LAWN, RM			PROLIFERATION OF HUMAN SMOOTH-MUSCLE CELLS PROMOTED BY LIPOPROTEIN(A)	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PLASMINOGEN ACTIVATION; APOLIPOPROTEIN(A); ATHEROSCLEROSIS; FACTOR-BETA-1; QUANTITATION; INHIBITION; EXPRESSION; BINDING; FIBRIN	Elevated blood concentrations of lipoprotein(a) [Lp(a)] and its constituent, apolipoprotein(a) [apo(a)], constitute a major risk factor for atherosclerosis, but their physiological activities remain obscure. Lp(a) and purified apo(a) stimulated the growth of human smooth muscle cells in culture. This effect resulted from inhibition of plasminogen activation, and consequently the activation by plasmin of latent transforming growth factor-beta, which is an inhibitor of smooth muscle cell growth. Because smooth muscle proliferation is one of the hallmarks of atherosclerotic lesions, these results point to a plausible mechanism for the atherogenic activity of Lp(a).	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,SCH CLIN MED,CAMBRIDGE CB2 2QQ,ENGLAND	Stanford University; University of Cambridge; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATTEGAY EJ, 1990, CELL, V102, P1217; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COLLETTA AA, 1990, BR J CANCER RES, V82, P132; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRAINGER DJ, 1992, BIOCHEM J, V283, P403, DOI 10.1042/bj2830403; GRAINGER DJ, UNPUB; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; KNIGHT BL, 1991, ATHEROSCLEROSIS, V87, P227, DOI 10.1016/0021-9150(91)90025-X; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NIENDORF AM, 1988, VIRCHOWS ARCH A, V417, P105; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	32	354	372	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1655	1658		10.1126/science.8503012	http://dx.doi.org/10.1126/science.8503012			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503012				2022-12-28	WOS:A1993LG17600032
J	KNOWLTON, N; WEIGT, LA; SOLORZANO, LA; MILLS, DK; BERMINGHAM, E				KNOWLTON, N; WEIGT, LA; SOLORZANO, LA; MILLS, DK; BERMINGHAM, E			DIVERGENCE IN PROTEINS, MITOCHONDRIAL-DNA, AND REPRODUCTIVE COMPATIBILITY ACROSS THE ISTHMUS OF PANAMA	SCIENCE			English	Article							EASTERN PACIFIC; 2 SIDES; GENETICS; NEOGENE	It is widely believed that gene flow connected many shallow water populations of the Caribbean and eastern Pacific until the Panama seaway closed 3.0 to 3.5 million years ago. Measurements of biochemical and reproductive divergence for seven closely related, transisthmian pairs of snapping shrimps (Alpheus) indicate, however, that isolation was staggered rather than simultaneous. The four least divergent pairs provide the best estimate for rates of molecular divergence and speciation. Ecological, genetic, and geological data suggest that gene flow was disrupted for the remaining three pairs by environmental change several million years before the land barrier was complete.			KNOWLTON, N (corresponding author), SMITHSONIAN TROP RES INST, UNIT 0948, APO AA, MIAMI, FL 34002 USA.		Mills, DeEtta/G-8532-2015	Mills, DeEtta/0000-0002-9977-7834				BERMINGHAM E, 1993, P NATL ACAD SCI USA, V90, P2734, DOI 10.1073/pnas.90.7.2734; BURTON RS, 1982, ESTUARINE COMP, P537, DOI DOI 10.1016/B978-0-12-404070-0.50038-7; Chace F.A. Jr., 1972, Smithsonian Contributions to Zoology, VNo. 98, P1; CHAKRABORTY R, 1977, EVOLUTION, V31, P347, DOI 10.1111/j.1558-5646.1977.tb01017.x; COATES AG, 1992, GEOL SOC AM BULL, V104, P814, DOI 10.1130/0016-7606(1992)104<0814:COTIOP>2.3.CO;2; Collins L.S., 1992, PALEONTOLOGICAL SOC, V6, P67; COLLINS T, 1992, PALEONTOL SOC SPEC P, V6, P68; COYNE JA, 1989, EVOLUTION, V43, P362, DOI [10.2307/2409213, 10.1111/j.1558-5646.1989.tb04233.x]; DUQUECARO H, 1990, PALAEOGEOGR PALAEOCL, V77, P203, DOI 10.1016/0031-0182(90)90178-A; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; GLYNN P W, 1972, Bulletin of the Biological Society of Washington, V2, P13; GROSBERG RK, 1982, ECOLOGY, V63, P894, DOI 10.2307/1937228; HASSON PF, 1986, MICROPALEONTOLOGY, V32, P32, DOI 10.2307/1485698; HOLTHUIS L B, 1980, Zoologische Mededelingen (Leiden), V55, P47; JACKSON JBC, 1993, SCIENCE, V260, P1624, DOI 10.1126/science.260.5114.1624; JONES DS, 1985, GREAT AM BIOTIC INTE, P325; Jordan DS, 1908, AM NAT, V42, P73, DOI 10.1086/278905; KEIGWIN L, 1982, SCIENCE, V217, P350, DOI 10.1126/science.217.4557.350; Keller G., 1989, J S AM EARTH SCI, V2, P73, DOI DOI 10.1016/0895-9811(89)90028-X; Kim W, 1988, SMITHSONIAN CONTRIBU, V454, P1, DOI DOI 10.5479/SI.00810282.454; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KNOWLTON N, 1982, BEHAV ECOL SOCIOBIOL, V10, P289, DOI 10.1007/BF00302819; KNOWLTON N, 1985, B MAR SCI, V37, P893; Knowlton Nancy, 1992, Proceedings of the San Diego Society of Natural History, V18, P1; LESSIOS HA, 1984, EVOLUTION, V38, P1144, DOI 10.1111/j.1558-5646.1984.tb00382.x; LESSIOS HA, 1979, NATURE, V280, P599, DOI 10.1038/280599a0; LESSIOS HA, 1990, AM NAT, V135, P1, DOI 10.1086/285028; LESSIOS HA, 1981, EVOLUTION, V35, P618, DOI 10.1111/j.1558-5646.1981.tb04924.x; LESSIOS HA, 1990, EVOLUTION, V44, P933, DOI 10.1111/j.1558-5646.1990.tb03815.x; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; MAYR E, 1954, EVOLUTION, V8, P1, DOI 10.2307/2405661; Mayr E., 1963, ANIMAL SPECIES EVOLU; MCCOMMAS SA, 1982, MAR BIOL, V68, P169, DOI 10.1007/BF00397603; Murphy Robert W., 1990, P45; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; NEI M, 1978, GENETICS, V89, P583; Nolan BA, 1970, FORMA FUNCT, V2, P289; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; RUBINOFF RW, 1971, EVOLUTION, V25, P88, DOI 10.1111/j.1558-5646.1971.tb01861.x; SAITO T, 1976, GEOLOGY, V4, P305, DOI 10.1130/0091-7613(1976)4<305:GSOCDI>2.0.CO;2; Swofford D., 1998, PAUP PHYLOGENETIC AN; SWOFFORD DL, 1981, J HERED, V72, P281, DOI 10.1093/oxfordjournals.jhered.a109497; VAWTER AT, 1980, EVOLUTION, V34, P705, DOI 10.1111/j.1558-5646.1980.tb04009.x; Vermeij G.J., 1978, BIOGEOGRAPHY ADAPTAT; WEINBERG JR, 1989, MAR BIOL, V103, P143, DOI 10.1007/BF00543341	45	449	457	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1629	1632		10.1126/science.8503007	http://dx.doi.org/10.1126/science.8503007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503007				2022-12-28	WOS:A1993LG17600023
J	REES, WA; KELLER, RW; VESENKA, JP; YANG, GL; BUSTAMANTE, C				REES, WA; KELLER, RW; VESENKA, JP; YANG, GL; BUSTAMANTE, C			EVIDENCE OF DNA BENDING IN TRANSCRIPTION COMPLEXES IMAGED BY SCANNING FORCE MICROSCOPY	SCIENCE			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; INITIATION; ELONGATION; FILMS	Complexes of Escherichia coli RNA polymerase with DNA containing the lambda P(L) promoter have been deposited on mica and imaged in air with a scanning force microscope. The topographic images reveal the gross spatial relations of the polymerase relative to the DNA template. The DNA appears bent in open promoter complexes containing RNA polymerase bound to the promoter and appears more severely bent in elongation complexes in which RNA polymerase has synthesized a 15-nucleotide transcript. This difference could be related to the conformational changes that accompany the maturation of open promoter complexes into elongation complexes and suggests that formation of the elongation complex involves a considerable modification of the spatial relations between the polymerase and the DNA template.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R37GM015792, R01GM015792, R01GM029158, R01GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-32543, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA H, 1992, NATURE, V358, P171, DOI 10.1038/358171a0; ARNDT K, 1990, J MOL BIOL, V211, P79; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, IN PRESS CURR OPIN S; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; EDSALL JT, 1953, PROTEINS           B, V1, P549; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HANSMA HG, 1992, SCIENCE, V256, P1180, DOI 10.1126/science.256.5060.1180; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HIRSH J, 1976, J MOL BIOL, V108, P471, DOI 10.1016/S0022-2836(76)80131-3; KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUHNKE G, 1987, EMBO J, V6, P507, DOI 10.1002/j.1460-2075.1987.tb04782.x; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINDSAY SM, 1992, SPIE P, V1639, P127; MEISENBERGER O, 1980, FEBS LETT, V112, P117; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NOVAK RL, 1968, J BIOL CHEM, V243, P6068; REES WA, UNPUB; RHODES G, 1974, J BIOL CHEM, V249, P6675; SCHAFER R, 1973, EUR J BIOCHEM, V33, P207, DOI 10.1111/j.1432-1033.1973.tb02671.x; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THUNDAT T, 1992, ULTRAMICROSCOPY, V42, P1101, DOI 10.1016/0304-3991(92)90409-D; TICHELAAR W, 1983, EUR J BIOCHEM, V135, P263, DOI 10.1111/j.1432-1033.1983.tb07647.x; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YANG J, 1992, FEBS LETT, V301, P173, DOI 10.1016/0014-5793(92)81241-D	38	205	210	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1646	1649		10.1126/science.8503010	http://dx.doi.org/10.1126/science.8503010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503010				2022-12-28	WOS:A1993LG17600029
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			HUNTING FOR THE CAUSE - HOW FAR TO GO	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NEPHROTIC SYNDROME; NEOPLASIA		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.				NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER; NLM NIH HHS [LM 4493] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ALPERS CE, 1986, KIDNEY INT, V30, P465, DOI 10.1038/ki.1986.209; BERNARD DB, 1991, PRINCIPLES PRACTICE, P250; COLTHARP WH, 1991, ANN THORAC SURG, V1, P308; COUSER WG, 1992, CECIL TXB MED, P559; EAGEN JW, 1977, KIDNEY INT, V11, P297, DOI 10.1038/ki.1977.47; EDDY DM, 1991, COMMON SCREENING TES, P312; FER MF, 1981, AM J MED, V71, P704, DOI 10.1016/0002-9343(81)90241-2; GAGLIANO RG, 1976, AM J MED, V60, P1026, DOI 10.1016/0002-9343(76)90575-1; GLASSOCK RJ, 1991, HARRISONS PRINCIPLES, P1170; GORRY GA, 1978, NEW ENGL J MED, V298, P486, DOI 10.1056/NEJM197803022980904; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; Hricik D E, 1982, Dis Mon, V28, P1; LEE JC, 1966, ANN INTERN MED, V64, P41, DOI 10.7326/0003-4819-64-1-41; MAJOR RH, 1945, CLASSIC DESCRIPTIONS, P534; PAPPER S, 1984, POSTGRAD MED, V76, P147, DOI 10.1080/00325481.1984.11698785; PAPPER S, 1984, POSTGRAD MED, V76, P153; ROW PG, 1975, Q J MED, V44, P207; STEVENS PE, 1988, J ROY SOC MED, V81, P416, DOI 10.1177/014107688808100719; STRIKER LJ, 1991, PRINCIPLES PRACTICE, P335; TAPE TG, 1990, COMMON DIAGNOSTIC TE, P79; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P62; 1989, GUIDE CLIN PREVENTIV, P67	22	8	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1621	1624		10.1056/NEJM199306033282209	http://dx.doi.org/10.1056/NEJM199306033282209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8487804				2022-12-28	WOS:A1993LE28900009
J	BAIRD, DT; GLASIER, AF				BAIRD, DT; GLASIER, AF			DRUG-THERAPY - HORMONAL CONTRACEPTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL-CONTRACEPTIVES; BREAST-CANCER; CARBOHYDRATE-METABOLISM; INTRAUTERINE-DEVICE; WOMEN; RISK; AGENTS; PROGESTOGENS; METAANALYSIS; EXPERIENCE				BAIRD, DT (corresponding author), UNIV EDINBURGH, CTR REPROD BIOL, DEPT OBSTET & GYNAECOL, 37 CHALMERS ST, EDINBURGH EH3 9EW, SCOTLAND.							ADAMS MR, 1990, AM J OBSTET GYNECOL, V163, P1388, DOI 10.1016/0002-9378(90)91353-E; ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x; [Anonymous], 1987, JAMA, V257, P796; [Anonymous], 1990, Lancet, V336, P955; BAIRD DT, 1991, IPPF MED B, V25, P1; BAIRD DT, 1992, RECENT ADV ENDOCRINO, P83; BARDIN CW, 1991, J CLIN ENDOCR METAB, V73, P4, DOI 10.1210/jcem-73-1-4; BATISTA MC, 1992, J CLIN ENDOCR METAB, V74, P565, DOI 10.1210/jc.74.3.565; BENNINK HJT, 1990, ADV CONTRACEPT, V6, P293; BERAL V, 1988, LANCET, V2, P1331; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGQUIST C, 1979, LANCET, V2, P215; Cancer and Steroid Hormone Study Investigators, 1986, NEW ENGL J MED, V315, P405, DOI 10.1056/NEJM198608143150701; Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650; CHILVERS C, 1989, LANCET, V1, P973; CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; DARCANGUES C, 1990, CONTRACEPTION MECHAN; DEKRETSER DM, 1976, PROC R SOC SER B-BIO, V195, P161; DICZFALUSY E, 1970, ENDOMETRIAL BLEEDING, V127, P287; DICZFALUSY E, 1982, HORMONAL FACTORS FER, P75; DOLL R, 1975, SCOT MED J, V20, P305, DOI 10.1177/003693307502000615; Fathalla M, 1988, RES HUMAN REPROD, P341; FORTNEY JA, 1990, IPPF MED B, V24, P3; FOSTER DC, 1989, SEMIN REPROD ENDOCR, V7, P205, DOI 10.1055/s-2007-1021401; FOTHERBY K, 1989, BRIT MED J, V298, P1049, DOI 10.1136/bmj.298.6680.1049; FRASER HM, 1989, J CLIN ENDOCR METAB, V69, P996, DOI 10.1210/jcem-69-5-996; Fraser I S, 1981, Med J Aust, V1, P3; FRASER IS, 1989, CONTRACEPTION SCI PR, P111; GLASIER A, 1990, BAILLIERE CLIN OB GY, V4, P283, DOI 10.1016/S0950-3552(05)80227-5; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; GUILLEBAUD J, 1991, HDB FAMILY PLANNING, P63; HELLER CG, 1950, FERTIL STERIL, V1, P415; HOWIE PW, 1985, BRIT J OBSTET GYNAEC, V92, P1001, DOI 10.1111/j.1471-0528.1985.tb02993.x; LAUKARAN V H, 1987, International Journal of Gynecology and Obstetrics, V25, P129; LEDGER WL, 1992, HUM REPROD, V7, P945, DOI 10.1093/oxfordjournals.humrep.a137776; LUUKKAINEN T, 1986, CONTRACEPTION, V33, P139, DOI 10.1016/0010-7824(86)90080-6; MAMMEN EF, 1982, AM J OBSTET GYNECOL, V142, P781; NILSSON CG, 1984, FERTIL STERIL, V41, P52; PARKES AS, 1977, SCI QUOTATIONS HARVE, P116; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; PHILLIPS A, 1987, CONTRACEPTION, V36, P181, DOI 10.1016/0010-7824(87)90013-8; Pincus G., 1965, CONTROL FERTILITY; POLLER L, 1973, RECENT ADV THROMBOSI, P181; POWLES TJ, 1989, LANCET, V2, P97; RAMCHARAN S, 1981, NIH81564 PUBL, V3; REBAR RW, 1991, CONTRACEPTION, V44, P1, DOI 10.1016/0010-7824(91)90101-K; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROWE PJ, 1987, CONTRACEPTION, V35, P363; ROWE PJ, 1990, CONTRACEPTION, V41, P105, DOI 10.1016/0010-7824(90)90141-H; SHOUPE D, 1987, AM J OBSTET GYNECOL, V157, P1421, DOI 10.1016/S0002-9378(87)80236-3; SILVESTRE L, 1991, LANCET, V338, P39, DOI 10.1016/0140-6736(91)90018-K; SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A; SIVIN I, 1988, STUD FAMILY PLANN, V19, P81, DOI 10.2307/1966493; SPELLACY WN, 1982, AM J OBSTET GYNECOL, V142, P732; SPICER DV, 1991, CONTRACEPTION, V44, P289, DOI 10.1016/0010-7824(91)90019-C; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; SWAHN ML, 1991, LANCET, V338, P942, DOI 10.1016/0140-6736(91)91805-5; THOMAS DB, 1991, LANCET, V338, P833; THOMAS DB, 1985, BRIT MED J, V290, P961; TYSON JE, 1989, SEMIN REPROD ENDOCR, V7, P231, DOI 10.1055/s-2007-1021405; VANLOOK PFA, 1989, OXFORD REV REPROD B, V11, P1; Vessey M, 1985, BR J FAMILY PLANNING, V10, P117; VESSEY MP, 1977, LANCET, V2, P731; VESSEY MP, 1976, PROC R SOC SER B-BIO, V195, P69, DOI 10.1098/rspb.1976.0099; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; 1988, POPUL REP A, V16, P1; 1983, STUD FAMILY PLANN, V14, P159; 1977, LANCET, V2, P727; 1969, LANCET, V2, P783; 1992, WHO TECH REP SER, V817, P22; 1991, LANCET, V338, P856; 1987, LANCET, V1, P1179	76	64	93	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1543	1549						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479492				2022-12-28	WOS:A1993LC94100008
J	PEYRON, R; AUBENY, E; TARGOSZ, V; SILVESTRE, L; RENAULT, M; ELKIK, F; LECLERC, P; ULMANN, A; BAULIEU, EE				PEYRON, R; AUBENY, E; TARGOSZ, V; SILVESTRE, L; RENAULT, M; ELKIK, F; LECLERC, P; ULMANN, A; BAULIEU, EE			EARLY TERMINATION OF PREGNANCY WITH MIFEPRISTONE (RU-486) AND THE ORALLY ACTIVE PROSTAGLANDIN MISOPROSTOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UTERINE CONTRACTILITY; ANALOG; INDUCTION; ABORTION; INTERRUPTION; COMBINATION; RECEPTOR; EXPOSURE; WOMEN; RU486	Background and Methods. The combination of mifepristone (RU 486) and a prostaglandin analogue given either intramuscularly or intravaginally is effective in terminating early pregnancy, but the prostaglandin component of the regimen is cumbersome to administer and has side effects. We conducted two studies to determine the efficacy of 600 mg of mifepristone followed by a small dose of misoprostol, an orally active prostaglandin E1 analogue, for the same purpose. In the first study, 505 women who had had amenorrhea for less than 50 days received 400 mug of misoprostol 48 hours after receiving mifepristone, if the pregnancy was not terminated within that period. In the second study, 390 women initially received the same treatment, but if the pregnancy was not terminated within four hours after the administration of misoprostol, they were offered an additional 200-mug dose of misoprostol. Results. In study 1, the rate of success (termination of pregnancy and complete expulsion of the conceptus) was 96.9 percent (95 percent confidence interval, 94.1 to 97.7 percent) - similar to the success rate of approximately 95 percent for mifepristone followed by the intramuscular or intravaginal administration of prostaglandin. Abortion occurred in 2.9 percent of the women within 48 hours after the administration of mifepristone, in 60.9 percent within 4 hours after the administration of misoprostol, and in 33.2 percent thereafter. The failures included ongoing pregnancies in four women (0.8 percent) and incomplete abortions in nine (1.8 percent); two other women (0.4 percent) required vacuum aspiration for prolonged uterine bleeding. In study 2, pregnancy was terminated in 5.5 percent of the women before the administration of misoprostol and within four hours after the first dose of misoprostol in 69.1 percent. Among the 71 women who received a second dose of misoprostol, 67 had complete abortions, 2 had partial retention of the conceptus, 1 had synechia with ongoing pregnancy, and 1 had an ectopic pregnancy. One ongoing pregnancy, which was terminated by vacuum aspiration, was recorded among the 27 women who declined to take the second dose of misoprostol. The overall rate of success of the regimen with the optional second dose of misoprostol was 98.7 percent (95 percent confidence interval, 96.8 to 99.5 percent). No woman had any serious adverse event. Conclusions. The combination of mifepristone and misoprostol is effective for the termination of early pregnancy in terms of success, tolerance, safety, and practicality.	INSERM, U33, 80 RUE GEN LECLERC, F-94276 LE KREMLIN BICETRE, FRANCE; LABS ROUSSEL, DEPT MED, PARIS, FRANCE; HOP BROUSSAIS, CTR ORTHOGENIE, SERV PR P POITOUT, F-75674 PARIS 14, FRANCE; HOP BICETRE, HORMONOL LAB, F-94270 LE KREMLIN BICETRE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Sanofi France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay								[Anonymous], 1991, LANCET, V337, P969; AUBENY E, 1991, CR ACAD SCI III-VIE, V312, P539; AVRECH OM, 1991, FERTIL STERIL, V56, P385; Baulieu E.E., 1985, ANTIPROGESTIN STEROI, P1; BAULIEU EE, 1989, JAMA-J AM MED ASSOC, V262, P1808, DOI 10.1001/jama.262.13.1808; BERGSTROM S, 1972, SCIENCE, V175, P1280, DOI 10.1126/science.175.4027.1280; BERGSTROM S, 1967, SCIENCE, V157, P382, DOI 10.1126/science.157.3787.382; BYGDEMAN M, 1985, CONTRACEPTION, V32, P45, DOI 10.1016/0010-7824(85)90115-5; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COLLINS PW, 1985, DIGEST DIS SCI, V30, pS114, DOI 10.1007/BF01309395; COUZINET B, 1986, NEW ENGL J MED, V315, P1565, DOI 10.1056/NEJM198612183152501; DUBOIS C, 1988, CR ACAD SCI III-VIE, V306, P57; Fleiss JL., 1981, STAT METHODS RATES P, P14; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; HERRMANN WL, 1985, ANTIPROGESTIN STEROI, P179; HERTING RL, 1986, DIGEST DIS SCI, V31, pS47, DOI 10.1007/BF01309323; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; KOVACS L, 1984, CONTRACEPTION, V29, P399, DOI 10.1016/0010-7824(84)90014-3; LIM BH, 1990, LANCET, V336, P257; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; RODGER MW, 1989, CONTRACEPTION, V40, P439, DOI 10.1016/0010-7824(89)90051-6; RODGER MW, 1987, LANCET, V2, P1415; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; SOMELL C, 1990, GYNECOL OBSTET INVES, V30, P224, DOI 10.1159/000293274; SONTAG SJ, 1985, DIGEST DIS SCI, V30, pS159, DOI 10.1007/BF01309403; SWAHN ML, 1989, HUM REPROD, V4, P21, DOI 10.1093/oxfordjournals.humrep.a136838; SWAHN ML, 1990, CONTRACEPTION, V41, P461, DOI 10.1016/0010-7824(90)90056-2; TEMPLETON A, 1990, BRIT J OBSTET GYNAEC, V97, P480; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; VANLOOK PFA, 1992, SPECIAL PROGRAMME RE, P37; WOLF JP, 1990, CONTRACEPTION, V41, P85, DOI 10.1016/0010-7824(90)90129-J; 1989, CURR PROBL, V27, P2	34	270	278	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1509	1513		10.1056/NEJM199305273282101	http://dx.doi.org/10.1056/NEJM199305273282101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479487				2022-12-28	WOS:A1993LC94100001
J	SIXMA, HJ; LANGERAK, EH; SCHRIJVERS, GJP; VANDERBENT, J				SIXMA, HJ; LANGERAK, EH; SCHRIJVERS, GJP; VANDERBENT, J			ATTEMPTING TO REDUCE HOSPITAL COSTS BY STRENGTHENING PRIMARY CARE INSTITUTIONS - THE DUTCH HEALTH-CARE DEMONSTRATION PROJECT IN THE NEW TOWN OF ALMERE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOME		ALMERE HLTH CARE CORP,ALMERE,NETHERLANDS; UNIV UTRECHT,INST HLTH SERV RES,UTRECHT,NETHERLANDS; NATL HOSP INST,UTRECHT,NETHERLANDS	Netherlands Institute for Health Services Research; Utrecht University	SIXMA, HJ (corresponding author), NETHERLANDS INST PRIMARY HLTH CARE,UTRECHT,NETHERLANDS.							BAKKER DH, 1992, AUG INT MED GEOGR S; CHALLIS D, 1987, BR J SOCIAL WORK, V18, P13; FOETS M, 1992, DUTCH NATIONAL SURVE; HELSLOOT RSM, 1991, CHALLENGES OPEN EVA; HUGHES SL, 1987, HEALTH SERV RES, V22, P19; Lamberts H., 1987, ICPC INT CLASSIFICAT; SCHRIJVERS AJP, 1991, JAMA-J AM MED ASSOC, V266, P2215, DOI 10.1001/jama.266.16.2215; SIXMA H, 1992, EHBO ALMERE, V2; SIXMA HJM, 1991, ZIEKTEN VERRICHTINGE; THORSLUND M, 1988, HEALTH POLICY, V10, P41, DOI 10.1016/0168-8510(88)90086-3; VANDEBENT J, 1993, KLINISCHE CONSUMPTIE; VANDERVELDEN J, 1992, DUTCH NATIONAL SURVE; Vertrees J C, 1989, Health Care Financ Rev, V10, P65; 1981, HLTH ALL SERIES, V1; [No title captured]; 1986, MONTH B POPUL STAT; 1988, POPULATION STATISTIC; 1983, PROJECTPLAN ALMERE 1	18	1	1	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2567	2572						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487425				2022-12-28	WOS:A1993LB45000041
J	SCHERLY, D; NOUSPIKEL, T; CORLET, J; UCLA, C; BAIROCH, A; CLARKSON, SG				SCHERLY, D; NOUSPIKEL, T; CORLET, J; UCLA, C; BAIROCH, A; CLARKSON, SG			COMPLEMENTATION OF THE DNA-REPAIR DEFECT IN XERODERMA-PIGMENTOSUM GROUP-G CELLS BY A HUMAN CDNA RELATED TO YEAST RAD2	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE; DISORDERS; CLONING	DEFECTS in human DNA repair proteins can give rise to the autosomal recessive disorders xeroderma pigmentosum (XP) and Cockayne's syndrome (CS), sometimes even together1-3. Seven XP and three CS complementation groups have been identified that are thought to be due to mutations in genes from the nucleotide excision repair pathway2,3. Here we isolate frog and human complementary DNAs that encode proteins resembling RAD2, a protein involved in this pathway in yeast4,5. Alignment of these three polypeptides, together with two other RAD2 related proteins6,7, reveals that their conserved sequences are largely confined to two regions. Expression of the human cDNA in vivo restores to normal the sensitivity to ultraviolet light and unscheduled DNA synthesis of lymphoblastoid celts from XP group G, but not CS group A. The XP-G correcting protein XPGC is generated from a messenger RNA of approximately 4 kilobases that is present in normal amounts in the XP-G cell line.	UNIV GENEVA,MED CTR,DEPT MED BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	SCHERLY, D (corresponding author), UNIV GENEVA,MED CTR,DEPT GENET & MICROBIOL,9 AVE CHAMPEL,CH-1211 GENEVA 4,SWITZERLAND.		Bairoch, Amos/X-7411-2019	Bairoch, Amos/0000-0003-2826-6444				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BAITOCH A, 1991, NUCLEIC ACIDS RES, V19, P2247; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BOOTSMA D, 1991, ANN GENET-PARIS, V34, P143; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLEAVER JE, 1981, DNA REPAIR LABORATOR, P277; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; HANANIAN J, 1980, CLIN GENET, V17, P39; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEEDER JS, 1989, ANAL BIOCHEM, V177, P364, DOI 10.1016/0003-2697(89)90067-5; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHMANN A R, 1987, Cancer Reviews, V7, P82; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MORIKAWA K, 1993, CURR OPIN STRUC BIOL, V3, P17, DOI 10.1016/0959-440X(93)90196-R; NICOLET CM, 1985, GENE, V36, P225, DOI 10.1016/0378-1119(85)90177-5; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ROBBINS JH, 1991, HUM GENET, V88, P242; SCHERLY D, IN PRESS J MOL BIOL; SPICKOFSKY N, 1990, DNA PROT ENG TECH, V2, P14; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; XU SY, 1991, J BIOL CHEM, V266, P4425	30	199	202	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					182	185		10.1038/363182a0	http://dx.doi.org/10.1038/363182a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483504				2022-12-28	WOS:A1993LB80100054
J	PELTOMAKI, P; AALTONEN, LA; SISTONEN, P; PYLKKANEN, L; MECKLIN, JP; JARVINEN, H; GREEN, JS; JASS, JR; WEBER, JL; LEACH, FS; PETERSEN, GM; HAMILTON, SR; DELACHAPELLE, A; VOGELSTEIN, B				PELTOMAKI, P; AALTONEN, LA; SISTONEN, P; PYLKKANEN, L; MECKLIN, JP; JARVINEN, H; GREEN, JS; JASS, JR; WEBER, JL; LEACH, FS; PETERSEN, GM; HAMILTON, SR; DELACHAPELLE, A; VOGELSTEIN, B			GENETIC-MAPPING OF A LOCUS PREDISPOSING TO HUMAN COLORECTAL-CANCER	SCIENCE			English	Article							TUMOR SUPPRESSOR GENES; FAMILY SYNDROME; SYNDROME-II; IDENTIFICATION; CARCINOMA; CHROMOSOME-5Q21; MUTATIONS; FAP	Genetic linkage analysis was used to determine whether a specific chromosomal locus could be implicated in families with a history of early onset cancer but with no other unique features. Close linkage of disease to anonymous microsatellite markers on chromosome 2 was demonstrated in two large kindreds. The pairwise lod scores for linkage to marker D2S123 in these kindreds were 6.39 and 1.45 at zero recombination, and multipoint linkage with flanking markers resulted in lod scores of 6.47 and 6.01. These results prove the existence of a genetically determined predisposition to colorectal cancer that has important ramifications for understanding and preventing this disease.	UNIV HELSINKI,DEPT MED GENET,POB 21,SF-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT MED SCI,SF-00310 HELSINKI,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; JYVASKYLA CENT HOSP,DEPT SURG,SF-40620 JYVASKYLA,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT SURG 2,SF-00290 HELSINKI 29,FINLAND; MEM UNIV NEWFOUNDLAND,FAC MED,ST JOHNS A1B 3V6,NEWFOUNDLAND,CANADA; UNIV AUCKLAND,SCH MED,DEPT PATHOL,AUCKLAND,NEW ZEALAND; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH & HYG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21231	University of Helsinki; University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; Memorial University Newfoundland; University of Auckland; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			Mecklin, Jukka-Pekka/AAB-5378-2020; Aaltonen, Lauri/A-5375-2010; Mecklin, Jukka-Pekka/AAC-9650-2019	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Peltomaki, Paivi/0000-0001-8819-2980	NCI NIH HHS [CA 47527, CA 35494] Funding Source: Medline; NHGRI NIH HHS [HG 00248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035494, R01CA047527, R01CA035494] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAKALA T, 1991, CANCER, V68, P1656, DOI 10.1002/1097-0142(19911001)68:7<1656::AID-CNCR2820680732>3.0.CO;2-7; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; JARVINEN HJ, 1992, GUT, V33, P357, DOI 10.1136/gut.33.3.357; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEE F, 1991, GUT, V32, P509, DOI 10.1136/gut.32.5.509; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; MECKLIN JP, 1991, CANCER, V68, P1109, DOI 10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-S; MECKLIN JP, 1987, GASTROENTEROLOGY, V93, P1021, DOI 10.1016/0016-5085(87)90565-8; MULVIHILL JJ, 1983, PREVENTION HEREDITAR, P61; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAKSTIS AJ, 1989, CYTOGENET CELL GENET, V51, P1057; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1992, CANCER RES, V52, P4530; SHILOH Y, 1985, NUCLEIC ACIDS RES, V13, P5403, DOI 10.1093/nar/13.14.5403; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Warthin AS, 1913, ARCH INTERN MED, V12, P546; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT WC, 1984, NEW ENGL J MED, V310, P697, DOI 10.1056/NEJM198403153101106	32	803	821	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					810	812		10.1126/science.8484120	http://dx.doi.org/10.1126/science.8484120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484120				2022-12-28	WOS:A1993LA74400031
J	HOROWITZ, MC				HOROWITZ, MC			CYTOKINES AND ESTROGEN IN BONE - ANTI-OSTEOPOROTIC EFFECTS	SCIENCE			English	Editorial Material							OSTEOBLAST-LIKE CELLS; PARATHYROID-HORMONE; RELEASE; INTERLEUKIN-1; RESORPTION; RECEPTORS; INVITRO				HOROWITZ, MC (corresponding author), YALE UNIV,SCH MED,DEPT ORTHOPAED & REHABIL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; CHAUDHARY LR, 1992, ENDOCRINOLOGY, V130, P2528, DOI 10.1210/en.130.5.2528; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; FAVUS MJ, 1990, PRIMER METABOLIC BON, P151; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GULSHAN S, 1990, SCAND J IMMUNOL, V31, P691, DOI 10.1111/j.1365-3083.1990.tb02820.x; HOROWITZ MC, 1989, J CLIN INVEST, V83, P149, DOI 10.1172/JCI113852; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; OURSLER MJ, 1992, J BONE MINER RES, V7, pS111; PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616; PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134	18	386	409	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 30	1993	260	5108					626	627		10.1126/science.8480174	http://dx.doi.org/10.1126/science.8480174			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480174				2022-12-28	WOS:A1993KZ64100019
J	TOMKINSON, AE; BARDWELL, AJ; BARDWELL, L; TAPPE, NJ; FRIEDBERG, EC				TOMKINSON, AE; BARDWELL, AJ; BARDWELL, L; TAPPE, NJ; FRIEDBERG, EC			YEAST DNA-REPAIR AND RECOMBINATION PROTEINS RAD1 AND RAD10 CONSTITUTE A SINGLE-STRANDED-DNA ENDONUCLEASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; EXCISION REPAIR; MOLECULAR CHARACTERIZATION; MITOTIC RECOMBINATION; NUCLEOTIDE-SEQUENCE; CDNA CLONING; GENE; HELICASE; PURIFICATION; HOMOLOGY	DAMAGE-SPECIFIC recognition and incision of DNA during nucleotide excision repair in yeast1 and mammalian cells2 requires multiple gene products. Amino-acid sequence homology between several yeast and mammalian genes suggests that the mechanism of nucleotide excision repair is conserved in eukaryotes2-7, but very little is known about its biochemistry. In the yeast Saccharomyces cerevisiae at least 6 genes are needed for this process, including RAD1 and RAD10 (ref. 1). Mutations in the two genes inactivate nucleotide excision repair8,9 and result in a reduced efficiency of mitotic recombinational events between repeated sequences10-15. The Rad10 protein has a stable and specific interaction with Rad1 protein16,17 and also binds to single-stranded DNA and promotes annealing of homologous single-stranded DNA18 The amino-acid sequence of the yeast Rad10 protein is homologous with that of the human excision repair gene ERCC1 (ref. 3). Here we demonstrate that a complex of purified Rad1 and Rad10 proteins specifically degrades single-stranded DNA by an endonucleolytic mechanism. This endonuclease activity is presumably required to remove non-homologous regions of single-stranded DNA during mitotic recombination between repeated sequences as previously suggested13, and may also be responsible for the specific incision of damaged DNA during nucleotide excision repair.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363				AGUILERA A, 1989, GENETICS, V123, P683; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BARDWELL AJ, IN PRESS MOL MICROBI; BARDWELL L, 1990, BIOCHEMISTRY-US, V29, P3119, DOI 10.1021/bi00464a031; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FORMOSA T, 1991, J METH ENZYM, V208, P24; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; NAEGELI H, IN PRESS J BIOL CHEM; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; THOMAS BJ, 1989, GENETICS, V123, P725; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	29	177	181	3	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					860	862		10.1038/362860a0	http://dx.doi.org/10.1038/362860a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479526				2022-12-28	WOS:A1993KZ56300064
J	MCKENZIE, SA; KURTIANYK, O; KIDD, M; KNOWLES, D; LIPMAN, H				MCKENZIE, SA; KURTIANYK, O; KIDD, M; KNOWLES, D; LIPMAN, H			ADVICE TO A MOSCOW CHILDRENS HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article								At the request of the largest children's hospital in Moscow, McKenzie and colleagues made recommendations for improving the service. Restrictions on visiting and fears of contracting illness from nondisposable needles have discouraged the local population from using the hospital. Consequently the hospital is underused and overstaffed. Serious shortages of drugs and surgical supplies compromise care. Fundamental changes are needed in nursing and postgraduate education. The authors encouraged their Russian colleagues to address the health care needs of their local population and to develop family centred care, and they offered training in London.	KINGS FUND COLL,LONDON,ENGLAND; TUSHINSKAYA CHILDRENS HOSP CHARITABLE TRUST,LONDON W1M 7AF,ENGLAND		MCKENZIE, SA (corresponding author), QUEEN ELIZABETH HOSP CHILDREN,NURSING SERV,LONDON E2 8PS,ENGLAND.							BARANOV AA, 1992, ARCH DIS CHILD, V66, P542; DELAMOTHE T, 1992, BRIT MED J, V304, P1432, DOI 10.1136/bmj.304.6839.1432; RICHARDS T, 1992, BRIT MED J, V305, P1516, DOI 10.1136/bmj.305.6868.1516; RYAN M, 1992, BRIT MED J, V304, P101, DOI 10.1136/bmj.304.6819.101; 1993, NHS7 AUD COMM REP	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					914	916		10.1136/bmj.306.6882.914	http://dx.doi.org/10.1136/bmj.306.6882.914			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490422	Bronze, Green Published			2022-12-28	WOS:A1993KW38700031
J	BLISKA, JB; GALAN, JE; FALKOW, S				BLISKA, JB; GALAN, JE; FALKOW, S			SIGNAL-TRANSDUCTION IN THE MAMMALIAN-CELL DURING BACTERIAL ATTACHMENT AND ENTRY	CELL			English	Review							ENTEROPATHOGENIC ESCHERICHIA-COLI; PSEUDOTUBERCULOSIS INVASIN PROTEIN; TISSUE-CULTURE CELLS; MONOCYTE COMPLEMENT RECEPTORS; OUTER-MEMBRANE PROTEIN; YERSINIA-PSEUDOTUBERCULOSIS; EPITHELIAL-CELLS; VIRULENCE PLASMID; HEP-2 CELLS; SALMONELLA-TYPHIMURIUM		STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; NIH, NATL INST ALLERGY & INFECT DIS, ROCKY MT LAB, HAMILTON, MT 59840 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BLISKA, JB (corresponding author), SUNY, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195, R29AI030492, R37AI030492, R01AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26-195, AI30492] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; ATKINSON M, 1992, J BACTERIOL, V174, P4356, DOI 10.1128/JB.174.13.4356-4360.1992; BALDWIN TJ, 1990, INFECT IMMUN, V58, P761, DOI 10.1128/IAI.58.3.761-765.1990; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BLISKA JB, 1992, INFECT IMMUN, V60, P2475; BOLIN I, 1982, INFECT IMMUN, V37, P506; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BUKHOLM G, 1984, ACTA PATH MICRO IM B, V92, P145; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHIANG TM, 1989, J BIOL CHEM, V264, P2957; CLEMENS JC, 1991, MOL MICROBIOL, V5, P2617, DOI 10.1111/j.1365-2958.1991.tb01970.x; CORNELIS G, 1987, REV INFECT DIS, V9, P64; CORNELIS GR, 1989, MOL MICROBIOL, V3, P1455, DOI 10.1111/j.1365-2958.1989.tb00129.x; DIRITA VJ, 1989, ANNU REV GENET, V23, P455; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; DONNENBERG MS, 1989, J INFECT DIS, V160, P452, DOI 10.1093/infdis/160.3.452; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; DOWLING JN, 1992, MICROBIOL REV, V56, P32, DOI 10.1128/MMBR.56.1.32-60.1992; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; ELWELL LP, 1980, ANNU REV MICROBIOL, V34, P465, DOI 10.1146/annurev.mi.34.100180.002341; EMODY L, 1989, J BACTERIOL, V171, P6674; ENNIS E, 1993, J EXP MED, V177, P207, DOI 10.1084/jem.177.1.207; ERNST RK, 1990, INFECT IMMUN, V58, P2014, DOI 10.1128/IAI.58.6.2014-2016.1990; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FALKOW S, 1987, REV INFECT DIS, V9, pS450; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Fujimura Yoshinori, 1992, Journal of Clinical Electron Microscopy, V25, P35; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOGUEN JD, 1986, INFECT IMMUN, V51, P788, DOI 10.1128/IAI.51.3.788-794.1986; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GULIG PA, 1993, IN PRESS MOL MICROBI; HANSKI C, 1989, INFECT IMMUN, V57, P673, DOI 10.1128/IAI.57.3.673-678.1989; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V40, P37, DOI 10.1016/0378-1097(87)90512-X; HEESEMANN J, 1985, J CLIN MICROBIOL, V22, P168, DOI 10.1128/JCM.22.2.168-175.1985; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INMAN LR, 1983, J CLIN INVEST, V71, P1, DOI 10.1172/JCI110737; ISBERG RR, 1988, INFECT IMMUN, V56, P2133, DOI 10.1128/IAI.56.8.2133-2138.1988; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1990, MOL BIOL MED, V7, P73; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISBERG RR, 1989, INFECT IMMUN, V57, P1998, DOI 10.1128/IAI.57.7.1998-2005.1989; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; JERSE AE, 1991, INFECT IMMUN, V59, P3869, DOI 10.1128/IAI.59.11.3869-3875.1991; JOHNSON RJ, 1992, J LEUKOCYTE BIOL, V52, P3, DOI 10.1002/jlb.52.1.3; JONES BD, 1992, INFECT IMMUN, V60, P2475, DOI 10.1128/IAI.60.6.2475-2480.1992; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAPPERUD G, 1987, INFECT IMMUN, V55, P2247, DOI 10.1128/IAI.55.9.2247-2254.1987; KELLYWINTENBERG K, 1990, J BACTERIOL, V172, P5135, DOI 10.1128/jb.172.9.5135-5139.1990; KIHLSTROM E, 1977, ACTA PATH MICRO IM B, V85, P322; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEUNG KY, 1989, J BACTERIOL, V171, P4623, DOI 10.1128/jb.171.9.4623-4632.1989; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; LIAN CJ, 1987, J MED MICROBIOL, V24, P219, DOI 10.1099/00222615-24-3-219; LIAN CJ, 1987, INFECT IMMUN, V55, P1176, DOI 10.1128/IAI.55.5.1176-1183.1987; LINDLER LE, 1993, IN PRESS MOL MICROBI, V8; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; LONDON E, 1992, MOL MICROBIOL, V6, P3277, DOI 10.1111/j.1365-2958.1992.tb02195.x; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MADSHUS IH, 1992, CURR TOP MICROBIOL, V175, P1; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MANJARREZHERNANDEZ HA, 1992, LANCET, V339, P521, DOI 10.1016/0140-6736(92)90340-9; MANJARREZHERNANDEZ HA, 1991, FEBS LETT, V292, P121, DOI 10.1016/0014-5793(91)80848-W; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MILLER VL, 1990, J BACTERIOL, V172, P1062, DOI 10.1128/jb.172.2.1062-1069.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, CURR TOP MICROBIOL, V138, P15; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOON HW, 1983, INFECT IMMUN, V41, P1340, DOI 10.1128/IAI.41.3.1340-1351.1983; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAYNE NR, 1987, J EXP MED, V166, P1377, DOI 10.1084/jem.166.5.1377; PEPE J, 1993, IN PRESS P NATL ACAD; PIERSON DE, 1990, INFECT IMMUN, V58, P1059, DOI 10.1128/IAI.58.4.1059-1064.1990; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; PORTNOY DA, 1985, CURR TOP MICROBIOL, V118, P29; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; REISNER BS, 1992, INFECT IMMUN, V60, P5242, DOI 10.1128/IAI.60.12.5242-5252.1992; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROSENSHINE I, 1993, BIOESSAYS, V15, P17, DOI 10.1002/bies.950150104; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; ROSQVIST R, 1986, MICROB PATHOGENESIS, V1, P229, DOI 10.1016/0882-4010(86)90047-1; ROSQVIST R, 1988, NATURE, V334, P522, DOI 10.1038/334522a0; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHULZEKOOPS H, 1992, INFECT IMMUN, V60, P2153, DOI 10.1128/IAI.60.6.2153-2159.1992; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIMONET M, 1990, INFECT IMMUN, V58, P841, DOI 10.1128/IAI.58.3.841-845.1990; SIMONET M, 1992, INFECT IMMUN, V60, P366, DOI 10.1128/IAI.60.2.366-373.1992; SIMONET M, 1992, INFECT IMMUN, V60, P4414, DOI 10.1128/IAI.60.10.4414-4417.1992; SJOLANDER A, 1988, EUR J CELL BIOL, V134, P473; SKURNIK M, 1989, MOL MICROBIOL, V3, P517, DOI 10.1111/j.1365-2958.1989.tb00198.x; SLOMIANY BL, 1992, BIOCHEM BIOPH RES CO, V186, P1496, DOI 10.1016/S0006-291X(05)81575-X; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; STRALEY SC, 1991, MICROB PATHOGENESIS, V10, P87, DOI 10.1016/0882-4010(91)90069-M; STRALEY SC, 1993, IN PRESS INFECT IMMU; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TERTTI R, 1992, INFECT IMMUN, V60, P3021, DOI 10.1128/IAI.60.7.3021-3024.1992; TESH VL, 1992, MICROB PATHOGENESIS, V12, P245, DOI 10.1016/0882-4010(92)90043-N; TRANVANNHIEU T, 1991, J BIOL CHEM, V266, P24367; WALKER RI, 1990, ANNU REV MED, V41, P393; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	157	301	308	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					903	920		10.1016/0092-8674(93)90270-Z	http://dx.doi.org/10.1016/0092-8674(93)90270-Z			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500180	Bronze			2022-12-28	WOS:A1993LF06100008
J	GIDDINGS, JC				GIDDINGS, JC			FIELD-FLOW FRACTIONATION - ANALYSIS OF MACROMOLECULAR, COLLOIDAL, AND PARTICULATE MATERIALS	SCIENCE			English	Review							MOLECULAR-WEIGHT DISTRIBUTIONS; SIZE CHARACTERIZATION; THERMAL-DIFFUSION; PARTICLE-SIZE; RIVER WATER; SEDIMENTATION; SEPARATION; CELLS; CHROMATOGRAPHY; PROTEINS	Field-flow fractionation (FFF) is a family of flexible elution techniques capable of simultaneous separation and measurement. Its sample domain extends across a broad macromolecular-colloidal-particulate continuum from about 1 nanometer to more than 100 micrometers and incorporates both simple and complex macromaterials of biological, biomedical, industrial, and environmental relevance. Complex materials are separated into components to simplify measurement. Component properties measurable by FFF include mass, size, density, charge, diffusivity, and thickness of adsorbed layers. When characterization by these properties is inadequate, other measurement tools can be readily coupled to FFF, either off-line or on-line, by virtue of its flow-elution operation. This article describes the principles and major subtechniques of the FFF family along with application of its measurement and separative capabilities.			GIDDINGS, JC (corresponding author), UNIV UTAH, DEPT CHEM, FIELD FLOW FRACTIONAT RES CTR, SALT LAKE CITY, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010851] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM10851-36] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARLAUSKAS RA, 1993, ACS SYM SER, V521, P2; ARNER EC, 1989, BIOCHIM BIOPHYS ACTA, V993, P100, DOI 10.1016/0304-4165(89)90148-7; BARMAN BN, 1989, POWDER TECHNOL, V59, P53, DOI 10.1016/0032-5910(89)80095-6; BARMAN BN, 1992, LANGMUIR, V8, P51, DOI 10.1021/la00037a012; BARMAN BN, IN PRESS ANAL BIOCH; BECKETT R, 1987, ENVIRON TECHNOL LETT, V8, P339, DOI 10.1080/09593338709384493; BECKETT R, 1987, ENVIRON SCI TECHNOL, V21, P289, DOI 10.1021/es00157a010; BECKETT R, 1988, WATER RES, V22, P1535, DOI 10.1016/0043-1354(88)90166-2; BECKETT R, 1990, J CHROMATOGR, V517, P435, DOI 10.1016/S0021-9673(01)95739-5; BECKETT R, 1991, LANGMUIR, V7, P2040, DOI 10.1021/la00058a013; BECKETT R, IN PRESS ENV TECHNOL; BECKETT R, 1989, ACS SYM SER, V219, P65; BECKETT R, 1993, ENV PARTICLES, V2, P157; BENINCASA MA, 1992, ANAL CHEM, V64, P790, DOI 10.1021/ac00031a016; BIGELOW JC, 1991, ACS SYM SER, V464, P146; CALDWELL KD, 1988, ANAL CHEM, V60, pA959, DOI 10.1021/ac00168a001; CALDWELL KD, 1972, SCIENCE, V176, P296, DOI 10.1126/science.176.4032.296; CALDWELL KD, 1981, J PHARM SCI, V70, P1350, DOI 10.1002/jps.2600701216; CALDWELL KD, 1981, COLLOID SURFACE, V3, P233, DOI 10.1016/0166-6622(81)80040-6; CALDWELL KD, 1989, J COLLOID INTERF SCI, V132, P256, DOI 10.1016/0021-9797(89)90235-X; CALDWELL KD, 1984, INVEST OPHTH VIS SCI, V25, P153; CALDWELL KD, 1992, J CHROMATOGR, V604, P63, DOI 10.1016/0021-9673(92)85529-3; CALDWELL KD, 1981, J CHROMATOGR, V215, P323, DOI 10.1016/S0021-9673(00)81411-9; CALDWELL KD, 1980, J VIROL METHODS, V1, P241, DOI 10.1016/0166-0934(80)90022-1; CALDWELL KD, 1984, CELL BIOPHYS, V6, P233, DOI 10.1007/BF02788630; CALDWELL KD, IN PRESS ANAL CHEM; CARDOT PJP, 1991, J CHROMATOGR-BIOMED, V568, P93, DOI 10.1016/0378-4347(91)80343-B; CHASE MW, 1985, J PHYS CHEM REF DATA, V14, P1; CHITTLEBOROUGH DJ, 1992, SOIL SCI, V153, P341, DOI 10.1097/00010694-199205000-00001; Cox R. G., 1977, International Journal of Multiphase Flow, V3, P201, DOI 10.1016/0301-9322(77)90001-5; COX RG, 1968, CHEM ENG SCI, V23, P147, DOI 10.1016/0009-2509(68)87059-9; DAVIS JM, 1991, ANAL CHIM ACTA, V246, P161, DOI 10.1016/S0003-2670(00)80673-X; Giddings J.C., 1989, PHYS METHODS CHEM, P867; Giddings J.C., 1966, SEP SCI, P123, DOI DOI 10.1080/01496396608049439; Giddings J.C., 1991, UNIFIED SEPARATION S; GIDDINGS JC, 1981, SEPAR SCI TECHNOL, V16, P549, DOI 10.1080/01496398108058117; GIDDINGS JC, 1981, ANAL CHEM, V53, P1170, DOI 10.1021/ac00234a001; GIDDINGS JC, 1983, J COLLOID INTERF SCI, V92, P66, DOI 10.1016/0021-9797(83)90117-0; GIDDINGS JC, 1991, ACS SYM SER, V472, P198; GIDDINGS JC, 1991, ACS SYM SER, V464, P128; GIDDINGS JC, 1988, CHEM ENG NEWS, V66, P34, DOI 10.1021/cen-v066n041.p034; GIDDINGS JC, 1976, SCIENCE, V193, P1244, DOI 10.1126/science.959835; GIDDINGS JC, 1987, J CHROMATOGR, V395, P19, DOI 10.1016/S0021-9673(01)94097-X; GIDDINGS JC, 1989, J CHROMATOGR, V480, P21, DOI 10.1016/S0021-9673(01)84277-1; GIDDINGS JC, 1979, SEPAR SCI TECHNOL, V14, P611, DOI 10.1080/01496397908057159; GIDDINGS JC, 1977, ANAL BIOCHEM, V81, P395, DOI 10.1016/0003-2697(77)90710-2; GIDDINGS JC, 1979, PURE APPL CHEM, V51, P1459, DOI 10.1351/pac197951071459; GIDDINGS JC, 1991, ANAL CHEM, V63, P2869, DOI 10.1021/ac00024a013; GIDDINGS JC, 1981, SEPAR SCI TECHNOL, V16, P607, DOI 10.1080/01496398108058119; GIDDINGS JC, 1974, ANAL CHEM, V46, P1917, DOI 10.1021/ac60349a046; GIDDINGS JC, 1976, J CHROMATOGR, V125, P3, DOI 10.1016/S0021-9673(00)93808-1; GIDDINGS JC, 1978, SEPAR SCI TECHNOL, V13, P637, DOI 10.1080/01496397808057119; GIDDINGS JC, 1977, J VIROL, V21, P131, DOI 10.1128/JVI.21.1.131-138.1977; GIDDINGS JC, 1975, SEPAR SCI, V10, P133, DOI 10.1080/00372367508058996; GIDDINGS JC, 1991, KONA POWDER PART J, V9, P200, DOI DOI 10.14356/kona.1991025; GILBART J, 1987, J CHROMATOGR, V387, P428, DOI 10.1016/S0021-9673(01)94548-0; GRUSHKA E, 1973, SEPAR PURIF METHOD, V2, P127, DOI 10.1080/03602547408068793; GUNDERSON JJ, 1984, SEPAR SCI TECHNOL, V19, P667, DOI 10.1080/01496398408060668; HO BP, 1974, J FLUID MECH, V65, P365, DOI 10.1017/S0022112074001431; HOFFSTETTERKUHN S, 1992, ANAL BIOCHEM, V206, P300, DOI 10.1016/0003-2697(92)90370-M; JANCA J, 1983, TRAC-TREND ANAL CHEM, V2, P278, DOI 10.1016/0165-9936(83)87054-X; JONSSON JA, 1989, ANAL CHEM, V61, P11; KARAISKAKIS G, 1982, INT J ENVIRON AN CH, V12, P1, DOI 10.1080/03067318208071566; KIRKLAND JJ, 1983, J CHROMATOGR, V255, P255, DOI 10.1016/S0021-9673(01)88289-3; KIRKLAND JJ, 1992, J CHROMATOGR, V593, P339, DOI 10.1016/0021-9673(92)80303-C; KIRKLAND JJ, 1988, ANAL CHEM, V60, P610, DOI 10.1021/ac00158a002; LANGWOST B, 1992, CHROMATOGRAPHIA, V34, P317, DOI 10.1007/BF02268362; LEVIN S, 1991, BIOMED CHROMATOGR, V5, P133, DOI 10.1002/bmc.1130050308; LI JT, 1991, LANGMUIR, V7, P2034, DOI 10.1021/la00058a012; LITZEN A, 1989, J CHROMATOGR, V476, P413, DOI 10.1016/S0021-9673(01)93885-3; LITZEN A, UNPUB; LIU G, 1992, CHROMATOGRAPHIA, V34, P483, DOI 10.1007/BF02290241; Liu M., UNPUB; LIU MK, IN PRESS MACROMOLECU; LOU J, UNPUB; MARTIN M, 1992, NATO ADV SCI INST SE, V383, P513; MARTIN M, 1980, ANAL CHEM, V52, P2293, DOI 10.1021/ac50064a014; MARTIN M, 1993, ANAL CHEM, V65, pA315, DOI 10.1021/ac00054a722; MARTIN M, 1987, PARTICLE SIZE ANAL 1, P65; MCCARTHY JF, 1989, ENVIRON SCI TECHNOL, V23, P496, DOI 10.1021/es00063a602; MERINODUGAY A, 1992, J CHROMATOGR-BIOMED, V579, P73, DOI 10.1016/0378-4347(92)80364-V; MOON MH, 1992, ANAL CHEM, V64, P3029, DOI 10.1021/ac00047a027; MOON MH, IN PRESS J PHARM BIO; MOZERSKY SM, 1988, ANAL BIOCHEM, V172, P113, DOI 10.1016/0003-2697(88)90419-8; MYERS MN, 1993, ACS SYM SER, V521, P47; MYERS MN, 1982, ANAL CHEM, V54, P2284, DOI 10.1021/ac00250a032; MYERS MN, 1974, SEPAR SCI, V9, P47, DOI 10.1080/01496397408080043; RATANATHANAWONG SK, UNPUB; RATANATHANAWONGS SK, 1992, ANAL CHEM, V64, P6, DOI 10.1021/ac00025a003; RATANATHANAWONGS SK, 1993, ACS SYM SER, V521, P13; RATANATHANAWONGS SK, 1991, ACS SYM SER, V472, P229; SCHALLINGER LE, 1984, SCIENCE, V225, P434, DOI 10.1126/science.6377495; SCHIMPF ME, 1989, J POLYM SCI POL PHYS, V27, P1317, DOI 10.1002/polb.1989.090270610; SCHIMPF ME, 1993, ACS SYM SER, V521, P63; SCHIMPF ME, 1990, J POLYM SCI POL PHYS, V28, P2673, DOI 10.1002/polb.1990.090281313; SCHIMPF ME, 1993, AM LAB SHELTON   FEB, P21; SGIDDINGS JC, 1970, J PHYS CHEM-US, V74, P4291; SHARMA RV, IN PRESS APPL ENV MI; SHIUNDU PM, UNPUB; SINCLAIR P, 1989, HYDROBIOLOGIA, V176, P239, DOI 10.1007/BF00026559; SKLAVIADIS T, 1992, VIRUS RES, V26, P241, DOI 10.1016/0168-1702(92)90016-3; TAYLOR HE, 1992, ANAL CHEM, V64, P2036, DOI 10.1021/ac00042a005; WAHLUND KG, 1989, J CHROMATOGR, V461, P73, DOI 10.1016/S0021-9673(00)94276-6; WILLIAMS PS, 1992, CHEM ENG COMMUN, V111, P121, DOI 10.1080/00986449208935984; WILLIAMS PS, 1987, ANAL CHEM, V59, P2038, DOI 10.1021/ac00144a007; YANG FJ, 1974, ANAL CHEM, V46, P1924, DOI 10.1021/ac60349a009; YANG FS, 1983, J COLLOID INTERF SCI, V93, P115, DOI 10.1016/0021-9797(83)90391-0; YANG FS, 1984, ANAL BIOCHEM, V138, P488, DOI 10.1016/0003-2697(84)90844-3; YONKER CR, 1985, J VIROL METHODS, V11, P145, DOI 10.1016/0166-0934(85)90038-2	109	979	1037	6	305	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1993	260	5113					1456	1465		10.1126/science.8502990	http://dx.doi.org/10.1126/science.8502990			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502990				2022-12-28	WOS:A1993LF05800027
J	HARADA, T; KAGAMIYAMA, H; HATAKEYAMA, K				HARADA, T; KAGAMIYAMA, H; HATAKEYAMA, K			FEEDBACK-REGULATION MECHANISMS FOR THE CONTROL OF GTP CYCLOHYDROLASE-I ACTIVITY	SCIENCE			English	Article							6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; PHENYLALANINE-HYDROXYLASE; INTERFERON-GAMMA; ADRENAL-MEDULLA; NITRIC-OXIDE; RAT STRIATUM; TETRAHYDROBIOPTERIN; BIOPTERIN; COFACTOR; BIOSYNTHESIS	Guanosine triphosphate (GTP) cyclohydrolase I, the rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin (BH4), is subject to feedback inhibition by BH4, a cofactor for phenylalanine hydroxylase. Inhibition was found to depend specifically on BH4 and the presence of another protein (p35). The inhibition occurred through BH4-dependent complex formation between p35 protein and GTP cyclohydrolase I. Furthermore, the inhibition was specifically reversed by phenylalanine, and, in conjunction with p35, phenylalanine reduced the cooperativity of GTP cyclohydrolase I. These findings also provide a molecular basis for high plasma BH4 concentrations observed in patients with hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency.	OSAKA MED COLL, DEPT BIOCHEM, TAKATSUKI, OSAKA 569, JAPAN	Osaka Medical College								ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BECK B, 1983, ACTA PAEDIATR SCAND, V72, P449, DOI 10.1111/j.1651-2227.1983.tb09745.x; BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; COTE LJ, 1975, J NEUROBIOL, V6, P233, DOI 10.1002/neu.480060209; DHONDT JL, 1983, EUR J PEDIATR, V141, P92, DOI 10.1007/BF00496797; GREENGARD O, 1976, BIOCHEM J, V154, P619, DOI 10.1042/bj1540619; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATAKEYAMA K, 1992, J BIOL CHEM, V267, P20734; KAUFMAN S, 1985, BIOCHEM SOC T, V13, P433, DOI 10.1042/bst0130433; KAUFMAN S, 1967, ANNU REV BIOCHEM, V36, P171, DOI 10.1146/annurev.bi.36.070167.001131; KAUFMAN S, 1978, NEW ENGL J MED, V299, P673, DOI 10.1056/NEJM197809282991301; KAUFMAN S, 1982, PEDIATRICS, V70, P376; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KETTLER R, 1974, NATURE, V249, P476, DOI 10.1038/249476a0; KOSHIMURA K, 1990, J NEUROCHEM, V54, P1391, DOI 10.1111/j.1471-4159.1990.tb01974.x; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCINNES RR, 1984, J CLIN INVEST, V73, P458, DOI 10.1172/JCI111232; MILSTIEN S, 1975, J BIOL CHEM, V250, P4777; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIEDERWIESER A, 1982, EUR J PEDIATR, V138, P110, DOI 10.1007/BF00441135; NIEDERWIESER A, 1987, EUR J PEDIATR, V146, P228, DOI 10.1007/BF00716465; PARNIAK MA, 1989, BIOCHEM CELL BIOL, V67, P293, DOI 10.1139/o89-044; SCHOTT K, 1992, EXP CELL RES, V200, P105, DOI 10.1016/S0014-4827(05)80077-1; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; Stadtman E.R., 1970, ENZYMES, V1, P397; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WOLF WA, 1991, J NEUROCHEM, V57, P1191, DOI 10.1111/j.1471-4159.1991.tb08279.x; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; [No title captured]	39	143	146	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1993	260	5113					1507	1510		10.1126/science.8502995	http://dx.doi.org/10.1126/science.8502995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502995				2022-12-28	WOS:A1993LF05800037
J	GIRARD, PM; LANDMAN, R; GAUDEBOUT, C; OLIVARES, R; SAIMOT, AG; JELAZKO, P; GAUDEBOUT, C; CERTAIN, A; BOUE, F; BOUVET, E; LECOMPTE, T; COULAUD, JP				GIRARD, PM; LANDMAN, R; GAUDEBOUT, C; OLIVARES, R; SAIMOT, AG; JELAZKO, P; GAUDEBOUT, C; CERTAIN, A; BOUE, F; BOUVET, E; LECOMPTE, T; COULAUD, JP			DAPSONE PYRIMETHAMINE COMPARED WITH AEROSOLIZED PENTAMIDINE AS PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA AND TOXOPLASMOSIS IN HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS PATIENTS; CEREBRAL TOXOPLASMOSIS; CHEMOPROPHYLAXIS; PREVENTION; SULFAMETHOXAZOLE; AGRANULOCYTOSIS; EFFICACY; TRIAL; VIRUS	Background. Pneumocystis carinii pneumonia and toxoplasmic encephalitis are frequent life-threatening opportunistic infections in patients with human immunodeficiency virus (HIV) infection. Primary prophylaxis against P. carinii pneumonia is now common, but there are few data on regimens for primary prophylaxis against toxoplasmosis. Methods. We conducted a randomized trial that compared two prophylactic regimens: dapsone (50 mg per day) plus pyrimethamine (50 mg per week) was compared with aerosolized pentamidine (300 mg per month). The patients had symptomatic HIV infection, no history of P. carinii pneumonia or symptomatic toxoplasmosis, and CD4+ counts below 200 per cubic millimeter (0.2 x 10(9) per liter). Results. In an intention-to-treat analysis, after a median follow-up of 539 days P. carinii pneumonia developed in 10 patients in each group, whereas toxoplasmosis developed in 32 of 176 patients in the pentamidine group and 19 of 173 patients in the dapsone-pyrimethamine group. Those assigned to pentamidine had a risk of P. carinii pneumonia that was similar to the risk in those assigned to dapsone-pyrimethamine (adjusted relative risk, 1.13; 95 percent confidence interval, 0.44 to 2.92; P = 0.79), but a higher risk of toxoplasmosis (adjusted relative risk, 1.81; 95 percent confidence interval, 1.12 to 2.94; P = 0.02). Among the 262 patients with serologic evidence of past exposure to Toxoplasma gondii, the relative risk of symptomatic toxoplasmosis was 2.37 times higher in those assigned to pentamidine (95 percent confidence interval, 1.3 to 4.4; P = 0.006). More patients discontinued dapsone-pyrimethamine than pentamidine because of toxicity (42 vs. 3; P<0.001). Survival was similar in the two groups. Conclusions. For primary prevention of P. carinii pneumonia, dapsone-pyrimethamine is as effective, though not as well tolerated, as aerosolized pentamidine. Dapsone-pyrimethamine also prevents first episodes of toxoplasmosis.	HOP BICHAT CLAUDE BERNARD,SERV MALAD INFECT & TROP,PARIS,FRANCE; HOP BICHAT CLAUDE BERNARD,THE PHARM,PARIS,FRANCE; HOP ST LOUIS,SERV MALAD INFECT & TROP,F-75010 PARIS,FRANCE; SERV MED INTERNE,CLAMART,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	GIRARD, PM (corresponding author), INSERM,U13,190 BLVD MACDONALD,F-75019 PARIS,FRANCE.							ALLEGRA CJ, 1990, J CLIN INVEST, V85, P371, DOI 10.1172/JCI114448; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; BEVERLEY JKA, 1957, BRIT J PHARM CHEMOTH, V12, P189, DOI 10.1111/j.1476-5381.1957.tb00119.x; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BRUCECHWATT LJ, 1984, BRIT MED J, V288, P65, DOI 10.1136/bmj.288.6410.65-d; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; CLOTET B, 1991, AIDS, V5, P601, DOI 10.1097/00002030-199105000-00024; CLUMECK N, 1991, EUR J CLIN MICROBIOL, V10, P177, DOI 10.1007/BF01964454; COX DR, 1972, J R STAT SOC B, V34, P187; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DEROUIN F, 1991, ANTIMICROB AGENTS CH, V35, P252, DOI 10.1128/AAC.35.2.252; DEROUIN F, 1986, BIOMED PHARMACOTHER, V40, P231; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GIRARD PM, 1989, LANCET, V1, P1348; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HEALD A, 1991, ANN INTERN MED, V115, P760, DOI 10.7326/0003-4819-115-10-760; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HOLLAND GN, 1988, AM J OPHTHALMOL, V106, P653, DOI 10.1016/0002-9394(88)90697-6; HOROWITZ HW, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90649-N; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1984, ANTIMICROB AGENTS CH, V26, P436, DOI 10.1128/AAC.26.4.436; HUGHES WT, 1990, LANCET, V336, P1066, DOI 10.1016/0140-6736(90)92533-N; JACOBSON MA, 1992, LANCET, V339, P333, DOI 10.1016/0140-6736(92)91649-S; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KEMPER CA, 1990, AIDS, V4, P1145, DOI 10.1097/00002030-199011000-00015; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LUCAS CR, 1989, MED J AUSTRALIA, V151, P30, DOI 10.5694/j.1326-5377.1989.tb128450.x; MALLOLAS J, 1991, LANCET, V337, P1162, DOI 10.1016/0140-6736(91)92829-Q; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; MATHERON S, 1990, 6TH INT C AIDS SAN F, V1, P241; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; METROKA CE, 1991, NEW ENGL J MED, V325, P737; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; MURPHY RL, 1991, AM J MED, V90, P418, DOI 10.1016/0002-9343(91)80080-6; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OGNIBENE AJ, 1970, ANN INTERN MED, V72, P521, DOI 10.7326/0003-4819-72-4-521; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POMEROY C, 1992, CLIN INFECT DIS, V14, P863, DOI 10.1093/clinids/14.4.863; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SELIK RM, 1987, AIDS, V1, P175; SLAVIN MA, 1992, AIDS, V6, P1169, DOI 10.1097/00002030-199210000-00017; TSCHIRHART D, 1988, ARCH PATHOL LAB MED, V112, P1237; 1989, MMWR MORB MORTAL S5, V38, P1; 1992, B EPIDEMIOL HEBD, V19, P81; 1989, MMWR MORB MORTAL WKL, V38, P263; 1989, MMWR MORB MORTAL WKL, V38, P256	54	197	200	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1514	1520		10.1056/NEJM199305273282102	http://dx.doi.org/10.1056/NEJM199305273282102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479488	Bronze			2022-12-28	WOS:A1993LC94100002
J	SERIZAWA, H; CONAWAY, JW; CONAWAY, RC				SERIZAWA, H; CONAWAY, JW; CONAWAY, RC			PHOSPHORYLATION OF C-TERMINAL DOMAIN OF RNA POLYMERASE-II IS NOT REQUIRED IN BASAL TRANSCRIPTION	NATURE			English	Article							PREINITIATION COMPLEX; BETA-GAMMA; INITIATION; PURIFICATION; PROMOTER; KINASE; ALPHA; FORM	PHOSPHORYLATION of the heptapeptide repeats in the C-terminal domain (CTD) of the largest subunit of RNA polymerase II has been widely proposed as an essential step in transcription initiation1-8 on the basis of findings indicating (1) that the CTDs of RNA polymerase II molecules actively engaged in transcription are highly phosphorylated4,9,10; (2) that polymerase molecules containing non-phosphorylated CTDs preferentially enter the preinitiation complex3,11,12 where they are subsequently phosphorylated3,13; and (3) that essential initiation factors b from yeast14-16, delta from rat17,18, and BTF2(TFIIH) from human cells19-21 have closely associated CTD-kinase activities. Here we take advantage of a highly purified enzyme system which supports both CTD phosphorylation and basal transcription to test this hypothesis directly. Using the isoquinoline sulphonamide derivative H-8, which is a potent inhibitor of CTD kinase, we show that basal transcription occurs in the absence of CTD phosphorylation.			SERIZAWA, H (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	29	157	159	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					371	374		10.1038/363371a0	http://dx.doi.org/10.1038/363371a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497323				2022-12-28	WOS:A1993LD91700060
J	MAKAROV, VL; LEJNINE, S; BEDOYAN, J; LANGMORE, JP				MAKAROV, VL; LEJNINE, S; BEDOYAN, J; LANGMORE, JP			NUCLEOSOMAL ORGANIZATION OF TELOMERE-SPECIFIC CHROMATIN IN RAT	CELL			English	Article							OXYTRICHA MACRONUCLEAR DNA; RIBOSOMAL-RNA GENES; SACCHAROMYCES-CEREVISIAE; PROTEIN INTERACTIONS; INTERPHASE NUCLEI; BINDING PROTEIN; SEQUENCE; TETRAHYMENA; LOCATION; TERMINI	Rat liver interphase chromosomes have telomeres 20-100 kb in length. Micrococcal nuclease digestion of nuclei cleaves telomeres with a uniform 157 bp periodicity, producing soluble particles that sediment in sucrose gradients exactly like oligonucleosomes. The monomeric telomere particles comigrate with nucleosome core particles on nucleoprotein and DNA gels but do not bind H1. DNAase I cleaves telomere nucleoprotein into a series of bands spaced by about 10.4 bp and with the same intensity distribution as bands from bulk nucleosomes. Removal of H1 from chromatin alters the sedimentation properties of telomeres in parallel with bulk chromatin. Thus, telomeres of mammals are constructed of closely spaced nucleosomes, in contrast with the telomeres of lower eukaryotes, which show no evidence of nucleosomal structure.	UNIV MICHIGAN, GRAD PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL SCI, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MAKAROV, VL (corresponding author), UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [5T32GM07315, GM44403] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUDARF ML, 1986, J BIOL CHEM, V261, P363; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; DANNA JA, 1989, BIOCHEMISTRY-US, V28, P2895, DOI 10.1021/bi00433a022; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; EDWARDS CA, 1984, J MOL BIOL, V180, P73, DOI 10.1016/0022-2836(84)90431-5; FINCH JT, 1975, P NATL ACAD SCI USA, V72, P3320, DOI 10.1073/pnas.72.9.3320; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRUENBAUM Y, 1984, J CELL SCI, P223; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LIU A, 1991, GENE DEV, V5, P4959; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Maniatis T., 1982, MOL CLONING; MAREKOV LN, 1981, ANAL BIOCHEM, V115, P93, DOI 10.1016/0003-2697(81)90529-7; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NOLL H, 1989, METHOD ENZYMOL, V170, P55; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; OMORI A, 1980, NUCLEIC ACIDS RES, V8, P5363, DOI 10.1093/nar/8.22.5363; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; OSIPOVA TN, 1986, MOL BIOL+, V20, P63; PENNINGS S, 1992, NUCLEIC ACIDS RES, V20, P6667, DOI 10.1093/nar/20.24.6667; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; RAWLINS DJ, 1991, CHROMOSOMA, V100, P424, DOI 10.1007/BF00364552; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; van Holde KE., 1989, SPRINGER SERIES MOL; VANDEKKEN H, 1989, J CELL SCI, V94, P299; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; VINCENZ C, 1991, NUCLEIC ACIDS RES, V19, P1325, DOI 10.1093/nar/19.6.1325; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7279, DOI 10.1021/bi00346a039; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	71	155	164	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					775	787		10.1016/0092-8674(93)90256-P	http://dx.doi.org/10.1016/0092-8674(93)90256-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500170	Green Published			2022-12-28	WOS:A1993LD83000015
J	TAKEDA, J; MIYATA, T; KAWAGOE, K; IIDA, Y; ENDO, Y; FUJITA, T; TAKAHASHI, M; KITANI, T; KINOSHITA, T				TAKEDA, J; MIYATA, T; KAWAGOE, K; IIDA, Y; ENDO, Y; FUJITA, T; TAKAHASHI, M; KITANI, T; KINOSHITA, T			DEFICIENCY OF THE GPI ANCHOR CAUSED BY A SOMATIC MUTATION OF THE PIG-A GENE IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	CELL			English	Article							CELL-ADHESION MOLECULE; DECAY-ACCELERATING FACTOR; INSITU HYBRIDIZATION; MEMBRANE ATTACHMENT; PROTEIN-ANCHOR; N-CAM; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; GLYCOPROTEIN; SURFACE	Paroxysmal nocturnal hemoglobinuria is an acquired hematopoietic disease characterized by abnormal blood cell populations in which the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor is deficient. Deficiency of surface expressions of GPI-anchored complement inhibitors leads to complement-mediated hemolysis. Here we report that PIG-A, which participates in the early step of GPI anchor biosynthesis, is the gene responsible for paroxysmal nocturnal hemoglobinuria. Affected granulocytes and B lymphocytes had the same somatic mutation of PIG-A, indicating their clonal origin from a multipotential hematopoietic stem cell. We localized PIG-A to the X chromosome, which accounts for expression of the recessive phenotype of the somatic mutation and the fact that the same one of the multiple biosynthetic steps is affected in all patients so far characterized.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT INTERNAL MED,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,BRANCH HOSP,SCH MED,DEPT INTERNAL MED,NAGOYA 461,JAPAN; FUKUSHIMA MED COLL,DEPT BIOCHEM,FUKUSHIMA 96012,JAPAN	Osaka University; Nagoya University; Fukushima Medical University	TAKEDA, J (corresponding author), OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN.		Miyata, Toshio/A-4872-2010; Kinoshita, Taroh/C-7353-2009					BESSLER M, 1992, BLOOD, V80, P844; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; INOUE N, 1993, IN PRESS J BIOL CHEM, V268; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JOSTEN KM, 1991, BLOOD, V78, P3162; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAHONEY JF, 1992, BLOOD, V79, P1400; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NICHOLSONWELLER A, 1985, NEW ENGL J MED, V312, P1091, DOI 10.1056/NEJM198504253121704; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSSE WF, 1989, BLOOD REV, V3, P192, DOI 10.1016/0268-960X(89)90016-7; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT J, 1990, BLOOD, V76, P1181; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SYMINGTON BE, 1990, J BIOL CHEM, V265, P14069; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1992, INT IMMUNOL, V4, P1263, DOI 10.1093/intimm/4.11.1263; UEDA E, 1989, J IMMUNOL, V143, P1274; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; [No title captured]	52	806	823	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					703	711		10.1016/0092-8674(93)90250-T	http://dx.doi.org/10.1016/0092-8674(93)90250-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500164				2022-12-28	WOS:A1993LD83000009
J	DYNLACHT, BD; WEINZIERL, ROJ; ADMON, A; TJIAN, R				DYNLACHT, BD; WEINZIERL, ROJ; ADMON, A; TJIAN, R			THE DTAF(II)80 SUBUNIT OF DROSOPHILA TFIID CONTAINS BETA-TRANSDUCIN REPEATS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; PROTEIN; GENE; CDC4; COACTIVATORS; EXPRESSION; HOMOLOGY; SEQUENCE; COMPLEX	A KEY component of the RNA polymerase II transcriptional apparatus, TFIID, is a multi-protein complex containing the TATA box-binding protein (TBP) and at least seven tightly associated factors (TAFs)1,2. Although the functions of most TFIID subunits are unknown, it is clear that TAFs are not necessary for basal activity but that one or more are required for regulated transcription, and so behave as coactivators1-4. The presence of multiple subunits indicates that there is an intricate assembly process and that TAFs may be responsible for other activities. We have described the properties of the subunit dTAF(II)110, which can interact directly with the transcriptional activator Sp1 (ref. 5). In addition, the largest subunit, dTAF(II)250, binds directly to TBP and links other TAFs to the complex6. Here we describe the cloning, expression and partial characterization of the Drosophila TAF of M(r) 80,000, dTAF(II)80. Sequence analysis reveals that dTAF(II)80 contains several copies of the WD40 (beta-transducin) repeat7. Moreover, dTAF(II)80 shares extended sequence similarity with an Arabidopsis gene, COP1, which encodes a putative transcription factor that is thought to regulate development8. We have expressed recombinant dTAF(II)80 and begun to characterize its interaction with other members of the TFIID complex. Purified recombinant dTAF(II)80 is unable to bind TBP directly or to interact strongly with the C-terminal domain of dTAF(II)250 (DELTAN250). Instead, dTAF(II)80 is only able to recognize and interact with a higher-order complex containing TBP, DELTAN250, 110 and 60. These findings suggest the formation of TFIID may require an ordered assembly of the TAFs, some of which bind directly to TBP and others that are tethered to the complex as a result of specific TAF/TAF interactions.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley				Admon, Arie/0000-0003-0504-3950				BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DENG ZW, 1992, CELL, V71, P791; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; PETERSON TA, 1984, NATURE, V309, P556, DOI 10.1038/309556a0; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	22	118	122	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					176	179		10.1038/363176a0	http://dx.doi.org/10.1038/363176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483503				2022-12-28	WOS:A1993LB80100052
J	ODONOVAN, A; WOOD, RD				ODONOVAN, A; WOOD, RD			IDENTICAL DEFECTS IN DNA-REPAIR IN XERODERMA-PIGMENTOSUM GROUP-G AND RODENT ERCC GROUP-5	NATURE			English	Article							COMPLEMENTATION GROUP-G; COCKAYNE SYNDROME; CELL-EXTRACTS; GROUP-A; MICROINJECTION; FIBROBLASTS; RADIATION; PROTEIN	HUMANS with the complementation group G form of the inherited syndrome xeroderma pigmentosum (XP) are hypersensitive to solar ultraviolet light because of a defect in nucleotide-excision repair of DNA1-4. Some individuals are also affected with Cockayne's syndrome, and have neurological abnormalities. Here we report that the DNA repair deficiency of XP-G cell extracts can be corrected by addition of protein fractions from normal cells. Repair proficiency can also be restored by mixing XP-G cell extracts with extracts from different repair-defective cell lines, with one exception. Extracts from cells representing group 5 of a set of ultraviolet-sensitive rodent mutants fail to complement XP-G extracts. XP-G and group 5 correcting activities co-elute after approximately 1,000-fold purification from HeLa cells. An antibody directed against a recombinant fragment of the XP-G complementing protein (XPGC) inhibits excision repair by normal cell extracts, and activity can be restored with an XP-G/group 5 complementing fraction. These data strongly suggest that the XPGC and group 5 correcting (ERCC5) proteins are identical.			ODONOVAN, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BARBIS DP, 1986, MUTAT RES, V165, P175, DOI 10.1016/0167-8817(86)90052-0; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; ICHIHASHI M, 1985, J INVEST DERMATOL, V85, P284, DOI 10.1111/1523-1747.ep12276776; JAEKEN J, 1989, HUM GENET, V83, P339; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; RIBONI R, 1992, CANCER RES, V52, P6690; ROBBINS JH, 1991, HUM GENET, V88, P242; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; TAKAHASHI E, 1992, JPN J CANCER RES, V83, P1117, DOI 10.1111/j.1349-7006.1992.tb02731.x; THOMPSON LH, 1987, SOMAT CELL MOLEC GEN, V13, P539, DOI 10.1007/BF01534495; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; WARBURTON D, 1991, CYTOGENET CELL GENET, V58, P1984; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD R, 1992, MUTAT RES, V95, P505; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YAMAIZUMI M, 1986, P NATL ACAD SCI USA, V83, P1476, DOI 10.1073/pnas.83.5.1476	28	111	115	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					185	188		10.1038/363185a0	http://dx.doi.org/10.1038/363185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483505				2022-12-28	WOS:A1993LB80100055
J	SLOANLANCASTER, J; EVAVOLD, BD; ALLEN, PM				SLOANLANCASTER, J; EVAVOLD, BD; ALLEN, PM			INDUCTION OF T-CELL ANERGY BY ALTERED T-CELL-RECEPTOR LIGAND ON LIVE ANTIGEN-PRESENTING CELLS	NATURE			English	Article							UNRESPONSIVENESS; PROLIFERATION; STIMULATION; ACTIVATION; CLONES; RESTIMULATION; MOLECULES; OCCUPANCY; INVITRO; EVENTS	ACTIVATION of CD4+ T helper cells results from the occupancy of the T-cell receptor (TCR) by immunogenic peptide bound to a class II major histocompatibility complex (MHC) molecule1, together with a co-stimulatory signal from the antigen-presenting cell (APC)2. This activation leads to proliferation, cytokine production (Th1 or Th2 profile) and cytolysis3. Engagement of the TCR in the absence of co-stimulation causes Th1 cells to become unresponsive to subsequent antigenic stimulation4-6. We have previously demonstrated that analogues of an immunogenic peptide could stimulate Th1 and Th2 cells to carry out some effector functions without inducing proliferation7,25, a phenomenon we term partial activation. Here we study the consequences of such partial activation through the TCR of two Th1 clones using peptide analogues presented by a live APC. A peptide analogue that is unable to stimulate clonal proliferation or production of cytokine or inositol phosphate can induce the T cells to become profoundly unresponsive to subsequent stimulation with the immunogenic peptide. Thus, altering the ligand of the TCR by using a peptide analogue on a functional APC sends a signal to Th1 clones that results in anergy.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID,ST LOUIS,MO 63110	Washington University (WUSTL)				Evavold, Brian/0000-0002-3561-3494				ALLEN PM, 1984, J IMMUNOL, V132, P1077; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DESILVA DR, 1991, J IMMUNOL, V147, P3261; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, IN PRESS J IMMUN; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KURZINGER K, 1981, J IMMUNOL, V127, P596; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; QUILL H, 1987, J IMMUNOL, V138, P3704; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILDE DB, 1984, J IMMUNOL, V133, P636; WILDE DB, 1984, J IMMUNOL, V132, P1632	26	580	599	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					156	159		10.1038/363156a0	http://dx.doi.org/10.1038/363156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483498				2022-12-28	WOS:A1993LB80100046
J	MCCONNELL, SJ; YAFFE, MP				MCCONNELL, SJ; YAFFE, MP			INTERMEDIATE FILAMENT FORMATION BY A YEAST PROTEIN ESSENTIAL FOR ORGANELLE INHERITANCE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; TRANSFORMATION; TUBULIN; ACTIN	Intermediate filaments are abundant cytoskeletal components whose specific cellular functions are poorly understood. The Saccharomyces cerevisiae protein MDM1 displays structure and solubility properties that are similar to those of intermediate filament proteins of animal cells. Yeast cells that have a mutant form of MDM1 exhibit temperature-sensitive growth and defective transfer of nuclei and mitochondria to daughter cells during incubation at the nonpermissive temperature of 37-degrees-C. The purified, wild-type MDM1 protein readily forms 10-nanometer-wide filaments at either 4-degrees-C or 37-degrees-C. In contrast, the purified, mutant protein forms filaments at 4-degrees-C but fails to form such structures at 37-degrees-C. These results suggest that intermediate filament proteins are universal components of eukaryotic cells.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; DOMINGO A, 1992, P223; FUCHS E, 1991, Current Biology, V1, P284, DOI 10.1016/0960-9822(91)90085-B; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEORGATOS SD, 1989, J CELL BIOL, V108, P2069, DOI 10.1083/jcb.108.6.2069; Goldman R. D., 1990, CELLULAR MOL BIOL IN, P3; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; MCCONNELL SJ, 1992, J CELL BIOL, V118, P385, DOI 10.1083/jcb.118.2.385; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MCCONNELL SK, UNPUB; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; STEINERT P, 1982, METHOD CELL BIOL, V24, P399; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS JH, 1984, MOL BIOL CYTOSKELETO, P153; WANG E, 1978, J CELL BIOL, V79, P708, DOI 10.1083/jcb.79.3.708; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401	24	78	80	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					687	689		10.1126/science.8480179	http://dx.doi.org/10.1126/science.8480179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480179				2022-12-28	WOS:A1993KZ64100036
J	YACHANDRA, VK; DEROSE, VJ; LATIMER, MJ; MUKERJI, I; SAUER, K; KLEIN, MP				YACHANDRA, VK; DEROSE, VJ; LATIMER, MJ; MUKERJI, I; SAUER, K; KLEIN, MP			WHERE PLANTS MAKE OXYGEN - A STRUCTURAL MODEL FOR THE PHOTOSYNTHETIC OXYGEN-EVOLVING MANGANESE CLUSTER	SCIENCE			English	Article							X-RAY ABSORPTION; WATER OXIDATION CENTER; ELECTRON-PARAMAGNETIC RESONANCE; PHOTOSYSTEM-II; CRYSTAL-STRUCTURE; O-2-EVOLVING COMPLEX; MAGNETIC-PROPERTIES; SPLITTING ENZYME; O-2 EVOLUTION; SPECTROSCOPY	In the photosynthetic evolution of oxygen, water oxidation occurs at a catalytic site that includes four manganese atoms together with the essential cofactors, the calcium and chlorine ions. A structural model and a determination of the manganese oxidation states based on x-ray absorption spectroscopy are presented. The salient features, in both higher plants and cyanobacteria, are a pair of di-mu-oxo bridged manganese binuclear clusters linked by a mono-mu-oxo bridge, one proximal calcium atom, and one halide. In dark-adapted samples, manganese occurs in oxidation states (III) and (IV). Data from oriented membranes display distinct dichroism, precluding highly symmetrical structures for the manganese complex.	LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley								BABCOCK GT, 1987, NEW COMPREHENSIVE BI, V15, P125; BASHKIN JS, 1987, J AM CHEM SOC, V109, P6502, DOI 10.1021/ja00255a041; BIANCONI A, 1985, BIOCHEM BIOPH RES CO, V131, P98, DOI 10.1016/0006-291X(85)91775-9; BLUM H, 1978, J MAGN RESON, V30, P385, DOI 10.1016/0022-2364(78)90108-7; BONVOISIN J, 1992, BIOPHYS J, V61, P1076, DOI 10.1016/S0006-3495(92)81917-3; BOSSEK U, 1990, J AM CHEM SOC, V112, P6387, DOI 10.1021/ja00173a031; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; BOUSSAC A, 1988, BIOCHEMISTRY-US, V27, P3476, DOI 10.1021/bi00409a052; BRUDVIG GW, 1986, P NATL ACAD SCI USA, V83, P4586, DOI 10.1073/pnas.83.13.4586; BRUDVIG GW, 1990, ADV EPR APPLICATIONS, P839; BURGHAUS O, 1992, RES PHOTOSYNTHESIS, V2, P109; CHRISTMAS C, 1987, J CHEM SOC CHEM COMM, P1303, DOI 10.1039/c39870001303; CHRISTOU G, 1987, BIOCHIM BIOPHYS ACTA, V895, P259, DOI 10.1016/S0304-4173(87)80005-8; COLE J, 1987, BIOCHIM BIOPHYS ACTA, V890, P395, DOI 10.1016/0005-2728(87)90169-1; COLEMAN WJ, 1990, PHOTOSYNTH RES, V23, P1, DOI 10.1007/BF00030059; CONRADSON SD, 1985, J AM CHEM SOC, V107, P7935, DOI 10.1021/ja00312a022; CORRIE AR, 1990, CURRENT RES PHOTOSYN, V1, P793; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEROSE VJ, 1991, BIOCHEMISTRY-US, V30, P1335, DOI 10.1021/bi00219a025; DEROSE VJ, 1990, LBL29795 U CAL REP; DEXHEIMER SL, 1992, J AM CHEM SOC, V114, P2821, DOI 10.1021/ja00034a010; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; GEORGE GN, 1989, SCIENCE, V243, P789, DOI 10.1126/science.2916124; GHANOTAKIS DF, 1984, FEBS LETT, V167, P127, DOI 10.1016/0014-5793(84)80846-7; GOODIN DB, 1984, BIOCHIM BIOPHYS ACTA, V767, P209, DOI 10.1016/0005-2728(84)90189-0; GUILES RD, 1990, BIOCHEMISTRY-US, V29, P486, DOI 10.1021/bi00454a024; HADDY A, 1992, BIOCHIM BIOPHYS ACTA, V1099, P25, DOI 10.1016/0304-4173(92)90004-X; HANSSON O, 1982, BIOCHIM BIOPHYS ACTA, V679, P261, DOI 10.1016/0005-2728(82)90296-1; HOMANN PH, 1987, J BIOENERG BIOMEMBR, V19, P105, DOI 10.1007/BF00762720; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KUSUNOKI M, 1990, J BIOCHEM-TOKYO, V108, P560, DOI 10.1093/oxfordjournals.jbchem.a123242; KUSUNOKI M, 1992, RES PHOTOSYNTHESIS, V2, P279; MACLACHLAN DJ, 1992, BIOCHEM J, V285, P569, DOI 10.1042/bj2850569; MCDERMOTT AE, 1988, BIOCHEMISTRY-US, V27, P4021, DOI 10.1021/bi00411a019; MCKALE AG, 1988, J AM CHEM SOC, V110, P3763, DOI 10.1021/ja00220a008; Natoli C. R., 1983, SPRINGER SERIES CHEM, V27, P43; ONO T, 1988, FEBS LETT, V227, P147, DOI 10.1016/0014-5793(88)80886-X; ONO T, 1992, SCIENCE, V258, P1335, DOI 10.1126/science.258.5086.1335; ONO T, 1991, BIOCHEMISTRY-US, V30, P6836, DOI 10.1021/bi00242a005; ONO TA, 1990, CURRENT RES PHOTOSYN, V1, P741; PECORARO VL, 1992, MANGANESE REDOX ENZY, P197; PENNERHAHN JE, 1990, J AM CHEM SOC, V112, P2549, DOI 10.1021/ja00163a011; PLAKSIN PM, 1972, J AM CHEM SOC, V94, P2121, DOI 10.1021/ja00761a059; RIGGS JJ, 1992, J AM CHEM SOC, V114, P10650; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; RUTHERFORD AW, 1985, BIOCHIM BIOPHYS ACTA, V807, P189, DOI 10.1016/0005-2728(85)90122-7; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; SANDUSKY PO, 1983, FEBS LETT, V162, P339, DOI 10.1016/0014-5793(83)80784-4; SANDUSKY PO, 1986, BIOCHIM BIOPHYS ACTA, V849, P85, DOI 10.1016/0005-2728(86)90099-X; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SHEATS JE, 1987, J AM CHEM SOC, V109, P1435, DOI 10.1021/ja00239a025; SIVARAJA M, 1989, BIOCHEMISTRY-US, V28, P9459, DOI 10.1021/bi00450a032; STEBLER M, 1986, INORG CHEM, V25, P4743, DOI 10.1021/ic00246a032; VINCENT JB, 1987, J CHEM SOC CHEM COMM, P236, DOI 10.1039/c39870000236; WIEGHARDT K, 1988, J AM CHEM SOC, V110, P7398, DOI 10.1021/ja00230a021; WIEGHARDT K, 1985, J CHEM SOC CHEM COMM, P347, DOI 10.1039/c39850000347; WIEGHARDT K, 1989, ANGEW CHEM INT EDIT, V28, P1153, DOI 10.1002/anie.198911531; WIEGHARDT K, 1987, J CHEM SOC CHEM COMM, P651, DOI 10.1039/c39870000651; WIEGHARDT K, 1983, ANGEW CHEM, V95, P320; WIEGHARDT K, 1986, ANGEW CHEM, V98, P1026; YACHANDRA VK, 1987, BIOCHEMISTRY-US, V26, P5974, DOI 10.1021/bi00393a005; YACHANDRA VK, UNPUB; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; YOCUM CF, 1992, MANGANESE REDOX ENZY, P71; ZHENG M, 1992, RES PHOTOSYNTHESIS, V2, P305	65	436	438	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 30	1993	260	5108					675	679		10.1126/science.8480177	http://dx.doi.org/10.1126/science.8480177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480177				2022-12-28	WOS:A1993KZ64100033
J	BURKE, DP; BOWDEN, DF				BURKE, DP; BOWDEN, DF			MODIFIED PEDIATRIC RESUSCITATION CHART	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine whether a modified paediatric resuscitation reference chart improves the speed and accuracy of calculation of doses of drugs in simulated paediatric cardiopulmonary arrests when compared with the chart devised by Oakley. Design-A prospective study in which a series of randomly assigned questions was used to compare the performance of doctors using the two charts. Setting-Accident and emergency departments in two hospitals. Subjects-31 senior house officers. Main outcome measures-The speed and accuracy of calculation of volumes of drugs to be administered. Results-The modified chart significantly increased the accuracy of the calculations (62/62 v 43/62, p < 0.05), the speed of correct calculations (6.8 s v 36.0 s, p < 0.0001), and the number of calculations that were completed (62/62 v 50/62, p < 0.001). Conclusions-The modified paediatric resuscitation chart should supersede the existing chart.	DUDLEY RD GEN HOSP,DEPT ACCID & EMERGENCY,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		BURKE, DP (corresponding author), ROYAL HOSP WOLVERHAMPTON,DEPT ACCID & EMERGENCY,WOLVERHAMPTON WV2 1BT,ENGLAND.							OAKLEY PA, 1988, BRIT MED J, V297, P817, DOI 10.1136/bmj.297.6652.817	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1096	1098		10.1136/bmj.306.6885.1096	http://dx.doi.org/10.1136/bmj.306.6885.1096			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495154	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500020
J	WADE, OL				WADE, OL			BRITISH NATIONAL FORMULARY - ITS BIRTH, DEATH, AND REBIRTH	BRITISH MEDICAL JOURNAL			English	Article								The British National Formulary is a direct descendant of the National War Formulary, in which the titles of the preparations were in Latin and the doses in minims and grains. The British National Formulary was born in 1948, did a good job for about 20 years, but sickened and died in 1976. It was reborn in 1981. Parturition was painful with a very hostile reception from the media and the drug industry, but it survived and has grown in stature. The 25th edition was published in February. Wish it well for the next 25 issues!										DRURY VMM, 1978, TREATMENT HDB DRUG T; WADE OL, 1992, AVANCES TERAPEUTICA, V16, P204	2	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1051	1054		10.1136/bmj.306.6884.1051	http://dx.doi.org/10.1136/bmj.306.6884.1051			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490505	Green Published, Bronze			2022-12-28	WOS:A1993KY44800029
J	SEVER, P; BEEVERS, G; BULPITT, C; LEVER, A; RAMSAY, L; REID, J; SWALES, J				SEVER, P; BEEVERS, G; BULPITT, C; LEVER, A; RAMSAY, L; REID, J; SWALES, J			MANAGEMENT GUIDELINES IN ESSENTIAL-HYPERTENSION - REPORT OF THE 2ND WORKING PARTY OF THE BRITISH-HYPERTENSION-SOCIETY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE	Several important new issues have arisen in the management of patients with hypertension. A working party of the British Hypertension Society has therefore reviewed available intervention studies on anti-hypertensive treatment and made recommendations on blood pressure thresholds for intervention, on non-pharmacological and pharmacological treatments, and on treatment goals. This report also provides guidelines on blood pressure measurement, essential investigations, referrals for specialist advice, follow up, and stopping treatment.	DUDLEY RD GEN HOSP, DEPT MED, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT GERIATR MED, LONDON W12 0NN, ENGLAND; WESTERN INFIRM & ASSOCIATED HOSP, MRC, BLOOD PRESSURE UNIT, GLASGOW G11 6NT, SCOTLAND; UNIV SHEFFIELD, ROYAL HALLAMSHIRE HOSP, DEPT PHARMACOL & THERAPEUT, SHEFFIELD S10 20JF, ENGLAND; WESTERN INFIRM & ASSOCIATED HOSP, GARDINER INST, DEPT MED & THERAPEUT, GLASGOW G11 6NT, SCOTLAND; LEICESTER ROYAL INFIRM, DEPT MED, LEICESTER LE2 7LX, ENGLAND	Imperial College London; University of Sheffield; University of Glasgow; University of Leicester	SEVER, P (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT CLIN PHARMACOL & THERAPEUT, LONDON W2 1NY, ENGLAND.							[Anonymous], 1991, Arch Intern Med, V151, P1413; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FLETCHER AE, 1992, HYPERTENSION, V19, P499, DOI 10.1161/01.HYP.19.6.499; HAMILTON M, 1964, LANCET, V1, P235; HJEMDAHL P, 1992, J HYPERTENS, V10, P1437, DOI 10.1097/00004872-199210120-00001; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; OBRIEN E, 1991, J HYPERTENS, V9, pS63; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; PICKERING TG, 1991, J HYPERTENS, V9, pS2; PICKERING TG, 1990, J HYPERTENS, V8, pS43; ROSMAN J, 1990, Journal of Drug Development, V3, P129; Stamler J, 1989, Hypertension, V13, pI2; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; 1990, CURRENT SCI, P5; 1985, BMJ, V261, P97; 1991, JAMA-J AM MED ASSOC, V265, P255; 1987, BMJ, V295, P1245; 1992, NUTR METAB, V2, P113; 1989, J HYPERTENS, V7, P689	27	371	372	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	1993	306	6883					983	987		10.1136/bmj.306.6883.983	http://dx.doi.org/10.1136/bmj.306.6883.983			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490481	Green Published, Bronze			2022-12-28	WOS:A1993KX43600026
J	MOORE, L; DIXON, J				MOORE, L; DIXON, J			LESSONS FROM LITHUANIA - RETHINKING PUBLIC-HEALTH TRAINING	BRITISH MEDICAL JOURNAL			English	Article								Lithuania faces stark problems that are familiar to most countries in the former Soviet Union: high morbidity and mortality rates, pollution, an unstable economy, and rapid changes in the financing and organisation of health care. In this environment Moore and Dixon visited Kaunas Medical Academy to help identify how training in public health medicine could contribute towards improving the health of the population. Although over 200 hours are devoted to public health training for medical undergraduates, teaching is unfocused, fragmented, and includes little epidemiology-the core subject for public health physicians. Teaching is mainly through long lectures with few group discussions. Student participation and motivation are low. As well as recommending redesign of the curriculum, Moore and Dixon suggested training in teaching methods for teachers. They also suggested that postgraduate training in public health should begin and should be targeted at hospital managers, teaching staff, and existing public health physicians.			MOORE, L (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							CHEMIAUSKAS G, 1991, PECULIARITIES HLTH C; LOWRY S, 1992, BRIT MED J, V305, P1277, DOI 10.1136/bmj.305.6864.1277; Secretary of State for Social Services, 1988, PUBLIC HLTH ENGLAND; 1989, WORLD HLTH STATISTIC, P27; 1992, LANCET, V341, P210; 1991, LITHUANIA HLTH SECTO; 1992, TEMPUS SCHEME COOPER	7	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					911	914		10.1136/bmj.306.6882.911	http://dx.doi.org/10.1136/bmj.306.6882.911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490421	Green Published, Bronze			2022-12-28	WOS:A1993KW38700029
J	LLOYD, BW; BARNETT, P				LLOYD, BW; BARNETT, P			USE OF PROBLEM LISTS IN LETTERS BETWEEN HOSPITAL DOCTORS AND GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article											LLOYD, BW (corresponding author), N MIDDLESEX HOSP,NHS TRUST,LONDON N18 1QX,ENGLAND.							MUNRO J, 1990, MACLEODS CLIN EXAMIN; Swash M., 1989, HUTCHISONS CLIN METH; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105	3	55	55	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					247	247		10.1136/bmj.306.6872.247	http://dx.doi.org/10.1136/bmj.306.6872.247			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8507242	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100020
J	HOWLAND, J; SMITH, GS; MANGIONE, T; HINGSON, R; DEJONG, W; BELL, N				HOWLAND, J; SMITH, GS; MANGIONE, T; HINGSON, R; DEJONG, W; BELL, N			MISSING THE BOAT ON DRINKING AND BOATING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALCOHOL		BOSTON UNIV,SCH MED,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02118; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHN SNOW RES & TRAINING INST INC,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Boston University; Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health	HOWLAND, J (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,85 E NEWTON ST,BOSTON,MA 02118, USA.			Howland, Jonathan/0000-0001-8079-1188; DeJong, William/0000-0003-4964-0466; Smith, Gordon/0000-0002-2911-3071				FENWICK DC, 1980, BOATMANS BIBLE, P361; GIERTSEN JC, 1970, MED SCI LAW, V10, P216, DOI 10.1177/002580247001000404; GOODEN B, 1984, MED J AUSTRALIA, V141, P478, DOI 10.5694/j.1326-5377.1984.tb132881.x; HOWLAND J, 1990, PUBLIC HEALTH REP, V105, P415; HOWLAND J, 1990, 118TH AM PUBL HLTH A; HOWLAND J, 1992, SECRETARYS NATIONAL; HOWLAND J, 1991, IN PRESS MMWR MORB M; KATKIN ES, 1970, Q J STUD ALCOHOL S, V5, P101; MALONEY ES, 1989, CHAPMAN PILOTING, P46; MANGIONE T, 1992, 120TH AM PUBLIC HLTH; MENGERT P, 1992, CGD0992 REP; PEELER MO, 1990, THESIS J HOPKINS U; ROUSMANIERE J, 1989, ANNAPOLIS BOOK SEAMA, P65; 1978, CG1300375 DEP TRANSP; 1987, BOATING COURSE SAIL; 1992, P167541 US COAST GUA; 1985, NTSBSS8302 TRANSP RE; 1991, AM RED CROSS NATIONA; 1984, ALCOHOL BOATING SURV	19	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					91	92		10.1001/jama.270.1.91	http://dx.doi.org/10.1001/jama.270.1.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510303				2022-12-28	WOS:A1993LK36600030
J	REDELMEIER, DA; ROZIN, P; KAHNEMAN, D				REDELMEIER, DA; ROZIN, P; KAHNEMAN, D			UNDERSTANDING PATIENTS DECISIONS - COGNITIVE AND EMOTIONAL PERSPECTIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREFERENCES; DISGUST; BIAS	Objective.-To describe ways in which intuitive thought processes and feelings may lead patients to make suboptimal medical decisions. Design.-Review of past studies from the psychology literature. Results.-Intuitive decision making is often appropriate and results in reasonable choices; in some situations, however, intuitions lead patients to make choices that are not in their best interests. People sometimes treat safety and danger categorically, undervalue the importance of a partial risk reduction, are influenced by the way in which a problem is framed, and inappropriately evaluate an action by its subsequent outcome. These strategies help explain examples where risk perceptions conflict with standard scientific analyses. In the domain of emotions, people tend to consider losses as more significant than the corresponding gains, are imperfect at predicting future preferences, distort their memories of past personal experiences, have difficulty resolving inconsistencies between emotions and rationality, and worry with an intensity disproportionate to the actual danger. In general, such intangible aspects of clinical care have received little attention in the medical literature. Conclusion.-We suggest that an awareness of how people reason is an important clinical skill that can be promoted by knowledge of selected past studies in psychology.	UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV PENN,PHILADELPHIA,PA 19104; UNIV CALIF BERKELEY,BERKELEY,CA 94720	University of Toronto; University of Pennsylvania; University of California System; University of California Berkeley	REDELMEIER, DA (corresponding author), WELLESLEY COLL HOSP,RES INST,JONES BLDG,ROOM 123,160 WELLESLEY S E,TORONTO M4Y 1J3,ONTARIO,CANADA.							ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; Bell DE, 1988, DECISION MAKING; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; CHRISTENSENSZALANSKI JJJ, 1984, MED DECIS MAKING, V4, P47, DOI 10.1177/0272989X8400400108; DAWSON NV, 1988, MED DECIS MAKING, V8, P259, DOI 10.1177/0272989X8800800406; FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V1, P288, DOI 10.1037/0096-1523.1.3.288; FREDERICKSON BL, IN PRESS J PERS SOC; HARKER LA, 1992, ANN INTERN MED, V116, P731, DOI 10.7326/0003-4819-116-9-731; Hogarth R.M., 1990, INSIGHTS DECISION MA; JAUCHEM JR, 1992, J CLIN EPIDEMIOL, V45, P1137, DOI 10.1016/0895-4356(92)90154-F; KAHNEMAN D, 1991, J ECON PERSPECT, V5, P193, DOI 10.1257/jep.5.1.193; Kassirer JP., 2009, LEARNING CLIN REASON; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; LINVILLE PW, 1991, J PERS SOC PSYCHOL, V60, P5, DOI 10.1037/0022-3514.60.1.5; LLEWELLYNTHOMAS HA, 1992, CAN MED ASSOC J, V147, P859; MCGERVEY J, 1986, PROBABILITIES EVERYD; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MERZ JF, 1990, J LEGAL MED, V11, P321, DOI 10.1080/01947649009510831; MEYEROWITZ BE, 1987, J PERS SOC PSYCHOL, V52, P500, DOI 10.1037/0022-3514.52.3.500; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; OWENS DK, 1992, AM J MED, V92, P503, DOI 10.1016/0002-9343(92)90747-Y; POLAK BCP, 1972, ACTA MED SCAND, V192, P409; REDELMEIER DA, 1992, PSYCHOL SCI, V3, P191, DOI 10.1111/j.1467-9280.1992.tb00025.x; REDELMEIER DA, 1992, MED DECIS MAKING, V12, P338; ROZIN P, 1987, PSYCHOL REV, V94, P23, DOI 10.1037/0033-295X.94.1.23; ROZIN P, 1986, J PERS SOC PSYCHOL, V50, P703, DOI 10.1037/0022-3514.50.4.703; ROZIN P, 1990, CULTURAL PSYCHOL ESS; SIMON H, 1959, MODELS MAN; SLEET DA, 1987, J TRAUMA, V27, P695, DOI 10.1097/00005373-198707000-00001; Sox HC, 1988, MED DECISION MAKING; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TVERSKY A, 1992, PSYCHOL SCI, V3, P358, DOI 10.1111/j.1467-9280.1992.tb00047.x; VISCUSI WK, 1987, RAND J ECON, V18, P465, DOI 10.2307/2555636; WAGENER JJ, 1986, HEALTH PSYCHOL, V5, P481; WILSON DK, 1990, J APPL SOC PSYCHOL, V20, P531, DOI 10.1111/j.1559-1816.1990.tb00426.x; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; [No title captured]; 1991, NEW ENGL J MED, V325, P445	42	403	405	1	69	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					72	76		10.1001/jama.270.1.72	http://dx.doi.org/10.1001/jama.270.1.72			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LK366	8510300				2022-12-28	WOS:A1993LK36600027
J	THIBAULT, GE				THIBAULT, GE			ONE MORE HYPOTHESIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHOLESTEROL EMBOLIZATION; EMBOLISM				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							ARVOLD DS, 1981, MINN MED, V64, P141; Bloom M G, 1972, Minn Med, V55, P1099; CAPPIELLO RA, 1989, SEMIN ARTHRITIS RHEU, V18, P240, DOI 10.1016/0049-0172(89)90044-9; CROSS SS, 1991, J CLIN PATHOL, V44, P859, DOI 10.1136/jcp.44.10.859; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; FISHER ER, 1960, AM J MED, V29, P176, DOI 10.1016/0002-9343(60)90015-2; FLORY CM, 1945, AM J PATHOL, V21, P549; KAPLAN K, 1962, ARCH INTERN MED, V110, P218, DOI 10.1001/archinte.1962.03620200078014; KASSIRER JP, 1969, NEW ENGL J MED, V280, P812, DOI 10.1056/NEJM196904102801506; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; KAUFMAN JL, 1987, SURGERY, V102, P63; LEROY D, 1981, ANN DERMATOL VENER, V108, P665; QUEEN M, 1990, AM J CARDIOL, V65, P1042, DOI 10.1016/0002-9149(90)91014-W; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; SMITH MC, 1981, AM J MED, V71, P174, DOI 10.1016/0002-9343(81)90290-4; VARANASI UR, 1979, J AM GERIATR SOC, V27, P407, DOI 10.1111/j.1532-5415.1979.tb01677.x	16	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					38	42		10.1056/NEJM199307013290108	http://dx.doi.org/10.1056/NEJM199307013290108			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505943				2022-12-28	WOS:A1993LJ33800008
J	ADLER, NE; BOYCE, WT; CHESNEY, MA; FOLKMAN, S; SYME, SL				ADLER, NE; BOYCE, WT; CHESNEY, MA; FOLKMAN, S; SYME, SL			SOCIOECONOMIC INEQUALITIES IN HEALTH - NO EASY SOLUTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SOCIAL-CLASS; RISK-FACTORS; BREAST-CANCER; UNITED-STATES; LIFE EVENTS; SURVIVAL; WOMEN; RACE; SUSCEPTIBILITY	Objective.-Socioeconomic status (SES) is strongly associated with risk of disease and mortality. Universal health insurance is being debated as one remedy for such health inequalities. This article considers mechanisms through which SES affects health and argues that a broader and more comprehensive approach is needed. Data Sources.-Published articles surveyed using MEDLINE and review articles and bibliographies. Methods and Results.-Research is reviewed on the association of SES with health outcomes in different countries, including those with universal health coverage. Socioeconomic status relates to health at all levels of the SES hierarchy, and access to care accounts for little of this association. Other mechanisms are suggested and implications for policy and clinical practice are discussed. Conclusion.-Health insurance coverage alone is not likely to reduce significantly SES differences in health. Attention should be paid both in policy decisions and in clinical practice to other SES-related factors that may influence patterns of health and disease.	UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, SCH PUBL HLTH, DEPT BIOMED & ENVIRONM HLTH SCI, BERKELEY, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	ADLER, NE (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, GRAD PROGRAM HLTH PSYCHOL, 1350 7TH AVE, SAN FRANCISCO, CA 94143 USA.							ADELSTEIN AM, 1980, J TOXICOL ENV HEALTH, V6, P953, DOI 10.1080/15287398009529916; [Anonymous], 1979, HLTH PEOPLE SURGEON; ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; Black D., 1982, INEQUALITIES HLTH BL; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; BUNKER JP, 1989, PATHWAYS HLTH, pR15; BYRNE DG, 1980, PSYCHOSOM MED, V42, P1; Caldwell J. C., 1982, THEORY FERTILITY DEC; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; CAULEY JA, 1991, MED SCI SPORT EXER, V23, P343; Chapin CV, 1924, AM J PUBLIC HEALTH, V14, P647, DOI 10.2105/AJPH.14.8.647-a; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Coombs Lolagene C., 1941, MED CARE, V1, P246; DALEN JE, 1991, ARCH INTERN MED, V151, P860, DOI 10.1001/archinte.151.5.860; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEVESA SS, 1980, JNCI-J NATL CANCER I, V65, P515; DIEHR PK, 1991, MED CARE, V10, P989; DOLL R, 1992, AM J PUBLIC HEALTH, V82, P933, DOI 10.2105/AJPH.82.7.933; Dutton D. B., 1989, PATHWAYS HLTH ROLE S, P29; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P571, DOI 10.1037/0022-3514.50.3.571; FRIEDMAN E, 1991, JAMA-J AM MED ASSOC, V265, P2491, DOI 10.1001/jama.265.19.2491; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P2559, DOI 10.1001/jama.265.19.2559; GOULD JB, 1988, PEDIATRICS, V82, P896; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HAAN M, 1985, REPORT SECRETARYS TA; HAAN MN, 1989, PATHWAYS HLTH ROLE S, P76; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HARBURG E, 1973, J CHRON DIS, V26, P595, DOI 10.1016/0021-9681(73)90064-7; HARLAN LC, 1991, AM J PUBLIC HEALTH, V81, P885, DOI 10.2105/AJPH.81.7.885; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HOUSE JS, 1991, AGING HLTH BEHAVIORS; JAMES SA, 1987, AM J EPIDEMIOL, V126, P664, DOI 10.1093/oxfordjournals.aje.a114706; JEFFERY RW, 1991, INT J OBESITY, V15, P689; KAHN HS, 1991, AM J PUBLIC HEALTH, V81, P319, DOI 10.2105/AJPH.81.3.319; KAPLAN GA, 1986, 114TH ANN M AM PUBL; KESSLER RC, 1986, J HEALTH SOC BEHAV, V27, P107, DOI 10.2307/2136310; KIM KK, 1992, SOC SCI MED, V34, P837, DOI 10.1016/0277-9536(92)90253-M; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LUNDBERG O, 1991, SOC SCI MED, V32, P385, DOI 10.1016/0277-9536(91)90339-E; MARMOT MG, 1978, BMJ-BRIT MED J, V2, P1109, DOI 10.1136/bmj.2.6145.1109; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MCLEOD JD, 1990, J HEALTH SOC BEHAV, V31, P162, DOI 10.2307/2137170; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATNO ME, 1960, PUBLIC HEALTH REP, V75, P841, DOI 10.2307/4590937; RODIN J, 1977, J PERS SOC PSYCHOL, V35, P897, DOI 10.1037/0022-3514.35.12.897; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SOBEL J, 1989, PSYCHOL BULL, V105, P260; Stamler R, 1987, HYPERTENSION, V9, P641; STEINHORN SC, 1986, AM J EPIDEMIOL, V124, P85, DOI 10.1093/oxfordjournals.aje.a114373; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; Susser MW, 1985, SOCIOLOGY MED; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; VAGERO D, 1991, SOC SCI MED, V32, P367, DOI 10.1016/0277-9536(91)90337-C; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; WILHELMSEN L, 1988, AM HEART J, V115, P242, DOI 10.1016/0002-8703(88)90644-8; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WINKELSTEIN W, 1993, JAMA-J AM MED ASSOC, V269, P2504, DOI 10.1001/jama.269.19.2504; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WISE PH, 1988, PEDIATR CLIN N AM, V35, P1169; 1987, SMOKING TOBACCO HLTH	75	708	720	3	105	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3140	3145		10.1001/jama.269.24.3140	http://dx.doi.org/10.1001/jama.269.24.3140			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505817				2022-12-28	WOS:A1993LH14500029
J	FIGDOR, MC; STERN, CD				FIGDOR, MC; STERN, CD			SEGMENTAL ORGANIZATION OF EMBRYONIC DIENCEPHALON	NATURE			English	Article							CHICK-EMBRYO; NEURONAL DEVELOPMENT; NERVOUS-SYSTEM; SOMITE CELLS; EXPRESSION; MOUSE; FOREBRAIN; PATTERN; DROSOPHILA; HINDBRAIN	THE diencephalon is a complex integration centre and intricate relay station of the vertebrate brain1-3. Its development involves the generation of great cellular diversity and neuronal specificity. We report here that it becomes organized in steps, through a stereotyped sequence of neuromeric subdivisions. Diencephalic neuromeres define four cellular domains (D1-D4) that can be followed throughout development, each unit contributing to a well defined part of the adult structural pattern. We propose that the segmental identity of each diencephalic unit is specified by a unique combination of genes4-13, maintained by polyclonal cell lineage restrictions. A comparison of vertebrate and arthropod development suggests that the basic principles that control anterior axial patterning and set up neuronal specificity in the embryonic central nervous system are highly conserved in evolution.	UNIV OXFORD,DEPT HUMAN ANAT,S PARKS RD,OXFORD OX1 3QX,ENGLAND; INST HISTOL & EMBRYOL,A-1090 VIENNA,AUSTRIA	University of Oxford			Stern, Claudio D/C-6265-2008; Stern, Claudio/AAZ-7381-2021	Stern, Claudio D/0000-0002-9907-889X; Stern, Claudio/0000-0002-9907-889X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN J, 1988, J COMP NEUROL, V275, P346, DOI 10.1002/cne.902750304; [Anonymous], 1966, STUDIES DIENCEPHALON; Ariens Kappers C. N., 1960, COMP ANATOMY NERVOUS; BATE CM, 1981, J EMBRYOL EXP MORPH, V61, P317; BERGQUIST H, 1964, PROGR BRAIN RES, V5, P223; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; COOPER NGF, 1986, J COMP NEUROL, V249, P157, DOI 10.1002/cne.902490204; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; KEYSER AJM, 1972, ACTA ANAT        S59, V83, P1; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; LAWRENCE PA, 1990, NATURE, V344, P382, DOI 10.1038/344382a0; LAYER PG, 1990, DEVELOPMENT, V109, P613; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGREW LL, 1992, DEVELOPMENT, V115, P463; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RENDAHL H, 1924, ACTA ZOOLOGICA, V5, P119; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Sarnat H. B., 1981, EVOLUTION NERVOUS SY, V2nd; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STERN CD, 1986, J EMBRYOL EXP MORPH, V91, P209; STERN CD, 1987, DEVELOPMENT, V99, P261; STERN CD, 1988, DEVELOPMENT, V104, P231; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VAAGE S, 1969, SEGMENTATION PRIMITI; VONKUPFFER K, 1906, HDB VERGLEICHENDEN E, V2; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	37	369	371	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					630	634		10.1038/363630a0	http://dx.doi.org/10.1038/363630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510755				2022-12-28	WOS:A1993LH13900057
J	CLEMETSON, DBA; MOSS, GB; WILLERFORD, DM; HENSEL, M; EMONYI, W; HOLMES, KK; PLUMMER, F; NDINYAACHOLA, J; ROBERTS, PL; HILLIER, S; KREISS, JK				CLEMETSON, DBA; MOSS, GB; WILLERFORD, DM; HENSEL, M; EMONYI, W; HOLMES, KK; PLUMMER, F; NDINYAACHOLA, J; ROBERTS, PL; HILLIER, S; KREISS, JK			DETECTION OF HIV DNA IN CERVICAL AND VAGINAL SECRETIONS - PREVALENCE AND CORRELATES AMONG WOMEN IN NAIROBI, KENYA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HETEROSEXUAL TRANSMISSION; INFECTION; RISK; FEMALE; TYPE-1; ASSOCIATION; ECTOPY; SEMEN	Objective.-Factors that influence heterosexual transmission of the human immunodeficiency virus (HIV), including sexually transmitted diseases, contraceptive practices, sexual practices, HIV-related immunosuppression, and presence of cervical ectopy and the penile foreskin, have been identified through cross-sectional and prospective cohort epidemiologic studies. To more directly characterize factors that influence infectivity, we conducted a study of HIV shedding from the genital tract in women. Design.-Ninety-seven HIV-seropositive women attending a sexually transmitted disease clinic in Nairobi, Kenya, completed a questionnaire and underwent a physical examination and an evaluation for sexually transmitted diseases. Cervical and vaginal secretions were obtained for HIV DNA detection using polymerase chain reaction amplification. Results.-Human immunodeficiency virus DNA was detected by polymerase chain reaction in 28 (33%) of 84 cervical samples and 13 (17%) of 77 vaginal samples. The prevalence of H IV was higher in specimens from the endocervix than from the vaginal wall (P=.002), and there was no correlation between presence of virus at the two sites. After adjusting for age, cervical HIV shedding was independently associated with oral contraceptive pill use (odds ratio [OR], 11.6; 95% confidence interval [CI], 1.7 to 77.6), cervical mucopus (OR, 6.2; 95% CI, 0.9 to 41.4; P=.05), cervical ectopy (OR, 5.0; 95% CI, 1.5 to 16.9), and pregnancy (OR, 4.5; 95% CI, 1.2 to 16.3). Conclusions.-Human immunodeficiency virus was detected in one third of cervical samples and one sixth of vaginal samples. The presence of HIV DNA in cervical secretions was significantly associated with oral contraceptive pill use, cervical ectopy, and pregnancy. There was a marginally significant association with cervical mucopus. The identification of factors that increase the infectivity of women suggests potential strategies for reducing heterosexual transmission of HIV.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; UNIV NAIROBI, DEPT MED MICROBIOL, NAIROBI, KENYA; UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Nairobi; University of Manitoba			, Holmes/K-6215-2019					ANDERSON D, 1990, 6TH INT C AIDS SAN F; ANDERSON DJ, 1990, CONRAD W S, P167, DOI 10.1017/CBO9780511666582.008; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; [Anonymous], 1992, BMJ, V304, P809; CAMERON DW, 1989, LANCET, V2, P403; DAVEY DA, 1986, DEWHURSTS TXB OBSTET, P126; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOLDACRE MJ, 1978, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6115.748; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; KRONE WJA, 1990, J ACQ IMMUN DEF SYND, V3, P517; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; LOUV WC, 1989, AM J OBSTET GYNECOL, V160, P396, DOI 10.1016/0002-9378(89)90456-0; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PIOT P, 1990, SCAND J INFECT DIS, P89; PLOURDE PJ, 1991, 1ST HAEM DUCR S INT; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POLITCH J, 1991, 7TH INT C AIDS FLOR; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; SCHUURS AHWM, 1990, J STEROID BIOCHEM, V35, P157, DOI 10.1016/0022-4731(90)90270-3; SINGER A, 1976, CERVIX, P105; STYRT B, 1991, REV INFECT DIS, V13, P1139; VOGT MW, 1987, ANN INTERN MED, V106, P380, DOI 10.7326/0003-4819-106-3-380; VOGT MW, 1986, LANCET, V1, P525; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WOFSY CB, 1986, LANCET, V1, P527; 1992, CURRENT FUTURE DIMEN	33	224	231	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2860	2864		10.1001/jama.269.22.2860	http://dx.doi.org/10.1001/jama.269.22.2860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497089				2022-12-28	WOS:A1993LE93600021
J	KESSLER, DA				KESSLER, DA			INTRODUCING MEDWATCH - A NEW APPROACH TO REPORTING MEDICATION AND DEVICE ADVERSE-EFFECTS AND PRODUCT PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											KESSLER, DA (corresponding author), US FDA,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							BEARD K, 1992, DRUG AGING, V2, P356, DOI 10.2165/00002512-199202040-00008; BOLGER G, 1992, American Pharmacy, V32, P47; DUNN KW, 1992, BRIT J PLAST SURG, V45, P315, DOI 10.1016/0007-1226(92)90060-B; GELB LN, 1993, FDA MED B, V23, P7; GELB LN, 1992, FDA MED B, V22, P2; GRIFFIN JP, 1986, ADVERSE DRUG REACT, V1, P23; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; JOHNSON JM, 1991, FOOD DRUG LAW J, V46, P665; KENNEDY DL, 1991, JAMA-J AM MED ASSOC, V266, P2878; NIERENBERG DW, 1986, CLIN PHARMACOL THER, V40, P483, DOI 10.1038/clpt.1986.212; Nightingale S L, 1990, JAMA, V264, P2863; PECK CC, 1993, JAMA-J AM MED ASSOC, V269, P1550, DOI 10.1001/jama.269.12.1550; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; RHEINSTEIN PH, 1992, AM FAM PHYSICIAN, V46, P873; ROSSI AC, 1988, JAMA-J AM MED ASSOC, V259, P1203, DOI 10.1001/jama.259.8.1203; Scott H D, 1987, R I Med J, V70, P311; STEHLIN D, 1992, FDA CONSUM, V26, P17; 1993, ACCREDITATION MANUAL; 1991, 6002460039 FOOD DRUG	19	230	233	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2765	2768		10.1001/jama.269.21.2765	http://dx.doi.org/10.1001/jama.269.21.2765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492403				2022-12-28	WOS:A1993LD67100027
J	HEALY, B				HEALY, B			DOES VASECTOMY CAUSE PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH, BLDG 31, ROOM 2B19, BETHESDA, MD 20892 USA.							1993, JAMA-J AM MED ASSOC, V269, P878; IN PRESS EUR J CANCE; 1993, J CLIN EPIDEMIOL, V46, P163; 1990, AM J EPIDEMIOL, V132, P1062; 1993, JAMA-J AM MED ASSOC, V269, P873; 1993, AM J EPIDEMIOL, V137, P263; 1991, CANCER CAUSE CONTROL, V2, P113; 1993, JAMA-J AM MED ASSOC, V269, P913; 1990, AM J EPIDEMIOL, V132, P1051	9	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2620	2620		10.1001/jama.269.20.2620	http://dx.doi.org/10.1001/jama.269.20.2620			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487436				2022-12-28	WOS:A1993LC86500010
J	LEWIN, JC; SYBINSKY, PA				LEWIN, JC; SYBINSKY, PA			HAWAII EMPLOYER MANDATE AND ITS CONTRIBUTION TO UNIVERSAL ACCESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Much national debate centers around national models in which an employer mandate plays an important role in providing for health care coverage for all Americans. Hawaii has had the nation's only health insurance employer mandate for almost 20 years, yet little is known nationally about the mandate itself or Hawaii's experience with it. This article describes the long-term effects of Hawaii's employer mandate on health care access and costs, and offers reflections on the potentials of national health care reform based on Hawaii's experience.			LEWIN, JC (corresponding author), DEPT HLTH,1250 PUNCHBOWL ST,HONOLULU,HI 96813, USA.							FRIEDMAN EA, 1993, ALOHA WAY HLTH CARE; NAKAMURA A, 1981, RES STATISTICS REPOR; RIESENFELD SA, 1971, PREPAID HLTH CARE HA; SCHWARTZ K, 1990, J HLTH POLIT POLICY, V15, P779; SIEGEL PZ, 1991, MMWR-MORBID MORTAL W, V55, P1; STENSON RV, 1992, HAWAII MED J, V51, P14; VANSTEENYWK J, 1978, EVALUATION IMPACT HA; ZEDLEWSKI SR, 1992, PAY PLAY EMPLOYER MA; 1992, HAWAII HLTH CARE SUR; 1989, POLICY WORKING PAPER; 1992, AM PUBLIC HLTH REPOR; 1992, MEASURING UNINSURED; 1992, CONSUM REP, V57, P530; 1993, UNIVERSAL HEALTHCARE; 1992, HAWAI HLTH PROFILE 1, P2; 1992, HAWAII HLTH PROFILE, P20; 1987, MED INDIGENT HAWAII; 1991, NW NATIONAL LIFE STA	18	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2538	2543		10.1001/jama.269.19.2538	http://dx.doi.org/10.1001/jama.269.19.2538			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487419				2022-12-28	WOS:A1993LB45000035
J	MULLIGAN, RC				MULLIGAN, RC			THE BASIC SCIENCE OF GENE-THERAPY	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; BETA-GLOBIN GENE; EXPRESSION; INVIVO; LONG; DELIVERY; VIRUS; LUNG; 5-FLUOROURACIL; INHIBITION	The development over the past decade of methods for delivering genes to mammalian cells has stimulated great interest in the possibility of treating human disease by gene-based therapies. However, despite substantial progress, a number of key technical issues need to be resolved before gene therapy can be safely and effectively applied in the clinic. Future technological developments, particularly in the areas of gene delivery and cell transplantion, will be critical for the successful practice of gene therapy.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	MULLIGAN, RC (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.							ANACHINI A, 1987, IMMUNOL TODAY, V8, P305; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BENDER MA, 1989, MOL CELL BIOL, V9, P1426, DOI 10.1128/MCB.9.4.1426; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; BREAKEFIELD XO, 1992, NEW BIOL, V53, P230; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CHATTERJEE S, 1992, SCIENCE, V258, P1485, DOI 10.1126/science.1359646; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CORNETTA K, 1990, HUM GENE THER, V1, P15, DOI 10.1089/hum.1990.1.1-15; CORRELL PH, 1992, BLOOD, V80, P331; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; DRANOFF G, IN PRESS P NATL ACAD; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FENJVES ES, 1989, P NATL ACAD SCI USA, V86, P8803, DOI 10.1073/pnas.86.22.8803; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; FRIEDMANN T, 1992, CANCER, V70, P1810, DOI 10.1002/1097-0142(19920915)70:4+<1810::AID-CNCR2820701624>3.0.CO;2-3; GAGE FH, 1991, TRENDS NEUROSCI, V14, P328, DOI 10.1016/0166-2236(91)90156-O; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GROSFELD F, 1987, CELL, V48, P957; HARRISON DE, 1991, BLOOD, V78, P1237; HAZINSKI TA, 1991, AM J RESP CELL MOL, V4, P206, DOI 10.1165/ajrcmb/4.3.206; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HORWITZ MC, 1990, VIROLOGY, pCH60; HUGHES PFD, 1992, J CLIN INVEST, V89, P1817, DOI 10.1172/JCI115786; HUGHES PFD, 1989, BLOOD, V78, P2481; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; JOHNSON PA, 1992, J VIROL, V66, P2952, DOI 10.1128/JVI.66.5.2952-2965.1992; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; KORNELUK RG, 1989, GENOMICS, V4, P146, DOI 10.1016/0888-7543(89)90293-0; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KRAUSS JC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P193, DOI 10.1016/0304-419X(92)90015-Q; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209; LYNCH CM, 1992, P NATL ACAD SCI USA, V89, P1138, DOI 10.1073/pnas.89.3.1138; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MILLER AD, 1990, BLOOD, V76, P271; MITANI K, 1993, HUM GENE THER, V4, P9, DOI 10.1089/hum.1993.4.1-9; MORGAN JR, 1987, SCIENCE, V237, P1476; MORGAN RA, 1990, AIDS RES HUM RETROV, V6, P183, DOI 10.1089/aid.1990.6.183; MOULLIER P, IN PRESS NAT GENET; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULLIGAN RC, 1991, NOBEL SYMP, V80, P143; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NOVAK U, 1990, P NATL ACAD SCI USA, V87, P3386, DOI 10.1073/pnas.87.9.3386; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; ORY D, UNPUB; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PLAVEC I, 1993, BLOOD, V81, P1384; PODDA S, 1992, P NATL ACAD SCI USA, V89, P9676, DOI 10.1073/pnas.89.20.9676; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAMESH N, 1993, HUM GENE THER, V4, P3, DOI 10.1089/hum.1993.4.1-3; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; ROE TY, IN PRESS EMBO J; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; ROSSI JJ, 1992, ADV EXP MED BIOL, V312, P95; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHUENING FG, 1991, BLOOD, V78, P2568; SHENK T, 1979, COLD SPRING HARB SYM, V44, P367, DOI 10.1101/SQB.1980.044.01.041; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; STRATFORDPERRICAUDET LD, 1992, BONE MARROW TRANSPL, V9, P151; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SZILVASSY SJ, 1989, P NATL ACAD SCI USA, V86, P8798, DOI 10.1073/pnas.86.22.8798; VACANTI J, 1991, SCIENCE, V254, P1802; VALENTINE RC, 1965, J MOL BIOL, V13, P13, DOI 10.1016/S0022-2836(65)80076-6; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1991, J BIOL CHEM, V266, P14338; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; 1993, MAR P NIH REC ADV CO	107	1502	2161	8	300	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					926	932		10.1126/science.8493530	http://dx.doi.org/10.1126/science.8493530			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493530				2022-12-28	WOS:A1993LB79100032
J	DELAMOTHE, T				DELAMOTHE, T			THE NEW NHS - THE 2ND YEAR - EAST-BIRMINGHAM - ALL CHANGE	BRITISH MEDICAL JOURNAL			English	Article																		DELAMOTHE T, 1992, BRIT MED J, V304, P1109, DOI 10.1136/bmj.304.6834.1109; DELAMOTHE T, 1991, BRIT MED J, V303, P842, DOI 10.1136/bmj.303.6806.842; DELAMOTHE T, 1991, BRIT MED J, V302, P714, DOI 10.1136/bmj.302.6778.714; WILSON F, 1993, NEWS REV         APR	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1255	1258		10.1136/bmj.306.6887.1255	http://dx.doi.org/10.1136/bmj.306.6887.1255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499858	Green Published, Bronze			2022-12-28	WOS:A1993LB80400022
J	VEEKEN, H				VEEKEN, H			LETTER FROM PERU - A COUNTRY TORN APART BY VIOLENCE	BRITISH MEDICAL JOURNAL			English	Article											VEEKEN, H (corresponding author), MED FRONTIERES,POB 10014,1001 EA AMSTERDAM,NETHERLANDS.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1263	1264		10.1136/bmj.306.6887.1263	http://dx.doi.org/10.1136/bmj.306.6887.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB804	8499861	Bronze, Green Published			2022-12-28	WOS:A1993LB80400026
J	FEIG, LA				FEIG, LA			THE MANY ROADS THAT LEAD TO RAS	SCIENCE			English	Editorial Material							GUANINE-NUCLEOTIDE EXCHANGE; CYCLASE PATHWAY; PROTEIN; CEREVISIAE; PRODUCT; CDC25				FEIG, LA (corresponding author), TUFTS UNIV,SCH MED,SACKLER SCH GRAD BIOMED SCI,DEPT BIOCHEM,136 HARRISON AVE,BOSTON,MA 02111, USA.							BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, IN PRESS SCIENCE; CICCHETTI P, 1992, NATURE, V257, P803; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100	28	186	192	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					767	768		10.1126/science.8484117	http://dx.doi.org/10.1126/science.8484117			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484117				2022-12-28	WOS:A1993LA74400018
J	THIBODEAU, SN; BREN, G; SCHAID, D				THIBODEAU, SN; BREN, G; SCHAID, D			MICROSATELLITE INSTABILITY IN CANCER OF THE PROXIMAL COLON	SCIENCE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISMS; COLORECTAL-CARCINOMA; GENE-MUTATIONS; SOMATIC CHANGES; POLYPOSIS-COLI; ALLELIC LOSS; DNA; IDENTIFICATION; LOCUS	Colorectal tumor DNA was examined for somatic instability at (CA)n repeats on human chromosomes 5q, 15q, 17p, and 18q. Differences between tumor and normal DNA were detected in 25 of the 90 (28 percent) tumors examined. This instability appeared as either a substantial change in repeat length (often heterogeneous in nature) or a minor change (typically two base pairs). Microsatellite instability was significantly correlated with the tumor's location in the proximal colon (P = 0.003), with increased patient survival (P = 0.02), and, inversely, with loss of heterozygosity for chromosomes 5q, 17p, and 18q. These data suggest that some colorectal cancers may arise through a mechanism that does not necessarily involve loss of heterozygosity.			THIBODEAU, SN (corresponding author), MAYO CLIN & MAYO FDN,MOLEC GENET LAB,970 HILTON BLDG,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER; NCI NIH HHS [CA-15083-18E8.1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; ASTLER VB, 1954, ANN SURG, V139, P846, DOI 10.1097/00000658-195406000-00015; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOLTZ EM, 1990, BRIT J CANCER, V62, P23, DOI 10.1038/bjc.1990.222; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DELATTRE O, 1989, LANCET, V2, P353; ERISMAN MD, 1988, ONCOGENE, V2, P367; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEY MF, 1988, J CLIN INVEST, V82, P1532, DOI 10.1172/JCI113762; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAGODA PJL, 1989, HUM GENET, V84, P35, DOI 10.1007/BF00210667; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LITT M, 1989, AM J HUM GENET, V44, P397; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MATSUMURA Y, 1992, CANCER RES, V52, P2174; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; Rousseau Francois, 1992, Human Mutation, V1, P91, DOI 10.1002/humu.1380010202; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; THIBODEAU SN, UNPUB; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4035, DOI 10.1093/nar/18.13.4035; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2201; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	38	2752	2853	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					816	819		10.1126/science.8484122	http://dx.doi.org/10.1126/science.8484122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484122				2022-12-28	WOS:A1993LA74400033
J	ROBERTS, WM				ROBERTS, WM			SPATIAL CALCIUM BUFFERING IN SACCULAR HAIR-CELLS	NATURE			English	Article							BINDING PROTEIN; TRANSMITTER RELEASE; RANA-CATESBEIANA; ACTIVE ZONES; BULL-FROG; DIFFUSION; LOCALIZATION; SELECTIVITY; TRANSPORT; IONS	THE potential importance of intracellular calcium-binding proteins in rapid and highly localized Ca2+ signalling is poorly understood. During fast synaptic transmission, which occurs at specialized active zones where Ca2+ diffuses only a few tens of nanometres from channels to neurotransmitter release sites1, a cytoplasmic Ca2+ buffer would have to be extremely fast or present in millimolar concentrations to intercept a significant fraction of the calcium ions en route to their targets2-5. Therefore, Ca2+ buffers have been presumed to be unimportant in fast exocytosis1,6,7 and another fast calcium-mediated process, electrical resonance in hair cells4,8. Here I present evidence to the contrary by showing that hair cells in the frog sacculus contain millimolar concentrations of a mobile cytoplasmic calcium buffer that captures Ca2+ within a few microseconds after it enters through presynaptic Ca2+ channels and carries it away from the point of entry. This spatial buffering reduces the presynaptic free Ca2+ by up to 60 per cent and probably restricts the region in which the internal calcium ion concentration exceeds 1 muM to within <250 nm of each synaptic site. The buffer can thus influence both electrical resonance and synaptic transmission. Calbindin-D28K or a related protein may serve as the mobile calcium buffer, an action similar to its function in transporting Ca2+ across intestinal epithelial cells.			ROBERTS, WM (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.			Roberts, William/0000-0001-9762-4255				ADLER EM, 1991, J NEUROSCI, V11, P1496; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; Conner J.A., 1982, Lectures on Mathematics in the Life Sciences, V15, P79; DECHESNE CJ, 1988, HEARING RES, V33, P273, DOI 10.1016/0378-5955(88)90157-8; FEHER JJ, 1989, CELL CALCIUM, V10, P189, DOI 10.1016/0143-4160(89)90002-X; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; FETTIPLACE R, 1987, TRENDS NEUROSCI, V10, P421, DOI 10.1016/0166-2236(87)90013-0; GILLESPIE PG, 1991, J CELL BIOL, V112, P625, DOI 10.1083/jcb.112.4.625; HEHER E, 1992, J PHYSL, V450, P273; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P237, DOI 10.1113/jphysiol.1988.sp017119; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P275, DOI 10.1113/jphysiol.1988.sp017120; Korn S.J., 1991, METHODS NEUROSCIENCE, VVolume 4, P364; KUTCHAI H, 1970, BIOPHYS J, V10, P38, DOI 10.1016/S0006-3495(70)86284-1; LEATHERS VL, 1990, J BIOL CHEM, V265, P9838; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Neher E., 1986, EXPT BRAIN RES SERIE, P80; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; ROBERTS W M, 1991, Society for Neuroscience Abstracts, V17, P1486; ROBERTS W M, 1992, Biophysical Journal, V61, pA142; ROBERTS WM, 1991, ANN NY ACAD SCI, V635, P221, DOI 10.1111/j.1749-6632.1991.tb36494.x; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SHEPHERD GMG, 1989, P NATL ACAD SCI USA, V86, P4973, DOI 10.1073/pnas.86.13.4973; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018	28	234	236	0	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 6	1993	363	6424					74	76		10.1038/363074a0	http://dx.doi.org/10.1038/363074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479539				2022-12-28	WOS:A1993LA68200062
J	BICKLER, G; SUTTON, S				BICKLER, G; SUTTON, S			INACCURACY OF FHSA REGISTERS - HELP FROM ELECTORAL REGISTERS	BRITISH MEDICAL JOURNAL			English	Article							POPULATION		INST PSYCHIAT,ICRF,HLTH BEHAV UNIT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	BICKLER, G (corresponding author), SE LONDON HLTH AUTHOR,LONDON SE1 9RY,ENGLAND.			Sutton, Stephen/0000-0003-1610-0404; Bickler, Graham/0000-0001-8935-2368				BOWLING A, 1989, BRIT MED J, V298, P545, DOI 10.1136/bmj.298.6673.545; BOWLING A, 1989, J EPIDEMIOL COMMUN H, V43, P391, DOI 10.1136/jech.43.4.391; MCEWEN J, 1989, BRIT MED J, V299, P104, DOI 10.1136/bmj.299.6691.104; SILMAN AJ, 1984, BRIT MED J, V289, P415, DOI 10.1136/bmj.289.6442.415; 1992, CERVICAL BREAST SCRE	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1167	1167		10.1136/bmj.306.6886.1167	http://dx.doi.org/10.1136/bmj.306.6886.1167			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499818	Green Published, Bronze			2022-12-28	WOS:A1993LA68500021
J	PARSONS, WL; GODWIN, M; ROBBINS, C; BUTLER, R				PARSONS, WL; GODWIN, M; ROBBINS, C; BUTLER, R			PREVALENCE OF CERVICAL PATHOGENS IN WOMEN WITH AND WITHOUT INFLAMMATORY CHANGES ON SMEAR TESTING	BRITISH MEDICAL JOURNAL			English	Article							CHLAMYDIA-TRACHOMATIS INFECTION	Objective-To assess correlation between nonspecific cervicitis, inflammation, or exudate on cervical smears tests and confirmed presence of known cervical pathogens. Design-Investigation of women attending a family practice clinic for smear test by microbiological screening for Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum Trichomonas vaginalis, Candida species, group B streptococcus, Gardnerella vaginalis, and Neisseria gonorrhoeae. Setting-Family practice teaching clinic in a university hospital. Patients-411 women presenting for a smear test. Main outcome measures-Prevalence of genital infections associated with presence or absence of inflammatory changes on cervical smear. Results-Of the 132 women with inflammatory changes on cervical smear, 64 (48%) had positive cultures. Of the 248 without inflammatory changes, 117 (47%) had positive cultures. Subgroup analysis on individual organisms also showed no significant difference between the two groups. Conclusion-Reports of inflammatory changes on cervical smear testing are a poor indicator of infection.			PARSONS, WL (corresponding author), MEM UNIV NEWFOUNDLAND,HLTH SCI CTR,FAMILY PRACTICE UNIT,ST JOHNS A1B 3V6,NEWFOUNDLAND,CANADA.							ADDISS DG, 1987, FAM PLANN PERSPECT, V19, P252, DOI 10.2307/2135105; Bertolino J G, 1992, Fam Med, V24, P447; BOWIE WR, 1981, CAN MED ASSOC J, V124, P1477; DORMAN SA, 1983, AM J CLIN PATHOL, V79, P421, DOI 10.1093/ajcp/79.4.421; EMBIL JA, 1985, CAN MED ASSOC J, V138, P34; GEERLING S, 1985, ACTA CYTOL, V29, P671; KELLY BA, 1990, BRIT J GEN PRACT, V40, P238; KIVIAT NB, 1985, JAMA-J AM MED ASSOC, V253, P989, DOI 10.1001/jama.253.7.989; Koss L.G., 1992, DIAGNOSTIC CYTOLOGY; MASSE R, 1991, CAN MED ASSOC J, V145, P953; SHAFER MA, 1985, AM J OBSTET GYNECOL, V151, P765, DOI 10.1016/0002-9378(85)90516-2; SMITH JR, 1991, BRIT MED J, V302, P82, DOI 10.1136/bmj.302.6768.82; SMITH TF, 1977, HEALTH LAB SCI, V14, P30; WEISMEIER E, 1987, J REPRODUCT MED, V32, P251; WILSON JD, 1990, BRIT MED J, V300, P638, DOI 10.1136/bmj.300.6725.638	15	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1173	1174		10.1136/bmj.306.6886.1173	http://dx.doi.org/10.1136/bmj.306.6886.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499824	Green Published, Bronze			2022-12-28	WOS:A1993LA68500028
J	CLARKE, AR; PURDIE, CA; HARRISON, DJ; MORRIS, RG; BIRD, CC; HOOPER, ML; WYLLIE, AH				CLARKE, AR; PURDIE, CA; HARRISON, DJ; MORRIS, RG; BIRD, CC; HOOPER, ML; WYLLIE, AH			THYMOCYTE APOPTOSIS INDUCED BY P53-DEPENDENT AND INDEPENDENT PATHWAYS	NATURE			English	Article							DNA FRAGMENTATION; GENE; CELLS; P53; EXPRESSION; INDUCTION; DEATH	DEATH by apoptosis is characteristic of cells undergoing deletion during embryonic development, T- and B-cell maturation and endocrine-induced atrophy1. Apoptosis can be initiated by various agents1-5 and may be a result of expression of the oncosuppressor gene p53 (refs 6-8). Here we study the dependence of apoptosis on p53 expression in cells from the thymus cortex. Short-term thymocyte cultures were prepared from mice constitutively heterozygous or homozygous for a deletion in the p53 gene introduced into the germ line after gene targeting. Wild-type thymocytes readily undergo apoptosis after treatment with ionizing radiation, the glucocorticoid methylprednisolone, or etoposide (an inhibitor of topoisomerase II), or after Ca2+-dependent activation by phorbol ester and a calcium ionophore. In contrast, homozygous null p53 thymocytes are resistant to induction of apoptosis by radiation or etoposide, but retain normal sensitivity to glucocorticoid and calcium. The time-dependent apoptosis that occurs in untreated cultures is unaffected by p53 status. Cells heterozygous for p53 deletion are partially resistant to radiation and etoposide. Our results show that p53 exerts a significant and dose-dependent effect in the initiation of apoptosis, but only when it is induced by agents that cause DNA-strand breakage.			CLARKE, AR (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PATHOL, CANC RES CAMPAIGN LABS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Purdie, Colin/0000-0002-1258-4010				ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERTRAND R, 1991, CANCER RES, V51, P6280; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISEKI R, 1991, J IMMUNOL, V147, P4286; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; WALKER PR, 1991, CANCER RES, V51, P1078; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHIVOTOVSKY BD, 1982, INT J RADIAT BIOL, V42, P199, DOI 10.1080/09553008214551081	26	2426	2473	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1993	362	6423					849	852		10.1038/362849a0	http://dx.doi.org/10.1038/362849a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479523				2022-12-28	WOS:A1993KZ56300060
J	HANKEY, GJ; DENNIS, MS; SLATTERY, JM; WARLOW, CP				HANKEY, GJ; DENNIS, MS; SLATTERY, JM; WARLOW, CP			WHY IS THE OUTCOME OF TRANSIENT ISCHEMIC ATTACKS DIFFERENT IN DIFFERENT GROUPS OF PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC ATTACKS; ATRIAL-FIBRILLATION; RISK FACTOR; PROGNOSIS; OXFORDSHIRE; PREVALENCE; STROKE	The outcomes of each of three large cohorts of patients with transient ischaemic attacks, which were studied in the same country at much the same time with the same methods, were compared and found to be quite different from each other. The differences in outcome were related not only to different strategies of treatment but also to differences in the prevalence and level of important prognostic factors (for example, case mix) and other factors such a the time delay from transient ischaemic attack to entry into the study and the play of chance. The implications for purchasers of health care are that they cannot rely solely on non-randomised comparisons of outcome of patients treated in competing units as a measure of the quality of care (which has only rather modest effects) without accounting for other factors that may influence outcome such as the nature of the illness, the case mix, observer bias, and the play of chance.	WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	HANKEY, GJ (corresponding author), ROYAL PERTH HOSP,DEPT NEUROL,PERTH,WA 6001,AUSTRALIA.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				CAMPBELL A, 1974, BRIT HEART J, V36, P1005; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DONNAN GA, 1989, LANCET, V2, P643; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P116; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; HOWARD G, 1989, NEUROLOGY, V39, P982, DOI 10.1212/WNL.39.7.982; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; ROSE G, 1978, BRIT HEART J, V40, P636; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1991, LANCET, V337, P1235; 1989, STATISTICS CONFIDENC, P50; 1991, J NEUROL NEUROSUR PS, V54, P1044; 1988, EGRET EPIDEMIOLOGICA; 1988, BMJ, V296, P320; 1991, NEW ENGL J MED, V325, P445	21	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1107	1111		10.1136/bmj.306.6885.1107	http://dx.doi.org/10.1136/bmj.306.6885.1107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495158	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500026
J	IDZIKOWSKI, C; SHAPIRO, CM				IDZIKOWSKI, C; SHAPIRO, CM			ABC OF SLEEP DISORDERS - NON-PSYCHOTROPIC DRUGS AND SLEEP	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	IDZIKOWSKI, C (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1118	1121		10.1136/bmj.306.6885.1118	http://dx.doi.org/10.1136/bmj.306.6885.1118			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495162	Green Published, Bronze			2022-12-28	WOS:A1993KZ56500030
J	NISHIZONOMAHER, A; SAKAMAKI, H; MIZUKAMI, H; KURAKI, T; MINAKAWA, K; MASUDA, Y				NISHIZONOMAHER, A; SAKAMAKI, H; MIZUKAMI, H; KURAKI, T; MINAKAWA, K; MASUDA, Y			LEUKEMIA LINKED TO EATING DISORDERS	BRITISH MEDICAL JOURNAL			English	Article							ANOREXIA-NERVOSA		KEIO UNIV,DIV HAEMATOL,TOKYO 160,JAPAN; TOKYO KOMAGOME HOSP,DEPT HAEMATOL,BUNKYO KU,TOKYO 113,JAPAN; NATL DEF MED COLL,DIV INTERNAL MED 3,TOKOROZAWA,SAITAMA 359,JAPAN; TOKYO INST PSYCHIAT,SETAGAYA KU,TOKYO,JAPAN	Keio University; National Defense Medical College - Japan; Tokyo Institute of Psychiatry	NISHIZONOMAHER, A (corresponding author), KEIO UNIV,SCH MED,DEPT NEUROPSYCHIAT,SHINJUKU KU,TOKYO 160,JAPAN.		Mizukami, Hiroaki/D-7674-2013	Mizukami, Hiroaki/0000-0001-8954-874X				CASON J, 1986, CLIN EXP IMMUNOL, V64, P370; DOWD PS, 1984, P NUTR SOC, V43, pA90; GOLLA JA, 1981, AM J CLIN NUTR, V34, P2756, DOI 10.1093/ajcn/34.12.2756; KAY J, 1983, SOUTH MED J, V76, P1008, DOI 10.1097/00007611-198308000-00018; MANT MJ, 1972, BRIT J HAEMATOL, V23, P737, DOI 10.1111/j.1365-2141.1972.tb03488.x	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					830	831		10.1136/bmj.306.6881.830	http://dx.doi.org/10.1136/bmj.306.6881.830			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490376	Green Published, Bronze			2022-12-28	WOS:A1993KV34800022
J	SEMPOS, CT; CLEEMAN, JI; CARROLL, MD; JOHNSON, CL; BACHORIK, PS; GORDON, DJ; BURT, VL; BRIEFEL, RR; BROWN, CD; LIPPEL, K; RIFKIND, BM				SEMPOS, CT; CLEEMAN, JI; CARROLL, MD; JOHNSON, CL; BACHORIK, PS; GORDON, DJ; BURT, VL; BRIEFEL, RR; BROWN, CD; LIPPEL, K; RIFKIND, BM			PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG UNITED-STATES ADULTS - AN UPDATE BASED ON GUIDELINES FROM THE 2ND REPORT OF THE NATIONAL-CHOLESTEROL-EDUCATION-PROGRAM ADULT TREATMENT PANEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To estimate the current levels and trends in the proportion of US adults with high blood cholesterol based on guidelines from the second report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP II). Design.-Nationally representative cross-sectional surveys. Setting/Participants.-Data for 7775 participants 20 years of age and older from phase 1 of the third National Health and Nutrition Examination Survey (NHANES III) (data collected from 1988 through 1991) and for 9797 participants 20 through 74 years of age from NHANES II (data collected from 1976 through 1980) were used. Results.-From the data collection period in NHANES II (1976 through 1980) to the period in NHANES III (1988 through 1991), the proportion of adults with high blood cholesterol levels (greater-than-or-equal-to 240 mg/dL [6.21 mmol/L]) fell from 26% to 20%, while the proportion with desirable levels (<200 mg/dL [5.17 mmol/L]) rose f rom 44% to 49%. Currently, using the ATP II guidelines and NHANES III data, 40% of all adults 20 years of age and older would require fasting lipoprotein analysis; and 29% of all adults would be candidates for dietary therapy (as compared with 36%, using NHANES II data). Based on 1990 population data, it is estimated that approximately 52 million Americans 20 years of age and older would be candidates for dietary therapy. Assuming that dietary intervention would reduce low-density lipoprotein (LDL) cholesterol levels by 10%, as many as 7% of all adult Americans (approximately 12.7 million) might be candidates for cholesterol-lowering drugs. This estimate reflects approximately 4 million adults with established coronary heart disease, of whom half are aged 65 years and older, and up to 8.7 million adults without established coronary heart disease, of whom up to 3.1 million are aged 65 years and older. Conclusions.-Substantial progress has been made in reducing the prevalence of high blood cholesterol; yet a large proportion of all adults, approximately 29%, require dietary intervention for high blood cholesterol.	NHLBI,NATL CHOLESTEROL EDUC PROGRAM,BLDG 31,ROOM 4A-05,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD; JOHNS HOPKINS UNIV,CTR CHILDRENS MED & SURG,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Johns Hopkins University								CLEEMAN JI, 1989, CLIN LAB MED, V9, P7, DOI 10.1016/S0272-2712(18)30638-3; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FEINLEIB M, IN PRESS CAN J CARDI; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROLICH ED, 1988, HYPERTENSION, V11, pA210; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIFKIND BM, 1983, ATHEROSCLEROSIS, V4; Rose G, 1982, CARDIOVASCULAR SURVE; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; 1988, ARCH INTERN MED, V148, P36; 1961, HLTH PEOPLE 200 NATI; 1985, VITAL HLTH STAT 1, V19; 1993, JAMA-J AM MED ASSOC, V269, P3015; 1991, NATIONAL HLTH NUTRIT; 1976, EXAMINATION STAFF PR; [No title captured]	18	306	314	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3009	3014		10.1001/jama.269.23.3009	http://dx.doi.org/10.1001/jama.269.23.3009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501843				2022-12-28	WOS:A1993LF94100030
J	COOPMAN, SA; JOHNSON, RA; PLATT, R; STERN, RS				COOPMAN, SA; JOHNSON, RA; PLATT, R; STERN, RS			CUTANEOUS DISEASE AND DRUG-REACTIONS IN HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; MANIFESTATIONS; AIDS; COMPLICATIONS; INPATIENTS	Background. Skin diseases, including adverse reactions to drugs, are thought to be more common among patients with human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) than among other persons. These skin conditions can be disabling or disfiguring and may require discontinuation of essential drugs. Methods. We identified 684 HIV-infected members of a 265,000-member health maintenance organization and reviewed their medical records to determine the frequency of dermatologic diagnoses from April 1, 1988, through January 15, 1991. We compared the rates of visits per year for skin conditions by HIV-infected men, 20 to 49 years of age, with those by non-HIV-infected men. We used an automated prescription data base to quantify exposures to drugs. Results. Of the 684 HIV-infected patients, 540 (79 percent) were given one or more dermatologic diagnoses, for a total of 2281 diagnoses, including 188 cutaneous reactions to drugs. There were 43 hospitalizations for cellulitis (n = 15), cutaneous drug reactions (n = 13), or other skin problems. As compared with non-HIV-infected men, the men with AIDS had visit rates that were at least 5 times higher for 18 of the 20 most common infectious and inflammatory skin conditions and at least 15 times higher for 9 conditions. Drugs with the highest rate of cutaneous reactions (per 1000 courses) included trimethoprim-sulfamethoxazole (149), sulfadiazine (200), trimethoprim-dapsone (156), and aminopenicillins (93). The number of diagnoses of skin conditions increased according to the stage of disease: it was lowest in patients immediately before the documentation of HIV infection and highest in patients with a diagnosis of AIDS. Conclusions. Cutaneous diseases, including drug reactions, are extremely common in patients with HIV infection, and their incidence increases as immune function deteriorates.	BETH ISRAEL HOSP, DEPT DERMATOL, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD COMMUNITY HLTH PLAN, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								BATTEGAY M, 1989, LANCET, V2, P1100; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; COOPMAN SA, 1991, ARCH DERMATOL, V127, P714, DOI 10.1001/archderm.127.5.714; DEHOVITZ JA, 1985, ANN INTERN MED, V103, P479, DOI 10.7326/0003-4819-103-3-479_2; DOVER JS, 1991, ARCH DERMATOL, V127, P1383, DOI 10.1001/archderm.127.9.1383; DOVER JS, 1991, ARCH DERMATOL, V127, P1549, DOI 10.1001/archderm.127.10.1549; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P451, DOI 10.1016/S0190-9622(88)70197-8; JAFFE HS, 1983, LANCET, V2, P1109; KAUPPINEN K, 1984, ACTA DERM-VENEREOL, V64, P320; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; LI MM, 1988, Y MED SPREADSHEET ST; MCNEELY MC, 1989, J AM ACAD DERMATOL, V21, P1213, DOI 10.1016/S0190-9622(89)70332-7; MITSUYASU R, 1983, NEW ENGL J MED, V308, P1535, DOI 10.1056/NEJM198306233082512; MULROY R, 1973, BRIT MED J, V1, P554, DOI 10.1136/bmj.1.5852.554; PORTEOUS DM, 1991, ARCH DERMATOL, V127, P740, DOI 10.1001/archderm.127.5.740; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2683, DOI 10.1001/archinte.148.12.2683; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; SAIAG P, 1992, J AM ACAD DERMATOL, V26, P567, DOI 10.1016/0190-9622(92)70082-Q; WINTROUB BU, 1985, J AM ACAD DERMATOL, V13, P167, DOI 10.1016/S0190-9622(85)70156-9; 1991, VITAL HLTH STATIS 13, V106; 1987, MMWR MORB MORTAL S1, V36, pS1	27	366	377	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1670	1674		10.1056/NEJM199306103282304	http://dx.doi.org/10.1056/NEJM199306103282304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8487826				2022-12-28	WOS:A1993LF05400004
J	RUIZ, CE; GAMRA, H; ZHANG, HP; GARCIA, EJ; BOUCEK, MM				RUIZ, CE; GAMRA, H; ZHANG, HP; GARCIA, EJ; BOUCEK, MM			STENTING OF THE DUCTUS-ARTERIOSUS AS A BRIDGE TO CARDIAC TRANSPLANTATION IN INFANTS WITH THE HYPOPLASTIC LEFT-HEART SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MODIFIED FONTAN PROCEDURE; DISEASE; PROSTAGLANDIN-E1; INFUSION; SURGERY				RUIZ, CE (corresponding author), LOMA LINDA UNIV,MED CTR,PEDIAT CARDIOL SECT,RM 4433,11234 ANDERSON ST,POB 2000,LOMA LINDA,CA 92354, USA.							BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; BAILEY LL, 1986, NEW ENGL J MED, V315, P940; BECKER GJ, 1991, CIRCULATION, V83, P122; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CHANG AC, 1991, J AM COLL CARDIOL, V17, P1143, DOI 10.1016/0735-1097(91)90845-Z; CHIAVARELLI M, 1991, HEART SURGERY 1991, P491; COE JY, 1991, J AM COLL CARDIOL, V18, P837, DOI 10.1016/0735-1097(91)90810-V; COLE RB, 1981, PEDIATRICS, V67, P816; FARRELL PE, 1992, CIRCULATION, V85, P116, DOI 10.1161/01.CIR.85.1.116; FREEDOM RM, 1989, HEART DISEASE INFANT, P515; HOUDE C, 1992, CIRCULATION, V86, P632; LAMBERT EC, 1966, PEDIATRICS, V37, P343; LEV M, 1952, LAB INVEST, V1, P61; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; MAYER JE, 1992, CIRCULATION, V85, P372, DOI 10.1161/01.CIR.85.1.372; MURDISON KA, 1990, CIRCULATION, V82, P199; NOONAN J A, 1958, Pediatr Clin North Am, V5, P1029; NORWOOD WI, 1980, AM J CARDIOL, V45, P87, DOI 10.1016/0002-9149(80)90224-6; NORWOOD WI, 1983, NEW ENGL J MED, V308, P23, DOI 10.1056/NEJM198301063080106; OLAUGHLIN MP, 1991, CIRCULATION, V83, P1923, DOI 10.1161/01.CIR.83.6.1923; RINGEL RE, 1982, RADIOLOGY, V142, P657, DOI 10.1148/radiology.142.3.7199748; ROSENTHAL E, 1992, Journal of the American College of Cardiology, V19, p25A; SCHATZ RA, 1989, CIRCULATION, V79, P445, DOI 10.1161/01.CIR.79.2.445	23	68	73	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1605	1608		10.1056/NEJM199306033282205	http://dx.doi.org/10.1056/NEJM199306033282205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8487802				2022-12-28	WOS:A1993LE28900005
J	GINSBURG, PB; HOGAN, C				GINSBURG, PB; HOGAN, C			PHYSICIAN RESPONSE TO FEE CHANGES - A CONTRARY VIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GINSBURG, PB (corresponding author), PHYSICIAN PAYMENT REVIEW COMMISS,2120 L ST NW,SUITE 510,WASHINGTON,DC 20037, USA.							ESCARCE JJ, 1993, JAMA-J AM MED ASSOC, V269, P2513, DOI 10.1001/jama.269.19.2513; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P349, DOI 10.2105/AJPH.83.3.349; 1991, FED REG         1125, V56, P59502; 1991, FED REG         0605, V56, P25792; 1991, 1991 PHYS PAYM REV C; 1993, 1993 PHYS PAYM REV C	6	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2550	2552		10.1001/jama.269.19.2550	http://dx.doi.org/10.1001/jama.269.19.2550			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487422				2022-12-28	WOS:A1993LB45000038
J	CHIEN, KR				CHIEN, KR			MOLECULAR ADVANCES IN CARDIOVASCULAR BIOLOGY	SCIENCE			English	Editorial Material							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; ATRIAL-NATRIURETIC-FACTOR; CARDIAC GENE-EXPRESSION; LOW-DENSITY-LIPOPROTEIN; INDUCIBLE EXPRESSION; BLOOD-PRESSURE; RAT; HYPERTENSION; HEPATOCYTES; MYOCYTES		UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	CHIEN, KR (corresponding author), AMER HEART ASSOC, BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA.							CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KLEINERT HD, 1992, SCIENCE, V257, P1940, DOI 10.1126/science.1411510; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MILLERHANCE WC, UNPUB; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; OBRIEN TX, IN PRES P NATL ACAD; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OLSON EN, 1992, TRENDS CARDIOVAS MED, V2, P163, DOI 10.1016/1050-1738(92)90044-S; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROBBINS J, 1992, TRENDS CARDIOVAS MED, V2, P44, DOI 10.1016/1050-1738(92)90003-B; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROCKMAN HA, UNPUB; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014; WILSON JM, 1992, J BIOL CHEM, V267, P963; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHU H, IN PRESS MOL CELL BI	46	67	81	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					916	917		10.1126/science.8493528	http://dx.doi.org/10.1126/science.8493528			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493528				2022-12-28	WOS:A1993LB79100029
J	BRADLEY, D				BRADLEY, D			PROPHYLAXIS AGAINST MALARIA FOR TRAVELERS FROM THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								To provide revised guidance on malaria prevention for the medical advisers of travellers from the United Kingdom going overseas to malarious areas, a committee of those most involved in giving advice and with specialist expertise in the United Kingdom agreed a policy document. There is a need for all travellers to be aware of the risk of malaria and to take measures to avoid being bitten by anopheline mosquitos, especially at night. Chemoprophylaxis is recommended also for most malarious areas. In view of the increasing prevalence of strains of Plasmodium falciparum resistant to chloroquine and proguanil, mefloquine is added to the list of recommended drugs for more areas than in the past, and is the preferred chemoprophylactic for east and central Africa. Chloroquine with proguanil continues to be widely appropriate. Detailed recommendations are given for each country. Travellers out of reach of prompt medical assistance are advised to carry treatment doses of a standby drug: halofantrine, Fansidar, or quinine. The need for full compliance with any regimen is emphasised. No prophylaxis is totally effective. Malaria must be considered in the differential diagnosis of any fever in someone who has visited an endemic area within the past year.	PUBL HLTH LAB SERV,MALARIA REFERENCE LAB,SALISBURY SP4 0JG,WILTS,ENGLAND		BRADLEY, D (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.								0	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1247	1252		10.1136/bmj.306.6887.1247	http://dx.doi.org/10.1136/bmj.306.6887.1247			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499856	Green Published, Bronze			2022-12-28	WOS:A1993LB80400020
J	COX, J; MULHOLLAND, H				COX, J; MULHOLLAND, H			AN INSTRUMENT FOR ASSESSMENT OF VIDEOTAPES OF GENERAL-PRACTITIONERS PERFORMANCE	BRITISH MEDICAL JOURNAL			English	Article							STANDARDIZED SIMULATED PATIENTS	Objectives-To identify those important characteristics of doctors' and patients' behaviour that distinguish between ''good'' and ''bad'' consultations when viewed on videotape; to use these characteristics to develop a reliable instrument for assessing general practitioners' performance in their own consultations. Design-Questionnaires completed by patients, general practitioner trainers, and general practitioner trainees. Reliability of draft instrument tested by general practitioner trainers. Setting-All vocational training schemes for general practice in the Northern region of England. Subjects-First stage: 76 patients in seven groups, 108 general practice trainers in 12 groups, and 122 general practice trainees in 10 groups. Second stage: 85 general practice trainers in 12 groups. Main outcome measures-Trainers' ratings of importance; alpha coefficients of draft instrument by trainee, group, and consultation. Results-6890 characteristics of good and bad consultations were consolidated into a draft assessment instrument consisting of 46 pairs of definitions separated by six point bipolar scales. Nine statement pairs given low importance ratings by trainers were eliminated, reducing the instrument to 37 statement pairs. To test reliability, general practitioner trainers used the instrument to assess three consultations. With the exception of one group of trainers, all alpha coefficients exceeded the acceptable level of 0.80. Conclusion-The instrument produced is reliable for assessing general practitioners' performance in their own consultations.	UNIV NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV DUNDEE,CTR MED EDUC,DUNDEE DD1 4HN,SCOTLAND	Newcastle University - UK; University of Dundee				Cox, Jim/0000-0002-3118-1292				Agar Michael, 1986, SPEAKING ETHNOGRAPHY; BLIGH J, 1991, POSTGRADUATE ED GENE, V2, P28; BROOK RA, 1976, MED CARE, V14, P63; Byrne P.S., 1976, DOCTORS TALKING PATI; COLLIVER JA, 1991, MED EDUC, V25, P303, DOI 10.1111/j.1365-2923.1991.tb00071.x; Fraser R, 1992, APPROACHES ASSESSMEN, P192; GRAY DP, 1988, J ROY COLL GEN PRACT, V38, P344; HARDEN RM, 1979, ASSESSMENT MED COMPE; HAYS RB, 1990, MED EDUC, V244, P110; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; KILPATRICK R, 1993, BRIT J GEN PRACT, V43, P2; LOCKIE C, 1990, EXAMINATION MEMBERSH; MCLESKEY CH, 1978, ANESTHESIOLOGY, V49, P224, DOI 10.1097/00000542-197809000-00021; Miller GE, 1962, TEACHING LEARNING ME; MULHOLLAND H, 1991, HORIZONS, V5, P274; Neufeld VR, 1985, ASSESSING CLIN COMPE; NORMAN GR, 1985, J MED EDUC, V60, P925; PENDLETON B, 1984, CONSULTATION APPROAC; PREMI J, 1991, ACAD MED, V66, P56, DOI 10.1097/00001888-199101000-00018; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P94; RETHANS JJ, 1991, BRIT J GEN PRACT, V41, P97; RETHANS JJE, 1987, BRIT MED J, V294, P809, DOI 10.1136/bmj.294.6575.809; RUTTER DR, 1976, LANCET, V2, P558; Strauss AL., 1990, J ENVIRON PSYCHOL; TAMBLYN RM, 1991, MED EDUC, V25, P100, DOI 10.1111/j.1365-2923.1991.tb00035.x; VANDERVLEUTEN CPM, 1992, CURRENT DEV ASSESSIN; VU NV, 1992, MED EDUC, V26, P99, DOI 10.1111/j.1365-2923.1992.tb00133.x; 1992, ACCREDITATION REGION; 1972, FUTURE GENERAL PRACT; 1992, JOINT COMMITTEE POST	31	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1043	1046		10.1136/bmj.306.6884.1043	http://dx.doi.org/10.1136/bmj.306.6884.1043			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490501	Green Published, Bronze			2022-12-28	WOS:A1993KY44800023
J	DOUGLAS, NJ				DOUGLAS, NJ			ABC OF SLEEP DISORDERS - THE SLEEP-APNEA HYPOPNEA SYNDROME AND SNORING	BRITISH MEDICAL JOURNAL			English	Article											DOUGLAS, NJ (corresponding author), UNIV EDINBURGH,RESP MED UNIT RIE,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Douglas, Neil/B-1491-2013						0	18	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1057	1060		10.1136/bmj.306.6884.1057	http://dx.doi.org/10.1136/bmj.306.6884.1057			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490507	Bronze, Green Published			2022-12-28	WOS:A1993KY44800032
J	HIGGS, R				HIGGS, R			HUMAN FRAILTY SHOULD NOT BE PENALIZED	BRITISH MEDICAL JOURNAL			English	Article											HIGGS, R (corresponding author), KINGS COLL SCH MED & DENT,LONDON SE5 8RX,ENGLAND.							Beauchamp TLC, 2019, PRINCIPLES BIOMEDICA; Gillon Ranan., 1985, PHILOS MED ETHICS	2	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1049	1050		10.1136/bmj.306.6884.1049	http://dx.doi.org/10.1136/bmj.306.6884.1049			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490503	Green Published, Bronze			2022-12-28	WOS:A1993KY44800027
J	WHITELEY, SM; MURPHY, PG; KIROLLOS, RW; SWINDELLS, SR				WHITELEY, SM; MURPHY, PG; KIROLLOS, RW; SWINDELLS, SR			LESSON OF THE WEEK - HEADACHE AFTER DURAL PUNCTURE	BRITISH MEDICAL JOURNAL			English	Article									GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Leeds General Infirmary; Saint James's University Hospital								ABOULEISH E, 1975, ANESTH ANALG, V54, P459; EDELMAN JD, 1980, ANESTHESIOLOGY, V52, P166; NEWRICK P, 1982, BRIT MED J, V285, P341, DOI 10.1136/bmj.285.6338.341-a; REID JA, 1991, BRIT J ANAESTH, V67, P674, DOI 10.1093/bja/67.6.674	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					917	918		10.1136/bmj.306.6882.917	http://dx.doi.org/10.1136/bmj.306.6882.917			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490423	Green Published, Bronze			2022-12-28	WOS:A1993KW38700032
J	LITZELMAN, DK; SLEMENDA, CW; LANGEFELD, CD; HAYS, LM; WELCH, MA; BILD, DE; FORD, ES; VINICOR, F				LITZELMAN, DK; SLEMENDA, CW; LANGEFELD, CD; HAYS, LM; WELCH, MA; BILD, DE; FORD, ES; VINICOR, F			REDUCTION OF LOWER-EXTREMITY CLINICAL ABNORMALITIES IN PATIENTS WITH NONINSULIN-DEPENDENT DIABETES-MELLITUS - A RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS, NONINSULIN-DEPENDENT; AMPUTATION; FOOT ULCERS; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES	CARE; EPIDEMIOLOGY; AMPUTATION; PHYSICIANS; EDUCATION; REMINDERS	Objective: To evaluate the effect of a patient. health care provider, and systems intervention on the prevalence of risk factors for lower extremity amputation in patients with non-insulin-dependent diabetes. Design: Blinded, randomized, controlled trial. Setting: Academic general medicine practice. Participants: Of the 395 patients with non-insulin-dependent diabetes who underwent the initial patient assessment, 352 completed the study. Intervention: The 12-month intervention was multi-faceted. Patients received foot-care education and entered into a behavioral contract for desired self-foot care, which was reinforced through telephone and postcard reminders. Health care providers were given practice guidelines and informational flow sheets on foot-related risk factors for amputation in diabetic patients. In addition, the folders for intervention patients had special identifiers that prompted health care providers to 1) ask that patients remove their footwear, 2) perform foot examinations, and 3) provide foot-care education. Results: Patients receiving the intervention were less likely than control patients to have serious foot lesions (baseline prevalence, 2.9%; odds ratio, 0.41 (95% Cl, 0. 1 6 to 1.001; P = 0.05) and other dermatologic abnormalities. Also, they were more likely to report appropriate self-foot-care behaviors, to have foot examinations during office visits (68% compared with 28%; P < 0.001), and to receive foot-care education from health care providers (42% compared with 18%; P < 0.001). Physicians assigned to intervention patients were more likely than physicians assigned to control patients to examine patients' feet for ulcers, pulses, and abnormal dermatologic conditions and to refer patients to the podiatry clinic (10.6% compared with 5.0%; P = 0.04). Conclusions: An intervention designed to reduce risk factors for lower extremity amputations positively affected patient self-foot-care behavior as well as the foot care given by health care providers and reduced the prevalence of lower extremity clinical disease in patients with diabetes.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	Indiana University System; Indiana University-Purdue University Indianapolis; Centers for Disease Control & Prevention - USA	LITZELMAN, DK (corresponding author), REGENSTRIEF INST HLTH CARE, 5TH FLOOR, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.			Litzelman, Debra/0000-0003-2162-8756	PHS HHS [200-08-0661] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AREZZO JC, 1986, DIABETES, V35, P590, DOI 10.2337/diabetes.35.5.590; ASSAL JP, 1985, DIABETOLOGIA, V28, P602, DOI 10.1007/BF00281995; BAILEY TS, 1985, AM J MED, V78, P371, DOI 10.1016/0002-9343(85)90326-2; BARNETT GO, 1990, AM J PUBLIC HEALTH, V80, P527, DOI 10.2105/AJPH.80.5.527; BATES B, 1979, GUIDE PHYSICAL EXAMI, P305; Bessman A N, 1982, Compr Ther, V8, P32; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; COHEN SJ, 1983, DIABETES CARE, V6, P499, DOI 10.2337/diacare.6.5.499; Coleman WC, 1988, DIABETIC FOOT, P293; DAVIDSON JK, 1981, ED DIABETIC PATIENTS, P329; EBSKOV B, 1980, PROSTHET ORTHOT INT, V4, P77; HARRIS M, 1979, DIABETES, V28, P1039; Holewski J J, 1988, J Rehabil Res Dev, V25, P1; LEVIN ME, 1988, DIABETIC FOOT, P23; LITZELMAN DK, 1993, IN PRESS J GEN INTER; MAZZUCA SA, 1986, DIABETES CARE, V9, P1, DOI 10.2337/diacare.9.1.1; MCDONALD CJ, 1988, M D COMPUT, V5, P34; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; PECORARO R, 1990, WOUNDS, V2, P65; REIBER GE, 1992, ANN INTERN MED, V117, P97, DOI 10.7326/0003-4819-117-2-97; ROSENQVIST U, 1984, ACTA MED SCAND, P55; RUNYAN JW, 1975, JAMA-J AM MED ASSOC, V231, P264, DOI 10.1001/jama.231.3.264; SILBERT S, 1952, DIABETES, V1, P297, DOI 10.2337/diab.1.4.297; SMITH DM, 1987, J GEN INTERN MED, V2, P231, DOI 10.1007/BF02596446; SOSENKO JM, 1990, DIABETES CARE, V13, P1057, DOI 10.2337/diacare.13.10.1057; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1991, MED CARE, V29, pJS57; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1985, FOOT NOTES; 1988, DIABETIC FOOT CARE A; 1992, DIABETES US STRATEGY, P2	34	331	335	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					36	41		10.7326/0003-4819-119-1-199307010-00006	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498761				2022-12-28	WOS:A1993LJ26600006
J	CUMMINS, RO				CUMMINS, RO			CODE MAGIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3076	3076		10.1001/jama.269.24.3076	http://dx.doi.org/10.1001/jama.269.24.3076			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505799				2022-12-28	WOS:A1993LH14500001
J	EVANS, RW				EVANS, RW			ORGAN PROCUREMENT EXPENDITURES AND THE ROLE OF FINANCIAL INCENTIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSPLANT ORGANS; DONATION; ALTRUISM; LIFE	Objectives.-To evaluate the billed charges for organ procurement and to consider the role of financial incentives to encourage organ donation. Design.-Observational study. Data were obtained on donor organ acquisition charges from a random sample of kidney, heart, liver, heart-lung, and pancreas transplants. Setting.-The data were based on 28.7% of all transplants performed in the United States in 1988. Main Outcome Measure.-Total charges for donor organ acquisition. Results.-The median charges (1988 dollars) for donor organs were as follows: kidney, $12 290; heart, $12 578; liver, $16 281; heart-lung, $12 028; and pancreas, $15 400. Since 1983, kidney acquisition charges have increased by 12.9%, heart charges by 64.1%, and liver charges by 61.8%, after adjusting for inflation. Between 9% and 31% of total transplant procedure-specific charges were associated with donor organ acquisition. Conclusions.-There is wide unexplained variation in organ procurement charges. Data on actual costs are required to establish the appropriateness of current charges. Prevailing billing and payment methods should be reevaluated in an effort to address a variety of issues related to reimbursement. Current payment methods may actually contribute to cost inefficiency. Finally, while financial incentives may enhance the efficiency of organ procurement efforts, they will adversely affect the cost-effectiveness of transplantation.			EVANS, RW (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,HLTH SERV EVALUAT SECT,ROCHESTER,MN 55905, USA.							ALTSHULER JS, 1992, JAMA-J AM MED ASSOC, V267, P2037, DOI 10.1001/jama.1992.03480150043029; [Anonymous], 1991, Lancet, V337, P1470; BATTEN HL, 1987, HEALTH AFFAIR, V6, P35, DOI 10.1377/hlthaff.6.2.35; BAUMGARTNER WA, 1990, HEART HEART LUNG TRA; BROWN E, 1991, JAMA-J AM MED ASSOC, V265, P510; CHILDRESS JF, 1992, UNOS UPDATE, V8, P8; DANIEL WW, 1991, BIOSTATISTICS F ANAL; DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Evans R W, 1990, Clin Transpl, P319; Evans R W, 1990, Clin Transpl, P343; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; EVANS RW, 1992, TRANSPLANTATION, V53, P1041, DOI 10.1097/00007890-199205000-00014; EVANS RW, 1992, LANCET, V339, P185, DOI 10.1016/0140-6736(92)90254-Z; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; EVANS RW, 1992, TRANSPLANT P, V24, P2152; EVANS RW, 1985, TRANSPLANT P, V17, P129; EVANS RW, 1986, SURG CLIN N AM, V66, P603; EVANS RW, IN PRESS CLIN TRANSP; EVANS RW, 1991, BHARC10091020 BATT S; EVANS RW, 1991, TOO OLD HLTH CARE CO, P44; EVANS RW, 1987, MED SOC CLIN DECISIO, P61; EVANS RW, 1991, NATIONAL COOPERATIVE; EVANS RW, 1990, TRANSPLANT REV, V4, P1; EVANS RW, 1983, COST MULTIORGAN PROC; FINKLER SA, 1982, ANN INTERN MED, V96, P101; Fox R. C., 1992, SPARE PARTS ORGAN RE; FOX RC, 1974, COURAGE FAIL; GABRIEL R, 1991, LANCET, V337, P104, DOI 10.1016/0140-6736(91)90755-E; Kevorkian J, 1989, Med Law, V7, P557; Kish L, 1965, SURVEY SAMPLING; KITTUR DS, 1991, LANCET, V338, P1441, DOI 10.1016/0140-6736(91)92735-K; PETERS TG, 1992, DIALYSIS TRANSPLANT, V21, P270; PETERS TG, 1991, JAMA-J AM MED ASSOC, V265, P1302, DOI 10.1001/jama.265.10.1302; PETERS TG, 1992, DIALYSIS TRANSPLANT, V21, P273; PETERS TG, 1992, DIALYSIS TRANSPLANT, V21, P290; Poullier J P, 1992, Health Care Financ Rev, V13, P167; PROTTAS JM, 1983, MILBANK FUND Q, V61, P278, DOI 10.2307/3349908; PROTTAS JM, 1991, J HEALTH POLIT POLIC, V16, P121, DOI 10.1215/03616878-16-1-121; PROTTAS JM, 1992, TRANSPLANTATION, V53, P1371, DOI 10.1097/00007890-199206000-00040; ROPER WL, 1987, FED REGISTER, V52, P10935; SCHWINDT R, 1986, J HEALTH POLIT POLIC, V11, P483, DOI 10.1215/03616878-11-3-483; SIMMONS RG, 1991, SOCIOL QUART, V32, P1, DOI 10.1111/j.1533-8525.1991.tb00342.x; Simmons RG, 1987, GIFT LIFE EFFECT ORG; TOLLE SW, 1987, ANN INTERN MED, V106, P740, DOI 10.7326/0003-4819-106-5-740; VINING AR, 1988, J POLICY ANAL MANAG, V7, P706, DOI 10.2307/3323490; WARREN J, 1992, TRANSPLANT NEWS, V2, P3; WILENSKY GR, 1991, FED REGISTER, V58, P15006; WOODALL J, 1989, LANCET, V1, P849; 1992, UNOS UPDATE, V8, P46; 1992, SURVEY REVEALS SURPR; 1986, TRANSPLANTATION, V41, P1; 1990, ANN REPORT US SCI RE; 1987, 7 YEAR SUMMARY IOPA; 1992, PHS921232 NATL CTR H; 1987, UNOS UPDATE, V3, P12; 1981, END STAGE RENAL DISE; 1980, END STAGE RENAL DISE; 1991, CONT DIAL NEPHROL, V12, P22; 1987, OAI018600108 DEP HLT; 1993, GAOHRD9356 US GEN AC; 1992, 03328 HLTH CARE FIN; 1991, OEI018801331 DEP HLT; 1983, JAMA-J AM MED ASSOC, V250, P2961	65	37	39	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3113	3118		10.1001/jama.269.24.3113	http://dx.doi.org/10.1001/jama.269.24.3113			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LH145	8505813				2022-12-28	WOS:A1993LH14500024
J	MATTHEWS, DA; SUCHMAN, AL; BRANCH, WT				MATTHEWS, DA; SUCHMAN, AL; BRANCH, WT			MAKING CONNECTIONS - ENHANCING THE THERAPEUTIC POTENTIAL OF PATIENT-CLINICIAN RELATIONSHIPS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN PATIENT RELATIONS; EMPATHY	MEDICINE; CARE	Healers must try to understand what the illness means to the patient and create a therapeutic sense of connection in the patient-clinician relationship. A favorable climate for ''connexional'' experiences can be created through the use of various interviewing techniques. Attending to rapport, silencing internal talk, accessing unconscious processes, and communicating understanding can help clinicians enhance their sensitivity to the subtle clues on which issues of meaning and connection often depend. Several risks are associated with the establishment of closer patient-clinician relationships, including dependence and power issues, sexual attraction, and deeper exposure of the clinician to the patient's pain. Prepared with an awareness of these risks and techniques to address them, clinicians are encouraged to deepen their level of dialogue with patients, to compare their experiences with those of other clinicians, and to thereby develop a more systematic understanding of therapeutic relationships.	HIGHLAND HOSP, 1000 S AVE, ROCHESTER, NY 14620 USA; NATL INST HEALTHCARE RES, ARLINGTON, VA USA; NATL CTR CHRON FATIGUE, ARLINGTON, VA 22201 USA; UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14642 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Rochester; University of Rochester; Harvard University; Harvard Medical School								BANDLER R, 1979, FROGS PRINCES; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BRANCH WT, 1990, AM J MED, V88, P56, DOI 10.1016/0002-9343(90)90128-Z; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; Frankel R, 1991, HMO PRACTICE, V5, P114; HIATT JF, 1986, SOUTH MED J, V79, P736, DOI 10.1097/00007611-198606000-00022; INUI TS, 1991, SEP CTR ADV STUD BEH; IRWIN H, 1991, AUSTR J COMMUNICATIO, V18, P14; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; MATTHEWS DA, 1988, AM J MED SCI, V295, P159, DOI 10.1097/00000441-198803000-00001; MCMURRAY RJ, 1991, JAMA-J AM MED ASSOC, V266, P2741, DOI 10.1001/jama.1991.03470190089035; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; RADETSKY M, 1985, JAMA-J AM MED ASSOC, V254, P1361, DOI 10.1001/jama.1985.03360100115026; REAMES HR, 1989, ARCH INTERN MED, V149, P1951, DOI 10.1001/archinte.149.9.1951; REIK T, 1949, LISTENING 3RD EAR, P157; ROGERS CR, 1961, BECOMING PERSON THER, P39; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; STEINER R, 1947, KNOWLEDGE HIGHER WOR, P75; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; SUCHMAN AL, IN PRESS MED INTERVI; WILLIAMSON PR, 1991, J GEN INTERN MED, V6, P179, DOI 10.1007/BF02598321	25	115	115	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					973	977		10.7326/0003-4819-118-12-199306150-00010	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489112				2022-12-28	WOS:A1993LF93700010
J	DETOLEDO, GA; FERNANDEZCHACON, R; FERNANDEZ, JM				DETOLEDO, GA; FERNANDEZCHACON, R; FERNANDEZ, JM			RELEASE OF SECRETORY PRODUCTS DURING TRANSIENT VESICLE FUSION	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; MOUSE MAST-CELLS; CAPACITANCE MEASUREMENTS; CHROMAFFIN CELLS; EXOCYTOSIS; GRANULES; VOLTAMMETRY; INVITRO; MATRIX; PORE	PATCH-CLAMP experiments have shown that fusion of secretory granules with the plasma membrane does not always occur as an all-or-none event, but can develop slowly in a fluctuating manner or can be transient1-5. These observations suggested that release could be detected during such incomplete fusion events. To test this hypothesis we have combined patch-clamp measurements of the activity of single exocytotic fusion pores in beige mouse mast cells with the electrochemical detection of serotonin released during the exocytotic events. We report here that on fusion pore opening there is a small release of serotonin which is directly proportional to the pore conductance. We also show that a significant release occurs during transient fusion events. These results demonstrate, to our knowledge for the first time, release of a neurotransmitter from a secretory vesicle that did not undergo complete fusion.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic	DETOLEDO, GA (corresponding author), UNIV SEVILLA,FAC MED,DEPT FISIOL MED & BIOFIS,AVDA SANCHEZ PIZJUAN 4,E-41009 SEVILLE,SPAIN.		IBIS, FISIOLOGIA/O-9485-2015; Alvarez de Toledo, Guillermo/I-2888-2015; Fernandez-Chacon, Rafael/E-6303-2010	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Fernandez-Chacon, Rafael/0000-0002-9845-9885				ALMERS W, 1989, SECRETION ITS CONTRO, P269; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; DETOLEDO GA, 1988, CELL PHYSL BLOOD, P333; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERNANDEZ-CHACO R, 1992, Biophysical Journal, V61, pA226; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heuser JE, 1977, HDB PHYSL, VI, P261; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LUDOWYKE RI, 1986, BIOCHEMISTRY-US, V25, P6287, DOI 10.1021/bi00368a068; MILLAR J, 1990, J ELECTROANAL CHEM, V282, P33, DOI 10.1016/0022-0728(91)85088-7; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RABENSTEIN DL, 1987, BIOCHEMISTRY-US, V26, P6923, DOI 10.1021/bi00396a010; TATHAM PER, 1991, PFLUG ARCH EUR J PHY, V419, P409, DOI 10.1007/BF00371124; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	21	492	492	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					554	558		10.1038/363554a0	http://dx.doi.org/10.1038/363554a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505984				2022-12-28	WOS:A1993LF93900054
J	RUOHOLABAKER, H; GRELL, E; CHOU, TB; BAKER, D; JAN, LY; JAN, YN				RUOHOLABAKER, H; GRELL, E; CHOU, TB; BAKER, D; JAN, LY; JAN, YN			SPATIALLY LOCALIZED RHOMBOID IS REQUIRED FOR ESTABLISHMENT OF THE DORSAL-VENTRAL AXIS IN DROSOPHILA OOGENESIS	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; PATTERN-FORMATION; DORSOVENTRAL PATTERN; CELL FATE; TRANSMEMBRANE PROTEIN; EMBRYONIC POLARITY; NEUROGENIC GENES; SERINE PROTEASE; NERVOUS-SYSTEM	The establishment of dorsal-ventral asymmetry of the Drosophila embryo requires a group of genes that act maternally. None of the previously identified dorsal-ventral axis genes are known to produce asymmetrically localized gene products during oogenesis. We show that rhomboid (rho), a novel member of this group, encodes a protein that is localized on the apical surface of the dorsal-anterior follicle cells surrounding the oocyte. Loss of rho function causes ventralization of the eggshell and the embryo, whereas ectopic expression leads to dorsalization of both structures. Thus, spatially restricted rho is necessary and sufficient for dorsal-ventral axis formation. We propose, based on these observations and double mutant experiments, that the spatially restricted rho protein leads to selective activation of the epidermal growth factor receptor in the dorsal follicle cells and subsequently the specification of the dorsal follicle cells.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	RUOHOLABAKER, H (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012; Chou, Tze-Bin/S-1188-2017	Baker, David/0000-0001-7896-6217; Chou, Tze-Bin/0000-0003-2453-0164; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P140; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CLIFFORD RJ, 1989, GENETICS, V123, P771; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FREEMAN M, 1992, DEVELOPMENT, V116, P335; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; King R. C., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; PROST E, 1988, GENE DEV, V2, P891, DOI 10.1101/gad.2.7.891; RAY RP, 1991, DEVELOPMENT, V113, P35; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHUPBACH T, 1991, CELL CELL INTERACTIO, P1163; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRADLING A, 1992, DROSOPHILA DEV, P1; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; Wieschaus E., 1986, P199; WIESCHAUS E, 1979, CELL LINEAGE STEM CE, P291; ZAK NB, 1990, DEVELOPMENT, V109, P865	58	137	138	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					953	965		10.1016/0092-8674(93)90273-S	http://dx.doi.org/10.1016/0092-8674(93)90273-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500182	Bronze			2022-12-28	WOS:A1993LF06100011
J	KOSTMAN, JR; DINUBILE, MJ				KOSTMAN, JR; DINUBILE, MJ			NODULAR LYMPHANGITIS - A DISTINCTIVE BUT OFTEN UNRECOGNIZED SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Review						LYMPHANGITIS; SPOROTRICHUM; NOCARDIA; LEISHMANIA; FRANCISELLA	NOCARDIA-BRASILIENSIS INFECTION; CUTANEOUS LEISHMANIASIS; MYCOBACTERIUM-MARINUM; SPOROTRICHOID SPREAD; DISSEMINATION; DISEASE; SUSCEPTIBILITIES; ASTEROIDES; FORTUITUM; SPECTRUM	Purpose: To describe nodular lymphangitis by reviewing the clinical and epidemiologic features of this disease with an emphasis on distinguishing specific etiologic agents. Data Sources: English-language articles were identified through a MEDLINE search (1966 to September 1992) using sporotrichosis, lymphangitis, and sporotrichoid as key words; additional references were selected from the bibliographies of identified articles. In addition, three new patients with nodular lymphangitis are described. Study Selection: One hundred fifty articles were reviewed to determine details of the etiologic agents and clinical signs and symptoms of patients with nodular lymphangitis. Data Synthesis: Nodular lymphangitis develops most commonly after cutaneous inoculation with Sporothrix schenckii, Nocardia brasiliensis, Mycobacterium marinum, Leishmania braziliensis, and Francisella tularensis. The setting in which infection is acquired is useful in differentiating among the various organisms causing infection. Sporotrichosis and leishmaniasis can have longer incubation periods than do the other common causes of nodular lymphangitis. A painful ulcer at the site of the initial lesion suggests tularemia; frankly purulent drainage often accompanies infections with Francisella and Nocardia species. Ulcerated or suppurating lymphangitic nodules occur commonly with Nocardia infections. Patients with nodular lymphangitis who fail to respond to empiric treatment for sporotrichosis should be evaluated for other organisms with appropriate biopsies and cultures. Conclusions: Nodular lymphangitis has distinctive clinical signs and symptoms, most commonly due to infection with a limited number of organisms. A detailed history, accompanied by information obtained from skin biopsy specimens using appropriate stains and cultures, should allow specific, effective therapy for most of these infections.	COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, CAMDEN, NJ USA	Rutgers State University Camden; Rutgers State University New Brunswick; Rutgers State University Medical Center								AARONSON CM, 1974, SOUTHERN MED J, V67, P117, DOI 10.1097/00007611-197401000-00029; ADAMS RM, 1970, J AMER MED ASSOC, V211, P457, DOI 10.1001/jama.211.3.457; AHN CH, 1987, AM REV RESPIR DIS, V135, P10; ALGINDAN Y, 1989, INT J DERMATOL, V28, P248, DOI 10.1111/j.1365-4362.1989.tb04814.x; BALLOU WR, 1987, LANCET, V2, P13; BAUMGARTEN A, 1961, MED J AUSTRALIA, V2, P321, DOI 10.5694/j.1326-5377.1961.tb69527.x; BELLIVEAU RR, 1977, WESTERN J MED, V127, P245; BEYT BE, 1981, MEDICINE, V60, P95, DOI 10.1097/00005792-198103000-00003; Bradsher R W, 1988, Infect Dis Clin North Am, V2, P877; BROWN BA, 1992, ANTIMICROB AGENTS CH, V36, P180, DOI 10.1128/AAC.36.1.180; BROWN J, 1977, CAN MED ASSOC J, V117, P912; CONVIT J, 1987, LANCET, V1, P401; Craven R B, 1991, Infect Dis Clin North Am, V5, P165; DICKEY RF, 1968, ARCH DERMATOL, V98, P385, DOI 10.1001/archderm.98.4.385; Duncan W C, 1968, Tex Med, V64, P66; EVANS ME, 1985, MEDICINE, V64, P251, DOI 10.1097/00005792-198507000-00006; EVENPAZ Z, 1976, BRIT J DERMATOL, V94, P435, DOI 10.1111/j.1365-2133.1976.tb06122.x; Foshay L, 1940, MEDICINE, V19, P1, DOI 10.1097/00005792-194002000-00001; GEZUELE E, 1973, BRIT J DERMATOL, V89, P305, DOI 10.1111/j.1365-2133.1973.tb02979.x; GLICKMAN FS, 1983, J AM ACAD DERMATOL, V8, P703, DOI 10.1016/S0190-9622(83)80226-6; GRAHAM WR, 1982, J AM ACAD DERMATOL, V7, P785, DOI 10.1016/S0190-9622(82)70161-6; GREER KE, 1979, ARCH DERMATOL, V115, P738, DOI 10.1001/archderm.115.6.738; Guy WH, 1920, ARCH DERMATOL SYPH, V2, P137, DOI 10.1001/archderm.1920.02350080003001; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; Hessen M T, 1988, Pa Med, V91, P58; HIGGINS EM, 1988, CLIN EXP DERMATOL, V13, P234, DOI 10.1111/j.1365-2230.1988.tb00686.x; Hironaga M., 1977, Japanese Journal of Medical Mycology, V18, P29; ITOH M, 1986, DERMATOLOGICA, V172, P209, DOI 10.1159/000249337; JOLLY HW, 1972, ARCH DERMATOL, V106, P32, DOI 10.1001/archderm.106.1.32; KAHN FW, 1981, AM J MED, V70, P859, DOI 10.1016/0002-9343(81)90543-X; KALB RE, 1985, J AM ACAD DERMATOL, V13, P125, DOI 10.1016/S0190-9622(85)70154-5; KERDELVEGAS F, 1982, INT J DERMATOL, V21, P291, DOI 10.1111/j.1365-4362.1982.tb03135.x; Knoper S R, 1988, Infect Dis Clin North Am, V2, P861; KUBBA R, 1987, INT J DERMATOL, V26, P300, DOI 10.1111/j.1365-4362.1987.tb00193.x; KUBBA R, 1987, J AM ACAD DERMATOL, V16, P1183, DOI 10.1016/S0190-9622(87)70155-8; LAMBERTUS MW, 1988, CUTIS, V42, P38; LAMPE RM, 1981, J PEDIATR-US, V99, P593, DOI 10.1016/S0022-3476(81)80266-1; LEELARASAMEE A, 1989, REV INFECT DIS, V11, P413; LORIA PR, 1976, ARCH DERMATOL, V112, P517, DOI 10.1001/archderm.112.4.517; MARDEN PD, 1975, REV SOC BRAS MED TRO, V9, P306; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; MITCHELL G, 1975, AM REV RESPIR DIS, V112, P721; MOORE M, 1967, ARCH DERMATOL, V95, P390, DOI 10.1001/archderm.95.4.390; MOTLEY RJ, 1990, BRIT J DERMATOL, V122, P705, DOI 10.1111/j.1365-2133.1990.tb07294.x; MURDOCH ME, 1989, CLIN EXP DERMATOL, V14, P309, DOI 10.1111/j.1365-2230.1989.tb01990.x; NAHAS LF, 1981, PLAST RECONSTR SURG, V68, P593, DOI 10.1097/00006534-198110000-00020; NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528; OWENS DW, 1969, ARCH DERMATOL, V100, P54, DOI 10.1001/archderm.100.1.54; PADRON S, 1973, SOUTH MED J, V66, P609, DOI 10.1097/00007611-197305000-00023; Perfect J R, 1989, Infect Dis Clin North Am, V3, P77; PHILPOTT JA, 1963, ARCH DERMATOL, V88, P158, DOI 10.1001/archderm.1963.01590200046008; POWELL KE, 1978, JAMA-J AM MED ASSOC, V240, P232, DOI 10.1001/jama.240.3.232; RAPAPORT J, 1966, ARCH DERMATOL, V93, P62, DOI 10.1001/archderm.93.1.62; ROBERTS OOB, 1986, TXB DERMATOLOGY, P886; SATTERWHITE TK, 1979, JAMA-J AM MED ASSOC, V242, P333, DOI 10.1001/jama.242.4.333; SHUTTLEWORTH D, 1989, BRIT J DERMATOL, V120, P683, DOI 10.1111/j.1365-2133.1989.tb01356.x; SMEGO RA, 1984, REV INFECT DIS, V6, P164; SMITH AG, 1975, AM J CLIN PATHOL, V64, P263; SPIER S, 1977, ARCH DERMATOL, V113, P1104, DOI 10.1001/archderm.113.8.1104; TANAKA S, 1989, DERMATOLOGICA, V178, P228, DOI 10.1159/000248434; TESH RB, 1966, NEW ENGL J MED, V275, P597, DOI 10.1056/NEJM196609152751107; TOSH FE, 1964, ARCH INTERN MED, V114, P118, DOI 10.1001/archinte.1964.03860070164022; TRIMBLE JR, 1956, ARCH DERMATOL, V74, P405, DOI 10.1001/archderm.1956.01550100073014; TSUBOI R, 1986, ARCH DERMATOL, V122, P1183, DOI 10.1001/archderm.122.10.1183; VANCUTSEM J, 1987, REV INFECT DIS, V9, pS15; VANNESS GB, 1971, SCIENCE, V172, P1303, DOI 10.1126/science.172.3990.1303; WALLACE RJ, 1983, REV INFECT DIS, V5, P657; WALLACE RJ, 1985, J INFECT DIS, V152, P500, DOI 10.1093/infdis/152.3.500; WALLACE RJ, 1991, ANTIMICROB AGENTS CH, V35, P773, DOI 10.1128/AAC.35.4.773; Wheat L J, 1988, Infect Dis Clin North Am, V2, P841; WILSON J W, 1953, Calif Med, V79, P233; WILSON JP, 1989, MEDICINE, V68, P38, DOI 10.1097/00005792-198901000-00003; WILSON JW, 1955, ARCH DERMATOL, V71, P39, DOI 10.1001/archderm.1955.01540250041008; Winn R E, 1988, Infect Dis Clin North Am, V2, P899; WISHNITZER R, 1984, DERMATOLOGICA, V169, P215, DOI 10.1159/000249609; WLODAVER CG, 1988, ARCH DERMATOL, V124, P659, DOI 10.1001/archderm.124.5.659; Wright ET, 1959, ARCH DERMATOL, V79, P118; ZECLER E, 1977, ARCH DERMATOL, V113, P642, DOI 10.1001/archderm.113.5.642	78	79	80	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					883	888		10.7326/0003-4819-118-11-199306010-00009	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480962				2022-12-28	WOS:A1993LD25200009
J	WANG, CY; PETRYNIAK, B; THOMPSON, CB; KAELIN, WG; LEIDEN, JM				WANG, CY; PETRYNIAK, B; THOMPSON, CB; KAELIN, WG; LEIDEN, JM			REGULATION OF THE ETS-RELATED TRANSCRIPTION FACTOR ELF-1 BY BINDING TO THE RETINOBLASTOMA PROTEIN	SCIENCE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; LONG TERMINAL REPEAT; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; DNA-BINDING; LEUKEMIA-VIRUS; FACTOR E2F; SEQUENCE	The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029673] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI29673-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HORWITZ JM, 1989, SCIENCE, V243, P937; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Wang C.-W., UNPUB; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	52	206	212	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1330	1335		10.1126/science.8493578	http://dx.doi.org/10.1126/science.8493578			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493578				2022-12-28	WOS:A1993LE02500045
J	WEISS, RA				WEISS, RA			HOW DOES HIV CAUSE AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-HELPER LYMPHOCYTES; FOLLICULAR DENDRITIC CELLS; HUMAN PERIPHERAL-BLOOD; MONONUCLEAR PHAGOCYTES; HOMOSEXUAL MEN; INFECTED INDIVIDUALS; TYPE-1; LYMPHADENOPATHY; DISEASE	Many questions have been posed about acquired immunodeficiency syndrome (AIDS) pathogenesis. Is human immunodeficiency virus (HIV) both necessary and sufficient to cause AIDS? Is AIDS essentially an autoimmune disease, triggering apoptosis, or is virus infection the cause of T helper lymphocyte depletion? What is the significance of HIV tropism and the role of macrophages and dendritic cells in AIDS? Is there viral latency and why is there usually a long period between infection and AIDS? Is HIV variation a crucial aspect of its pathogenesis and, if so, do virulent strains emerge? Although this article provides few definitive answers, it aims to focus commentary on salient points. Overall, it is increasingly evident that both the tropism and burden of HIV infection correlate closely with the manifestations of disease.			WEISS, RA (corresponding author), INST CANC RES, CHESTER BEATTY LABS, FULHAM RD, LONDON SW3 6JB, ENGLAND.							ALMOND N, 1993, J GEN VIROL, V74, P865, DOI 10.1099/0022-1317-74-5-865; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855; ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1984, LANCET, V2, P370; ASCHER MS, 1993, NATURE, V362, P103, DOI 10.1038/362103a0; ASJO B, 1986, LANCET, V2, P234; ASJO B, COMMUNICATION; BAIER M, 1991, P NATL ACAD SCI USA, V88, P8126, DOI 10.1073/pnas.88.18.8126; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER HIV AIDS; BERGERON L, 1992, J VIROL, V66, P2389, DOI 10.1128/JVI.66.4.2389-2397.1992; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BRINCHMANN JE, 1991, J VIROL, V65, P2019, DOI 10.1128/JVI.65.4.2019-2023.1991; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; CHAPEL A, 1992, J VIROL, V66, P3966, DOI 10.1128/JVI.66.6.3966-3970.1992; CHENGMAYER C, 1991, VIROLOGY, V181, P288, DOI 10.1016/0042-6822(91)90494-V; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, 1991, EUR J IMMUNOL, V21, P665, DOI 10.1002/eji.1830210319; COLLIN M, 1992, THESIS U OXFORD; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CORBITT G, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91561-N; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DUESBERG P, 1993, LANCET, V341, P957, DOI 10.1016/0140-6736(93)91247-J; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; DUESBERG PH, 1989, P NATL ACAD SCI USA, V86, P755, DOI 10.1073/pnas.86.3.755; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Ewald P W, 1991, Hum Nat, V2, P1, DOI 10.1007/BF02692179; EWALD PW, 1992, SCIENCE, V257, P10; FAUCI AS, 1993, NEW ENGL J MED, V328, P429, DOI 10.1056/NEJM199302113280610; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FENYO EM, 1988, J VIROL, V62, P4414; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1991, J VIROL, V65, P3853, DOI 10.1128/JVI.65.7.3853-3863.1991; GENDELMAN HE, 1990, AIDS, V4, P221, DOI 10.1097/00002030-199003000-00007; GILKS C, COMMUNICATION; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLUCKMAN JC, 1993, SCIENCE, V259, P1809, DOI 10.1126/science.8456306; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GORRELL MD, 1992, J VIROL, V66, P2679, DOI 10.1128/JVI.66.5.2679-2688.1992; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HABESHAW J, 1992, IMMUNOL TODAY, V13, P207, DOI 10.1016/0167-5699(92)90155-Z; HARTUNG S, 1992, J VIROL, V66, P2143, DOI 10.1128/JVI.66.4.2143-2149.1992; HENTGES F, 1992, CLIN EXP IMMUNOL, V88, P237, DOI 10.1111/j.1365-2249.1992.tb03067.x; HIRSCH I, 1992, VIROLOGY, V186, P647, DOI 10.1016/0042-6822(92)90031-J; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HUMPHREY JH, 1984, LANCET, V2, P643; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANOSSY G, 1992, IMMUNODEFICIENCY HIV; JEFFRIES DJ, COMMUNICATION; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KASPER P, 1993, AIDS RES HUM RETROV, V9, P153, DOI 10.1089/aid.1993.9.153; KATSENI VL, 1993, LANCET, V341, P271, DOI 10.1016/0140-6736(93)92617-3; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNIGHT S, COMMUNICATION; KOOT M, IN PRESS ANN INTERN; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LAZDINS JK, 1992, AIDS RES HUM RETROV, V8, P505, DOI 10.1089/aid.1992.8.505; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MACATONIA SE, 1992, IMMUNOLOGY, V75, P576; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MEYAARD L, 1993, IMMUNOL TODAY, V14, P161, DOI 10.1016/0167-5699(93)90279-T; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHIE CA, 1993, TRENDS MICROBIOL, V1, P41; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; Miedema F, 1992, Immunodefic Rev, V3, P173; MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595; MULDER D, 1992, 8 INT AIDS C; NOVEMBRE FJ, 1993, J VIROL, V67, P2466, DOI 10.1128/JVI.67.5.2466-2474.1993; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; NOWAK MA, 1992, J THEOR BIOL, V159, P329, DOI 10.1016/S0022-5193(05)80728-3; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; OKA S, 1992, 8 INT AIDS C; OVERBAUGH J, 1991, J VIROL, V65, P7025, DOI 10.1128/JVI.65.12.7025-7031.1991; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; PHILLIPS AN, 1993, LANCET, V341, P1023, DOI 10.1016/0140-6736(93)91111-X; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Root-Bernstein R., 1993, RETHINKING AIDS TRAG; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1993, LANCET, V341, P658, DOI 10.1016/0140-6736(93)90421-C; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SELLON DC, 1992, J VIROL, V66, P5906, DOI 10.1128/JVI.66.10.5906-5913.1992; SHARMA DP, 1992, J VIROL, V66, P3550, DOI 10.1128/JVI.66.6.3550-3556.1992; SHEARER GM, 1991, AIDS, V5, P245, DOI 10.1097/00002030-199103000-00001; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; STANLEY SK, 1993, J ACQ IMMUN DEF SYND, V6, P142; STEEL CM, 1988, LANCET, V1, P1185; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TENNERRACZ K, 1985, LANCET, V1, P105; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TSAI WP, 1992, AIDS RES HUM RETROV, V8, P1749, DOI 10.1089/aid.1992.8.1749; VALENTIN A, 1991, J ACQ IMMUN DEF SYND, V4, P751; VALENTIN A, 1992, THESIS KAROLINSKA I; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; WAINHOBSON S, IN PRESS EVOLUTIONAR; WANG RYH, 1992, LANCET, V340, P1312, DOI 10.1016/0140-6736(92)92493-Y; WATANABE M, 1991, J VIROL, V65, P3344, DOI 10.1128/JVI.65.6.3344-3348.1991; WEBSTER A, 1992, CLIN EXP IMMUNOL, V88, P6; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WEISS RA, 1990, NATURE, V345, P659, DOI 10.1038/345659a0; WEISS RA, 1993, RETROVIRIDAE, V2, P1; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; ZACK J, 1991, J VIROL, V65, P2102; ZANGERLE R, 1993, AIDS, V7, P175, DOI 10.1097/00002030-199302000-00004	141	501	525	2	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1273	1279		10.1126/science.8493571	http://dx.doi.org/10.1126/science.8493571			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493571				2022-12-28	WOS:A1993LE02500033
J	BULENGORANSBY, SM; GRIFFITHS, CEM; KIMBROUGHGREEN, CK; FINKEL, LJ; HAMILTON, TA; ELLIS, CN; VOORHEES, JJ				BULENGORANSBY, SM; GRIFFITHS, CEM; KIMBROUGHGREEN, CK; FINKEL, LJ; HAMILTON, TA; ELLIS, CN; VOORHEES, JJ			TOPICAL TRETINOIN (RETINOIC ACID) THERAPY FOR HYPERPIGMENTED LESIONS CAUSED BY INFLAMMATION OF THE SKIN IN BLACK PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYDROQUINONE BLEACHING CREAMS; PHOTOAGED SKIN; COLOR; PIGMENTATION	Background and Methods. Irregular disfiguring skin hyperpigmentation due to inflammation may develop in black persons. We investigated the treatment of this hyperpigmentation with topical tretinoin (0.1 percent retinoic acid cream). Fifty-four subjects completed a 40-week randomized, double-blind, vehicle-controlled study. Twenty-four subjects applied tretinoin daily to the face, arms, or both areas, and 30 subjects applied vehicle cream. At base line and after 40 weeks of treatment, each subject's postinflammatory hyperpigmented lesions and normal skin were assessed by clinical and colorimetric evaluations and by analysis of biopsy specimens. Results. The facial postinflammatory hyperpigmented lesions of the tretinoin-treated subjects were significantly lighter after the 40 weeks of therapy than those of the vehicle-treated subjects (P<0.001); overall improvement was first noted after 4 weeks of tretinoin treatment. At the end of treatment, colorimetry demonstrated a 40 percent lightening of the lesions toward normal skin color in the tretinoin-treated lesions, as compared with an 18 percent lightening in vehicle-treated lesions (P = 0.05). The epidermal melanin content in the lesions decreased by 23 percent with tretinoin and by 3 percent with vehicle (P = 0.24). Normal skin was minimally lightened by tretinoin as compared with vehicle, according to both clinical evaluation (0.1 vs. -0.1 unit change on an 8-point scale; P = 0.055) and colorimetry (P<0.001). Retinoid dermatitis developed in 12 of the 24 tretinoin-treated subjects who completed the study (50 percent) and in 1 tretinoin-treated subject who withdrew from the study, but diminished as the study progressed. Conclusions. Topical application of tretinoin significantly lightens postinflammatory hyperpigmentation; to a clinically minimal but statistically significant degree, it also lightens normal skin in black persons.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,DERMATOPATHOL UNIT,1910 TAUBMAN CTR,1500 E MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Griffiths, Christopher E.M./P-5448-2014; Ellis, Charles/ABA-7264-2021	Griffiths, Christopher E.M./0000-0001-5371-4427; Ellis, Charles/0000-0001-9436-7628				ANDREASSI L, 1990, PHOTODERMATOL PHOTO, V7, P20; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FINDLAY GH, 1975, BRIT J DERMATOL, V93, P613, DOI 10.1111/j.1365-2133.1975.tb05110.x; GRIMES PE, 1988, DERMATOL CLIN, V6, P271, DOI 10.1016/S0733-8635(18)30673-9; HOSHAW RA, 1985, ARCH DERMATOL, V121, P105, DOI 10.1001/archderm.121.1.105; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; KENNEY JA, 1989, CLIN DERMATOL, V7, P1, DOI 10.1016/0738-081X(89)90052-7; KLIGMAN AM, 1975, ARCH DERMATOL, V111, P40; KLIGMAN AM, 1986, J AM ACAD DERMATOL, V15, P836, DOI 10.1016/S0190-9622(86)70242-9; MCDONALD CJ, 1973, PROG DERMATOL, V7, P15; OLSEN EA, 1992, J AM ACAD DERMATOL, V26, P215, DOI 10.1016/0190-9622(92)70030-J; ORLOW SJ, 1990, J INVEST DERMATOL, V94, P461, DOI 10.1111/1523-1747.ep12874568; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; SERUP J, 1990, CLIN EXP DERMATOL, V15, P267, DOI 10.1111/j.1365-2230.1990.tb02087.x; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527	16	142	144	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1438	1443		10.1056/NEJM199305203282002	http://dx.doi.org/10.1056/NEJM199305203282002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479462	Bronze			2022-12-28	WOS:A1993LB78300002
J	MORTONJONES, TJ; PRINGLE, MAL				MORTONJONES, TJ; PRINGLE, MAL			PRESCRIBING COSTS IN DISPENSING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine differences in prescribing between dispensing and non-dispensing practices. Setting-The 108 practices covered by Lincolnshire Family Health Services Authority. Design-Analysis of prescribing data for 1990-1 from PD2 reports from the Prescription Pricing Authority in relation to data on practice characteristics obtained from Lincolnshire Family Health Services Authority; and aggregated level 3 prescribing and cost information (PACT data) for 10 selected drugs from the Prescription Pricing Authority to examine amounts prescribed. Main outcome measures-Prescribing cost per patient, items per patient, and cost per item in dispensing and non-dispensing practices. Results-Dispensing practices had higher prescribing costs per patient than non-dispensing practices. This difference held for non-dispensing patients within dispensing practices. Structural features failed to explain the differences in prescribing cost, except for the higher numbers of elderly patients in dispensing practices (which explained 13% of the difference) and the number of partners (5%). The main determinant of the difference was the lower use of generic drugs in dispensing practices (84%). Dispensing patients were prescribed lower quantities of drugs on average for each item. Conclusions-Dispensing practices could reduce their prescribing expenditure to that of non-dispensing practices by increasing their prescribing of generic drugs. The shorter prescribing intervals for dispensing patients may be due to dispensing fees being related to the number of prescribed items.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; DYER C, 1988, BRIT MED J, V296, P735; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GEDDES GL, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1990, ANAL PRESCRIBING GEN; JENNINGS SJ, 1988, BRIT MED J, V296, P936, DOI 10.1136/bmj.296.6626.936-h; MORTONJONES AJ, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478-a; MORTONJONES AJ, IN PRESS BMJ; ROBERTS D, 1992, BRIT MED J, V305, P187, DOI 10.1136/bmj.305.6846.187-c; 1991, 1990 1991 PRESCR PRI, P8; 1991, HLTH SERVICES INDICA	12	37	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1244	1246		10.1136/bmj.306.6887.1244	http://dx.doi.org/10.1136/bmj.306.6887.1244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499855	Bronze, Green Published			2022-12-28	WOS:A1993LB80400019
J	FAHAL, IH; MURRY, N; CHU, P; BELL, GM				FAHAL, IH; MURRY, N; CHU, P; BELL, GM			ACUTE-RENAL-FAILURE DURING INTERFERON TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter							NEPHROTIC SYNDROME				FAHAL, IH (corresponding author), ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L7 8XP,ENGLAND.		Fahal, Ibrahim/ABC-1366-2021	Fahal, Ibrahim/0000-0003-4897-6427				AVERBUCH SD, 1984, NEW ENGL J MED, V310, P32, DOI 10.1056/NEJM198401053100107; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; QUESADA JR, 1986, J CLIN ONCOL, V4, P234, DOI 10.1200/JCO.1986.4.2.234; ROTH MS, 1986, AM J MED, V81, P871, DOI 10.1016/0002-9343(86)90360-8; SELBY P, 1985, BRIT MED J, V290, P1180, DOI 10.1136/bmj.290.6476.1180; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701	6	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					973	973		10.1136/bmj.306.6883.973	http://dx.doi.org/10.1136/bmj.306.6883.973			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490476	Green Published, Bronze			2022-12-28	WOS:A1993KX43600020
J	SOYLAND, E; FUNK, J; RAJKA, G; SANDBERG, M; THUNE, P; RUSTAD, L; HELLAND, S; MIDDELFART, K; ODU, S; FALK, ES; SOLVOLL, K; BJORNEBOE, GEA; DREVON, CA				SOYLAND, E; FUNK, J; RAJKA, G; SANDBERG, M; THUNE, P; RUSTAD, L; HELLAND, S; MIDDELFART, K; ODU, S; FALK, ES; SOLVOLL, K; BJORNEBOE, GEA; DREVON, CA			EFFECT OF DIETARY SUPPLEMENTATION WITH VERY-LONG-CHAIN N-3 FATTY-ACIDS IN PATIENTS WITH PSORIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FISH OIL; EICOSAPENTAENOIC ACID; CLINICAL MANIFESTATIONS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND; METABOLITES; IMPROVEMENT; NEUTROPHIL; INVITRO; THERAPY	Background. In several studies dietary fish oil has been found to have a beneficial effect on psoriasis, but the results are contradictory and based mainly on open studies or studies of small numbers of patients. Methods. In a four-month double-blind, multicenter trial, we randomly assigned 145 patients with moderate-to-severe psoriasis to receive in their diet either highly purified ethyl esters of n-3 fatty acids (''fish oil''; 6 g of oil per day, containing 5 g of eicosapentaenoic and docosahexaenoic acid) or an isoenergetic amount of corn oil containing mainly n-6 fatty acids. All the patients were advised to reduce their intake of saturated fatty acids. A 48-hour dietary recall was performed, and the fatty-acid pattern in the serum phospholipids was monitored in a subgroup of patients. Results. In the fish-oil group, n-3 fatty acids were increased in serum phospholipids (P<0.001), the ratio of arachidonic acid to eicosapentaenoic acid decreased (P<0.001), and the level of n-6 fatty acids decreased (P<0.001). In the corn-oil group, only docosahexaenoic acid increased significantly (P<0.05). The ratio of polyunsaturated to saturated fatty acids increased in both groups. Plasma concentrations of triacylglycerol decreased from base line in the fish-oil group (P<0.05). The score on the Psoriasis Area and Severity Index, as evaluated by the physicians, did not change significantly during the trial in either group. This was also true of a total subjective score reported by the patients, but a selected area of skin in the corn-oil group showed a significant reduction in the clinical signs (P<0.05). Scaling was reduced from base line in both groups (P<0.01). The fish-oil group had less cellular infiltration (P<0.01), and the corn-oil group had improvement in desquamation and redness (P<0.05). There was no clinically important difference between the two study groups. Among the patients in the fish-oil group, an increase in the concentration of n-3 fatty acids in serum phospholipids was not accompanied by clinical improvement, whereas in the corn-oil group there was a significant correlation between clinical improvement and an increase in eicosapentaenoic acid and total n-3 fatty acids. Conclusions. Dietary supplementation with very-long-chain n-3 fatty acids was no better than corn-oil supplementation in treating psoriasis. Clinical improvement was not correlated with an increase in the concentration of n-3 fatty acids in serum phospholipids among the patients in the fish-oil group, whereas there was a significant correlation between clinical improvement and an increase in eicosapentaenoic acid and total n-3 fatty acids in the corn-oil group.	UNIV TROMSO, N-9001 TROMSO, NORWAY; UNIV TRONDHEIM, TRONDHEIM, NORWAY; NATL HOSP NORWAY, DEPT DERMATOL, OSLO 1, NORWAY; UNIV BERGEN, N-5014 BERGEN, NORWAY; ULLEVAL HOSP, DEPT DERMATOL, OSLO 1, NORWAY; HAUKELAND HOSP, DEPT DERMATOL, N-5016 BERGEN, NORWAY; REG HOSP, DEPT DERMATOL, TROMSO, NORWAY	UiT The Arctic University of Tromso; University of Oslo; National Hospital Norway; University of Bergen; University of Oslo; University of Bergen; Haukeland University Hospital	SOYLAND, E (corresponding author), UNIV OSLO, INST NUTR RES, POB 1046, N-0316 OSLO, NORWAY.		Drevon, Christian A/F-6012-2010					ABERER W, 1981, J INVEST DERMATOL, V76, P202, DOI 10.1111/1523-1747.ep12525745; ALLEN BR, 1985, BRIT J DERMATOL, V113, P777; BAADSGAARD O, 1989, J INVEST DERMATOL, V92, P190, DOI 10.1111/1523-1747.ep12276718; BAKER BS, 1984, BRIT J DERMATOL, V110, P555; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BARKER JNWN, 1991, LANCET, V338, P227, DOI 10.1016/0140-6736(91)90357-U; BITTINER SB, 1988, LANCET, V1, P378; BJORNEBOE A, 1987, BRIT J DERMATOL, V117, P463, DOI 10.1111/j.1365-2133.1987.tb04926.x; BJORNEBOE A, 1988, BRIT J DERMATOL, V118, P77, DOI 10.1111/j.1365-2133.1988.tb01753.x; BONAA KH, 1990, NEW ENGL J MED, V322, P795, DOI 10.1056/NEJM199003223221202; CRAWFORD MA, 1983, BRIT MED BULL, V39, P210, DOI 10.1093/oxfordjournals.bmb.a071820; Drevon C. A., 1990, Naringsforskning, V34, P56; DREVON CA, 1991, FREE RADICAL RES COM, V14, P229, DOI 10.3109/10715769109088952; DREVON CA, 1992, NUTR REV, V50, P38; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; GUPTA AK, 1989, BRIT J DERMATOL, V120, P801, DOI 10.1111/j.1365-2133.1989.tb01378.x; KELLEY VE, 1985, J IMMUNOL, V134, P1914; KETTLER AH, 1988, J AM ACAD DERMATOL, V18, P1267, DOI 10.1016/S0190-9622(88)70133-4; KRAGBALLE K, 1985, BRIT J DERMATOL, V113, P43, DOI 10.1111/j.1365-2133.1985.tb02043.x; KRAGBALLE K, 1989, ACTA DERM-VENEREOL, V69, P23; KREMER JM, 1985, LANCET, V1, P184; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; MAURICE PDL, 1987, BRIT J DERMATOL, V117, P599, DOI 10.1111/j.1365-2133.1987.tb07492.x; MILLER CC, 1989, LIPIDS, V24, P998, DOI 10.1007/BF02544068; NENSETER MS, 1992, ARTERIOSCLER THROMB, V12, P369, DOI 10.1161/01.ATV.12.3.369; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; RIVERS JPW, 1981, BRIT MED BULL, V37, P59, DOI 10.1093/oxfordjournals.bmb.a071677; SANTOLI D, 1990, J CLIN INVEST, V85, P424, DOI 10.1172/JCI114455; SOYLAND E, 1993, EUR J CLIN INVEST, V23, P112, DOI 10.1111/j.1365-2362.1993.tb00750.x; TERANO T, 1989, ADV PROSTAG THROMB L, V19, P610; VANGOSSUM A, 1988, AM J CLIN NUTR, V48, P1394, DOI 10.1093/ajcn/48.6.1394; VERBEY NLJ, 1990, INVEST OPHTH VIS SCI, V31, P1526; VOORHEES JJ, 1983, ARCH DERMATOL, V119, P541, DOI 10.1001/archderm.119.7.541; ZIBOH VA, 1986, ARCH DERMATOL, V122, P1277, DOI 10.1001/archderm.122.11.1277	35	83	86	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1812	1816		10.1056/NEJM199306243282504	http://dx.doi.org/10.1056/NEJM199306243282504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502270	Bronze			2022-12-28	WOS:A1993LH21000004
J	DECKER, D				DECKER, D			PROPHYLACTIC MASTECTOMY FOR FAMILIAL BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK				DECKER, D (corresponding author), CANC CARE ASSOCIATES,ROYAL OAK,MI, USA.							ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO;2-0; HENDERSON I, 1990, CURR PROBL CANCER, V14, P166; OTTMAN R, 1983, LANCET, V2, P556	3	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2608	2609						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487430				2022-12-28	WOS:A1993LC86500003
J	PETER, M; GARTNER, A; HORECKA, J; AMMERER, G; HERSKOWITZ, I				PETER, M; GARTNER, A; HORECKA, J; AMMERER, G; HERSKOWITZ, I			FAR1 LINKS THE SIGNAL-TRANSDUCTION PATHWAY TO THE CELL-CYCLE MACHINERY IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; POSITIVE FEEDBACK; MATING-PHEROMONE; GENE; START; STE12; DIVISION; ARREST; CLN2	Alpha factor induces arrest of yeast a cells in G1 and transcription of genes involved in mating. Prior work indicates that FUS3, a member of the MAP kinase family, and FAR1, whose molecular activity is unknown, contribute to cell cycle arrest by inhibiting G1 cyclins. Here we show that FAR1 is a substrate for FUS3 and that this phosphorylation regulates association of FAR1 with CDC28-CLN2 kinase. We show also that FAR1 is phosphorylated in vitro by the CDC28-CLN2 complex and in vivo in a CDC28-dependent manner. Mutational analysis of FAR1 reveals a correlation between its ability to associate with CDC28-CLN2 and to arrest the cell cycle. These results suggest that FAR1 protein is the link between the signaling pathway and the cell cycle machinery.	UNIV VIENNA,LUDWIG BOLTZMANN FORSCH STELLE,INST BIOCHEM & MOLEK ZELLBIOL,A-1030 VIENNA,AUSTRIA; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143	Ludwig Boltzmann Institute; University of Vienna; University of Oregon; University of Oregon; University of California System; University of California San Francisco	PETER, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,PROGRAM GENET,SAN FRANCISCO,CA 94143, USA.			Gartner, Anton/0000-0003-4639-9902	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030027, P01GM031286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30027, GM31286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOL MOL; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIZUELA L, 1987, EMBO J, V6, P3707; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CHANG F, 1991, THESIS U CALIFORNIA; CLAERKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, CELL, V258, P478; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Ducommun B, 1991, Semin Cell Biol, V2, P233; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; FUJIMURA H, 1990, CURR GENET, V18, P395, DOI 10.1007/BF00309907; FUJIMURA H, 1991, CURR GENET, V2, P205; FUTCHER BA, 1991, SEMIN CELL BIOL, V2, P205; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GU Y, 1992, EMBO J, V11, P3996; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARLOW E, 1988, ANTIBODIES LABORATOR; HICKS JB, 1976, GENETICS, V83, P245; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NEIMAN AM, 1990, CELL REGUL, V1, P391, DOI 10.1091/mbc.1.5.391; OGAS J, 1992, THESIS U CALIFORNIA; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1980, GENETICS, V95, P561; Reed SI, 1991, CURR OPIN GENET DEV, V1, P391, DOI 10.1016/S0959-437X(05)80305-3; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUBIN G, 1975, METHOD CELL BIOL, P45; Sambrook J, 1989, MOL CLONING LABORATO; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; Sherman F., 1982, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprague George F. Jr., 1992, Current Biology, V2, P587, DOI 10.1016/0960-9822(92)90159-8; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VALDIVIESO HM, 1993, MOL CELL BIOL, V13, P1013; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P100; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	74	309	311	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					747	760		10.1016/0092-8674(93)90254-N	http://dx.doi.org/10.1016/0092-8674(93)90254-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500168				2022-12-28	WOS:A1993LD83000013
J	LOWENFELS, AB; MAISONNEUVE, P; CAVALLINI, G; AMMANN, RW; LANKISCH, PG; ANDERSEN, JR; DIMAGNO, EP; ANDRENSANDBERG, A; DOMELLOF, L				LOWENFELS, AB; MAISONNEUVE, P; CAVALLINI, G; AMMANN, RW; LANKISCH, PG; ANDERSEN, JR; DIMAGNO, EP; ANDRENSANDBERG, A; DOMELLOF, L			PANCREATITIS AND THE RISK OF PANCREATIC-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAST MEDICAL HISTORY; BEVERAGE CONSUMPTION; ALCOHOL; TOBACCO; EPIDEMIOLOGY; POPULATION; CARCINOMA; SMOKING; COFFEE	Background. The results of case-control studies and anecdotal reports suggest that pancreatitis may be a risk factor for pancreatic cancer, but there have been no studies of sufficient size and power to assess the magnitude of the relation between these two diseases. Methods and Results. We undertook a multicenter historical cohort study of 2015 subjects with chronic pancreatitis who were recruited from clinical centers in six countries. A total of 56 cancers were identified among these patients during a mean (+/-SD) follow-up of 7.4+/-6.2 years. The expected number of cases of cancer calculated from country-specific incidence data and adjusted for age and sex was 2.13, yielding a standardized incidence ratio (the ratio of observed to expected cases) of 26.3 (95 percent confidence interval, 19.9 to 34.2). For subjects with a minimum of two or five years of follow-up, the respective standardized incidence ratios were 16.5 (95 percent confidence interval, 11.1 to 23.7) and 14.4 (95 percent confidence interval, 8.5 to 22.8). The cumulative risk of pancreatic cancer in subjects who were followed for at least 2 years increased steadily, and 10 and 20 years after the confidence interval, 1.0 to 2.6 percent) and 4.0 percent (95 percent confidence interval, 2.0 to 5.9 percent), respectively. Conclusions. The risk of pancreatic cancer is significantly elevated in subjects with chronic pancreatitis and appears to be independent of sex, country, and type of pancreatitis.	NEW YORK MED COLL, DEPT COMMUNITY & PREVENT MED, VALHALLA, NY 10595 USA; EUROPEAN INST ONCOL, DIV EPIDEMIOL & BIOSTAT, MILAN, ITALY; UNIV VERONA, SERV GASTROENTEROL & DIGEST ENDOSCOPY, I-37100 VERONA, ITALY; UNIV HOSP ZURICH, DEPT MED, GASTROENTEROL SERV, CH-8091 ZURICH, SWITZERLAND; UNIV GOTTINGEN, DEPT INTERNAL MED, W-3400 GOTTINGEN, GERMANY; MUNICIPAL HOSP LUNEBURG, DEPT INTERNAL MED, LUNEBURG, GERMANY; UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT GASTROENTEROL, DK-2650 HVIDOVRE, DENMARK; MAYO CLIN & MAYO FDN, GASTROINTESTINAL RES UNIT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, ROCHESTER, MN 55905 USA; UNIV LUND, DEPT SURG, S-22101 LUND, SWEDEN; OREBRO MED CTR HOSP, DEPT SURG, OREBRO, SWEDEN	New York Medical College; IRCCS European Institute of Oncology (IEO); University of Verona; University of Zurich; University Zurich Hospital; University of Gottingen; University of Copenhagen; Mayo Clinic; Mayo Clinic; Lund University	LOWENFELS, AB (corresponding author), NEW YORK MED COLL, DEPT SURG, VALHALLA, NY 10595 USA.		Lowenfels, Albert/ABD-8388-2021; Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610; Andersen, Jens Rikardt/0000-0003-3503-8474				Alcohol Drinking, 1988, IARC MONOGRAPHS EVAL; AMMANN RW, 1984, GASTROENTEROLOGY, V86, P820; AMMANN RW, 1984, GASTROENTEROLOGY, V87, P744; [Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; BOURLIERE M, 1991, GUT, V32, P1392, DOI 10.1136/gut.32.11.1392; CAVALLINI G, 1989, PANCREAS, V4, P300, DOI 10.1097/00006676-198906000-00005; CLAVEL F, 1989, INT J CANCER, V43, P17, DOI 10.1002/ijc.2910430105; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; DEMESQUITA HBB, 1991, INT J CANCER, V49, P816, DOI 10.1002/ijc.2910490604; DIMAGNO EP, 1988, MED CLIN N AM, V72, P979, DOI 10.1016/S0025-7125(16)30725-8; GHADIRIAN P, 1991, CANCER-AM CANCER SOC, V67, P2664, DOI 10.1002/1097-0142(19910515)67:10&lt;2664::AID-CNCR2820671043&gt;3.0.CO;2-K; GOLD EB, 1985, CANCER-AM CANCER SOC, V55, P460, DOI 10.1002/1097-0142(19850115)55:2<460::AID-CNCR2820550229>3.0.CO;2-V; GROSS JB, 1986, EXOCRINE PANCREAS BI, P829; HAAS O, 1990, HEPATO-GASTROENTEROL, V37, P350; HIATT RA, 1988, INT J CANCER, V41, P794, DOI 10.1002/ijc.2910410603; KRAG E, 1981, SCAND J GASTROENTERO, V16, P305; LANKISCH PG, 1990, ACTA CHIR SCAND, V156, P273; LAVECCHIA C, 1990, ONCOLOGY-BASEL, V47, P463; LIN JT, 1988, PANCREAS, V3, P111, DOI 10.1097/00006676-198802000-00020; LOWENFELS AB, 1987, PANCREAS, V2, P694, DOI 10.1097/00006676-198711000-00012; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MILLS PK, 1988, CANCER-AM CANCER SOC, V61, P2578, DOI 10.1002/1097-0142(19880615)61:12&lt;2578::AID-CNCR2820611232&gt;3.0.CO;2-0; MISRA SP, 1990, INT J PANCREATOL, V6, P307; NEGLIA JP, 1991, J PEDIATR-US, V119, P764, DOI 10.1016/S0022-3476(05)80296-3; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; THOMAS PG, 1990, WORLD J SURG, V14, P32, DOI 10.1007/BF01670542; VELEMA JP, 1986, EPIDEMIOL REV, V8, P28, DOI 10.1093/oxfordjournals.epirev.a036294; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WHITTEMORE AS, 1983, J CHRON DIS, V36, P251, DOI 10.1016/0021-9681(83)90059-0; WYNDER EL, 1973, JNCI-J NATL CANCER I, V50, P645, DOI 10.1093/jnci/50.3.645; YEN S, 1982, AM J EPIDEMIOL, V116, P407, DOI 10.1093/oxfordjournals.aje.a113425; 1987, IARC SCI PUBL, V82, P272; 1987, CANCER INCIDENCE 5 C, P1; 1991, NCI NIH912789 PUBL; 1992, SAS SYSTEM RELEASE 6	36	1292	1354	2	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1433	1437		10.1056/NEJM199305203282001	http://dx.doi.org/10.1056/NEJM199305203282001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479461				2022-12-28	WOS:A1993LB78300001
J	DIAMOND, GA				DIAMOND, GA			POSTINFARCTION RISK STRATIFICATION - IS PREVENTIVE WAR WINNABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; MANAGEMENT				DIAMOND, GA (corresponding author), CEDARS SINAI MED CTR,DIV CARDIOL,8700 BEVERLY BLVD,LOS ANGELES,CA 90048, USA.							BLAIR C, 1957, LIFE            0225, P89; BODENHEIMER MM, 1992, ANN INTERN MED, V116, P927, DOI 10.7326/0003-4819-116-11-927; DEBUSK RF, 1989, ANN INTERN MED, V110, P470, DOI 10.7326/0003-4819-110-6-470; DIAMOND GA, IN PRESS J AM COLL C; DITTUS RS, 1987, J AM COLL CARDIOL, V10, P869, DOI 10.1016/S0735-1097(87)80282-6; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; FUBINI A, 1992, INT J CARDIOL, V34, P3419; KULICK DL, 1991, AM HEART J, V121, P641, DOI 10.1016/0002-8703(91)90747-6; MICKLEY H, 1903, AM J CARDIOL, V71, P139; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379	11	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2418	2419		10.1001/jama.269.18.2418	http://dx.doi.org/10.1001/jama.269.18.2418			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	8479070				2022-12-28	WOS:A1993LA67500039
J	BUDAY, L; DOWNWARD, J				BUDAY, L; DOWNWARD, J			EPIDERMAL GROWTH-FACTOR REGULATES P21(RAS) THROUGH THE FORMATION OF A COMPLEX OF RECEPTOR, GRB2 ADAPTER PROTEIN, AND SOS NUCLEOTIDE EXCHANGE FACTOR	CELL			English	Article							AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; RAS PROTEINS; P21RAS; ONCOGENE; STIMULATION; ACTIVATION; GDP; SIMILARITY	Antisera against murine Son of sevenless (Sos) recognize a protein of M(r) 155,000 in rat-1 fibroblasts with specific guanine nucleotide exchange activity toward p21c-Ha-ras. Epidermal growth factor (EGF) receptor coimmunoprecipitates with Sos from EGF-stimulated, but not quiescent, cells. The SH2 and SH3 domain-containing ''adapter'' protein Grb2 is also found in Sos immunoprecipitates in an EGF-inducible manner. In vitro reconstitution shows that Grb2 is required for the binding of activated EGF receptor to Sos. A phosphopeptide corresponding to tyrosine 1068 of the EGF receptor blocks both the assembly of the complex and EGF stimulation of nucleotide exchange on p21ras in a permeabilized cell system. These results suggest that EGF-induced activation of nucleotide exchange on p21ras proceeds through the recruitment of cytosolic Sos to a complex with EGF receptor and Grb2 at the plasma membrane.			BUDAY, L (corresponding author), IMPERIAL CANC RES FUND, SIGNAL TRANSDUCT LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Downward, Julian/0000-0002-2331-4729				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN S, 1982, J BIOL CHEM, V257, P1523; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GATES RE, 1985, BIOCHEMISTRY-US, V24, P5209, DOI 10.1021/bi00340a038; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAVES JD, 1991, J IMMUNOL, V146, P3709; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HARLOW E, 1988, ANTIBODIES LABORATOR; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUROYA K, 1992, ONCOGENE, V7, P277; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TORTI M, 1992, J BIOL CHEM, V267, P8293; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	1063	1091	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					611	620		10.1016/0092-8674(93)90146-H	http://dx.doi.org/10.1016/0092-8674(93)90146-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490966				2022-12-28	WOS:A1993LA74300020
J	MOLYNEUX, M; FOX, R				MOLYNEUX, M; FOX, R			DIAGNOSIS AND TREATMENT OF MALARIA IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Review							SEVERE FALCIPARUM-MALARIA; CEREBRAL MALARIA; EXCHANGE-TRANSFUSION; CONTROLLED TRIAL; DOUBLE-BLIND; QUININE; CHILDREN; DEXAMETHASONE; QUINIDINE; INFUSION		FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND		MOLYNEUX, M (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,ENGLAND.							[Anonymous], 1993, BRUCE CHWATTS ESSENT; BERGIN JJ, 1967, MIL MED, V132, P522, DOI 10.1093/milmed/132.7.522; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CHIODINI PL, 1990, LANCET, V335, P554, DOI 10.1016/0140-6736(90)90798-A; CONLON CP, 1990, LANCET, V335, P472, DOI 10.1016/0140-6736(90)90704-9; CURTIS CF, 1984, J TROP MED HYG, V87, P101; DAVIS TME, 1990, J INFECT DIS, V161, P1305, DOI 10.1093/infdis/161.6.1305; GILLES HM, 1991, MANAGEMENT SEVERE CO; HOFFMAN SL, 1988, J INFECT DIS, V158, P325, DOI 10.1093/infdis/158.2.325; HULBERT TV, 1992, CLIN INFECT DIS, V14, P922, DOI 10.1093/clinids/14.4.922; KWIATKOWSKI D, 1991, LANCET, V337, P1281; LEWIS SJ, 1992, BMJ-BRIT MED J, V305, P741, DOI 10.1136/bmj.305.6856.741; LOOAREESUWAN S, 1985, LANCET, V2, P4, DOI 10.1016/S0140-6736(85)90056-X; MEEK SR, 1986, AM J TROP MED HYG, V35, P246, DOI 10.4269/ajtmh.1986.35.246; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; MOLYNEUX ME, 1989, Q J MED, V71, P441; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; PHILLIPS RE, 1985, NEW ENGL J MED, V312, P1273, DOI 10.1056/NEJM198505163122001; TEASDALE G, 1974, LANCET, V2, P81; TRANG TTM, 1992, CLIN INFECT DIS, V15, P874, DOI 10.1093/clind/15.5.874; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; WARRELL DA, 1990, T ROY SOC TROP MED H, V2, P1; WATTANAGOON Y, 1986, BRIT MED J, V293, P11, DOI 10.1136/bmj.293.6538.11; White N. J., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P55; WHITE NJ, 1988, LANCET, V2, P64; WHITE NJ, 1983, AM J TROP MED HYG, V32, P1; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WINTERS RA, 1992, AM J MED, V93, P243, DOI 10.1016/0002-9343(92)90228-4; 1992, WHO WEEKLY EPIDEMIOL, V67, P161	32	48	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1175	1180		10.1136/bmj.306.6886.1175	http://dx.doi.org/10.1136/bmj.306.6886.1175			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499825	Bronze, Green Published			2022-12-28	WOS:A1993LA68500029
J	MADAN, I				MADAN, I			PREEMPLOYMENT CHEST RADIOGRAPHY FOR HEALTH-SERVICE STAFF - WHO NEEDS IT	BRITISH MEDICAL JOURNAL			English	Article							TUBERCULOSIS				MADAN, I (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT OCCUPAT HLTH,LONDON SE1 7EH,ENGLAND.			madan, ira/0000-0003-2200-7329				COCKCROFT A, 1990, BRIT MED J, V300, P1723; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; 1990, BMJ, V300, P995; 1992, THORAX, V47, P770	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1041	1042		10.1136/bmj.306.6884.1041	http://dx.doi.org/10.1136/bmj.306.6884.1041			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490499	Green Published, Bronze			2022-12-28	WOS:A1993KY44800021
J	CARDOZO, L				CARDOZO, L			IS ROUTINE INDUCTION OF LABOR AT TERM EVER JUSTIFIED	BRITISH MEDICAL JOURNAL			English	Article							PROLONGED PREGNANCY	Balancing the risks of prolonged gestation against those of induced labour is difficult. Risks to the fetus increase slightly after 42 weeks' gestation but women having labour induced are more likely to have instrumental deliveries or babies with low Apgar scores. Since many women are now expressing a preference for minimal interference in childbirth the most acceptable management of post-term pregnancy seems to be increased fetal surveillance. Each case needs to be considered individually and it is important that the woman is involved in the decision to induce.			CARDOZO, L (corresponding author), UNIV LONDON KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND.							AUGENSEN K, 1987, BRIT MED J, V294, P1192, DOI 10.1136/bmj.294.6581.1192; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P683, DOI 10.3109/00016348909006139; BOYD ME, 1988, AM J OBSTET GYNECOL, V158, P334, DOI 10.1016/0002-9378(88)90150-0; CARDOZO L, 1986, BMJ-BRIT MED J, V293, P1059, DOI 10.1136/bmj.293.6554.1059; CHAPPATTE O, 1992, LANCET, V339, P122; GIBB DMF, 1982, BRIT J OBSTET GYNAEC, V89, P292, DOI 10.1111/j.1471-0528.1982.tb04698.x; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; KELLEHER C, IN PRESS J OBSTET GY; MCCOLGIN SW, 1990, OBSTET GYNECOL, V76, P678; PEARCE JM, 1991, OBSTET GYNECOL, V77, P204, DOI 10.1097/00006250-199102000-00008; SAUNDERS N, 1991, LANCET, V338, P1190, DOI 10.1016/0140-6736(91)92044-3	11	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					840	841		10.1136/bmj.306.6881.840	http://dx.doi.org/10.1136/bmj.306.6881.840			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490378	Bronze, Green Published			2022-12-28	WOS:A1993KV34800025
J	STRAIN, EC; STITZER, ML; LIEBSON, IA; BIGELOW, GE				STRAIN, EC; STITZER, ML; LIEBSON, IA; BIGELOW, GE			DOSE-RESPONSE EFFECTS OF METHADONE IN THE TREATMENT OF OPIOID DEPENDENCE	ANNALS OF INTERNAL MEDICINE			English	Article						SUBSTANCE DEPENDENCE; METHADONE; DOSE-RESPONSE RELATIONSHIP, DRUG; COCAINE; NARCOTICS	ACQUIRED IMMUNODEFICIENCY SYNDROME; INTRAVENOUS-DRUG-USERS; HEROIN-ADDICTS; ABUSE; MAINTENANCE; INFECTION	Objective: To compare the dose effectiveness of low to moderate doses of methadone in a sample of a contemporary population of opioid abusers, because the optimal dosing of methadone in the treatment of opioid dependence remains an issue. Design: A randomized, double-blind, placebo-controlled study. Setting: A methadone treatment research clinic. Patients: Participants (n = 247) were opioid-dependent patients with a high rate of cocaine use. Intervention: All participants were initially treated with active methadone for a minimum of 5 weeks and then received 15 weeks of stable dosing at 50, 20, or 0 mg per day. Individual counseling and group therapy were included. Measurements: Treatment retention and illicit drug use as determined by intensive urine monitoring. Results: Retention was better for patients who remained on active medication. By treatment week 20, retention was 52.4% for the 50-mg, 41.5% for the 20-mg, and 21.0% for the 0-mg group (50 versus 0 and 20 versus 0, P < 0.05; 50 versus 20, P > 0.05). Only the 50-mg treatment group had a reduced rate of opioid-positive urine samples (56.4% versus 67.6% and 73.6% for the 20-mg and 0-mg groups, respectively; P < 0.05) and cocaine-positive urine samples (52.6% versus 62.4% and 67.1% for the 20- and 0-mg groups, respectively; P < 0.05). Conclusions: There is a dose-response effect for methadone treatment. Doses as low as 20 mg may improve retention but are inadequate for suppressing illicit drug use.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIDA NIH HHS [R01-DA05792] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005792] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BALL J, 1988, PROBLEMS DRUG DEPEND, P224; Ball J.C., 2012, EFFECTIVENESS METHAD; BALL JC, 1988, J HEALTH SOC BEHAV, V29, P214, DOI 10.2307/2137033; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CONDELLI WS, 1991, J SUBST ABUSE TREAT, V8, P203, DOI 10.1016/0740-5472(91)90040-H; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; CRAIG RJ, 1980, INT J ADDICT, V15, P701, DOI 10.3109/10826088009040049; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; DOLE VP, 1989, JAMA-J AM MED ASSOC, V262, P1681, DOI 10.1001/jama.262.12.1681; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; FUDALA PJ, 1990, PROBLEMS DRUG DEPEND, P587; GARBUTT GD, 1972, 4TH P NAT C METH TRE, P411; GOLDSTEIN A, 1973, 5TH P NAT C METH TRE, P21; GOLDSTEIN A, 1970, 3RD P NAT C METH TRE, P31; HANBURY R, 1986, Advances in Alcohol and Substance Abuse, V6, P97; HARGREAVES WA, 1983, NATIONAL I DRUG ABUS; Hubbard RL, 1989, DRUG ABUSE TREATMENT; IGUCHI MY, 1991, AM J DRUG ALCOHOL AB, V17, P279, DOI 10.3109/00952999109027552; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; JOHNSON RE, 1990, PROBLEMS DRUG DEPEND, P585; KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P2970, DOI 10.1001/jama.260.20.2970; KOSTEN TR, 1986, AM J DRUG ALCOHOL AB, V12, P1, DOI 10.3109/00952998609083739; KOZEL NJ, 1986, SCIENCE, V234, P970, DOI 10.1126/science.3490691; LING W, 1976, ARCH GEN PSYCHIAT, V33, P709; MCCAUL ME, 1983, NATIONAL I DRUG ABUS, V43; MCGLOTHLIN WH, 1981, ARCH GEN PSYCHIAT, V38, P1055; MCLELLAN AT, 1982, JAMA-J AM MED ASSOC, V247, P1423, DOI 10.1001/jama.247.10.1423; Simpson D.D., 1990, OPIOID ADDICTION TRE; WEST AP, 1991, ARCH INTERN MED, V151, P1493, DOI 10.1001/archinte.151.8.1493; 1990, DHHS911729 NAT I DRU; 1990, METHADONE MAINTENANC; 1991, DHHS911816 NAT I DRU; 1990, DHHS901682 NAT I DRU	33	176	182	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					23	27		10.7326/0003-4819-119-1-199307010-00004	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498759				2022-12-28	WOS:A1993LJ26600004
J	FREEMAN, DL				FREEMAN, DL			THE NEXT PATIENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; LONELINESS; SOCIAL SUPPORT; CONSTIPATION		An internist describes a routine office visit of a patient with intractable constipation. After reiterating his usual advice, the physician unwittingly discovers in his patient an undercurrent of sorrow. For a fleeting moment, they make an emotional connection, but then return to their previous roles.											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					978	978		10.7326/0003-4819-118-12-199306150-00011	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489113				2022-12-28	WOS:A1993LF93700011
J	CUMBERLEDGE, S; KRASNOW, MA				CUMBERLEDGE, S; KRASNOW, MA			INTERCELLULAR SIGNALING IN DROSOPHILA SEGMENT FORMATION RECONSTRUCTED INVITRO	NATURE			English	Article							POLARITY GENE ARMADILLO; WINGLESS; EXPRESSION; EMBRYOS; EMBRYOGENESIS; REQUIREMENTS; EPIDERMIS; PROTEIN	GENETIC studies show that intercellular signalling is involved in key steps in Drosophila melanogaster development, but it has not previously been possible to investigate these processes in simplified in vitro systems. Analysis of engrailed (en) and wingless (wg) and other segment polarity genes suggests that two or more intercellular signalling processes may be involved in intrasegmental patterning1-3. Expression of en and wg begins about three hours after egg laying, in adjacent rows of cells in the posterior half of each segmental primordium4-7. In wg- embryos and in conditional mutants in which wg function is inactivated during a critical period between three and five hours after egg laying, early en expression begins normally but then disappears within several hours4,8-10. The wg gene encodes a protein highly similar to the product of the mouse Wnt-1 proto-oncogene, a secreted glycoprotein11,12; wg protein is proposed to function as an extracellular signal, maintaining en expression and activating other molecular and morphogenetic processes in nearby cells4,8,9,13. Several lines of evidence support the model, including the secretion of wg protein in the embryo7,14, genetic mosaic experiments15-17 and cell lineage studies18. We tested this model using purified embryonic cells isolated by whole animal cell sorting19, and validated three key predictions: (1) when en-expressing cells from early embryos are grown alone in culture, they rapidly and selectively lose en expression; (2) purified wg-expressing cells provide a locally active signal that prevents this loss; (3) heterologous cells engineered to express wg also show signalling activity, indicating that wg protein alone, or in conjunction with more generally expressed factors, is the signal.			CUMBERLEDGE, S (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRASNOW MA, 1991, SCIENCE, V251, P81, DOI 10.1126/science.1898782; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7	21	45	46	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					549	552		10.1038/363549a0	http://dx.doi.org/10.1038/363549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505983				2022-12-28	WOS:A1993LF93900052
J	KRISHNAN, SN; FREI, E; SWAIN, GP; WYMAN, RJ				KRISHNAN, SN; FREI, E; SWAIN, GP; WYMAN, RJ			PASSOVER - A GENE REQUIRED FOR SYNAPTIC CONNECTIVITY IN THE GIANT FIBER SYSTEM OF DROSOPHILA	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; FASCICLIN-II; MELANOGASTER; PROTEIN; LOCUS; ADHESION; SEQUENCES; MUTATIONS; MEMBRANE	Passover (Pas) flies fail to jump in response to a light-off stimulus. The mutation disrupts specific synapses of the giant fibers (GFs), command neurons for this response. Pas was cloned from a P element-induced allele. The cDNA encodes a putative membrane protein of 361 amino acids. Null, hypomorphic, and dominant alleles were sequenced. In the adult central nervous system, and in the pupa during GF synapse formation, Pas is consistently expressed in the GF and in a large thoracic cell in the location of its postsynaptic targets. Pas establishes a new gene family. The Drosophila ogre protein, required for postembryonic neuroblast development, is 47% identical; the C. elegans Unc-7 protein, which when mutated alters the connectivity of a few neurons, is 33% identical.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University					NIGMS NIH HHS [GM-39813] Funding Source: Medline; NINDS NIH HHS [NS-07314] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039813] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIRD DH, 1990, GENETICS, V126, P1045; BAIRD DH, 1988, THESIS YALE U NEW HA; BARID DH, 1993, IN PRESS J NEUROBIOL, V24; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GOODMAN CS, 1992, NERVE GROWTH CONE, P283; Gorczyca M., 1984, Journal of Neurogenetics, V1, P289, DOI 10.3109/01677068409107093; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KING DG, 1980, J NEUROCYTOL, V9, P753, DOI 10.1007/BF01205017; KOTO M, 1981, BRAIN RES, V221, P213, DOI 10.1016/0006-8993(81)90772-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIPSHITZ HD, 1985, DEV BIOL, V108, P56, DOI 10.1016/0012-1606(85)90009-0; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOSE A, 1992, CELL, V70, P537; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; Power ME, 1943, J MORPHOL, V72, P517, DOI 10.1002/jmor.1050720306; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER LE, 1990, J BIOL CHEM, V265, P6890; SINGH NR, 1989, NEUROBIOLOGY SENSORY, P203; STARICH TA, 1993, GENETICS, V133, P527; SWAIN GP, 1990, BRAIN RES, V535, P147, DOI 10.1016/0006-8993(90)91833-3; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; THOMAS JB, 1984, J NEUROSCI, V4, P530; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATANABE T, 1990, GENETICS, V126, P1033; WATARSTON R, 1992, NAT GENET, V152, P172; WYMAN RJ, 1983, COLD SPRING HARB SYM, V48, P641, DOI 10.1101/SQB.1983.048.01.068	45	84	85	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					967	977		10.1016/0092-8674(93)90274-T	http://dx.doi.org/10.1016/0092-8674(93)90274-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500183	Bronze			2022-12-28	WOS:A1993LF06100012
J	HAMERSCASTERMAN, C; ATARHOUCH, T; MUYLDERMANS, S; ROBINSON, G; HAMERS, C; SONGA, EB; BENDAHMAN, N; HAMERS, R				HAMERSCASTERMAN, C; ATARHOUCH, T; MUYLDERMANS, S; ROBINSON, G; HAMERS, C; SONGA, EB; BENDAHMAN, N; HAMERS, R			NATURALLY-OCCURRING ANTIBODIES DEVOID OF LIGHT-CHAINS	NATURE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; VARIANT SURFACE GLYCOPROTEIN; ESCHERICHIA-COLI; SEGMENTAL FLEXIBILITY; TRYPANOSOMA-BRUCEI; BINDING-PROTEIN; GENERATION; DIFFERENTIATION; REPERTOIRE; MOLECULES	RANDOM association of VL and VH repertoires contributes considerably to antibody diversity1. The diversity and the affinity are then increased by hypermutation in B cells located in germinal centres2. Except in the case of 'heavy chain' disease3, naturally occurring heavy-chain antibodies have not been described, although antigen binding has been demonstrated for separated heavy chains4 or cloned VH domains5. Here we investigate the presence of considerable amounts of IgG-like material of M(r) 100K in the serum of the camel (Camelus dromedarius)6. These molecules are composed of heavy-chain dimers and are devoid of light chains, but nevertheless have an extensive antigen-binding repertoire, a finding that calls into question the role of light chains in the camel. Camel heavy-chain IgGs lack CH1, which in one IgG class might be structurally replaced by an extended hinge. Heavy-chain IgGs are a feature of all camelids. These findings open new perspectives in the engineering of antibodies.	VRIJE UNIV BRUSSELS, INST MOLEC BIOL, PAARDENST 65, B-1640 RHODE ST GENESE, BELGIUM; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	Vrije Universiteit Brussel; Trinity College Dublin			Muyldermans, Serge V/C-6418-2016; Abrams, William R/A-5782-2008; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575				BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DUNNICK W, 1980, NUCLEIC ACIDS RES, V8, P1475, DOI 10.1093/nar/8.7.1475; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; FLEISCHMAN JB, 1962, ARCH BIOCHEM BIOPHYS, P174; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JACKSON T, 1992, MOL IMMUNOL, V29, P667, DOI 10.1016/0161-5890(92)90204-B; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KLEIN J, 1990, IMMUNOLOGY; KOBAT EA, 1987, SEQUENCES PROTEINS I, P511; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; ROHOLT O, 1964, P NATL ACAD SCI USA, V51, P173, DOI 10.1073/pnas.51.2.173; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY L, 1989, P NATL ACAD SCI USA, V86, P5728, DOI 10.1073/pnas.86.15.5728; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; SONGA EB, 1988, ANN SOC BELG MED TR, V68, P233; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; UNGAR-WARON H, 1987, Israel Journal of Veterinary Medicine, V43, P198; UTSUMI S, 1964, BIOCHEMISTRY-US, V3, P1329, DOI 10.1021/bi00897a024; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0	26	1992	2778	49	412	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					446	448		10.1038/363446a0	http://dx.doi.org/10.1038/363446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502296				2022-12-28	WOS:A1993LE93800057
J	ANNAS, GJ				ANNAS, GJ			PHYSICIAN-ASSISTED SUICIDE - MICHIGANS TEMPORARY SOLUTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA							Annas, George/0000-0001-5836-7831				Annas G., 1993, STANDARD CARE LAW AM; ANNAS GJ, 1991, HASTINGS CENT REP, V21, P33, DOI 10.2307/3562337; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; Foderaro Lisa W, 1991, N Y Times Web, P25; GIANELLI D, 1992, AM MED NEWS     1005, P37; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KEVORKIAN J, 1991, PRESCRIPTION MED; Lifton R. J., 1986, NAZI DOCTORS MED KIL; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 1993, DEATH DIGNITY MAKING; Smith George P, 1989, Univ Calif Davis Law Rev, V22, P275; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMAS L, 1980, ANN AM ACAD POLIT SS, V447, P1, DOI 10.1177/000271628044700102; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1989, PRESCRIBING PRACTICE; 1993, LANCET, V341, P209; 1988, JAMA-J AM MED ASSOC, V259, P272; 1992, JAMA-J AM MED ASSOC, V267, P2229	18	30	30	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1573	1576		10.1056/NEJM199305273282121	http://dx.doi.org/10.1056/NEJM199305273282121			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC941	8479510	Green Published			2022-12-28	WOS:A1993LC94100036
J	HUGHES, W; LEOUNG, G; KRAMER, F; BOZZETTE, SA; SAFRIN, S; FRAME, P; CLUMECK, N; MASUR, H; LANCASTER, D; CHAN, C; LAVELLE, J; ROSENSTOCK, J; FALLOON, J; FEINBERG, J; LAFON, S; ROGERS, M; SATTLER, F				HUGHES, W; LEOUNG, G; KRAMER, F; BOZZETTE, SA; SAFRIN, S; FRAME, P; CLUMECK, N; MASUR, H; LANCASTER, D; CHAN, C; LAVELLE, J; ROSENSTOCK, J; FALLOON, J; FEINBERG, J; LAFON, S; ROGERS, M; SATTLER, F			COMPARISON OF ATOVAQUONE (566C80) WITH TRIMETHOPRIM-SULFAMETHOXAZOLE TO TREAT PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HYDROXYNAPHTHOQUINONE; PENTAMIDINE; POTENT	Background. Both trimethoprim-sulfamethoxazole and pentamidine are effective as treatments for Pneumocystis carinii pneumonia, but adverse effects frequently limit their use. Atovaquone (566C80) is a new hydroxynaphthoquinone with activity against P. carinii. Methods. We conducted a double-blind, multicenter study in patients with the acquired immunodeficiency syndrome and mild or moderately severe P. carinii pneumonia. They were randomly assigned to 21 days of orally administered treatment three times daily with either atovaquone (750 mg) or trimethoprim (320 mg) plus sulfamethoxazole (1600 mg). Results. Of the 322 patients with histologically confirmed P. carinii pneumonia, 160 received atovaquone and 162 received trimethoprim-sulfamethoxazole. Of those who could be evaluated for therapeutic efficacy, 28 of 138 patients given atovaquone (20 percent) and 10 of 146 patients given trimethoprim-sulfamethoxazole (7 percent) did not respond (P = 0.002). Treatment-limiting adverse effects required a change of therapy in 11 patients in the atovaquone group (7 percent) and 33 patients in the trimethoprim-sulfamethoxazole group (20 percent) (P = 0.001). Therapy involving only the initial drug was successful and free of adverse effects in 62 percent of those assigned to atovaquone and 64 percent of those assigned to trimethoprim-sulfamethoxazole. Within four weeks of the completion of treatment, there were 11 deaths in the atovaquone group (4 due to P. carinii pneumonia) and 1 death in the trimethoprim-sulfamethoxazole group (P = 0.003). Diarrhea at entry was associated with lower plasma drug concentrations (P = 0.009), therapeutic failure (P<0.001), and death (P<0.001) in the atovaquone group but not in the trimethoprim-sulfamethoxazole group. Conclusions. For the treatment of P. carinii pneumonia, atovaquone is less effective than trimethoprim-sulfamethoxazole, but it has fewer treatment-limiting adverse effects.	DAVIES MED CTR, DEPT MED, SAN FRANCISCO, CA USA; LOS ANGELES CTY HOSP, LOS ANGELES, CA USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV CINCINNATI, CINCINNATI, OH 45221 USA; HOP UNIV ST PIERRE, B-1000 BRUSSELS, BELGIUM; NIH, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA; UNIV TENNESSEE CTR HLTH SCI, REG MED CTR, DEPT MED, MEMPHIS, TN 38163 USA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; INFECT DIS RES CONSORTIUM, ATLANTA, GA USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA; BURROUGHS WELLCOME CO, DEPT INFECT DIS & IMMUNOL, RES TRIANGLE PK, NC 27709 USA; NIAID, DIV AIDS, AIDS CLIN TRIALS GRP, BETHESDA, MD 20892 USA; NIAID, CALIF CLIN TRIALS GRP, BETHESDA, MD 20892 USA	California Pacific Medical Center; University of Southern California; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Georgetown University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HUGHES, W (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.			feinberg, judith/0000-0003-4206-7214				[Anonymous], 1989, SAS STAT USERS GUIDE, V2; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FLEISS JL, 1973, STATISTICAL METHODS, P29; FRY M, 1984, BIOCHEM PHARMACOL, V33, P2115, DOI 10.1016/0006-2952(84)90581-1; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; HAMMOND DJ, 1985, MOL BIOCHEM PARASIT, V14, P97, DOI 10.1016/0166-6851(85)90109-4; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; HUGHES WT, 1991, J INFECT DIS, V163, P843, DOI 10.1093/infdis/163.4.843; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280	13	235	237	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1521	1527		10.1056/NEJM199305273282103	http://dx.doi.org/10.1056/NEJM199305273282103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8479489				2022-12-28	WOS:A1993LC94100003
J	STAMPFER, MJ; HENNEKENS, CH; MANSON, JE; COLDITZ, GA; ROSNER, B; WILLETT, WC				STAMPFER, MJ; HENNEKENS, CH; MANSON, JE; COLDITZ, GA; ROSNER, B; WILLETT, WC			VITAMIN-E CONSUMPTION AND THE RISK OF CORONARY-DISEASE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; FOOD FREQUENCY QUESTIONNAIRE; ALPHA-TOCOPHEROL LEVELS; ISCHEMIC HEART-DISEASE; PLASMA BETA-CAROTENE; DIETARY QUESTIONNAIRE; ATHEROSCLEROTIC LESIONS; VALIDATION; OXIDATION; REPRODUCIBILITY	Background. Interest in the antioxidant vitamin E as a possible protective nutrient against coronary disease has intensified with the recognition that oxidized low-density lipoprotein may be involved in atherogenesis. Methods. In 1980, 87,245 female nurses 34 to 59 years of age who were free of diagnosed cardiovascular disease and cancer completed dietary questionnaires that assessed their consumption of a wide range of nutrients, including vitamin E. During follow-up of up to eight years (679,485 person-years) that was 97 percent complete, we documented 552 cases of major coronary disease (437 nonfatal myocardial infarctions and 115 deaths due to coronary disease). Results. As compared with women in the lowest fifth of the cohort with respect to vitamin E intake, those in the top fifth had a relative risk of major coronary disease of 0.66 (95 percent confidence interval, 0.50 to 0.87) after adjustment for age and smoking. Further adjustment for a variety of other coronary risk factors and nutrients, including other antioxidants, had little effect on the results. Most of the variability in intake and reduction in risk was attributable to vitamin E consumed as supplements. Women who took vitamin E supplements for short periods had little apparent benefit, but those who took them for more than two years had a relative risk of major coronary disease of 0.59 (95 percent confidence interval, 0.38 to 0.91) after adjustment for age, smoking status, risk factors for coronary disease, and use of other antioxidant nutrients (including multi-vitamins). Conclusions. Although these prospective data do not prove a cause-and-effect relation, they suggest that among middle-aged women the use of vitamin E supplements is associated with a reduced risk of coronary heart disease. Randomized trials of vitamin E in the primary and secondary prevention of coronary disease are being conducted; public policy recommendations about the wide-spread use of vitamin E should await the results of these trials.	HARVARD UNIV,SCH MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40935] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL 24074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; DEMAIO SJ, 1992, J AM COLL NUTR, V11, P68; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; GEY KF, 1987, AM J CLIN NUTR, V45, P1368, DOI 10.1093/ajcn/45.5.1368; GILLILAN RE, 1977, AM HEART J, V93, P444, DOI 10.1016/S0002-8703(77)80406-7; HAEGER K, 1974, AM J CLIN NUTR, V27, P1179, DOI 10.1093/ajcn/27.8.1179; HUNTER DJ, 1988, AM J EPIDEMIOL, V127, P1240, DOI 10.1093/oxfordjournals.aje.a114916; JIALAL I, 1992, J LIPID RES, V33, P899; KAGAN VE, 1992, J LIPID RES, V33, P385; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LIVINGSTONE PD, 1958, LANCET, V2, P602; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; PACKER L, 1991, AM J CLIN NUTR, V53, pS1050, DOI 10.1093/ajcn/53.4.1050S; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REGNSTROM J, 1992, LANCET, V339, P1183, DOI 10.1016/0140-6736(92)91129-V; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stocker R, 1991, OXIDATIVE STRESS OXI, P213; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; Walker AE, 1981, STROKE S1, V12, P13; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1983, AM J CLIN NUTR, V38, P559, DOI 10.1093/ajcn/38.4.559; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS HT, 1971, SURG GYNECOL OBSTETR, V132, P662; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; 1992, J MYOCARDIAL ISCHEMI, V4, P27; [No title captured]; 1971, IHD5TH WHO WORK GROU	55	1682	1741	2	71	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1444	1449		10.1056/NEJM199305203282003	http://dx.doi.org/10.1056/NEJM199305203282003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479463				2022-12-28	WOS:A1993LB78300003
J	DOWDY, SF; HINDS, PW; LOUIE, K; REED, SI; ARNOLD, A; WEINBERG, RA				DOWDY, SF; HINDS, PW; LOUIE, K; REED, SI; ARNOLD, A; WEINBERG, RA			PHYSICAL INTERACTION OF THE RETINOBLASTOMA PROTEIN WITH HUMAN D-CYCLINS	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; VIRUS-40 LARGE-T; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; CANDIDATE ONCOGENE; G1 CYCLIN; BINDING	The retinoblastoma protein (pRb) functions as a regulator of cell proliferation and in turn is regulated by cyclin-dependent kinases. Cyclins D1 and D3 can form complexes with pRb that resemble those formed by several viral oncoproteins and are disrupted by the adenovirus E1A oncoprotein and derived peptides. These cyclins contain a sequence motif similar to the pRb-binding conserved region II motif of the viral oncoproteins. Alteration of this motif in cyclin Dl prevents formation of cyclin D1-pRb complexes while enhancing the biological activity of cyclin D1 assayed in vivo. We conclude that cyclins D1 and D3 interact with pRb in a fashion distinct from cyclins A and E, which can induce pRb hyperphosphorylation, and that cyclin D1 activity may be regulated by its association with pRb.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, CTR CANC, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Scripps Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	DOWDY, SF (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.			Louie, Kenway/0000-0002-9665-5436	NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006, R01GM038328, R37GM038328] Funding Source: NIH RePORTER; NCI NIH HHS [CA55909] Funding Source: Medline; NIGMS NIH HHS [GM46006, GM38328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1988, P NATL ACAD SCI USA, V85, P2234; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1980, GENETICS, V95, P561; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBERG CL, 1993, IN PRESS ONCOGENE; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS ME, 1993, IN PRESS LEUKEMIA; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	96	800	821	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					499	511		10.1016/0092-8674(93)90137-F	http://dx.doi.org/10.1016/0092-8674(93)90137-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490963				2022-12-28	WOS:A1993LA74300011
J	SHVARTZMAN, P; TABENKIN, H; ROSENTZWAIG, A; DOLGINOV, F				SHVARTZMAN, P; TABENKIN, H; ROSENTZWAIG, A; DOLGINOV, F			TREATMENT OF STREPTOCOCCAL PHARYNGITIS WITH AMOXICILLIN ONCE-A-DAY	BRITISH MEDICAL JOURNAL			English	Article							ACUTE RHEUMATIC-FEVER; PENICILLIN; RESURGENCE; THERAPY	Objective-To evaluate treatment of group A beta haemolytic streptococcal pharyngitis with amoxycillin once daily compared with phenoxymethylpenicillin three or four times a day. Design-Randomised controlled study of consecutive patients presenting with symptoms suggestive of group A beta haemolytic streptococcal pharyngitis in whom culture of a throat swab yielded positive results. Setting-Five family medicine practices. Subjects-157 patients aged over 3 years who required treatment with antibiotics. Main outcome measures-Clinical response, bacteriological response, days at work and school lost, and compliance. Results-During the period of the study 393 patients presented with symptoms suggesting streptococcal pharyngitis; 157 of them had throat swabs that yielded positive results on culture. Eighty two were treated with phenoxymethylpenicillin and 75 with amoxycillin. No difference was observed in the clinical response, days at work and school lost (139 days for 64 patients taking phenoxymethylpenicillin v 100 days for 57 patients taking amoxycillin; p > 0.2), or residual positive cultures after two days (6 (7.3%) v 3 (4%); p > 0.5). A significant difference in the bacteriological response was found after 14 days (5 (6.1%) v 0; p < 0.04) with no positive cultures observed in the amoxycillin group. Conclusion-These findings support the hypothesis that amoxycillin once daily is as effective as phenoxymethylpenicillin in the treatment of group A beta haemolytic streptococcal pharyngitis.	CENT EMEK HOSP,IL-18101 AFULA,ISRAEL	Emek Medical Center	SHVARTZMAN, P (corresponding author), BEN GURION UNIV NEGEV,DEPT FAMILY MED,POB 653,IL-84105 BEER SHEVA,ISRAEL.		SHVARTZMAN, PESACH/F-2134-2012					AYD FJ, 1974, JAMA-J AM MED ASSOC, V230, P263, DOI 10.1001/jama.230.2.263; BREESE BB, 1965, AM J DIS CHILD, V110, P125, DOI 10.1001/archpedi.1965.02090030135003; COMBS JT, 1992, PEDIATR INFECT DIS J, V11, P132, DOI 10.1097/00006454-199202000-00018; DEMELKER RA, 1991, BRIT J GEN PRACT, V41, P504; DILLON HC, 1984, PHARYNGITIS MANAGEME, P133; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; GEORGES P, 1992, CLIN INFECTIOUS DI S, V14, P218; GERBER MA, 1986, J PEDIATR-US, V109, P531, DOI 10.1016/S0022-3476(86)80139-1; GERBER MA, 1989, AM J DIS CHILD, V143, P153, DOI 10.1001/archpedi.1989.02150140039016; HOSIER DM, 1987, AM J DIS CHILD, V141, P730, DOI 10.1001/archpedi.1987.04460070032015; KITZESCOHEN R, 1992, DRUG FORMULARY, P37; Raz R, 1989, Harefuah, V117, P390; REED BD, 1991, J FAM PRACTICE, V32, P138; REYNOLDS EF, 1989, MARTINDALE EXTRA PHA, P115; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557	18	68	82	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1170	1172		10.1136/bmj.306.6886.1170	http://dx.doi.org/10.1136/bmj.306.6886.1170			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499823	Green Published			2022-12-28	WOS:A1993LA68500027
J	NAZARETH, I; KING, M				NAZARETH, I; KING, M			DECISION-MAKING BY GENERAL-PRACTITIONERS IN DIAGNOSIS AND MANAGEMENT OF LOWER URINARY-TRACT SYMPTOMS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL JUDGMENT	Objective-To identify factors influencing decision making by general practitio Setting-Two suburban London general practices. Subjects-Women presenting to their family doctor with lower urinary tract symptoms. Design-After each consultation the doctor completed a questionnaire on presenting symptoms; clinical examination; investigations undertaken; presence of psychological, social, and menstrual problems; patients' requests for antibiotics; antibiotic prescribing; knowledge of the patient; attitude towards the consultation; and any other factors assisting in diagnosis and management. Finally, doctors predicted the presence or absence of clinically important bacteriuria. Each woman completed a demographic questionnaire, the 12 item general health questionnaire, and the modified menstrual distress questionnaire, after which each provided a clean catch midstream urine sample. Case notes were examined for information on previous reports of results of urine analysis. Results-When the general practitioners did not know the patients well they were 4.5 times more likely to assume that there was a clinically important infection. When they knew the patient well, they were four times more likely to make a correct prediction of the test result and 12 times less likely to prescribe antibiotics. Doctors were five times more likely to predict the test result correctly in patients from social classes 1 and 2 and were six times more likely to prescribe antibiotics for the older women in the sample. Conclusions-In women presenting with urinary tract symptoms, these family practitioners seemed to take no particular regard of physicial, psychological, or menstrual factors in making their assessments. They were most accurate in their prediction of the result of urine analysis and least likely to prescribe antibiotics when they had a good general knowledge of the patient. Which came first, the diagnosis or prescribing, is difficult to say and probably differed in individual cases. Doctors tended to be more conservative in their management of older women and those whom they knew less well.	ROYAL FREE HOSP, SCH MED, DEPT ACAD PSYCHIAT, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	NAZARETH, I (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				Altman DG, 1991, PRACTICAL STATISTICS; ANDERSON JE, 1981, CAN FAM PHYSICIAN, V27, P1909; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BROOKE JB, 1984, MED INFORM, V9, P45, DOI 10.3109/14639238409010937; BROOKS D, 1978, BACTERIOLOGICAL EXAM, P39; CLARE AW, 1979, EMOTION REPRODUCTI A, V20, P177; DOBBS FF, 1987, J ROY COLL GEN PRACT, V37, P100; GAYMANS R, 1976, LANCET, V2, P674; Goldberg DP., 1972, DETECTION PSYCHIATRI; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; MOND NC, 1965, LANCET, V1, P514; MOOS RH, 1969, AM J OBSTET GYNECOL, V103, P390, DOI 10.1016/0002-9378(69)90499-2; MOOS RH, 1968, PSYCHOSOM MED, V30, P853, DOI 10.1097/00006842-196811000-00006; ODOWD TC, 1984, BRIT MED J, V288, P1347, DOI 10.1136/bmj.288.6427.1347; Raynes N V, 1980, J R Coll Gen Pract, V30, P166; 1982, LANCET, V2, P694; 1986, MORBIDITY STATISTICS, P159	19	37	38	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1103	1106		10.1136/bmj.306.6885.1103	http://dx.doi.org/10.1136/bmj.306.6885.1103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495157	Bronze, Green Published			2022-12-28	WOS:A1993KZ56500024
J	SHIU, M				SHIU, M			REFUSING TO TREAT SMOKERS IS UNETHICAL AND A DANGEROUS PRECEDENT	BRITISH MEDICAL JOURNAL			English	Article											SHIU, M (corresponding author), DAVID RYDDERCH HLTH CTR,BIRMINGHAM B32 3SD,ENGLAND.								0	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1048	1049		10.1136/bmj.306.6884.1048	http://dx.doi.org/10.1136/bmj.306.6884.1048			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490502	Bronze, Green Published			2022-12-28	WOS:A1993KY44800026
J	KATZ, M; SHAPIRO, CM				KATZ, M; SHAPIRO, CM			ABC OF SLEEP DISORDERS - DREAMS AND MEDICAL ILLNESS	BRITISH MEDICAL JOURNAL			English	Article											KATZ, M (corresponding author), UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA.							Haskell R., 1985, J MED HUMANITIES BIO, V6, P46, DOI [10.1007/BF01149838, DOI 10.1007/BF01149838]; MILLER L, 1989, PSYCHOANAL REV, V76, P375; NATHAN R J, 1981, Hillside Journal of Clinical Psychiatry, V3, P139; SHAPIRO CM, 1986, BRIT MED J, V292, P1161, DOI 10.1136/bmj.292.6529.1161; SHAPIRO CM, 1988, WENNERGREN INT S SER, V50, P53; SMITH RC, 1984, PSYCHOTHER PSYCHOSOM, V41, P167, DOI 10.1159/000287806; SMITH RC, 1987, J NERV MENT DIS, V175, P201, DOI 10.1017/S0022112087000363	7	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					993	995		10.1136/bmj.306.6883.993	http://dx.doi.org/10.1136/bmj.306.6883.993			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX436	8490484	Green Published, Bronze			2022-12-28	WOS:A1993KX43600029
J	NICHOLSON, M; WHITE, D				NICHOLSON, M; WHITE, D			COUNTDOWN TO COMMUNITY CARE - OLD PEOPLES HOMES - THE RELATIVES VIEW	BRITISH MEDICAL JOURNAL			English	Article								On 1 April new arrangements came into force for arranging and funding residential care for elderly people in Britain. From now on those who seem to need full time care will be assessed first by care managers employed by local authority social services departments. This may lead to admission to an old people's home or a nursing home. Local authorities have been told to consult both users and carers about such decisions. But what about relatives who have not actually been giving care directly? The Relatives Association was set up last year as a voluntary organisation for the relatives and friends of older people living in residential homes. Below, its vice president, Mavis Nicholson, a journalist and broadcaster whose mother died of Alzheimer's disease in a residential home last year, gives her personal view of being such a relative. And Dorothy White, the association's founder, explains what the future may hold for elderly residents and their relatives.	RELAT ASSOC,LONDON NW1 9PG,ENGLAND									WHITE DM, 1993, RELATIVE VIEWS	1	2	2	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					918	920		10.1136/bmj.306.6882.918	http://dx.doi.org/10.1136/bmj.306.6882.918			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490424	Bronze, Green Published			2022-12-28	WOS:A1993KW38700033
J	SWEDBERG, K; KJEKSHUS, J				SWEDBERG, K; KJEKSHUS, J			ACE INHIBITORS AFTER MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Letter									UNIV OSLO,NATL HOSP,DEPT MED,OSLO 3,NORWAY	University of Oslo; National Hospital Norway	SWEDBERG, K (corresponding author), GOTHENBURG UNIV,OSTRA HOSP,DIV MED,CARDIOL SECT,S-41685 GOTHENBURG,SWEDEN.		Swedberg, Karl/B-2475-2008					KJEKSUS J, 1992, Journal of the American College of Cardiology, V19, p206A; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; VANNAN MA, 1993, BRIT MED J, V306, P531, DOI 10.1136/bmj.306.6877.531	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					926	927		10.1136/bmj.306.6882.926-b	http://dx.doi.org/10.1136/bmj.306.6882.926-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490427	Green Published			2022-12-28	WOS:A1993KW38700045
J	LOKEY, RH				LOKEY, RH			RETRIEVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					32	32		10.1001/jama.270.1.32	http://dx.doi.org/10.1001/jama.270.1.32			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510288				2022-12-28	WOS:A1993LK36600007
J	LAINE, L; ELNEWIHI, HM; MIGIKOVSKY, B; SLOANE, R; GARCIA, F				LAINE, L; ELNEWIHI, HM; MIGIKOVSKY, B; SLOANE, R; GARCIA, F			ENDOSCOPIC LIGATION COMPARED WITH SCLEROTHERAPY FOR THE TREATMENT OF BLEEDING ESOPHAGEAL-VARICES	ANNALS OF INTERNAL MEDICINE			English	Article						ESOPHAGEAL AND GASTRIC VARICES; SCLEROTHERAPY; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; LIGATION	RANDOMIZED CONTROLLED TRIAL; INJECTION SCLEROTHERAPY; ACUTE HEMORRHAGE; TAMPONADE	Objective: Comparison of the safety and efficacy of endoscopic sclerotherapy and ligation for the treatment of bleeding esophageal varices. Design: Randomized, controlled trial. Setting: An urban county hospital. Patients: Patients with clinically severe bleeding from esophageal varices. Intervention: A total of 77 patients were randomly assigned to receive sclerotherapy or ligation at the initial endoscopic examination. Treatment was repeated weekly until variceal obliteration was achieved. After eradication, patients had endoscopic examinations every 3 months or for any episode of rebleeding. Recurrent varices were treated with the originally assigned form of endoscopic therapy. Measurements: Patients were assessed for further bleeding, for transfusion requirements, for time in hospital, for variceal eradication, for number of treatment sessions required, for complications, for treatment failure, and for risk of death. Results: Rebleeding tended to be less frequent with ligation than with sclerotherapy: 10 of 38 (26%) compared with 17 of 39 (44%) (difference, 17% [95% CI, -4% to 38%]), but results in the two groups were comparable for blood transfusions, for length of hospital stay, and for risk of death. Comparison of Kaplan-Meier estimates of time to rebleeding and death showed no statistical differences between treatments. Complications were less common in the ligation group: fewer patients in the ligation group had esophageal strictures (0 of 38 compared with 13 of 39 [33%]; P < 0.001) and had complicated esophageal ulcers (1 of 38 [2.6%] compared with 6 of 39 [15%]; P = 0.11). In addition, fewer ligation treatments were required to achieve variceal eradication (4.1 +/- 0.3 compared with 6.2 +/- 0.4; P < 0.001). Conclusion: Endoscopic ligation causes statistically fewer local complications than sclerotherapy and achieves variceal eradication more rapidly. Ligation is a viable alternative to sclerotherapy and may have some advantages as a treatment for bleeding esophageal varices.			LAINE, L (corresponding author), UNIV SO CALIF, SCH MED, DEPT MED, DIV GASTROINTESTINAL LAC12137, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.							DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; KOUTSOMANIS D, 1992, Gastroenterology, V102, pA835; LAINE L, 1991, WESTERN J MED, V155, P274; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; MORETO M, 1988, SURG GYNECOL OBSTET, V167, P331; PAQUET KJ, 1985, HEPATOLOGY, V5, P580, DOI 10.1002/hep.1840050409; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Reveille RM, 1991, GASTROINTEST ENDOSC, V37, P243; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; STIEGMANN GV, 1988, AM SURGEON, V54, P105; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; STIEGMANN GV, 1989, GASTROINTEST ENDOSC, V35, P431, DOI 10.1016/S0016-5107(89)72850-9; VALENZUELA JE, 1989, HEPATOLOGY, V10, P958, DOI 10.1002/hep.1840100611; VANSTIEGMANN G, 1986, GASTROINTEST ENDOSC, V32, P230, DOI 10.1016/S0016-5107(86)71815-4; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219	19	267	273	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					1	7		10.7326/0003-4819-119-1-199307010-00001	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498757				2022-12-28	WOS:A1993LJ26600001
J	FARLEY, MM; HARVEY, RC; STULL, T; SMITH, JD; SCHUCHAT, A; WENGER, JD; STEPHENS, DS				FARLEY, MM; HARVEY, RC; STULL, T; SMITH, JD; SCHUCHAT, A; WENGER, JD; STEPHENS, DS			A POPULATION-BASED ASSESSMENT OF INVASIVE DISEASE DUE TO GROUP-B STREPTOCOCCUS IN NONPREGNANT ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METROPOLITAN ATLANTA; III POLYSACCHARIDE; CONJUGATE VACCINE; INFECTION; BACTEREMIA; MENINGITIS; INFANTS; WOMEN	Background. Group B streptococci (Streptococcus agalactiae) are a major cause of meningitis and septicemia in neonates and pregnant women, but the importance of group B streptococcal disease in nonpregnant adults has not been clearly defined. Methods. We conducted a prospective surveillance of the pathogens responsible for meningitis for a period of 24 months in 35 hospitals and a referral laboratory in metropolitan Atlanta. We reviewed the clinical and laboratory records of all the nonpregnant adults identified as having invasive group B streptococcal disease during this period. Results. During 1989 and 1990 there were 424 patients with invasive group B streptococcal disease (annual incidence, 9.2 cases per 1 00,000 population). Of these patients, 46 percent were 1 month of age or younger, 6 percent were older than 1 month but younger than 18 years of age, and 48 percent were 18 or older. Men and nonpregnant women accounted for 68 percent (n = 140) of all cases among adults (annual incidence, 4.4 per 100,000). Clinical and laboratory records were available for 137. In the nonpregnant adult patients (age, 18 to 99 years), the most common clinical diagnoses were skin, soft-tissue, or bone infection (in 36 percent); bacteremia with no identified source (30 percent); urosepsis (14 percent); pneumonia (9 percent); and peritonitis (7 percent). Risk factors included older age (greater-than-or-equal-to 60 years), the presence of diabetes meilitus, the presence of malignant neoplasms, and infection with the human immunodeficiency virus. The mortality rate in nonpregnant adults was 21 percent, accounting for 67 percent of all deaths related to group B streptococcal infection during the surveillance period. Conclusions. Invasive group B streptococcal infection is a major problem not only in pregnant women and neonates but also in nonpregnant adults, especially those who are elderly and those who have chronic diseases.	GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA	Emory University; Centers for Disease Control & Prevention - USA	FARLEY, MM (corresponding author), VET AFFAIRS MED CTR,1670 CLAIRMONT RD,DECATUR,GA 30033, USA.		Stephens, David S/A-8788-2012					BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAKER CJ, 1990, INFECT DIS, P742; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; EYKYN SJ, 1991, LANCET, V338, P446, DOI 10.1016/0140-6736(91)91069-7; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LERNER PI, 1975, J INFECT DIS, V131, pS9, DOI 10.1093/infdis/131.Supplement.S9; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; OPAL SM, 1988, ARCH INTERN MED, V148, P641, DOI 10.1001/archinte.148.3.641; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; VERGHESE A, 1986, REV INFECT DIS, V8, P912; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; ZANGWILLKM, 1992, MMWR MORB MORTAL WKL, V41, P25; 1992, DIABETES SURVEILLANC, P60; 1985, NEW VACCINE DEV ESTA, V2, P423; 1990, NCI FACT BOOK 1990, P46	25	387	398	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1807	1811		10.1056/NEJM199306243282503	http://dx.doi.org/10.1056/NEJM199306243282503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502269				2022-12-28	WOS:A1993LH21000003
J	CABLE, RG				CABLE, RG			EXERCISE AND BLOOD DONATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CABLE, RG (corresponding author), UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032, USA.							GLEDHILL N, 1982, MED SCI SPORT EXER, V14, P183; KLEIN HG, 1985, NEW ENGL J MED, V312, P854, DOI 10.1056/NEJM198503283121311; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; SIMON TL, 1981, JAMA-J AM MED ASSOC, V245, P2038, DOI 10.1001/jama.245.20.2038; 1991, STANDARDS BLOOD BANK	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3167	3167						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505821				2022-12-28	WOS:A1993LH14500036
J	CANO, RJ; POINAR, HN; PIENIAZEK, NJ; ACRA, A; POINAR, GO				CANO, RJ; POINAR, HN; PIENIAZEK, NJ; ACRA, A; POINAR, GO			AMPLIFICATION AND SEQUENCING OF DNA FROM A 120-135-MILLION-YEAR-OLD WEEVIL	NATURE			English	Article							EXTRACTION	DNA has been successfully isolated from both fossilized plant1 and animal tissues2-6. The oldest material, dated as 25-40 million years old (Tertiary), was obtained from amber-entombed been4,5 and termites6. Tissues from both these insects yielded DNA of good quality, which could be amplified by the polymerase chain reaction (PCR) and subsequently sequenced, including the genes encoding 18S ribosomal RNA5,6 and 16S rRNA6. We report here the extraction of DNA from a 120-135-million-year-old weevil (Nemonychidae, Coleoptera) found in Lebanese amber, PCR amplification of segments of the 18S rRNA gene and the internal transcribed spacer, and the corresponding nucleotide sequences of their 315- and 226-base-pair fragments, respectively. These sequences were used for preliminary phylogenetic analysis of the nemonychidae, sequence with three extant coleopterans: Lecontellus pinicola (Nemonychidae), Hypera brunneipennis (Curculionidae) and the mealworm Tenebrio molitor (Tenebrionidae), and two extant dipterans: the fruitfly Drosophila melanogaster (Drosophilidae) and mosquito Aedes albopictus (Culicidae) for the purpose of ascertaining the origin of the extracted and amplified DNA. The results revealed that the PCR-amplified material is that of the extinct nemonychid weevil. This represents the oldest fossil DNA ever extracted and sequenced, extending by 80 million years the age of any previously reported DNA4-6.	CTR DIS CONTROL,PARASIT DIS BRANCH,ATLANTA,GA 30333; AMER UNIV BEIRUT,DEPT ENVIRONM HLTH,BEIRUT,LEBANON; UNIV CALIF BERKELEY,DEPT ENTOMOL SCI,BERKELEY,CA 94720	Centers for Disease Control & Prevention - USA; American University of Beirut; University of California System; University of California Berkeley	CANO, RJ (corresponding author), CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,DEPT BIOL SCI,SAN LUIS OBISPO,CA 93407, USA.							Arnoldi L.V., 1977, Trudy Paleontologicheskogo Instituta, V161, P142; BANDEL K, 1981, JB GEOL PALEONT MK, V1, P19; CANO R J, 1992, Medical Science Research, V20, P619; CANO RJ, 1992, MED SCI RES, V20, P649; CROWSON RA, 1985, ENTOMOL GEN, V11, P57; CROWSON RA, 1974, 10 ATT C NAZ IT ENT, P1; Crowson RA, 1981, BIOL COLEOPTERA; DAMS E, 1988, NUCLEIC ACIDS RES, V16, pR87, DOI 10.1093/nar/16.suppl.r87; DESALLE R, 1992, SCIENCE, V257, P1860; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HEDGES SB, 1992, MOL BIOL EVOL, V9, P366; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; JUNG JM, 1991, INT J LEGAL MED, V104, P145, DOI 10.1007/BF01369719; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kuschel G., 1983, GeoJournal, V7, P499; KUSCHEL G, IN PRESS ENT SCAND; Poinar Jr GO, 1992, LIFE AMBER; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schlee D., 1970, NEUES JB GEOL PAL, V1, P40; SCHLEE W, 1978, BERNESTEIN, P1; SWOFFORD D, 1991, ILLINOIS NAT HIST SU; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WHALLEY P, 1981, INSECTS LEBANESE AMB; White T.J., 1990, PCR PROTOCOLS GUIDE, P315	27	190	207	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					536	538		10.1038/363536a0	http://dx.doi.org/10.1038/363536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505978				2022-12-28	WOS:A1993LF93900047
J	CONWAY, GA; EPSTEIN, MR; HAYMAN, CR; MILLER, CA; WENDELL, DA; GWINN, M; KARON, JM; PETERSEN, LR				CONWAY, GA; EPSTEIN, MR; HAYMAN, CR; MILLER, CA; WENDELL, DA; GWINN, M; KARON, JM; PETERSEN, LR			TRENDS IN HIV PREVALENCE AMONG DISADVANTAGED YOUTH - SURVEY RESULTS FROM A NATIONAL JOB-TRAINING PROGRAM, 1988 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IMMUNODEFICIENCY-VIRUS INFECTION; ADOLESCENTS; WOMEN; AIDS; POOR	Objective.-To describe trends in the prevalence of human immunodeficiency virus (HIV) among socially and educationally disadvantaged US youth. Design.-Analysis of demographic and geographic trends of HIV infection among Job Corps students from January 1988 through December 1992. Setting.-The Job Corps is a national training program for disadvantaged and out-of-school youth. Population Screened.-Youths aged 16 to 21 years who entered the Job Corps residential training centers during the survey period. Main Outcome Measure.-Trends in prevalence of HIV infection among Job Corps students stratified by sex, age, race, and region of the country. Results.-Of the 269 956 Job Corps students screened, 812 (0.3%) tested positive for the antibody to HIV type 1. Seroprevalence of HIV for young men decreased from 3.6 per 1000 in 1988 to 2.2 per 1000 in 1992 (chi2 test for trend, P<.001). Seroprevalence for young women increased from 2.1 per 1000 in 1988 to 4.2 per 1000 in 1990 (P=.001), with seroprevalence remaining stable from 1990 through 1992. The decreasing trends in HIV prevalence among men and increasing trends among women were primarily due to changes in seroprevalence in African-American students. Conclusions.-The overall prevalence of HIV infection of three per 1000 is high, given the youth of Job Corps students. The significant rise in HIV rates among female Job Corps students provides evidence of the increasing risk of infection for socioeconomically disadvantaged young women. Reasons for the declining trend in HIV prevalence among male Job Corps students are not clear, Efforts to prevent the spread of HIV infection among adolescents must focus on the group that is hardest to reach-out-of-school and impoverished youth.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,TECH INFORMAT ACT,1600 CLIFTON RD,ATLANTA,GA 30333; US DEPT LABOR,EMPLOYMENT & TRAINING ADM,OFF JOB CORPS,WASHINGTON,DC 20210	Centers for Disease Control & Prevention - USA; United States Department of Labor								BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; DANGELO LJ, 1991, PEDIATRICS, V88, P982; FIFE D, 1992, AIDS, V5, P1111; GAYLE HD, 1991, PEDIATRIC AIDS CHALL, P38; KRUEGER LE, 1990, AIDS, V4, P811, DOI 10.1097/00002030-199008000-00015; SHAYNE VT, 1991, WOMEN HEALTH, V17, P21, DOI 10.1300/J013v17n01_02; STLOUIS ME, 1991, JAMA-J AM MED ASSOC, V266, P2387, DOI 10.1001/jama.266.17.2387; WENDELL D, 1991, AJDC, V146, P76; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1993, HIV AIDS SURVEILLANC, P1; 1992, PREVALENCE HIV 1 ANT; 1990, JOB CORPS BRIEF PROG; 1993, 9231 US DEP LAB JOB; 1992, IMPROVING MINORITY H, P43	14	38	38	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2887	2889		10.1001/jama.269.22.2887	http://dx.doi.org/10.1001/jama.269.22.2887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497093				2022-12-28	WOS:A1993LE93600026
J	GROENINK, M; FOUCHIER, RAM; BROERSEN, S; BAKER, CH; KOOT, M; VANTWOUT, AB; HUISMAN, HG; MIEDEMA, F; TERSMETTE, M; SCHUITEMAKER, H				GROENINK, M; FOUCHIER, RAM; BROERSEN, S; BAKER, CH; KOOT, M; VANTWOUT, AB; HUISMAN, HG; MIEDEMA, F; TERSMETTE, M; SCHUITEMAKER, H			RELATION OF PHENOTYPE EVOLUTION OF HIV-1 TO ENVELOPE V2 CONFIGURATION	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120; GLYCOPROTEIN; REGIONS; TROPISM; PANEL	Biological variability of human immunodeficiency virus type-1 (HIV-1) is involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS). Syncytium-inducing (SI) HIV-1 variants emerge in 50 percent of infected individuals during infection, preceding accelerated CD4+ T cell loss and rapid progression to AIDS. The V1 to V2 and V3 region of the viral envelope glycoprotein gp120 contained the major determinants of SI capacity. The configuration of a hypervariable locus in the V2 domain appeared to be predictive for non-SI to SI phenotype conversion. Early prediction of HIV-1 phenotype evolution may be useful for clinical monitoring and treatment of asymptomatic infection.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS	University of Amsterdam	GROENINK, M (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.		Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869				ANDEWEG AC, IN PRESS J VIROL; ASJO B, 1986, LANCET, V2, P660; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; GROENINK M, 1992, J VIROL, V66, P6175, DOI 10.1128/JVI.66.10.6175-6180.1992; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; GROENINK M, UNPUB; HO DD, 1991, P NATL ACAD SCI USA, V88, P8949, DOI 10.1073/pnas.88.20.8949; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOOT M, IN PRESS J INFECT DI; MYERS G, 1990, HUMAN RETROVIRUSES A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, VIROLOGY, V171, P149, DOI 10.1016/0042-6822(89)90521-7; TERSMETTE M, 1989, LANCET, V1, P983; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992	24	207	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1513	1516		10.1126/science.8502996	http://dx.doi.org/10.1126/science.8502996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502996				2022-12-28	WOS:A1993LF05800039
J	BLUMENTHAL, D				BLUMENTHAL, D			TOTAL QUALITY MANAGEMENT AND PHYSICIANS CLINICAL DECISIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE		MASSACHUSETTS GEN HOSP, HLTH POLICY RES & DEV UNIT, MPEC, 50 STANIFORD ST, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, GEN INTERNAL MED UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT MED & HLTH CARE POLICY, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								[Anonymous], 1990, CLIN PRACTICE GUIDEL; Berwick D. M, 1990, CURING HLTH CARE NEW; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; DEMING WE, 1986, CRISIS; GRAYSON MA, 1992, HOSPITALS, V66, P26; GREENFIELD S, 1992, MED CARE, V30, pMS23, DOI 10.1097/00005650-199205001-00003; HEILIG S, 1990, HEALTHCARE FORUM JUL, P19; HRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617; Juran J. M., 1989, JURAN LEADERSHIP QUA; Kleefield S, 1991, QRB Qual Rev Bull, V17, P138; KOSKA MT, 1992, HOSPITALS, V66, P62; KUPERMAN G, 1991, MED DECIS MAKING, V11, pS60, DOI 10.1177/0272989X9101104s11; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; OLEARY D, 1992, JOINT COMMISSION JAN, P2; RAY BH, 1991, PROFIT MOTIVE PATIEN; SCHERKENBACH WB, 1986, DEMING ROUTE; Wadsworth HM, 2002, MODERN METHODS QUALI; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; 1992, NEWS I HLTH CARE IMP, V1, P8	25	62	62	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2775	2778		10.1001/jama.269.21.2775	http://dx.doi.org/10.1001/jama.269.21.2775			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492405				2022-12-28	WOS:A1993LD67100029
J	YOUNGNER, SJ; ARNOLD, RM				YOUNGNER, SJ; ARNOLD, RM			ETHICAL, PSYCHOSOCIAL, AND PUBLIC-POLICY IMPLICATIONS OF PROCURING ORGANS FROM NON-HEART-BEATING CADAVER DONORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICING INTUBATION; NEWLY DEAD; PROCUREMENT		UNIV HOSP CLEVELAND, CLIN ETH PROGRAM, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR BIOMED ETH, CLEVELAND, OH 44106 USA; UNIV PITTSBURGH, CTR MED ETH, DEPT MED, DIV GEN INTERNAL MED, PITTSBURGH, PA 15260 USA	University Hospitals of Cleveland; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	YOUNGNER, SJ (corresponding author), UNIV HOSP CLEVELAND, DEPT MED, DIV GEN INTERNAL MED, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA.							ANAISE D, 1990, TRANSPLANTATION, V49, P290, DOI 10.1097/00007890-199002000-00013; [Anonymous], 1968, JAMA, V205, P337; ATKINS J, 1986, ANN EMERG MED, V15, P178; Burdick James F., 1993, Kennedy Institute of Ethics Journal, V3, P199; CALLENDER CO, 1991, NEW ENGL J MED, V325, P442, DOI 10.1056/NEJM199108083250631; CAPLAN AL, 1989, CLIN TRANSPLANT, V3, P170; CAPLAN AL, 1992, TRANSPLANT P, V24, P722; CAPLAN AL, 1992, SURG GEN WORKSH INCR, P199; Caplan Arthur L., 1993, Kennedy Institute of Ethics Journal, V3, P251; Childress James F., 1993, Kennedy Institute of Ethics Journal, V3, P203; Cole David, 1993, Kennedy Institute of Ethics Journal, V3, P145; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P113; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P131; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; Fox Renee C., 1993, Kennedy Institute of Ethics Journal, V3, P231; Frader Joel, 1993, Kennedy Institute of Ethics Journal, V3, P189; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; GRENVIK A, 1992, OPUSC MED, V37, P33; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; KOOSTRA G, 1991, TRANSPL P, V23, P910; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Lynn Joanne, 1993, Kennedy Institute of Ethics Journal, V3, P167; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MEISEL A, 1986, CRIT CARE MED, V14, P239, DOI 10.1097/00003246-198603000-00016; NATHAN H, 1992, OCT C ETH PSYCH PUBL; NATHAN HM, 1991, TRANSPLANTATION, V51, P142, DOI 10.1097/00007890-199101000-00022; NOVELLO A, 1992, SURGEON GENERALS WOR; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; PROTTAS JM, 1991, J HEALTH POLIT POLIC, V16, P121, DOI 10.1215/03616878-16-1-121; PROTTAS JM, 1986, ATTITUDES INCENTIVES; ROBBINS RA, 1990, DEATH STUD, V14, P219, DOI 10.1080/07481189008252363; Robertson John A., 1993, Kennedy Institute of Ethics Journal, V3, P241; ROSENTAL R, 1991, TRANSPLANT P, V23, P2588; RUERS TJM, 1986, TRANSPLANT P, V18, P408; Shaw Byers W. Jr., 1993, Kennedy Institute of Ethics Journal, V3, P179; SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919; SPITAL A, 1986, ARCH INTERN MED, V146, P1993, DOI 10.1001/archinte.146.10.1993; Starzl TE., 1992, PUZZLE PEOPLE MEMOIR, V1st ed; STRYKER J, 1989, NEW ENGL J MED, V320, P396; Tomlinson T, 1993, Kennedy Inst Ethics J, V3, P157; Weisbard Alan J., 1993, Kennedy Institute of Ethics Journal, V3, P217; YOUNGNER SJ, 1990, TRANSPLANT P, V22, P1014; YOUNGNER SJ, 1992, ARCH NEUROL-CHICAGO, V49, P570, DOI 10.1001/archneur.1992.00530290162028; 1981, DEFINING DEATH; 1992, UNOS UPDATE      JUN, P15; 1988, HASTINGS CENT REP S, V18, P5; 1992, U PITTSBURGH MED CTR; 1983, DECIDING FORGO LIFE; 1990, SOLVING ORGAN SHORTA	50	94	97	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2769	2774		10.1001/jama.269.21.2769	http://dx.doi.org/10.1001/jama.269.21.2769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492404				2022-12-28	WOS:A1993LD67100028
J	HOWCROFT, TK; STREBEL, K; MARTIN, MA; SINGER, DS				HOWCROFT, TK; STREBEL, K; MARTIN, MA; SINGER, DS			REPRESSION OF MHC CLASS-I GENE PROMOTER ACTIVITY BY 2-EXON TAT OF HIV	SCIENCE			English	Article							NF-KAPPA-B; EXPRESSION; RECOGNITION; MODULATION; INFECTION; PROTEINS; PRODUCT; DENSITY; H-2KB	Major histocompatibility complex (MHC) class I molecules are the major receptors for viral peptides and serve as targets for specific cytotoxic T lymphocytes. Human immunodeficiency virus-type 1 (HIV-1) specifically decreased activity of an MHC class I gene promoter up to 12-fold. Repression was effected by the HIV-1 Tat protein derived from a spliced viral transcript (two-exon Tat). These studies define an activity for two-exon Tat distinct from that of one-exon Tat and suggest a mechanism whereby HIV-1-infected cells might be able to avoid immune surveillance, allowing the virus to persist in the infected host.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B-17,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FLORES RV, 1984, J IMMUNOL, V132, P2767; GODING LR, 1990, CRC CRIT REV IMMUNOL, V10, P53; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HOWCROFT TK, UNPUB; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045	23	203	205	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1320	1322		10.1126/science.8493575	http://dx.doi.org/10.1126/science.8493575			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493575	Green Submitted			2022-12-28	WOS:A1993LE02500042
J	WAHLESTEDT, C; GOLANOV, E; YAMAMOTO, S; YEE, F; ERICSON, H; YOO, H; INTURRISI, CE; REIS, DJ				WAHLESTEDT, C; GOLANOV, E; YAMAMOTO, S; YEE, F; ERICSON, H; YOO, H; INTURRISI, CE; REIS, DJ			ANTISENSE OLIGODEOXYNUCLEOTIDES TO NMDA-R1 RECEPTOR-CHANNEL PROTECT CORTICAL-NEURONS FROM EXCITOTOXICITY AND REDUCE FOCAL ISCHEMIC INFARCTIONS	NATURE			English	Article							ISCHEMIC BRAIN-DAMAGE; GLUTAMATE NEUROTOXICITY; ANTAGONIST; RAT; AFFINITY; BINDING	THE excitatory amino acid, L-glutamate, acting through its N-methyl-D-aspartate (NMDA) receptor, may contribute to neuronal death following cerebral vascular occlusion1-3. In support of this hypothesis, NMDA receptor antagonists reduce the volume of infarction produced by occlusion of the middle cerebral artery in vivo4,5 and attenuate Ca2+ influx and neuronal death elicited by L-glutamate or NMDA in vitro3,6. A complementary DNA coding for a major component of the NMDA receptor channel complex, a single protein of M(r) 105.5K (NMDA-R1), has been isolated from rat brain7. Here we demonstrate that inhibition of the synthesis of NMDA-R1 by treatment with antisense oligodeoxynucleotides selectively reduces the expression of NMDA receptors, prevents the neurotoxicity elicited by NMDA in vitro and reduces the volume of the focal ischaemic infarction produced by occlusion of the middle cerebral artery in the rat.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University	WAHLESTEDT, C (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT NEUROL & NEUROSURG,DIV NEUROBIOL,411 E 69TH ST,NEW YORK,NY 10021, USA.		Wahlestedt, Claes/A-7039-2009; Golanov, Eugene/B-6462-2011	Golanov, Eugene/0000-0003-0220-822X				BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BUCHHALTER JR, 1992, NEUROMETHODS, V23, P241; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; FRANKLIN SB, IN PRESS MOL BRAIN R; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HONORE T, 1989, BIOCHEM PHARMACOL, V38, P3207, DOI 10.1016/0006-2952(89)90615-1; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MORYOSHI K, 1991, NATURE, V354, P31; MURPHY DE, 1988, BRIT J PHARMACOL, V95, P932, DOI 10.1111/j.1476-5381.1988.tb11723.x; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RANSOM RW, 1990, LIFE SCI, V46, P1103, DOI 10.1016/0024-3205(90)90420-V; REIS DJ, 1991, J CEREBR BLOOD F MET, V11, P810, DOI 10.1038/jcbfm.1991.139; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; Toulme J. J., 1992, Antisense RNA and DNA., P175; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941	21	376	404	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					260	263		10.1038/363260a0	http://dx.doi.org/10.1038/363260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8487863				2022-12-28	WOS:A1993LC86600052
J	CAPER, P				CAPER, P			MANAGED COMPETITION THAT WORKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								President Clinton has advocated managed competition within a global budget as a long-term strategy for simultaneously controlling health care costs and expanding access to medical care to all Americans. This proposal is intended to show how these two seemingly conflicting goals can be simultaneously accomplished Managed competition, as it has been conceptualized to date, is primarily a strategy for reforming the system of providing health services. To work, it must be joined with a strategy for reforming our system of financing and paying for those services and of limiting overall system capacity. ''Managed Competition That Works'' is a proposal that would create a single trust-funded national system of health insurance, implemented through a system of vouchers to individuals. Global budgeting would be accomplished through establishment of the voucher's value each year. The trust fund would pay health plans for all medical care by capitation, but health plans would be free to negotiate a variety of payment arrangements with physicians, hospitals, and other providers. All plans would be required to offer a standard package of benefits, but would have great flexibility in offering benefits beyond the scope of the standard package, if those benefits replace high-cost with lower-cost services or permit the plan to compete more effectively for market share. This proposal would establish firm but acceptable national budget limits; provide universal, comprehensive, and uniform insurance coverage; eliminate cost shifting; encourage competition; reward efficiency-improving innovation; greatly reduce the need for centralized micromanagement of medical care; and retain local determination and a somewhat reduced level of consumer choice. Although this proposal is written as a national plan, trust funds could be implemented at the state level, if problems associated with portability of benefits among states could be solved.			CAPER, P (corresponding author), CODMAN RES GRP INC,444 MT SUPPORT RD,SUITE 3,LEBANON,NH 03766, USA.							BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; CAPER P, 1993, HEALTH AFFAIR, V12, P174, DOI 10.1377/hlthaff.12.1.174; Reich R., 1991, WORK NATIONS; REICH RB, 1991, NY TIMES        0120, P16	4	8	8	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2524	2526		10.1001/jama.269.19.2524	http://dx.doi.org/10.1001/jama.269.19.2524			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487416				2022-12-28	WOS:A1993LB45000032
J	WINSTON, RML; HANDYSIDE, AH				WINSTON, RML; HANDYSIDE, AH			NEW CHALLENGES IN HUMAN INVITRO FERTILIZATION	SCIENCE			English	Article							HUMAN PREIMPLANTATION EMBRYOS; HUMAN OOCYTES; INSITU HYBRIDIZATION; ZONA PELLUCIDA; MOUSE OOCYTES; CRYOPRESERVATION; SPERM; IMPLANTATION; PREGNANCIES; CHROMOSOME	This review assesses some scientific and ethical problems with human in vitro fertilization. Improved selection of viable embryos, better culture conditions, and greater understanding of the uterine environment will increase success and prevent multiple pregnancy. Further advances will also improve oocyte cryopreservation, in vitro maturation of oocytes, knowledge of sperm function, and sperm microinjection. Preimplantation diagnosis will help avoid genetic diseases and increase understanding of embryonic defects and the viability of zygotes. The greatest ethical problem with all these developments seems to be delivery of these complex treatments when health-care resources are increasingly limited.			WINSTON, RML (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DU CANE RD,LONDON W12 0NN,ENGLAND.							AITKEN RJ, 1987, J REPROD FERTIL, V81, P459; ALHASANI S, 1987, HUM REPROD, V2, P695, DOI 10.1093/oxfordjournals.humrep.a136616; Angell R R, 1989, Prog Clin Biol Res, V294, P181; ANGELL RR, 1987, HUM REPROD, V2, P721, DOI 10.1093/oxfordjournals.humrep.a136621; ASCH RH, 1992, INFERTILITY, P279; BOLAND NI, 1991, J REPROD FERTIL, V8, P8; BUSTER JE, 1985, AM J OBSTET GYNECOL, V153, P211, DOI 10.1016/0002-9378(85)90116-4; CHEN C, 1986, LANCET, V1, P884, DOI 10.1016/S0140-6736(86)90989-X; COHEN J, 1988, LANCET, V2, P162; COHEN J, 1991, J IN VITRO FERTIL EM, V8, P179, DOI 10.1007/BF01130802; CONAGHAN J, 1993, J ASSIST REPROD GEN, V10, P21, DOI 10.1007/BF01204436; DAWSON KJ, 1991, LANCET, V337, P1543, DOI 10.1016/0140-6736(91)93232-X; DOR J, 1991, GYNECOL ENDOCRINOL, V5, P203, DOI 10.3109/09513599109028442; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; EPPIG JJ, 1989, BIOL REPROD, V41, P268, DOI 10.1095/biolreprod41.2.268; FISHEL SB, 1992, INFERTILITY, P115; GORDON JW, 1988, FERTIL STERIL, V50, P68; GOSDEN RG, 1992, INFERTILITY, P263; GRIFFIN DK, 1991, HUM REPROD, V6, P101, DOI 10.1093/oxfordjournals.humrep.a137241; GRIFFIN DK, 1992, HUM GENET, V89, P18, DOI 10.1007/BF00207035; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; HARDY K, 1989, HUM REPROD, V4, P188, DOI 10.1093/oxfordjournals.humrep.a136869; HERTIG AT, 1952, PAEDIATRICS, V23, P202; KOLA I, 1988, TERATOLOGY, V38, P467, DOI 10.1002/tera.1420380510; MENEZO Y, 1992, HUM REPROD, V7, P101, DOI 10.1093/humrep/7.suppl_1.101; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PLACHOT M, 1992, HUM REPROD, V7, P89, DOI 10.1093/humrep/7.suppl_1.89; PLACHOT M, 1987, HUM REPROD, V2, P29, DOI 10.1093/oxfordjournals.humrep.a136484; SAUER MV, 1993, LANCET, V341, P321, DOI 10.1016/0140-6736(93)90132-Z; SCHRURS BM, 1993, HUM REPROD, V8, P296, DOI 10.1093/oxfordjournals.humrep.a138040; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; UENO J, 1991, HUM REPROD, V6, P901, DOI 10.1093/oxfordjournals.humrep.a137455; WINSTON RML, 1991, BAILLIERE CLIN OB GY, V5, P551, DOI 10.1016/S0950-3552(05)80258-5; ZENZES MT, 1992, LANCET, V340, P391, DOI 10.1016/0140-6736(92)91471-J; 1992, FERTIL STERIL, V57, P15; 1990, BRIT MED J, V300, P1229; 1992, HUMAN FERTILISATION	41	38	40	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					932	936		10.1126/science.8493531	http://dx.doi.org/10.1126/science.8493531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493531				2022-12-28	WOS:A1993LB79100033
J	REGENSBURGTUINK, AJG; HOOYKAAS, PJJ				REGENSBURGTUINK, AJG; HOOYKAAS, PJJ			TRANSGENIC N-GLAUCA PLANTS EXPRESSING BACTERIAL VIRULENCE GENE VIRF ARE CONVERTED INTO HOSTS FOR NOPALINE STRAINS OF A-TUMEFACIENS	NATURE			English	Article							OCTOPINE TI-PLASMID; AGROBACTERIUM-TUMEFACIENS; TRANSFORMATION; REGION; MUTANTS; VECTORS; PROTEINS	TUMOURS are induced by Agrobacterium tumefaciens on a variety of plants1-3. The virulence determinants of A. tumefaciens reside on a large tumour-inducing (Ti) plasmid. This plasmid carries two regions essential for tumour induction, namely the T region and the Vir region. During infection the T region is transferred to the plant cell, where it becomes stably integrated in one of the host chromosomes as T-DNA. Expression of T-DNA leads to the production of the plant hormones auxin and cytokinin, as well as to the synthesis of specific amino-acid derivatives termed opines. Agrobacterium strains are classified according to the types of opines produced by the tumours they induce. The Vir region contains genes that are expressed in the bacterium and are required for T-DNA transfer to plant cells, and several other genes that affect the efficiency of transfer and the host range. Vir regions from different Ti plasmids may vary slightly in the genes they contain: for instance, the virF gene, which is present in the Vir-region of octopine Ti plasmids, is absent from nopaline Ti plasmids4,5. Mutation of the virF gene leads to a weakened virulence of octopine strains on tomato6 and Nicotiana glauca (shrub tobacco)4. Nopaline strains are strongly attenuated in N. glauca compared with octopine strains because of the absence of the virF virulence gene from the Ti plasmid in nopaline strains4. The virF gene product way be transferred to and be active in plant cells. Here we isolate transgenic N. glanca plants in which the virF coding sequence is expressed using the cauliflower mosaic virus 35S promoter. The presence of the VirF protein converts the non-host N. glanca into a host for tumour formation by A. tumefaciens nopaline strains and octopine virF mutants. Our results indicate that certain virulence gene products such as the VirF protein may be transferred to plant cells during tumour induction, where they function as mediators of T-DNA transfer.	INST MOLEC PLANT SCI,CLUSIUS LAB,WASSENAARSEWEG 64,2333 AL LEIDEN,NETHERLANDS				Hooykaas, Paul JJ/S-4256-2017	Hooykaas, Paul JJ/0000-0002-9736-6927				BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; DUMS F, 1991, MOL GEN GENET, V229, P357, DOI 10.1007/BF00267456; GODDIJN OJM, 1991, THESIS LEIDEN U; HOOYKAAS PJJ, 1984, PLASMID, V11, P195, DOI 10.1016/0147-619X(84)90026-X; HOOYKAAS PJJ, 1980, J BACTERIOL, V143, P1295, DOI 10.1128/JB.143.3.1295-1306.1980; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; KOEKMAN BP, 1982, PLASMID, V7, P119, DOI 10.1016/0147-619X(82)90072-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSL M, 1992, J BIOL CHEM, V267, P20471; MATTANOVICH D, 1989, NUCLEIC ACIDS RES, V17, P6747, DOI 10.1093/nar/17.16.6747; MELCHERS LS, 1990, PLANT MOL BIOL, V14, P249, DOI 10.1007/BF00018565; MELCHERS LS, 1987, VIRULENCE AGROBACTER, P167; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; OOMS G, 1982, PLASMID, V7, P15, DOI 10.1016/0147-619X(82)90023-3; OTTEN L, 1984, MOL GEN GENET, V195, P159, DOI 10.1007/BF00332739; OTTEN L, 1985, MOL GEN GENET, V199, P189, DOI 10.1007/BF00330258; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; POSSOT O, 1992, MOL MICROBIOL, V6, P95, DOI 10.1111/j.1365-2958.1992.tb00841.x; Sambrook J, 1989, MOL CLONING LABORATO; VANCANNEYT G, 1990, MOL GEN GENET, V220, P245, DOI 10.1007/BF00260489; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	25	67	77	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					69	71		10.1038/363069a0	http://dx.doi.org/10.1038/363069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479538				2022-12-28	WOS:A1993LA68200060
J	FLOREY, CD				FLOREY, CD			SAMPLE-SIZE FOR BEGINNERS	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; POWER	The common failure to include an estimation of sample size in grant proposals imposes a major handicap on applicants, particularly for those proposing work in any aspect of research in the health services. Members of research committees need evidence that a study is of adequate size for there to be a reasonable chance of a clear answer at the end. A simple illustrated explanation of the concepts in determining sample size should encourage the faint hearted to pay more attention to this increasingly important aspect of grantsmanship.			FLOREY, CD (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND.							BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BROWN RA, 1990, MED STATISTICS MICRO; Casagrande J. T., 1978, APPLIED STATISTICS, V27, P176; DALY LE, 1991, BRIT MED J, V302, P333, DOI 10.1136/bmj.302.6772.333; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GARDNER MJ, 1989, STATISTICS CONFIDENC; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LEMESHOW S, 1990, ADEQUACY SAMPLER SIZ; MILLER DK, 1988, BRIT MED J, V297, P672, DOI 10.1136/bmj.297.6649.672	9	91	93	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1181	1184		10.1136/bmj.306.6886.1181	http://dx.doi.org/10.1136/bmj.306.6886.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499826	Green Published, Bronze			2022-12-28	WOS:A1993LA68500030
J	LEAR, J; DANIELS, RG				LEAR, J; DANIELS, RG			MUSCLE CRAMPS RELATED TO CORTICOSTEROIDS	BRITISH MEDICAL JOURNAL			English	Letter											LEAR, J (corresponding author), NORTHAMPTON GEN HOSP,NORTHAMPTON NN1 5BD,ENGLAND.		lear, john/I-5465-2015	lear, john/0000-0002-2969-9922				PALMER KNV, 1978, BRIT MED J, V2, P833, DOI 10.1136/bmj.2.6140.833-b; PORTNOY J, 1992, ANN ALLERGY, V69, P71	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1169	1169		10.1136/bmj.306.6886.1169-c	http://dx.doi.org/10.1136/bmj.306.6886.1169-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499821	Green Published, Bronze			2022-12-28	WOS:A1993LA68500026
J	DEKKER, N; COX, M; BOELENS, R; VERRIJZER, CP; VANDERVLIET, PC; KAPTEIN, R				DEKKER, N; COX, M; BOELENS, R; VERRIJZER, CP; VANDERVLIET, PC; KAPTEIN, R			SOLUTION STRUCTURE OF THE POU-SPECIFIC DNA-BINDING DOMAIN OF OCT-1	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSCRIPTION FACTORS; DISTANCE CONSTRAINTS; CRYSTAL-STRUCTURE; FACTOR-III; PROTEIN; REPLICATION; SEQUENCE; COMPLEX	THE transcription factor Oct-1 belongs to a family containing a POU DNA-binding domain. This bipartite domain is composed of a POU-specific domain (POU(s)) and a POU-homeodomain (POU(hd)) connected by a flexible linker. The left half of the optimal POU binding site, the octamer ATGCAAAT, is recognized by POU(s) and the right half by POU(hd). We have determined the solution structure of POU(s) by nuclear magnetic resonance. It consists of four alpha-helices connected by short loops. Helices I and IV are in a parallel coiled-coil arrangement. The folding topology appears to be similar to that of the bacteriophage lambda-repressor and 434 repressor. For the well defined parts of the protein (residues 1-71), the average root-mean square deviation for the backbone atoms is 0.9 angstrom. Based on the observed selective exchange broadening in the (N-15, H-1)-HMQC (heteronuclear multiple quantum coherence) spectrum of the POU(s)-DNA complex we conclude that DNA-binding is mediated by helix III. We propose a model for the POU-DNA complex in which both recognition helices from the two subdomains have adjacent positions in the major groove.	UNIV UTRECHT,BIJVOET CTR BIOMOLEC RES,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3521 GG UTRECHT,NETHERLANDS	Utrecht University; Utrecht University			Boelens, Rolf/B-4702-2009	Boelens, Rolf/0000-0002-6939-8913				BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLM L, IN PRESS J MOL BIOL; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KONING TMG, 1990, J MAGN RESON, V90, P111, DOI 10.1016/0022-2364(90)90369-K; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1988, J VIROL, V62, P3092, DOI 10.1128/JVI.62.9.3092-3102.1988; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402	26	140	147	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					852	855		10.1038/362852a0	http://dx.doi.org/10.1038/362852a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479524				2022-12-28	WOS:A1993KZ56300061
J	JOHNSTON, DW; GOLD, A; KENTISH, J; SMITH, D; VALLANCE, P; SHAH, D; LEACH, G; ROBINSON, B				JOHNSTON, DW; GOLD, A; KENTISH, J; SMITH, D; VALLANCE, P; SHAH, D; LEACH, G; ROBINSON, B			EFFECT OF STRESS MANAGEMENT ON BLOOD-PRESSURE IN MILD PRIMARY HYPERTENSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RELAXATION THERAPY; CONTROLLED TRIAL; WORKSITE	Objective-To establish whether stress management had a larger effect than a control treatment on resting blood pressure, ambulatory blood pressure, and left ventricular mass. Design-A 12 week baseline period of habituation to measurement of blood pressure was followed by randomisation to either stress management or mild exercise for six months and follow up six months later. Setting-General practice, district general hospital, and medical school. Patients-Of the 184 patients aged under 60 with mild primary hypertension who entered the baseline habituation period, 88 were excluded because they failed to meet the entry criteria or they withdrew from the study. The remaining 46 men and 50 women underwent treatment. Interventions-10 clinical sessions and daily practice at home of either stress management based on relaxation or non-aerobic stretching exercises. Mildly stressful 15 minute interviews before and after treatment. Main outcome measures-Diastolic and systolic blood pressure in the clinic and during 12 hours of ambulatory recording, and left ventricular mass measured by echocardiography. Results-The patients' blood pressure fell during habituation (systolic pressure from 152 mm Hg to 140 mm Hg, diastolic pressure from 98 to 93 mm Hg), but neither resting nor ambulatory blood pressure was changed by the treatments. Left ventricular mass was also unchanged. Blood pressure rose during the stressful interview, but this rise was reduced by stress management (systolic pressure rose by 7.4 mm Hg before treatment and by 3.7 mm Hg after treatment). Conclusion-Stress management of a type advocated for treating mild primary hypertension is ineffective in lowering blood pressure in patients who are well habituated to measuring blood pressure.	ST GEORGE HOSP, SCH MED, DEPT PSYCHOL, LONDON SW17 0RE, ENGLAND; ST GEORGE HOSP, DEPT PHARMACOL & CLIN PHARMACOL, LONDON SW17 0RE, ENGLAND; ST GEORGE HOSP, DEPT CARDIOL, LONDON SW17 0RE, ENGLAND	St Georges University London; St Georges University London; St Georges University London			Johnston, Derek/C-5344-2008					AGRAS WS, 1987, PSYCHOSOM MED, V49, P264, DOI 10.1097/00006842-198705000-00005; [Anonymous], 1981, LANCET, V2, P539; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; [Anonymous], 1977, BMJ-BRIT MED J, V1, P1437; BENNETT P, 1991, J PSYCHOSOM RES, V35, P209, DOI 10.1016/0022-3999(91)90075-Y; CHESNEY MA, 1987, PSYCHOSOM MED, V49, P250, DOI 10.1097/00006842-198705000-00004; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; Diem K., 1970, SCI TABLES, VSeventh; IRVINE MJ, 1991, PSYCHOSOM MED, V53, P587, DOI 10.1097/00006842-199111000-00001; IRVINE MJ, 1986, J PSYCHOSOM RES, V30, P437, DOI 10.1016/0022-3999(86)90083-8; JOHNSTON DW, 1991, HYPERTENSION, V17, pS63; JOHNSTON DW, 1986, BIOL PSYCHOL FACTORS, P550; MacMahon S., 1989, HYPERTENSION S1, V13, P45; PATEL C, 1981, BRIT MED J, V282, P2005, DOI 10.1136/bmj.282.6281.2005; PATEL C, 1975, LANCET, V2, P93; PATEL C, 1988, BRIT MED J, V296, P21, DOI 10.1136/bmj.296.6614.21; PATEL C, 1985, BRIT MED J, V290, P1103, DOI 10.1136/bmj.290.6475.1103; Pickering TG., 1991, AMBULATORY MONITORIN; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; ROSENMAN RH, 1964, JAMA-J AM MED ASSOC, V189, P15; SOUTHAM MA, 1982, ARCH GEN PSYCHIAT, V39, P715; TAYLOR CB, 1977, ARCH GEN PSYCHIAT, V34, P339; VANMONTFRANS GA, 1990, BRIT MED J, V300, P1368, DOI 10.1136/bmj.300.6736.1368	23	43	44	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	1993	306	6883					963	966		10.1136/bmj.306.6883.963	http://dx.doi.org/10.1136/bmj.306.6883.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490471	Bronze, Green Published			2022-12-28	WOS:A1993KX43600016
J	REES, DC; KELSEY, H; RICHARDS, JDM				REES, DC; KELSEY, H; RICHARDS, JDM			ACUTE HEMOLYSIS INDUCED BY HIGH-DOSE ASCORBIC-ACID IN GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							G-6-PD DEFICIENCY; INDUCED HEMOLYSIS; ERYTHROCYTES		UNIV COLL HOSP LONDON,DEPT HAEMATOL,LONDON WC1E 6AU,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London			Rees, David/B-6789-2011	Rees, David/0000-0003-3647-1050				BUHL R, 1989, LANCET, V2, P1294; CAMPBELL GD, 1975, ANN INTERN MED, V82, P810, DOI 10.7326/0003-4819-82-6-810_1; CATHCART RF, 1984, MED HYPOTHESES, V14, P423, DOI 10.1016/0306-9877(84)90149-X; DACIE J, 1985, HAEMOLYTIC ANAEMIA, P365; HAREKEH S, 1991, AM J CLIN NUTR, V54, P1231; HOFFBRAND AV, 1989, POSTGRADUATE HAEMATO, P146; MEHTA JB, 1990, LANCET, V336, P944, DOI 10.1016/0140-6736(90)92317-B; RIVERA MP, 1989, MED HYPOTHESES, V30, P95, DOI 10.1016/0306-9877(89)90092-3; UDOMRATN T, 1977, BLOOD, V49, P471; WILSON CWM, 1973, LANCET, V1, P1058; WINTERBOURN CC, 1979, BRIT J HAEMATOL, V41, P245, DOI 10.1111/j.1365-2141.1979.tb05853.x	11	88	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					841	842		10.1136/bmj.306.6881.841	http://dx.doi.org/10.1136/bmj.306.6881.841			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490379	Bronze, Green Published			2022-12-28	WOS:A1993KV34800026
J	STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C				STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C			RESIDENTIAL CARE FOR ELDERLY PEOPLE - A DECADE OF CHANGE	BRITISH MEDICAL JOURNAL			English	Article							HOMES	Objective-To determine the changes between 1979 and 1990 in demography and dependency levels in elderly people in residential care. Design-Censuses of those aged 65 years and over in any type of residential care at midnight on 11 December 1979 and 27 November 1990. Setting-Leicestershire District Health Authority (population 865 133, 1991 census), coterminous with county and social services boundaries. Main outcome measures-Age, sex, length of stay, and dependency levels (measured by activities of daily living). Results-In 1990 (1979), 6079 (4678) elderly people were enumerated in 241 (133) establishments, a 30% increase in the numbers of elderly people in residential care and an 82% increase in the number of establishments between 1979 and 1990. Dependency levels rose between 1979 and 1990 in all but the geriatric sector, the greatest increases being found in private residential homes where the largest percentage increase in the number of residents had occurred. Conclusions-Dependency levels in residential care have risen substantially, particularly in the private sector, even beyond levels expected from the greater numbers of elderly people. With the impending move to community care, dependency levels are likely to rise further, and more appropriate staff training and medical input to homes will become necessary.	UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,POB 65,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND; DEPT HLTH,LONDON SW1A 2NS,ENGLAND; UNIV LEICESTER,DEPT PSYCHIAT,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED ELDERLY,LEICESTER LE1 7RH,ENGLAND; LEICESTERSHIRE CTY COUNCIL,DEPT SOCIAL SERV,SERV OLDER PEOPLE,LEICESTER,ENGLAND	University of Leicester; University of Leicester; University of Leicester; University of Leicester				Jagger, Carol/0000-0002-6377-9926				BAKER RJ, 1985, GLIM 3 77 USER REFER; CAMPBELL H, 1990, AGE AGEING, V19, P318, DOI 10.1093/ageing/19.5.318; Clarke M, 1979, HLTH TRENDS, V11, P17; DAY P, 1987, BRIT MED J, V294, P384, DOI 10.1136/bmj.294.6568.384; Donaldson L J, 1983, Health Trends, V15, P58; DONALDSON LJ, 1983, PUBLIC HEALTH, V97, P257, DOI 10.1016/S0033-3506(83)80101-2; GODBER C, 1984, BRIT MED J, V288, P1473, DOI 10.1136/bmj.288.6429.1473; GOSNEY M, 1991, HLTH TRENDS, V22, P153; Griffiths R, 1988, COMMUNITY CARE AGEND; GRUNDY E, 1982, BRIT MED J, V284, P799, DOI 10.1136/bmj.284.6318.799; GRUNDY E, 1987, BRIT MED J, V294, P626, DOI 10.1136/bmj.294.6572.626; JAGGER C, 1991, INT J EPIDEMIOL, V20, P234, DOI 10.1093/ije/20.1.234; LAING, 1988, CARE ELDERLY PEOPLE; LOWY S, 1988, BMJ, V296, P541; STOTT D J, 1990, Health Bulletin (Edinburgh), V48, P17; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; WILKIN D, 1978, BRIT MED J, V2, P1274, DOI 10.1136/bmj.2.6147.1274; 1975, BETTER SERVICES MENT; 1991, NATIONAL POPULAT PP2; 1989, CARING PEOPLE COMMUN; 1988, POSITIVE CHOICE; 1990, MORTALITY STATIS DHI	22	36	36	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					827	830		10.1136/bmj.306.6881.827	http://dx.doi.org/10.1136/bmj.306.6881.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490375	Bronze, Green Published			2022-12-28	WOS:A1993KV34800021
J	ROSMAN, NP; COLTON, T; LABAZZO, J; GILBERT, PL; GARDELLA, NB; KAYE, EM; VANBENNEKOM, C; WINTER, MR				ROSMAN, NP; COLTON, T; LABAZZO, J; GILBERT, PL; GARDELLA, NB; KAYE, EM; VANBENNEKOM, C; WINTER, MR			A CONTROLLED TRIAL OF DIAZEPAM ADMINISTERED DURING FEBRILE ILLNESSES TO PREVENT RECURRENCE OF FEBRILE SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-LEVELS; SODIUM VALPROATE; CONVULSIONS; CHILDREN; PHENOBARBITONE; PROPHYLAXIS; PRIMIDONE	Background. Phenobarbital, once widely prescribed to prevent febrile seizures, is now in disfavor because of its side effects and lack of efficacy. Diazepam, administered only during episodes of fever, may be a safe, effective agent to prevent the recurrence of febrile seizures. Methods. We conducted a randomized, double-blind, placebo-controlled trial among 406 children (mean age,24 months) who had at least one febrile seizure. Diazepam (0.33 mg per kilogram of body weight) or placebo was administered orally every eight hours during all febrile illnesses. Results. During a mean follow-up of 1.9 years (a period during which 90 percent of febrile seizures recur), our intention-to-treat analysis showed a reduction of 44 percent in the risk of febrile seizures per person-year with diazepam (relative risk = 0,56; 95 percent confidence interval, 0.38 to 0.81; P = 0.002). A survival analysis of the length of time to the first recurrent febrile seizure did not show a significant difference between the treatment groups (P = 0.064 by the log-rank test), but after adjustment for covariates, diazepam was found to have a benefit (P = 0.027 by Cox regression analysis). An analysis restricted to children who had seizures while actually receiving the study medication (7 in the diazepam group and 29 in the placebo group) showed an 82 percent reduction in the risk of febrile seizures with diazepam (relative risk = 0.18; 95 percent confidence interval, 0.09 to 0.37; P<0.001). Of the 153 children who took at least one dose of diazepam, 39 percent had ataxia, lethargy, or irritability or at least one other moderate side effect that was reversed after a reduction in the dose. There were no severe side effects. Conclusions. Oral diazepam, given only when fever is present, is safe and reduces the risk of recurrent febrile seizures.	TUFTS UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT NEUROL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT NEUROL, DIV PEDIAT NEUROL, BOSTON, MA 02111 USA; BOSTON UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, BOSTON, MA 02215 USA	Tufts University; Tufts University; Boston University			Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Rosman, N./0000-0002-7702-8015	NINDS NIH HHS [2 RO1 NS 24620] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024620] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGURELL S, 1975, EPILEPSIA, V16, P277, DOI 10.1111/j.1528-1157.1975.tb06058.x; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; AUTRET E, 1990, J PEDIATR-US, V117, P490, DOI 10.1016/S0022-3476(05)81104-7; BERG AT, 1992, NEW ENGL J MED, V327, P1122, DOI 10.1056/NEJM199210153271603; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; FERNGREN HG, 1974, EPILEPSIA, V15, P27, DOI 10.1111/j.1528-1157.1974.tb03994.x; FREEMAN JM, 1992, NEW ENGL J MED, V327, P1161, DOI 10.1056/NEJM199210153271610; HERRANZ JL, 1984, EPILEPSIA, V25, P89, DOI 10.1111/j.1528-1157.1984.tb04160.x; HIRTZ DG, 1989, PEDIATR CLIN N AM, V36, P365; HOHJO M, 1986, BRAIN DEV-JPN, V8, P559; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KNUDSEN FU, 1991, ACTA NEUROL SCAND, V83, P1; LAWLESS JF, 1982, STATISTICAL MODELS M; LOMBROSO CT, 1989, EPILEPSIA, V30, pS11, DOI 10.1111/j.1528-1157.1989.tb05819.x; MINAGAWA K, 1981, BRAIN DEV-JPN, V3, P385, DOI 10.1016/S0387-7604(81)80067-8; Minagawa K, 1985, No To Hattatsu, V17, P162; NELSON KB, 1978, PEDIATRICS, V61, P720; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; NEWTON RW, 1988, ARCH DIS CHILD, V63, P1189, DOI 10.1136/adc.63.10.1189; NEWTON RW, 1988, DEV MED CHILD NEUROL, V30, P402; Rosman N P, 1987, Emerg Med Clin North Am, V5, P719; ROSMAN NP, 1992, CONT PEDIATR, V9, P12; SCHMIDT D, 1989, ANTIEPILEPTIC DRUGS, P735; TRIMBLE MR, 1989, CLEV CLIN J MED, V56, pS140; VIALA A, 1971, PSYCHIAT NEUROL NEUR, V74, P153; WALLACE SJ, 1980, BRIT MED J, V280, P353, DOI 10.1136/bmj.280.6211.353; WALLACE SJ, 1988, CHILD FEBRILE SEIZUR, P1; WOLF SM, 1977, PEDIATRICS, V59, P378; WOLF SM, 1981, FEBRILE SEIZURES, P127	29	130	134	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					79	84		10.1056/NEJM199307083290202	http://dx.doi.org/10.1056/NEJM199307083290202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510706				2022-12-28	WOS:A1993LL19600002
J	SPIRO, IJ; YANDELL, DW; LI, C; SAINI, S; FERRY, J; POWELSON, J; KATKOV, WN; COSIMI, AB				SPIRO, IJ; YANDELL, DW; LI, C; SAINI, S; FERRY, J; POWELSON, J; KATKOV, WN; COSIMI, AB			LYMPHOMA OF DONOR ORIGIN OCCURRING IN THE PORTA-HEPATIS OF A TRANSPLANTED LIVER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; BONE-MARROW TRANSPLANTATION; RENAL-ALLOGRAFT RECIPIENT; EPSTEIN-BARR VIRUS; IMMUNOBLASTIC SARCOMA; CELLS; DNA; POLYMORPHISMS; LEUKEMIA		MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard T.H. Chan School of Public Health	SPIRO, IJ (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114, USA.		Li, Chuan-Yuan/H-4148-2013					ELFENBEIN GJ, 1978, BLOOD, V52, P627; FERRY JA, 1989, MODERN PATHOL, V2, P583; FIALKOW PJ, 1971, LANCET, V1, P251; GAMBACORTA M, 1991, TRANSPLANTATION, V51, P920, DOI 10.1097/00007890-199104000-00041; GOH KO, 1977, AM J HEMATOL, V2, P283, DOI 10.1002/ajh.2830020310; GOSSETT TC, 1979, NEW ENGL J MED, V300, P904, DOI 10.1056/NEJM197904193001606; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HARRIS KM, 1987, RADIOLOGY, V162, P697, DOI 10.1148/radiology.162.3.3544033; HJELLE B, 1989, TRANSPLANTATION, V47, P945, DOI 10.1097/00007890-198906000-00005; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; MEDURI G, 1991, TRANSPLANT P, V23, P2649; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NEWBURGER PE, 1981, NEW ENGL J MED, V304, P712, DOI 10.1056/NEJM198103193041206; SCHUBACH WH, 1982, BLOOD, V60, P180; STARZL TE, 1984, LANCET, V1, P583; THOMAS ED, 1972, LANCET, V1, P1310; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YOUSEM SA, 1989, HUM PATHOL, V20, P361, DOI 10.1016/0046-8177(89)90046-4	21	62	63	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					27	29		10.1056/NEJM199307013290105	http://dx.doi.org/10.1056/NEJM199307013290105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505941				2022-12-28	WOS:A1993LJ33800005
J	WYLER, DJ				WYLER, DJ			DRUG-THERAPY - MALARIA CHEMOPROPHYLAXIS FOR THE TRAVELER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLASMODIUM-FALCIPARUM MALARIA; AMERICAN TRAVELERS; UNITED-STATES; RESISTANT MALARIA; ANTIBODY-RESPONSE; ENDEMIC AREA; FIELD TRIALS; PROPHYLAXIS; MEFLOQUINE; CHLOROQUINE		TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University	WYLER, DJ (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,DIV GEOG MED & INFECT DIS,750 WASHINGTON ST,BOX 041,BOSTON,MA 02111, USA.							ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; BAIRD JK, 1991, AM J TROP MED HYG, V44, P547, DOI 10.4269/ajtmh.1991.44.547; BARRY M, 1991, AM J TROP MED HYG, V44, P79, DOI 10.4269/ajtmh.1991.44.79; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BOUDREAU EF, 1988, B WORLD HEALTH ORGAN, V66, P227; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; CANFIELD CJ, 1974, B WORLD HEALTH ORGAN, V50, P203; CHILDS GE, 1991, AM J TROP MED HYG, V44, P553, DOI 10.4269/ajtmh.1991.44.553; COLWELL EJ, 1973, ANN TROP MED PARASIT, V67, P125, DOI 10.1080/00034983.1973.11686870; DELANEY TJ, 1974, ACTA DERM-VENEREOL, V54, P487; DESJARDINS RE, 1979, CLIN PHARMACOL THER, V26, P372; FISHER GU, 1970, AM J TROP MED HYG, V19, P27, DOI 10.4269/ajtmh.1970.19.27; FOGH S, 1988, BMJ-BRIT MED J, V296, P820, DOI 10.1136/bmj.296.6625.820; GOZAL D, 1991, ANTIMICROB AGENTS CH, V35, P373, DOI 10.1128/AAC.35.2.373; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; KELLER P, 1989, TRAVEL MED, P10; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; LOBEL H O, 1991, American Journal of Tropical Medicine and Hygiene, V45, P273; LOBEL HO, 1987, J INFECT DIS, V155, P1205, DOI 10.1093/infdis/155.6.1205; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; LOBEL HO, 1987, JAMA-J AM MED ASSOC, V257, P2626, DOI 10.1001/jama.257.19.2626; LOBEL HO, 1985, LANCET, V1, P873; LOBEL HO, 1989, TRAVEL MED, P81; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; MILLER LH, 1974, AM J TROP MED HYG, V23, P309, DOI 10.4269/ajtmh.1974.23.309; MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; NEVILL CG, 1988, BMJ-BRIT MED J, V297, P401, DOI 10.1136/bmj.297.6645.401; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; PACI E, 1991, INT TOURIST ARRIVALS; PANG LW, 1989, B WORLD HEALTH ORGAN, V67, P51; PANG LW, 1987, LANCET, V1, P1161; PAPPAIOANOU M, 1988, B WORLD HEALTH ORGAN, V66, P477; PAPPAIOANOU M, 1986, NEW ENGL J MED, V314, P280, DOI 10.1056/NEJM198601303140504; PEARLMAN EJ, 1980, AM J TROP MED HYG, V29, P1131, DOI 10.4269/ajtmh.1980.29.1131; Peters W, 1970, CHEMOTHERAPY DRUG RE; PETO TEA, 1986, LANCET, V1, P1256; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; PHILLIPSHOWARD PA, 1986, BRIT MED J, V293, P932, DOI 10.1136/bmj.293.6552.932; PHILLIPSHOWARD PA, 1989, TRAVEL MED, P90; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; RACCURT CP, 1991, AM J TROP MED HYG, V45, P319, DOI 10.4269/ajtmh.1991.45.319; RAEBER PA, 1982, SOZ PRAVENTIV MED, V27, P266, DOI 10.1007/BF02079665; RINGWALD P, 1990, T ROY SOC TROP MED H, V84, P348, DOI 10.1016/0035-9203(90)90311-2; SHANKS GD, 1992, MIL MED, V157, P4, DOI 10.1093/milmed/157.1.4; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; WOLFE MS, 1985, BRIT MED J, V290, P1466, DOI 10.1136/bmj.290.6480.1466; WYLER DJ, 1984, JAMA-J AM MED ASSOC, V251, P2420, DOI 10.1001/jama.251.18.2420; 1991, WKLY EPIDEMIOL REC, V66, P167; 1991, MMWR MORB MORTAL WKL, V40, P72; 1988, B WORLD HEALTH ORGAN, V66, P177; 1983, B WORLD HEALTH ORGAN, V61, P169; 1990, HHS CDC908280 PUBL; 1991, WKLY EPIDEMIOL REC, V66, P157	57	44	44	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					31	37						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505942				2022-12-28	WOS:A1993LJ33800007
J	ROUAULT, TA				ROUAULT, TA			HEREDITARY HEMOCHROMATOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							IRON DEPLETION; HYPOGONADISM				ROUAULT, TA (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							ADAMS PC, 1991, AM J MED, V90, P445; BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; CONRAD ME, 1963, BLOOD, V22, P406, DOI 10.1182/blood.V22.4.406.406; COOK JD, 1990, AM J CLIN NUTR, V51, P301, DOI 10.1093/ajcn/51.2.301; COX TM, 1989, EUR J HAEMATOL, V42, P113; CRAWFORD DHG, 1991, DRUGS, V41, P875, DOI 10.2165/00003495-199141060-00005; CRAWFORD R, 1992, IRON ELEPHANT; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; GRANICK S, 1946, J BIOL CHEM, V164, P737; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; JANKOVIC GM, 1991, AM J HEMATOL, V38, P153, DOI 10.1002/ajh.2830380218; JANKOVIC GM, 1989, EUR J HAEMATOL, V43, P265; KELLY TM, 1984, ANN INTERN MED, V101, P629, DOI 10.7326/0003-4819-101-5-629; MILDER MS, 1980, MEDICINE, V59, P34, DOI 10.1097/00005792-198001000-00002; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SCHUMACHER HR, 1988, ANN NY ACAD SCI, V526, P224, DOI 10.1111/j.1749-6632.1988.tb55508.x; SIEMONS LJ, 1987, J CLIN ENDOCR METAB, V65, P585, DOI 10.1210/jcem-65-3-585; SIMON M, 1988, ANN NY ACAD SCI, V526, P11, DOI 10.1111/j.1749-6632.1988.tb55488.x; SMITH LH, 1990, WESTERN J MED, V153, P296; [No title captured]	22	12	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3152	3154		10.1001/jama.269.24.3152	http://dx.doi.org/10.1001/jama.269.24.3152			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505819				2022-12-28	WOS:A1993LH14500031
J	JONIDES, J; SMITH, EE; KOEPPE, RA; AWH, E; MINOSHIMA, S; MINTUN, MA				JONIDES, J; SMITH, EE; KOEPPE, RA; AWH, E; MINOSHIMA, S; MINTUN, MA			SPATIAL WORKING-MEMORY IN HUMANS AS REVEALED BY PET	NATURE			English	Article							PREFRONTAL CORTEX; IMAGERY	THE concept of working memory is central to theories of human cognition because working memory is essential to such human skills as language comprehension and deductive reasoning1-4. Working memory is thought to be composed of two parts, a set of buffers that temporarily store information in either a phonological or visuospatial form, and a central executive responsible for various computations such as mental arithmetic5,6. Although most data on working memory come from behavioural studies of normal and brain-injured humans7, there is evidence about its physiological basis from invasive studies of monkeys8-10. Here we report positron emission tomography (PET) studies of regional cerebral blood flow in normal humans that reveal activation in right-hemisphere prefrontal, occipital, parietal and premotor cortices accompanying spatial working memory processes. These results begin to uncover the circuitry of a working memory system in humans.	UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; PRESBYTERIAN UNIV HOSP, DIV NUCL MED, PITTSBURGH, PA 15213 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	JONIDES, J (corresponding author), UNIV MICHIGAN, DEPT PSYCHOL, ANN ARBOR, MI 48109 USA.			Awh, Edward/0000-0002-5211-5278; Minoshima, Satoshi/0000-0002-0043-3047				BADDELEY A, 1988, J MEM LANG, V27, P586, DOI 10.1016/0749-596X(88)90028-9; Baddeley A.D., 1986, WORKING MEMORY THOUG; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; CHAFEE M, 1989, SOC NEUR ABSTR, V15, P786; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; FARAH MJ, 1988, PSYCHOL REV, V95, P307, DOI 10.1037/0033-295X.95.3.307; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOLDENBERG G, 1987, NEUROPSYCHOLOGIA, V25, P473, DOI 10.1016/0028-3932(87)90072-8; Goldmanrakic PS., 1987, HDB PHYSL NERVOUS SY, P373; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Holding D.H., 1985, PSYCHOL CHESS SKILL; KOSSLYN SM, IN PRESS J COGN NEUR; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; MINOSHIMA S, 1993, J NUCL MED, V34, P322; PASSINGHAM RE, 1985, BEHAV NEUROSCI, V99, P3, DOI 10.1037/0735-7044.99.1.3; Talairach J., 1988, COPLANAR STEREOTAXIC; Tesak J, 2005, NEUROPSYCHOLOGICAL I	21	914	925	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					623	625		10.1038/363623a0	http://dx.doi.org/10.1038/363623a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510752	Green Published			2022-12-28	WOS:A1993LH13900054
J	ERNST, E; RESCH, KL				ERNST, E; RESCH, KL			FIBRINOGEN AS A CARDIOVASCULAR RISK FACTOR - A METAANALYSIS AND REVIEW OF THE LITERATURE	ANNALS OF INTERNAL MEDICINE			English	Review						FIBRINOGEN; MYOCARDIAL INFARCTION; CEREBROVASCULAR DISORDERS; ARTERIAL OCCLUSIVE DISEASES; RISK FACTORS	ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; BLOOD RHEOLOGY; HEMOSTATIC FUNCTION; CIGARETTE-SMOKING; ATHEROSCLEROSIS; SPEEDWELL; VISCOSITY; SEVERITY	Purpose: To evaluate the possibility that fibrinogen represents a cardiovascular risk factor. Data Identification: A computerized literature search (1980 to 1992) identified all published epidemiologic studies on fibrinogen and cardiovascular disease. Clinical and basic research data were found by separate searches. References of all papers thus obtained were studied and relevant papers included. Study Selection: Six prospective epidemiologic studies were included in a meta-analysis (one study was excluded because the study population was nonrepresentative). Clinical papers were reviewed separately for other evidence of causation. Data Extraction: The correlation of fibrinogen levels on the subsequent incidence of myocardial infarction, stroke, and peripheral arterial occlusive disease was assessed and the causality of the association was analyzed. Calculations were made to examine fibrinogen level (in tertiles) versus cardiovascular risk. Odds ratios of high versus low tertile were computed. Results of Data Analysis: All prospective studies showed that fibrinogen was associated with subsequent myocardial infarction or stroke. A total of 92 147 person-years was covered by these investigations. Odds ratios varied between 1.8 (95% CI, 1.2 to 2.5) in the Framingham and 4.1 (CI, 2.3 to 6.9) in the GRIPS study, with a summary odds ratio of 2.3 (CI, 1.9 to 2.8). Associations existed between fibrinogen and other cardiovascular risk factors, but after multivariate analysis, only the association between fibrinogen and cardiovascular events remained. The majority of the preconditions for causality were fulfilled, indicating that fibrinogen is pathophysiologically related to cardiovascular events. Conclusions: Fibrinogen can be considered a major cardiovascular risk factor. Future studies of cardiovascular morbidity and death should include this variable.			ERNST, E (corresponding author), UNIV VIENNA, AKH, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.							BAKER IA, 1982, BRIT HEART J, V47, P490, DOI 10.1136/hrt.47.5.490; BALLEISEN L, 1987, LANCET, V2, P461; Barnes A, 1987, CLIN HEMORHEOL, P275; BROADHURST P, 1990, ATHEROSCLEROSIS, V85, P169, DOI 10.1016/0021-9150(90)90108-U; COOK NS, 1990, TRENDS PHARMACOL SCI, V11, P444, DOI 10.1016/0165-6147(90)90125-R; COULL BM, 1991, STROKE, V22, P162, DOI 10.1161/01.STR.22.2.162; CREMER P, 1992, DIAGNOSE LABOR, V42, P28; DIMINNO G, 1986, ARTERIOSCLEROSIS, V6, P203, DOI 10.1161/01.ATV.6.2.203; DORMANDY J, 1982, AM HEART J, V104, P1364, DOI 10.1016/0002-8703(82)90169-7; DORMANDY JA, 1973, BRIT MED J, V4, P576, DOI 10.1136/bmj.4.5892.576; EISENBER.S, 1966, CIRCULATION, V33, P10; ELLIOTT FA, 1961, NEUROLOGY, V11, P120, DOI 10.1212/WNL.11.2.120; ERIKSSON H, 1992, FIBRINOGEN NEW CARDI; ERNST E, 1986, ATHEROSCLEROSIS, V59, P263, DOI 10.1016/0021-9150(86)90121-8; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; ERNST E, 1988, STROKE, V19, P634, DOI 10.1161/01.STR.19.5.634; ERNST E, 1988, ARTERIOSCLEROSIS, V8, P385, DOI 10.1161/01.ATV.8.4.385; ERNST E, 1988, CLIN HEMORHEOL, V8, P507; ERNST E, 1987, ATHEROSCLEROSIS, V64, P75, DOI 10.1016/0021-9150(87)90057-8; ERNST E, 1992, CLIN PHARMACY, V11, P968; ERNST E, 1990, BRIT HEART J, V64, P248; ERNST E, 1987, BRIT J HAEMATOL, V65, P485, DOI 10.1111/j.1365-2141.1987.tb04155.x; ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x; ERNST E, 1992, FIBRINOGEN NEW CARDI; FEINSTEIN AR, 1985, CLIN EPIDEMIOL, P422; FOLSOM A, 1992, FIBRINOGEN NEW CARDI; FOWKES FGR, 1992, LANCET, V339, P693, DOI 10.1016/0140-6736(92)90596-U; FULTON RM, 1976, LANCET, V2, P1161; GANDA AF, 1992, FIBRINOGEN NEW CARDI; GILCHRIST E, 1952, Edinb Med J, V59, P561; GROTTA JC, 1989, NEUROLOGY, V39, P1325, DOI 10.1212/WNL.39.10.1325; HAMSTEN A, 1987, LANCET, V2, P988; HANDA K, 1989, ATHEROSCLEROSIS, V77, P209, DOI 10.1016/0021-9150(89)90083-X; HEINRICH J, 1991, THROMB HAEMOSTASIS, V65, P815; HUMPHRIES SE, 1987, LANCET, V1, P1452, DOI 10.1016/S0140-6736(87)92205-7; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KANNEL WB, 1992, FIBRINOGEN NEW CARDI; KOENIG W, 1989, ANGIOLOGY, V40, P153, DOI 10.1177/000331978904000301; KOENIG W, 1992, ATHEROSCLEROSIS, V94, P93, DOI 10.1016/0021-9150(92)90234-8; KOENIG W, 1992, CIRCULATION, V85, P2197, DOI 10.1161/01.CIR.85.6.2197; LANDIN K, 1990, J INTERN MED, V227, P273, DOI 10.1111/j.1365-2796.1990.tb00157.x; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LETCHER RL, 1981, AM J MED, V70, P1195, DOI 10.1016/0002-9343(81)90827-5; LOSNER S, 1954, ARCH INTERN MED, V93, P231, DOI 10.1001/archinte.1954.00240260067006; LOWE GDO, 1988, CLIN HEMORHEOL, V8, P517; LOWE GDO, 1980, THROMB HAEMOSTASIS, V42, P1503; LOWE GDO, 1980, BRIT MED J, V280, P673, DOI 10.1136/bmj.280.6215.673; MARTIN JF, 1991, LANCET, V338, P1409, DOI 10.1016/0140-6736(91)92719-I; MCDONALD L, 1957, LANCET, V2, P457; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1980, LANCET, V1, P1050; MOLLER L, 1991, ARTERIOSCLER THROMB, V11, P344, DOI 10.1161/01.ATV.11.2.344; PALARETI G, 1992, FIBRINOGEN NEW CARDI; PHEAR D, 1957, LANCET, V2, P270; POWELL JT, 1988, LANCET, V1, P121; RESCH KL, 1992, ANN INTERN MED, V117, P371, DOI 10.7326/0003-4819-117-5-371; SCHMITZ A, 1990, DIABETIC MED, V7, P521, DOI 10.1111/j.1464-5491.1990.tb01435.x; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; SPODICK DH, 1985, ANN INTERN MED, V102, P699, DOI 10.7326/0003-4819-102-5-699; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; THOMPSON WD, 1989, J PATHOL, V159, P97, DOI 10.1002/path.1711590203; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WISEMAN S, 1989, BRIT MED J, V299, P643, DOI 10.1136/bmj.299.6700.643; YARNELL JWG, 1987, J CLIN PATHOL, V40, P909, DOI 10.1136/jcp.40.8.909; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	71	921	949	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					956	963		10.7326/0003-4819-118-12-199306150-00008	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489110				2022-12-28	WOS:A1993LF93700008
J	SMITH, RG; CHENG, K; SCHOEN, WR; PONG, SS; HICKEY, G; JACKS, T; BUTLER, B; CHAN, WWS; CHAUNG, LYP; JUDITH, F; TAYLOR, J; WYVRATT, MJ; FISHER, MH				SMITH, RG; CHENG, K; SCHOEN, WR; PONG, SS; HICKEY, G; JACKS, T; BUTLER, B; CHAN, WWS; CHAUNG, LYP; JUDITH, F; TAYLOR, J; WYVRATT, MJ; FISHER, MH			A NONPEPTIDYL GROWTH-HORMONE SECRETAGOGUE	SCIENCE			English	Article							PITUITARY-CELLS; INVIVO ACTIVITY; GH RELEASE; HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2; DISCOVERY; INVITRO; ACTS; MEN	A nonpeptidyl secretagogue for growth hormone of the structure 3-amino-3-methyl-N-(2,3,4,5-tetrahydro-2-oxo-1-{[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methy1}-1H-1-benzazepin-3(R)-yl)-butanamide (L-692,429) has been identified. L-692,429 synergizes with the natural growth hormone secretagogue growth hormone-releasing hormone and acts through an alternative signal transduction pathway. The mechanism of action of L-692,429 and studies with peptidyl and nonpeptidyl antagonists suggest that this molecule is a mimic of the growth hormone-releasing hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6). L-692,429 is an example of a nonpeptidyl specific secretagogue for growth hormone.	MERCK RES LABS, DEPT BASIC MED CHEM, RAHWAY, NJ 07065 USA	Merck & Company	SMITH, RG (corresponding author), MERCK RES LABS, DEPT BASIC ANIM SCI RES, RAHWAY, NJ 07065 USA.							BLAKE AD, 1991, J ENDOCRINOL, V129, P11, DOI 10.1677/joe.0.1290011; BOWERS CY, 1990, J CLIN ENDOCR METAB, V70, P975, DOI 10.1210/jcem-70-4-975; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BRIXEN K, 1990, J BONE MINER RES, V5, P609; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; CHENG K, UNPUB; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HICKEY G, UNPUB; HOMBURG R, 1990, CLIN ENDOCRINOL, V32, P781, DOI 10.1111/j.1365-2265.1990.tb00925.x; HORBER FF, 1990, J CLIN INVEST, V86, P265, DOI 10.1172/JCI114694; HORWELL D C, 1988, Drugs of the Future, V13, P1061; MOMANY FA, 1984, ENDOCRINOLOGY, V114, P1531, DOI 10.1210/endo-114-5-1531; MORGAN BA, 1989, ANNU REP MED CHEM, V24, P243; MURPHY WJ, 1992, P NATL ACAD SCI USA, V89, P4481, DOI 10.1073/pnas.89.10.4481; NEILL JD, 1983, ENDOCRINOLOGY, V112, P1135, DOI 10.1210/endo-112-3-1135; OPNG SS, 1992, 74TH P M END SOC BET, P255; PONG SS, 1991, 73RD P ANN M END SOC, P88; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SCHOEN WR, UNPUB; SHIBASAKI T, 1984, J CLIN ENDOCR METAB, V58, P212, DOI 10.1210/jcem-58-1-212	24	317	355	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1640	1643		10.1126/science.8503009	http://dx.doi.org/10.1126/science.8503009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LG176	8503009				2022-12-28	WOS:A1993LG17600027
J	LAMME, VAF; VANDIJK, BW; SPEKREIJSE, H				LAMME, VAF; VANDIJK, BW; SPEKREIJSE, H			CONTOUR FROM MOTION PROCESSING OCCURS IN PRIMARY VISUAL-CORTEX	NATURE			English	Article							EVOKED-POTENTIALS; STRIATE CORTEX; CAT; CELLS; CONNECTIONS; ORIENTATION; SELECTIVITY; MECHANISMS; NEURONS	RELATIVE motion is one of the most salient cues for segmentation of a visual scene into separate objects. This is illustrated by the vivid contours that are perceived when random dot patterns move in different directions1,2. Once motion is hatted in such displays the segmentation contours disappear. This makes random dot patterns ideal for the study of contour from motion processing in isolation. Contour from motion processing obviously relies on direction-selective neurons, which are found in many visual cortical areas3-5. It is, however, largely unknown at what level of processing their signals interact to serve the global process of motion-based image segmentation. To answer this quesion, we recorded visually evoked potentials, both in man and in awake monkey, to a stimulus specifically designed to signal the presence of neuronal activity related to contour from motion processing. We report here that response components specific to contour from motion were elicited only when the stimulus yielded a contour percept. In awake monkey, the sources of these components were located within the supra- and infra-granular layers of primary visual cortex. We conclude that V1 is involved in image segmentation processing.	NETHERLANDS OPHTHALM RES INST,POB 12141,1100 AC AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,MED PHYS LAB,1105 AZ AMSTERDAM,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam								ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; BLASDEL GG, 1985, J NEUROSCI, V5, P3350; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; DAGNELIE G, 1989, VISUAL NEUROSCI, V3, P509, DOI 10.1017/S0952523800009858; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; HILDRETH EC, 1987, ANNU REV NEUROSCI, V10, P477, DOI 10.1146/annurev.ne.10.030187.002401; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KRAUT MA, 1985, ELECTROEN CLIN NEURO, V62, P300, DOI 10.1016/0168-5597(85)90007-3; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, IN PRESS VISUAL NEUR; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; MNAKAYAMA K, 1985, VISION RES, V25, P427; NICHOLSON C, 1975, J NEUROPHYSIOL, V38, P356, DOI 10.1152/jn.1975.38.2.356; NOTHDURFT HC, 1985, VISION RES, V25, P99, DOI 10.1016/0042-6989(85)90084-7; ORBAN GA, 1987, J NEUROPHYSIOL, V57, P1792, DOI 10.1152/jn.1987.57.6.1792; SCHIMMEL H, 1967, SCIENCE, V157, P92, DOI 10.1126/science.157.3784.92; SPORNS O, 1991, P NATL ACAD SCI USA, V88, P129, DOI 10.1073/pnas.88.1.129; Van Essen D. C., 1985, CEREBRAL CORTEX, V3	19	74	74	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					541	543		10.1038/363541a0	http://dx.doi.org/10.1038/363541a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505980				2022-12-28	WOS:A1993LF93900049
J	ANDERSON, R				ANDERSON, R			AIDS - TRENDS, PREDICTIONS, CONTROVERSY	NATURE			English	Editorial Material											ANDERSON, R (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ADES AE, 1989, J EPIDEMIOL COMMUN H, V43, P53, DOI 10.1136/jech.43.1.53; ANDERSON R M, 1991; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; CHIN J, 1992, WORLD HLTH STAT Q, V45, P22; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HYMAN JM, 1988, MATH BIOSCI, V90, P415, DOI 10.1016/0025-5564(88)90078-8; NORMAN C, 1985, SCIENCE, V230, P1020, DOI 10.1126/science.2997927; IN PRESS COMM DIS RE; 1993, MORBID WKLY REP, V41, P1; 1993, COMMUNICAB DIS REP, V3, pR1; 1993, WHOEC36 COLL CTR AID, P1	13	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					393	394		10.1038/363393a0	http://dx.doi.org/10.1038/363393a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502292	Bronze			2022-12-28	WOS:A1993LE93800025
J	HIGGINS, MW; ENRIGHT, PL; KRONMAL, RA; SCHENKER, MB; ANTONCULVER, H; LYLES, M				HIGGINS, MW; ENRIGHT, PL; KRONMAL, RA; SCHENKER, MB; ANTONCULVER, H; LYLES, M			SMOKING AND LUNG-FUNCTION IN ELDERLY MEN AND WOMEN - THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FORCED EXPIRATORY VOLUME; PULMONARY-FUNCTION; ADULT-POPULATION; ONE 2ND; MORTALITY; DISEASE; RISK; PREDICTORS; TECUMSEH; CANCER	Objective.-To investigate relationships between cigarette smoking and pulmonary function in elderly men and women. Design.-Cross-sectional analysis of baseline data from a prospective, population-based study of risk factors, preclinical, and overt cardiovascular and pulmonary disease. Setting.-Defined communities in Forsyth County, North Carolina; Pittsburgh, Pa; Sacramento County, California; and Washington County, Maryland. Population.-A total of 5201 noninstitutionalized men and women 65 years of age and older. Main Outcome Measures.-Pulmonary function; means of forced expiratory volume in 1 second (FEV1) and forced vital capacity and prevalence of low FEV1 levels. Results.-Prevalence of cigarette smoking was 10% to 20% and higher in women than men and in blacks than whites. Forced vital capacity and FEV1 levels were related positively to height and white race and negatively to age and waist girth. Age- and height-adjusted FEV1 means were 23% and 18% lower in male and female current smokers, respectively, than in never smokers but not reduced in never smokers currently living with a smoker. Smokers who quit before age 40 years had FEV1 levels similar to never smokers, but FEV1 levels were lower by 7% and 14% in smokers who quit at ages 40 to 60 years and older than 60 years, respectively. Lung function was related inversely to pack-years of cigarette use. Prevalence rates of impaired lung function were highest in current smokers and lowest in never smokers. Regression coefficients for the smoking variables were smaller in persons without cardiovascular or respiratory conditions than in the total cohort. Conclusions.-Cigarette smoking is associated with reduced pulmonary function in elderly men and women. However, smokers who quit, even after age 60 years, have better pulmonary function than continuing smokers.	UNIV ARIZONA,CTR RESP SCI,TUCSON,AZ 85721; CARDIOVAS HLTH STUDY COORDINATING CTR,SEATTLE,WA; UNIV CALIF IRVINE,CALIF COLL MED,IRVINE,CA 92717; UNIV CALIF DAVIS,DIV OCCUPAT & ENVIRONM MED,DAVIS,CA 95616; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT GERIATR MED,WINSTON SALEM,NC 27103	University of Arizona; University of California System; University of California Irvine; University of California System; University of California Davis; Wake Forest University; Wake Forest Baptist Medical Center	HIGGINS, MW (corresponding author), NHLBI,FED BLDG,ROOM 2C08,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA.				PHS HHS [N01-87086, N01-87079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECKLAKE M, 1991, AM REV RESPIR DIS, V144, P1202; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286, DOI 10.1164/ajrccm/137.2.286; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125, DOI 10.1164/ajrccm/147.1.125; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GARDNER RM, 1987, AM REV RESPIR DIS, V136, P1285; HIGGINS MW, 1982, AM REV RESPIR DIS, V125, P144; HIGGINS MW, 1970, ARCH ENVIRON HEALTH, V21, P418, DOI 10.1080/00039896.1970.10667260; HIGGINS MW, 1984, AM REV RESPIR DIS, V130, P380; KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; MILLER A, 1988, CHEST, V94, P1187, DOI 10.1378/chest.94.6.1187; NELSON SB, 1990, CHEST, V97, P288, DOI 10.1378/chest.97.2.288; NOMURA A, 1991, AM REV RESPIR DIS, V144, P307, DOI 10.1164/ajrccm/144.2.307; NORUSIS MJ, 1990, SPSS PCT STATISTICS; TELL GS, IN PRESS ANN EPIDEMI; WARE JH, 1990, AM J EPIDEMIOL, V132, P685, DOI 10.1093/oxfordjournals.aje.a115710; 1989, 898411 DEP HLTH HUM; 1992, PREVENTION PROFILE H; 1992, MMWR MORB MORTAL WKL, V41, P354; [No title captured]; 1984, PHS8450205 DEP HLTH	24	85	87	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2741	2748		10.1001/jama.269.21.2741	http://dx.doi.org/10.1001/jama.269.21.2741			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492399				2022-12-28	WOS:A1993LD67100023
J	COHEN, J				COHEN, J			FLYING DUTCHMAN - GOUDSMIT,JAAP	SCIENCE			English	Item About an Individual																		COHEN J, 1993, SCIENCE, V260, P1260, DOI 10.1126/science.8493566; COHEN J, 1993, SCIENCE, V260, P1259, DOI 10.1126/science.8493565	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1263	1263		10.1126/science.8493569	http://dx.doi.org/10.1126/science.8493569			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493569				2022-12-28	WOS:A1993LE02500026
J	LATIF, F; TORY, K; GNARRA, J; YAO, M; DUH, FM; ORCUTT, ML; STACKHOUSE, T; KUZMIN, I; MODI, W; GEIL, L; SCHMIDT, L; ZHOU, FW; LI, H; WEI, MH; CHEN, F; GLENN, G; CHOYKE, P; WALTHER, MM; WENG, YK; DUAN, DSR; DEAN, M; GLAVAC, D; RICHARDS, FM; CROSSEY, PA; FERGUSONSMITH, MA; LEPASLIER, D; CHUMAKOV, I; COHEN, D; CHINAULT, AC; MAHER, ER; LINEHAN, WM; ZBAR, B; LERMAN, MI				LATIF, F; TORY, K; GNARRA, J; YAO, M; DUH, FM; ORCUTT, ML; STACKHOUSE, T; KUZMIN, I; MODI, W; GEIL, L; SCHMIDT, L; ZHOU, FW; LI, H; WEI, MH; CHEN, F; GLENN, G; CHOYKE, P; WALTHER, MM; WENG, YK; DUAN, DSR; DEAN, M; GLAVAC, D; RICHARDS, FM; CROSSEY, PA; FERGUSONSMITH, MA; LEPASLIER, D; CHUMAKOV, I; COHEN, D; CHINAULT, AC; MAHER, ER; LINEHAN, WM; ZBAR, B; LERMAN, MI			IDENTIFICATION OF THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE	SCIENCE			English	Article							RENAL-CELL CARCINOMA; POINT MUTATIONS; CANCER; CHROMOSOME-5Q21; REGION; FAP	A gene discovered by positional cloning has been identified as the von Hippel-Lindau (VHL) disease tumor suppressor gene. A restriction fragment encompassing the gene showed rearrangements in 28 of 221 VHL kindreds. Eighteen of these rearrangements were due to deletions in the candidate gene, including three large nonoverlapping deletions. Intragenic mutations were detected in cell lines derived from VHL patients and from sporadic renal cell carcinomas. The VHL gene is evolutionarily conserved and encodes two widely expressed transcripts of approximately 6 and 6.5 kilobases. The partial sequence of the inferred gene product shows no homology to other proteins, except for an acidic repeat domain found in the procyclic surface membrane glycoprotein of Trypanosoma brucei.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702; NCI,SURG BRANCH,BETHESDA,MD 20892; NCI,CANC DIAG BRANCH,BETHESDA,MD 20892; NCI,DEPT RADIOL,CTR CLIN,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; MAHER, EAMONN R/A-9507-2008	Dean, Michael C/0000-0003-2234-0631; MAHER, EAMONN R/0000-0002-6226-6918; Gnarra, James/0000-0002-6369-3110; Le Paslier, Denis/0000-0003-4335-9956				CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSSEY PA, IN PRESS HUM MOL GEN; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LATIF F, 1993, CANCER RES, V53, P861; Latif F., 1992, American Journal of Human Genetics, V51, pA63; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MAHER ER, 1990, J MED GENET, V27, P311, DOI 10.1136/jmg.27.5.311; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, GENOMICS, V8, P957; MAHER ER, UNPUB; MCKUSICK VA, 1883, MENDELIAN INHERITANC, P534; MOWATT MR, 1989, MOL CELL BIOL, V9, P1332, DOI 10.1128/MCB.9.3.1332; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P244; RICHARDS FM, 1993, J MED GENET, V30, P104, DOI 10.1136/jmg.30.2.104; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TRAFATTER JA, 1993, CELL, V72, P791; VANCE JM, 1992, AM J HUM GENET S, V51, P203; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; White R, 1992, CURR OPIN GENET DEV, V2, P53, DOI 10.1016/S0959-437X(05)80321-1; YAO M, IN PRESS HUM GENET	37	2249	2360	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1317	1320		10.1126/science.8493574	http://dx.doi.org/10.1126/science.8493574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493574				2022-12-28	WOS:A1993LE02500041
J	MERSON, MH				MERSON, MH			SLOWING THE SPREAD OF HIV - AGENDA FOR THE 1990S	SCIENCE			English	Article											MERSON, MH (corresponding author), WHO,GLOBAL PROGRAM AIDS,CH-1211 GENEVA 27,SWITZERLAND.							ESPARZA J, 1992, RETROVIRUSES HUMAN A, P217; VIRAVAIDYA M, 1991, EC IMPACT AIDS THAIL; IN PRESS EFFECTIVE A; 1993, WHOGPACNPEVA931 GLOB; 1993, UNPUB POTENTIAL VACC; 1993, GPADIR932 WHO GLOB P; 1991, WHO TECH REP SER, V810	7	97	106	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1266	1268		10.1126/science.8493570	http://dx.doi.org/10.1126/science.8493570			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493570				2022-12-28	WOS:A1993LE02500030
J	ESCARCE, JJ				ESCARCE, JJ			EFFECTS OF LOWER SURGICAL FEES ON THE USE OF PHYSICIAN SERVICES UNDER MEDICARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAYMENT REFORM; HETEROSCEDASTICITY	Background and Objective.-The changes in physician fees that will occur under the resource-based Medicare Fee Schedule (MFS) are similar to those that took place under the Omnibus Budget Reconciliation Act of 1987 (OBRA 87), when Medicare fees for selected ''overpriced'' procedures and diagnostic tests were reduced. To gain insight regarding the changes in utilization that may occur under the MFS, this study examines the effects of the OBRA 87 fee reductions on the use of physician services by Medicare patients. Data and Methods.-The five specialties that were most affected by the OBRA 87 fee reductions were studied: ophthalmology, thoracic surgery, urology, orthopedic surgery, and gastroenterology. Medicare physician claims files for 1987 and 1989 were used to obtain data on utilization and fees. Multivariate regression analysis was used to assess the effect of changes in fees on changes in utilization. Results.-The best estimate of the effect of the OBRA 87 fee reductions on overall physician-services utilization, obtained by pooling the five study specialties, was that every 1% decrease in fees led to a 0.09% decrease in the volume and complexity of services (95% confidence interval, 0.49% decrease to 0.31% increase). This result was not sensitive to minor changes in the covariates included in the regression model. Conclusion.-To calculate payment levels during the transition to the MFS, the Health Care Financing Administration assumed that physicians whose Medicare revenue declines under the MFS will increase service volume and complexity enough to make up one half of the lost revenue. The findings of this study suggest that the Health Care Financing Administration's assumption was, at best, extreme.	JOHN A HARTFORD FDN,NEW YORK,NY; UNIV PENN,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								[Anonymous], 1987, OMNIBUS BUDGET RECON; BREUSCH TS, 1979, ECONOMETRICA, V47, P1287, DOI 10.2307/1911963; CHRISTENSEN S, 1992, HEALTH SERV RES, V27, P65; Dutton B L Jr, 1981, Health Care Financ Rev, V3, P137; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P349, DOI 10.2105/AJPH.83.3.349; HOLAHAN J, 1990, JAMA-J AM MED ASSOC, V263, P1658, DOI 10.1001/jama.263.12.1658; JOHNSSON J, 1993, AM MED NEWS, V36, P1; JOHNSSON J, 1993, AM MED NEWS, V36, P52; LEE PR, 1991, JAMA-J AM MED ASSOC, V266, P1562, DOI 10.1001/jama.266.11.1562; MAGEE L, 1990, AM STAT, V44, P250, DOI 10.2307/2685352; MCGUIRE TG, 1991, J HEALTH ECON, V10, P385, DOI 10.1016/0167-6296(91)90022-F; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; PAULY MV, 1991, REGULATING DOCTORS F, P288; Rice T, 1984, Adv Health Econ Health Serv Res, V5, P129; Rice T, 1982, Health Care Financ Rev, V3, P67; RICE TH, 1983, MED CARE, V21, P803, DOI 10.1097/00005650-198308000-00004; ROPER WL, 1988, NEW ENGL J MED, V319, P865, DOI 10.1056/NEJM198809293191311; TODD JS, 1991, JAMA-J AM MED ASSOC, V266, P1566, DOI 10.1001/jama.266.11.1566; WEDIG G, 1989, J HEALTH POLIT POLIC, V14, P601, DOI 10.1215/03616878-14-3-601; ZUCKERMAN S, 1992, INQUIRY-J HEALTH CAR, V29, P391; 1990, 1990 PHYS PAYM REV C; 1991, PART B MEDICARE ANN; 1987, 1987 PHYS PAYM REV C; 1991, FED REG         1125, V56, P59502; 1989, PHYSICIANS CURRENT P; 1991, 1991 HLTH CAR FIN AD; 1991, 1991 PHYS PAYM REV C; 1990, PART B MEDICARE CARR; 1991, FED REG         0909, V56, P45926; 1991, PUBLICATION PHYSICIA, V916; 1989, PART B MEDICARE ANN	32	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2513	2518		10.1001/jama.269.19.2513	http://dx.doi.org/10.1001/jama.269.19.2513			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB450	8487414				2022-12-28	WOS:A1993LB45000030
J	WANG, HW; WYSOCKI, CJ; GOLD, GH				WANG, HW; WYSOCKI, CJ; GOLD, GH			INDUCTION OF OLFACTORY RECEPTOR SENSITIVITY IN MICE	SCIENCE			English	Article							ANDROSTENONE; ABILITY; MOUSE	Repeated exposure to olfactory ligands (odorants) increased peripheral olfactory sensitivity in mice. For two unrelated ligands, androstenone and isovaleric acid, induction of olfactory sensitivity was odorant-specific and occurred only in inbred strains that initially had low sensitivity to the exposure odorant. These data demonstrate stimulus-induced plasticity in a sensory receptor cell, suggesting a form of stimulus-controlled gene expression. Induction with two unrelated odorants implies that olfactory induction is a general phenomenon that may occur in a large fraction of the human population.			WANG, HW (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.							AMOORE JE, 1991, GENETICS PERCEPTION, V3, pCH23; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; GETCHELL TV, 1987, NEUROBIOLOGY TASTE S, pCH5; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; KENT PF, 1992, J NEUROPHYSIOL, V68, P1804, DOI 10.1152/jn.1992.68.5.1804; Labows J.N., 1984, PERFUMER FLAVOURIST, V9, P21; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; OTTOSON D, 1956, ACTA PHYSIOL SCAND, V35, P7; SHIRLEY SG, 1987, BIOCHEM J, V245, P175, DOI 10.1042/bj2450175; TROITSKAYA V T, 1987, Neirofiziologiya, V19, P133; Wang Hai-Wei, 1992, Chemical Senses, V17, P714; WHISSELBUECHY D, 1976, NATURE, V242, P271; WYSOCKI CJ, 1989, P NATL ACAD SCI USA, V86, P7976, DOI 10.1073/pnas.86.20.7976; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; WYSOCKI CJ, 1989, CHEM SENSES NUTRITIO; WYSOCKI CJ, UNPUB	19	150	154	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					998	1000		10.1126/science.8493539	http://dx.doi.org/10.1126/science.8493539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493539				2022-12-28	WOS:A1993LB79100048
J	MILBURN, MV; HASSELL, AM; LAMBERT, MH; JORDAN, SR; PROUDFOOT, AEI; GRABER, P; WELLS, TNC				MILBURN, MV; HASSELL, AM; LAMBERT, MH; JORDAN, SR; PROUDFOOT, AEI; GRABER, P; WELLS, TNC			A NOVEL DIMER CONFIGURATION REVEALED BY THE CRYSTAL-STRUCTURE AT 2.4 ANGSTROM RESOLUTION OF HUMAN INTERLEUKIN-5	NATURE			English	Article							AMINO-ACID SEQUENCE; 3-DIMENSIONAL STRUCTURE; RECEPTOR	INTERLEUKIN-5 (IL-5) is a lineage-specific cytokine for eosinophilpoiesis and plays an important part in diseases associated with increased eosinophils, such as asthma1,2. Human IL-5 is a disulphide-linked homodimer with 115 amino-acid residues in each chain 2. The crystal structure at 2.4 angstrom resolution reveals a novel two-domain structure, with each domain showing a striking similarity to the cytokine fold found in granulocyte macrophage3 and macrophage4 colony-stimulating factors, IL-2 (ref. 5), IL-4 (ref. 6), and human7 and porcine8 growth hormones. IL-5 is unique in that each domain requires the participation of two chains. The IL-5 structure consists of two left-handed bundles of four helices laid end to end and two short beta-sheets on opposite sides of the molecule. Surprisingly, the C-terminal strand and helix of one chain complete a bundle of four helices and a beta-sheet with the N-terminal three helices and one strand of the other chain. The structure of IL-5 provides a molecular basis for the design of antagonists and agonists that would delineate receptor recognition determinants critical in signal transduction. This structure determination extends the family of the cytokine bundle of four helices and emphasizes its fundamental significance and versatility in recognizing its receptor.	GLAXO RES INST,DEPT STRUCT & BIOPHYS CHEM,RES TRIANGLE PK,NC 27709; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline; GlaxoSmithKline	MILBURN, MV (corresponding author), CHILDRENS HOSP MED CTR,MOLEC MED LAB,ENDERS 673,300 LONGWOOD AVE,BOSTON,MA 02115, USA.			Wells, Timothy/0000-0001-9796-847X				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P246; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; HASSELL AM, 1993, J MOL BIOL, V229, P1150, DOI 10.1006/jmbi.1993.1110; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KODAMA S, 1991, BIOCHEM BIOPH RES CO, V178, P514, DOI 10.1016/0006-291X(91)90137-V; LAMBERT MH, 1989, J COMPUT CHEM, V10, P770, DOI 10.1002/jcc.540100603; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MCKENZIE ANJ, 1991, MOL IMMUNOL, V28, P155, DOI 10.1016/0161-5890(91)90099-6; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MIYAJIMA A, 1992, REV IMMUNOL, V10, P295; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; Parry D A, 1988, J Mol Recognit, V1, P107, DOI 10.1002/jmr.300010302; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PROUDFOOT AEI, 1991, FEBS LETT, V283, P61, DOI 10.1016/0014-5793(91)80553-F; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAKAHASHI T, 1990, MOL IMMUNOL, V9, P911; TAKATSU K, 1992, CURR OPIN IMMUNOL, V4, P299, DOI 10.1016/0952-7915(92)90080-X; TAKATSU K, 1991, MICROBIOL IMMUNOL, V35, P593, DOI 10.1111/j.1348-0421.1991.tb01591.x; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999	35	233	245	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					172	176		10.1038/363172a0	http://dx.doi.org/10.1038/363172a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483502				2022-12-28	WOS:A1993LB80100051
J	LI, N; BATZER, A; DALY, R; YAJNIK, V; SKOLNIK, E; CHARDIN, P; BARSAGI, D; MARGOLIS, B; SCHLESSINGER, J				LI, N; BATZER, A; DALY, R; YAJNIK, V; SKOLNIK, E; CHARDIN, P; BARSAGI, D; MARGOLIS, B; SCHLESSINGER, J			GUANINE-NUCLEOTIDE-RELEASING FACTOR HSOS1 BINDS TO GRB2 AND LINKS RECEPTOR TYROSINE KINASES TO RAS SIGNALING	NATURE			English	Article							GROWTH-FACTOR; VULVAR INDUCTION; PC12 CELLS; DIFFERENTIATION; REQUIREMENT; P21RAS.GTP; SEVENLESS; PATHWAY; GENE	MANY of the actions of receptor tyrosine kinases are mediated by the protein Ras1-5, including the activation of various downstream serine/threonine kinases and the stimulation of growth and differentiation6-12. The human protein Grb2 binds to ligand-activated growth factor receptors and downstream effector proteins through its Src-homology (SH) domains SH2 and SH3, respectively13,14, and like its homologue from Caenorhabditis elegans, Sem-5, apparently forms part of a highly conserved pathway by which these receptors can control Ras activity15-18. Here we show that the SH3 domains of Grb2 bind to the carboxy-terminal part of hSos1, the human homologue of the Drosophila guanine-nucleotide-releasing factor for Ras, which is essential for control of Ras activity by epidermal growth factor receptor and sevenless19,20. Moreover, a synthetic 10-amino-acid peptide containing the sequence PPVPPR specifically blocks the interaction. These results indicate that the Grb2/hSos1 complex couples activated EGF receptor to Ras signalling.	KAPLAN CANC CTR,NEW YORK,NY 10016; CNRS,INST PHARMACOL MOLEC,F-06560 VOLBONNE,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Centre National de la Recherche Scientifique (CNRS); Cold Spring Harbor Laboratory	LI, N (corresponding author), NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016, USA.		Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Bar-Sagi, Dafna/0000-0003-2597-8948				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, UNPUB NATURE; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZAKISADCOCK M, 1993, NATURE, V362; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, IN PRESS EMBO J; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	30	920	943	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					85	88		10.1038/363085a0	http://dx.doi.org/10.1038/363085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479541				2022-12-28	WOS:A1993LA68200066
J	START, RD; DELARGYAZIZ, Y; DORRIES, CP; SILCOCKS, PB; COTTON, DWK				START, RD; DELARGYAZIZ, Y; DORRIES, CP; SILCOCKS, PB; COTTON, DWK			CLINICIAN AND THE CORONIAL SYSTEM - ABILITY OF CLINICIAN TO RECOGNIZE REPORTABLE DEATHS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the ability of clinicians to recognise deaths which require referral to the coroner. Design-Postal questionnaire consisting of 16 fictitious case histories, 14 of which contained a clear indication for referral to the coroner. Setting-Large teaching hospital. Coroner's office. Subjects-200 clinicians from general medical and surgical firms and senior staff of the local coroner's office (two coroner's officers and the two deputy coroners). Main outcome measures-Number of correct assessments on questionnaire. Results-The mean recognition score for the clinicians was 9.11 (range 3-14) with no difference between the clinical grades. All of the coroner's senior staff recorded maximum recognition scores of 16. Conclusions-The study highlights several features of the coronial system which are poorly understood by clinicians and provides the basis for an initiative to improve the medicolegal education of all clinicians.	UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; MEDICOLEGAL CTR,OFF HER MAJESTYS CORONER,SHEFFIELD S3 7ES,ENGLAND	University of Sheffield	START, RD (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,POB 596,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.							Elstein AS, 1978, MED PROBLEM SOLVING; Harre Rom, 1972, EXPLANATION SOCIAL B; KNIGHT B, 1987, LEGAL ASPECTS MED PR; OPPENHEIM AN, 1984, QUESTIONNAIRE DESIGN; START RD, 1992, J CLIN PATHOL, V45, P254, DOI 10.1136/jcp.45.3.254; 1992, HOME OFFICE STATISTI	6	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1038	1041		10.1136/bmj.306.6884.1038	http://dx.doi.org/10.1136/bmj.306.6884.1038			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490498	Bronze, Green Published			2022-12-28	WOS:A1993KY44800020
J	BERRIOS, GE; SHAPIRO, CM				BERRIOS, GE; SHAPIRO, CM			ABC OF SLEEP DISORDERS - I DONT GET ENOUGH SLEEP, DOCTOR	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	BERRIOS, GE (corresponding author), UNIV CAMBRIDGE,DEPT PSYCHIAT,CAMBRIDGE,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					843	846		10.1136/bmj.306.6881.843	http://dx.doi.org/10.1136/bmj.306.6881.843			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490380	Green Published, Bronze			2022-12-28	WOS:A1993KV34800027
J	RONA, RJ; GULLIFORD, MC; CHINN, S				RONA, RJ; GULLIFORD, MC; CHINN, S			EFFECTS OF PREMATURITY AND INTRAUTERINE GROWTH ON RESPIRATORY HEALTH AND LUNG-FUNCTION IN CHILDHOOD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; DISTRESS SYNDROME; CHILDREN; STANDARDS; PREGNANCY; SYMPTOMS; HISTORY; TRICEPS; MOTHERS; ASTHMA	Objective-To determine whether birth weight and gestational age are associated with respiratory illness and lung function in children aged 5-11 years. Design-Cross sectional analysis of parent reported birth weight, gestational age, and respiratory symptoms; parental smoking and social conditions; forced vital capacity (FVC), forced expiratory volume in one second (FEV1), forced expiratory rates between 25% and 75% and 75% and 85% (FEF25-75 and FEF75-85), and height. Setting-Primary schools in England and Scotland in 1990. Subjects-5573 children aged 5-11 (63.3% of eligible children) had respiratory symptoms analysed and 2036 children (67.1% of eligible children) had lung function measured. Main outcome measures-Symptoms of asthma, bronchitis, occasional and frequent wheeze, cough first thing in the morning, and cough at any other time and lung function. Results-Birth weight adjusted for gestational age was significantly associated with all lung function measurements, except FEF25-75. The association remained for FVC (b=0.475, 95% confidence interval 0.181 to 0.769) and FEV1 (b=0.502, 0.204 to 0.800) after adjustment for gestational age, parental smoking, and social factors. FEF75-85 was the only lung function related to gestational age. Respiratory symptoms, especially wheeze most days (adjusted odds ratio 0.9, 0.84 to 0.97) were significantly associated with prematurity. Every extra week of gestation reduced the risk of severe wheeze by about 10%. Conclusions-Lung function is affected mainly by intrauterine environment while respiratory illness, especially wheezing, in childhood is related to prematurity.			RONA, RJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT PUBL HLTH MED, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND.		Gulliford, Martin C/I-8606-2018; Rona, Roberto J/C-2348-2011	Gulliford, Martin C/0000-0003-1898-9075; Rona, Roberto/0000-0003-3739-5571				ALHO OP, 1990, INT J PEDIATR OTORHI, V19, P129, DOI 10.1016/0165-5876(90)90218-G; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERTRAND JM, 1985, NEW ENGL J MED, V312, P742, DOI 10.1056/NEJM198503213121202; BLAND JM, 1990, J R STAT SOC C-APPL, V39, P229; CHAN KN, 1988, ARCH DIS CHILD, V63, P905, DOI 10.1136/adc.63.8.905; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; CHINN S, 1992, EUR J CLIN NUTR, V46, P489; COLE TJ, 1988, J R STAT SOC A STAT, V151, P385, DOI 10.2307/2982992; GALDESSEBALDT M, 1989, PEDIATR PULM, V7, P259, DOI 10.1002/ppul.1950070412; GREENBERGER PA, 1985, NEW ENGL J MED, V312, P897, DOI 10.1056/NEJM198504043121406; GREENOUGH A, 1990, J PERINAT MED, V18, P489, DOI 10.1515/jpme.1990.18.6.489; GREENOUGH A, 1992, REVERSIBLE OBSTRUCTI, V6, P31; MANSELL AL, 1987, J PEDIATR-US, V110, P111, DOI 10.1016/S0022-3476(87)80301-3; Osborn A.F., 1984, SOCIAL LIFE BRITAINS; RONA RJ, 1977, ANN HUM BIOL, V4, P501, DOI 10.1080/03014467700002511; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SEIDMAN DS, 1987, BRIT J OBSTET GYNAEC, V94, P731, DOI 10.1111/j.1471-0528.1987.tb03717.x; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1975, ARCH DIS CHILD, V50, P142, DOI 10.1136/adc.50.2.142; TILLEY BC, 1985, AM J EPIDEMIOL, V121, P269, DOI 10.1093/oxfordjournals.aje.a113997	23	210	217	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	1993	306	6881					817	820		10.1136/bmj.306.6881.817	http://dx.doi.org/10.1136/bmj.306.6881.817			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490372	Green Published, Bronze			2022-12-28	WOS:A1993KV34800018
J	GURALNIK, JM; LAND, KC; BLAZER, D; FILLENBAUM, GG; BRANCH, LG				GURALNIK, JM; LAND, KC; BLAZER, D; FILLENBAUM, GG; BRANCH, LG			EDUCATIONAL STATUS AND ACTIVE LIFE EXPECTANCY AMONG OLDER BLACKS AND WHITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALAMEDA COUNTY; UNITED-STATES; NATURAL DEATH; MORTALITY; COMPRESSION; PREDICTORS; MORBIDITY; DISEASE; ELDERS; RISK	Background and Methods. Persons of low socioeconomic status are known to have reduced life expectancy. In a study of the relation of socioeconomic status to disability-free or active life expectancy among older persons, we analyzed prospectively gathered data on 2219 blacks and 1838 whites who were 65 years of age or older in the Piedmont region of North Carolina. We defined disability as the inability to perform independently one or more basic functional activities such as walking, bathing, dressing, eating, and using the toilet. For subgroups defined by sex, race, and education, statistical models were used to estimate, for persons at each year of age, the probability of transition from not being disabled or being disabled at base line to not being disabled, being disabled, or having died one year later. These transition probabilities were then entered into increment-decrement life tables to generate estimates of total, active, and disabled life expectancy (with total life expectancy equal to active life expectancy plus disabled life expectancy). Results. Sixty-five-year-old black men had a lower total life expectancy (11.4 years) and active life expectancy (10 years) than white men (total life expectancy, 12.6 years; active life expectancy, 11.2 years), although the differences were reduced after we controlled for education. The estimates for 65-year-old black women (total life expectancy, 18.7 years; active life expectancy, 15.9 years) were similar to those for white women. Black men and women 75 years old and older had higher values for total life expectancy and active life expectancy than whites, and the differences were larger after stratification for education. Education had a substantially stronger relation to total life expectancy and active life expectancy than did race. At the age of 65, those with 12 or more years of education had an active life expectancy that was 2.4 to 3.9 years longer than the values for those with less education in all the four subgroups defined by sex and race. Overall, the subgroups with longer total life expectancy and active life expectancy also lived more years with a disability. Conclusions. Among older blacks and whites, the level of education, a measure of socioeconomic status, has a greater effect than race on total life expectancy and active life expectancy.	DUKE UNIV,DEPT SOCIOL,DURHAM,NC 27706; DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DURHAM,NC 27710; BOSTON UNIV,SCH MED,BOSTON,MA 02118; ABT ASSOCIATES INC,CAMBRIDGE,MA 02138	Duke University; Duke University; Duke University; Boston University; ABT Associates	GURALNIK, JM (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WISCONSIN AVE,RM 3C-309,BETHESDA,MD 20892, USA.				NIA NIH HHS [N01-AG-1-2102] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG012102] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P492; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; BRANCH LG, 1991, J GERONTOL, V46, pM145, DOI 10.1093/geronj/46.4.M145; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Branch LG., 1989, J AGING HEALTH, V1, P370, DOI [10.1177/089826438900100306, DOI 10.1177/089826438900100306]; CORONIHUNTLEY J, 1990, NIH90495 PUBL; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FULTON JP, 1984, VITAL HLTH STATIS 10, V167; Gibson R C, 1991, J Aging Health, V3, P335, DOI 10.1177/089826439100300302; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURALNIK JM, 1990, NATIONS HLTH, P42; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HOUSE JS, 1992, AGING HLTH BEHAV HLT, P1; Kaplan G., 1991, J AGING HEALTH, V3, P155; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KATZ S, 1985, COMMITTEE AGING SOC, P57; KEIL JE, 1992, AM J PUBLIC HEALTH, V82, P1133, DOI 10.2105/AJPH.82.8.1133; KEIL JE, 1989, J CLIN EPIDEMIOL, V42, P521, DOI 10.1016/0895-4356(89)90148-0; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; Land KC, 1982, MULTIDIMENSION MATH, P1; London D., 1985, GRADUATION REVISION; MANTON KG, 1979, GERONTOLOGIST, V19, P291, DOI 10.1093/geront/19.3.291; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1984, LANCET, V1, P1003; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; Rogers A., 1975, INTRO MULTIREGIONAL; ROGERS RG, 1992, DEMOGRAPHY, V29, P287, DOI 10.2307/2061732; ROGERS RG, 1989, MILBANK Q, V67, P370, DOI 10.2307/3350221; ROGOT E, 1992, PUBLIC HEALTH REP, V107, P457; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; SALONEN JT, 1982, J EPIDEMIOL COMMUN H, V36, P294, DOI 10.1136/jech.36.4.294; SCHNEIDER EL, 1983, NEW ENGL J MED, V309, P854, DOI 10.1056/NEJM198310063091411; SCHOEN R, 1980, DEMOGRAPHY, V17, P297, DOI 10.2307/2061105; Schoen R, 1988, MODELING MULTIGROUP; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; TUMA N, 1980, INVOKING RATE; 1991, DHHS PHS911101 NAT C; 1982, B BUREAU LABOR STATI, V2135; 1990, DHHS PHS7955701 DEP	47	364	365	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					110	116		10.1056/NEJM199307083290208	http://dx.doi.org/10.1056/NEJM199307083290208			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL196	8510687				2022-12-28	WOS:A1993LL19600008
J	DROLLER, MJ; ANDERSON, JR; BECK, JC; BREMNER, WJ; EVANS, K; GRAY, M; KEENEY, AH; LANZISERA, PJ; LIAO, WC; RICHARDSON, DW; ROHNER, TJ; SHORTLIFFE, LD; TURNER, WR; ZITRIN, A; HALL, WH				DROLLER, MJ; ANDERSON, JR; BECK, JC; BREMNER, WJ; EVANS, K; GRAY, M; KEENEY, AH; LANZISERA, PJ; LIAO, WC; RICHARDSON, DW; ROHNER, TJ; SHORTLIFFE, LD; TURNER, WR; ZITRIN, A; HALL, WH			IMPOTENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NIH, OFF MED APPLICAT RES,FED BLDG,ROOM 618, 7550 WISCONSIN AVE, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DEPT UROL, NEW YORK, NY 10029 USA; UNIV NEBRASKA, MED CTR, DEPT PREVENT & SOCIETAL MED, OMAHA, NE 68105 USA; UNIV CALIF LOS ANGELES, SCH MED, MULTICAMPUS PROGRAM GERIATR MED & GERONTOL, LOS ANGELES, CA USA; VET AFFAIRS MED CTR, SEATTLE, WA USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; KAISER PERMANENTE, DEPT UROL, DALLAS, TX USA; GEORGIA STATE UNIV, SCH NURSING, ALPHARETTA, GA USA; AMER FDN UROL DIS, BALTIMORE, MD USA; HENRY FORD HLTH SCI CTR, DEPT PSYCHIAT, PSYCHOL INTERNSHIP PROGRAM, DETROIT, MI USA; RES TRIANGLE INST, CTR EPIDEMIOL & MED STUDIES, RES TRIANGLE PK, NC 27709 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT CARDIOL, RICHMOND, VA 23298 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DIV UROL, HERSHEY, PA 17033 USA; STANFORD UNIV, PACKARD CHILDRENS HOSP, SCH MED, DEPT UROL, STANFORD, CA 94305 USA; MED UNIV S CAROLINA, DEPT UROL, CHARLESTON, SC 29425 USA; NYU, SCH MED, NEW YORK, NY 10003 USA	National Institutes of Health (NIH) - USA; Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of Nebraska Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Kaiser Permanente; University System of Georgia; Georgia State University; Henry Ford Health System; Henry Ford Hospital; Research Triangle Institute; Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Lucile Packard Children's Hospital (LPCH); Stanford University; Medical University of South Carolina; New York University									0	1816	1878	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					83	90						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510302				2022-12-28	WOS:A1993LK36600029
J	JURKOVICH, GJ; RIVARA, FP; GURNEY, JG; FLIGNER, C; RIES, R; MUELLER, BA; COPASS, M				JURKOVICH, GJ; RIVARA, FP; GURNEY, JG; FLIGNER, C; RIES, R; MUELLER, BA; COPASS, M			THE EFFECT OF ACUTE ALCOHOL-INTOXICATION AND CHRONIC ALCOHOL-ABUSE ON OUTCOME FROM TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURY SEVERITY SCORE; TUMOR NECROSIS FACTOR; SCREENING-TEST; CONSUMPTION; MICHIGAN; ETHANOL; POPULATION; EMERGENCY; ACCIDENTS; CARE	Objective.-To determine the effect of acute alcohol intoxication and chronic alcohol abuse on morbidity and mortality from trauma. Design.-Prospective cohort study. Patients.-Blunt or penetrating trauma patients at least 18 years of age admitted to one trauma center or dying at the injury scene. Main Outcome Measures.-Mortality, complications (infection, pneumonia, respiratory failure, or multiple organ failure), and length of hospital stay. Results.-Acute intoxication had no effect on risk of dying-at the injury scene, within the first 24 hours of hospitalization, after the first 24 hours, or overall. Acute intoxication also did not increase the risk of complications and was associated with shorter lengths of stay. Patients with both biochemical and behavioral evidence of chronic alcohol abuse had a twofold increased risk of complications, particularly pneumonia and any infection, compared with those with no evidence of chronic alcohol-abuse. Conclusions.-Chronic, but not acute, alcohol abuse adversely affects outcome from trauma. Attention to the problem of chronic alcohol abuse in trauma patients is necessary, and screening trauma patients for chronic alcohol abuse appears to be warranted.	UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PSYCHIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIAAA NIH HHS [R01-AA07116] Funding Source: Medline; PHS HHS [R40/CCR-002570] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007116] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baker S, 1992, INJURY FACTBOOK; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DESIDERIO MA, 1986, J TRAUMA, V26, P467, DOI 10.1097/00005373-198605000-00011; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; DSOUZA NB, 1989, ALCOHOL CLIN EXP RES, V13, P295, DOI 10.1111/j.1530-0277.1989.tb00329.x; ELMER O, 1981, LANCET, V2, P639; Fleming M. F, 1989, J SUBST ABUSE, V1, P173, DOI [10.1016/S0899-3289(88)80020-8, DOI 10.1016/S0899-3289(88)80020-8]; Garriott J C, 1983, Clin Lab Med, V3, P385; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GERSHMAN H, 1991, Journal of Emergency Medicine, V9, P307, DOI 10.1016/0736-4679(91)90371-L; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JERRELLS TR, 1991, DRUGS ABUSE IMMUNITY; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; KRANZLER HR, 1990, ALCOHOL CLIN EXP RES, V14, P119, DOI 10.1111/j.1530-0277.1990.tb00457.x; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; LIEDTKE AJ, 1975, AM J CARDIOL, V35, P243, DOI 10.1016/0002-9149(75)90008-9; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MARTIN CS, 1990, ALCOHOL CLIN EXP RES, V14, P853, DOI 10.1111/j.1530-0277.1990.tb01827.x; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; NELSON S, 1991, ADV EXP MED BIOL, V288, P245; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; PERRINE MW, 1988, SURGEON GENERALS WOR, P35; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; POLLOCK DA, 1989, J TRAUMA, V29, P827; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; ROBERTS PJ, 1987, IMMUNOLOGY, V62, P581; ROSALKI SB, 1974, CLIN CHEM, V20, P1384; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH FE, 1976, J CHRON DIS, V29, P35, DOI 10.1016/0021-9681(76)90066-7; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; STERNBACH G L, 1990, Emergency Medicine Clinics of North America, V8, P793; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WAGNER F, 1992, J STUD ALCOHOL, V53, P277, DOI 10.15288/jsa.1992.53.277; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1988, MMWR MORB MORTAL WKL, V37, P753; 1989, ALCOHOL TRAUMA; 1988, ICDMAP DETERMING INJ; 1985, INJURY AM CONTINUING	53	222	223	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					51	56		10.1001/jama.270.1.51	http://dx.doi.org/10.1001/jama.270.1.51			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510296				2022-12-28	WOS:A1993LK36600022
J	EISENBERG, DM; DELBANCO, TL; BERKEY, CS; KAPTCHUK, TJ; KUPELNICK, B; KUHL, J; CHALMERS, TC				EISENBERG, DM; DELBANCO, TL; BERKEY, CS; KAPTCHUK, TJ; KUPELNICK, B; KUHL, J; CHALMERS, TC			COGNITIVE-BEHAVIORAL TECHNIQUES FOR HYPERTENSION - ARE THEY EFFECTIVE	ANNALS OF INTERNAL MEDICINE			English	Review						HYPERTENSION; BEHAVIOR THERAPY; BIOFEEDBACK (PSYCHOLOGY); RELAXATION TECHNIQUES; COGNITIVE THERAPY	HIGH BLOOD-PRESSURE; RANDOMIZED CONTROLLED TRIAL; PROGRESSIVE MUSCLE-RELAXATION; CORONARY HEART-DISEASE; MILD HYPERTENSION; STRESS MANAGEMENT; DOUBLE-BLIND; POTASSIUM SUPPLEMENTATION; CROSSOVER TRIAL; CLINICAL-TRIALS	Purpose: To assess by analysis of published controlled trials the efficacy of cognitive behavioral therapies (such as biofeedback, relaxation, meditation) for essential hypertension. Data Identification: Randomized controlled trials published in the English language between 1970 and 1991 identified from the MEDLINE database and bibliographic references from these articles. Study Selection: Limited to studies involving randomized assignment to a treatment group consisting of one or more cognitive behavioral interventions or a concurrent control group consisting of no therapy, a waiting list, regular monitoring, or placebo intervention. Results of Data Synthesis: Although we identified more than 800 published works, only 26 met entry criteria. We identified a number of methodologic short-comings, including small sample size, inconsistencies regarding baseline blood pressure determinations and types of control groups, and the possibility of confounding by multiple noncognitive cointerventions (diet, exercise) and expectancy (the placebo effect). In meta-analyses involving 1264 patients, differences in mean blood pressure reduction varied according to the duration of baseline blood pressure measurements and type of control groups studied. In 16 comparisons involving baseline periods of more than 1 day, with patients (n = 368) assigned to either a cognitive therapy or a placebo intervention (sham biofeedback, ''pseudo-meditation''), systolic and diastolic blood pressures decreased by 2.8 mm Hg (95% CI, -0.8 to 6.4) and 1.3 mm Hg (CI, -1.3 to 3.8), respectively. These changes were neither statistically nor clinically significant. Conclusion: Cognitive interventions for essential hypertension are superior to no therapy but not superior to credible sham techniques or to self-monitoring alone. The literature on this subject is limited by a variety of methodologic inadequacies. No single cognitive behavioral technique appears to be more effective than any other.	HARVARD UNIV, SCH PUBL HLTH, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	EISENBERG, DM (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005936] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS-05936] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACHMON J, 1989, PSYCHOSOM MED, V51, P152, DOI 10.1097/00006842-198903000-00005; ADSETT CA, 1989, PSYCHOSOM MED, V51, P523, DOI 10.1097/00006842-198909000-00004; AGRAS WS, 1983, J CONSULT CLIN PSYCH, V51, P792, DOI 10.1037/0022-006X.51.5.792; AGRAS WS, 1987, PSYCHOSOM MED, V49, P264, DOI 10.1097/00006842-198705000-00005; ANAND BK, 1961, INDIAN J MED RES, V49, P90; [Anonymous], 1981, LANCET, V2, P539; [Anonymous], 1982, Lancet, V1, P185; BALI LR, 1979, PSYCHOSOM MED, V41, P637, DOI 10.1097/00006842-197912000-00005; BEARY JF, 1974, PSYCHOSOM MED, V36, P115, DOI 10.1097/00006842-197403000-00003; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BENSON H, 1975, Journal of Human Stress, V1, P37; Benson H., 1975, RELAXATION RESPONSE; BERGLUND G, 1981, LANCET, V1, P744; Bernstein D.A., 1973, PROGR RELAXATION TRA; BIERENBAUM ML, 1988, AM J HYPERTENS, V1, pS149, DOI 10.1093/ajh/1.3.149S; BLANCHARD EB, 1979, J APPL BEHAV ANAL, V12, P99, DOI 10.1901/jaba.1979.12-99; BLANCHARD EB, 1988, BIOFEEDBACK SELF-REG, V13, P25, DOI 10.1007/BF00998877; Brauer A P, 1979, J Behav Med, V2, P21, DOI 10.1007/BF00846560; Brosse T.A., 1946, MAIN CURR MOD THOUGH, P77; CAPPUCCIO FP, 1987, J HYPERTENS, V5, P67, DOI 10.1097/00004872-198702000-00010; CHALMERS JP, 1989, LANCET, V1, P399; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHARLESWORTH EA, 1984, PSYCHOSOM MED, V46, P387, DOI 10.1097/00006842-198409000-00001; CHESNEY MA, 1987, PSYCHOSOM MED, V49, P250, DOI 10.1097/00006842-198705000-00004; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COTTIER C, 1984, ARCH INTERN MED, V144, P1954, DOI 10.1001/archinte.144.10.1954; CROWTHER JH, 1983, J BEHAV MED, V6, P169, DOI 10.1007/BF00845379; CURB J D, 1985, American Journal of Preventive Medicine, V1, P36; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; EISEN SA, 1987, J GEN INTERN MED, V2, P298, DOI 10.1007/BF02596162; ELLIOTT P, 1988, BRIT MED J, V297, P319; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ENGEL BT, 1983, PSYCHOSOM MED, V45, P23, DOI 10.1097/00006842-198303000-00004; ENGEL BT, 1981, PSYCHOSOM MED, V43, P255, DOI 10.1097/00006842-198106000-00007; EVERLY GS, 1989, CLIN GUIDE TREATMENT; FODOR JG, 1990, CLIN EXP HYPERTENS A, V12, P729, DOI 10.3109/10641969009073495; FRANKEL BL, 1978, PSYCHOSOM MED, V40, P276, DOI 10.1097/00006842-197806000-00002; GLASGOW MS, 1982, PSYCHOSOM MED, V44, P155, DOI 10.1097/00006842-198205000-00002; GLASGOW MS, 1989, PSYCHOSOM MED, V51, P10, DOI 10.1097/00006842-198901000-00002; GOLDSTEIN IB, 1984, PSYCHOSOM MED, V46, P398, DOI 10.1097/00006842-198409000-00002; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAFNER RJ, 1982, BIOFEEDBACK SELF-REG, V7, P305, DOI 10.1007/BF00998923; HATCH JP, 1985, BIOFEEDBACK SELF-REG, V10, P119, DOI 10.1007/BF01000749; HAVELICK RJ, 1981, BIOFEEDBACK CLIN PRA; HOELSCHER TJ, 1986, J CONSULT CLIN PSYCH, V54, P217, DOI 10.1037/0022-006X.54.2.217; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; INUI TS, 1981, MED CARE, V19, P1061, DOI 10.1097/00005650-198110000-00008; IRVINE MJ, 1986, J PSYCHOSOM RES, V30, P437, DOI 10.1016/0022-3999(86)90083-8; JACOB RG, 1985, BEHAV MODIF, V9, P32, DOI 10.1177/01454455850091003; Jacobson E, 1929, PROGR RELAXATION; JORGENSEN RS, 1981, BEHAV RES THER, V19, P467, DOI 10.1016/0005-7967(81)90073-5; KHAW KT, 1982, LANCET, V2, P1127; King M., 1987, BEHAV COGN PSYCHOTH, V16, P335, DOI [10.1017/S0141347300014208, DOI 10.1017/S0141347300014208]; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KLEIN LE, 1988, HYPERTENSION, V11, pS61; LAGRONE R, 1988, J CLIN PSYCHOL, V44, P271, DOI 10.1002/1097-4679(198803)44:2<271::AID-JCLP2270440230>3.0.CO;2-Q; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LITTLE BC, 1984, LANCET, V1, P865; LUBORSKY L, 1982, PSYCHOSOM MED, V44, P203, DOI 10.1097/00006842-198205000-00006; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MACGREGOR GA, 1982, LANCET, V2, P567; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATLOU SM, 1986, J HYPERTENS, V4, P61, DOI 10.1097/00004872-198602000-00010; MAXWELL MH, 1984, ARCH INTERN MED, V144, P1581, DOI 10.1001/archinte.144.8.1581; MCCARRON DA, 1985, ANN INTERN MED, V103, P825, DOI 10.7326/0003-4819-103-6-825; MCGRADY AV, 1981, BIOFEEDBACK SELF-REG, V6, P343, DOI 10.1007/BF01000659; MEICHENBAUM D, 1985, STRESS INNOCULATION; MILLER NE, 1987, ENCY NEUROSCIENCE, P122; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; Olton DS, 1980, BIOFEEDBACK CLIN APP; PATEL C, 1981, BRIT MED J, V282, P2005, DOI 10.1136/bmj.282.6281.2005; PATEL C, 1975, LANCET, V2, P93; PATEL C, 1988, BRIT MED J, V296, P21, DOI 10.1136/bmj.296.6614.21; PATEL C, 1985, BRIT MED J, V290, P1103, DOI 10.1136/bmj.290.6475.1103; PATEL C, 1991, COMPLETE GUIDE STRES; PAULY MV, 1986, AM J MED, V81, P1, DOI 10.1016/0002-9343(86)90520-6; PENDER NJ, 1984, RES NURS HEALTH, V7, P197, DOI 10.1002/nur.4770070308; POTTER JF, 1984, LANCET, V1, P119; PUDDEY IB, 1985, CLIN EXP PHARMACOL P, V12, P257, DOI 10.1111/j.1440-1681.1985.tb02643.x; PUDDEY IB, 1987, LANCET, V1, P647; REISIN E, 1983, ANN INTERN MED, V98, P315, DOI 10.7326/0003-4819-98-3-315; REITMAN D, 1987, CONTROL CLIN TRIALS, V8, P282; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SEER P, 1980, Journal of Behavioral Medicine, V3, P59, DOI 10.1007/BF00844914; SHAPIRO DH, 1978, ARCH GEN PSYCHIAT, V35, P294; Shapiro DH, 1980, MEDITATION SELF REGU; SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3; SIANI A, 1988, J HYPERTENS, V6, P253, DOI 10.1097/00004872-198803000-00011; SOMERS PJ, 1989, BIOFEEDBACK SELF-REG, V14, P309, DOI 10.1007/BF00999122; SOUTHAM MA, 1982, ARCH GEN PSYCHIAT, V39, P715; STAMLER R, 1989, ARCH INTERN MED, V149, P661, DOI 10.1001/archinte.149.3.661; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; TAYLOR CB, 1977, ARCH GEN PSYCHIAT, V34, P339; UNDERHILL LH, 1986, WESTERN J MED, V145, P853; VAKIL RJ, 1950, LANCET, V259, P871; WADDEN TA, 1984, J PSYCHOSOM RES, V28, P53, DOI 10.1016/0022-3999(84)90040-0; WALLACE RK, 1972, SCI AM, V226, P84, DOI 10.1038/scientificamerican0272-84; WALLACE RK, 1971, AM J PHYSIOL, V221, P795, DOI 10.1152/ajplegacy.1971.221.3.795; WALLACE RK, 1970, SCIENCE, V167, P1751, DOI 10.1126/science.167.3926.1751; WEIDMANN P, 1985, J HYPERTENS, V3, P297, DOI 10.1097/00004872-198508000-00001; WEISS SM, 1984, HYPERTENSION PSYCHOP; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WOOLFOLKK RL, 1984, MEDITATION CLASSIC C, P674; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; ZOCCALI C, 1986, J HYPERTENS, V4, pS676; ZURAWSKI RM, 1987, J PSYCHOSOM RES, V31, P453, DOI 10.1016/0022-3999(87)90003-1	111	102	102	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					964	972		10.7326/0003-4819-118-12-199306150-00009	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489111				2022-12-28	WOS:A1993LF93700009
J	FIGUEROAQUINTANILLA, D; SALAZARLINDO, E; SACK, B; LEONBARUA, R; SARABIAARCE, S; CAMPOSSANCHEZ, M; EYZAGUIRREMACCAN, E				FIGUEROAQUINTANILLA, D; SALAZARLINDO, E; SACK, B; LEONBARUA, R; SARABIAARCE, S; CAMPOSSANCHEZ, M; EYZAGUIRREMACCAN, E			A CONTROLLED TRIAL OF BISMUTH SUBSALICYLATE IN INFANTS WITH ACUTE WATERY DIARRHEAL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESCHERICHIA-COLI; SUB-SALICYLATE; CHILDREN	Background. Bismuth subsalicylate is a common constituent of over-the-counter medications for diarrhea. However, it is uncertain whether bismuth offers any more benefit than standard oral rehydration therapy with early feeding. Methods. We conducted a placebo-controlled, randomized trial to evaluate the effect of bismuth subsalicylate (100 or 150 mg per kilogram of body weight per day for up to 5 days) on the duration and volume of acute watery diarrhea in 275 male infants and young boys (mean age, 13.5 months). Serum salicylate and bismuth levels were monitored throughout the study and were also measured two weeks after discharge. All the patients received fluid replacement by the oral route and early feeding of easily digestible foods with high caloric density. Results. Diarrhea stopped within 120 hours of admission in 74 percent of the patients given placebo, 89 percent of those given 100 mg of bismuth per kilogram (P = 0.009 vs. the placebo group), and 88 percent of those given 150 mg of bismuth per kilogram (P = 0.019 vs. the placebo group). As compared with the patients given placebo, those given bismuth had significant reductions in their total stool output (P = 0.015), total intake of oral rehydration solution (P = 0.013), and duration of hospitalization (P = 0.005); there was no significant difference between the two groups given bismuth in these clinical outcomes. All measurements of bismuth and salicylate concentrations in blood were well below concentrations considered toxic. No adverse reactions were seen. Conclusions. Treatment with bismuth subsalicylate decreases the duration of diarrhea and is a safe and effective adjunct to oral rehydration therapy for infants and young children with acute watery diarrhea.	UNIV PERUANA CAYETANO HEREDIA,AP 4314,LIMA 10,PERU; INST NACL SALUD NINO,LIMA,PERU; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218	Universidad Peruana Cayetano Heredia; Johns Hopkins University				Campos-Sanchez, Miguel/0000-0003-4650-1225				BAUER JD, 1962, BRAYC CLIN LABORATOR, P511; BIERER DW, 1990, REV INFECT DIS, V12, pS3; BROWN KH, 1988, J PEDIATR-US, V112, P191, DOI 10.1016/S0022-3476(88)80055-6; BURNS R, 1974, BRIT MED J, V1, P220, DOI 10.1136/bmj.1.5901.220; DUPONT HL, 1977, GASTROENTEROLOGY, V73, P715; DUPONT HL, 1980, JAMA-J AM MED ASSOC, V243, P237, DOI 10.1001/jama.243.3.237; DUPONT HL, 1990, REV INFECT DIS, V12, pS64; ERICSSON CD, 1977, J INFECT DIS, V136, P693, DOI 10.1093/infdis/136.5.693; ERICSSON CD, 1990, REV INFECT DIS, V12, pS16; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P191; FROOMES PRA, 1988, CLIN CHEM, V34, P382; GRAHAM DY, 1983, GASTROENTEROLOGY, V85, P1017; GRYBOSKI JD, 1990, REV INFECT DIS, V12, pS36; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HILLEMAND P, 1977, SEM HOP PARIS, V53, P1663; LAGIER G, 1980, THERAPIE, V35, P315; MANHART MD, 1990, REV INFECT DIS, V12, pS11; PAZZAGLIA G, 1991, J CLIN MICROBIOL, V29, P1151, DOI 10.1128/JCM.29.6.1151-1156.1991; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SORIANOBRUCHER H, 1991, PEDIATRICS, V87, P18; STEFFEN R, 1988, J INFECT DIS, V157, P1008, DOI 10.1093/infdis/157.5.1008; STEINHOFF MC, 1980, GASTROENTEROLOGY, V78, P1495; WARD RL, 1985, ANTIMICROB AGENTS CH, V27, P306, DOI 10.1128/AAC.27.3.306; 1989, TRETMENT PREVENTION; 1983, MANUAL LABORATORY IN; 1990, RATIONAL USE DRUGS M	26	63	64	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1653	1658		10.1056/NEJM199306103282301	http://dx.doi.org/10.1056/NEJM199306103282301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8487823	Bronze			2022-12-28	WOS:A1993LF05400001
J	STAMNES, MA; ROTHMAN, JE				STAMNES, MA; ROTHMAN, JE			THE BINDING OF AP-1 CLATHRIN ADAPTER PARTICLES TO GOLGI MEMBRANES REQUIRES ADP-RIBOSYLATION FACTOR, A SMALL GTP-BINDING PROTEIN	CELL			English	Article							COATED VESICLES; BREFELDIN-A; BETA-COP; APPARATUS; EXPRESSION; TRANSPORT; HOMOLOGY; COFACTOR; COMPLEX; CELLS	The small GTP-binding protein, ADP-ribosylation factor (ARF), has previously been shown to mediate the binding to Golgi membranes of the coatomer of non-clathrin-coated (COP-coated) vesicles. We now report that ARF is also required for the binding of the AP-1 adaptor protein of clathrin-coated vesicles to Golgi membranes. The binding of coat proteins from both clathrin- and COP-coated vesicles requires an additional Golgi membrane-associated factor. These results suggest that a mechanistic similarity underlies diverse types of vesicle coats.			STAMNES, MA (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, ROCKEFELLER RES LAB, NEW YORK, NY 10021 USA.			Stamnes, Mark/0000-0002-5869-7985				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BREW K, 1975, J BIOL CHEM, V250, P1434; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, IN PRESS NATURE; PALMER DJ, 1993, IN PRESS J BIOL CHEM; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	38	367	376	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					999	1005		10.1016/0092-8674(93)90277-W	http://dx.doi.org/10.1016/0092-8674(93)90277-W			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500185	Bronze			2022-12-28	WOS:A1993LF06100015
J	SU, TP; PAGLIARO, M; SCHMIDT, PJ; PICKAR, D; WOLKOWITZ, O; RUBINOW, DR				SU, TP; PAGLIARO, M; SCHMIDT, PJ; PICKAR, D; WOLKOWITZ, O; RUBINOW, DR			NEUROPSYCHIATRIC EFFECTS OF ANABOLIC-STEROIDS IN MALE NORMAL VOLUNTEERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANDROGENIC STEROIDS; MEN; METHYLTESTOSTERONE; MESTEROLONE; DEPENDENCE; HORMONES; STATE	Objective.-To evaluate the acute effects of anabolic steroids on mood and behavior in male normal volunteers. Design.-A 2-week, double-blind (subject and rater), fixed-order, placebo-controlled crossover trial of methyltestosterone. Setting.-An inpatient research unit at the National Institutes of Health. Subjects.-A volunteer sample of 20 men who were medication free, free of medical and psychiatric illness, not involved in athletic training, and had no prior history of anabolic steroid use. Intervention.-A sequential trial for 3 days each of the following four drug conditions: placebo baseline, low-dose methyltestosterone (40 mg/d), high-dose methyltestosterone (240 mg/d), and placebo withdrawal. Main Outcome Measures.-Mood and behavioral ratings were completed during each drug condition and included both subjective and objective measures. Results.-Significant (P<.05) albeit subtle increases in symptom scores were observed during high-dose methyltestosterone administration compared with baseline in positive mood (euphoria, energy, and sexual arousal), negative mood (irritability, mood swings, violent feelings, and hostility), and cognitive impairment (distractibility, forgetfulness, and confusion). An acute manic episode was observed in one of the 20 subjects, representing a 5% incidence, even under these conservative conditions. An additional subject became hypomanic. Baseline characteristics including family psychiatric history or previous drug abuse did not predict symptom changes. Conclusion.-This is the first placebo-controlled prospective study demonstrating the adverse and activating mood and behavioral effects of anabolic steroids.	NIMH,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT NURSING,MENTAL HLTH NURSING SERV,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of California System; University of California San Francisco	SU, TP (corresponding author), NIMH,BIOL PSYCHIAT BRANCH,BEHAV ENDOCRINOL SECT,9000 ROCKVILLE PIKE,BLDG 10,ROOM 3N238,BETHESDA,MD 20892, USA.		Wolkowitz, Owen M/J-6649-2013	Wolkowitz, Owen M/0000-0003-0655-5042; Pickar, David/0000-0002-8596-3687				ANNITTO WJ, 1980, J CLIN PSYCHIAT, V41, P143; BAHRKE MS, 1990, NEW ENGL J MED, V323, P834; BARKER S, 1987, BRIT J PSYCHIAT, V151, P564, DOI 10.1192/S0007125000217698; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BEUMONT PJV, 1972, PSYCHOL MED, V2, P70, DOI 10.1017/S0033291700045633; BROWER KJ, 1989, AM J PSYCHIAT, V146, P1075; BROWER KJ, 1989, J CLIN PSYCHIAT, V50, P31; CHOI P Y L, 1990, Human Psychopharmacology, V5, P349, DOI 10.1002/hup.470050407; COLBURN TR, 1976, ISA T, V15, P149; COWART VS, 1989, JAMA-J AM MED ASSOC, V261, P1855; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREINHAR JP, 1985, J CLIN PSYCHIAT, V46, P354; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HANNAN CJ, 1991, PSYCHONEUROENDOCRINO, V16, P335, DOI 10.1016/0306-4530(91)90019-P; Hyler S, 1987, PERSONALITY DIAGNOST; HYLER SE, 1989, COMPR PSYCHIAT, V30, P170, DOI 10.1016/0010-440X(89)90070-9; Itil T M, 1979, Psychopharmacol Bull, V15, P31; ITIL TM, 1984, METHOD FIND EXP CLIN, V6, P331; ITIL TM, 1974, CURR THER RES CLIN E, V16, P1147; KASHKIN KB, 1989, JAMA-J AM MED ASSOC, V262, P3166, DOI 10.1001/jama.262.22.3166; LAL S, 1991, PROG NEURO-PSYCHOPH, V15, P263, DOI 10.1016/0278-5846(91)90090-N; Lefavi R. G., 1990, J SPORT BEHAVIOR, V13, P157, DOI [10.1002/hup.470050407, DOI 10.1002/HUP.470050407]; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Perry P., 1990, ANN CLIN PSYCHIATRY, V2, P11, DOI [10.3109/10401239009150000, DOI 10.3109/10401239009150000]; POPE HG, 1988, AM J PSYCHIAT, V145, P487; Spielberger C., 1983, STAI MANUAL; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; TENNANT F, 1988, NEW ENGL J MED, V319, P578; TILZEY A, 1981, BMJ, V285, P349; TOURTELLOTTE W, 1964, POST LUMBAR PUNCTURE; VOGEL W, 1985, J CLIN PSYCHIAT, V46, P6; WILLIAMSON DJ, 1992, J PSYCHOPHARMACOL, V6, P20, DOI 10.1177/026988119200600107; WILSON IC, 1974, AM J PSYCHIAT, V131, P21, DOI 10.1176/ajp.131.1.21; 1988, JAMA-J AM MED ASSOC, V259, P1703; 1989, PHYSICIANS DESK REFE, P851	36	286	291	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2760	2764		10.1001/jama.269.21.2760	http://dx.doi.org/10.1001/jama.269.21.2760			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492402				2022-12-28	WOS:A1993LD67100026
J	KRIEGER, JN; JENNY, C; VERDON, M; SIEGEL, N; SPRINGWATER, R; CRITCHLOW, CW; HOLMES, KK				KRIEGER, JN; JENNY, C; VERDON, M; SIEGEL, N; SPRINGWATER, R; CRITCHLOW, CW; HOLMES, KK			CLINICAL MANIFESTATIONS OF TRICHOMONIASIS IN MEN	ANNALS OF INTERNAL MEDICINE			English	Article						TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS; URETHRITIS; NEISSERIA-GONORRHOEAE; CHLAMYDIA TRACHOMATIS	CHLAMYDIA-TRACHOMATIS; NONGONOCOCCAL URETHRITIS; VAGINAL TRICHOMONIASIS; ETIOLOGY; CULTURES	Objective: To determine the prevalence and clinical manifestations of trichomoniasis among sexually active men. Design: Survey of two groups of men attending a sexually transmitted disease clinic. Subjects had a comprehensive sexual history and clinical examination plus cultures for Trichomonas vaginalis, Neisseria gonorrhoeae, and Chlamydia trachomatis. Participants: The study included 147 sexual partners of women with trichomoniasis and 300 subjects selected randomly from heterosexual men coming to the same clinic for evaluation of new problems. Main Outcome Measures: Isolation of T. vaginalis was compared with urogenital signs and symptoms. Results: The prevalence of T. vaginalis was 33 of 147 (22% [95% CI, 16% to 29%]) among sexual contacts of women with trichomoniasis and 17 of 300 (6% [CI, 3% to 9%]) among heterosexual men attending the same clinic. Men with trichomoniasis alone were more likely to complain of urethral discharge (P < 0.01), to have discharge on examination (P < 0.03), and to have inflammatory cells in their urethral secretions (P < 0.01) than were men who did not have T. vaginalis, N. gonorrhoeae, or C. trachomatis. Trichomonas vaginalis remained associated with nongonococcal nonchlamydial urethritis (adjusted odds ratio 3.8; CI, 1.1 to 11.2) after adjustment for race, age, number of sex partners in the previous 6 months, exposure to a partner with trichomoniasis, and history of trichomoniasis, urethritis, or gonorrhea. Conclusions: Trichomoniasis was common among men at risk for sexually transmitted diseases and was associated with symptoms and signs of urethritis.			KRIEGER, JN (corresponding author), UNIV WASHINGTON, SCH MED, DEPT UROL, RL-10, 1959 PACIFIC ST NE, SEATTLE, WA 98195 USA.		, Holmes/K-6215-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038955] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK38955] Funding Source: Medline; NCIRD CDC HHS [IP30 27757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCIRD CDC HHS		ACKERS JP, 1978, BRIT J VENER DIS, V54, P168; BOWIE WR, 1977, J CLIN INVEST, V59, P735, DOI 10.1172/JCI108694; CATTERALL RD, 1972, MED CLIN N AM, V56, P1203, DOI 10.1016/S0025-7125(16)32345-8; COUTTS W E, 1959, Urol Int, V9, P189; DAVIS W, 1980, STATISTICAL METHODS, V1, P192; DYKERS JR, 1975, NEW ENGL J MED, V293, P23, DOI 10.1056/NEJM197507032930106; Fair W R, 1976, Urology, V7, P169, DOI 10.1016/0090-4295(76)90305-8; FEO LG, 1956, BRIT J VENER DIS, V32, P233; FISHER I, 1969, BRIT J VENER DIS, V45, P252; GARDNER WA, 1986, ARCH PATHOL LAB MED, V110, P430; GLANTZ SA, 1981, PRIMER BIOSTATISTICS, P352; HAGER WD, 1980, JAMA-J AM MED ASSOC, V244, P1219, DOI 10.1001/jama.244.11.1219; HOFFMANN B, 1961, BRIT J VENER DIS, V37, P172; HOLMES KK, 1975, NEW ENGL J MED, V292, P1199, DOI 10.1056/NEJM197506052922301; Honigberg B.M., 1978, P275; Kenny GE, 1991, MANUAL CLIN MICROBIO, P478; KOSTIC P K, 1959, Urol Int, V9, P171; KRIEGER JN, 1988, JAMA-J AM MED ASSOC, V259, P1223, DOI 10.1001/jama.259.8.1223; KRIEGER JN, 1981, INVEST UROL, V18, P411; KRIEGER JN, 1990, TRICHOMONADS PARASIT, P235; KUBERSKI T, 1980, SEX TRANSM DIS, V7, P135, DOI 10.1097/00007435-198007000-00010; LANCELEY F., 1953, BRIT JOUR VENEREAL DIS, V29, P213; LATIF AS, 1987, SEX TRANSM DIS, V14, P9, DOI 10.1097/00007435-198701000-00002; LOSSICK JG, 1990, REV INFECT DIS, V12, pS665; MANTEL N, 1959, J NATL CANCER I, V22, P719; MORELLO JA, 1980, MANUAL CLIN MICROBIO, P111; PETERSON WF, 1966, AM J OBSTET GYNECOL, V94, P343, DOI 10.1016/0002-9378(66)90654-5; SAXENA SB, 1991, SEX TRANSM DIS, V18, P138, DOI 10.1097/00007435-199107000-00002; SCHAPIRA HE, 1965, J UROLOGY, V93, P303, DOI 10.1016/S0022-5347(17)63763-7; SOWMINI CN, 1973, BRIT J VENER DIS, V49, P469; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; SYLVESTRE L, 1960, Can Med Assoc J, V83, P1195; TUTTLE JP, 1977, J UROLOGY, V118, P1024, DOI 10.1016/S0022-5347(17)58285-3; WATT L, 1960, BRIT J VENER DIS, V36, P163; WESTON TET, 1963, BRIT J VENER DIS, V39, P251; WHITTINGTON MJ, 1957, BRIT J VENER DIS, V33, P80; WILSON A, 1980, BRIT J VENER DIS, V56, P46; WOLNERHANSSEN P, 1989, JAMA-J AM MED ASSOC, V261, P571; YODER BL, 1981, J CLIN MICROBIOL, V13, P1036, DOI 10.1128/JCM.13.6.1036-1039.1981; 1989, MORB MORTAL WKLY REP, V38, P1	40	75	77	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					844	849		10.7326/0003-4819-118-11-199306010-00003	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480958				2022-12-28	WOS:A1993LD25200003
J	MEYN, MS				MEYN, MS			HIGH SPONTANEOUS INTRACHROMOSOMAL RECOMBINATION RATES IN ATAXIA-TELANGIECTASIA	SCIENCE			English	Article							MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; RECEPTOR GENES; DNA-REPAIR; G2 PHASE; FIBROBLASTS; RADIOSENSITIVITY; HYPERSENSITIVITY; HETEROZYGOTES	Ataxia-telangiectasia (A-T) is an inherited human disease associated with neurologic degeneration, immune dysfunction, and high cancer risk. It has been proposed that the underlying abnormality in A-T is a defect in genetic recombination that interferes with immune gene rearrangements and the repair of DNA damage. Recombination was studied in A-T and control human fibroblast lines by means of two recombination vectors. Unexpectedly, spontaneous intrachromosomal recombination rates were 30 to 200 times higher in A-T fibroblast lines than in normal cells, whereas extrachromosomal recombination frequencies were near normal. Increased recombination is thus a component of genetic instability in A-T and may contribute to the cancer risk seen in A-T patients.	YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA	Yale University	MEYN, MS (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038588] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38588] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BHATTACHARYYA NP, 1989, MUTAT RES, V211, P205, DOI 10.1016/0027-5107(89)90003-1; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; COHEN MM, 1989, ADV HUM GENET, V18, P43; COX R, 1984, BRIT J CANCER, V49, P67; DASGUPTA UB, 1980, MOL GEN GENET, V178, P617, DOI 10.1007/BF00337869; EJIMA Y, 1990, INT J RADIAT BIOL, V58, P989, DOI 10.1080/09553009014552301; GATTI RA, 1991, CLIN IMMUNOL IMMUNOP, V61, pS10, DOI 10.1016/S0090-1229(05)80032-7; GREEN MHL, 1987, J CELL SCI, P127; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; HERZING LBK, UNPUB; HILGERS G, 1987, CARCINOGENESIS, V8, P315, DOI 10.1093/carcin/8.2.315; HILGERS G, 1989, MUTAGENESIS, V4, P271, DOI 10.1093/mutage/4.4.271; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOBAYASHI Y, 1991, J IMMUNOL, V147, P3201; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; Luria SE, 1943, GENETICS, V28, P491; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MIRZAYANS R, 1991, CARCINOGENESIS, V12, P19, DOI 10.1093/carcin/12.1.19; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PATERSON MC, 1979, ANNU REV GENET, V13, P291, DOI 10.1146/annurev.ge.13.120179.001451; PETERSON RDA, 1989, IMMUNOL TODAY, V10, P313, DOI 10.1016/0167-5699(89)90087-X; PIPPARD EC, 1988, CANCER RES, V48, P2929; ROSIN MP, 1989, HUM GENET, V83, P133, DOI 10.1007/BF00286705; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378; SMITH PJ, 1985, INT J RADIAT BIOL, V47, P701, DOI 10.1080/09553008514550941; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; THACKER J, 1989, MUTAT RES, V220, P187, DOI 10.1016/0165-1110(89)90024-9; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZIV Y, 1989, CANCER RES, V49, P2495	45	219	222	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1327	1330		10.1126/science.8493577	http://dx.doi.org/10.1126/science.8493577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493577				2022-12-28	WOS:A1993LE02500044
J	ROSENBLATT, WH; ARIYAN, C; GUTTER, V; SILVERMAN, DG				ROSENBLATT, WH; ARIYAN, C; GUTTER, V; SILVERMAN, DG			CASE-BY-CASE ASSESSMENT OF RECOVERABLE MATERIALS FOR OVERSEAS DONATION FROM 1318 SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To provide a mechanism for addressing the need for consistency and projection in overseas donation of surgical supplies, we conducted a case-by-case inventory of unused materials recovered from all surgical procedures in our facility over a 2.5-month period. Design.-Unused surgical supplies were recovered in coded bags from individual cases and inventoried. Setting.-patient operating rooms at Yale-New Haven Hospital. Main Outcome Measure.-The weight and dollar value of recovered materials were tallied for each case type; these were then extrapolated according to the frequency with which each procedure is performed in the United States to provide an estimate of the impact of a nationwide recovery program. Results.-The value of supplies recovered ranged from $1 (bone marrow transplant) to greater than $40 (liver and vulva/perineum procedures). By extrapolation to case-specific data from the National Hospital Discharge Survey (1990), we estimate that a nationwide recovery program could yield more than $193 million in charitable material and reduce operating room waste by more than 1.7 million kilograms (1948 tons). Conclusions.-Consistency and organization would contribute greatly to efforts to alleviate existing medical supply needs in the developing world. This case-by-case assessment should enable participating centers to project more effectively the outcome of such collections and allow the coordination of efforts. Though unlikely to be adopted by all operating theaters in the United States, the potential charitable contributions from a nationwide recovery program are significant.			ROSENBLATT, WH (corresponding author), YALE UNIV,SCH MED,DEPT ANESTHESIOL,TMP-3,333 CEDAR ST,POB 333,NEW HAVEN,CT 06510, USA.							CAPERS RS, 1992, HARTFORD COURAN 1212, pD1; COBEY JC, 1993, JAMA-J AM MED ASSOC, V269, P986, DOI 10.1001/jama.1993.03500080034013; CRONE RK, 1992, JAMA-J AM MED ASSOC, V268, P1462, DOI 10.1001/jama.268.11.1462; DEGOYET CD, 1993, JAMA-J AM MED ASSOC, V269, P986; ROSENBLATT WH, 1992, JAMA-J AM MED ASSOC, V268, P1441, DOI 10.1001/jama.268.11.1441; TIESZEN ME, 1992, JAMA-J AM MED ASSOC, V267, P2765, DOI 10.1001/jama.267.20.2765; 1992, DETAILED DIAGNOSES P	7	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2647	2649		10.1001/jama.269.20.2647	http://dx.doi.org/10.1001/jama.269.20.2647			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487448				2022-12-28	WOS:A1993LC86500029
J	WEBB, DW; SUPER, M; NORMAND, ICS; OSBORNE, JP				WEBB, DW; SUPER, M; NORMAND, ICS; OSBORNE, JP			LESSON OF THE WEEK - TUBEROUS SCLEROSIS AND POLYCYSTIC KIDNEY-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD		ROYAL UNITED HOSP, BATH UNIT RES PAEDIAT, BATH BA1 3NG, ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP, PAEDIAT GENET UNIT, MANCHESTER M27 1HA, LANCS, ENGLAND; SOUTHAMPTON GEN HOSP, DEPT CHILD HLTH, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	Royal Manchester Children's Hospital; University of Southampton				Webb, David/0000-0002-0762-8277				BALLIGAND JL, 1990, TRANSPLANTATION, V49, P515, DOI 10.1097/00007890-199003000-00008; BERNSTEIN J, 1991, ANN NY ACAD SCI, V615, P36; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; KAPLAN BS, 1989, J PEDIATR-US, V115, P867, DOI 10.1016/S0022-3476(89)80735-8; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PROESMANS W, 1982, PEDIATRICS, V70, P971; SEDMAN A, 1987, KIDNEY INT, V31, P1000, DOI 10.1038/ki.1987.98; STILLWELL TJ, 1987, J UROLOGY, V138, P477, DOI 10.1016/S0022-5347(17)43234-4	8	30	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1993	306	6887					1258	1259		10.1136/bmj.306.6887.1258	http://dx.doi.org/10.1136/bmj.306.6887.1258			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499859	Green Published, Bronze			2022-12-28	WOS:A1993LB80400023
J	FERREDAMARE, AR; PRENDERGAST, GC; ZIFF, EB; BURLEY, SK				FERREDAMARE, AR; PRENDERGAST, GC; ZIFF, EB; BURLEY, SK			RECOGNITION BY MAX OF ITS COGNATE DNA THROUGH A DIMERIC B/HLH/Z DOMAIN	NATURE			English	Article							LOOP-HELIX PROTEIN; C-MYC; NEGATIVE REGULATOR; BINDING PROTEINS; LEUCINE ZIPPER; TRANSCRIPTION; MOTIF; MYOD; REFINEMENT; ENHANCER	The three-dimensional structure of the basic/helix-loop-helix/leucine zipper domain of the transcription factor Max complexed with DNA has been determined by X-ray crystallography at 2.9 angstrom resolution. Max binds as a dimer to its recognition sequence CACGTG by direct contacts between the alpha-helical basic region and the major groove. This symmetric homodimer, a new protein fold, is a parallel, left-handed, four-helix bundle, with each monomer containing two alpha-helical segments separated by a loop. The two alpha-helical segments are composed of the basic region plus helix 1 and helix 2 plus the leucine repeat, respectively. As in GCN4, the leucine repeat forms a parallel coiled coil.	ROCKEFELLER UNIV, MOLEC BIOPHYS LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST LAB, NEW YORK, NY 10021 USA; KAPLAN CANC CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA; NYU MED CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10016 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; New York University				Ziff, Edward/0000-0001-7389-8649; Burley, Stephen K./0000-0002-2487-9713				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; [Anonymous], 1989, EMBO J, V8, P1; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR V 3 0 MANUAL; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS LJ, 1993, ONCOGENE, V8, P125; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FINKELSTEIN KD, 1992, REV SCI INSTRUM, V63, P305, DOI 10.1063/1.1142976; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER F, 1991, ONCOGENE, V6, P1099; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	66	628	639	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	1993	363	6424					38	45		10.1038/363038a0	http://dx.doi.org/10.1038/363038a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479534				2022-12-28	WOS:A1993LA68200050
J	ROSS, R				ROSS, R			THE PATHOGENESIS OF ATHEROSCLEROSIS - A PERSPECTIVE FOR THE 1990S	NATURE			English	Review							SMOOTH-MUSCLE CELLS; LOW-DENSITY-LIPOPROTEIN; FIBROBLAST GROWTH-FACTOR; FAT-FED RABBITS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HERITABLE HYPERLIPIDEMIC RABBIT; LOW-LEVEL HYPERCHOLESTEROLEMIA; VASCULAR ENDOTHELIAL-CELLS; HUMAN CORONARY-ARTERIES; MACROPHAGE-RICH AREAS	Atherosclerosis, the principal cause of heart attack, stroke and gangrene of the extremities, is responsible for 50% of all mortality in the USA, Europe and Japan. The lesions result from an excessive, inflammatory-fibroproliferative response to various forms of insult to the endothelium and smooth muscle of the artery wall. A large number of growth factors, cytokines and vasoregulatory molecules participate in this process. Our ability to control the expression of genes encoding these molecules and to target specific cell types provides opportunities to develop new diagnostic and therapeutic agents to induce the regression of the lesions and, possibly, to prevent their formation.			ROSS, R (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PATHOL, SM-30, SEATTLE, WA 98195 USA.		Tanaka, Gohichi/A-1684-2010					AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BAIRD A, 1990, PEPTIDE GROWTH FACTO, P369; BANSKOTA NK, 1989, MOL ENDOCRINOL, V3, P1183, DOI 10.1210/mend-3-8-1183; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Botting R, 1989, Arch Mal Coeur Vaiss, V82 Spec No 4, P11; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPBELL GR, 1988, ARCH PATHOL LAB MED, V112, P977; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHAUDHURY AR, 1991, J CELL BIOCHEM, V47, P224; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DARTSCH PC, 1989, ATHEROSCLEROSIS, V80, P149, DOI 10.1016/0021-9150(89)90023-3; DAVIES MJ, 1988, BRIT HEART J, V60, P459; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES PF, 1986, LAB INVEST, V55, P5; DZAU VJ, 1990, J CARDIOVASC PHARM, V15, pS59, DOI 10.1097/00005344-199000155-00009; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FERRELL M, 1992, CIRCULATION, V85, P1630, DOI 10.1161/01.CIR.85.4.1630; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FOLKMAN J, 1988, AM J PATHOL, V130, P393; French J E, 1966, Int Rev Exp Pathol, V5, P253; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FUSTER V, 1992, ENGL J MED, V326, P242; GERRITY RG, 1985, ARTERIOSCLEROSIS, V5, P55, DOI 10.1161/01.ATV.5.1.55; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GORDON D, 1989, THROMB HAEMOSTASIS, V62, P131; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GOWN AM, 1986, AM J PATHOL, V125, P191; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HAJJAR KA, 1987, J EXP MED, V166, P235, DOI 10.1084/jem.166.1.235; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HULTGARDHNILSSON A, 1991, DIFFERENTIATION, V47, P99, DOI 10.1111/j.1432-0436.1991.tb00227.x; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LIBBY P, 1989, AM REV RESPIR DIS, V140, P1114, DOI 10.1164/ajrccm/140.4.1114; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LIBBY P, 1986, AM J PATHOL, V124, P179; LIBBY P, 1991, LAB INVEST, V64, P5; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOSKUTOFF DJ, 1990, ANN NY ACAD SCI, V598, P238, DOI 10.1111/j.1749-6632.1990.tb42296.x; LUSCHER TF, 1990, AM J HYPERTENS, V3, P317, DOI 10.1093/ajh/3.4.317; MAJESKY MW, 1990, J BIOL CHEM, V265, P1082; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MINICK CR, 1979, AM J PATHOL, V96, P673; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MONCADA S, 1986, CLIN HAEMATOL, V15, P273; MONCADA S, 1990, NITRICOXIDE L ARGINI; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; MORISAKI N, 1988, ATHEROSCLEROSIS, V71, P165, DOI 10.1016/0021-9150(88)90140-2; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1987, J CELL PHYSIOL, P1, DOI 10.1002/jcp.1041330403; MUNRO JM, 1988, LAB INVEST, V58, P249; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; NILSSON J, 1986, ATHEROSCLEROSIS, V62, P185, DOI 10.1016/0021-9150(86)90093-6; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PALMBERG L, 1987, J CELL SCI, V88, P151; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSENBERG RD, 1985, FED PROC, V44, P404; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P24, DOI 10.1161/01.ATV.7.1.24; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; ROSENFELD ME, 1990, TOXICOL PATHOL, V18, P560; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1984, AM J PATHOL, V114, P79; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; ROSS R, 1976, SCIENCE, V193, P1094, DOI 10.1126/science.822515; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; RUBIN K, 1988, LANCET, V1, P1353; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS WA, 1985, ANN NY ACAD SCI, V454, P305, DOI 10.1111/j.1749-6632.1985.tb11870.x; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TOLINS JP, 1991, HYPERTENSION, V17, P909, DOI 10.1161/01.HYP.17.6.909; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; Virchow R., 1856, GESAMM ABHANDL WISSE, P458; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; 1985, WHO TECH REP SERV, V143, P1	128	9510	10127	20	1021	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1993	362	6423					801	809		10.1038/362801a0	http://dx.doi.org/10.1038/362801a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479518				2022-12-28	WOS:A1993KZ56300045
J	RYAN, M				RYAN, M			RUSSIAN REPORT - PERSONALIA AND THE CURRENT HEALTH CRISIS	BRITISH MEDICAL JOURNAL			English	Article								Recent changes in the Russian government introduced by Boris Yeltsin include the appointment of Eduard Nechaev as health minister at the beginning of this year. The appointment received little publicity in the West, although his predecessor was sacked after only one year for failing to make any effort to improve health care. The challenges facing the new minister are enormous. Not only does he have to introduce a new medical insurance system but he has to tackle the problems of falling population, rising childhood illness linked to poor diet, and the spread of polio and diphtheria. It remains to be seen whether his experience in the military medical service has equipped him for the job.			RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							RYAN M, IN PRESS SOCIAL TREN	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					909	911		10.1136/bmj.306.6882.909	http://dx.doi.org/10.1136/bmj.306.6882.909			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490420	Bronze, Green Published			2022-12-28	WOS:A1993KW38700028
J	KINLEN, LJ; OBRIEN, F; CLARKE, K; BALKWILL, A; MATTHEWS, F				KINLEN, LJ; OBRIEN, F; CLARKE, K; BALKWILL, A; MATTHEWS, F			RURAL-POPULATION MIXING AND CHILDHOOD LEUKEMIA - EFFECTS OF THE NORTH-SEA-OIL INDUSTRY IN SCOTLAND, INCLUDING THE AREA NEAR DOUNREAY NUCLEAR SITE	BRITISH MEDICAL JOURNAL			English	Article							INFECTIOUS-DISEASES; LEUKEMIA; CHILDREN; VIRUS	Objective-To determine if any excess of childhood leukaemia and non-Hodgkin's lymphoma was associated with certain striking examples of population mixing in rural Scotland produced by the North Sea oil industry. Design-Details were traced for over 30 000 workers involved in the construction of the large oil terminals in the Shetland and Orkney islands in northern Scotland or employed offshore. Home addresses of the 17 160 Scottish residents were postcoded, integrated with census data, and then classified as urban or rural. Rural postcode sectors, ranked by proportion of oil workers, were grouped into three categories with similar numbers of children but contrasting densities of oil workers. The incidence of leukaemia and non-Hodgkin's lymphoma was examined in these rural (and also in urban) categories in the periods 1974-8, 1979-83 and 1984-8. Setting-Scotland. Subjects-Young people below age 25. Results-A significant excess of leukaemia and non-Hodgkin's lymphoma was found in 1979-83 in the group of rural home areas with the largest proportion of oil workers, following closely on large increases in the workforce. The area near the Dounreay nuclear installation, where an excess of leukaemia is already well known, was within the rural high oil category. Conclusion-The findings support the infection hypothesis that population mixing can increase the incidence of childhood leukaemia in rural areas. They also suggest that the recent excess in the Dounreay-Thurso area is due to population mixing linked to the oil industry, promoted by certain unusual local demographic factors.	INST CANC RES,DIV EPIDEMIOL,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.		Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388; Balkwill, Angela/0000-0002-6327-6245				ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; ALEXANDER FE, 1992, BRIT J CANCER, V65, P589, DOI 10.1038/bjc.1992.119; ALVAREZ A, 1986, OFFSHORE N SEA JOURN; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BLACK RJ, 1992, BRIT MED J, V304, P1401, DOI 10.1136/bmj.304.6839.1401; BOLIN SR, 1985, AM J VET RES, V46, P573; BRESLOW NE, 1987, IARC SCI PUBL, V82, P95; CARR BJ, 1982, P I MECH ENG, V196, P239; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; GRANT CK, 1980, CANCER RES, V40, P823; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MACGREGOR JD, 1981, BRIT MED J, V282, P434, DOI 10.1136/bmj.282.6262.434; MACGREGOR JD, 1980, 8021 COMM DIS SCOTL; Miles A, 1983, TOPLEY WILSONS PRINC, V1, P413; ONIONS DE, 1987, CANCER SURV, V6, P161; Topley WWC, 1942, PROC R SOC SER B-BIO, V130, P337, DOI 10.1098/rspb.1942.0005; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, 2ND COMM MED ASP RAD; 1981, SULLOM VOE SCENE	25	84	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					743	748		10.1136/bmj.306.6880.743	http://dx.doi.org/10.1136/bmj.306.6880.743			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490337	Green Published, Bronze			2022-12-28	WOS:A1993KU17300019
J	PARKES, JD				PARKES, JD			ABC OF SLEEP DISORDERS - DAYTIME SLEEPINESS	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	PARKES, JD (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,LONDON SE5 8RX,ENGLAND.								0	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					772	775		10.1136/bmj.306.6880.772	http://dx.doi.org/10.1136/bmj.306.6880.772			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490342	Green Published, Bronze			2022-12-28	WOS:A1993KU17300031
J	FOON, KA; THIRUVENGADAM, R; SAVEN, A; BERNSTEIN, ZP; GALE, RP				FOON, KA; THIRUVENGADAM, R; SAVEN, A; BERNSTEIN, ZP; GALE, RP			GENETIC RELATEDNESS OF LYMPHOID MALIGNANCIES - TRANSFORMATION OF CHRONIC LYMPHOCYTIC-LEUKEMIA AS A MODEL	ANNALS OF INTERNAL MEDICINE			English	Review						LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; GENE REARRANGEMENT	B-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; IMMUNOGLOBULIN LIGHT-CHAINS; NERVOUS-SYSTEM LYMPHOMA; NON-HODGKINS LYMPHOMA; SINGLE CLONAL ORIGIN; ACUTE BLAST CRISIS; C-MYC ONCOGENE; RICHTERS SYNDROME; MULTIPLE-MYELOMA	Objective: Studies concerning the genetic relatedness between chronic lymphocytic leukemia and the more aggressive B-cell cancers that develop in about 10% of affected persons were reviewed. These B-cell cancers include large B-cell lymphoma (the Richter syndrome), prolymphocytic transformation, acute lymphoblastic leukemia, and multiple myeloma. Two possible relations were evaluated: development from the chronic lymphocytic leukemia clone (clonal evolution) and development of a genetically unrelated, independent second cancer. Data Sources: An English-language medical literature search was done using MEDLINE (1982 to 1992) and CANCERLIT (1982 to 1992). An extensive manual search of the literature that included meeting abstracts and reports was also done. Approximately 500 articles, abstracts, and book chapters were identified; 102 were selected for detailed analysis. Data Analysis: Analysis of genetic relatedness between the two cancers considered concordance for immunoglobulin gene rearrangements, for immunoglobulin isotypes and idiotypes, and for cytogenetic abnormalities. Conclusions: In the case of large B-cell lymphoma, generally thought to arise from the chronic lymphocytic leukemia clone, approximately one half of the patients had genetically unrelated cancers. In prolymphocytic transformation, all cases studied appeared to evolve from the chronic lymphocytic leukemia clone. The few studies of acute lymphoblastic leukemia and multiple myeloma showed genetic relatedness in some cases and unrelatedness in others. These data indicate that progression to more aggressive B-cell cancers in persons with chronic lymphocytic leukemia can result from either clonal evolution or from an independent transforming event.	UNIV KENTUCKY, DEPT MED, DIV HEMATOL & ONCOL, LEXINGTON, KY 40506 USA; SCRIPPS CLIN & RES FDN, LA JOLLA, CA 92037 USA; ROSWELL PK CANC INST, BUFFALO, NY USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of Kentucky; Scripps Research Institute; Roswell Park Cancer Institute; University of California System; University of California Los Angeles	FOON, KA (corresponding author), UNIV KENTUCKY, MARKEY CANC CTR, 800 ROSE ST, ROOM 140, LEXINGTON, KY 40536 USA.							ARMITAGE JO, 1978, CANCER, V41, P422, DOI 10.1002/1097-0142(197802)41:2<422::AID-CNCR2820410207>3.0.CO;2-X; BALTIMORE D, 1981, CELL, V26, P295, DOI 10.1016/0092-8674(81)90196-3; BAYLISS KM, 1990, AM J CLIN PATHOL, V93, P117, DOI 10.1093/ajcp/93.1.117; BERNARD DJ, 1991, CANCER, V67, P997, DOI 10.1002/1097-0142(19910215)67:4<997::AID-CNCR2820670423>3.0.CO;2-L; BERTOLI LF, 1987, BLOOD, V70, P45; BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BRECHER M, 1990, AM J CLIN PATHOL, V93, P333, DOI 10.1093/ajcp/93.3.333; BROUET JC, 1985, BRIT J HAEMATOL, V59, P55, DOI 10.1111/j.1365-2141.1985.tb02963.x; BROUET JC, 1973, BMJ-BRIT MED J, V4, P23, DOI 10.1136/bmj.4.5883.23; BROWETT PJ, 1988, BRIT J HAEMATOL, V70, P126, DOI 10.1111/j.1365-2141.1988.tb02446.x; CHATTERJEE M, 1990, BLOOD, V76, P1825; CLEARY ML, 1988, J EXP MED, V167, P582, DOI 10.1084/jem.167.2.582; COOPER MD, 1985, LEUKEMIA RECENT ADV, P453; COSSMAN J, 1984, J CLIN INVEST, V73, P587, DOI 10.1172/JCI111247; COSSMAN J, 1988, ARCH PATHOL LAB MED, V112, P117; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DICK FR, 1978, CANCER, V41, P283, DOI 10.1002/1097-0142(197801)41:1<283::AID-CNCR2820410140>3.0.CO;2-H; FERMAND JP, 1985, BLOOD, V66, P291; FITZGERALD PH, 1973, BRIT J HAEMATOL, V25, P171, DOI 10.1111/j.1365-2141.1973.tb01727.x; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FRENKEL EP, 1981, AM J HEMATOL, V10, P391, DOI 10.1002/ajh.2830100409; FRIZZERA G, 1981, CANCER RES, V41, P4262; FU SM, 1978, J EXP MED, V148, P1570, DOI 10.1084/jem.148.6.1570; GHANI AM, 1986, CANCER, V57, P75, DOI 10.1002/1097-0142(19860101)57:1<75::AID-CNCR2820570116>3.0.CO;2-X; GORDON J, 1984, J IMMUNOL, V132, P541; HAN T, 1984, J CLIN ONCOL, V2, P1121, DOI 10.1200/JCO.1984.2.10.1121; HAN T, 1987, SEMIN HEMATOL, V24, P257; HANTO DW, 1982, NEW ENGL J MED, V306, P913, DOI 10.1056/NEJM198204153061506; HAROUSSEAU JL, 1981, CANCER-AM CANCER SOC, V48, P1302, DOI 10.1002/1097-0142(19810915)48:6<1302::AID-CNCR2820480609>3.0.CO;2-Q; HIETER PA, 1981, NATURE, V290, P368, DOI 10.1038/290368a0; HOFFMANN KD, 1977, ARCH INTERN MED, V137, P232, DOI 10.1001/archinte.137.2.232; IFRAH N, 1987, EUR J HAEMATOL, V39, P376; JEHA MT, 1981, BLOOD, V57, P617; JONCAS JH, 1990, J CLIN ONCOL, V8, P378, DOI 10.1200/JCO.1990.8.3.378; JULIUSSON G, 1983, SCAND J IMMUNOL, V17, P51, DOI 10.1111/j.1365-3083.1983.tb00765.x; JULIUSSON G, 1985, BLOOD, V65, P134; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KATAYAMA I, 1980, AM J PATHOL, V99, P399; KAY NE, 1986, BRIT J HAEMATOL, V63, P389, DOI 10.1111/j.1365-2141.1986.tb05564.x; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; KJELDSBERG CR, 1981, CANCER, V48, P2447, DOI 10.1002/1097-0142(19811201)48:11<2447::AID-CNCR2820481118>3.0.CO;2-B; KORSMEYER SJ, 1981, P NATL ACAD SCI-BIOL, V78, P7096, DOI 10.1073/pnas.78.11.7096; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LANE PK, 1988, AM J CLIN PATHOL, V89, P254, DOI 10.1093/ajcp/89.2.254; LAURENT G, 1981, ACTA HAEMATOL-BASEL, V65, P60, DOI 10.1159/000207150; LEVY R, 1987, IMMUNOL REV, V96, P43, DOI 10.1111/j.1600-065X.1987.tb00508.x; LONG JC, 1975, AM J CLIN PATHOL, V63, P786; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MCDONNELL JM, 1986, CANCER, V58, P2031, DOI 10.1002/1097-0142(19861101)58:9<2031::AID-CNCR2820580913>3.0.CO;2-J; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MELO JV, 1986, BRIT J HAEMATOL, V64, P77, DOI 10.1111/j.1365-2141.1986.tb07575.x; MICHIELS JJ, 1989, LEUKEMIA, V3, P819; MILLER ALC, 1984, LEUKEMIA RES, V8, P905, DOI 10.1016/0145-2126(84)90111-5; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MILLER RA, 1989, NEW ENGL J MED, V321, P851, DOI 10.1056/NEJM198909283211302; MIYAMURA K, 1990, CANCER, V66, P140, DOI 10.1002/1097-0142(19900701)66:1<140::AID-CNCR2820660125>3.0.CO;2-I; MONFORTE R, 1988, ACTA HAEMATOL-BASEL, V80, P116, DOI 10.1159/000205615; NOVICE FM, 1989, INT J DERMATOL, V28, P36, DOI 10.1111/j.1365-4362.1989.tb01307.x; NOWELL P, 1981, BLOOD, V58, P183; OKAMURA J, 1982, J IMMUNOL, V128, P2276; ONEILL BP, 1989, CANCER-AM CANCER SOC, V64, P1296, DOI 10.1002/1097-0142(19890915)64:6<1296::AID-CNCR2820640621>3.0.CO;2-E; OSTROWSKI M, 1989, AM J CLIN PATHOL, V91, P215, DOI 10.1093/ajcp/91.2.215; PARKER BA, 1990, BLOOD S, V76, pA367; PEDERSENBJERGAARD J, 1978, SCAND J HAEMATOL, V21, P256; PINES A, 1984, CANCER-AM CANCER SOC, V54, P1904, DOI 10.1002/1097-0142(19841101)54:9<1904::AID-CNCR2820540921>3.0.CO;2-E; PISTOIA V, 1991, BLOOD, V78, P797, DOI 10.1182/blood.V78.3.797.bloodjournal783797; PITTMAN S, 1983, CANCER GENET CYTOGEN, V9, P355, DOI 10.1016/0165-4608(83)90084-5; PITTMAN S, 1984, BRIT J HAEMATOL, V58, P649, DOI 10.1111/j.1365-2141.1984.tb06112.x; PREUDHOMME JL, 1972, BLOOD-J HEMATOL, V40, P777, DOI 10.1182/blood.V40.6.777.777; PURTILO DT, 1980, LANCET, V1, P300; RAGHAVACHAR A, 1987, BLOOD, V70, P1079; Richter MN, 1928, AM J PATHOL, V4, P285; ROBERT KH, 1983, SCAND J IMMUNOL, V17, P397, DOI 10.1111/j.1365-3083.1983.tb00805.x; RUDIKOFF S, 1984, P NATL ACAD SCI US, V81; SALTMAN DL, 1989, BLOOD, V74, P2062; SIEGELMAN MH, 1985, J EXP MED, V161, P850, DOI 10.1084/jem.161.4.850; SNYDER LS, 1988, AM REV RESPIR DIS, V138, P980, DOI 10.1164/ajrccm/138.4.980; STARK AN, 1986, LEUKEMIA RES, V10, P1225, DOI 10.1016/0145-2126(86)90241-9; SUN T, 1990, HUM PATHOL, V21, P722, DOI 10.1016/0046-8177(90)90032-Z; TEILLAUD JL, 1983, SCIENCE, V222, P721, DOI 10.1126/science.6356353; TOHDA S, 1990, AM J HEMATOL, V35, P32, DOI 10.1002/ajh.2830350108; TORELLI UL, 1987, BRIT J HAEMATOL, V65, P165, DOI 10.1111/j.1365-2141.1987.tb02259.x; TOTTERMAN TH, 1980, NATURE, V288, P176, DOI 10.1038/288176a0; TRUMP DL, 1980, AM J MED, V68, P539, DOI 10.1016/0002-9343(80)90300-9; TRUMPER L, 1988, KLIN WOCHENSCHR, V66, P736, DOI 10.1007/BF01726417; VANDONGEN JJM, 1984, BLOOD, V64, P571; VANENDERT PM, 1990, BRIT J CANCER, V62, P248, DOI 10.1038/bjc.1990.269; VILLALONACALERO M, 1991, P AN M AM SOC CLIN, V10, P230; WALDMANN TA, 1985, ANN INTERN MED, V102, P497, DOI 10.7326/0003-4819-102-4-497; WICK MR, 1980, MAYO CLIN PROC, V55, P108; WILLIAMS J, 1991, AM J SURG PATHOL, V15, P33, DOI 10.1097/00000478-199101000-00004; WRIGHT JJ, 1987, J CLIN ONCOL, V5, P735, DOI 10.1200/JCO.1987.5.5.735; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZARRABI MH, 1977, ARCH INTERN MED, V137, P1059, DOI 10.1001/archinte.137.8.1059; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904	102	63	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					63	73		10.7326/0003-4819-119-1-199307010-00011	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498765				2022-12-28	WOS:A1993LJ26600011
J	BREKKE, OH; MICHAELSEN, TE; SANDIN, R; SANDLIE, I				BREKKE, OH; MICHAELSEN, TE; SANDIN, R; SANDLIE, I			ACTIVATION OF COMPLEMENT BY AN IGG MOLECULE WITHOUT A GENETIC HINGE	NATURE			English	Article							SEGMENTAL FLEXIBILITY; 3-DIMENSIONAL STRUCTURE; IMMUNOGLOBULIN-G; CHIMERIC HUMAN; C1Q BINDING; ANTIBODIES; EXPRESSION; REGION; SITE	THE hinge region links the two Fab arms to the Fc portion of the IgG molecule. It mediates flexibility to the molecule and serves as a connecting structure between the two heavy chains. In addition it provides space between the Fab and Fc parts. All three properties have been proposed to be important for the ability of IgG to initiate complement activation leading to complement-mediated cell lysis (CML)1. Here we report the construction of a hinge-deleted mouse-human chimaeric IgG3 molecule with specificity for the hapten NIP (3-iodo-4-hydroxy-5-nitrophenacetyl), HM-1. HM-1 lacks the genetic hinge, but has an introduced cysteine between Ala 231 (EU numbering) and Pro 232 in the lower hinge encoded by the C(H)2 exon. The introduced cysteine forms a disulphide bond between the two heavy chains of the molecule. In CML, HM-1 shows a greater activity than IgG3 wild type. This is the first time an IgG molecule without a genetic hinge has been found to be active in CML. We conclude that the hinge functioning as a spacer is not a prerequisite for complement activation. Rather, its major role seems to be to connect the heavy chains to each other in the amino-terminal part of C(H)2. Because HM-1 is expected to have low Fab-Fc flexibility, this molecular feature is probably of no importance for complement activation.	UNIV OSLO,DEPT BIOL,POB 1050,N-0316 BLINDERN,NORWAY; NATL INST PUBL HLTH,N-0462 OSLO,NORWAY	University of Oslo				Michaelsen, Terje Einar/0000-0001-8877-8519				AASE A, IN PRESS J IMMUNOL; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DEUTSCH HF, 1971, J IMMUNOL, V107, P929; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; ITO W, 1985, BIOCHEMISTRY-US, V24, P6467, DOI 10.1021/bi00344a024; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MICHAELSEN TE, 1990, SCAND J IMMUNOL, V32, P517, DOI 10.1111/j.1365-3083.1990.tb03192.x; MICHAELSEN TE, 1976, SCAND J IMMUNOL, V5, P1123; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Nezlin R, 1990, Adv Immunol, V48, P1, DOI 10.1016/S0065-2776(08)60750-6; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RAJAN SS, 1983, MOL IMMUNOL, V20, P787, DOI 10.1016/0161-5890(83)90057-3; SANDLIE I, 1989, EUR J IMMUNOL, V19, P1599, DOI 10.1002/eji.1830190912; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SEEGAN GW, 1979, P NATL ACAD SCI USA, V76, P907, DOI 10.1073/pnas.76.2.907; SILVERTON EW, 1977, P NATL ACAD SCI USA, V74, P5140, DOI 10.1073/pnas.74.11.5140; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162	25	35	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					628	630		10.1038/363628a0	http://dx.doi.org/10.1038/363628a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510754				2022-12-28	WOS:A1993LH13900056
J	GRUNDY, SM; BILHEIMER, D; CHAIT, A; CLARK, LT; DENKE, M; HAVEL, RJ; HAZZARD, WR; HULLEY, SB; HUNNINGHAKE, DB; KREISBERG, RA; KRISETHERTON, P; MCKENNEY, JM; NEWMAN, MA; SCHAEFER, EJ; SOBEL, BE; SOMELOFSKI, C; WEINSTEIN, MC; BREWER, HB; CLEEMAN, JI; DONATO, KA; ERNST, N; HOEG, JM; RIFKIND, BM; ROSSOUW, J; SEMPOS, CT; GALLIVAN, JM; HARRIS, MN; QUINTADLER, L				GRUNDY, SM; BILHEIMER, D; CHAIT, A; CLARK, LT; DENKE, M; HAVEL, RJ; HAZZARD, WR; HULLEY, SB; HUNNINGHAKE, DB; KREISBERG, RA; KRISETHERTON, P; MCKENNEY, JM; NEWMAN, MA; SCHAEFER, EJ; SOBEL, BE; SOMELOFSKI, C; WEINSTEIN, MC; BREWER, HB; CLEEMAN, JI; DONATO, KA; ERNST, N; HOEG, JM; RIFKIND, BM; ROSSOUW, J; SEMPOS, CT; GALLIVAN, JM; HARRIS, MN; QUINTADLER, L			SUMMARY OF THE 2ND REPORT OF THE NATIONAL-CHOLESTEROL-EDUCATION-PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT-TREATMENT-PANEL-II)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NHLBI,NATL CHOLESTEROL EDUC PROGRAM,BLDG 31,ROOM 4A-05,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793					0	2292	2331	0	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3015	3023		10.1001/jama.1993.03500230097036	http://dx.doi.org/10.1001/jama.1993.03500230097036			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501844				2022-12-28	WOS:A1993LF94100031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA WARNS HEARING-AID MANUFACTURERS TO AVOID MISLEADING ADVERTISING CLAIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2964	2964						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501827				2022-12-28	WOS:A1993LF94100005
J	IONOV, Y; PEINADO, MA; MALKHOSYAN, S; SHIBATA, D; PERUCHO, M				IONOV, Y; PEINADO, MA; MALKHOSYAN, S; SHIBATA, D; PERUCHO, M			UBIQUITOUS SOMATIC MUTATIONS IN SIMPLE REPEATED SEQUENCES REVEAL A NEW MECHANISM FOR COLONIC CARCINOGENESIS	NATURE			English	Article							ARBITRARY PRIMERS; CHAIN-REACTION; DNA; POLYMORPHISMS; MUTAGENESIS; INVITRO; CANCER	SPONTANEOUS errors in DNA replication have been suggested to play a significant role in neoplastic transformation and to explain the chromosomal alterations seen in cancer cells1. A defective replication factor could increase the mutation rate in clonal variants arising during tumour progression, but despite intensive efforts, increases in tumour cell mutation rates have not been unambiguously shown2. Here we use an unbiased genomic fingerprinting technique3 to show that 12 per cent of colorectal carcinomas carry somatic deletions in poly(dA . dT) sequences and other simple repeats. We estimate that cells from these tumours can carry more than 100,000 such mutations. Only tumours with affected poly(dA . dT) sequences carry mutations in the other simple repeats examined, and such mutations can be found in all neoplastic regions of multiple tumours from the same patient, including adenomas. Tumours with these mutations show distinctive genotypic and phenotypic features. We conclude that these mutations reflect a previously undescribed form of carcinogenesis in the colon (predisposition to which may be inherited) mediated by a mutation in a DNA replication factor resulting in reduced fidelity for replication or repair (a 'mutator mutation').	CALIF INST BIOL RES,11099 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033	University of Southern California			Peinado, Miguel A./A-5591-2008	Peinado, Miguel A./0000-0002-4090-793X; Perucho, Manuel/0000-0002-2169-2662				ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS CC, 1991, CANCER RES, V51, pS5023; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KAHN S, 1987, ANTICANCER RES, V7, P639; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOEB LA, 1974, CANCER RES, V34, P2311; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PEINADO MA, 1993, INT J ONCOL, V2, P123; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SHIBATA D, IN PRESS J NATN CANC; SHIBATA D, 1992, AM J PATHOL, V141, P1; SINNETT D, 1990, GENOMICS, V7, P331, DOI 10.1016/0888-7543(90)90166-R; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUGARBAKER P, 1985, CANCER PRINCIPLES PR, P814; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	23	2347	2414	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					558	561		10.1038/363558a0	http://dx.doi.org/10.1038/363558a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505985				2022-12-28	WOS:A1993LF93900055
J	PAGEL, M				PAGEL, M			HONEST SIGNALING AMONG GAMETES	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; A-FACTOR; ALPHA-FACTOR; YEAST; COURTSHIP; SELECTION; INDUCTION; PARTNERS; GENE	THE gametes of many lower eukaryotic organisms emit pheromones that attract gametes of the opposite mating type or sex1-4. Gametes move or grow in the direction of the highest pheromone concentration, suggesting that the strength of the pheromonal signal is used to infer proximity, or that the strongest signal is most likely to be noticed. Here I offer a new explanation of pheromonal signalling and chemotaxis in gametes. I show that pheromonal signals can be interpreted as sexually selected traits that honestly advertise variation in quality among gametes, given that signals are costly to produce and that gametes compete; by 'quality' I refer to some aspect of a gamete's fitness. A gamete's preference for a mating partner, then, is predicted to vary with the quality of a prospective partner as inferred from the strength of its signal. This view can explain characteristics of the signalling and mate selection behaviours of gametes that are not predicted by models of mate choice based on proximity or 'passive attraction' to the strongest signal5. These include repeated partner exchanges2, escalated exchanges of mating pheromones6-9, and rejection of gametes that signal at low levels8,9.			PAGEL, M (corresponding author), UNIV LONDON, QUEEN MARY & WESTFIELD COLL, SCH MATH SCI, LONDON E1 4NS, ENGLAND.							ACHSTETTER T, 1989, MOL CELL BIOL, V9, P4507, DOI 10.1128/MCB.9.10.4507; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSSON M, 1986, EVOLUTION, V40, P804, DOI 10.1111/j.1558-5646.1986.tb00540.x; CRANDALL M, 1977, RECEPTORS RECOGNITIO, P45; CRANDALL M, 1978, S SOC EXPT BIOL CELL, P105; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; MACHLIS L, 1973, PLANT PHYSIOL, V52, P527, DOI 10.1104/pp.52.6.527; MASCARENHAS JP, 1978, RECEPTORS RECOGNIT B, P169; Maynard Smith J., 1982, pi; Miller R.L., 1985, P275; MUSGRAVE A, 1987, TRENDS BIOCHEM SCI, V12, P470, DOI 10.1016/0968-0004(87)90232-5; Parker G.A., 1982, P173; Pomiankowski A.N., 1988, Oxford Surveys in Evolutionary Biology, V5, P136; POMMERVILLE J, 1977, EXP CELL RES, V109, P43, DOI 10.1016/0014-4827(77)90042-8; STRAZDIS JR, 1983, NATURE, V305, P543, DOI 10.1038/305543a0; WIESE L, 1978, S SOC EXPT BIOL CELL, P83; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	23	30	31	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					539	541		10.1038/363539a0	http://dx.doi.org/10.1038/363539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505979				2022-12-28	WOS:A1993LF93900048
J	BRAUN, MM; COTE, TR; RABKIN, CS				BRAUN, MM; COTE, TR; RABKIN, CS			TRENDS IN DEATH WITH TUBERCULOSIS DURING THE AIDS ERA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; INFECTION; EPIDEMIC; MORTALITY; IMPACT	Objective.-To describe and analyze recent changes in tuberculosis mortality in the United States during the acquired immunodeficiency syndrome (AIDS) epidemic. Design.-We used National Center for Health Statistics multiple-cause mortality data and analyzed deaths with tuberculosis (1980 through 1990) and/or AIDS (1987 through 1990) as an underlying or associated cause. We also categorized the 50 states and the District of Columbia into high (five states), medium (23 states), and low (23 states) AIDS incidence groups and then compared the groups' rates of death with tuberculosis during the period 1980 through 1990. Study Population.-Residents of the United States who died in the period 1980 through 1990. Main Outcome Measures.-Death certificates indicating AIDS and/or tuberculosis. Results.-A bimodal age distribution of persons dying with tuberculosis has emerged concurrent with the AIDS epidemic. A new peak spanning the ages 20 to 49 years accompanies the preexisting peak in the elderly. In 1990, 54.2% (729/1344) of the deaths with tuberculosis in persons 20 to 49 years of age occurred in persons who also had AIDS listed on their death certificates. During the period 1987 through 1990, there was an increasing trend in the proportion of AIDS deaths that also had tuberculosis: 2.3% (353/15 075) in 1987, 2.5% (460/18 649) in 1988, 3.0% (738/24 607) in 1989, and 3.0% (836/27 975) in 1990 (P<.001). Of AIDS deaths in 1990, 1.6% (253/15 565) of whites died with tuberculosis, compared with 4.7% (400/8533) of blacks (P<.001) and 4.7% (172/3666) of Hispanics (P<.001). In the high AIDS incidence states, the rate of death with tuberculosis in persons aged 20 to 49 years rose from 0.61 to 2.82 per 100 000 population in the period 1982 through 1990, an increase of 362%. For this age group in the states with medium and low AIDS incidence, the rates of death with tuberculosis during this period rose 52% and 47% (from 0.44 to 0.67 and from 0.19 to 0.28 per 100 000 population), respectively. The increases in the rate of death with tuberculosis within all three groups and the differences among the groups were all highly statistically significant (P<.001). Conclusion.-The AIDS epidemic has significantly increased the number and rate of tuberculosis deaths in younger adults through 1990, although in this study discrimination of deaths due to tuberculosis from deaths with tuberculosis was not possible. Vigorous efforts to prevent and treat tuberculosis and AIDS are indicated to reverse the trends we have described.	NCI,ENVIRONM EPIDEMIOL BRANCH,ENVIRONM STUDIES SECT,BETHESDA,MD 20892; NCI,VIRAL STUDIES SECT,BETHESDA,MD 20892; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								[Anonymous], 1992, MMWR Recomm Rep, V41, P51; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; CASTRO KG, 1992, MMWR MORB MORTAL WKL, V41, P6; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732	24	64	67	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2865	2868		10.1001/jama.269.22.2865	http://dx.doi.org/10.1001/jama.269.22.2865			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497090				2022-12-28	WOS:A1993LE93600022
J	LONG, SR; STASKAWICZ, BJ				LONG, SR; STASKAWICZ, BJ			PROKARYOTIC PLANT PARASITES	CELL			English	Article							CLONED AVIRULENCE GENES; SYRINGAE PV GLYCINEA; PSEUDOMONAS-SYRINGAE; RHIZOBIUM-MELILOTI; AGROBACTERIUM-TUMEFACIENS; MOLECULAR CHARACTERIZATION; CULTIVAR SPECIFICITY; MICROBE INTERACTIONS; NITROGEN-FIXATION; VIRULENCE GENES		UNIV CALIF BERKELEY, DEPT PLANT PATHOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	LONG, SR (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM30962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRON PG, 1992, J BACTERIOL, V174, P4120, DOI 10.1128/jb.174.12.4120-4129.1992; ANKENBAUER RG, 1990, J BACTERIOL, V172, P6442, DOI 10.1128/jb.172.11.6442-6446.1990; ANKENBAUER RG, 1991, MOL PLANT MICROBE IN, V4, P400, DOI 10.1094/MPMI-4-400; ANTHAMATTEN D, 1991, MOL GEN GENET, V225, P38, DOI 10.1007/BF00282640; ARLAT M, 1992, MOL PLANT MICROBE IN, V5, P187, DOI 10.1094/MPMI-5-187; ARLAT M, 1991, MOL PLANT MICROBE IN, V4, P211, DOI 10.1094/MPMI-4-211; ARP DJ, 1992, BIOL NITROGEN FIXATI, P432; BAEV N, 1992, J BACTERIOL, V174, P7555, DOI 10.1128/JB.174.23.7555-7565.1992; BARTA TM, 1992, J BACTERIOL, V174, P3021, DOI 10.1128/JB.174.9.3021-3029.1992; BATTISTI L, 1992, P NATL ACAD SCI USA, V89, P5625, DOI 10.1073/pnas.89.12.5625; BEER SV, 1993, CURR PLANT SCI BIOT, V14, P281; BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BISSELING T, 1992, ADV MOL GENETICS PLA, P365; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BONAS U, 1989, MOL GEN GENET, V218, P127, DOI 10.1007/BF00330575; BOUCHER CA, 1992, ANNU REV PHYTOPATHOL, V30, P443, DOI 10.1146/annurev.py.30.090192.002303; BREEDVELD MW, 1993, J BACTERIOL, V175, P750, DOI 10.1128/JB.175.3.750-757.1993; BREWIN NJ, 1991, ANNU REV CELL BIOL, V7, P191, DOI 10.1146/annurev.cb.07.110191.001203; BREWIN NJ, 1992, ADV MOL GENETICS PLA, P369; BUENDIA AM, 1991, MOL MICROBIOL, V5, P1519, DOI 10.1111/j.1365-2958.1991.tb00799.x; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CASTLE LA, 1992, J BACTERIOL, V174, P1478, DOI 10.1128/jb.174.5.1478-1486.1992; CHANG CH, 1992, J BACTERIOL, V174, P7033, DOI 10.1128/JB.174.21.7033-7039.1992; CHARLES TC, 1992, ANNU REV PHYTOPATHOL, V30, P463, DOI 10.1146/annurev.py.30.090192.002335; CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677; CITOVSKY V, 1992, MOL SIGNALS PLANT MI, P169; CLARKE HRG, 1992, CELL, V71, P191, DOI 10.1016/0092-8674(92)90348-G; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; COPLIN DL, 1992, MOL PLANT MICROBE IN, V5, P266, DOI 10.1094/MPMI-5-266; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; DANIELS MJ, 1993, CURR PLANT SCI BIOT, V14, P423; DEBRUIJN FJ, 1991, CURR OPIN BIOTECH, V2, P184, DOI 10.1016/0958-1669(91)90008-S; DEFEYTER R, 1991, MOL PLANT MICROBE IN, V4, P423, DOI 10.1094/MPMI-4-423; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DEPHILIP P, 1992, MOL GEN GENET, V235, P49, DOI 10.1007/BF00286180; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DILWORTH M, 1984, TRENDS BIOCHEM SCI, V9, P519, DOI 10.1016/0968-0004(84)90280-9; DILWORTH MJ, 1992, BIOL CHEM NITROGEN F; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DJORDJEVIC SP, 1987, J BACTERIOL, V169, P53, DOI 10.1128/jb.169.1.53-60.1987; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; Evans, 1992, BIOL NITROGEN FIXATI, P293; FELLAY R, 1991, ADV MOL GENETICS PLA, P44; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FILLINGHAM AJ, 1992, PHYSIOL MOL PLANT P, V40, P1, DOI 10.1016/0885-5765(92)90066-5; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; Gelvin S.B., 1992, MOL SIGNALS PLANT MI, P137; GELVIN SB, 1990, PLANT PHYSIOL, V92, P281, DOI 10.1104/pp.92.2.281; GENIN S, 1992, MOL MICROBIOL, V6, P3065, DOI 10.1111/j.1365-2958.1992.tb01764.x; GENIN S, 1992, ADV MOL GENETICS PLA, P259; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; Gray J.X., 1992, MOL SIGNALS PLANT MI, P359; GRIMM C, 1991, J BACTERIOL, V173, P575; GROSS DC, 1991, ANNU REV PHYTOPATHOL, V29, P247, DOI 10.1146/annurev.py.29.090191.001335; HAN DC, 1992, J BACTERIOL, V174, P7040, DOI 10.1128/JB.174.21.7040-7043.1992; HAWES M, 1990, PLANT CELL REP, V6, P287; HE SY, 1993, IN PRESS CELL, V73; HENNECKE H, 1992, ADV MOL GENETICS PLA, P199; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; HERRERAESTRELLA A, 1990, P NATL ACAD SCI USA, V87, P9534, DOI 10.1073/pnas.87.24.9534; HIRSCH AM, 1992, NEW PHYTOL, V122, P211, DOI 10.1111/j.1469-8137.1992.tb04227.x; HOPKINS CM, 1992, MOL PLANT MICROBE IN, V5, P451, DOI 10.1094/MPMI-5-451; HOTTER GS, 1991, J BACTERIOL, V173, P851, DOI 10.1128/jb.173.2.851-859.1991; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; HRABAK EM, 1992, APPL ENVIRON MICROB, V58, P1440; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG JZ, 1990, J BACTERIOL, V172, P3879, DOI 10.1128/jb.172.7.3879-3887.1990; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; Kahn M. L., 1985, Nitrogen fixation research progress. Proceedings of the 6th International Symposium on Nitrogen Fixation, Corvallis, OR, USA, August 4-10. 1985., P193; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KAO CC, 1992, J BACTERIOL, V174, P1068, DOI 10.1128/jb.174.3.1068-1071.1992; KEARNEY B, 1988, NATURE, V332, P541, DOI 10.1038/332541a0; KEARNEY B, 1990, NATURE, V346, P385, DOI 10.1038/346385a0; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KEEN NT, 1993, CURR PLANT SCI BIOT, V14, P211; Kijne J.W., 1992, BIOL NITROGEN FIXATI, P349; KIJNE JW, 1992, MOL SIGNALS PLANT MI, P281; Klement Z., 1990, METHODS PHYTOBACTERI, P469; KNIGHT TJ, 1992, MOL SIGNALS PLANT MI, P261; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P94, DOI 10.1094/MPMI-3-094; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; Kondorosi A, 1992, MOL SIGNALS PLANT MI, P325; KOUKOLIKOVANICOLA Z, 1993, J BACTERIOL, V175, P723; LEE KH, 1992, P NATL ACAD SCI USA, V89, P8666, DOI 10.1073/pnas.89.18.8666; LEIGH JA, 1992, ANNU REV MICROBIOL, V46, P307, DOI 10.1146/annurev.mi.46.100192.001515; LESSL M, 1992, J BIOL CHEM, V267, P20471; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; LINDGREN PB, 1988, MOL GEN GENET, V211, P499, DOI 10.1007/BF00425707; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; LOIS AF, 1993, J BACTERIOL, V175, P1103, DOI 10.1128/JB.175.4.1103-1109.1993; Long S. R., 1988, MOL GENETICS PLANT M; LONG SR, 1991, ADV MOL GENETICS PLA, V1, P127; MANTIS NJ, 1992, J BACTERIOL, V174, P1189, DOI 10.1128/jb.174.4.1189-1196.1992; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MARIE C, 1992, MOL MICROBIOL, V6, P843, DOI 10.1111/j.1365-2958.1992.tb01535.x; Merrick M.J., 1992, BIOL NITROGEN FIXATI, P835; MINSAVAGE GV, 1990, MOL PLANT MICROBE IN, V3, P41, DOI 10.1094/MPMI-3-041; MIRANDA A, 1992, J BACTERIOL, V174, P2288, DOI 10.1128/JB.174.7.2288-2297.1992; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MORRIS RO, 1986, ANNU REV PLANT PHYS, V37, P509, DOI 10.1146/annurev.pp.37.060186.002453; MURATA H, 1991, MOL PLANT MICROBE IN, V4, P239, DOI 10.1094/MPMI-4-239; MURPHY M, 1992, MOL SIGNALS PLANT MI, P377; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAZOUR GJ, 1992, J BACTERIOL, V174, P4169, DOI 10.1128/jb.174.12.4169-4174.1992; PETERS NK, 1990, MOL PLANT MICROBE IN, V3, P4, DOI 10.1094/MPMI-3-004; PHILLIPS DA, 1991, RECENT ADV PHYTOCHEM, V26, P1; PIERRE M, 1992, ADV MOL GENETICS PLA, P143; POTRYKUS I, 1991, ANNU REV PLANT PHYS, V42, P205, DOI 10.1146/annurev.pp.42.060191.001225; PRICE NPJ, 1992, IN PRESS MOL MICROBI, V6; RAHME LG, 1992, J BACTERIOL, V174, P5895; REAM W, 1989, ANNU REV PHYTOPATHOL, V27, P583, DOI 10.1146/annurev.py.27.090189.003055; REUBER TL, 1991, BIOCHEM SOC T, V19, P636, DOI 10.1042/bst0190636; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; ROTH L, 1991, MOL GENETICS PLANT M, P24; RUAN XA, 1992, J BACTERIOL, V174, P3467, DOI 10.1128/JB.174.11.3467-3473.1992; SALMERON J, 1993, IN PRESS MOL GEN GEN; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHELL M, 1993, IN PRESS ANN REV MIC; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P6109, DOI 10.1128/JB.174.19.6109-6116.1992; SCHULTE R, 1992, PLANT CELL, V4, P79, DOI 10.1105/tpc.4.1.79; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S; SHARMA SB, 1990, GENE DEV, V4, P344, DOI 10.1101/gad.4.3.344; SINKAR VP, 1987, J BIOSCIENCES, V11, P47, DOI 10.1007/BF02704657; SPAINK HP, 1992, PLANT MOL BIOL, V20, P977, DOI 10.1007/BF00027167; SPENA A, 1992, ADV MOL GENETICS PLA, P109; Stacey G., 1992, BIOL NITROGEN FIXATI; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; SUTTON MJ, 1992, ADV MOL GENETICS PLA, P163; SWANSON JA, 1993, IN PRESS GENETICS; SWARUP S, 1992, MOL PLANT MICROBE IN, V5, P204, DOI 10.1094/MPMI-5-204; TRIPLETT EW, 1992, ANNU REV MICROBIOL, V46, P399, DOI 10.1146/annurev.mi.46.100192.002151; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; URZAINQUI A, 1992, J BACTERIOL, V174, P3403, DOI 10.1128/jb.174.10.3403-3406.1992; VANBRUSSEL AAN, 1992, SCIENCE, V257, P70, DOI 10.1126/science.257.5066.70; VASSE J, 1992, ADV MOL GENETICS PLA, P381; Verma DPS, 1992, MOL SIGNALS PLANT MI; WAGNER VT, 1992, J BACTERIOL, V174, P5999, DOI 10.1128/jb.174.18.5999-6003.1992; WANEY VR, 1991, MOL PLANT MICROBE IN, V4, P623, DOI 10.1094/MPMI-4-623; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WEI ZM, 1992, J BACTERIOL, V174, P1875, DOI 10.1128/jb.174.6.1875-1882.1992; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WEINSTEIN M, 1992, MOL MICROBIOL, V6, P2041, DOI 10.1111/j.1365-2958.1992.tb01377.x; Werner D., 1992, BIOL NITROGEN FIXATI, P399; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; YODER MD, 1993, IN PRESS SCIENCE; YOUNG JPW, 1989, TRENDS ECOL EVOL, V4, P341, DOI 10.1016/0169-5347(89)90089-X; Zambryski PC, 1992, PLANT MOL BIOL, V43, P465	162	131	133	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					921	935		10.1016/0092-8674(93)90271-Q	http://dx.doi.org/10.1016/0092-8674(93)90271-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500181	Bronze			2022-12-28	WOS:A1993LF06100009
J	MATTAJ, IW				MATTAJ, IW			RNA RECOGNITION - A FAMILY MATTER	CELL			English	Review							TAT; PEPTIDES; BINDING; REVEALS; MOTIF				MATTAJ, IW (corresponding author), EUROPEAN MOLEC BIOL LAB,GENE EXPRESS PROGRAMME,W-6900 HEIDELBERG,GERMANY.			Mattaj, Iain/0000-0002-5537-8284				ANDERSON JT, 1993, IN PRESS MOLC ELL BI, V13; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; DREYFUSS G, 1993, IN PRESS ANN REV BIO, V62; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FRANK D, 1992, GENE DEV, V6, P2112, DOI 10.1101/gad.6.11.2112; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIBSON TJ, 1993, IN PRESS FEBS LETT; GIBSON TJ, 1993, IN PRESS TRENDS BIOC, V18; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STJOHNSON D, 1992, P NATL ACAD SCI USA, V869, P10979; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; TAN R, 1993, IN PRESS CELL, V73; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015	32	266	270	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					837	840		10.1016/0092-8674(93)90265-R	http://dx.doi.org/10.1016/0092-8674(93)90265-R			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500177	Bronze			2022-12-28	WOS:A1993LF06100003
J	GRIN, JM; MCCABE, EJ; WHITE, WB				GRIN, JM; MCCABE, EJ; WHITE, WB			MANAGEMENT OF HYPERTENSION AFTER AMBULATORY BLOOD-PRESSURE MONITORING	ANNALS OF INTERNAL MEDICINE			English	Article						BLOOD PRESSURE MONITORS; AMBULATORY CARE; HYPERTENSION; PHYSICIANS PRACTICE PATTERNS; MONITORING, PHYSIOLOGICAL	ANTIHYPERTENSIVE THERAPY; CARDIAC-FUNCTION; EXERCISE	Objective: To study the test-ordering behavior of practicing physicians regarding ambulatory monitoring of blood pressure and to assess changes in patient management after this study. Design: Cross-sectional assessment of physicians' practice habits regarding the ordering of ambulatory blood pressure monitoring and a longitudinal study of patient management after monitoring. Setting: Physicians' offices in central Connecticut. Participants: Two hundred thirty-seven consecutive patients referred by 65 community- and hospital-based physicians. Measurements: Indications for ambulatory blood pressure monitoring, changes in diagnosis and therapy, and office blood pressures before and after the ambulatory blood pressure study. Results: The main indications for ordering the test included borderline hypertension (27% of studies ordered), assessment of blood pressure control during drug therapy (25%), evaluation for ''white coat'' or ''office'' hypertension (22%), and drug-resistant hypertension (16%). After the ambulatory blood pressure study, only 13% of the patients had further testing (for example, echocardiography); the diagnosis was changed in 41% of the patients, and antihypertensive therapy was changed in 46%. In 122 patients for whom data were complete, office blood pressure measured by the referring physician decreased from 161/96 +/- 22/12 mm Hg before the ambulatory blood pressure study to 151/86 +/- 27/12 mm Hg 3 months after the study (P = 0.004 for systolic blood pressure and P < 0.001 for diastolic blood pressure). One to 2 years after the study, office blood pressure was 149/86 +/- 24/12 mm Hg (P > 0.2 compared with 3 months after the study). Seventy-two percent of the patients had a lower office blood pressure within 3 months of the ambulatory blood pressure study. Conclusions: Practicing physicians use ambulatory blood pressure recordings for appropriate indications, and data from the monitoring studies affected the management of patients with hypertension.	UNIV CONNECTICUT, CTR HLTH,SCH MED,HYPERTENS & VASC DIS SECT, 263 FARMINGTON AVE, FARMINGTON, CT 06032 USA	University of Connecticut								BASS MJ, 1991, CLIN INVEST MED, V14, P256; KRAKOFF LR, 1988, AM HEART J, V116, P1152, DOI 10.1016/0002-8703(88)90180-9; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; RION F, 1985, J HYPERTENS, V3, P139, DOI 10.1097/00004872-198504000-00005; ROCCELLA E, 1990, ARCH INTERN MED, V150, P2270; WHITE LJ, 1986, ANN INTERN MED, V104, P275; WHITE WB, 1986, ARCH INTERN MED, V146, P2196, DOI 10.1001/archinte.146.11.2196; WHITE WB, 1989, AM J CARDIOL, V63, P94, DOI 10.1016/0002-9149(89)91083-7; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; WHITE WB, 1989, J HYPERTENS, V7, P967, DOI 10.1097/00004872-198912000-00007; WHITE WB, 1991, CLIN INVEST MED, V14, P224; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; WHITE WB, 1989, AM HEART J, V117, P145, DOI 10.1016/0002-8703(89)90669-8	15	39	39	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					833	837		10.7326/0003-4819-118-11-199306010-00001	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480956				2022-12-28	WOS:A1993LD25200001
J	GLASSMAN, AH; ROOSE, SP; BIGGER, JT				GLASSMAN, AH; ROOSE, SP; BIGGER, JT			THE SAFETY OF TRICYCLIC ANTIDEPRESSANTS IN CARDIAC PATIENTS - RISK-BENEFIT RECONSIDERED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ARRHYTHMIA SUPPRESSION TRIAL; MAJOR DEPRESSIVE DISORDER; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; IMIPRAMINE HYDROCHLORIDE; MORTALITY; FLUOXETINE; DISEASE; NORTRIPTYLINE		COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV CARDIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University	GLASSMAN, AH (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP, DEPT CLIN PSYCHOPHARMACOL, NEW YORK, NY 10032 USA.							ALTAMURA AC, 1989, INT J CLIN PHARM RES, V9, P391; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1991, Circulation, V84, P1831; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1977, NEW ENGL J MED, V296, P206, DOI 10.1056/NEJM197701272960407; BIGGER JT, 1990, AM J CARDIOL, V65, pD3; BUFF DD, 1991, J CLIN PSYCHIAT, V52, P174; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; CONNOLLY SJ, 1984, AM J CARDIOL, V53, P516, DOI 10.1016/0002-9149(84)90023-7; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DAVIS JM, 1989, COMPREHENSIVE TXB PS, V2, P1627; DUNNER DL, 1992, J CLIN PSYCHIAT, V53, P57; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLISON JM, 1990, J CLIN PSYCHIAT, V51, P385; FALK RH, 1989, ANN INTERN MED, V111, P107, DOI 10.7326/0003-4819-111-2-107; FEDER R, 1991, J CLIN PSYCHIAT, V52, P139; FEDOROFF JP, 1989, J CLIN PSYCHIAT, V50, P18; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P20; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; GEORGOTAS A, 1987, BRIT J PSYCHIAT, V151, P102, DOI 10.1192/bjp.151.1.102; GIARDINA EGV, 1986, J AM COLL CARDIOL, V7, P1363, DOI 10.1016/S0735-1097(86)80158-9; GIARDINA EGV, 1987, CLIN PHARMACOL THER, V42, P20, DOI 10.1038/clpt.1987.102; GIARDINA EGV, 1982, AM J CARDIOL, V50, P172, DOI 10.1016/0002-9149(82)90025-X; GIARDINA EGV, 1979, CIRCULATION, V60, P1045, DOI 10.1161/01.CIR.60.5.1045; GLASSMAN AH, 1985, AM J PSYCHIAT, V142, P155; GLASSMAN AH, 1981, ARCH GEN PSYCHIAT, V38, P815; GLASSMAN AH, 1987, PSYCHOPHARMACOLOGY 3, P1437; GRAM LF, 1986, PSYCHOPHARMACOLOGY, V90, P131; GUILLIBERT E, 1989, ACTA PSYCHIAT SCAND, V80, P132, DOI 10.1111/j.1600-0447.1989.tb07192.x; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE54, DOI 10.1016/0002-9149(87)90204-9; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Klein DF, 1980, DIAGNOSIS DRUG TREAT; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; NYTH AL, 1992, ACTA PSYCHIAT SCAND, V86, P138, DOI 10.1111/j.1600-0447.1992.tb03242.x; PRATT CM, 1990, AM J CARDIOL, V65, P103, DOI 10.1016/0002-9149(90)90034-X; RAWLING DA, 1979, J PHARMACOL EXP THER, V209, P371; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROOSE SP, 1991, AM J PSYCHIAT, V148, P512; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; Salzman Carl, 1993, Am J Geriatr Psychiatry, V1, P21, DOI 10.1097/00019442-199300110-00004; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; THORSTRAND C, 1976, ACTA MED SCAND, V199, P337; WELD FM, 1980, CIRC RES, V46, P167, DOI 10.1161/01.RES.46.2.167; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 1990, J AFFECT DISORDERS, V18, P289	48	193	197	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2673	2675		10.1001/jama.269.20.2673	http://dx.doi.org/10.1001/jama.269.20.2673			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487453				2022-12-28	WOS:A1993LC86500034
J	RIMM, EB; STAMPFER, MJ; ASCHERIO, A; GIOVANNUCCI, E; COLDITZ, GA; WILLETT, WC				RIMM, EB; STAMPFER, MJ; ASCHERIO, A; GIOVANNUCCI, E; COLDITZ, GA; WILLETT, WC			VITAMIN-E CONSUMPTION AND THE RISK OF CORONARY HEART-DISEASE IN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEINS; ALCOHOL-CONSUMPTION; ALPHA-TOCOPHEROL; BETA-CAROTENE; CIGARETTE-SMOKING; PLASMA-LEVELS; ANTIOXIDANTS; MACROPHAGES; ATHEROGENESIS; QUESTIONNAIRE	Background. The oxidative modification of low-density lipoproteins increases their incorporation into the arterial intima, an essential step in atherogenesis. Although dietary antioxidants, such as vitamin C, carotene, and vitamin E, have been hypothesized to prevent coronary heart disease, prospective epidemiologic data are sparse. Methods. In 1986, 39,910 U.S. male health professionals 40 to 75 years of age who were free of diagnosed coronary heart disease, diabetes, and hypercholesterolemia completed detailed dietary questionnaires that assessed their usual intake of vitamin C, carotene, and vitamin E in addition to other nutrients. During four years of follow-up, we documented 667 cases of coronary disease. Results. After controlling for age and several coronary risk factors, we observed a lower risk of coronary disease among men with higher intakes of vitamin E (P for trend = 0.003). For men consuming more than 60 IU per day of vitamin E, the multivariate relative risk was 0.64 (95 percent confidence interval, 0.49 to 0.83) as compared with those consuming less than 7.5 IU per day. As compared with men who did not take vitamin E supplements, men who took at least 100 IU per day for at least two years had a multivariate relative risk of coronary disease of 0.63 (95 percent confidence interval, 0.47 to 0.84). Carotene intake was not associated with a lower risk of coronary disease among those who had never smoked, but it was inversely associated with the risk among current smokers (relative risk, 0.30; 95 percent confidence interval, 0.11 to 0.82) and former smokers (relative risk, 0.60; 95 percent confidence interval, 0.38 to 0.94). In contrast, a high intake of vitamin C was not associated with a lower risk of coronary disease. Conclusions. These data do not prove a causal relation, but they provide evidence of an association between a high intake of vitamin E and a lower risk of coronary heart disease in men. Public policy recommendations with regard to the use of vitamin E supplements should await the results of additional studies.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	RIMM, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; BEATON GH, 1979, AM J CLIN NUTR, V32, P2546, DOI 10.1093/ajcn/32.12.2546; BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; DEMAIO SJ, 1992, J AM COLL NUTR, V11, P68; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; DIPLOCK AT, 1991, AM J CLIN NUTR, V53, pS189, DOI 10.1093/ajcn/53.1.189Sb; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; GABH Rose, 1982, WHO MONOGRAPH SERIES; Gaziano J. M., 1992, American Journal of Epidemiology, V136, P985; GAZIANO JM, 1990, CIRCULATION, V82, P201; GEY KF, 1987, AM J CLIN NUTR, V45, P1368, DOI 10.1093/ajcn/45.5.1368; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; HARATS D, 1989, ATHEROSCLEROSIS, V79, P245, DOI 10.1016/0021-9150(89)90130-5; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOSHINO E, 1990, JPEN-PARENTER ENTER, V14, P300, DOI 10.1177/0148607190014003300; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; JIALAL I, 1991, J CLIN INVEST, V87, P597, DOI 10.1172/JCI115035; JIALAL I, 1992, J LIPID RES, V33, P899; KALBFLEISCH JH, 1986, BRIT J NUTR, V55, P71, DOI 10.1079/BJN19860011; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; NIERENBERG DW, 1989, AM J EPIDEMIOL, V130, P511, DOI 10.1093/oxfordjournals.aje.a115365; NIKI E, 1991, AM J CLIN NUTR, V53, pS201, DOI 10.1093/ajcn/53.1.201S; PARTHASARATHY S, 1992, J CLIN INVEST, V89, P1618, DOI 10.1172/JCI115757; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; Rothman K, 1986, MODERN EPIDEMIOLOGY; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1983, AM J CLIN PATHOL, V79, P714, DOI 10.1093/ajcp/79.6.714; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; Stocker R, 1991, OXIDATIVE STRESS OXI, P213; STREET DA, 1991, AM J EPIDEMIOL, V134, P719; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1976, COMPOSITION FOODS HD; 1977, NUTR REV, V35, P57; 1989, RECOMMENDED DIETARY	49	1946	1989	3	101	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1450	1456		10.1056/NEJM199305203282004	http://dx.doi.org/10.1056/NEJM199305203282004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479464	Bronze			2022-12-28	WOS:A1993LB78300004
J	LANZAVECCHIA, A				LANZAVECCHIA, A			IDENTIFYING STRATEGIES FOR IMMUNE INTERVENTION	SCIENCE			English	Article							MHC CLASS-II; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; MYELIN BASIC-PROTEIN; TOXIC LYMPHOCYTES-T; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELL; LISTERIA-MONOCYTOGENES; MONOCLONAL-ANTIBODIES; SURFACE-ANTIGEN	In recent years the molecular basis of antigen recognition by T cells has been unraveled and the various pathways that control T cell activation and functional specialization have been defined. Consequently, it is now possible to delineate various strategies for intervention with the immune system to design protective vaccines, to induce an effective response to tumor antigens, and to control graft rejection and autoimmune diseases.			LANZAVECCHIA, A (corresponding author), BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND.							ABRIGNANI S, 1990, P NATL ACAD SCI USA, V87, P6136, DOI 10.1073/pnas.87.16.6136; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BENJAMIN RJ, 1986, J EXP MED, V163, P1539, DOI 10.1084/jem.163.6.1539; BERG J, 1991, P NATL ACAD SCI USA, V88, P4723, DOI 10.1073/pnas.88.11.4723; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLOOM BR, 1992, ANNU REV IMMUNOL, V10, P453, DOI 10.1146/annurev.iy.10.040192.002321; BLOOM BR, 1992, IMMUNOL TODAY, V13, P131, DOI 10.1016/0167-5699(92)90110-S; BOSCO M, 1990, J IMMUNOL, V145, P3136; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRETT SJ, 1988, J EXP MED, V168, P357, DOI 10.1084/jem.168.1.357; BROCKER A, IN PRESS EUR J IMMUN; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BURSTEIN HJ, 1993, J EXP MED, V177, P457, DOI 10.1084/jem.177.2.457; BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CAPRA JD, 1993, IMMUNOLOGIST, V1, P16; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CARDING SR, 1993, J EXP MED, V177, P475, DOI 10.1084/jem.177.2.475; CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8; CELIS E, 1984, SCIENCE, V224, P297, DOI 10.1126/science.6231724; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COHEN IR, 1989, COLD SPRING HARB SYM, V54, P879; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAY MJ, 1992, J EXP MED, V175, P655, DOI 10.1084/jem.175.3.655; DEBRUIJN MLH, 1991, EUR J IMMUNOL, V21, P2963, DOI 10.1002/eji.1830211210; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FORNI G, 1985, J IMMUNOL, V134, P1305; FRANCO A, 1992, J EXP MED, V175, P1195, DOI 10.1084/jem.175.5.1195; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GAUR A, 1993, SCIENCE, V259, P91, DOI 10.1126/science.8418501; GAUTAM AM, 1992, J IMMUNOL, V148, P3049; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUTCHINGS P, 1992, EUR J IMMUNOL, V22, P1913, DOI 10.1002/eji.1830220735; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ITAYA T, 1987, CANCER RES, V47, P3136; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JORGENSEN T, 1980, SCAND J IMMUNOL, V11, P29, DOI 10.1111/j.1365-3083.1980.tb00205.x; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; KAWAMURA H, 1986, J IMMUNOL, V136, P58; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; KHOURI SJ, 1991, J EXP MED, V174, P1355; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KRUSKALL MS, 1992, J EXP MED, V175, P495, DOI 10.1084/jem.175.2.495; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAKE P, 1976, IMMUNOL COMMUN, V5, P795, DOI 10.3109/08820137609047620; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LANE P, COMMUNICATION; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1988, J EXP MED, V167, P345, DOI 10.1084/jem.167.2.345; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LOCKSLEY RM, 1991, IMMUNOPARASITOLOGY T; MACATONIA SE, 1989, J EXP MED, V169, P1255, DOI 10.1084/jem.169.4.1255; MALEFYT RD, 1991, J EXP MED, V174, P915; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOREIN B, 1988, NATURE, V332, P287, DOI 10.1038/332287a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MULLER I, 1989, EUR J IMMUNOL, V19, P865, DOI 10.1002/eji.1830190513; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; NEEFJES JJ, 1993, CURR OPIN IMMUNOL, V5, P27, DOI 10.1016/0952-7915(93)90077-6; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OKI A, 1985, J EXP MED, V161, P897, DOI 10.1084/jem.161.5.897; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PARDOLL D, 1992, CURR OPIN IMMUNOL, V4, P619, DOI 10.1016/0952-7915(92)90037-F; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMMENSEE HG, 1991, BONE MARROW TRANSPL, V7, P26; REDDY R, 1991, J IMMUNOL METHODS, V141, P157, DOI 10.1016/0022-1759(91)90142-3; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; RIDDELL SR, 1992, SCIENCE, V257, P238; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROOSNEK E, 1989, J EXP MED, V170, P297, DOI 10.1084/jem.170.1.297; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; SALGAME PR, 1991, SCIENCE, V274, P259; SASAZUKI T, 1989, IMMUNOLOGY, P21; SCHERER MT, 1989, COLD SPRING HARB SYM, V54, P497; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SEDER RA, 1992, J IMMUNOL, V148, P1652; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SERCARZ E, 1991, IMMUNOL TODAY, V12, P111, DOI 10.1016/0167-5699(91)90094-A; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; STAERZ UD, 1986, IMMUNOL TODAY, V7, P241, DOI 10.1016/0167-5699(86)90112-X; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEW JG, 1989, IMMUNOL TODAY, V10, P229, DOI 10.1016/0167-5699(89)90258-2; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1984, CELL, V39, P13, DOI 10.1016/0092-8674(84)90187-9; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRAUNECKER A, 1991, EMBO J, V10, P3655, DOI 10.1002/j.1460-2075.1991.tb04932.x; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Uhr J W, 1968, Adv Immunol, V8, P81, DOI 10.1016/S0065-2776(08)60465-4; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; VANBINNENDIJK RS, 1992, J EXP MED, V176, P119, DOI 10.1084/jem.176.1.119; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1992, CURR OPIN IMMUNOL, V4, P608, DOI 10.1016/0952-7915(92)90035-D; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VANPEL A, 1982, P NATL ACAD SCI-BIOL, V79, P4718; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATTS C, UNPUB; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943	208	210	250	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					937	944		10.1126/science.8493532	http://dx.doi.org/10.1126/science.8493532			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493532				2022-12-28	WOS:A1993LB79100034
J	ROZAKISADCOCK, M; FERNLEY, R; WADE, J; PAWSON, T; BOWTELL, D				ROZAKISADCOCK, M; FERNLEY, R; WADE, J; PAWSON, T; BOWTELL, D			THE SH2 AND SH3 DOMAINS OF MAMMALIAN GRB2 COUPLE THE EGF RECEPTOR TO THE RAS ACTIVATOR MSOS1	NATURE			English	Article							TYROSINE KINASE; PROTEIN; GROWTH; REQUIREMENT; STIMULATION; EXCHANGE; CELLS	MANY tyrosine kinases, including the receptors for hormones such as epidermal growth factor (EGF), nerve growth factor and insulin, transmit intracellular signals through Ras proteins1-4. Ligand binding to such receptors stimulates Ras guanine-nucleotide-exchange activity5-9 and increases the level of GTP-bound Ras10-12, suggesting that these tyrosine kinases may activate a guanine-nucleotide releasing protein (GNRP). In Caenorhabditis elegans and Drosophila, genetic studies have shown that Ras activation by tyrosine kinases requires the protein Sem-5/drk, which contains a single Src-homology (SH) 2 domain and two flanking SH3 domains13-15. Sem-5 is homologous to the mammallian protein Grb2, which binds the autophosphorylated EGF receptor and other phosphotyrosine-containing proteins such as Shc through its SH2 domain16-17. Here we show that in rodent fibroblasts, the SH3 domains of Grb2 are bound to the proline-rich carboxy-terminal tail of mSos1, a protein homologous to Drosophila Sos. Sos is required for Ras signalling18-20 and contains a central domain related to known Ras-GNRPs21-23. EGF stimulation induces binding of the Grb2-mSos1 complex to the autophosphorylated EGF receptor, and mSos1 phosphorylation. Grb2 therefore appears to link tyrosine kinases to a Ras-GNRP in mammalian cells.	UNIV MELBOURNE,HOWARD FLOREY INST EXPTL PHYSIOL & MED,PARKVILLE,VIC 3052,AUSTRALIA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013; Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525; Wade, John/0000-0002-1352-6568	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	32	963	984	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					83	85		10.1038/363083a0	http://dx.doi.org/10.1038/363083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8479540				2022-12-28	WOS:A1993LA68200065
J	CAULEY, JA; CUMMINGS, SR; SEELEY, DG; BLACK, D; BROWNER, W; KULLER, LH; NEVITT, MC				CAULEY, JA; CUMMINGS, SR; SEELEY, DG; BLACK, D; BROWNER, W; KULLER, LH; NEVITT, MC			EFFECTS OF THIAZIDE DIURETIC THERAPY ON BONE MASS, FRACTURES, AND FALLS	ANNALS OF INTERNAL MEDICINE			English	Article						DIURETICS, THIAZIDE; BONE DENSITY; FRACTURES; ACCIDENTAL FALLS; OSTEOPOROSIS	HIP FRACTURE; ELDERLY WOMEN; POSTMENOPAUSAL WOMEN; MINERAL CONTENT; RISK; DRUGS; PREVALENCE; PREVENTION; ESTROGEN; DENSITY	Objective: To determine the relation between the use of thiazide diuretics and bone mass, fractures, and falls in older women. Design: Cross-sectional study of thiazide diuretics, bone mass, and prevalent vertebral deformities; cohort analysis of thiazide diuretics and nonspinal fractures and falls. Setting: Four clinical centers located in Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon: and the Monongahela Valley, Pennsylvania. Participants: A total of 9704 ambulatory, nonblack women who were 65 years or older. Measurements: Information on thiazide use, demographic data, medical history, and anthropometric measurements were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident falls and fractures were ascertained every 4 months. Results: Women using thiazide diuretics for more than 10 years had significantly higher bone mass than women who had never used thiazide diuretics (for example, 0.381 g/cm2 compared with 0.355 g/cm2 for the distal radius [P < 0.001]). Current users of thiazide diuretics had an incidence of falls (relative risk, 1.06; 95% Cl, 0.90 to 1.25) that was similar to that of those who had never used these drugs. After adjusting for age, body weight, functional status, total calcium intake, duration of estrogen replacement therapy, and self-reported health status, we found that current users of thiazide diuretics who had taken these drugs for more than 10 years had a risk for nonspinal (relative risk, 0.99; Cl, 0.81 to 1.20) and osteoporotic (relative risk, 0.98; Cl, 0.79 to 1.22) fractures that was similar to that of women who had never used thiazides; however, thiazide users did have a lower risk for fractures of the hip (relative risk, 0.63; Cl, 0.34 to 1.16) and wrist (relative risk, 0.66: Cl. 0.40 to 1.08), neither of which was significant. Conclusions: Thiazide diuretics have no effect on a woman's risk for falling or for experiencing nonspinal fractures. The trend toward a lower risk for hip and wrist fractures is consistent with findings in previous cohort studies but may reflect selection factors for the use of thiazide diuretics. A randomized trial is needed to determine the effect of thiazide diuretics on the incidence of fractures.	UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CAULEY, JA (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, A524 CRABTREE HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408	NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05394, AG05407] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLANDDAVENPORT P, 1985, AM J OBSTET GYNECOL, V152, P630, DOI 10.1016/S0002-9378(85)80035-1; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BLACK DM, 1991, J BONE MINER RES, V6, P883; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CUMMING RG, 1991, AGE AGEING, V20, P455, DOI 10.1093/ageing/20.6.455; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1990, CLIN ORTHOP RELAT R, P163; ETTINGER B, 1992, J BONE MINER RES, V7, P449; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HALE WE, 1984, J AM GERIATR SOC, V32, P5, DOI 10.1111/j.1532-5415.1984.tb05142.x; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HUNT I, 1988, AM J EPIDEMIOL, V128, P903; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LACROIX A Z, 1991, Comprehensive Therapy, V17, P30; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LINDSAY R, 1987, J BONE MINER RES  S1, V2, pS223; MIDDLER S, 1973, METABOLISM, V22, P139, DOI 10.1016/0026-0495(73)90264-3; MYERS MG, 1978, CAN MED ASSOC J, V119, P581; NEVITT M, 1990, 2ND 50 YEARS PROMOTI; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; RASHIQ S, 1986, BRIT MED J, V292, P861, DOI 10.1136/bmj.292.6524.861; RAY WA, 1991, ANN INTERN MED, V115, P64, DOI 10.7326/0003-4819-115-1-64; RAY WA, 1989, LANCET, V1, P687; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; STEINICHE T, 1989, APMIS, V97, P302, DOI 10.1111/j.1699-0463.1989.tb00792.x; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; TRANSBOL I, 1982, METABOLISM, V31, P383, DOI 10.1016/0026-0495(82)90115-9; VOGEL JM, 1987, OSTEOPOROSIS UPDATE, P219; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; YENDT ER, 1978, KIDNEY INT, V13, P397, DOI 10.1038/ki.1978.58; 1981, STATISTICAL METHODS; 1984, JAMA-J AM MED ASSOC, V252, P799; 1991, DRUG EVALUATIONS ANN, P683	41	134	138	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1993	118	9					666	673		10.7326/0003-4819-118-9-199305010-00002	http://dx.doi.org/10.7326/0003-4819-118-9-199305010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY502	8489642				2022-12-28	WOS:A1993KY50200002
J	NICHOLSON, KG				NICHOLSON, KG			IMMUNIZATION AGAINST INFLUENZA AMONG PEOPLE AGED OVER 65 LIVING AT HOME IN LEICESTERSHIRE DURING WINTER 1991-2	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; REDUCTION; DEATHS; IMMUNIZATION; PNEUMONIA; MORTALITY	Objectives-To assess the size of the elderly population for whom influenza vaccine is indicated and how many are vaccinated. Design-Cohort questionnaire study. Setting-Leicestershire general practices. Subjects-800 elderly subjects selected at random from the Leicestershire family health services authority list who were not living in residential care, 565 of whom returned a questionnaire. Main outcome measures-Patient profile, vaccine offers, vaccination status, and reasons for not accepting vaccine. Results-170 of 334 (51%) people aged 65-74 years and 106 of 205 (52%) aged greater-than-or-equal-to 75 years had one or more medical indications for influenza vaccine. 195 people were offered vaccine, 49 of whom had no risk factor. 152 offers were made opportunistically during visits to the practice and only six were made in writing or by telephone. Overall 113 of 266 patients with known medical indications were immunised. Vaccine was accepted by 148 of 189 (78%) offered it, and, as judged by acceptance in sequential years, influenza vaccine was well tolerated. The main reasons for not being vaccinated were misconception about risk status and inadequate advice from doctors. Conclusions-The prevalence of medical indications for vaccine is not large enough to justify a policy of universal immunisation. Most patients offered vaccine accept it and tolerate it well. Improved targeting and education is needed to increase immunisation of people at risk.			NICHOLSON, KG (corresponding author), DEPT MICROBIOL,MED SCI BLDG,POB 138,LEICESTER LE1 9HN,ENGLAND.							ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; CURWEN M, 1990, BRIT MED J, V300, P896; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HOWELLS CHL, 1975, LANCET, V1, P381; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; SERFLING RE, 1967, AM J EPIDEMIOL, V86, P433, DOI 10.1093/oxfordjournals.aje.a120753; Serie C, 1977, Dev Biol Stand, V39, P317; WISELKA MJ, 1992, LANCET, V339, P367; 1990, IMMUNISATION INFECTI	16	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					974	976		10.1136/bmj.306.6883.974	http://dx.doi.org/10.1136/bmj.306.6883.974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490478	Bronze, Green Published			2022-12-28	WOS:A1993KX43600023
J	WASSERSTEIN, AG				WASSERSTEIN, AG			CHANGING PATTERNS OF MEDICAL-PRACTICE - PROTEIN RESTRICTION FOR CHRONIC-RENAL-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; PHYSICIANS PRACTICE PATTERNS; DIETARY PROTEINS; HISTORY OF MEDICINE; NUTRITION	DISEASE; ABLATION; THERAPY; DIET; RATS	The use of dietary protein restriction for renal failure has fluctuated during the past 125 years. These fluctuations reflect not only the state of medical knowledge but also social, economic, and cultural factors. Factors inhibiting use of dietary treatment have been its status as an aspect of hygiene rather than as active therapy; the opinions of dominant practitioners and scientists around midcentury, including a presumption that renal adaptation to a high-protein diet must be appropriate; fear of malnutrition and a cultural belief in the virtue of dietary protein; unwillingness by physicians and patients to restrict consumption or lifestyle; and professional identification with the technologies of dialysis and renal transplantation. Factors promoting dietary treatment have been rediscovery of previous work on protein-induced renal injury; a sense that homeostatic compensations could have adverse consequences; federal incentives to curb consumption of scarce resources such as renal dialysis; and the integration of research on, and therapeutic use of diet into scientific medicine. A large ongoing study of dietary protein restriction to limit renal injury will add to our knowledge of this treatment; its application will surely be informed by social and cultural considerations.			WASSERSTEIN, AG (corresponding author), HOSP UNIV PENN, DIV RENAL ELECTROLYTE, 7TH FLOOR, CRB BLDG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.							Addis T, 1924, ARCH INTERN MED, V34, P243, DOI 10.1001/archinte.1924.00120020109010; ADDIS T, 1948, GLOMERULAR NEPHRITIS, P237; ADDIS T, 1948, GLOMERULAR NEPHRITIS, P287; Addis T, 1948, GLOMERULAR NEPHRITIS; ADDIS T, 1946, DANGER INTRAVENOUS I, P254; AHLSTROM T, 1991, KIDNEY PATIENTS BOOK; Beale LS, 1869, KIDNEY DIS URINARY D, P85; BERGSTROM J, 1984, CLIN NEPHROL, V21, P29; BERLYNE GM, 1979, CLIN NEPHROL, V11, P63; BERNARD C, 1957, INTRO STUDY EXPT MED, P181; BORST JGG, 1948, LANCET, V254, P824; BRAS G, 1964, TOXICOL APPL PHARM, V6, P247, DOI 10.1016/0041-008X(64)90065-1; BRICKER NS, 1964, J CLIN INVEST, V43, P1915, DOI 10.1172/JCI105065; BRICKER NS, 1972, NEW ENGL J MED, V286, P1093; BRICKER NS, 1965, MEDICINE, V44, P263, DOI 10.1097/00005792-196507000-00001; BUCHT H, 1949, SCAND J CLIN LAB INV, V1, P277, DOI 10.3109/00365514909056658; BULL GM, 1949, LANCET, V257, P229; CHANUBIN M, 1932, ARCH INTERN MED, V49, P767; Chanutin A, 1934, ARCH INTERN MED, V54, P720, DOI 10.1001/archinte.1934.00160170063006; Chanutin A, 1936, ARCH INTERN MED, V58, P60, DOI 10.1001/archinte.1936.00170110068005; CLARK JK, 1951, J CLIN INVEST, V30, P745, DOI 10.1172/JCI102488; DRUMMOND JC, 1922, J PHYSL, V61, P413; Farr LE, 1939, J EXP MED, V70, P615, DOI 10.1084/jem.70.6.615; GIORDANO C, 1963, J LAB CLIN MED, V62, P231; GIOVANNETTI S, 1964, LANCET, V1, P1000; GIOVANNETTI S, 1985, NEPHRON, V40, P1, DOI 10.1159/000183419; HEGSTED DM, 1946, J LAB CLIN MED, V31, P261; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; IBELS LS, 1978, NEW ENGL J MED, V298, P122, DOI 10.1056/NEJM197801192980302; Jackson H, 1926, J BIOL CHEM, V67, P101; KLAHR S, 1989, NEW ENGL J MED, V320, P864, DOI 10.1056/NEJM198903303201310; KOPPLE JD, 1973, MEDICINE, V52, P583, DOI 10.1097/00005792-197311000-00004; LALICH JJ, 1970, ARCH PATHOL, V89, P548; LUSK G, 1928, ELEMENTS SCI NUTRITI; LUSK G, 1928, ELEMENTS SCI NUTRITI, P448; MacKay EM, 1928, AM J PHYSIOL, V86, P459, DOI 10.1152/ajplegacy.1928.86.2.459; MERRILL JP, 1965, TREATMENT RENAL FAIL, P212; Moise TS, 1927, ARCH PATHOL LAB MED, V4, P530; MORRISON AB, 1966, J EXP MED, V123, P829, DOI 10.1084/jem.123.5.829; MORRISON AB, 1962, LAB INVEST, V11, P321; NAGLE RB, 1969, LAB INVEST, V21, P519; Newburgh LH, 1931, J CLIN INVEST, V10, P153, DOI 10.1172/JCI100336; Newburgh LH, 1928, ARCH INTERN MED, V42, P801, DOI 10.1001/archinte.1928.00130230003001; Newburgh LH, 1919, ARCH INTERN MED, V24, P359, DOI 10.1001/archinte.1919.00090270003001; OLIVER J, 1950, J UROLOGY, V63, P373, DOI 10.1016/S0022-5347(17)68776-7; PEITZMAN SJ, 1989, MILBANK Q, V67, P16, DOI 10.2307/3350183; PEITZMAN SJ, 1990, KIDNEY INT, V37, P833, DOI 10.1038/ki.1990.53; Peters JP, 1926, ARCH INTERN MED, V37, P153, DOI 10.1001/archinte.1926.00120200003001; PETERS JP, 1946, QUANTITATIVE CLIN CH, P687; PLATT R, 1952, CLIN SCI, V11, P217; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1980, NEW ENGL J MED, V303, P996, DOI 10.1056/NEJM198010233031708; SELDIN DW, 1971, DISEASES KIDNEY, P244; Sherman HC, 1920, J BIOL CHEM, V41, P97; SHIMAMURA T, 1975, AM J PATHOL, V79, P95; Smadel JE, 1939, AM J PATHOL, V15, P199; SMITH H, 1951, KIDNEY STRUCTURE FUN, P621; SMITH HW, 1951, KIDNEY STRUCTURE FUN, P470; WALSER M, 1978, NEPHRON, V21, P57, DOI 10.1159/000181373; Walser M, 1975, Clin Nephrol, V3, P180; WALSER M, 1979, CLIN NEPHROL, V11, P66; WALSER M, 1976, KIDNEY, P1627; WARNER JH, 1986, THERAPEUTIC PERSPECT, P240; YOSHIDA Y, 1988, KIDNEY INT, V33, P855, DOI 10.1038/ki.1988.77; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; 1985, NUTRITION ED US MED, P9; 1985, NUTRITION RES US MED, P15; 1985, NUTRITION ED US MED, P12	68	16	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					79	85		10.7326/0003-4819-119-1-199307010-00013	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498767				2022-12-28	WOS:A1993LJ26600013
J	FRIEDMAN, SL; FLIER, JS; EPSTEIN, F; GLICKMAN, R; SCHEELE, G				FRIEDMAN, SL; FLIER, JS; EPSTEIN, F; GLICKMAN, R; SCHEELE, G			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE CELLULAR BASIS OF HEPATIC-FIBROSIS - MECHANISMS AND TREATMENT STRATEGIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAT-STORING CELLS; NORMAL RAT-LIVER; TRANSFORMING GROWTH FACTOR-BETA-1; EXTRACELLULAR-MATRIX; COLLAGEN PRODUCTION; LIPID-PEROXIDATION; FACTOR RECEPTORS; GENE-EXPRESSION; VIRAL-HEPATITIS; KUPFFER CELLS		SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco			Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DK 27643, DK 37340, DK 31198] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031198, R01DK031198, R01DK037340] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENSON DM, 1988, GASTROENTEROLOGY, V95, P441, DOI 10.1016/0016-5085(88)90502-1; ARMENDARIZBORUNDA J, 1989, MATRIX, V9, P150, DOI 10.1016/S0934-8832(89)80034-4; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; BACHEM MG, 1989, J CLIN CHEM CLIN BIO, V27, P555; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Bissell D M, 1990, Prog Liver Dis, V9, P143; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BURSCH W, 1989, HEPATOLOGY, V9, P830, DOI 10.1002/hep.1840090607; CASINI A, 1991, HEPATOLOGY, V13, P758, DOI 10.1016/0270-9139(91)92576-T; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHOJKIER M, 1989, J BIOL CHEM, V264, P16957; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FRIEDMAN SL, 1990, SEMIN LIVER DIS, V10, P20, DOI 10.1055/s-2008-1040454; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P549, DOI 10.1002/hep.1840150330; FRIEDMAN SL, 1990, HEPATOLOGY, V12, P609, DOI 10.1002/hep.1840120326; FRIEDMANSL, 1991, HEPATOLOGY, V14, pA113; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; GEUBEL AP, 1991, GASTROENTEROLOGY, V100, P1701, DOI 10.1016/0016-5085(91)90672-8; GRESSNER AM, 1992, HEPATOLOGY, V16, P1250; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; HOUGLUM K, 1990, J CLIN INVEST, V86, P1991, DOI 10.1172/JCI114934; HULTCRANTZ R, 1991, J CLIN INVEST, V87, P45, DOI 10.1172/JCI114999; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; INUZUKA S, 1990, HEPATOLOGY, V12, P249, DOI 10.1002/hep.1840120211; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; JOHNSON SJ, 1992, J PATHOL, V166, P351, DOI 10.1002/path.1711660406; KAMIMURA S, 1992, HEPATOLOGY, V16, P448, DOI 10.1002/hep.1840160225; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KIRK AP, 1980, GUT, V21, P78, DOI 10.1136/gut.21.1.78; LEO MA, 1982, NEW ENGL J MED, V307, P597, DOI 10.1056/NEJM198209023071006; LI JJ, 1992, HEPATOLOGY, V15, P373, DOI 10.1002/hep.1840150303; LIEBER CS, 1990, ALCOHOL ALCOHOLISM, V25, P157, DOI 10.1093/oxfordjournals.alcalc.a044990; LOREAL O, 1991, FEBS LETT, V290, P9, DOI 10.1016/0014-5793(91)81213-R; LOREAL O, 1992, GASTROENTEROLOGY, V102, P980, DOI 10.1016/0016-5085(92)90186-3; MAHER JJ, 1988, GASTROENTEROLOGY, V94, P1053, DOI 10.1016/0016-5085(88)90566-5; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MARTINEZHERNANDEZ A, 1985, LAB INVEST, V53, P166; MATSUOKA M, 1989, LIVER, V9, P71; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MCGUIRE RF, 1992, HEPATOLOGY, V15, P989, DOI 10.1002/hep.1840150603; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; MILANI S, 1989, AM J PATHOL, V134, P1175; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; PIETRANGELO A, 1992, Gastroenterology, V102, pA868; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; RAMADORI G, 1992, GASTROENTEROLOGY, V103, P1313, DOI 10.1016/0016-5085(92)91522-6; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; ROCKEY DC, 1992, HEPATOLOGY, V16, P776, DOI 10.1002/hep.1840160325; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; ROJKIND M, 1979, GASTROENTEROLOGY, V76, P710; RUBIN K, 1988, LANCET, V1, P1353; RUBIN K, 1988, SCAND J IMMUNOL, V27, P285, DOI 10.1111/j.1365-3083.1988.tb02349.x; SCHAFFNER F, 1963, GASTROENTEROLOGY, V44, P239; SCHWOGLER S, 1992, BIOCHEM BIOPH RES CO, V185, P768, DOI 10.1016/0006-291X(92)91692-J; SHIRATORI Y, 1986, J HEPATOL, V3, P294, DOI 10.1016/S0168-8278(86)80481-0; SINCLAIR SB, 1989, J CLIN INVEST, V84, P1063, DOI 10.1172/JCI114268; STERNLIEB I, 1968, NEW ENGL J MED, V278, P352, DOI 10.1056/NEJM196802152780702; TAKAHARA T, 1988, LAB INVEST, V59, P509; TSUKAMOTO H, 1991, CELLS OF THE HEPATIC SINUSOID, VOL 3, P453; WINWOOD PJ, 1992, HEPATOLOGY, V16, P606; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; 1991, J HEPATOL S3, V13	74	1405	1479	0	54	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1828	1835						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502273				2022-12-28	WOS:A1993LH21000008
J	DANGELO, A; DELLAVALLE, P; CRIPPA, L; PATTARINI, E; GRIMALDI, LME; DANGELO, SV				DANGELO, A; DELLAVALLE, P; CRIPPA, L; PATTARINI, E; GRIMALDI, LME; DANGELO, SV			BRIEF REPORT - AUTOIMMUNE PROTEIN-S DEFICIENCY IN A BOY WITH SEVERE THROMBOEMBOLIC DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DISSEMINATED INTRAVASCULAR COAGULATION; ANTICOAGULANT ACTIVITY; ORAL ANTICOAGULATION; C4B-BINDING PROTEIN; ENDOTHELIAL-CELLS; ANTITHROMBIN-III; ESCHERICHIA-COLI; FACTOR-VA; COFACTOR; PLASMA		UNIV MILAN,UNITA NEUROIMMUNOL,I-20122 MILAN,ITALY; UNIV MILAN,NEUROL CLIN,DIPARTIMENTO BIOTECNOL,I-20122 MILAN,ITALY	University of Milan; University of Milan	DANGELO, A (corresponding author), IST SCI HS RAFFAELE,SERV COAGULAZ,VIA OLGETTINA 60,I-20132 MILAN,ITALY.		Grimaldi, Luigi/L-2614-2019; D'Angelo, Armando/K-2583-2018	D'Angelo, Armando/0000-0002-9857-4509				BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BROEKMANS AW, 1985, THROMB HAEMOSTASIS, V53, P273; COMP PC, 1986, BLOOD, V68, P881; COMP PC, 1986, BLOOD, V67, P504; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1986, J BIOL CHEM, V261; DANGELO A, 1987, BLOOD, V69, P231; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DANGELO SV, 1989, THROMB HAEMOSTASIS, V62, P861; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; DANGELO SV, 1990, THROMB RES, V59, P985; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FAIR DS, 1986, BLOOD, V67, P1168; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILABERT J, 1988, THROMB RES, V49, P319, DOI 10.1016/0049-3848(88)90312-X; GREEN D, 1991, AM J MED S5A, V1, pS14; GRIMALDI LME, 1988, ANN NEUROL, V24, P227, DOI 10.1002/ana.410240209; GRUBER A, 1986, THROMB RES, V42, P579, DOI 10.1016/0049-3848(86)90221-5; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MARLAR RA, 1982, BLOOD, V59, P1067; MITCHELL CA, 1987, NEW ENGL J MED, V317, P1638, DOI 10.1056/NEJM198712243172606; SCHWARZ HP, 1986, THROMB HAEMOSTASIS, V56, P382; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TRAN TH, 1984, THROMB HAEMOSTASIS, V52, P112; VIGANODANGELO S, 1987, ANN INTERN MED, V107, P42, DOI 10.7326/0003-4819-107-1-42; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WALKER TS, 1991, AM J CLIN PATHOL, V95, P725, DOI 10.1093/ajcp/95.5.725; WEINSTEIN R, 1990, BLOOD, V76, pA442	32	93	93	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1753	1757		10.1056/NEJM199306173282405	http://dx.doi.org/10.1056/NEJM199306173282405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8497285	Bronze			2022-12-28	WOS:A1993LG03800005
J	GERSTEIN, RM; LIEBER, MR				GERSTEIN, RM; LIEBER, MR			EXTENT TO WHICH HOMOLOGY CAN CONSTRAIN CODING EXON JUNCTIONAL DIVERSITY IN V(D)J RECOMBINATION	NATURE			English	Article							STREPTOCOCCUS-PNEUMONIAE; GENE REARRANGEMENT; JOINING SIGNALS; IMMUNE-SYSTEM; ANTIBODIES; PHOSPHORYLCHOLINE; PHOSPHOCHOLINE; CELL; INSERTION; SEQUENCES	AMONG site-directed DNA recombination systems, V(D)J recombination is noteworthy in that identical reactants yield different recombination products at the junction of joined segments. This variation is the basis for diversity at the base of antigen receptor binding pockets and corresponds to V-(D)-J DNA junctions. An abundance of certain junctions has been noted1-5. It has been proposed that these junctions are favoured because they occur where short regions of homology in participating coding ends might align preferentially1. Here we use a system that is entirely free from cellular selection to show that the diversity of coding joints can be severely restricted when the coding ends participating in the reaction have short regions of homology. This constraint on diversity is diminished but not eliminated by terminal deoxynucleotidyl transferase, a mechanistic feature that has implications for the establishment of the immune repertoire.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; CLAFLIN JL, 1988, J IMMUNOL, V141, P4012; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1988, J IMMUNOL, V141, P1267; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; GEARHART PJ, 1981, NATURE, V291, P29, DOI 10.1038/291029a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HERZENBERG LA, 1989, CELL, V59, P953, DOI 10.1016/0092-8674(89)90748-4; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LAL RB, 1987, J IMMUNOL, V138, P3454; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, IN PRESS MOL CELL BI; POLLOK BA, 1984, NATURE, V311, P376, DOI 10.1038/311376a0; POTTER M, 1971, ANN NY ACAD SCI, V190, P306, DOI 10.1111/j.1749-6632.1971.tb13543.x; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	29	97	98	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					625	627		10.1038/363625a0	http://dx.doi.org/10.1038/363625a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510753				2022-12-28	WOS:A1993LH13900055
J	WOLTER, TJ				WOLTER, TJ			IN THE FOOTSTEPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2947	2947						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501823				2022-12-28	WOS:A1993LF94100001
J	COOK, DJ; GUYATT, GH; RYAN, G; CLIFTON, J; BUCKINGHAM, L; WILLAN, A; MCLLROY, W; OXMAN, AD				COOK, DJ; GUYATT, GH; RYAN, G; CLIFTON, J; BUCKINGHAM, L; WILLAN, A; MCLLROY, W; OXMAN, AD			SHOULD UNPUBLISHED DATA BE INCLUDED IN METAANALYSES - CURRENT CONVICTIONS AND CONTROVERSIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLICATION BIAS; CLINICAL RESEARCH; CONTROLLED TRIALS; PSYCHOLOGY; AGREEMENT; REVIEWS	Objective.-To identify the extent to which meta-analyses currently include unpublished data and whether editors, meta-analysts, and methodologists believe unpublished material should be included. Design.-This article describes two related studies: a literature review and a cross-sectional survey. Sample Selection.-For the literature review, we identified all articles indexed by the key word meta-analysis from January 1989 to February 1991 and determined whether unpublished material had been searched for, obtained, and included in the meta-analyses. For the cross-sectional survey, we surveyed authors of these meta-analyses, authors of articles addressing methodological issues in meta-analysis published during the same period, and editors of journals in which both types of articles were published. Intervention.-We asked the respondents about their attitudes concerning inclusion of unpublished data and publication of articles from which data had previously been included in a scientific overview. Main Outcome Measures.-Inclusion of unpublished data and opinions about whether unpublished material should be included in overviews and whether prior inclusion of data in an overview should bear on publication. Results.-Of 150 meta-analyses, 46 (30.7%) included unpublished data in their primary analysis. Of authors surveyed, 85% responded. Of the meta-analysts and methodologists, 77.7% felt that unpublished material should definitely or probably be included in scientific overviews; this was true of 46.9% of the editors. A total of 86.4% of the meta-analysts and methodologists and 53.2% of the editors felt that inclusion of data in a prior overview should have no bearing on full publication of original research. Conclusion.-While inclusion of unpublished data in scientific overviews remains controversial, most investigators directly involved in meta-analysis believe that unpublished data should not be systematically excluded. The most valid synthesis of available information will result when meta-analysts subject published and unpublished material to the same rigorous methodological evaluation and present results with and without unpublished sources of data.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT FAMILY MED, HAMILTON L8N 3Z5, ONTARIO, CANADA; SIR CHARLES GAIRDNER HOSP, DEPT AGRON, NEDLANDS, WA 6009, AUSTRALIA; ONTARIO MINIST HLTH, TORONTO M5W 1R5, ONTARIO, CANADA	McMaster University; McMaster University; University of Western Australia	COOK, DJ (corresponding author), MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, ROOM 2C12, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061				BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BERLIN JA, 1992, ONLINE J CURR CLIN T; CHALMERS TC, 1965, GASTROENTEROLOGY, V49, P22; CICCHETTI DV, 1976, YALE J BIOL MED, V49, P373; COOK DJ, 1991, CHEST, V100, P7, DOI 10.1378/chest.100.1.7; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; EASTERBROOK PJ, 1992, STAT MED, V11, P345, DOI 10.1002/sim.4780110307; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; INGELFINGER FJ, 1974, AM J MED, V56, P686, DOI 10.1016/0002-9343(74)90635-4; KOREN G, 1989, LANCET, V2, P1440; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Mahoney M.J., 1977, COGNITIVE THER RES, V1, P161, DOI [10.1007/BF01173636, DOI 10.1007/BF01173636]; MARSH HW, 1981, J EDUC PSYCHOL, V73, P872, DOI 10.1037/0022-0663.73.6.872; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SCOTT WA, 1974, AM PSYCHOL, V29, P698, DOI 10.1037/h0037631; SHADISH WR, 1989, CLIN PSYCHOL REV, V9, P589, DOI 10.1016/0272-7358(89)90013-5; SIGEL S, 1988, NONPARAMETRIC STAT, P213; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; WILLIAMSON JW, 1986, MED USE STATISTICS, P370; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	29	314	317	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2749	2753		10.1001/jama.269.21.2749	http://dx.doi.org/10.1001/jama.269.21.2749			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492400				2022-12-28	WOS:A1993LD67100024
J	JOSEPH, J; STRANGE, C; SAHN, SA				JOSEPH, J; STRANGE, C; SAHN, SA			PLEURAL EFFUSIONS IN HOSPITALIZED-PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						PLEURAL EFFUSION; ACQUIRED IMMUNODEFICIENCY SYNDROME; HOSPITALIZATION; ASTERISK HYPOALBUMINEMIA; PNEUMONIA	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; BLOOD-INSTITUTE WORKSHOP; PULMONARY COMPLICATIONS; PNEUMOCYSTIS-CARINII; KAPOSIS SARCOMA; NATIONAL-HEART; MANIFESTATIONS; PNEUMONIA; LYMPHOMA	Objective: To determine the incidence, cause, and characteristics of pleural effusions in hospitalized patients with the acquired immunodeficiency syndrome (AIDS). Design: Retrospective. Participants: A total of 222 patients with AIDS hospitalized between January 1986 and January 1992 at the Medical University of South Carolina hospitals. Results: Pleural effusions occurred in 59 patients for an overall incidence of 27%. The mean age of the patients was 35 +/- 2 years (SE) and the male to female ratio was 5:1. The cause was infectious in 39 (66%) patients, noninfectious in 18 (31%), and unknown in 2 (3%). Pleural effusions were caused by bacterial pneumonia in 18 (31%) patients, Pneumocystis carinii pneumonia in 9 (15%), Mycobacterium tuberculosis in 5 (8%), septic embolism in 2 (3%), Nocardia asteroides in 2 (3%), cryptococcus neoformans in 2 (3%), and Mycobacterium arium intracellulare in 1 (2%). Among noninfectious causes (n = 18), hypoalbuminemia was the cause in 11 patients (19%), cardiac failure in 3 (5%), and atelectasis, Kaposi sarcoma, uremic pleurisy, and adult respiratory distress syndrome in 1 (2%) each. Patients with AIDS who had pleural effusions had significantly lower serum albumin levels and had lower CD4 counts than did those without pleural effusions (P < 0.001). Conclusions: Pleural effusions are common in hospitalized patients with AIDS. Bacterial pneumonia is the most common cause for pleural effusion in AIDS. Large effusions are associated with Kaposi sarcoma and tuberculosis. Hypoalbuminemia is a common cause of noninfectious pleural effusions.			JOSEPH, J (corresponding author), MED UNIV S CAROLINA, DIV PULM & CRIT CARE MED, CHARLESTON, SC 29425 USA.			Strange, Charlie/0000-0002-8109-8067				ADAMS DA, 1960, ARCH INTERN MED, V106, P169; BALACHANDRAN I, 1990, ACTA CYTOL, V34, P486; COHEN BA, 1984, AM J ROENTGENOL, V143, P115, DOI 10.2214/ajr.143.1.115; ELWOOD LJ, 1991, ACTA CYTOL, V35, P761; GOODMAN P C, 1987, Postgraduate Radiology, V7, P3; Gottlieb M S, 1984, Chest, V86, p29S; GRUM EE, 1991, AM J MED SCI, V301, P329, DOI 10.1097/00000441-199105000-00007; HIRSCH A, 1979, THORAX, V34, P106, DOI 10.1136/thx.34.1.106; KATZ AS, 1989, CHEST, V96, P440, DOI 10.1378/chest.96.2.440; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LEE AM, 1991, SOUTHERN MED J, V84, P1278, DOI 10.1097/00007611-199110000-00031; MARCHEVSKY A, 1985, HUM PATHOL, V16, P659, DOI 10.1016/S0046-8177(85)80148-9; MARSHALL BC, 1990, AM J MED SCI, V300, P98, DOI 10.1097/00000441-199008000-00005; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; NAIDICH DP, 1987, SEMIN ROENTGENOL, V22, P14, DOI 10.1016/0037-198X(87)90019-8; OBRIEN RF, 1989, CHEST, V96, P460, DOI 10.1378/chest.96.3.460; OBRIEN RF, 1989, SEMIN RESPIR MED, V10, P12, DOI 10.1055/s-2007-1006146; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; SAHN SA, 1988, AM REV RESPIR DIS, V138, P184, DOI 10.1164/ajrccm/138.1.184; SCHNAPP LM, 1992, ARCH INTERN MED, V152, P1073, DOI 10.1001/archinte.152.5.1073; SIDER L, 1989, INVEST RADIOL, V24, P150, DOI 10.1097/00004424-198902000-00012; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; Strazzella W D, 1991, N J Med, V88, P39; SUSTER B, 1986, RADIOLOGY, V161, P87, DOI 10.1148/radiology.161.1.3489955; TARYLE DA, 1978, CHEST, V74, P170, DOI 10.1378/chest.74.2.170; YAMAMOTO S, 1976, IMMUNOLOGY, V30, P513	28	46	46	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					856	859		10.7326/0003-4819-118-11-199306010-00005	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480960				2022-12-28	WOS:A1993LD25200005
J	MANSER, E; LEUNG, T; SALIHUDDIN, H; TAN, L; LIM, L				MANSER, E; LEUNG, T; SALIHUDDIN, H; TAN, L; LIM, L			A NONRECEPTOR TYROSINE KINASE THAT INHIBITS THE GTPASE ACTIVITY OF P21(CDC42)	NATURE			English	Article							MOLECULAR-CLONING; PROTEIN; GENE; PRODUCT; YEAST; BCR; RAS	THE Ras-related Rho subfamily of GTP-binding proteins (p21s), which includes Rho, Rac and Cdc42Hs, is implicated in different aspects of cytoskeletal organization1,2. These proteins behave like Ras (p21ras) in that their active GTP-bound form is inactivated by intrinsic hydrolysis of the nucleotide gamma-phosphate, which can be stimulated by GTPase-activating proteins (GAPs). We have previously shown that there is a diversity of GAPs that recognize this subfamily3, including n-chimaerin, which is enriched in the hippocampus4; we also detected proteins that bind these p21 proteins and seem to inhibit GTP hydrolysis. We now report the characterization of a hippocampal complementary DNA encoding a tyrosine kinase that specifically binds Cdc42Hs in its GTP-bound form. This binding is mediated by a unique sequence of 47 amino acids C-terminal to an SH3 domain and inhibits both the intrinsic and GAP-stimulated GTPase activity of Cdc42Hs. Our findings indicate that there may be a regulatory mechanism that sustains the GTP-bound active form of Cdc42Hs and which is directly linked to a tyrosine phosphorylation pathway.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	MANSER, E (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1990, J BIOL CHEM, V265, P590; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V269, P106, DOI 10.1016/0003-9861(89)90091-X; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442	22	282	290	2	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					364	367		10.1038/363364a0	http://dx.doi.org/10.1038/363364a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497321				2022-12-28	WOS:A1993LD91700058
J	SMAS, CM; SUL, HS				SMAS, CM; SUL, HS			PREF-1, A PROTEIN CONTAINING EGF-LIKE REPEATS, INHIBITS ADIPOCYTE DIFFERENTIATION	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; ENHANCER BINDING-PROTEIN; INDUCED GENE-EXPRESSION; ADIPOSE CELL LINE; 3T3-L1 PREADIPOCYTES; DROSOPHILA-NOTCH; MESSENGER-RNAS; NUCLEOTIDE-SEQUENCE; BLOOD-COAGULATION; FACTOR-ALPHA	With the aim of identifying novel regulators of adipocyte differentiation, we have cloned and characterized preadipocyte factor 1 (pref-1), a novel member of the epidermal growth factor (EGF)-like family of proteins. Pref-1 is synthesized as a transmembrane protein with six tandem EGF-like repeats. In preadipocytes, multiple discrete forms of pref-1 protein of 45-60 kd are present, owing in part to N-linked glycosylation. While pref-1 mRNA is abundant in preadipocytes, its expression is completely abolished during differentiation of 3T3-L1 preadipocytes to adipocytes. Moreover, constitutive expression of pref-1 in preadipocytes, which in effect blocks its down-regulation, drastically inhibits adipose differentiation. This indicates that pref-1 functions asa negative regulator of adipocyte differentiation, possibly in a manner analogous to EGF-like proteins that govern cell fate decisions in invertebrates.			SMAS, CM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA.		Han, Zaiqi/AAI-2233-2019					ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; CALVO JC, 1991, CAMPJ, V266, P11237; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DANI C, 1989, J BIOL CHEM, V264, P10119; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DJIAN P, 1988, GENE DEV, V2, P1251, DOI 10.1101/gad.2.10.1251; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Maniatis T, 1989, MOL CLONING; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; NIES DE, 1991, J BIOL CHEM, V266, P2818; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SIDHU RS, 1979, J BIOL CHEM, V254, P1111; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WENZ HM, 1992, P NATL ACAD SCI USA, V89, P1065, DOI 10.1073/pnas.89.3.1065; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WISE LS, 1984, J BIOL CHEM, V259, P4827; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	75	551	576	2	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					725	734		10.1016/0092-8674(93)90252-L	http://dx.doi.org/10.1016/0092-8674(93)90252-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500166				2022-12-28	WOS:A1993LD83000011
J	WEINBERGER, SE				WEINBERGER, SE			MEDICAL PROGRESS - RECENT ADVANCES IN PULMONARY MEDICINE .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RESPIRATORY-DISTRESS SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; INVERSE RATIO VENTILATION; CONTROLLED CLINICAL-TRIAL; OBSTRUCTIVE LUNG-DISEASE; PLACEBO-CONTROLLED TRIAL; VIRUS-INFECTION				WEINBERGER, SE (corresponding author), BETH ISRAEL HOSP,DIV PULM & CRIT CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ASHBAUGH DG, 1967, LANCET, V2, P319; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BARBERA JA, 1992, AM REV RESPIR DIS, V145, P940, DOI 10.1164/ajrccm/145.4_Pt_1.940; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARRIO JL, 1986, AM REV RESPIR DIS, V134, P1094, DOI 10.1164/arrd.1986.134.5.1094; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P1095, DOI 10.1164/ajrccm/144.5.1095; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; CALHOON JH, 1991, J THORAC CARDIOV SUR, V101, P816; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHECHANI V, 1990, CHEST, V98, P1060, DOI 10.1378/chest.98.5.1060; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COOPER JD, 1990, ANN SURG, V212, P249, DOI 10.1097/00000658-199009000-00003; COOPER JD, 1989, AM REV RESPIR DIS, V139, P303, DOI 10.1164/ajrccm/139.2.303; DAUBER JH, 1990, CLIN CHEST MED, V11, P291; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; DAVIDSON PT, 1992, DRUGS, V43, P651, DOI 10.2165/00003495-199243050-00003; DEHOYOS AL, 1992, J THORAC CARDIOV SUR, V103, P295; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; DONNELLY SC, 1992, THORAX, V47, P260, DOI 10.1136/thx.47.4.260; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; DORINSKY PM, 1989, CHEST, V96, P885, DOI 10.1378/chest.96.4.885; DORINSKY PM, 1990, CLIN CHEST MED, V11, P581; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; ENHORNING G, 1989, AM REV RESPIR DIS, V140, P281, DOI 10.1164/ajrccm/140.2.281; EPSTEIN DM, 1987, CHEST, V91, P106, DOI 10.1378/chest.91.1.106; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARNER W, 1988, CHEST, V94, P779, DOI 10.1378/chest.94.4.779; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOLDSTEIN G, 1990, CLIN CHEST MED, V11, P773; GOOD RC, 1989, CLIN CHEST MED, V10, P315; GOOD RC, 1989, ANN INTERN MED, V110, P97, DOI 10.7326/0003-4819-110-2-97; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; HAAKE R, 1987, CHEST, V91, P608, DOI 10.1378/chest.91.4.608; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HAYDOCK DA, 1992, J THORAC CARDIOV SUR, V103, P329; HECKMATT JZ, 1990, LANCET, V335, P579, DOI 10.1016/0140-6736(90)90357-B; HENSON PM, 1992, AM REV RESPIR DIS, V145, P726, DOI 10.1164/ajrccm/145.3.726; HILL NS, 1992, AM REV RESPIR DIS, V145, P365, DOI 10.1164/ajrccm/145.2_Pt_1.365; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HURST JM, 1989, ARCH SURG-CHICAGO, V124, P1067; HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KAISER LR, 1991, ANN THORAC SURG, V52, P438, DOI 10.1016/0003-4975(91)90903-4; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; KOVACS JA, 1990, ANN INTERN MED, V113, P1, DOI 10.7326/0003-4819-113-1-1; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KRAMER EL, 1987, J NUCL MED, V28, P1107; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LEE VW, 1991, RADIOLOGY, V180, P409, DOI 10.1148/radiology.180.2.2068302; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MANDELL GL, 1988, AM REV RESPIR DIS, V138, P1103, DOI 10.1164/ajrccm/138.5.1103; MARCY TW, 1991, CHEST, V100, P494, DOI 10.1378/chest.100.2.494; MARCY TW, 1992, CURRENT PULMONOLOGY, P43; MARINI JJ, 1992, AM REV RESPIR DIS, V146, P2, DOI 10.1164/ajrccm/146.1.2; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; MASUR H, 1986, ANN INTERN MED, V104, P41, DOI 10.7326/0003-4819-104-1-41; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MAURER JR, 1992, CHEST, V101, P1056, DOI 10.1378/chest.101.4.1056; MCCARTHY PM, 1990, J THORAC CARDIOV SUR, V99, P54; MCCARTHY PM, 1992, CLEV CLIN J MED, V59, P307, DOI 10.3949/ccjm.59.3.307; MCCLELLAN MD, 1991, CHEST, V100, P1224, DOI 10.1378/chest.100.5.1224; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MILES PR, 1990, CHEST, V97, P1072, DOI 10.1378/chest.97.5.1072; MILLAR AB, 1990, AM REV RESPIR DIS, V141, P1474, DOI 10.1164/ajrccm/141.6.1474; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS JC, 1987, CHEST, V91, P63, DOI 10.1378/chest.91.1.63; MORRISON DL, 1990, CLIN CHEST MED, V11, P207; MORTON NS, 1990, THORAX, V45, P825, DOI 10.1136/thx.45.11.825; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NG VL, 1989, ARCH PATHOL LAB MED, V113, P488; OGNIBENE FP, 1984, AM REV RESPIR DIS, V129, P929; PASQUE MK, 1991, CIRCULATION, V84, P2275, DOI 10.1161/01.CIR.84.6.2275; PATTERSON GA, 1991, J THORAC CARDIOV SUR, V101, P623; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; POLISH LB, 1989, CHEST, V96, P1321, DOI 10.1378/chest.96.6.1321; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RINALDO JE, 1990, CLIN CHEST MED, V11, P621; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SATTLER FR, 1992, CHEST, V101, P451, DOI 10.1378/chest.101.2.451; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; STANDIFORD TJ, 1989, CHEST, V96, P1380, DOI 10.1378/chest.96.6.1380; STEAD WW, 1991, ANNU REV MED, V42, P267, DOI 10.1146/annurev.med.42.1.267; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; STRUMPF DA, 1990, CHEST, V98, P474, DOI 10.1378/chest.98.2.474; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; THEODORE J, 1990, CLIN CHEST MED, V11, P309; TODD TRJ, 1990, CLIN CHEST MED, V11, P259; TOMLINSON JR, 1989, CHEST, V96, P348, DOI 10.1378/chest.96.2.348; TRULOCK EP, 1992, CHEST, V102, P1049, DOI 10.1378/chest.102.4.1049; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; TSUNO K, 1990, J APPL PHYSIOL, V69, P956, DOI 10.1152/jappl.1990.69.3.956; WALDHORN RE, 1992, CHEST, V101, P516, DOI 10.1378/chest.101.2.516; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WHITE DA, 1989, AM REV RESPIR DIS, V140, P1763, DOI 10.1164/ajrccm/140.6.1763; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; YOUNES M, 1992, AM REV RESPIR DIS, V145, P121, DOI 10.1164/ajrccm/145.1.121; YOUNES M, 1992, AM REV RESPIR DIS, V145, P114, DOI 10.1164/ajrccm/145.1.114; ZIBRAK JD, 1986, CHEST, V90, P476, DOI 10.1378/chest.90.4.476; ZIBRAK JD, 1988, AM REV RESPIR DIS, V138, P1515, DOI 10.1164/ajrccm/138.6.1515; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, MMWR MORB MORTAL WKL, V40, P585; 1989, MORB MORTAL WKLY REP, V38, P236; 1986, NEW ENGL J MED, V314, P1140; [No title captured]; 1991, CORE CIRRICULUM TUBE; 1990, NEW ENGL J MED, V323, P1500; 1991, MMWR MORB MORTAL WKL, V40, P869	147	15	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1993	328	20					1462	1470		10.1056/NEJM199305203282007	http://dx.doi.org/10.1056/NEJM199305203282007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB783	8479466				2022-12-28	WOS:A1993LB78300007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			2 NEW CHILD VACCINES LICENSED - COMBINATION DTP AND HAEMOPHILUS-B CONJUGATE VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487398				2022-12-28	WOS:A1993LB45000006
J	HIRAI, Y; NAKAGAWA, S; TAKEICHI, M				HIRAI, Y; NAKAGAWA, S; TAKEICHI, M			REEXAMINATION OF THE PROPERTIES OF EPIMORPHIN AND ITS POSSIBLE ROLES	CELL			English	Note									KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyoto University	HIRAI, Y (corresponding author), BIOMAT RES INST,1 TAYA CHO,SAKAE KU,YOKOHAMA 244,JAPAN.		Takeichi, Masatoshi/G-5903-2012; Nakagawa, Shinichi/I-4192-2014	Takeichi, Masatoshi/0000-0002-9931-3378; Nakagawa, Shinichi/0000-0002-6806-7493				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HIRAI Y, 1993, IN PRESS BIOCH BIOPH; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; PELHAM HRB, 1993, CELL, V73	7	25	25	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					426	427		10.1016/0092-8674(93)90129-E	http://dx.doi.org/10.1016/0092-8674(93)90129-E			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490960				2022-12-28	WOS:A1993LA74300004
J	LOWE, SW; SCHMITT, EM; SMITH, SW; OSBORNE, BA; JACKS, T				LOWE, SW; SCHMITT, EM; SMITH, SW; OSBORNE, BA; JACKS, T			P53 IS REQUIRED FOR RADIATION-INDUCED APOPTOSIS IN MOUSE THYMOCYTES	NATURE			English	Article							WILD-TYPE; PROTEIN	THE p53 tumour suppressor gene is the most widely mutated gene in human tumorigenesis1,2. p53 encodes a transcriptional activator3-7 whose targets may include genes that regulate genomic stability8,9, the cellular response to DNA damage10,11, and cell-cycle progression12-13. Introduction of wild-type p53 into cell lines that have lost endogenous p53 function can cause growth arrest14-16 or induce a process of cell death known as apoptosis17,18. During normal development, self-reactive thymocytes undergo negative selection by apoptosis19, which can also be induced in immature thymocytes by other stimuli, including exposure to glucocorticoids15 and ionizing radiation16. Although normal negative selection involves signalling through the T-cell receptor14, the induction of apoptosis by other stimuli is poorly understood. We have investigated the requirement for p53 during apoptosis in mouse thymocytes. We report here that immature thymocytes lacking p53 die normally when exposed to compounds that may mimic T-cell receptor engagement and to glucocorticoids but are resistant to the lethal effects of ionizing radiation. These results demonstrate that p53 is required for radiation-induced cell death in the thymus but is not necessary for all forms of apoptosis.	MIT,CTR CANC RES,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; UNIV MASSACHUSETTS,DEPT VET & ANIM SCI,AMHERST,MA 01003; UNIV MASSACHUSETTS,PAIGE LAB 309,PROGRAM MOLEC & CELLULAR BIOL,AMHERST,MA 01003	Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	15	2873	2929	2	80	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					847	849		10.1038/362847a0	http://dx.doi.org/10.1038/362847a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479522				2022-12-28	WOS:A1993KZ56300059
J	OLINER, JD; PIETENPOL, JA; THIAGALINGAM, S; GVURIS, J; KINZLER, KW; VOGELSTEIN, B				OLINER, JD; PIETENPOL, JA; THIAGALINGAM, S; GVURIS, J; KINZLER, KW; VOGELSTEIN, B			ONCOPROTEIN MDM2 CONCEALS THE ACTIVATION DOMAIN OF TUMOR SUPPRESSOR-P53	NATURE			English	Article							P53 PROTEIN; WILD-TYPE; SEQUENCES; GENE	THE tumour-suppressor gene p53 is inactivated in most human malignancies1 either by missense mutations1 or by binding to oncogenic proteins2-4. In human soft tissue sarcomas, inactivation apparently results from MDM2 gene amplification4. MDM2 is an oncogene product5,6 that may function by binding to p53 and inhibiting its ability to activate transcription3 . Here we show that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain. The isolated p53 activation domain fused to another DNA-binding protein is also inactivated by MDM2, confirming that MDM2 can inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery.	JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Thiagalingam, Sam/0000-0001-5211-266X				DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EBINAYY, 1983, J BIOL CHEM, V258, P13258; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, IN PRESS P NATN ACAD; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; LAUTHER KK, 1992, SCIENCE, V256, P1333; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	27	1336	1388	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					857	860		10.1038/362857a0	http://dx.doi.org/10.1038/362857a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479525				2022-12-28	WOS:A1993KZ56300063
J	SWAIN, P				SWAIN, P			COUNTDOWN TO COMMUNITY CARE - HELPING DISABLED PEOPLE - THE USERS VIEW	BRITISH MEDICAL JOURNAL			English	Article								The main needs for most people with physical disabilities are housing and help with daily living. Thus, many of them will find the new emphasis on social aspects of community care particularly relevant. Peter Swain is a disabled man who leads a project in east Devon which ensures that disabled people have a voice in helping to shape the services they need. In this article he explains how the project, Living Options East Devon, works and how the new legislation for community care might affect disabled people.			SWAIN, P (corresponding author), LIVING OPT E DEVON,ASHCLYST CTR,EXETER EX1 3RB,ENGLAND.							FIELDER B, 1988, LIVING OPTIONS LOTTE; HOWE M, 1992, PATHWAYS QUALITY SER; McColl I, 1986, REV ARTIFICIAL LIMB; MURRAY T, 1991, SURVEY SERVICES YOUN; SWAIN P, 1988, SCANDINAVIAN STUDY T; 1991, LIGHTWEIGHT WHEELCHA; 1991, HOUSING PEOPLE DISAB; 1990, WHEELCHAIR SERVICES	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					990	992		10.1136/bmj.306.6883.990	http://dx.doi.org/10.1136/bmj.306.6883.990			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490483	Green Published, Bronze			2022-12-28	WOS:A1993KX43600028
J	BROCKLEHURST, JC				BROCKLEHURST, JC			URINARY-INCONTINENCE IN THE COMMUNITY - ANALYSIS OF A MORI POLL	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; WOMEN; HOME	Objectives-To investigate the prevalence of urinary incontinence among people living at home, their responses to it, and its emotional and social effects. Design-Random sample of 4007 adults interviewed in their own homes. Setting-Random sample of 178 constituency sampling points throughout Great Britain. Subjects-1883 men, 2124 women aged 30 and over. Main outcome measures-Responses to questionnaire. Results-6.6% (125) men and 14.0% (297) women had been incontinent of urine at some time-2.8% (52) men and 7.5% (159) women in the previous two months and 61% (124) of these for more than four years. 52% (108) had consulted their general practitioner at the onset of incontinence and a further 31% (65) later. Doctors commonly took a urine sample (163, 54%), referred the patient to a specialist (127, 42%), and prescribed tablets (109, 36%); only 22% (66) carried out an abdominal, rectal, or vaginal examination. Patients were not embarrassed in seeing their doctor and most thought they were treated sympathetically. 60% (265) of all those affected were concerned or worried about their incontinence, and in almost half incontinence limited their daily social activities. Conclusion-More people with incontinence seem to be consulting their doctors about it than has been found in previous studies, but the procedures carried out by general practitioners still seem to be suboptimal. Urinary incontinence has a profound effect on the day to day lives of most of those who suffer from it.			BROCKLEHURST, JC (corresponding author), PRISM INT,BRITISH ASSOC CONTINENCE CARE,PINEWOOD STUDIOS,IVER HEATH SL0 0NH,BUCKS,ENGLAND.							BATES P, 1979, J UROLOGY, V121, P551, DOI 10.1016/S0022-5347(17)56874-3; BRIGGS M, 1992, BRIT MED J, V304, P255, DOI 10.1136/bmj.304.6821.255; BROCKLEHURST J C, 1972, Age and Ageing, V1, P41, DOI 10.1093/ageing/1.1.41; JOLLEYS JV, 1988, BRIT MED J, V296, P1300, DOI 10.1136/bmj.296.6632.1300; MCGROTHER CW, 1987, AGE AGEING, V16, P105, DOI 10.1093/ageing/16.2.105; NEMIR A, 1954, AM J OBSTET GYNECOL, V68, P1166; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; VETTER NJ, 1981, LANCET, V2, P1275; WELLS T, 1984, UROLOGY ELDERLY, P119; WOLLIN LH, 1969, J UROLOGY, V101, P545; WYMAN JF, 1987, OBSTET GYNECOL, V70, P378	13	215	218	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					832	834		10.1136/bmj.306.6881.832	http://dx.doi.org/10.1136/bmj.306.6881.832			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490377	Bronze, Green Published			2022-12-28	WOS:A1993KV34800023
J	ROSEMOND, RL				ROSEMOND, RL			CARDIOVERSION DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ROSEMOND, RL (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37240, USA.							DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; SANCHEZDIAZ CJ, 1957, ARCH I CARDIOL MEX, V57, P387; UELAND K, 1981, Clinical Obstetrics and Gynecology, V24, P809, DOI 10.1097/00003081-198109000-00008	3	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3167	3167						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505820				2022-12-28	WOS:A1993LH14500037
J	MIRKIN, G				MIRKIN, G			STOOL ANALYSIS FOR ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20007, USA.							DANNA PL, 1991, LANCET, V337, P511, DOI 10.1016/0140-6736(91)91296-7; HOWARD DH, 1982, FUNGI PATHOGENIC HUM; ODDS FC, 1979, CANDIDA CANDIDIASIWS; VANMETRE TE, 1968, J ALLERGY, V41, P195, DOI 10.1016/0021-8707(68)90042-7	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2609	2609		10.1001/jama.269.20.2609	http://dx.doi.org/10.1001/jama.269.20.2609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487431				2022-12-28	WOS:A1993LC86500004
J	JONES, PH; WATT, FM				JONES, PH; WATT, FM			SEPARATION OF HUMAN EPIDERMAL STEM-CELLS FROM TRANSIT AMPLIFYING CELLS ON THE BASIS OF DIFFERENCES IN INTEGRIN FUNCTION AND EXPRESSION	CELL			English	Article							TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; MONOCLONAL-ANTIBODIES; INVOLUCRIN SYNTHESIS; STRATUM CORNEUM; BURN WOUNDS; FIBRONECTIN; ADHESION; CULTURE; INVITRO	The epidermis is believed to contain two types of proliferating cells: stem cells and cells with a lower capacity for self-renewal and higher probability of undergoing terminal differentiation (transit amplifying cells). We report that keratinocytes with characteristics of stem cells can be isolated from cultured human epidermis on the basis of high surface expression of beta1 integrins and rapid adhesion to extracellular matrix (ECM) proteins. Among keratinocytes there was a log linear relationship between the relative level of beta1 integrins on the cell surface and proliferative capacity; furthermore, the cells with the highest colony-forming efficiency adhered most rapidly to type IV collagen, fibronectin, or keratinocyte ECM. Proliferating keratinocytes that adhered more slowly had characteristics of transit amplifying cells: after one to five rounds of division, all of their daughters underwent terminal differentiation. Since stem cells can be isolated to greater than 90% purity on the basis of their adhesive properties, it will now be possible to investigate the mechanisms that regulate the fate of their progeny.			JONES, PH (corresponding author), IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ANDREWS RG, 1990, J EXP MED, V172, P355, DOI 10.1084/jem.172.1.355; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; CHRISTOPHERS E, 1971, J INVEST DERMATOL, V56, P165, DOI 10.1111/1523-1747.ep12260765; COMPTON CC, 1989, LAB INVEST, V60, P600; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; CURRY JL, 1967, DEV BIOL, V15, P395, DOI 10.1016/0012-1606(67)90034-6; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GREEN H, 1988, NEWS PHYSIOL SCI, V3, P53; HALL PA, 1989, DEVELOPMENT, V106, P619; HARLOW E, 1988, ANTIBODIES LABORATOR; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; HUME WJ, 1976, J CELL SCI, V22, P149; IVERSEN O H, 1968, Cell and Tissue Kinetics, V1, P351, DOI 10.1111/j.1365-2184.1968.tb00964.x; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KAY HEM, 1965, LANCET, V2, P418; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; Lane E B, 1990, Semin Cancer Biol, V1, P165; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; LENOIR MC, 1988, DEV BIOL, V130, P610, DOI 10.1016/0012-1606(88)90356-9; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORHENN VB, 1983, J INVEST DERMATOL, V81, pS127, DOI 10.1111/1523-1747.ep12540890; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; Potten C S, 1981, Int Rev Cytol, V69, P271; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1973, INT J RADIAT BIOL, V24, P537, DOI 10.1080/09553007314551441; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1991, CURR OPIN IMMUNOL, V3, P171, DOI 10.1016/0952-7915(91)90046-4; TENCHINI ML, 1993, IN PRESS CELL ADHESI; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1992, BIOCHEM SOC T, V20, P285, DOI 10.1042/bst0200285; WATT FM, 1993, IN PRESS KERATINOCYT; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WITHERS HR, 1967, RADIAT RES, V32, P227, DOI 10.2307/3572220	59	944	1029	1	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					713	724		10.1016/0092-8674(93)90251-K	http://dx.doi.org/10.1016/0092-8674(93)90251-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500165				2022-12-28	WOS:A1993LD83000010
J	SERAPHIN, B; KANDELSLEWIS, S				SERAPHIN, B; KANDELSLEWIS, S			3' SPLICE SITE RECOGNITION IN SACCHAROMYCES-CEREVISIAE DOES NOT REQUIRE BASE-PAIRING WITH U1 SNRNA	CELL			English	Article							PRE-MESSENGER-RNA; 5' CLEAVAGE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SACCHAROMYCES-CEREVISIAE; MAMMALIAN INTRONS; YEAST; SELECTION; SEQUENCES; INVITRO; PRECURSORS	The conserved nucleotides 9 and 10 of U1 small nuclear RNA (snRNA) have been proposed to base pair with either 5' exon or 3' splice site sequences. In S. pombe, U1 snRNA pairing with the conserved 3' splice site is required for the first step of splicing and viability. In contrast, we show that S. cerevisiae Ul mutants at positions 9 and 10 are fully functional. Splicing of several genes is normal in these strains, ruling out an essential base pairing between U1 snRNA and 3' splice sites. U1 snRNA positions 9 and 10 are shown to be involved in 5' splice site selection through their interaction with exon sequences. Our results demonstrate that some snRNA-pre-mRNA interactions are not evolutionarily conserved and that 3' splice site recognition occurs by different mechanisms in various organisms.			SERAPHIN, B (corresponding author), EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY.			Seraphin, Bertrand/0000-0002-5168-1921				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; IGEL AH, 1988, NATURE, V334, P450, DOI 10.1038/334450a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEBER S, 1988, NUCLEIC ACIDS RES, V16, P471, DOI 10.1093/nar/16.2.471; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521; ZHUANG Y, 1990, GENE, V90, P263, DOI 10.1016/0378-1119(90)90189-X; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	63	46	46	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					803	812		10.1016/0092-8674(93)90258-R	http://dx.doi.org/10.1016/0092-8674(93)90258-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500172				2022-12-28	WOS:A1993LD83000017
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DENTAL AMALGAM REPORT ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							DENTAL AMALGAM SCI R	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487398				2022-12-28	WOS:A1993LB45000005
J	SMITH, T				SMITH, T			INFLUENCE OF SOCIOECONOMIC-FACTORS ON ATTAINING TARGETS FOR REDUCING TEENAGE PREGNANCIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the rate of pregnancy and outcome in teenagers in areas of different socioeconomic conditions, and to assess the implication for achievement of government and local targets in reducing unwanted pregnancies in teenagers. Design-Records of pregnancies were obtained from hospital discharge files and rates of live and still births and abortions calculated for each postcode sector. Postcodes were grouped by categories of deprivation and by local government district. Setting-Tayside, Scotland. Subjects-Teenage girls admitted to National Health Service hospitals for delivery or abortion in 1980-90. Main outcome measures-Conception in girls aged under 16 by area of residence and relative proportion leading to live births or terminations. Rate of different outcomes in girls under the age of 20 by area of residence. Results-The pregnancy rate in girls aged under 16 was three times as high, and in all girls under 20 six times as high in the most deprived areas as in the most affluent areas. The proportion of teenage pregnancies ending in abortions was higher in the affluent areas, where two out of three ended in abortion compared with one out of four in the deprived areas. Conclusions-Although there was a higher pregnancy rate in teenagers in more deprived areas, the proportion ending in abortion was greater in more affluent areas, possibly due to social and parental pressure. The wide geographical variation in patterns of teenage pregnancy indicates the need for a small area rather than a regional approach to setting targets and devising measures of achieving them.			SMITH, T (corresponding author), TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND.							Carstairs V., 1991, DEPRIVATION HLTH SCO; SMITH T, 1992, J PUBLIC HEALTH MED, V14, P402, DOI 10.1093/oxfordjournals.pubmed.a042781; WILSON SH, 1992, J PUBLIC HEALTH MED, V14, P17; 1992, SCOTLANDS HLTH CHALL; 1992, HLTH NATION STRATEGY; 1991, 136 GEN REG OFF SCOT; 1992, BRIT STATISTICS 1990, P19; 1991, SCOTTISH HLTH STATIS	8	73	74	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1232	1235		10.1136/bmj.306.6887.1232	http://dx.doi.org/10.1136/bmj.306.6887.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB804	8499852	Green Published, Bronze			2022-12-28	WOS:A1993LB80400014
J	BAIN, J				BAIN, J			THE NEW NHS - THE 2ND YEAR - BUDGET HOLDING - HERE TO STAY	BRITISH MEDICAL JOURNAL			English	Article											BAIN, J (corresponding author), WESTGATE HLTH CTR,DEPT GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.							BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; BOSANQUET N, 1991, BRIT MED J, V303, P233, DOI 10.1136/bmj.303.6796.233; EVE R, 1991, BRIT MED J, V303, P167, DOI 10.1136/bmj.303.6795.167; FORBES JF, 1989, J ROY COLL GEN PRACT, V39, P355; GLENNERSTER H, 1992, FOOTHOLD FUND HOLDIN; MORRIS R, 1993, BRIT MED J, V306, P635, DOI 10.1136/bmj.306.6878.635; 1993, BMJ, V306, P539	8	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1185	1188		10.1136/bmj.306.6886.1185	http://dx.doi.org/10.1136/bmj.306.6886.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499827	Bronze, Green Published			2022-12-28	WOS:A1993LA68500031
J	VANTILBEURGH, H; EGLOFF, MP; MARTINEZ, C; RUGANI, N; VERGER, R; CAMBILLAU, C				VANTILBEURGH, H; EGLOFF, MP; MARTINEZ, C; RUGANI, N; VERGER, R; CAMBILLAU, C			INTERFACIAL ACTIVATION OF THE LIPASE PROCOLIPASE COMPLEX BY MIXED MICELLES REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							HUMAN LIPOPROTEIN-LIPASE; INHIBITOR COMPLEX; CATALYSIS; FAMILY; MODEL; SITE	The three-dimensional structure of the lipase-procolipase complex, co-crystallized with mixed micelles of phosphatidylcholine and bile salt, has been determined at 3 angstrom resolution by X-ray crystallography. The lid, a surface helix covering the catalytic triad of lipase, adopts a totally different conformation which allows phospholipid to bind to the enzyme's active site. The open lid is an essential component of the active site and interacts with procolipase. Together they form the lipid-water interface binding site. This reorganization of the lid structure provokes a second drastic conformational change in an active site loop, which in its turn creates the oxyanion hole (induced fit).	FAC SCI ST CHARLES, INST CHIM BIOL, F-13331 MARSEILLE, FRANCE; CNRS, GDR1000, LIPOLYSE ENZYMAT LAB, F-13402 MARSEILLE 9, FRANCE	Centre National de la Recherche Scientifique (CNRS)	VANTILBEURGH, H (corresponding author), FAC MED NORD, CNRS, LCCMB, BLVD P DRAMARD, F-13326 MARSEILLE 15, FRANCE.							Borgstrom B., 1984, P151; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DESNUELLE P, 1960, BIOCHIM BIOPHYS ACTA, V37, P570, DOI 10.1016/0006-3002(60)90532-1; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; ERLANSONALBERTSSON C, 1992, BIOCHIM BIOPHYS ACTA, V1125, P1, DOI 10.1016/0005-2760(92)90147-N; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; GUBERNATOR K, 1991, GBF MONOG SERIES, P9; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LOWE ME, 1992, J BIOL CHEM, V267, P17069; LUTHIPENG Q, 1992, EUR J BIOCHEM, V205, P383, DOI 10.1111/j.1432-1033.1992.tb16791.x; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; ROUSSEL A, 1991, SILICON GRAPHICS DIR; SARDA L, 1990, GBF GES BIOTECHNOL F, V16, P145; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P532; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	26	613	625	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1993	362	6423					814	820		10.1038/362814a0	http://dx.doi.org/10.1038/362814a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8479519				2022-12-28	WOS:A1993KZ56300047
J	KEIGHLEY, BD				KEIGHLEY, BD			THE ROYAL-COLLEGE-OF-GENERAL-PRACTITIONERS REVISITED	BRITISH MEDICAL JOURNAL			English	Article											KEIGHLEY, BD (corresponding author), THE CLIN,JOINT COMM POSTGRAD TRAINING GEN PRACTICE,BUCHANAN ST,BALFRON G63 OTS,STIRLING,SCOTLAND.							BOGLE I, 1993, GENERAL PRACTICE WAY; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; KEIGHLEY BD, 1980, BRIT MED J, V281, P1506, DOI 10.1136/bmj.281.6253.1506; Neighbour R., 1987, INNER CONSULTATION; NEIGHBOUR R, 1992, INNER APPRENTICE; 1972, FUTURE GENERAL PRACT	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					977	978		10.1136/bmj.306.6883.977	http://dx.doi.org/10.1136/bmj.306.6883.977			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490479	Green Published, Bronze			2022-12-28	WOS:A1993KX43600024
J	LIDEGAARD, O				LIDEGAARD, O			ORAL CONTRACEPTION AND RISK OF A CEREBRAL THROMBOEMBOLIC ATTACK - RESULTS OF A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							MULTIDIMENSIONAL CONTINGENCY-TABLES; EXACT CONDITIONAL TESTS; CIGARETTE-SMOKING; YOUNG-ADULTS; CEREBROVASCULAR-DISEASE; BLOOD-PRESSURE; STROKE; WOMEN; MORTALITY; HISTORIES	Objective-To assess the risk of cerebral thromboembolism in women using low dose oral contraceptives. Design-A retrospective case-control study. Setting-All Danish medical, neurological, neurosurgical, and gynaecological departments. Subjects-All 794 women in Denmark aged 15-44 who had suffered a cerebral thromboembolic attack during 1985-9 and 1588 age matched randomly selected controls. Result-Of 692/1584 case/control questionnaires sent out, 590/1396 (85.3%/88.1%) were returned. Among the cases, 15 refused to participate, 69 had a revised or unreliable diagnosis, 40 had had thromboembolic disease previously, 13 were pregnant, and 152 had a disease predisposing to a cerebral thromboembolic attack. Of the 323 cases without a known predisposition, 320 reported use or non-use of oral contraception. Among the 1396 controls, eight refused to participate, were mentally retarded, or lived abroad; 18 returned an uncompleted questionnaire; 17 had had thromboembolic disease previously; 31 were pregnant; and 130 had a disease predisposing to a cerebral thromboembolic attack. Thus 1198 non-predisposed controls were available, among whom 1197 reported use or non-use of oral contraception. Among the 320 cases, 116 (36.3%) were oral contraceptive users at the time of the cerebral thromboembolic attack. By comparison there were 191 users (16.0%) among the 1197 controls, giving a crude odds ratio of 3.0. After multivariate analysis, including confounder control for age, smoking, years of schooling, and trend in use of different types of oral contraceptives during 1985-90, pills containing 50 mug oestrogen were associated with an odds ratio for cerebral thromboembolic attack of 2.9 (95% confidence interval 1.6 to 5.4), those containing 30-40 mug oestrogen an odds ratio of 1.8 (1.1 to 2.9), those containing progestogen only an odds ratio of 0.9 (0.4 to 2.4). The odds ratio did not change with increasing age or with duration of oral contraceptive use. A 50% increased risk of a cerebral thromboembolic attacks among cigarette smokers (after confounder control) was independent of oral contraception status and age. Conclusion-Low dose oral contraceptives are associated with an increased risk of cerebral thromboembolic attack. Combined or sequential pills containing 30-40 mug oestrogen are associated with a one third reduced risk compared with preparations containing 50 mug oestrogen. Progestogen only pills did not increase the risk of a cerebral thromboembolic attack.			LIDEGAARD, O (corresponding author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT OBSTET & GYNAECOL,DK-2650 HVIDOVRE,DENMARK.							ABUZEID HAH, 1977, STROKE, V8, P106, DOI 10.1161/01.STR.8.1.106; ABUZEID HAH, 1975, PREV MED, V4, P567, DOI 10.1016/0091-7435(75)90042-0; Agresti A., 1984, ANAL ORDINAL CATEGOR; AHO K, 1986, STROKE, V17, P681, DOI 10.1161/01.STR.17.4.681; ANDERSON TW, 1970, CAN MED ASSOC J, V102, P1156; ARBUCKLE DD, 1982, PUBLIC HEALTH, V96, P96, DOI 10.1016/S0033-3506(82)80102-9; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BOTTIGER LE, 1971, ACTA MED SCAND, V190, P455; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COULTER A, 1986, CONTRACEPTION, V33, P127, DOI 10.1016/0010-7824(86)90079-X; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; FIRNHABER W, 1974, Z NEUROL, V206, P177, DOI 10.1007/BF00316532; FOGELHOLM R, 1973, ACTA NEUROL SCAND, V49, P415; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GLASS R, 1974, BRIT J PREV SOC MED, V28, P273; Gram L F, 1976, Ugeskr Laeger, V138, P1133; HARMSEN P, 1979, ACTA MED SCAND, V206, P337; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; HILLBOM M, 1978, LANCET, V2, P1181; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JICK H, 1978, ANN INTERN MED, V89, P58, DOI 10.7326/0003-4819-89-1-58; KANNEL WB, 1965, AM J PUBLIC HEALTH N, V55, P1355, DOI 10.2105/AJPH.55.9.1355; KAY CR, 1984, CLIN OBSTET GYNAECOL, V11, P759; KREINER S, 1987, SCAND J STAT, V14, P97; LAYDE PM, 1983, J ROY COLL GEN PRACT, V33, P75; LIDEGAARD O, 1987, ACTA NEUROL SCAND, V75, P427, DOI 10.1111/j.1600-0404.1987.tb05473.x; LIDEGAARD O, 1986, STROKE, V17, P670, DOI 10.1161/01.STR.17.4.670; Lidegaard O, 1982, Ugeskr Laeger, V144, P2769; MARKUSH RE, 1971, HSMHA HEALTH REP, V86, P74, DOI 10.2307/4594091; METTINGER KL, 1984, STROKE, V15, P795, DOI 10.1161/01.STR.15.5.795; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; MISHELL DR, 1989, AM J OBSTET GYNECOL, V161, P1385; NOMURA A, 1974, STROKE, V5, P483, DOI 10.1161/01.STR.5.4.483; OLECKNO WA, 1988, PUBLIC HEALTH, V102, P45, DOI 10.1016/S0033-3506(88)80009-X; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROBINS M, 1981, STROKE S1, V12, P45; ROSENBERG MJ, 1983, INT J EPIDEMIOL, V12, P84, DOI 10.1093/ije/12.1.84; SALONEN JT, 1982, STROKE, V13, P327, DOI 10.1161/01.STR.13.3.327; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; STOLLEY PD, 1978, AM J EPIDEMIOL, V107, P226, DOI 10.1093/oxfordjournals.aje.a112529; STOLLEY PD, 1989, EPIDEMIOL REV, V11, P241, DOI 10.1093/oxfordjournals.epirev.a036041; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; Walker AE, 1981, STROKE S1, V12, P13; WERMUTH N, 1990, J ROY STAT SOC B MET, V52, P21; WERMUTH N, 1983, BIOMETRIKA, V70, P537, DOI 10.2307/2336490; WHARTON C, 1988, POPUL REP A, V16, P6; WHITTABEV J, 1990, GRAPHICAL MODELS APP; WISEMAN RA, 1984, INT J FERTIL, V29, P198; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1973, NEW ENGL J MED, V288, P871	56	186	190	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					956	963		10.1136/bmj.306.6883.956	http://dx.doi.org/10.1136/bmj.306.6883.956			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490470	Green Published, Bronze			2022-12-28	WOS:A1993KX43600015
J	CHEN, ZM; KEECH, A; COLLINS, R; SLAVIN, B; CHEN, JS; CAMPBELL, TC; PETO, R				CHEN, ZM; KEECH, A; COLLINS, R; SLAVIN, B; CHEN, JS; CAMPBELL, TC; PETO, R			PROLONGED INFECTION WITH HEPATITIS-B VIRUS AND ASSOCIATION BETWEEN LOW BLOOD CHOLESTEROL CONCENTRATION AND LIVER-CANCER	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; VERTICAL TRANSMISSION; SURFACE-ANTIGEN; HEART-DISEASE; MORTALITY; RISK; MEN; POPULATION; TAIWAN; DEATH	Objective-To determine whether prolonged infection with hepatitis B virus is associated with a lower blood cholesterol concentration. Design-Cross sectional study. Setting-81 villages in rural China with a high prevalence of chronic infection with hepatitis B virus. Subjects-1556 apparently healthy men aged 35-64 years, randomly selected. Main outcome measures-Hepatitis B virus carrier state; plasma concentrations of cholesterol, apolipoprotein B, and apolipoprotein A I. Results-238 (15%) of the men were positive for hepatitis B surface antigen, indicating that they were chronic carriers. Plasma concentration of cholesterol was 4.2% (0.11 mmol/l) lower among carriers (that is, positive for hepatitis B surface antigen) than among non-carriers (95% confidence inverval 0.6% to 8.0% (0.01 to 0.21 mmol/l), p < 0.05), and apolipoprotein B concentration was 7.0% (0.036 g/l) lower (2.8% to 11.2% (0.014 to 0.058 g/l), p<0.001). In contrast, no association was observed between plasma concentrations of cholesterol or apolipoprotein and hepatitis B that had been eradicated (that is, patient positive for hepatitis B core antibody but negative for hepatitis B surface antigen). Conclusions-Chronic hepatitis B virus infection, which usually starts in early childhood in China, seems to lead not only to a greatly increased risk of death from liver disease but also to a somewhat lower cholesterol concentration in adulthood. This common cause produces an inverse association between cholesterol concentration and risk of death from liver cancer or from other chronic liver diseases.	UNIV OXFORD, RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,MRC, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT ENDOCRINOL & CHEM PATHOL, LONDON, ENGLAND; CHINESE ACAD PREVENT MED, INST NUTR & FOOD HYG, BEIJING, PEOPLES R CHINA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Radcliffe Infirmary; University of Oxford; University of London; King's College London; Chinese Center for Disease Control & Prevention; National Institute for Nutrition & Health, Chinese Center for Disease Control & Prevention; Cornell University	CHEN, ZM (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, IMPERIAL CANC RES FUND, OXFORD OX2 6HE, ENGLAND.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				[Anonymous], 1982, JAMA-J AM MED ASSOC, V248, P2853; BEAGLEHOLE R, 1980, BMJ-BRIT MED J, V280, P285, DOI 10.1136/bmj.280.6210.285; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1981, LANCET, V2, P1129; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cox DR, 1974, THEORETICAL STATISTI; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FEELY J, 1992, BRIT MED J, V304, P545, DOI 10.1136/bmj.304.6826.545; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JIANG YT, 1982, VIRAL HEPATITIS, P121; JUNYAO L, 1981, INT J EPIDEMIOL, V10, P127, DOI 10.1093/ije/10.2.127; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; LUMB PJ, IN PRESS J CLIN PATH; MA XK, 1984, CHINA PEOPLES LIBERA, V9, P1; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MEADE TW, 1987, THROMB RES, V45, P709, DOI 10.1016/0049-3848(87)90336-7; MOUNT JN, 1988, J CLIN PATHOL, V41, P471, DOI 10.1136/jcp.41.4.471; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1980, LANCET, V1, P523; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; UEYAMA Y, 1990, LANCET, V336, P707, DOI 10.1016/0140-6736(90)92204-U; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; [No title captured]	35	43	46	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					890	894		10.1136/bmj.306.6882.890	http://dx.doi.org/10.1136/bmj.306.6882.890			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490412	Green Published, Bronze			2022-12-28	WOS:A1993KW38700018
J	KELLETT, J				KELLETT, J			FOR DEBATE - LONG-TERM CARE ON THE NHS - A VANISHING PROSPECT	BRITISH MEDICAL JOURNAL			English	Article											KELLETT, J (corresponding author), ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.							JOLLY DJ, 1992, PSYCHIATRIC B, V16, P567; 1992, HOSPITAL HLTH SERVIC; 1992, DIRECTORY INDEPENDEN	3	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					846	848		10.1136/bmj.306.6881.846	http://dx.doi.org/10.1136/bmj.306.6881.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490381	Green Published, Bronze			2022-12-28	WOS:A1993KV34800028
J	WHITEHEAD, M; JUDGE, K; HUNTER, DJ; MAXWELL, R; SCHEUER, MA				WHITEHEAD, M; JUDGE, K; HUNTER, DJ; MAXWELL, R; SCHEUER, MA			TACKLING INEQUALITIES IN HEALTH - THE AUSTRALIAN EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article								Federal and state governments in Australia have embarked on a series of national initiatives which show a firm commitment to tackling social inequalities in health. The development of national goals and targets for health, for example, covers social and environmental conditions and sets differential targets for specific social groups with very poor health status. In a complementary initiative, a wide ranging analysis of the health care system-the National Health Strategy-has as one of its main objectives to improve the equitable impact of the health system. Where problems of access to and quality of services have been exposed, policies have been devised to deal with them. The exceptionally poor health of the Aboriginal community has elicited cross party support for action. Resources have been allocated to implement the National Aboriginal Health Strategy: to improve living and working conditions, education, and employment opportunities. Britain can glean much from the Australian experience.	KINGS FUND INST,LONDON NW1 7NF,ENGLAND; UNIV LEEDS,NUFFIELD INST HLTH SERV STUDIES,LEEDS LS2 9PL,ENGLAND; KING EDWARDS HOSP FUND LONDON,LONDON W2 4HT,ENGLAND	University of Leeds	WHITEHEAD, M (corresponding author), OLD SCH,WHITCHURCH SY13 4DR,SHROPS,ENGLAND.							BLACK D, 1992, INEQUALITIES HLTH; Laing W., 1992, GOING PRIVATE INDEPE; MACKLIN J, 1990, NATIONAL HLTH STRATE; Nutbeam D., 1993, GOALS TARGETS AUSTRA; WILCOX S, 1991, 4 NAT HLTH STRAT; 1992, 1992 9O BUDGET RELAT; 1992, AUSTR HLTH 1992; 1989, NATIONAL ABORIGINAL; 1986, INTERIM REPORT; 1992, MAKE YOU SICK INCOME; 1991, NATIONAL REPORT; 1991, PROTOCOL INVESTMENT; 1986, LOOKING BETTER HLTH; 1991, 2 NAT HLTH STRAT UN; 1992, HLTH NATION; 1988, EQUITY PREREQUISITE; 1987, DEPRIVATION ILL HLTH; 1991, MANIFESTO HLTH; 1988, HLTH ALL AUSTR REPOR; 1991, BUILDING HLTH BRITAI	20	5	5	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					783	787		10.1136/bmj.306.6880.783	http://dx.doi.org/10.1136/bmj.306.6880.783			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490345	Green Published, Bronze			2022-12-28	WOS:A1993KU17300034
J	SWEDO, SE; LENANE, MC; LEONARD, HL				SWEDO, SE; LENANE, MC; LEONARD, HL			LONG-TERM TREATMENT OF TRICHOTILLOMANIA (HAIR PULLING)	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CLOMIPRAMINE				SWEDO, SE (corresponding author), NIMH,BETHESDA,MD 20892, USA.							AZRIN NH, 1980, J BEHAV THER EXP PSY, V11, P13, DOI 10.1016/0005-7916(80)90045-2; POLLARD CA, 1991, J CLIN PSYCHIAT, V52, P128; SWEDO SE, 1992, PSYCHIAT CLIN N AM, V15, P777; SWEDO SE, 1989, NEW ENGL J MED, V321, P497, DOI 10.1056/NEJM198908243210803	4	53	55	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					141	142		10.1056/NEJM199307083290220	http://dx.doi.org/10.1056/NEJM199307083290220			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510704	Bronze			2022-12-28	WOS:A1993LL19600035
J	EGASHIRA, K; INOU, T; HIROOKA, Y; YAMADA, A; URABE, Y; TAKESHITA, A				EGASHIRA, K; INOU, T; HIROOKA, Y; YAMADA, A; URABE, Y; TAKESHITA, A			EVIDENCE OF IMPAIRED ENDOTHELIUM-DEPENDENT CORONARY VASODILATATION IN PATIENTS WITH ANGINA-PECTORIS AND NORMAL CORONARY ANGIOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; RESISTANCE VESSELS; ARTERY DISEASE; FLOW RESERVE; NITRIC-OXIDE; SYNDROME-X; ACETYLCHOLINE; HUMANS; TONE; VASOCONSTRICTION	Background. A group of patients has been described who have chest pain resembling angina and positive exercise tests, but normal coronary angiograms and no coronary-artery spasm. This constellation of features has sometimes been called syndrome X or microvascular angina. We attempted to determine whether endothelium-dependent vasodilatation of the coronary vasculature was impaired in patients with this syndrome. Methods. We infused the endothelium-dependent vasodilator acetylcholine and the endothelium-independent vasodilators papaverine and isosorbide dinitrate into the left coronary artery of 9 patients and 10 control subjects. The diameter of the left anterior descending coronary artery was assessed by quantitative angiography, and changes in coronary blood flow were estimated with the use of an intracoronary Doppler catheter. Results. Acetylcholine, given in doses of 1, 3, 10, and 30 mug per minute, increased coronary blood flow in a dose-dependent manner in both groups. However, the mean (+/-SD) acetylcholine-induced increases in coronary blood flow were significantly less (P<0.001) in the patients (8+/-14, 37+/-37, 59+/-67, and 103+/-77 percent, respectively) than in the controls (62+/-52, 186+/-93, 341+/-128, and 345+/-78 percent, respectively). The changes in coronary blood flow in response to 2 mg of isosorbide dinitrate (236+/-66 percent vs. 280+/-56 percent) and 10 mg of papaverine (366+/-168 percent vs. 411+/-92 percent) did not differ significantly between the patients and controls. The administration of papaverine resulted in myocardial lactate production in the patients but not in the controls. The three lower doses of acetylcholine caused a similar degree of dilatation of the left anterior descending coronary artery in the two groups, and the highest dose caused a similar degree of constriction in the two groups. Isosorbide dinitrate and papaverine caused a similar degree of dilatation in both groups. Conclusions. These findings suggest that endothelium-dependent dilatation of the resistance coronary arteries is defective in patients with anginal chest pain and normal coronary arteries, which may contribute to the altered regulation of myocardial perfusion in these patients.	KYUSHU UNIV, SCH MED, CARDIOVASC CLIN, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University	EGASHIRA, K (corresponding author), KYUSHU UNIV, SCH MED, ANGIOCARDIOL RES INST, 3-1-1 MAIDASHI, HIGASHI KU, FUKUOKA 812, JAPAN.							BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P349, DOI 10.1016/0033-0620(88)90003-5; CANNON RO, 1987, CIRCULATION, V75, P163, DOI 10.1161/01.CIR.75.1.163; CANTY JM, 1988, CIRCULATION S2, V78, P465; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CHRISTENSEN CW, 1991, CIRCULATION, V83, P294, DOI 10.1161/01.CIR.83.1.294; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; EGASHIRA K, 1992, J CLIN INVEST, V89, P1047, DOI 10.1172/JCI115646; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; EGASHIRA K, 1991, JPN CIRC J, V55, P1050, DOI 10.1253/jcj.55.1050; EPSTEIN SE, 1986, J AM COLL CARDIOL, V8, P459, DOI 10.1016/S0735-1097(86)80067-5; FIFER MA, 1991, CARDIAC CATHETERIZAT, P300; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GALASSI A R, 1991, Journal of the American College of Cardiology, V17, p227A; GELTMAN EM, 1990, J AM COLL CARDIOL, V16, P586, DOI 10.1016/0735-1097(90)90347-R; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P272; HODGSON JM, 1989, CIRCULATION, V79, P1043, DOI 10.1161/01.CIR.79.5.1043; KASKI JC, 1991, J AM COLL CARDIOL, V18, P50, DOI 10.1016/S0735-1097(10)80216-5; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; KIESZ RS, 1991, CARDIOVASC RES, V25, P1042, DOI 10.1093/cvr/25.12.1042; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; LUSCHER TF, 1990, J AM COLL CARDIOL, V15, P519; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MOSSERI M, 1986, CIRCULATION, V74, P964, DOI 10.1161/01.CIR.74.5.964; MOTZ W, 1991, AM J CARDIOL, V68, P996, DOI 10.1016/0002-9149(91)90485-4; NEWMAN CM, 1990, AM J CARDIOL, V66, P1070, DOI 10.1016/0002-9149(90)90507-W; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; VALLANCE P, 1989, LANCET, V2, P997; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; VRINTS CJM, 1992, J AM COLL CARDIOL, V19, P21, DOI 10.1016/0735-1097(92)90046-P; WHITE CW, 1988, PROG CARDIOVASC DIS, V31, P79, DOI 10.1016/0033-0620(88)90012-6; WILSON RF, 1986, CIRCULATION, V73, P444, DOI 10.1161/01.CIR.73.3.444; YAMAMOTO Y, 1987, CIRC RES, V61, P772, DOI 10.1161/01.RES.61.6.772; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	34	469	479	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1659	1664		10.1056/NEJM199306103282302	http://dx.doi.org/10.1056/NEJM199306103282302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	8487824				2022-12-28	WOS:A1993LF05400002
J	MOORE, J				MOORE, J			AIDS - STRIKING THE HAPPY MEDIA	NATURE			English	Editorial Material											MOORE, J (corresponding author), AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016, USA.							BROWN P, 1993, NEW SCI         0515; CHOW M, 1993, NATURE, V361, P650; GLUCKMAN JC, 1993, SCIENCE, V259, P1809, DOI 10.1126/science.8456306; 1993, LANCET, V341, P889	4	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					391	392		10.1038/363391a0	http://dx.doi.org/10.1038/363391a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502291				2022-12-28	WOS:A1993LE93800024
J	BARRETTCONNOR, E; KRITZSILVERSTEIN, D				BARRETTCONNOR, E; KRITZSILVERSTEIN, D			ESTROGEN REPLACEMENT THERAPY AND COGNITIVE FUNCTION IN OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; ESTRADIOL; MEMORY; MORTALITY; DEMENTIA; BRAIN	Objective.-To determine whether replacement estrogen delays or prevents loss of cognitive function in elderly women. Design.-A 15-year prospective and cross-sectional study. Setting.-Rancho Bernardo, a geographically defined community in Southern California. Participants.-Eight hundred women (80% of local surviving women from the original Rancho Bernardo cohort) aged 65 to 95 years. Estrogen use was evaluated at baseline between 1972 and 1974 and at follow-up between 1988 and 1991. Main Outcome Measures.-Twelve tests of cognitive function from eight standard instruments administered at follow-up between 1988 and 1991. Results.-Almost half of this older, educated cohort had used estrogen at some time after menopause, and one third were current users. The age-related decrement in cognitive function was similar for women who were current, past, or never users of estrogen. Age- and education-adjusted comparisons also failed to show any consistent association between performance on tests of cognitive function and baseline, past, current, or never estrogen use; estrogen dose; or duration of use. Among 132 statistical comparisons, only five statistically significant differences were observed, less than the number expected by chance alone. Furthermore, these significant differences occurred with different tests of cognitive function, and in only one instance was the better test score associated with current estrogen use. No biases were identified that could explain these negative results. Conclusions.-No compelling or internally consistent evidence for an effect of estrogen on cognitive function was found in these older women. These data do not support the hypothesis that estrogen use after the menopause preserves cognitive function in old age.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON E, 1987, AM J OBSTET GYNECOL, V156, P428, DOI 10.1016/0002-9378(87)90298-5; AYLWARD M, 1973, INT RESEARCH COMMUNI, V1, P30; BARRETTCONNOR E, 1992, ANNU REV MED, V43, P239, DOI 10.1146/annurev.med.43.1.239; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; EVANS DA, 1991, AM J EPIDEMIOL, V134, P403, DOI 10.1093/oxfordjournals.aje.a116102; Fedor-Freybergh P., 1977, ACTA OBSTET GYNECOL, V64, P5; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GANGAR KF, 1991, LANCET, V338, P839; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HACKMAN BW, 1977, CURR MED RES OPIN, V4, P21, DOI 10.1185/03007997709109380; HONJO H, 1989, J STEROID BIOCHEM, V34, P511; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KLAIBER EL, 1979, ARCH GEN PSYCHIAT, V36, P550; LIU IY, 1990, AM J EPIDEMIOL, V132, P136, DOI 10.1093/oxfordjournals.aje.a115625; LUINE V, 1980, BRAIN RES, V191, P273, DOI 10.1016/0006-8993(80)90332-7; LUINE VN, 1975, BRAIN RES, V86, P293, DOI 10.1016/0006-8993(75)90704-0; MALLESON J, 1953, LANCET, V2, P158; MALLESON J, 1973, FRONT HORM RES, V2, P118; MCEWEN BS, 1991, TRENDS ENDOCRIN MET, V2, P62, DOI 10.1016/1043-2760(91)90042-L; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; PALINKAS LA, 1992, OBSTET GYNECOL, V80, P30; RASKIN A, 1982, Psychopharmacology Bulletin, V18, P196; RAURAMO L, 1975, FRONT HORM RES, V8, P133; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Vanhulle G., 1976, CONSENSUS MENOPAUSE, P94; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEISS BL, 1987, AM J PSYCHIAT, V144, P386; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; WONG M, 1992, J NEUROSCI, V12, P3217, DOI 10.1523/JNEUROSCI.12-08-03217.1992	39	331	337	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2637	2641		10.1001/jama.269.20.2637	http://dx.doi.org/10.1001/jama.269.20.2637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LC865	8487446				2022-12-28	WOS:A1993LC86500027
J	BOURNE, TH; CAMPBELL, S; REYNOLDS, KM; WHITEHEAD, MI; HAMPSON, J; ROYSTON, P; CRAYFORD, TJB; COLLINS, WP				BOURNE, TH; CAMPBELL, S; REYNOLDS, KM; WHITEHEAD, MI; HAMPSON, J; ROYSTON, P; CRAYFORD, TJB; COLLINS, WP			SCREENING FOR EARLY FAMILIAL OVARIAN-CANCER WITH TRANSVAGINAL ULTRASONOGRAPHY AND COLOR BLOOD-FLOW IMAGING	BRITISH MEDICAL JOURNAL			English	Article							SONOGRAPHY; ULTRASOUND; MASSES; TUMORS; WOMEN	Objective-To assess the value of transvaginal ultrasonography with colour blood flow imaging in detecting early ovarian cancer in women with a family history of the disease. Design-Study of self referred symptomless women with a close relative who had developed the disease. Each woman was screened to detect persistent lesions and defined changes in ovarian volume. Morphological score and pulsatility index were recorded. Setting-Ovarian screening clinic. Subjects-1601 self referred women. Interventions-Women with a positive screening result were recommended to have further investigations. Main outcome measures-Findings at surgery and histology of abnormal ovaries. Morphological score greater-than-or-equal-to 5 and pulsatility index < 1.0 at last scan. Results-Women were aged 17 to 79 (mean 47) years; 959 (60%) were premenopausal, 469 (29%) were naturally postmenopausal, and 173 (11%) had had a hysterectomy. 157 women had a pedigree suggestive of the site specific ovarian cancer syndrome and 288 of multiple site cancers. 61 women had a positive screening result (3.8%, 95% confidence interval 2.9 to 4.9%), six of whom had primary ovarian cancer detected at surgery (five stage Ia, one stage III). Use of a high morphological score or a low pulsatility index increased the odds of finding ovarian cancer from 1:9 to about 2:5 (1:1 in the highest risk groups). Five interval cancers were reported (three ovarian and two peritoneal). Eight of the 11 cancers developed in women with pedigrees suggestive of inherited cancer. Conclusions-Transvaginal ultrasonography with colour flow imaging can effectively detect early ovarian cancer in women with a family history of the disease. The screening interval should be less than two years.	KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED PHYS,LONDON W12 0NN,ENGLAND	University of London; King's College London; Imperial College London			Bourne, Tom/I-6478-2012	Bourne, Tom/0000-0003-1421-6059				BHAN V, 1989, BRIT J OBSTET GYNAEC, V96, P1384, DOI 10.1111/j.1471-0528.1989.tb06299.x; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1991, GYNECOL ONCOL, V40, P253; BOURNE TH, 1992, BRIT J HOSP MED, V48, P454; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CAMPBELL S, 1990, BRIT J OBSTET GYNAEC, V97, P304, DOI 10.1111/j.1471-0528.1990.tb01806.x; CAMPBELL S, 1992, OVARIAN CANCER, V2, P237; COLLINS WP, 1992, OVARIAN CANCER, V2, P225; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; HATA K, 1991, INT J GYNECOL OBSTET, V36, P301, DOI 10.1016/0020-7292(91)90484-M; HOULSTON R, 1992, GYNECOL ONCOL, V47, P247, DOI 10.1016/0090-8258(92)90114-X; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; KAWAI M, 1992, OBSTET GYNECOL, V79, P163; KURJAK A, 1991, J ULTRAS MED, V10, P295; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; PETTERSSON F, 1991, INT J GYNECOL OBSTET, V36, P238; ROTTEM S, 1990, J CLIN ULTRASOUND, V18, P359, DOI 10.1002/jcu.1870180422; SASSONE AM, 1991, OBSTET GYNECOL, V78, P70; Serov S., 1973, INT HISTOLOGICAL CLA, V9; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; WEINER Z, 1992, OBSTET GYNECOL, V79, P159; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501	26	172	176	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1025	1029		10.1136/bmj.306.6884.1025	http://dx.doi.org/10.1136/bmj.306.6884.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490496	Bronze, Green Published			2022-12-28	WOS:A1993KY44800017
J	SUSANO, R; GARCIA, A; ALTADILL, A; FERRO, J				SUSANO, R; GARCIA, A; ALTADILL, A; FERRO, J			HYPERSENSITIVITY VASCULITIS RELATED TO NICOUMALONE	BRITISH MEDICAL JOURNAL			English	Letter							COUMARIN NECROSIS				SUSANO, R (corresponding author), HOSP CENT ASTURIAS,E-33006 OVIEDO,SPAIN.			Suzano, Rui/0000-0003-1656-0005				COLE MS, 1988, SURGERY, V103, P271; GRIFFIN JP, 1988, MANUAL ADVERSE DRUG, P137; KOCHWESER J, 1968, ANN INTERN MED, V68, P1365, DOI 10.7326/0003-4819-68-6-1365; LEVINE MN, 1986, SEMIN THROMB HEMOST, V12, P39, DOI 10.1055/s-2007-1003533; LOELIGER EA, 1988, MAYLERS SIDE EFFECTS, P309; MAGERUS PW, 1990, GOODMAN GILMANS PHAR, P1311; MCGEHEE WG, 1984, ANN INTERN MED, V101, P59, DOI 10.7326/0003-4819-101-1-59	7	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					973	973		10.1136/bmj.306.6883.973-a	http://dx.doi.org/10.1136/bmj.306.6883.973-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490477	Green Published, Bronze			2022-12-28	WOS:A1993KX43600021
J	GALGIANI, JN; CATANZARO, A; CLOUD, GA; HIGGS, J; FRIEDMAN, BA; LARSEN, RA; GRAYBILL, JR				GALGIANI, JN; CATANZARO, A; CLOUD, GA; HIGGS, J; FRIEDMAN, BA; LARSEN, RA; GRAYBILL, JR			FLUCONAZOLE THERAPY FOR COCCIDIOIDAL MENINGITIS	ANNALS OF INTERNAL MEDICINE			English	Article						FLUCONAZOLE; MENINGITIS, FUNGAL; COCCIDIOIDES; INJECTIONS, SPINAL; AMPHOTERICIN-B	CENTRAL NERVOUS-SYSTEM; AMPHOTERICIN-B; PHARMACOKINETIC PROPERTIES; ITRACONAZOLE; MYCOSES	Objective: To determine the efficacy and safety of fluconazole treatment of coccidioidal meningitis. Design: Uncontrolled clinical trial. Setting: Four university-based treatment centers in California, Arizona, and Texas. Most therapy was conducted without hospitalization. Patients: Fifty consecutive patients with active coccidioidal meningitis, of which 47 (94%) were evaluable. Twenty-five patients had received no previous treatment for their meningitis and nine had coinfection with human immunodeficiency virus (HIV). Intervention: Fluconazole was administered in an oral dose of 400 mg once per day for up to 4 years (median, 37 months) in responding patients. Concurrent therapy with another antifungal agent was prohibited. Measurements: Predefined assessment of infection-related abnormalities was done at the time of enrollment and was repeated at least every 4 months during treatment. Elimination of 40% or more of baseline abnormalities was considered a response. Results: Thirty-seven of 47 (79%; 95% CI, 61% to 90%) evaluable patients responded to treatment. Response rates were similar for patients with and without previous therapy, for patients with and without concomitant HIV infection, and for patients with and without pre-existing hydrocephalus. Most improvement occurred within 4 to 8 months after starting treatment. Patient symptoms resolved more quickly than did cerebrospinal fluid abnormalities. In 15 of 20 responding patients followed for 20 months or more, residual low-level cerebrospinal fluid abnormalities remained throughout therapy. No patient discontinued therapy because of drug-related side effects, although confusion developed in two patients that resolved when the dose of fluconazole was reduced. Conclusion: Fluconazole therapy is often effective in suppressing coccidioidal meningitis.	TUCSON MED CTR, TUCSON, AZ 85733 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX 78285 USA; AUDIE MURPHY MEM VET AFFAIRS MED CTR, SAN ANTONIO, TX USA	University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Southern California; University of Texas System; University of Texas at San Antonio (UTSA)	GALGIANI, JN (corresponding author), UNIV ARIZONA, VET AFFAIRS MED CTR, COLL MED, MED SERV 111, TUCSON, AZ 85723 USA.		Galgiani, John/GLT-7012-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott RH, 1936, ARCH PATHOL, V21, P320; BOUZA E, 1981, MEDICINE, V60, P139, DOI 10.1097/00005792-198105000-00001; BRMAMER KW, 1990, REV INFECT DIS S3, V12, pS318; CLASSEN DC, 1988, J INFECT DIS, V158, P903, DOI 10.1093/infdis/158.4.903; CRAVEN PC, 1983, ANN INTERN MED, V98, P160, DOI 10.7326/0003-4819-98-2-160; DERESINSKI SC, 1977, ARCH INTERN MED, V137, P1180, DOI 10.1001/archinte.137.9.1180; DEWSNUP DH, 1992, 36TH P ANN M COCC ST, P9; EINSTEIN HE, 1961, CALIF MED, V94, P339; GIFFORD MA, 1936, DATA COCCIDIOIDES FU, P39; GOLDSTEIN E, 1972, ANN INTERN MED, V77, P243, DOI 10.7326/0003-4819-77-2-243; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; Graybill J R, 1988, Ann N Y Acad Sci, V544, P488, DOI 10.1111/j.1749-6632.1988.tb40446.x; HARDIN TC, 1988, ANTIMICROB AGENTS CH, V32, P1310, DOI 10.1128/AAC.32.9.1310; HARRISON HR, 1983, PEDIATR INFECT DIS J, V2, P216, DOI 10.1097/00006454-198305000-00009; Kelly P. C., 1977, Coccidioidomycosis. Current clinical and diagnostic status., P239; Kelly P.C., 1980, COCCIDIOIDOMYCOSIS T, P163, DOI [10.1007/978-1-4757-1712-9_11, DOI 10.1007/978-1-4757-1712-9_11]; LABADIE EL, 1986, ARCH INTERN MED, V146, P2013, DOI 10.1001/archinte.146.10.2013; Pappagianis D., 1977, Coccidioidomycosis. Current clinical and diagnostic status., P223; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; SCHLUMBERGER HG, 1945, AM J MED SCI, V209, P483, DOI 10.1097/00000441-194504000-00008; SOBEL RA, 1984, HUM PATHOL, V15, P980, DOI 10.1016/S0046-8177(84)80128-8; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; VANPEER A, 1989, EUR J CLIN PHARMACOL, V36, P423, DOI 10.1007/BF00558308; VINCENT T, 1993, CLIN INFECT DIS, V16, P247, DOI 10.1093/clind/16.2.247; WIEDEN MA, 1983, J CLIN MICROBIOL, V18, P529, DOI 10.1128/JCM.18.3.529-534.1983; WINN W A, 1964, Calif Med, V101, P78; WINN WA, 1959, AM J MED, V27, P617, DOI 10.1016/0002-9343(59)90046-4; Winn WA, 1967, COCCIDIOIDOMYCOSIS, P55	30	150	154	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1993	119	1					28	35		10.7326/0003-4819-119-1-199307010-00005	http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ266	8498760				2022-12-28	WOS:A1993LJ26600005
J	NOVELLO, AC; PETERSON, HB; ARROWSMITHLOWE, JT; KELAGHAN, J; PERLMAN, JA				NOVELLO, AC; PETERSON, HB; ARROWSMITHLOWE, JT; KELAGHAN, J; PERLMAN, JA			CONDOM USE FOR PREVENTION OF SEXUAL TRANSMISSION OF HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US OFF SURGEON GEN,WASHINGTON,DC									FDA BROCHURE CONDOMS	1	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2840	2840		10.1001/jama.269.22.2840	http://dx.doi.org/10.1001/jama.269.22.2840			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497081				2022-12-28	WOS:A1993LE93600005
J	DEDIOS, AC; PEARSON, JG; OLDFIELD, E				DEDIOS, AC; PEARSON, JG; OLDFIELD, E			SECONDARY AND TERTIARY STRUCTURAL EFFECTS ON PROTEIN NMR CHEMICAL-SHIFTS - AN ABINITIO APPROACH	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; STAPHYLOCOCCAL NUCLEASE; C-13; MOLECULES; MODEL; CONFORMATION; SHIELDINGS; INHIBITOR; PROGRAM; DISTAL	Recent theoretical developments permit the prediction of H-1, C-13, N-15, and F-19 nuclear magnetic resonance chemical shifts in proteins and offer new ways of analyzing secondary and tertiary structure as well as for probing protein electrostatics. For C-13, phi,psi torsion angles dominate shielding for Calpha and Cbeta, but the addition of hydrogen bonding and electrostatics gives even better accord with experiment. For N-15H, side chain (chi1) torsion angles are also important, as are nearest neighbor sequence effects, whereas for H-1N, hydrogen bonding is particularly significant. For F-19, weak or long-range electrostatic fields dominate F-19 shielding nonequivalencies. The ability to predict chemical shifts in proteins from known or test structures opens new avenues to structure refinement or determination, especially for condensed systems.	UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			de Dios, Angel C/H-4034-2011		NHLBI NIH HHS [HL-19481] Funding Source: Medline; NIGMS NIH HHS [GM-14545, GM-40426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014545, R01GM040426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLERHAN.A, 1973, BIOCHEMISTRY-US, V12, P1335, DOI 10.1021/bi00731a013; ANDO I, 1984, MACROMOLECULES, V17, P457, DOI 10.1021/ma00133a036; AUGSPURGER J, 1992, J MAGN RESON, V100, P342, DOI 10.1016/0022-2364(92)90267-B; AUGSPURGER JD, 1991, J AM CHEM SOC, V113, P2447, DOI 10.1021/ja00007a015; AUGSPURGER JD, 1991, J PHYS CHEM-US, V95, P9230, DOI 10.1021/j100176a037; BATCHELOR JG, 1975, J AM CHEM SOC, V97, P3410, DOI 10.1021/ja00845a022; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUCKINGHAM AD, 1960, CAN J CHEM, V38, P300, DOI 10.1139/v60-040; BUCKINGHAM AD, 1960, MOL PHYS, V3, P219, DOI 10.1080/00268976000100261; CHESNUT DB, 1989, J COMPUT CHEM, V10, P648, DOI 10.1002/jcc.540100507; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CUMMINS PL, 1987, MOL PHYS, V61, P795, DOI 10.1080/00268978700101481; DEDIOS A, UNPUB; DEDIOS AC, 1993, CHEM PHYS LETT, V205, P108, DOI 10.1016/0009-2614(93)85175-N; DITCHFIELD R, 1972, J CHEM PHYS, V56, P5688, DOI 10.1063/1.1677088; DYKSTRA CE, IN PRESS CALCULATION; GLUSHKA J, 1989, J AM CHEM SOC, V111, P7716, DOI 10.1021/ja00202a009; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P9029, DOI 10.1073/pnas.89.19.9029; HANSEN AE, 1985, J CHEM PHYS, V82, P5035, DOI 10.1063/1.448625; JAMAN AI, 1991, CHEM PHYS, V154, P281, DOI 10.1016/0301-0104(91)80078-V; LE C, UNPUB; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; London F, 1937, J PHYS-PARIS, V8, P397, DOI 10.1051/jphysrad:01937008010039700; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MCDONALD CC, 1967, J AM CHEM SOC, V89, P6332, DOI 10.1021/ja01000a061; Mowbray S L, 1990, Receptor, V1, P41; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; OLDFIELD E, UNPUBN; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PEARSON JG, IN PRESS J AM CHEM S; Salem L., 1966, MOL ORBITAL THEORY C; SCHINDLER M, 1983, J AM CHEM SOC, V105, P1360, DOI 10.1021/ja00343a049; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TORCHIA DA, 1989, BIOCHEMISTRY-US, V28, P5509, DOI 10.1021/bi00439a028; TOSSELL JA, 1991, J MAGN RESON, V94, P301, DOI 10.1016/0022-2364(91)90108-6; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG JF, 1992, BIOCHEMISTRY-US, V31, P921, DOI 10.1021/bi00118a039; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WILLIAMSON MP, 1992, J BIOMOL NMR, V2, P83, DOI 10.1007/BF02192802; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005	45	430	433	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1491	1496		10.1126/science.8502992	http://dx.doi.org/10.1126/science.8502992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502992				2022-12-28	WOS:A1993LF05800033
J	DINGELL, JD				DINGELL, JD			SHATTUCK LECTURE - MISCONDUCT IN MEDICAL-RESEARCH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											DINGELL, JD (corresponding author), US HOUSE REPRESENTAT,SUBCOMM OVERSIGHT & INVEST,WASHINGTON,DC 20515, USA.							CREWDSON J, 1992, CHICAGO TRIBUNE 0708, P4; CREWDSON J, 1991, CHICAGO TRIBUNE 0716, P6; GLADWELL M, 1992, WASH POST       0714, pA3; GOSSELIN PG, 1991, BOSTON GLOBE    0521, P25; GOSSELIN PG, 1991, BOSTON GLOBE    0521, P1; HAMILTON DP, 1992, SCIENCE, V255, P1636, DOI 10.1126/science.11642983; HILTS PJ, 1991, NY TIMES        0321, pA1; HILTS PJ, 1991, NY TIMES        0321, pB10; HILTS PJ, 1992, NY TIMES        0714, pC3; KOHN A, 1986, FALSE PROPHETS FRAUD, P84; PICARD O, 1990, LANCET, V336, P179, DOI 10.1016/0140-6736(90)91699-B; SWAZEY JP, 1989, CGS COMMUNICATOR, V22, P1; SWAZEY JP, 1989, CGS COMMUNICATOR, V22, P7; VALENTINE PW, 1992, WASHINGTON POST 0709, pA12; WHEELER DL, 1992, CHRON HIGHER EDUC, V36, pA7; Willcox B L, 1992, Account Res, V2, P139, DOI 10.1080/08989629208573810; 1989, 100189 US HOUS REPR; 1992, 10275 US STAT HOUS R; 1987, MH32206 DEP HLTH HUM; 1989, 101187 US HOUS REPR; 1992, RESPONSIBLE SCI ENSU, P91; 1987, MH37449 DEP HLTH HUM; 1989, 10164 US HOUS REPR S	23	46	46	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1610	1615		10.1056/NEJM199306033282207	http://dx.doi.org/10.1056/NEJM199306033282207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	8487803				2022-12-28	WOS:A1993LE28900007
J	BELVILLE, R; POLLACK, SH; GODBOLD, JH; LANDRIGAN, PJ				BELVILLE, R; POLLACK, SH; GODBOLD, JH; LANDRIGAN, PJ			OCCUPATIONAL INJURIES AMONG WORKING ADOLESCENTS IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; DEATHS	Objective.-To determine the number, distribution, determinants, and health consequences of occupational injuries among working adolescents in New York State. Design.-A retrospective, population-based analysis of New York State workers' compensation award data and the Annual Demographic File, a supplement to the US Bureau of the Census Current Population Survey. Participants.-Adolescents, aged 14 through 17 years, who received workers' compensation awards for occupational injury from 1980 through 1987. Main Outcome Measures.-(1) Numbers, types, and rates of occupational injuries in working adolescents by age, sex, industry, and occupation; (2) health consequences of injury, especially disability and death; and (3) secular trends in injury award rates. Results.-A total of 9656 adolescents were compensated for occupational injuries; 4201 compensated adolescents (43.5%) suffered permanent disability; 31 working adolescents died. The annual mean rate of compensated occupational injury was 28.2 per 10 000 adolescent workers. Rates were higher in males than in females and ranged from 8.2 per 10 000 in 14-year-old male workers to 46.8 per 10 000 in 17-year-old male workers. Highest rates by industry were seen in manufacturing (49.0/10 000 adolescent workers) and agriculture (46.2/10 000). Unskilled labor was the most dangerous occupation (52.3/10 000). Conclusion.-Occupational injuries are a substantial and underrecognized contributor to the continuing epidemic of injury among adolescents.			BELVILLE, R (corresponding author), CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, DIV ENVIRONM & OCCUPAT MED, ONE GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [R01-0H-2717] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERKA MA, 1985, 113TH ANN M AM PUBL; [Anonymous], 1987, STANDARD IND CLASSIF; BAGLI C, 1989, NEW YORK OBSERV 0109, P10; BAKER B, 1990, COMMON CAUSE MAG JUL, P11; BAKER E L, 1988, Journal of Public Health Policy, V9, P198, DOI 10.2307/3343005; BAKER SP, 1984, INJURY FACT BOOK; BANCO L, 1992, PEDIATRICS, V89, P957; BARTH PS, 1980, WORKERS COMPENSATION, P120; BROOKS DR, IN PRESS AM J IND ME; BUTTERFIELD B, 1990, BOSTON GLOBE    0805; Cochran W.G, 1957, STAT METHODS, V6th ed; CORBAN T, 1988, CURRENT TRENDS YOUTH; DURSKI L, 1988, CHILD LABOR LAW REV; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HALPERIN SF, 1983, J ADOLESCENT HEALTH, V4, P275, DOI 10.1016/S0197-0070(83)80011-4; KOLATA G, 1992, NY TIMES        0621; NILSEN DM, 1984, J EARLY ADOLESC, V4, P189; Phillips Kevin P, 1990, POLITICS RICH POOR W; POLLACK SH, 1990, ANNU REV PUBL HEALTH, V11, P359; RIVARA FP, 1985, PEDIATRICS, V76, P567; ROBINSON JC, 1989, MILBANK Q, V67, P92, DOI 10.2307/3350237; RUNYAN CW, 1989, JAMA-J AM MED ASSOC, V262, P2273, DOI 10.1001/jama.262.16.2273; SCHOBER SE, 1988, AM J IND MED, V14, P585, DOI 10.1002/ajim.4700140509; SCOTT G, 1988, NEW YORK NEWSDA 0929; SURUDA A, 1991, AM J IND MED, V19, P739, DOI 10.1002/ajim.4700190607; WALLER AE, 1989, AM J PUBLIC HEALTH, V79, P310, DOI 10.2105/AJPH.79.3.310; 1987, VITAL STATISTICS US; 1992, STATISTICAL ABSTRACT, P913; 1986, CHILD LABOR RELATED; 1991, DATA BOOK CHILD ADOL; 1985, PUBLICATION US DEP L, V1330; 1985, INJURY AM CONTINUING; 1990, GAOHRD90116HUM RES D; 1988, ACCIDENT FACTS 1988; 1990, AJDC, V144, P627; 1980, STANDARD OCCUPATIONA; 1990, ANAL WORKERS COMPENS; 1991, GAOHRD9183BR HUM RES; 1989, MMWR MORB MORTAL WKL, V38, P27; 1991, WORKERS COMPENSATION; 1990, US DEP LABOR B, V2366; 1988, LS33178815M NY STAT	42	65	67	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2754	2759		10.1001/jama.269.21.2754	http://dx.doi.org/10.1001/jama.269.21.2754			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492401				2022-12-28	WOS:A1993LD67100025
J	BENNETT, CL; SCHWARZ, B; MARBERGER, M				BENNETT, CL; SCHWARZ, B; MARBERGER, M			HEALTH-CARE IN AUSTRIA - UNIVERSAL ACCESS, NATIONAL-HEALTH INSURANCE, AND PRIVATE HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RATES; TYROL; AIDS		DUKE UNIV,DEPT MED,DURHAM,NC 27706; UNIV VIENNA,SCH MED,INST SOZIALMED,A-1010 VIENNA,AUSTRIA; UNIV VIENNA,SCH MED,DEPT UROL,A-1010 VIENNA,AUSTRIA	Duke University; University of Vienna; University of Vienna	BENNETT, CL (corresponding author), VET AFFAIRS MED CTR,DEPT HLTH SERV RES & DEV 152,508 FULTON ST,DURHAM,NC 27705, USA.							AUHUBER I, 1984, WIEN KLIN WOCHENSCHR, V96, P426; BRENNER H, 1991, DRUG ALCOHOL DEPEN, V29, P177; ENGELMANN UH, 1990, J UROLOGY, V143, P64, DOI 10.1016/S0022-5347(17)39867-1; FARRELL M, 1992, BRIT MED J, V304, P489, DOI 10.1136/bmj.304.6825.489; FUCHS D, 1989, WIEN KLIN WOCHENSCHR, V101, P388; FUCHS D, 1985, LANCET, V1, P1506; GERSTNER G, 1987, Clinical and Experimental Obstetrics and Gynecology, V14, P84; GNANT MFX, 1991, TRANSPL P, V23, P2685; GRUNEWALD K, 1992, LANCET, V340, P43; HAIDINGER G, 1991, AUG P EUR REG M INT; HUBER J, 1990, CONTRACEPTION W EURO; KRAMSER A, 1992, LANCET, V339, P1531; LOIMER N, 1990, AIDS Care, V2, P281, DOI 10.1080/09540129008257741; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; SCHWARZ B, 1992, EUR J EPIDEMIOL, V8, P40, DOI 10.1007/BF02427390; SPERNERUNTERWEGER B, 1991, BRIT J ADDICT, V86, P225; STARY A, 1991, SEX TRANSM DIS, V18, P159, DOI 10.1097/00007435-199107000-00007; STUMMVOLL HK, 1992, 13TH P ANN M AM SOC; ZANGERLE R, 1992, J ACQ IMMUN DEF SYND, V5, P865; 1992, BERICHT SOZIALE LAGE; 1992, WHO1991 DEM YB; 1990, ORG EC COOPERATION D, V7; 1991, GESUNDHEITSWESEN OST; [No title captured]; 1992, TUBERCULOSIS PROGRAM; 1991, KRANKENANSTALTENSTAT	27	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2789	2794		10.1001/jama.269.21.2789	http://dx.doi.org/10.1001/jama.269.21.2789			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LD671	8492408				2022-12-28	WOS:A1993LD67100033
J	POPE, AM				POPE, AM			INDOOR ALLERGENS - ASSESSING AND CONTROLLING ADVERSE HEALTH-EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POPE, AM (corresponding author), INST MED,COMM HLTH EFFECTS INDOOR ALLERGENS,ROOM FO-3034,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2721	2721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492388				2022-12-28	WOS:A1993LD67100006
J	STEPHENSON, BJ; ROWE, BH; HAYNES, RB; MACHARIA, WM; LEON, G				STEPHENSON, BJ; ROWE, BH; HAYNES, RB; MACHARIA, WM; LEON, G			IS THIS PATIENT TAKING THE TREATMENT AS PRESCRIBED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICATION COMPLIANCE; THERAPY; DIGOXIN; DRUG		MCMASTER UNIV,MED CTR,HLTH INFORMAT RES UNIT,1200 MAIN ST W,ROOM 3H7,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DESIGN MEASUREMENT & EVALUAT PROGRAM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University			macharia, william/Q-6042-2018	macharia, william/0000-0002-4428-862X; Haynes, Robert Brian/0000-0002-1453-3196				CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DEUSCHLE KW, 1960, AM REV RESPIR DIS, V82, P1; ENGLAND ML, 1986, AM J MED SCI, V292, P264, DOI 10.1097/00000441-198611000-00002; FLETCHER SW, 1979, ARCH INTERN MED, V139, P635, DOI 10.1001/archinte.139.6.635; GILBERT JR, 1980, CAN MED ASSOC J, V123, P119; HAYNES RB, 1982, CIRCULATION, V65, P28, DOI 10.1161/01.CIR.65.1.28; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; INUI TS, 1981, MED CARE, V19, P1061, DOI 10.1097/00005650-198110000-00008; LEVENTHAL H, 1987, PATIENT EDUC COUNS, V10, P117, DOI 10.1016/0738-3991(87)90093-0; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; MARKOWITZ M, 1970, CIRCULATION, V41, P1077, DOI 10.1161/01.CIR.41.6.1077; MOLLICA J A, 1984, Controlled Clinical Trials, V5, P505, DOI 10.1016/0197-2456(84)90011-4; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; ROTH HP, 1970, CLIN PHARMACOL THER, V7, P49; RUDD P, 1990, CLIN PHARMACOL THER, V48, P676, DOI 10.1038/clpt.1990.211; Sackett DL, 1979, COMPLIANCE HLTH CARE; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P249; SCLAR DA, 1991, CLIN THER, V13, P436; STEWART M, 1987, AM J PREV MED, V3, P95; WOLFF K, 1991, CLIN PHARMACOL THER, V50, P199, DOI 10.1038/clpt.1991.125; [No title captured]; 1982, HYPERTENSION, V4, P415	24	284	285	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2779	2781		10.1001/jama.269.21.2779	http://dx.doi.org/10.1001/jama.269.21.2779			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492406				2022-12-28	WOS:A1993LD67100030
J	COLONNA, M; BROOKS, EG; FALCO, M; FERRARA, GB; STROMINGER, JL				COLONNA, M; BROOKS, EG; FALCO, M; FERRARA, GB; STROMINGER, JL			GENERATION OF ALLOSPECIFIC NATURAL-KILLER-CELLS BY STIMULATION ACROSS A POLYMORPHISM OF HLA-C	SCIENCE			English	Article							PARENTAL LYMPHOCYTES; EXPRESSION; NK; RECOGNITION; RESISTANCE; MOLECULES; ANTIGENS; GENE	The cytotoxicity of human natural killer (NK) cells is modulated by the major histocompatibility complex human leukocyte antigen (HLA)-C molecules on the surface of the target cell. Alloreactive NK cells specific for the NK-1 alloantigen could be reproducibly generated from individuals that were homozygous for HLA-C with asparagine at residue 77 and lysine at residue 80 [HLA-C(Asn77, Lys80] by stimulation with target cells that were homozygous for HLA-C(Ser77, Asn80); the reciprocal stimulation yielded NK cells specific for the NK-2 alloantigen. However, neither homozygous target cell stimulated the generation of alloreactive NK cells from heterozygous individuals. Thus, these data reveal an unanticipated difference between human NK alloreactivity defined by this system and murine ''hybrid resistance.''	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; CTR RIC AVIS,BERGAMO,ITALY; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University	COLONNA, M (corresponding author), IST NAZL RIC CANC,IMMUNOGENET LAB,I-16132 GENOA,ITALY.		Falco, Michela/K-1574-2016	Falco, Michela/0000-0002-0317-9830; Colonna, Marco/0000-0001-5222-4987	NCI NIH HHS [CA 47554] Funding Source: Medline; NIAID NIH HHS [KO8 AI01064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHADWICK BS, 1992, J IMMUNOL, V148, P2307; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CICCONE E, 1988, J EXP MED, V168, P2403, DOI 10.1084/jem.168.6.2403; CICCONE E, 1991, P NATL ACAD SCI USA, V88, P5477; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HERCEND T, 1985, J CLIN INVEST, V75, P932, DOI 10.1172/JCI111794; ISHIKAWA H, 1982, J IMMUNOL, V129, P1181; KAUFMAN DS, 1992, P NATL ACAD SCI USA, V89, P8337, DOI 10.1073/pnas.89.17.8337; KNOBLOCH C, 1988, TRANSPLANTATION, V45, P175, DOI 10.1097/00007890-198801000-00037; LANIER LL, 1986, J IMMUNOL, V136, P4480; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; SENTMAN CL, 1988, NAT IMMUN CELL GROW, V7, P95; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1992, J IMMUNOL, V149, P1185; SUZUKI N, 1990, J EXP MED, V172, P457, DOI 10.1084/jem.172.2.457; TAKIGUCHI M, 1989, J IMMUNOL, V143, P1372; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZEMMOUR J, 1992, J EXP MED, V176, P937, DOI 10.1084/jem.176.4.937	23	222	236	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1121	1124		10.1126/science.8493555	http://dx.doi.org/10.1126/science.8493555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493555				2022-12-28	WOS:A1993LC94200028
J	GOGUEN, B; KEDERSHA, N				GOGUEN, B; KEDERSHA, N			CLONOGENIC CYTOTOXICITY TESTING BY MICRODROP ENCAPSULATION	NATURE			English	Article							CELL		IMMUNOGEN INC,CAMBRIDGE,MA 02139	ImmunoGen, Inc.	GOGUEN, B (corresponding author), ONE CELL SYST INC,100 INMAN ST,CAMBRIDGE,MA 02139, USA.							[Anonymous], 1993, ISSUES RISK ASSESSME; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR; POWELL KT, 1990, BIO-TECHNOL, V8, P333, DOI 10.1038/nbt0490-333; WEAVER JC, 1988, BIO-TECHNOL, V6, P1084, DOI 10.1038/nbt0988-1084; WEAVER JC, 1991, BIO-TECHNOL, V9, P873, DOI 10.1038/nbt0991-873; WEAVER JC, 1991, GENERAL METHOD SEPAR, V2, P234	7	10	13	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					189	190		10.1038/363189a0	http://dx.doi.org/10.1038/363189a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483506				2022-12-28	WOS:A1993LB80100058
J	AALTONEN, LA; PELTOMAKI, P; LEACH, FS; SISTONEN, P; PYLKKANEN, L; MECKLIN, JP; JARVINEN, H; POWELL, SM; JEN, J; HAMILTON, SR; PETERSEN, GM; KINZLER, KW; VOGELSTEIN, B; DELACHAPELLE, A				AALTONEN, LA; PELTOMAKI, P; LEACH, FS; SISTONEN, P; PYLKKANEN, L; MECKLIN, JP; JARVINEN, H; POWELL, SM; JEN, J; HAMILTON, SR; PETERSEN, GM; KINZLER, KW; VOGELSTEIN, B; DELACHAPELLE, A			CLUES TO THE PATHOGENESIS OF FAMILIAL COLORECTAL-CANCER	SCIENCE			English	Article							TUMOR SUPPRESSOR GENES; MUTATIONS; IDENTIFICATION; CHROMOSOME-5Q21; TUMORIGENESIS; EXPRESSION; CARCINOMAS; ONCOGENES; LOCUS; P53	A predisposition to colorectal cancer is shown to be linked to markers on chromosome 2 in some families. Molecular features of ''familial'' cancers were compared with those of sporadic colon cancers. Neither the familial nor sporadic cancers showed loss of heterozygosity for chromosome 2 markers, and the incidence of mutations in KRAS, P53, and APC was similar in the two groups of tumors. Most of the familial cancers, however, had widespread alterations in short repeated DNA sequences, suggesting that numerous replication errors had occurred during tumor development. Thirteen percent of sporadic cancers had identical abnormalities and these cancers shared biologic properties with the familial cases. These data suggest a mechanism for familial tumorigenesis different from that mediated by classic tumor suppressor genes.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; UNIV HELSINKI,DEPT MED GENET,SF-00014 HELSINKI,FINLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH & HYG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21231; UNIV HELSINKI,DEPT MED SCI,SF-00310 HELSINKI,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; JYVASKYLA CENT HOSP,DEPT SURG,SF-40620 JYVASKYLA,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT SURG 2,SF-00290 HELSINKI 29,FINLAND	Johns Hopkins University; University of Helsinki; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital			Mecklin, Jukka-Pekka/AAC-9650-2019; Mecklin, Jukka-Pekka/AAB-5378-2020; Aaltonen, Lauri/A-5375-2010	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Peltomaki, Paivi/0000-0001-8819-2980	NATIONAL CANCER INSTITUTE [R01CA035494, R01CA047527, R37CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA 35494, CA 47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPO E, 1991, CANCER RES, V51, P4436; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; DUNLOP MG, 1992, BRIT J SURG, V79, P488, DOI 10.1002/bjs.1800790606; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GERMAN J, 1989, CLIN GENET, V35, P57; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LI SH, IN PRESS GENOMICS; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; LYNCH PM, 1977, DIS COLON RECTUM, V20, P661, DOI 10.1007/BF02586685; MCKINNEN PJ, 1987, HUM GENET, V175, P197; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P160, DOI 10.1007/BF02555012; MECKLIN JP, 1991, CANCER, V68, P1109, DOI 10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-S; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PERUCHO M, 1992, APR INT S HUM ONC MA; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, UNPUB; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1989, SCIENCE, V244, P217; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	38	2570	2630	1	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					812	816		10.1126/science.8484121	http://dx.doi.org/10.1126/science.8484121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484121				2022-12-28	WOS:A1993LA74400032
J	HANDYSIDES, S				HANDYSIDES, S			HELPING PEOPLE WITH DEMENTIA FEEL AT HOME	BRITISH MEDICAL JOURNAL			English	Article																		BURLEY R, 1992, EVERY HOUSE YOULL EV; MANSER M, 1991, PSYCHIATRY ELDERLY, P550; MARSHALL M, 1992, RECENT ADV PSYCHOGER, V2, P201; MURPHY E, 1991, ASYLUMS COMMUNITY CA, P6; NETTEN A, 1989, INT J GERIATR PSYCH, V4, P143, DOI 10.1002/gps.930040305; CR16 ROYAL COLL PSYC; 1976, POPULATION ESTIM PP1; 1991, NATIONAL POPULAT PP2	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1115	1117		10.1136/bmj.306.6885.1115	http://dx.doi.org/10.1136/bmj.306.6885.1115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ565	8495161	Bronze, Green Published			2022-12-28	WOS:A1993KZ56500029
J	GLOVER, GR; ROHDE, J; FARMER, RDT				GLOVER, GR; ROHDE, J; FARMER, RDT			IS THE MONEY FOLLOWING THE CLIENTS WITH LEARNING-DISABILITIES	BRITISH MEDICAL JOURNAL			English	Article								For the past decade patients with learning disabilities living in long stay mental handicap hospitals have been resettled in the community. Local authorities have also taken on the care of new patients who would once have been long stay residents. The imperfect data that are available suggest that in England about half the residents in mental handicap hospitals in 1981 are now the responsibility of local authorities; the figures for Wales and Northern Ireland are 38% and 33%. Data on revenue suggest that the savings to the health service are much less -perhaps 9% in Northern Ireland and 3.6% in England, although there have also been capital gains through the sale of hospitals. Existing methods of transferring money from health to local authorities-joint finance and ''dowries'' for individual patients -do not seem adequately to have compensated local authorities. Moreover, as patients still to be transferred are more severely disabled local authorities will require larger sums-about 26 000 Pounds per patient per year plus 39 200 Pounds in capital. If the government chooses not to transfer these resources from health authorities it will be switching funds away from learning disabled people to other care groups.			GLOVER, GR (corresponding author), CHARING CROSS & WESTMINTER MED SCH,ACAD DEPT PUBL HLTH & EPIDEMIOL,LONDON SW1P 2AR,ENGLAND.							FARMER RDT, 1990, BMJ, V601, P646; Fryers Tom, 1984, EPIDEMIOLOGY SEVERE; KENNY DJ, 1986, HLTH SERVICES MENTAL; Knapp M., 1992, CARE COMMUNITY CHALL; 1971, BETTER SERVICES MENT; 1990, COMMUNITY CARE SERVI; 1992, COMMUNITY CARE MANAG	7	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					987	990		10.1136/bmj.306.6883.987	http://dx.doi.org/10.1136/bmj.306.6883.987			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490482	Bronze, Green Published			2022-12-28	WOS:A1993KX43600027
J	SMITHSON, JE; KENNEDY, CTC; HUGHES, S				SMITHSON, JE; KENNEDY, CTC; HUGHES, S			A NEW SKIN LESION ASSOCIATED WITH INTRAVENOUS STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							ACUTE MYOCARDIAL-INFARCTION				SMITHSON, JE (corresponding author), SOUTHMEAD GEN HOSP,BRISTOL BS10 5NB,AVON,ENGLAND.							ALEXOPOULOS D, 1984, EUR HEART J, V5, P1010, DOI 10.1093/oxfordjournals.eurheartj.a061602; BUCKNALL C, 1988, BRIT HEART J, V59, P9; NOEL J, 1987, AM HEART J, V113, P395, DOI 10.1016/0002-8703(87)90287-0; STAFFORD PJ, 1989, BMJ-BRIT MED J, V299, P1310, DOI 10.1136/bmj.299.6711.1310	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					973	973		10.1136/bmj.306.6883.973-b	http://dx.doi.org/10.1136/bmj.306.6883.973-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490475	Green Published, Bronze			2022-12-28	WOS:A1993KX43600022
J	YEOH, C; DAVIES, H				YEOH, C; DAVIES, H			CLINICAL CODING - COMPLETENESS AND ACCURACY WHEN DOCTORS TAKE IT ON	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND	Imperial College London								SMITH AP, 1992, BRIT MED J, V305, P415, DOI 10.1136/bmj.305.6850.415; SMITH MW, 1989, NEW ZEAL MED J, V102, P507	2	37	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					972	972		10.1136/bmj.306.6883.972	http://dx.doi.org/10.1136/bmj.306.6883.972			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490474	Green Published, Bronze			2022-12-28	WOS:A1993KX43600019
J	REES, L; WASS, J				REES, L; WASS, J			LONDON AFTER TOMLINSON - UNDERGRADUATE MEDICAL-EDUCATION	BRITISH MEDICAL JOURNAL			English	Article								Pressures from students and teachers, from professional bodies, and from changes in the way health care is delivered are all forcing a rethink of how medical students should be taught. These pressures may be more intense in London but are not confined to it. The recommendation the Tomlinson report advocates that has been generally welcomed is for more investment in primary care in London. General practitioners have much to teach medical schools about effective ways of learning, but incentives for teaching students in general practive are currently low, organising such teaching is difficult and needs resources, and resistance within traditional medical school hierarchies needs to be overcome. Likewise, students value learning within local communities, but the effort demanded of public health departments and community organisations is great at a time when they are under greater pressure than ever before. The arguments over research that favour concentration in four multifaculty schools are less clear cut for undergraduate education, where personal support for students is important. An immediate concern is that the effort demanded for reorganising along the lines suggested by Tomlinson will not leave medical schools much energy for innovating.			REES, L (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,LONDON EC1A 7BE,ENGLAND.							BABAEIMAHANI L, 1992, MED EDUC, V26, P71; DOYAL L, 1991, B MED ETH, P19; ELTON L, 1993, TIMES HIGHER ED 0108; GREEN M, 1992, BRIT MED J, V305, P1081, DOI 10.1136/bmj.305.6861.1081; GRIFFITHS S, 1992, TIMES HIGHER ED  AUG, P2; HARVEYJONES J, 1992, BMA NEWS REV     DEC, P15; ILIFFE S, 1992, BRIT J GEN PRACT, V42, P390; JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; KNOX JDE, 1992, BRIT J GEN PRACT, V42, P499; LOWRY S, 1993, BMJ-BRIT MED J, V306, P51, DOI 10.1136/bmj.306.6869.51; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; NEWMAN GB, 1988, MED TEACH, V10, P227, DOI 10.3109/01421598809010547; POWELL E, 1992, BMA NEWS REV, P11; REES LH, 1991, KINGS FUND NEWS, V14, P3; TOWLE A, 1992, COMMUNITY BASED TEAC, V1; TOWLE A, 1991, CRITICAL THINKING FU; WEATHERALL DJ, 1991, BRIT MED J, V302, P1002, DOI 10.1136/bmj.302.6783.1002; WEATHERALL DJ, 1991, LANCET, V338, P3709; 1992, QUALITY ASSESSMENT; 1992, CELC1991 1992 CIT E; 1991, UNDERGRADUATE MED ED	21	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1993	306	6872					258	261		10.1136/bmj.306.6872.258	http://dx.doi.org/10.1136/bmj.306.6872.258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ591	8499026	Bronze, Green Published			2022-12-28	WOS:A1993KJ59100028
J	SCHIEPPATI, A; MOSCONI, L; PERNA, A; MECCA, G; BERTANI, T; GARATTINI, S; REMUZZI, G				SCHIEPPATI, A; MOSCONI, L; PERNA, A; MECCA, G; BERTANI, T; GARATTINI, S; REMUZZI, G			PROGNOSIS OF UNTREATED PATIENTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM PROGNOSIS; CONTROLLED TRIAL; NEPHROTIC SYNDROME; NATURAL-HISTORY; RENAL-FUNCTION; ACUTE-LEUKEMIA; GLOMERULONEPHRITIS; CHLORAMBUCIL; THERAPY; METHYLPREDNISOLONE	Background. Defining the most appropriate treatment for patients with idiopathic membranous nephropathy is a matter of controversy. The course of the disorder is often benign, and the immunosuppressive regimens used in some patients have uncertain benefits and substantial risks. We studied the natural history of idiopathic membranous nephropathy in patients who received only symptomatic therapy. Methods. We prospectively studied 100 consecutive patients (68 men and 32 women; mean [+/-SD] age, 51+/-17 years) with biopsy-proved idiopathic membranous nephropathy. The patients received diuretic or antihypertensive drugs as needed, but no glucocorticoid or immunosuppressive drugs. We examined the patients and measured their urinary protein excretion and serum creatinine concentrations every 6 months for a mean of 52 months. Results. Twenty-four (65 percent) of the 37 patients followed for at least five years had complete or partial remission of proteinuria; in 6 others (16 percent), end-stage renal disease developed, and they required dialysis. As calculated by the Kaplan-Meier method, the estimated probability (+/- the standard error of the estimate) of retaining adequate kidney function was 88+/-5 percent after five years and 73+/-7 percent after eight years. The prognosis was poorer in men and in patients over 50 years of age, but not in patients with the nephrotic syndrome, hypertension, or hypercholesterolemia. Conclusions. Most untreated patients with idiopathic membranous nephropathy maintain renal function for prolonged periods and are likely to have spontaneous remission. These results do not support the use of glucocorticoids and immunosuppressive drugs in patients with idiopathic membranous nephropathy.	MARIO NEGRI INST PHARMACOL RES,BERGAMO,ITALY; OSPED RIUNITI BERGAMO,DIV NEPHROL & DIALYSIS,I-24100 BERGAMO,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo			Perna, Annalisa/AAC-1323-2020; Garattini, Silvio/AAA-6390-2020; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Garattini, Silvio/0000-0003-0647-9297; Remuzzi, Giuseppe/0000-0002-6194-3446				BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; CAMERON JS, 1990, PEDIATR NEPHROL, V4, P193, DOI 10.1007/BF00858840; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COX DR, 1972, J R STAT SOC B, V34, P187; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; GARATTINI S, 1987, NEPHRON, V45, P1, DOI 10.1159/000184062; GLASSOCK RJ, 1991, SEMIN NEPHROL, V11, P138; GRUNWALD HW, 1979, ARCH INTERN MED, V139, P461, DOI 10.1001/archinte.139.4.461; HONKANEN E, 1986, CLIN NEPHROL, V25, P122; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIDA H, 1986, CLIN NEPHROL, V25, P64; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; LAGRUE G, 1975, KIDNEY INT, V8, P274; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MATHIESON PW, 1988, LANCET, V2, P869; MURPHY BF, 1992, CLIN NEPHROL, V37, P229; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PASSERINI P, 1992, G ITAL NEFROL S2, V9, P23; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; SHEARMAN JD, 1988, CLIN NEPHROL, V30, P320; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WASS V, 1981, NEPHRON, V27, P58, DOI 10.1159/000182025; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247; WILLIAMS PS, 1989, NEPHROL DIAL TRANSPL, V4, P181, DOI 10.1093/oxfordjournals.ndt.a091853; 1971, BMJ, V2, P239; 1976, CAN MED ASSOC J, V115, P1209	32	320	342	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					85	89		10.1056/NEJM199307083290203	http://dx.doi.org/10.1056/NEJM199307083290203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510707				2022-12-28	WOS:A1993LL19600003
J	BARBOUR, AG; FISH, D				BARBOUR, AG; FISH, D			THE BIOLOGICAL AND SOCIAL PHENOMENON OF LYME-DISEASE	SCIENCE			English	Article							IXODES-DAMMINI ACARI; ERYTHEMA CHRONICUM MIGRANS; SPIROCHETE BORRELIA-BURGDORFERI; CENTRAL-NERVOUS-SYSTEM; NEW-YORK-STATE; POLYMERASE CHAIN-REACTION; TICK-BORNE ENCEPHALITIS; WHITE-TAILED DEER; SOUTHERN NEW-YORK; DERMACENTOR-VARIABILIS	Lyme disease, unknown in the United States two decades ago, is now the most common arthropod-borne disease in the country and has caused considerable morbidity in several suburban and rural areas. The emergence of this disease is in part the consequence of the reforestation of the northeastern United States and the rise in deer populations. Unfortunately, an accurate estimation of its importance to human and animal health has not been made because of difficulties in diagnosis and inadequate surveillance activities. Strategies for prevention of Lyme disease include vector control and vaccines.	UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA; NEW YORK MED COLL, DEPT COMMUNITY & PREVENT MED, MED ENTOMOL LAB, VALHALLA, NY 10595 USA	University of Texas System; University of Texas Health San Antonio; New York Medical College	BARBOUR, AG (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248	NIAID NIH HHS [AI24424, AI29731, AI28956] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028956, R01AI024424, R01AI029731, R37AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM T, 1991, INFECT IMMUN, V59, P2579, DOI 10.1128/IAI.59.8.2579-2585.1991; AESCHLIMANN A, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P450; Afzelius A, 1910, ARCH DERMATOL SYPHIL, V101, P403; ALPERT B, 1992, NEW YORK STATE J MED, V92, P5; Anastos George, 1947, PSYCHE, V54, P178, DOI 10.1155/1947/81979; ANDERSON JF, 1988, ANN NY ACAD SCI, V539, P180, DOI 10.1111/j.1749-6632.1988.tb31852.x; ANDERSON JF, 1985, J CLIN MICROBIOL, V22, P36, DOI 10.1128/JCM.22.1.36-38.1985; ANDERSON JF, 1990, J WILDLIFE DIS, V26, P1, DOI 10.7589/0090-3558-26.1.1; ANDERSON JF, 1987, J CLIN MICROBIOL, V25, P1564, DOI 10.1128/JCM.25.8.1564-1566.1987; ANDERSON JF, 1984, YALE J BIOL MED, V57, P627; ARONOWITZ RA, 1991, MILBANK Q, V69, P79, DOI 10.2307/3350122; ASBRINK E, 1984, ACTA DERM-VENEREOL, V64, P291; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1992, INFECT AGENT DIS, V1, P50; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1983, CURR MICROBIOL, V8, P123, DOI 10.1007/BF01566969; BARBOUR AG, 1983, INFECT IMMUN, V41, P795, DOI 10.1128/IAI.41.2.795-804.1983; BARINAGA M, 1992, SCIENCE, V256, P1384, DOI 10.1126/science.1604309; BARNARD DR, 1989, USDA682 AGR RES SERV; BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; BATTALY GR, 1987, J NEW YORK ENTOMOL S, V95, P461; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENSON AB, 1987, P KALMS TRAVELS N AM, P797; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BLAAUW AAM, 1992, BRIT J RHEUMATOL, V31, P401; BOERLIN P, 1992, INFECT IMMUN, V60, P1677, DOI 10.1128/IAI.60.4.1677-1683.1992; BOUSEMAN JK, 1990, J MED ENTOMOL, V27, P556, DOI 10.1093/jmedent/27.4.556; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; BROWN RN, 1992, SCIENCE, V256, P1439, DOI 10.1126/science.1604318; BRUSCA JS, 1991, J BACTERIOL, V173, P8004, DOI 10.1128/jb.173.24.8004-8008.1991; BUNDOC VG, 1989, INFECT IMMUN, V57, P2733, DOI 10.1128/IAI.57.9.2733-2741.1989; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURRASCANO JJ, 1989, INT MED SPEC, V10, P102; CAREY AB, 1980, J MED ENTOMOL, V17, P89, DOI 10.1093/jmedent/17.1.89; CHU HJ, 1992, J AM VET MED ASSOC, V201, P403; COLLINS DL, 1949, J ECON ENTOMOL, V42, P110, DOI 10.1093/jee/42.1.110; COMSTOCK LE, 1989, INFECT IMMUN, V57, P1626, DOI 10.1128/IAI.57.5.1626-1628.1989; CONNELLY NA, 1987, WHITE TAILED DEER WE; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; COX HR, 1948, VIRAL RICKETTSIAL IN, P493; CRONON W, 1983, CHANGES LAND INDIANS, P241; CURRAN KL, 1993, J MED ENTOMOL, V30, P107, DOI 10.1093/jmedent/30.1.107; Daniel M., 1990, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V34, P243; DANIELS TJ, 1991, J MED ENTOMOL, V28, P537, DOI 10.1093/jmedent/28.4.537; DAVIDSON BE, 1992, J BACTERIOL, V174, P3766, DOI 10.1128/JB.174.11.3766-3774.1992; DEBLINGER RD, 1991, J MED ENTOMOL, V28, P708, DOI 10.1093/jmedent/28.5.708; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DURAY PH, 1987, AM J SURG PATHOL, V11, P47, DOI 10.1097/00000478-198700111-00005; EDELMAN R, 1991, VACCINE, V9, P531, DOI 10.1016/0264-410X(91)90236-Y; ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; FERDOWS MS, 1989, P NATL ACAD SCI USA, V86, P5969, DOI 10.1073/pnas.86.15.5969; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418; FILIPPOVA NA, 1985, TAIGA TICK; FILIPPOVA NA, 1991, MODERN ACAROLOGY; FISH D, 1990, J WILDLIFE DIS, V26, P339, DOI 10.7589/0090-3558-26.3.339; Fish D., 1992, First International Conference on Tick-borne Pathogens at the Host-Vector Interface: An Agenda for Research: Proceedings and abstracts, September 15-18, 1992, University of Minnesota College of Agriculture, Department of Entomology, and Minnesota Extension Service, Saint Paul, Minnesota, USA., P274; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GEORGE J, 1991, JUL SE LYM DIS WORKS; GERN L, 1991, MED VET ENTOMOL, V5, P431, DOI 10.1111/j.1365-2915.1991.tb00571.x; GINSBERG HS, 1992, NPSNRSUNJNRSM9220 NA; GODSEY MS, 1987, AM J TROP MED HYG, V37, P180, DOI 10.4269/ajtmh.1987.37.180; GOLANE A, 1992, PRIORITIES, P39; GOLDSTEIN MD, 1990, AM J PUBLIC HEALTH, V80, P1225, DOI 10.2105/AJPH.80.10.1225; GUSTAFSON R, 1990, SCAND J INFECT DIS, V22, P297, DOI 10.3109/00365549009027051; GUY EC, 1991, J CLIN PATHOL, V44, P610, DOI 10.1136/jcp.44.7.610; HALPERIN JJ, 1990, NEUROLOGY, V40, P1340, DOI 10.1212/WNL.40.9.1340; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; Hellerstrom S., 1950, SOUTH MED J, V43, P330; HINNEBUSCH J, 1991, J BACTERIOL, V173, P7233, DOI 10.1128/jb.173.22.7233-7239.1991; HOFMEISTER EK, 1992, J CLIN MICROBIOL, V30, P2625, DOI 10.1128/JCM.30.10.2625-2631.1992; HOWE TR, 1985, SCIENCE, V227, P645, DOI 10.1126/science.3969554; HUBALEK Z, 1991, ZBL BAKT-INT J MED M, V275, P133; HUMAIR PF, 1992, 5TH INT C LYM BORR A, pA51; JAMES AM, 1990, J MED ENTOMOL, V27, P324, DOI 10.1093/jmedent/27.3.324; JOHNSON BJB, 1992, 5TH INT C LYM BORR A, pA47; JOHNSON RC, 1990, J ANTIMICROB CHEMOTH, V25, P33, DOI 10.1093/jac/25.suppl_A.33; JOHNSON RC, 1986, INFECT IMMUN, V54, P897, DOI 10.1128/IAI.54.3.897-898.1986; JOHNSON RC, 1986, INFECT IMMUN, V53, P713, DOI 10.1128/IAI.53.3.713-714.1986; JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P496, DOI 10.1099/00207713-34-4-496; JOHNSON RC, 1990, ANTIMICROB AGENTS CH, V34, P2133, DOI 10.1128/AAC.34.11.2133; JONSSON M, 1992, INFECT IMMUN, V60, P1845, DOI 10.1128/IAI.60.5.1845-1853.1992; KAHL O, 1991, ANZ SCHADLINGSKD PFL, V64, P45, DOI 10.1007/BF01909742; KAHL O, 1988, ZENTRABL BAKTERIOL A, V270, P434; KALISH R A, 1991, Arthritis and Rheumatism, V34, pS43; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KAPLAN RF, 1991, J GENET INT MED, V3, P177; KARDATZKE JT, 1992, J MED ENTOMOL, V29, P669, DOI 10.1093/jmedent/29.4.669; KIM JH, 1989, AM J MED, V87, P201; KORENBERG EI, 1990, PARAZITOLOGIYA+, V24, P102; KORENBERRG EI, 1979, SPATIAL STRUCTURE SP; KRUGER H, 1991, J NEUROL, V238, P271; KRUPP LB, 1991, ARCH NEUROL-CHICAGO, V48, P1125, DOI 10.1001/archneur.1991.00530230033017; LANBO AS, 1992, MED VET ENTOMOL, V6, P165; LANE RS, 1988, J WILDLIFE DIS, V24, P1; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LANE RS, 1990, AM J TROP MED HYG, V42, P75, DOI 10.4269/ajtmh.1990.42.75; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LEBECH AM, 1991, J CLIN MICROBIOL, V29, P731, DOI 10.1128/JCM.29.4.731-737.1991; Lederberg J., 1992, EMERGING INFECTIONS; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; LEVINE JF, 1991, J MED ENTOMOL, V28, P668, DOI 10.1093/jmedent/28.5.668; LIEGNER KB, 1993, J AM ACAD DERMATOL, V28, P312, DOI 10.1016/0190-9622(93)70043-S; Lipshutz B, 1913, ARCH DERMATOL SYPH-G, V118, P349, DOI 10.1007/BF02076105; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUCKHART S, 1991, J MED ENTOMOL, V28, P652, DOI 10.1093/jmedent/28.5.652; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MA Y, 1991, INFECT IMMUN, V59, P671, DOI 10.1128/IAI.59.2.671-678.1991; MAGNARELLI LA, 1986, J WILDLIFE DIS, V22, P178, DOI 10.7589/0090-3558-22.2.178; MALAWISTA SE, 1989, RHEUMATOL INT, V9, P233; MANNING A, 1992, USA TODAY       1015, pD1; MARCONI RT, 1992, J BACTERIOL, V174, P241, DOI 10.1128/jb.174.1.241-244.1992; MAST WE, 1976, JAMA-J AM MED ASSOC, V236, P859, DOI 10.1001/jama.236.7.859; MATHER TN, 1987, AM J TROP MED HYG, V36, P609, DOI 10.4269/ajtmh.1987.36.609; MATHER TN, 1989, AM J EPIDEMIOL, V130, P143, DOI 10.1093/oxfordjournals.aje.a115306; MATUSCHKA FR, 1990, J MED ENTOMOL, V27, P385, DOI 10.1093/jmedent/27.3.385; MATUSCHKA FR, 1986, EXP APPL ACAROL, V2, P337, DOI 10.1007/BF01193900; MAUPIN GO, 1991, AM J EPIDEMIOL, V133, P1105, DOI 10.1093/oxfordjournals.aje.a115823; MCCROSSIN I, 1986, MED J AUSTRALIA, V144, P724, DOI 10.5694/j.1326-5377.1986.tb113715.x; MCENROE WD, 1977, ACAROLOGIA, V18, P618; MILCH LJ, 1989, J INFECT DIS, V160, P351, DOI 10.1093/infdis/160.2.351; MILLER GL, 1992, 5TH INT C LYM BORR A, pA45; Murray P, 1989, Conn Med, V53, P365; NABOKOV V. A., 1964, J HYG EPIDEMIOL MICROBIOL IMMUNOL, V8, P387; NADELMAN RB, 1991, SOUTHERN MED J, V84, P1263, DOI 10.1097/00007611-199110000-00024; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NADELMAN RB, 1993, MMWR-MORBID MORTAL W, V42, P39; NAKAO M, 1992, AM J TROP MED HYG, V47, P505, DOI 10.4269/ajtmh.1992.47.505; NAVERSEN DN, 1978, ARCH DERMATOL, V114, P253, DOI 10.1001/archderm.114.2.253; OLIVER JH, 1993, J MED ENTOMOL, V30, P54, DOI 10.1093/jmedent/30.1.54; OLSEN B, 1993, NATURE, V362, P340, DOI 10.1038/362340a0; Opdebeeck J. P., 1992, First International Conference on Tick-borne Pathogens at the Host-Vector Interface: An Agenda for Research: Proceedings and abstracts, September 15-18, 1992, University of Minnesota College of Agriculture, Department of Entomology, and Minnesota Extension Service, Saint Paul, Minnesota, USA., P233; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; PFISTER HW, 1984, J NEUROL, V118, P1; PIESMAN J, 1988, J MED ENTOMOL, V25, P336, DOI 10.1093/jmedent/25.5.336; Piesman J, 1991, Can J Infect Dis, V2, P55; PIESMAN J, 1986, J MED ENTOMOL, V23, P219, DOI 10.1093/jmedent/23.2.219; PIESMAN J, 1986, ACTA TROP, V43, P263; PROCHOROV BB, 1974, MAPPING IXODID TICKS; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSA PA, 1991, J CLIN MICROBIOL, V29, P524, DOI 10.1128/JCM.29.3.524-532.1991; ROSICKY B., 1954, ZOOL A ENT LISTY, V3, P37; RYDER JW, 1992, J MED ENTOMOL, V29, P525, DOI 10.1093/jmedent/29.3.525; SCHAIBLE UE, 1991, EUR J IMMUNOL, V21, P2397, DOI 10.1002/eji.1830211016; SCHMUTZHARD E, 1988, INFECTION, V16, P269, DOI 10.1007/BF01645068; SCHOELER GB, 1993, J MED ENTOMOL, V30, P80, DOI 10.1093/jmedent/30.1.80; SCHULZE TL, 1991, J MED ENTOMOL, V28, P624, DOI 10.1093/jmedent/28.5.624; SCHULZE TL, 1986, ZBL BAKT-INT J MED M, V263, P65; SCHULZE TL, 1984, J MED ENTOMOL, V21, P741, DOI 10.1093/jmedent/21.6.741; SCHWAN TG, 1987, J INFECT DIS, V156, P852, DOI 10.1093/infdis/156.5.852-a; SCRIMENTI RJ, 1970, ARCH DERMATOL, V102, P104, DOI 10.1001/archderm.102.1.104; SEVERINGHAUS CW, 1956, NY FISH GAME J, V3, P124; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIGAL LH, 1991, ANNU REV PUBL HEALTH, V12, P85, DOI 10.1146/annurev.pu.12.050191.000505; SIGAL LH, 1992, DRUGS, V43, P683, DOI 10.2165/00003495-199243050-00005; SIMON MM, 1991, J INFECT DIS, V164, P123, DOI 10.1093/infdis/164.1.123; SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989; SPIELMAN A, 1979, J MED ENTOMOL, V15, P218, DOI 10.1093/jmedent/15.3.218; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; Spielman A., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P147; STAFFORD KC, 1991, J MED ENTOMOL, V28, P32, DOI 10.1093/jmedent/28.1.32; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEWART A, 1982, MED J AUSTRALIA, V1, P139, DOI 10.5694/j.1326-5377.1982.tb132207.x; STONE R, 1992, SCIENCE, V258, P540, DOI 10.1126/science.1329204; SZCZEPANSKI A, 1990, J CLIN INVEST, V85, P1637, DOI 10.1172/JCI114615; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; TELTOW GJ, 1991, AM J TROP MED HYG, V44, P469, DOI 10.4269/ajtmh.1991.44.469; USPENSKY I, 1992, ANN NY ACAD SCI, V661, P244, DOI 10.1111/j.1749-6632.1992.tb26046.x; WEISBROD AR, 1989, APPL ENVIRON MICROB, V55, P1921, DOI 10.1128/AEM.55.8.1921-1924.1989; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WHITE DJ, 1991, JAMA-J AM MED ASSOC, V266, P1230, DOI 10.1001/jama.266.9.1230; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; Wilson Mark L., 1993, P126; WILSON ML, 1985, ANN ENTOMOL SOC AM, V78, P172, DOI 10.1093/aesa/78.2.172; WILSON ML, 1988, J MED ENTOMOL, V25, P224, DOI 10.1093/jmedent/25.4.224; YANG LM, 1992, INFECT IMMUN, V60, P3033, DOI 10.1128/IAI.60.8.3033-3041.1992; ZHANG W, 1992, 5TH INT C LYM BORR A, pA48; 1992, MORB MORTAL WKLY REP, V40, P1; 1990, WIS EPIDEMIOL B, V13, P1; 1992, OHIO VECTOR NEWS OHI, V11, P1; 1991, JAMA-J AM MED ASSOC, V266, P470; 1992, MORB MORTAL WKLY REP, V41, P505; 1991, LYME DIS SURV SUMM, V2, P1; 1990, MORB MORTAL WKLY REP, V39, P397	203	474	490	2	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1610	1616		10.1126/science.8503006	http://dx.doi.org/10.1126/science.8503006			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503006				2022-12-28	WOS:A1993LG17600019
J	REGEVIK, NK				REGEVIK, NK			MY HEROES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2910	2910		10.1001/jama.269.22.2910	http://dx.doi.org/10.1001/jama.269.22.2910			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497097				2022-12-28	WOS:A1993LE93600031
J	ROY, MJ; DAMATO, JJ; BURKE, DS				ROY, MJ; DAMATO, JJ; BURKE, DS			ABSENCE OF TRUE SEROREVERSION OF HIV-1 ANTIBODY IN SEROREACTIVE INDIVIDUALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; INFECTION; COHORT	Objectives.-First, to determine whether there is evidence for loss of human immunodeficiency virus type 1 (HIV-1) antibody in seroreactive individuals. Second, if true seroreversion occurs, to determine its incidence relative to errors in the testing process. Design.- A retrospective cohort study reviewing the results of 5 446 161 HIV-1 antibody tests performed on 2 580 974 individuals (the US Army HIV Data System) from 1985 through 1992. For all patients with one or more seroreactive sample followed by one or more nonreactive sample, we examined available records and retested the samples. Participants.-Serum samples had been obtained from active-duty and retired military personnel, their dependents, and applicants to the military. Results.-Of 4911 individuals reported to be seroreactive for HIV-1 by two independent samples, only six were potential seroreverters. Review of the six cases revealed that five actually were HIV-seroreactive patients who had samples from nonreactive individuals mistakenly attributed to them, while the sixth had a testing error proven by retesting the discrepant specimen. Errors in the testing process were identified (n=23) or suspected (n=3) in another 26 individuals who had not had independent confirmation of reactivity by a second sample. The cumulative error rate was 12.4 per 1 million patients tested. An additional group of 31 uninfected infants appeared to serorevert due to loss of antibody acquired from their HIV-1-infected mothers. Conclusions.-Review of this database demonstrates no evidence for true seroreversion of HIV-1 antibody status. We conclude that if seroreversion occurs at all, it is exceedingly rare. In fact, most (if not all) cases of apparent seroreversion represent errors of attribution or testing.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; WALTER REED ARMY INST RES,DIV RETROVIROL,WASHINGTON,DC 20307	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	ROY, MJ (corresponding author), WALTER REED ARMY MED CTR,DEPT MED,WASHINGTON,DC 20307, USA.			/0000-0002-5704-8094				BURGER H, 1985, ANN INTERN MED, V103, P545, DOI 10.7326/0003-4819-103-4-545; DAMATO J, 1988, LAB MED, V19, P577, DOI 10.1093/labmed/19.9.577; DAMATO JJ, 1991, LAB MED, V22, P107, DOI 10.1093/labmed/22.2.107; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; HOLMBERG SD, 1988, ANN INTERN MED, V109, P679, DOI 10.7326/0003-4819-109-8-679_2; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961; 1991, LANCET, V338, P253	10	31	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2876	2879		10.1001/jama.269.22.2876	http://dx.doi.org/10.1001/jama.269.22.2876			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497091				2022-12-28	WOS:A1993LE93600024
J	WOYCHIK, RP; WASSOM, JS; KINGSBURY, D				WOYCHIK, RP; WASSOM, JS; KINGSBURY, D			TBASE - A COMPUTERIZED DATABASE FOR TRANSGENIC ANIMALS AND TARGETED MUTATIONS	NATURE			English	Article									JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Johns Hopkins University	WOYCHIK, RP (corresponding author), OAK RIDGE NATL LAB,OAK RIDGE,TN 37831, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; LYON MF, 1989, GENETIC VARIANTS STR, P2; MALTAIS LJ, GBASE GENOMIC DATABA; 1992, ILAR NEWS, V34, P45	5	21	21	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					375	376		10.1038/363375a0	http://dx.doi.org/10.1038/363375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497324				2022-12-28	WOS:A1993LD91700061
J	COFFMAN, CR; SKOGLUND, P; HARRIS, WA; KINTNER, CR				COFFMAN, CR; SKOGLUND, P; HARRIS, WA; KINTNER, CR			EXPRESSION OF AN EXTRACELLULAR DELETION OF XOTCH DIVERTS CELL FATE IN XENOPUS-EMBRYOS	CELL			English	Article							DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; EARLY NEUROGENESIS; LATERAL INHIBITION; NEURAL INDUCTION; NOTCH LOCUS; ACTIVIN-A; N-CAM; RNA; MESODERM	Xotch is a Xenopus homolog of Notch, a receptor involved in cell fate decisions in Drosophila. Using an extracellular deletion construct, XotchDELTAE, we show that Xotch has a similar role in Xenopus embryos. Broad expression causes the loss of dorsal structures and the expansion and disorganization of the brain. Single blastomere injections of XotchDELTAE induce autonomous neural and mesodermal hypertrophy, even in the absence of cell division. XotchDELTAE inhibits the early expression of epidermal and neural crest markers yet enhances and extends the response of animal caps to mesodermal and neural induction. Our data suggest a mechanism for the function of Notch homologs in which they delay differentiation and leave undetermined cells competent to respond to later inductive signals.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Diego; Salk Institute	COFFMAN, CR (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.							ALBERS B, 1987, DEV GROWTH DIFFER, V29, P535; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLMAN A, 1986, J EMBRYOL EXP MORPH, V97, P197; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HOPWOOD ND, 1991, DEVELOPMENT, P95; Horstadius S., 1950, NEURAL CREST; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JONES EA, 1986, CELL, V44, P345, DOI 10.1016/0092-8674(86)90769-5; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Le Douarin N.M., 1982, NEURAL CREST; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MARKOPOULOU K, 1989, J NEUROGENET, V6, P11, DOI 10.3109/01677068909107097; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SAHA MS, 1989, CELL DIFFER DEV, V28, P153, DOI 10.1016/0922-3371(89)90001-4; SAKAGUCHI DS, 1989, DEV BIOL, V134, P158, DOI 10.1016/0012-1606(89)90086-9; Sambrook J, 1989, MOL CLONING LABORATO; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; XU T, 1992, DEVELOPMENT, V115, P913	68	343	358	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					659	671		10.1016/0092-8674(93)90247-N	http://dx.doi.org/10.1016/0092-8674(93)90247-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500162				2022-12-28	WOS:A1993LD83000006
J	HARDMAN, KA; HEATH, DA; NELSON, HM				HARDMAN, KA; HEATH, DA; NELSON, HM			HYPERCALCEMIA ASSOCIATED WITH CALCIPOTRIOL (DOVONEX) TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter									BURTON & DIST GEN HOSP,BURTON TRENT,ENGLAND		HARDMAN, KA (corresponding author), QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BOWER M, 1991, LANCET, V337, P701, DOI 10.1016/0140-6736(91)90280-3; DWYER C, 1991, LANCET, V338, P764, DOI 10.1016/0140-6736(91)91493-E	3	33	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					896	896		10.1136/bmj.306.6882.896-a	http://dx.doi.org/10.1136/bmj.306.6882.896-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490416	Bronze, Green Published			2022-12-28	WOS:A1993KW38700022
J	HENSHAW, RC; COOPER, K; ELREFAEY, H; SMITH, NC; TEMPLETON, AA				HENSHAW, RC; COOPER, K; ELREFAEY, H; SMITH, NC; TEMPLETON, AA			MEDICAL-MANAGEMENT OF MISCARRIAGE - NONSURGICAL UTERINE EVACUATION OF INCOMPLETE AND INEVITALE SPONTANEOUS-ABORTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article											HENSHAW, RC (corresponding author), ABERDEEN MATERN HOSP, DEPT OBSTET & GYNAECOL, ABERDEEN AB2 9ZD, SCOTLAND.			cooper, kevin/0000-0003-1486-0071				BYGDEMAN M, 1989, ACTA OBSTET GYN SCAN, P13; FRIEDMAN T, 1989, J ROY COLL GEN PRACT, V39, P456; Hertig AT, 1944, NEW ENGL J MED, V230, P797; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; 1990, LANCET, V336, P1480	5	71	72	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					894	895		10.1136/bmj.306.6882.894	http://dx.doi.org/10.1136/bmj.306.6882.894			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490413	Bronze, Green Published			2022-12-28	WOS:A1993KW38700019
J	LEAR, J; RAJAPAKSE, R				LEAR, J; RAJAPAKSE, R			LOW-BACK-PAIN ASSOCIATED WITH ANISTREPLASE	BRITISH MEDICAL JOURNAL			English	Letter							STREPTOKINASE				LEAR, J (corresponding author), LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND.		lear, john/I-5465-2015	lear, john/0000-0002-2969-9922				DICKINSON RJ, 1991, BRIT MED J, V302, P111; HANNAFORD P, 1992, BRIT MED J, V304, P915, DOI 10.1136/bmj.304.6831.915; PORTER NJ, 1991, BMJ, V302, P111; SHAH M, 1990, BRIT MED J, V301, P1219, DOI 10.1136/bmj.301.6762.1219-a	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					896	896		10.1136/bmj.306.6882.896-b	http://dx.doi.org/10.1136/bmj.306.6882.896-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490418	Green Published, Bronze			2022-12-28	WOS:A1993KW38700023
J	RAMSEY, BW; DORKIN, HL; EISENBERG, JD; GIBSON, RL; HARWOOD, IR; KRAVITZ, RM; SCHIDLOW, DV; WILMOTT, RW; ASTLEY, SJ; MCBURNIE, MA; WENTZ, K; SMITH, AL				RAMSEY, BW; DORKIN, HL; EISENBERG, JD; GIBSON, RL; HARWOOD, IR; KRAVITZ, RM; SCHIDLOW, DV; WILMOTT, RW; ASTLEY, SJ; MCBURNIE, MA; WENTZ, K; SMITH, AL			EFFICACY OF AEROSOLIZED TOBRAMYCIN IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PSEUDOMONAS-AERUGINOSA; INHALED ANTIBIOTICS; CROSSOVER DESIGNS; SELECTIVE MEDIA; GENTAMICIN; CHILDREN; CARBENICILLIN; SPUTUM; THERAPY; PLACEBO	Background Direct aerosol delivery of aminoglycosides such as tobramycin to the lower airways of patients with cystic fibrosis may control infection with Pseudomonas aeruginosa and improve pulmonary function, with low systemic toxicity. We conducted a randomized crossover study to evaluate the safety and efficacy of aerosolized tobramycin in patients with cystic fibrosis and P. aeruginosa infections. Methods. Seventy-one patients with stable pulmonary status were recruited from seven U.S. centers for the treatment of cystic fibrosis and randomly assigned to one of two crossover regimens. Group 1 received 600 mg of aerosolized tobramycin for 28 days, followed by half-strength physiologic saline (placebo) for two 28-day periods. Group 2 received placebo for 28 days, followed by tobramycin for two 28-day periods. Pulmonary function, the density of P. aeruginosa in sputum, ototoxicity, nephrotoxicity, and the emergence of tobramycin-resistant P. aeruginosa were monitored. Results. In the first 28-day period, treatment with tobramycin was associated with an increase in the percentage of the value predicted for forced expiratory volume in one second (9.7 percentage points higher than the value for placebo; P<0.001), forced vital capacity (6.2 percentage points higher than the value for placebo; P = 0.014), and forced expiratory flow at the midportion of the vital capacity (13.0 percentage points higher than the value for placebo; P<0.001). A decrease in the density of P. aeruginosa in sputum by a factor of 100 (P<0.001) was found during all periods of tobramycin administration. Neither ototoxicity nor nephrotoxicity was detected. The frequency of the emergence of tobramycin-resistant bacteria was similar during both tobramycin and placebo administration. Conclusions. The short-term aerosol administration of a high dose of tobramycin in patients with clinically stable cystic fibrosis is an efficacious and safe treatment for endobronchial infection with P. aeruginosa.	TUFTS UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02111 USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PEDIAT, SAN DIEGO, CA 92103 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19140 USA; UNIV CINCINNATI, DEPT PEDIAT, CINCINNATI, OH 45221 USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH COMMUNITY MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH COMMUNITY MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	Tufts University; Oregon Health & Science University; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Ohio; University of Cincinnati; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RAMSEY, BW (corresponding author), CHILDRENS HOSP & MED CTR, CYST FIBROSIS PROGRAM, 4800 SAND POINT WAY NE, POB C-5371, SEATTLE, WA 98105 USA.		Smith, Adam/GPS-8322-2022					ABRAMOWSKY CR, 1982, HUM PATHOL, V13, P934, DOI 10.1016/S0046-8177(82)80056-7; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BLACKPAYNE C, 1987, DIAGN MICR INFEC DIS, V6, P277, DOI 10.1016/0732-8893(87)90175-1; BRUMMETT RE, 1980, DRUGS, V19, P412, DOI 10.2165/00003495-198019060-00002; CARSWELL F, 1987, BRIT J DIS CHEST, V81, P356, DOI 10.1016/0007-0971(87)90184-7; EBBUTT AF, 1984, BIOMETRICS, V40, P219, DOI 10.2307/2530762; EDSTEIN M, 1983, J CHROMATOGR, V278, P445, DOI 10.1016/S0378-4347(00)84807-0; FRANZ MN, 1985, 26TH ANN M CYST FIBR; GIBSON LE, 1959, PEDIATRICS, V23, P545; HODSON ME, 1981, LANCET, V2, P1137; JENKINS SG, 1985, 26TH ANN M CYST FIBR; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KUN P, 1984, AUST PAEDIATR J, V20, P43; LASKA E, 1983, BIOMETRICS, V39, P1087, DOI 10.2307/2531343; LEVY J, 1983, J INFECT DIS, V148, P1069, DOI 10.1093/infdis/148.6.1069; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LONGRIDGE NS, 1987, J OTOLARYNGOL, V16, P97; MACLUSKY I, 1986, J PEDIATR-US, V108, P861, DOI 10.1016/S0022-3476(86)80758-2; MACLUSKY IB, 1989, PEDIATR PULM, V7, P42, DOI 10.1002/ppul.1950070110; MARKS MI, 1981, J PEDIATR-US, V98, P173, DOI 10.1016/S0022-3476(81)80631-2; MCLAUGHLIN FJ, 1983, J INFECT DIS, V147, P559, DOI 10.1093/infdis/147.3.559; MOORE RD, 1984, J INFECT DIS, V149, P23, DOI 10.1093/infdis/149.1.23; NATHANSON I, 1985, 26TH ANN M CYST FIBR; NEWMAN SP, 1988, THORAX, V43, P318, DOI 10.1136/thx.43.4.318; REDDING GJ, 1982, AM REV RESPIR DIS, V126, P31; SMITH AL, 1989, PEDIATR PULM, V7, P265, DOI 10.1002/ppul.1950070413; SMITH AL, 1988, J PEDIATR-US, V112, P547, DOI 10.1016/S0022-3476(88)80165-3; SPILKER B, 1991, GUIDE CLIN TRIALS, P69; STEAD RJ, 1987, BRIT J DIS CHEST, V81, P272, DOI 10.1016/0007-0971(87)90161-6; STEINKAMP G, 1989, PEDIATR PULM, V6, P91, DOI 10.1002/ppul.1950060207; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; TAUSSIG LM, 1980, J PEDIATR-US, V97, P668, DOI 10.1016/S0022-3476(80)80039-4; THORNSBERRY C, 1977, CUMITECH, V6, P1; WALL MA, 1983, LANCET, V1, P1325; WANG C, 1984, 25TH ANN M CYST FIBR; WEBER A, IN PRESS PEDIATR PUL; WONG K, 1984, J MED MICROBIOL, V17, P113, DOI 10.1099/00222615-17-2-113; 1990, M7A2 CLIN LAB STAND	39	351	368	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1740	1746		10.1056/NEJM199306173282403	http://dx.doi.org/10.1056/NEJM199306173282403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8497284				2022-12-28	WOS:A1993LG03800003
J	ASHTONRICKARDT, PG; VANKAER, L; SCHUMACHER, TNM; PLOEGH, HL; TONEGAWA, S				ASHTONRICKARDT, PG; VANKAER, L; SCHUMACHER, TNM; PLOEGH, HL; TONEGAWA, S			PEPTIDE CONTRIBUTES TO THE SPECIFICITY OF POSITIVE SELECTION OF CD8+ T-CELLS IN THE THYMUS	CELL			English	Article							RECEPTOR TRANSGENIC MICE; CLASS-I MOLECULES; ANTIGEN PRESENTATION; SELF-PEPTIDES; MHC MOLECULES; LYMPHOCYTES-T; H-2 ANTIGENS; TOLERANCE; EPITHELIUM; EXPRESSION	Mice deficient in the gene encoding the peptide transporter associated with antigen processing (TAP1) have drastically reduced levels of surface expression of MHC class I molecules and few CD8+ T cells. Addition of class I binding peptides to cultured fetal thymi from TAP1 mutant mice invariably allowed the rescue of class I expression, while only some of these peptides promoted the positive selection of CD8+ T cells, which were polyclonal and specific for the peptide-MHC complex. A nonselecting peptide was converted to a mixture of selecting peptides when the residues involved in the interaction with TCRs were altered. A mixture of self-peptides derived from C57BL/6 thymi induced positive selection of CD8+ T cells at concentrations that gave relatively low class I surface expression. The implication of these observations is that self-peptides determine, in part, the repertoire of specificities exhibited by CD8+ T cells.	MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ASHTONRICKARDT, PG (corresponding author), MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Schumacher, Ton/Y-2432-2019; Van Kaer, Luc/H-1033-2015	Schumacher, Ton/0000-0003-0517-8804; Van Kaer, Luc/0000-0001-5275-2309				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FARR AG, 1986, ANAT REC, V216, P85, DOI 10.1002/ar.1092160115; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JENKINSON EJ, 1981, J EXP MED, V153, P280, DOI 10.1084/jem.153.2.280; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANBLEEK GM, 1990, NATURE, V348, P213; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	32	269	274	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1041	1049		10.1016/0092-8674(93)90281-T	http://dx.doi.org/10.1016/0092-8674(93)90281-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500174	Bronze			2022-12-28	WOS:A1993LF06100019
J	COHEN, FE				COHEN, FE			THE PARALLEL BETA-HELIX OF PECTATE LYASE-C - SOMETHING TO SNEEZE AT	SCIENCE			English	Editorial Material							PROTEIN-STRUCTURE		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	COHEN, FE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.							BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; COHEN FE, 1980, NATURE, V285, P378, DOI 10.1038/285378a0; COLLOCH N, 1991, J MOL BIOL, V221, P603, DOI 10.1016/0022-2836(91)80075-6; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; STERNBERG MJE, 1977, J MOL BIOL, V110, P209; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	17	26	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1444	1445		10.1126/science.8502989	http://dx.doi.org/10.1126/science.8502989			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502989				2022-12-28	WOS:A1993LF05800024
J	SHAPIRO, L				SHAPIRO, L			PROTEIN LOCALIZATION AND ASYMMETRY IN THE BACTERIAL-CELL	CELL			English	Review							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; BUD SITE SELECTION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; SACCHAROMYCES-CEREVISIAE; CAULOBACTER-CRESCENTUS; TRANSCRIPTION FACTOR; DIVISION INHIBITOR; CYTOPLASMIC DOMAIN				SHAPIRO, L (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32506] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; AYALA JA, 1988, J BACTERIOL, V170, P3333, DOI 10.1128/jb.170.8.3333-3341.1988; BEALL B, 1992, J BACTERIOL, V174, P2398, DOI 10.1128/JB.174.7.2398-2403.1992; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BI E, 1990, J BACTERIOL, V172, P5602, DOI 10.1128/jb.172.10.5602-5609.1990; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOOS W, 1981, ARCH MICROBIOL, V129, P240, DOI 10.1007/BF00425258; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CARSON MJ, 1991, J BACTERIOL, V173, P2187, DOI 10.1128/JB.173.7.2187-2195.1991; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COOK WR, 1987, P NATL ACAD SCI USA, V84, P7144, DOI 10.1073/pnas.84.20.7144; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DAI K, 1992, J BACTERIOL, V174, P6145, DOI 10.1128/JB.174.19.6145-6151.1992; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DEGNEN ST, 1972, J MOL BIOL, V64, P671, DOI 10.1016/0022-2836(72)90090-3; DESCOTEAUX A, 1987, J BACTERIOL, V169, P1938, DOI 10.1128/jb.169.5.1938-1942.1987; DEWAR SJ, 1992, J BACTERIOL, V174, P6314, DOI 10.1128/JB.174.19.6314-6316.1992; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; ERRINGTON J, 1990, GENETICS BIOTECHNOLO, V3, P257; EVINGER M, 1979, P NATL ACAD SCI USA, V76, P175, DOI 10.1073/pnas.76.1.175; FREUDL R, 1987, GENE, V52, P31, DOI 10.1016/0378-1119(87)90392-1; GAELEN RL, 1979, J BIOL CHEM, V254, P11982; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Gober JW, 1991, CURR OPIN GENET DEV, V1, P324, DOI 10.1016/S0959-437X(05)80295-3; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOBER JW, 1991, BIOESSAYS, V13, P277, DOI 10.1002/bies.950130604; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; GOMES SL, 1984, J MOL BIOL, V177, P551; GUZMAN LM, 1992, J BACTERIOL, V174, P7716, DOI 10.1128/JB.174.23.7717-7728.1992; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; Haselkorn R, 1992, BIOL NITROGEN FIXATI, P166; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; ISHINO F, 1981, BIOCHEM BIOPH RES CO, V101, P905, DOI 10.1016/0006-291X(81)91835-0; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; NANNINGA N, 1991, PROKARYOTIC STRUCTUR, P185; NATHAN P, 1986, J MOL BIOL, V191, P433, DOI 10.1016/0022-2836(86)90138-5; NELSON DR, 1981, J BIOL CHEM, V256, P2589; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NEWTON A, 1990, ANNU REV MICROBIOL, V44, P689; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLA J, 1990, J BACTERIOL, V172, P5097, DOI 10.1128/jb.172.9.5097-5102.1990; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SCHWARTZ MA, 1988, J CELL BIOL, V107, P201, DOI 10.1083/jcb.107.1.201; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SNYDER JA, 1976, ANNU REV BIOCHEM, V45, P699, DOI 10.1146/annurev.bi.45.070176.003411; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SWOBODA KK, 1982, J GEN MICROBIOL, V128, P279; TORMO A, 1986, J BACTERIOL, V166, P985, DOI 10.1128/jb.166.3.985-992.1986; WALTER RJ, 1980, NATURE, V286, P724, DOI 10.1038/286724a0; WEINBAUM DL, 1980, NATURE, V286, P725, DOI 10.1038/286725a0; WOLDRINGH CL, 1991, RES MICROBIOL, V142, P309, DOI 10.1016/0923-2508(91)90046-D; Wolk CP, 1991, CURR OPIN GENET DEV, V1, P336	94	54	59	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					841	855		10.1016/0092-8674(93)90266-S	http://dx.doi.org/10.1016/0092-8674(93)90266-S			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500178	Bronze			2022-12-28	WOS:A1993LF06100004
J	BRADFORD, RH; DOWNTON, M; CHREMOS, AN; LANGENDORFER, A; STINNETT, S; NASH, DT; MANTELL, G; SHEAR, CL				BRADFORD, RH; DOWNTON, M; CHREMOS, AN; LANGENDORFER, A; STINNETT, S; NASH, DT; MANTELL, G; SHEAR, CL			EFFICACY AND TOLERABILITY OF LOVASTATIN IN 3390 WOMEN WITH MODERATE HYPERCHOLESTEROLEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERCHOLESTEROLEMIA; LOVASTATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOPROTEINS, LDL CHOLESTEROL; TRIGLYCERIDES	EXPANDED CLINICAL-EVALUATION; CORONARY-ARTERY BYPASS; LIPOPROTEIN CHOLESTEROL; SEX-DIFFERENCES; MORTALITY; PROGNOSIS; DISEASE; SURGERY; THERAPY; PLASMA	Objective: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia. Design: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks. Setting. Ambulatory patients recruited by 362 participating centers throughout the United States. Patients: Women (n = 3390) from the total cohort of 8245 volunteers. Measurements: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study. Results: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%). Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL). Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose. Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg). Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin. Conclusion: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women.	CLINTRIAL INC, RES TRIANGLE PK, NC USA; MERCK SHARP & DOHME LTD, W POINT, PA 19486 USA; SUNY HLTH SCI CTR, SYRACUSE, NY USA	Merck & Company; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	BRADFORD, RH (corresponding author), OKLAHOMA MED RES FDN, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA.			Stinnett, Sandra/0000-0001-7192-0195				BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRADFORD RH, 1990, AM J CARDIOL, V66, pB44, DOI 10.1016/0002-9149(90)90440-C; BUSH TL, 1990, ANN NY ACAD SCI, V592, P263; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1990, AM J CARDIOL, V66, pB1, DOI 10.1016/0002-9149(90)90434-3; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; Koch GG, 1988, BIOPHARMACEUTICAL ST, P403; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEAR CL, 1992, CIRCULATION, V85, P1293, DOI 10.1161/01.CIR.85.4.1293; WALDRON I, 1983, SOC SCI MED, V17, P1107, DOI 10.1016/0277-9536(83)90004-7; WINGARD DL, 1989, AM J EPIDEMIOL, V130, P601, DOI 10.1093/oxfordjournals.aje.a115374; 1988, JAMA-J AM MED ASSOC, V260, P359	20	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					850	855		10.7326/0003-4819-118-11-199306010-00004	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480959				2022-12-28	WOS:A1993LD25200004
J	SCHAPIRA, MM; MATCHAR, DB; YOUNG, MJ				SCHAPIRA, MM; MATCHAR, DB; YOUNG, MJ			THE EFFECTIVENESS OF OVARIAN-CANCER SCREENING - A DECISION-ANALYSIS MODEL	ANNALS OF INTERNAL MEDICINE			English	Article						OVARIAN NEOPLASMS; DECISION SUPPORT TECHNIQUES; MASS SCREENING; ANTIGENS, TUMOR-ASSOCIATED; SONICATION	TRANS-VAGINAL SONOGRAPHY; PROGNOSTIC FACTORS; EPIDEMIOLOGY; CARCINOMA	Objective: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal sonography. Design: Decision analysis was used to examine the no-screen compared with the screen strategy. Setting: Estimates of cancer incidence, survival, and life expectancy were derived from population-based data and clinical series. Subjects: A cohort of 40-year-old women of all races and residing in the United States. Interventions: A one-time screening intervention. The criterion standard for diagnosis of ovarian cancer was evaluation with exploratory laparotomy. Main Outcome Measure: Average years of life expectancy gained by women in the screened group. Results: Screening for ovarian cancer with a combination of CA 125 and transvaginal sonography increases the average life expectancy in the population by less than 1 day. Conclusions: Given the limited effect on overall life expectancy, it is unlikely that mass screening for ovarian cancer with CA 125 and transvaginal sonography would be an effective health policy.	MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; HENRY FORD HOSP, DETROIT, MI 48202 USA	Medical College of Wisconsin; Duke University; Henry Ford Health System; Henry Ford Hospital			Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108				ANDOLF E, 1986, BRIT J OBSTET GYNAEC, V93, P1286, DOI 10.1111/j.1471-0528.1986.tb07867.x; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BJORKHOLM E, 1982, ACTA RADIOL ONCOL, V21, P413; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CUTLER SJ, 1975, NCI MONOGRAPH, V41; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; FUNKHOUSER JW, 1975, ACTA CYTOL, V19, P538; HEINTZ APM, 1985, OBSTET GYNECOL, V66, P127; HIGGINS RV, 1989, GYNECOL ONCOL, V34, P402, DOI 10.1016/0090-8258(89)90181-9; JACOBS I, 1989, HUM REPROD, V4, P1; KEETTEL WC, 1974, AM J OBSTET GYNECOL, V120, P174, DOI 10.1016/0002-9378(74)90359-7; KENT SW, 1960, AM J OBSTET GYNECOL, V80, P430; MAIMAN M, 1991, OBSTET GYNECOL, V77, P563; NEIJT JP, 1984, LANCET, V2, P594; PARAZZINI F, 1991, GYNECOL ONCOL, V43, P9, DOI 10.1016/0090-8258(91)90003-N; PARKER RT, 1970, AM J OBSTET GYNECOL, V108, P878, DOI 10.1016/0002-9378(70)90329-7; PEARSE WH, 1954, OBSTET GYNECOL, V3, P32; PODELL RN, 1969, J CHRON DIS, V22, P451, DOI 10.1016/0021-9681(69)90007-1; PROROK PC, 1990, UROL CLIN N AM, V17, P699; REEVES RD, 1980, OBSTET GYNECOL, V55, P551; RODRIGUEZ MH, 1988, AM J OBSTET GYNECOL, V159, P810, DOI 10.1016/S0002-9378(88)80142-X; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SCHWARTZ PE, 1991, CLIN OBSTET GYNECOL, V34, P467, DOI 10.1097/00003081-199106000-00031; SIGURDSSON K, 1983, GYNECOL ONCOL, V15, P370, DOI 10.1016/0090-8258(83)90055-0; SLOTMAN BJ, 1988, ANTICANCER RES, V8, P417; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VANNAGELL JR, 1993, CANCER-AM CANCER SOC, V71, P1523, DOI 10.1002/cncr.2820710418; WOBBES T, 1984, J SURG ONCOL, V26, P135, DOI 10.1002/jso.2930260212; YANCIK R, 1986, AM J OBSTET GYNECOL, V154, P639, DOI 10.1016/0002-9378(86)90623-X; ZURAWSKI VR, 1988, GYNECOL ONCOL, V30, P7, DOI 10.1016/0090-8258(88)90039-X; 1990, GUIDE CLIN PREVENTIV, pR29; 1991, VITAL STATISTICS US; 1990, CA-CANCER J CLIN, V40, P2; 1966, JAMA-J AM MED ASSOC, V197, P775	36	48	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					838	843		10.7326/0003-4819-118-11-199306010-00002	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480957				2022-12-28	WOS:A1993LD25200002
J	BRADY, RL; DODSON, EJ; DODSON, GG; LANGE, G; DAVIS, SJ; WILLIAMS, AF; BARCLAY, AN				BRADY, RL; DODSON, EJ; DODSON, GG; LANGE, G; DAVIS, SJ; WILLIAMS, AF; BARCLAY, AN			CRYSTAL-STRUCTURE OF DOMAIN-3 AND DOMAIN-4 OF RAT CD4 - RELATION TO THE NH2-TERMINAL DOMAINS	SCIENCE			English	Article							CLASS-II MHC; ANTIGEN; BINDING; RETROVIRUS; RECEPTOR; MOLECULE; FRAGMENT; CELLS	The CD4 antigen is a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigens and is also a receptor for the human immunodeficiency virus. The extracellular portion of CD4 is predicted to fold into four immunoglobulin-like domains. The crystal structure of the third and fourth domains of rat CD4 was solved at 2.8 angstrom resolution and shows that both domains have immunoglobulin folds. Domain 3, however, lacks the disulfide between the beta sheets; this results in an expansion of the domain. There is a difference of 30 degrees in the orientation between domains 3 and 4 when compared with domains 1 and 2. The two CD4 fragment structures provide a basis from which models of the overall receptor can be proposed. These models suggest an extended structure comprising two rigid portions joined by a short and possibly flexible linker region.	UNIV OXFORD SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	BRADY, RL (corresponding author), UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND.							BARCLAY AN, 1992, LEUCOCYTE ANTIGENS F, P4; BRADY RL, UNPUB; BRUNGER AT, 1990, X PLOR MANUAL; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; FINCH JT, COMMUNICATION; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	28	140	143	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					979	983		10.1126/science.8493535	http://dx.doi.org/10.1126/science.8493535			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493535				2022-12-28	WOS:A1993LB79100042
J	SMEYNE, RJ; VENDRELL, M; HAYWARD, M; BAKER, SJ; MIAO, GG; SCHILLING, K; ROBERTSON, LM; CURRAN, T; MORGAN, JI				SMEYNE, RJ; VENDRELL, M; HAYWARD, M; BAKER, SJ; MIAO, GG; SCHILLING, K; ROBERTSON, LM; CURRAN, T; MORGAN, JI			CONTINUOUS C-FOS EXPRESSION PRECEDES PROGRAMMED CELL-DEATH INVIVO	NATURE			English	Article							NEURONS; LAYER	THE development of a multicellular organism involves a delicate balance among the processes of proliferation, differentiation and death. Naturally occurring cell death aids tissue remodelling, eliminates supernumerary cell populations and provides structural elements such as hair and skin. In the nervous system, selective cell death contributes to the formation and organization of the spinal cord and sympathetic ganglia1, retina2 and corpus callosum3. But cell death also occurs in several neuropathological conditions, such as amyelotrophic lateral sclerosis4 and Alzheimer's disease5. Therefore an elucidation of the mechanisms responsible for cell death is critical for an appreciation of both normal development and neuropathological disorders. Using a fos-lacZ transgenic mouse6, we provide evidence showing that the continuous expression of Fos beginning hours or days before the morphological demise of the cell, appears to be a hallmark of terminal differentiation and a harbinger of death.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding; Roche Holding			Morgan, James/GRO-2905-2022; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Morgan, James/N-8104-2018; Baker, Suzanne J/N-8167-2018; Curran, Tom/D-7515-2011	Morgan, James/0000-0002-8920-1065; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Smeyne, Richard/0000-0002-8459-5472				BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DAVIES AM, 1987, DEVELOPMENT, V101, P185; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; GRANT G, 1985, RAT NERVOUS SYST, P303; GREENE RM, 1976, J EMBRYOL EXP MORPH, V36, P225; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HANKIN MH, 1988, J COMP NEUROL, V272, P191, DOI 10.1002/cne.902720204; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MORGAN JI, 1991, REV NEUROSCI, V14, P421; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; PLAITAKIS A, 1990, ANN NEUROL, V28, P3, DOI 10.1002/ana.410280103; ROSS W, 1984, CANCER RES, V44, P5857; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SHULER CF, 1992, DEV BIOL, V154, P318, DOI 10.1016/0012-1606(92)90071-N; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Williams PL, 1989, GRAYS ANATOMY; WONG ROL, 1987, J COMP NEUROL, V262, P496, DOI 10.1002/cne.902620404; YIP HK, 1984, P NATL ACAD SCI-BIOL, V81, P6245, DOI 10.1073/pnas.81.19.6245	28	775	802	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					166	169		10.1038/363166a0	http://dx.doi.org/10.1038/363166a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8483500				2022-12-28	WOS:A1993LB80100049
J	GULBINS, E; COGGESHALL, KM; BAIER, G; KATZAV, S; BURN, P; ALTMAN, A				GULBINS, E; COGGESHALL, KM; BAIER, G; KATZAV, S; BURN, P; ALTMAN, A			TYROSINE KINASE-STIMULATED GUANINE-NUCLEOTIDE EXCHANGE ACTIVITY OF VAV IN T-CELL ACTIVATION	SCIENCE			English	Article							PROTEIN GAP; SIGNAL TRANSDUCTION; PHOSPHORYLATION; GTPASE; P21RAS; RAS; PROTOONCOGENE; SUPERFAMILY; EXPRESSION; INHIBITION	The hematopoietically expressed product of the vav proto-oncogene, Vav, shares homology with guanine nucleotide releasing factors (GRFs) [also called guanosine diphosphate-dissociation stimulators (GDSs)] that activate Ras-related small guanosine triphosphate (GTP)-binding proteins. Human T cell lysates or Vav immunoprecipitates possessed GRF activity that increased after T cell antigen receptor (TCR)-CD3 triggering; an in vitro-translated Vav fragment that contained the putative GRF domain was also active. Vav-associated GRF stimulation after TCR-CD3 ligation paralleled its tyrosine phosphorylation; both were blocked by a protein tyrosine kinase (PTK) inhibitor. Vav also was a substrate for the p56lck PTK. Thus, Vav is a PTK-regulated GRF that may be important in TCR-CD3-initiated signal transduction through the activation of Ras.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST,MONTREAL H3T 1E2,QUEBEC,CANADA; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,DEPT BIOL,CH-4002 BASEL,SWITZERLAND	Lady Davis Institute; McGill University; Roche Holding	GULBINS, E (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELL BIOL,LA JOLLA,CA 92037, USA.		Gulbins, Erich/L-6989-2014; Baier, Gottfried/E-8755-2012	Gulbins, Erich/0000-0002-3117-1342; Baier, Gottfried/0000-0002-2085-8325	NCI NIH HHS [CA35299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALAI M, 1992, J BIOL CHEM, V267, P18021; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DOWNWARD J, 1992, Current Biology, V2, P329, DOI 10.1016/0960-9822(92)90897-J; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; GALLAND F, 1992, ONCOGENE, V7, P585; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GULBINS E, UNPUB; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUNE CH, 1991, CURR OPIN IMMUNOL, V3, P287, DOI 10.1016/0952-7915(91)90026-W; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAIN KC, 1991, BIOTECHNIQUES, V10, P366; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MACARA IG, 1991, CELL SIGNAL, V3, P179, DOI 10.1016/0898-6568(91)90043-T; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1991, SCAND J IMMUNOL, V34, P259, DOI 10.1111/j.1365-3083.1991.tb01545.x; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	51	295	305	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					822	825		10.1126/science.8484124	http://dx.doi.org/10.1126/science.8484124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8484124				2022-12-28	WOS:A1993LA74400035
J	PETTICREW, M; MCKEE, M; JONES, J				PETTICREW, M; MCKEE, M; JONES, J			CORONARY-ARTERY SURGERY - ARE WOMEN DISCRIMINATED AGAINST	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BYPASS-SURGERY; HEART-DISEASE; MORTALITY; SEX; REVASCULARIZATION; TRANSPLANTATION; MANAGEMENT; ACCURACY; DELAY; BIAS	Objective-To determine whether the sex differences in access to cardiac surgery observed in the United States exist in the United Kingdom. Design-Retrospective analysis of routinely collected data. Setting-South West Thames and North West Thames regional health authorities. Subjects-8564 patients discharged from hospital with a principal diagnosis of coronary heart disease in 1987-8 in South West Thames region and 15 243 discharges in North West Thames region in 1990-1. Main outcome measures-Performance of angiography or coronary artery bypass surgery. Results-In all age groups and among patients with a principal diagnosis of either angina or chronic ischaemia men were significantly more likely than women to undergo revascularisation in both regions. Using multiple logistic regression to control for potential clinical and demographic confounders, the male to female odds ratio for revascularisation among all cases was 1.59 (95% confidence interval 1.25 to 2.03) in South West Thames region and 1.47 (1.32 to 1.63) in North West Thames region. Conclusion-There appears to be a systematic difference in the treatment received by men and women in the United Kingdom. The reasons for this are uncertain.			PETTICREW, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, HLTH SERV RES UNIT, LONDON WC1E 7HT, ENGLAND.		Petticrew, Mark/AAY-6274-2021; McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BROGAN D, 1988, NEW ENGL J MED, V319, P55; BROOK RH, 1988, LANCET, V1, P750; CHIRIKOS TN, 1984, WOMEN HEALTH, V9, P55, DOI 10.1300/J013v09n01_05; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DOUGLAS JS, 1981, CIRCULATION, V64, P11; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; FOSTER DA, 1992, NEW ENGL J MED, V326, P570; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KASSEBAUM DG, 1992, NEW ENGL J MED, V326, P571; KENNEDY JW, 1982, CIRCULATION, V66, P16; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND C M, 1988, Archives of Internal Medicine, V148, P1305, DOI 10.1001/archinte.148.6.1305; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; MACKINTOSH AF, 1986, J ROY COLL PHYS LOND, V20, P220; MARBER M, 1991, BRIT MED J, V302, P1189, DOI 10.1136/bmj.302.6786.1189; MCGEE HM, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283-a; MUKHERJEE AK, 1991, PUBLIC HEALTH, V105, P69, DOI 10.1016/S0033-3506(05)80319-1; OLDRIDGE MB, 1980, AM HEART J, V338, P1366; Payer Lynn, 1989, MED CULTURE; POSES RM, 1992, NEW ENGL J MED, V326, P570; REES JL, 1982, BRIT MED J, V284, P1856, DOI 10.1136/bmj.284.6332.1856; SELLAR C, 1990, J EPIDEMIOL COMMUN H, V44, P313, DOI 10.1136/jech.44.4.313; SHELDON WC, 1975, PROG CARDIOVASC DIS, V18, P237, DOI 10.1016/0033-0620(75)90013-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; 1990, EGRET EPIDEMIOLOGICA; 1988, HLTH UNINSURED; SPSSX DATA ANAL SYST	32	108	109	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	1993	306	6886					1164	1166		10.1136/bmj.306.6886.1164	http://dx.doi.org/10.1136/bmj.306.6886.1164			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499817	Green Published, Bronze			2022-12-28	WOS:A1993LA68500020
J	PHILIPP, R; POND, K; REES, G				PHILIPP, R; POND, K; REES, G			LITTER AND MEDICAL WASTE ON BATHING BEACHES IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									FARNBOROUGH COLL TECHNOL,DEPT SCI & ENVIRONM TECHNOL,FARNBOROUGH,ENGLAND; FARNBOROUGH COLL TECHNOL,NORWICH UNION COASTWATCH,FARNBOROUGH,ENGLAND		PHILIPP, R (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,WHO,COLLABORATING CTR ENVIRONM HLTH PROMOT & ECOL,BRISTOL BS8 2PR,ENGLAND.			Pond, Katherine/0000-0001-7907-5272				GODLEE F, 1991, BRIT MED J, V303, P1124, DOI 10.1136/bmj.303.6810.1124; WALKER A, 1992, BRIT MED J, V304, P242, DOI 10.1136/bmj.304.6821.242; 1991, ASSESSMENT STATE POL, P34; 1987, PUBLIC HLTH IMPLICAT, P25; 1990, 4TH HOUS COMM ENV CO, V1	5	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1042	1042		10.1136/bmj.306.6884.1042	http://dx.doi.org/10.1136/bmj.306.6884.1042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490500	Green Published, Bronze			2022-12-28	WOS:A1993KY44800022
J	BOOY, R; HODGSON, S; GRIFFITHS, H; CHAPEL, HM; MOXON, ER				BOOY, R; HODGSON, S; GRIFFITHS, H; CHAPEL, HM; MOXON, ER			ANTIBODY PERSISTENCE AFTER ACCELERATED IMMUNIZATION AGAINST HAEMOPHILUS-INFLUENZAE TYPE-B	BRITISH MEDICAL JOURNAL			English	Article							CONJUGATE VACCINE		UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT IMMUNOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	BOOY, R (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.		Booy, Robert/D-4188-2011					BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1992, LANCET, V340, P847, DOI 10.1016/0140-6736(92)92719-V; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; MADORE DV, 1990, PEDIATRICS, V85, P331; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P520, DOI 10.1136/adc.64.4.520	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					971	972		10.1136/bmj.306.6883.971	http://dx.doi.org/10.1136/bmj.306.6883.971			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490473	Bronze, Green Published			2022-12-28	WOS:A1993KX43600018
J	APPELMAN, CLM; CLAESSEN, JQPJ; TOUWOTTEN, FWMM; HORDIJK, GJ; DEMELKER, RA				APPELMAN, CLM; CLAESSEN, JQPJ; TOUWOTTEN, FWMM; HORDIJK, GJ; DEMELKER, RA			SEVERITY OF INFLAMMATION OF TYMPANIC MEMBRANE AS PREDICTOR OF CLINICAL COURSE OF RECURRENT ACUTE OTITIS-MEDIA	BRITISH MEDICAL JOURNAL			English	Article									UNIV UTRECHT,DEPT EAR NOSE & THROAT SURG,3511 ZC UTRECHT,NETHERLANDS	Utrecht University	APPELMAN, CLM (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,BIJLHOWERSTR 6,3511 ZC UTRECHT,NETHERLANDS.							APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; GLASSCOCK ME, 1990, SURGERY EAR, P170; SCHLESSELMAN J, 1982, CASE CONTROL STUDIES, P175; Siegel S., 1956, NONPARAMETRIC STAT B	4	11	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					895	895		10.1136/bmj.306.6882.895	http://dx.doi.org/10.1136/bmj.306.6882.895			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490414	Bronze, Green Published			2022-12-28	WOS:A1993KW38700020
J	DUPONT, HL; ERICSSON, CD				DUPONT, HL; ERICSSON, CD			DRUG-THERAPY - PREVENTION AND TREATMENT OF TRAVELERS DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TOXIGENIC ESCHERICHIA-COLI; PEACE-CORPS VOLUNTEERS; BISMUTH SUBSALICYLATE; TRIMETHOPRIM-SULFAMETHOXAZOLE; BACTERIAL ENTEROPATHOGENS; PROPHYLACTIC DOXYCYCLINE; SYMPTOMATIC TREATMENT; DEVELOPING-COUNTRIES; MEXICAN UNIVERSITY; FOOD-CONSUMPTION		UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	DUPONT, HL (corresponding author), UNIV TEXAS, SCH MED, CTR INFECT DIS, 6431 FANNIN, 1-729 JFB, HOUSTON, TX 77030 USA.		DuPont, Herbert/AAH-6776-2021					BANDRES JC, 1992, AM J MED SCI, V303, P289, DOI 10.1097/00000441-199205000-00003; BANDRES JC, 1988, ARCH INTERN MED, V148, P2261, DOI 10.1001/archinte.148.10.2261; BLACK FT, 1983, SCAND J INFECT DIS, V15, P189, DOI 10.3109/inf.1983.15.issue-2.11; BOLIVAR R, 1978, J INFECT DIS, V137, P324, DOI 10.1093/infdis/137.3.324; DEETZ TR, 1984, WATER RES, V18, P567, DOI 10.1016/0043-1354(84)90205-7; DICKENS DL, 1985, JAMA-J AM MED ASSOC, V253, P3141, DOI 10.1001/jama.253.21.3141; DUPONT HL, 1977, AM J EPIDEMIOL, V105, P37, DOI 10.1093/oxfordjournals.aje.a112353; DUPONT HL, 1992, ANTIMICROB AGENTS CH, V36, P87, DOI 10.1128/AAC.36.1.87; DUPONT HL, 1992, JAMA-J AM MED ASSOC, V267, P1932, DOI 10.1001/jama.267.14.1932; DUPONT HL, 1985, ANN INTERN MED, V102, P260, DOI 10.7326/0003-4819-102-2-260; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; DUPONT HL, 1982, NEW ENGL J MED, V307, P841, DOI 10.1056/NEJM198209303071401; DUPONT HL, 1983, GASTROENTEROLOGY, V84, P75; DUPONT HL, 1977, GASTROENTEROLOGY, V73, P715; DUPONT HL, 1976, NEW ENGL J MED, V295, P1520, DOI 10.1056/NEJM197612302952707; DUPONT HL, 1990, AM J MED, V88, pS20, DOI 10.1016/0002-9343(90)90271-E; DUPONT HL, 1993, GASTROENTEROLOGY, V104, P709, DOI 10.1016/0016-5085(93)91005-3; DUPONT HL, 1987, JAMA-J AM MED ASSOC, V257, P1347, DOI 10.1001/jama.257.10.1347; DUPONT HL, 1985, T AM CLIN CLIMAT ASS, V97, P32; ECHEVERRIA P, 1984, AM J EPIDEMIOL, V120, P912, DOI 10.1093/oxfordjournals.aje.a113962; ERICSSON CD, 1980, GASTROENTEROLOGY, V79, P812; ERICSSON CD, 1990, JAMA-J AM MED ASSOC, V263, P257, DOI 10.1001/jama.263.2.257; ERICSSON CD, 1983, ANN INTERN MED, V98, P20, DOI 10.7326/0003-4819-98-1-20; ERICSSON CD, 1985, GASTROENTEROLOGY, V88, P473, DOI 10.1016/0016-5085(85)90509-8; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; ERICSSON CD, 1982, JAMA-J AM MED ASSOC, V247, P2266, DOI 10.1001/jama.247.16.2266; FARTHING MJG, 1992, GASTROENTEROLOGY INT, V5, P162; FRACHTMAN RL, 1982, ARCH INTERN MED, V142, P1299, DOI 10.1001/archinte.142.7.1299; GORBACH SL, 1975, NEW ENGL J MED, V292, P933, DOI 10.1056/NEJM197505012921801; GORBACH SL, 1986, REV INFECT DIS, V8, pS109; GORBACH SL, 1990, GASTROENTEROLOGY, V99, P863, DOI 10.1016/0016-5085(90)90983-8; GOUGH A, 1979, TOXICOL APPL PHARM, V51, P177, DOI 10.1016/0041-008X(79)90020-6; GRAHAM DY, 1983, GASTROENTEROLOGY, V85, P1017; JOHNSON PC, 1986, ANTIMICROB AGENTS CH, V30, P671, DOI 10.1128/AAC.30.5.671; JOHNSON PC, 1986, JAMA-J AM MED ASSOC, V255, P757, DOI 10.1001/jama.255.6.757; JOHNSON PC, 1990, J INFECT DIS, V162, P389, DOI 10.1093/infdis/162.2.389; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; KEAN BH, 1963, ANN INTERN MED, V59, P605, DOI 10.7326/0003-4819-59-5-605; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; MATHEWSON JJ, 1985, J INFECT DIS, V151, P471, DOI 10.1093/infdis/151.3.471; MATTILA L, 1992, J INFECT DIS, V165, P385, DOI 10.1093/infdis/165.2.385; MENDELOWITZ PC, 1990, ANN INTERN MED, V112, P140, DOI 10.7326/0003-4819-112-2-140; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; MURRAY BE, 1985, J INFECT DIS, V152, P1107, DOI 10.1093/infdis/152.6.1107; OKHUYSEN PC, 1989, SCAND J GASTROENTERO, V24, P39, DOI 10.3109/00365528909091331; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; POZOOLANO JDD, 1978, GASTROENTEROLOGY, V74, P829; RADEMAKER CMA, 1989, EUR J CLIN MICROBIOL, V8, P690, DOI 10.1007/BF01963753; REVES RR, 1988, ARCH INTERN MED, V148, P2421, DOI 10.1001/archinte.148.11.2421; RYDER RW, 1981, J INFECT DIS, V144, P442, DOI 10.1093/infdis/144.5.442; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; SACK RB, 1979, GASTROENTEROLOGY, V76, P1368; SACK RB, 1984, AM J TROP MED HYG, V33, P460, DOI 10.4269/ajtmh.1984.33.460; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1986, ANTIMICROB AGENTS CH, V29, P625, DOI 10.1128/AAC.29.4.625; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; STEINHOFF MC, 1980, GASTROENTEROLOGY, V78, P1495; TACKET CO, 1988, NEW ENGL J MED, V318, P1240, DOI 10.1056/NEJM198805123181904; TAYLOR DN, 1991, ANN INTERN MED, V114, P731, DOI 10.7326/0003-4819-114-9-731; TAYLOR DN, 1986, REV INFECT DIS, V8, pS136; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; VANLOON FPL, 1989, GUT, V30, P492, DOI 10.1136/gut.30.4.492; VOLLET JJ, 1979, J MED VIROL, V4, P81, DOI 10.1002/jmv.1890040202; WANGER AR, 1988, J INFECT DIS, V158, P640, DOI 10.1093/infdis/158.3.640; WINGATE DL, 1990, LANCET, V335, P222, DOI 10.1016/0140-6736(90)90309-S; WISTROM J, 1989, J ANTIMICROB CHEMOTH, V23, P905, DOI 10.1093/jac/23.6.905; WISTROM J, 1987, J ANTIMICROB CHEMOTH, V20, P563, DOI 10.1093/jac/20.4.563; WOOD LV, 1983, APPL ENVIRON MICROB, V46, P328, DOI 10.1128/AEM.46.2.328-332.1983; WRIGHT RA, 1977, AM J EPIDEMIOL, V105, P330, DOI 10.1093/oxfordjournals.aje.a112390	72	230	239	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1821	1827						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502272				2022-12-28	WOS:A1993LH21000007
J	KONRAD, RJ; KRICKA, LJ; GOODMAN, DBP; GOLDMAN, J; SILBERSTEIN, LE				KONRAD, RJ; KRICKA, LJ; GOODMAN, DBP; GOLDMAN, J; SILBERSTEIN, LE			MYELOMA-ASSOCIATED PARAPROTEIN DIRECTED AGAINST THE HIV-1 P24 ANTIGEN IN AN HIV-1 SEROPOSITIVE PATIENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY; INFECTION; AIDS; PLASMA		UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,6 FOUNDERS BLDG,3400 SPRUCE ST,PHILADELPHIA,PA 19104	University of Pennsylvania								APPLEMAN ME, 1988, J INFECT DIS, V158, P193, DOI 10.1093/infdis/158.1.193; CARBONE A, 1991, CANCER, V68, P842, DOI 10.1002/1097-0142(19910815)68:4<842::AID-CNCR2820680429>3.0.CO;2-E; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; FRIEDMAN DF, 1991, J EXP MED, V174, P525, DOI 10.1084/jem.174.3.525; GRIMALDI LME, 1988, J IMMUNOL, V141, P114; HERIOT K, 1985, CLIN CHEM, V31, P1224; JACK HM, 1992, P NATL ACAD SCI USA, V89, P8482, DOI 10.1073/pnas.89.18.8482; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LEVINE AM, 1992, BLOOD, V80, P8; MANSA B, 1965, ACTA PATHOL MIC SC, V65, P303, DOI 10.1111/apm.1965.65.2.303; NG VL, 1988, BLOOD, V71, P1397; NG VL, 1989, BLOOD, V74, P2471; PAPADOPOULOS NM, 1988, CLIN CHEM, V34, P973; POTTER M, 1971, NEW ENGL J MED, V284, P831; REDMON B, 1992, NEW ENGL J MED, V326, P994, DOI 10.1056/NEJM199204093261505; SEI Y, 1989, IMMUNOL LETT, V20, P223, DOI 10.1016/0165-2478(89)90084-9; SELIGMANN M, 1973, SEMIN HEMATOL, V10, P163; SELIGMANN M, 1968, NATURE, V220, P711, DOI 10.1038/220711a0; Southern E, 1979, Methods Enzymol, V68, P152; TAICHMAN DB, 1988, CLIN CHEM, V34, P2377; VOELKERDING KV, 1989, AM J CLIN PATHOL, V92, P222, DOI 10.1093/ajcp/92.2.222	21	62	62	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1817	1819		10.1056/NEJM199306243282505	http://dx.doi.org/10.1056/NEJM199306243282505			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502271				2022-12-28	WOS:A1993LH21000005
J	MUSHLIN, AI; DETSKY, AS; PHELPS, CE; OCONNOR, PW; KIDO, DK; KUCHARCZYK, W; GIANG, DW; MOONEY, C; TANSEY, CM; HALL, WJ				MUSHLIN, AI; DETSKY, AS; PHELPS, CE; OCONNOR, PW; KIDO, DK; KUCHARCZYK, W; GIANG, DW; MOONEY, C; TANSEY, CM; HALL, WJ			THE ACCURACY OF MAGNETIC-RESONANCE-IMAGING IN PATIENTS WITH SUSPECTED MULTIPLE-SCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CLINICAL-EVALUATION; EVOKED-POTENTIALS; DIAGNOSIS; CT; SPECIFICITY; MRI; MS	Objective.-To design and implement a methodologically rigorous study to examine the accuracy of magnetic resonance imaging (MRI) in a patient population clinically suspected of having multiple sclerosis (MS). Design and Setting.-Three hundred three patients, who were referred to two university medical centers because of the suspicion of MS, underwent MRI of the head and double-dose, contrast-enhanced computed tomography (CT) of the head. The images were read by two observers individually and without knowledge of the clinical course or final diagnosis. Patients were followed up for at least 6 months and reevaluated clinically with subsequent neurological examination. Final diagnosis (MS or not MS) was made by a panel of neurologists on the basis of the clinical findings at presentation, those that developed during follow-up, and other diagnostic tests. The results of the imaging procedures were excluded to avoid incorporation bias. Diagnostic accuracy was assessed using receiver-operating characteristic analysis and likelihood ratios. Results.-Magnetic resonance imaging of the head was considerably more accurate than CT in diagnosing MS. The area under the receiver-operating characteristic curve for MS was 0.82 (compared with 0.52 for CT) indicating that MRI was a good but not definitively accurate test for MS. A ''definite MS'' reading on an MRI of the head was specific for MS (likelihood ratio, 24.9) and essentially established the diagnosis, especially in patients clinically designated as ''probable MS'' before testing. However, MRI of the head was negative for MS in 25% and equivocal in 40% of the patients considered to have MS by the diagnostic review committee (sensitivity, 58%). Conclusions.-Magnetic resonance imaging of the head provided assistance in the diagnosis of MS when lesions were visualized. Its ability far exceeded imaging with double-contrast CT. The sensitivity and, therefore, the predictive value of a negative MRI result for MS were, however, not sufficiently high for a normal MRI to be used to conclusively exclude the diagnosis of MS.	UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT RADIOL,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT NEUROL,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT BIOSTAT,ROCHESTER,NY 14627; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT NEUROL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT RADIOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Toronto; University of Toronto; University of Toronto	MUSHLIN, AI (corresponding author), UNIV ROCHESTER,DEPT COMMUNITY & PREVENT MED,ROCHESTER,NY 14627, USA.				PHS HHS [1-RO1-5427] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; Fleiss JL, 1981, STAT METHODS RATES P; GIANG DW, IN PRESS ARCH NEUROL; HALL WJ, 1992, EFFICIENCY WEIGHTED; HAUGHTON VM, 1986, RADIOLOGY, V160, P751, DOI 10.1148/radiology.160.3.3737914; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; LEE KH, 1991, NEUROLOGY, V41, P657, DOI 10.1212/WNL.41.5.657; MA G, IN PRESS MED DECIS M; METZ CE, 1984, INFORMATION PROCESSI, P432; Mosteller F., 1977, DATA ANAL REGRESSION, P133; MUSHLIN AI, IN PRESS ARCH NEUROL; OCONNOR P, IN PRESS ARCH NEUROL; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; PATY DW, 1989, NEUROLOGY, V39, P151, DOI 10.1212/WNL.39.1.151; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P109; YETKIN FZ, 1991, RADIOLOGY, V178, P447, DOI 10.1148/radiology.178.2.1987607	16	48	49	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3146	3151		10.1001/jama.269.24.3146	http://dx.doi.org/10.1001/jama.269.24.3146			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505818				2022-12-28	WOS:A1993LH14500030
J	SOWERS, M; CORTON, G; SHAPIRO, B; JANNAUSCH, ML; CRUTCHFIELD, M; SMITH, ML; RANDOLPH, JF; HOLLIS, B				SOWERS, M; CORTON, G; SHAPIRO, B; JANNAUSCH, ML; CRUTCHFIELD, M; SMITH, ML; RANDOLPH, JF; HOLLIS, B			CHANGES IN BONE-DENSITY WITH LACTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM PARATHYROID-HORMONE; MINERAL HOMEOSTASIS; WOMEN; PREGNANCY; CALCIUM; MASS; 1,25-DIHYDROXYVITAMIN-D; CALCITONIN; 25-HYDROXYVITAMIN-D; PERFORMANCE	Objective.-To test the a priori hypotheses that significant bone loss occurs in lactation of greater than 5 months' duration and that bone mass returns to baseline levels when breast-feeding ceases. Design.-Prospective cohort study design of 12 months' duration. Setting.-General community setting with recruitment occurring at birthing education classes. Participants.-Volunteer sample of 98 healthy women of white (n=95) and Asian (n=3) origin, aged 20 to 40 years, and 0 to 1 parity prior to parturition, grouped according to lactation duration: 0 through 1, 2 through 5, and 6 or more months. Main Outcome Measures.-Bone mineral density (BMD) of the proximal femur was measured by dual-energy x-ray densitometry at 2 weeks (baseline), 2 months, 4 months, 6 months, and 12 months following parturition, and BMD of the lumbar spine was measured at baseline, 6 months, and 12 months after parturition. Results.-Women with lactation duration of 6 months or longer had mean BMD losses of 5.1% and 4.8% at the lumbar spine and femoral neck, respectively, comparing baseline values with those at 6 months post partum. Women who breast-fed 0 through 1 month lost no BMD at either bone site. Bone loss in women who breast-fed 6 months or longer was not explained by differences in age, diet, body size, or physical activity. Among women who breast-fed 6 months or longer, there was evidence of return to baseline levels of the lumbar spine at 12 months after parturition. The BMD of the lumbar spine of those women who continued to breast-feed more than 9 months had increased but was still significantly lower than baseline. Conclusion.-Extended lactation (greater-than-or-equal-to 70% of energy intake is provided for greater-than-or-equal-to 6 months) is associated with bone loss; however, there is evidence of return to baseline BMD measurement at 12 months after parturition.	MED COLL S CAROLINA,DEPT NEONATOL,CHARLESTON,SC; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT FAMILY PRACTICE,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT OBSTET & GYNECOL,ANN ARBOR,MI 48109	Medical University of South Carolina; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	SOWERS, M (corresponding author), UNIV MICHIGAN,DEPT EPIDEMIOL,109 OBSERV ST,ANN ARBOR,MI 48109, USA.			Randolph, John/0000-0003-4901-7711	NIAMS NIH HHS [R29-AR39651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039651] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALDERMAN BW, 1986, AM J EPIDEMIOL, V124, P262, DOI 10.1093/oxfordjournals.aje.a114384; ALOIA JF, 1983, ARCH INTERN MED, V143, P1700, DOI 10.1001/archinte.143.9.1700; ATKINSON P J, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P555; BAIRD DT, 1979, J CLIN ENDOCR METAB, V49, P500, DOI 10.1210/jcem-49-4-500; BATSAKIS JG, 1982, DIAGN MED        MAY, P25; BENZIE D., 1956, Journal of Agricultural Science, V48, P175, DOI 10.1017/S0021859600030458; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BROMMAGE R, 1985, AM J PHYSIOL, V248, pE182, DOI 10.1152/ajpendo.1985.248.2.E182; BUTTE NF, 1984, AM J CLIN NUTR, V39, P296, DOI 10.1093/ajcn/39.2.296; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CHAN GM, 1982, AM J OBSTET GYNECOL, V144, P438, DOI 10.1016/0002-9378(82)90250-2; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUNNINGHAM AS, 1983, J PEDIATR-US, V103, P338, DOI 10.1016/S0022-3476(83)80392-8; DADA OA, 1982, CLIN CHIM ACTA, V123, P293; DAVIS OK, 1988, J CLIN ENDOCR METAB, V67, P850, DOI 10.1210/jcem-67-4-850; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; ELLINGER BM, 1952, BR J NUTR, V5, P235; FRISANCHO AR, 1971, INVEST RADIOL, V6, P119, DOI 10.1097/00004424-197103000-00006; GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6; GOLDSMITH NF, 1982, J BONE JOINT SURG AM, V101, P718; GRAY GE, 1980, J AM DIET ASSOC, V77, P534; GREER FR, 1984, AM J CLIN NUTR, V40, P562, DOI 10.1093/ajcn/40.3.562; GREER FR, 1982, AM J CLIN NUTR, V36, P431, DOI 10.1093/ajcn/36.3.431; GRIZZLE JE, 1969, BIOMETRICS, V25, P357, DOI 10.2307/2528795; HAGAMAN JR, 1990, J BONE MINER RES, V5, P123, DOI 10.1002/jbmr.5650050205; HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588; HILLMAN L, 1981, AM J OBSTET GYNECOL, V139, P471, DOI 10.1016/0002-9378(81)90327-6; JOHNSTON CC, 1981, RECENT ADV PATHOGENE, P285; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384; KHOSLA S, 1990, MAYO CLIN PROC, V65, P1408, DOI 10.1016/S0025-6196(12)62164-8; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KRUKOWSKI M, 1987, BONE, V8, P251, DOI 10.1016/8756-3282(87)90173-6; KUMAR R, 1980, NEW ENGL J MED, V302, P1143, DOI 10.1056/NEJM198005153022010; KUSHNER RF, 1986, AM J CLIN NUTR, V44, P417, DOI 10.1093/ajcn/44.3.417; LAMKE B, 1977, ACTA OBSTET GYN SCAN, V56, P217, DOI 10.3109/00016347709162123; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MILLER MA, 1989, BONE, V10, P279, DOI 10.1016/8756-3282(89)90065-3; MILLER SC, 1986, BONE, V7, P283, DOI 10.1016/8756-3282(86)90209-7; MILLER SC, 1982, CALCIFIED TISSUE INT, V34, P245, DOI 10.1007/BF02411245; PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954; Rosner B, 1982, FUNDAMENTALS BIOSTAT; ROWLAND GN, 1972, CALC TISS RES, V9, P179, DOI 10.1007/BF02061956; RYAN AS, 1991, PEDIATRICS, V88, P719; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SCHLECHTE JA, 1983, J CLIN ENDOCR METAB, V56, P1120, DOI 10.1210/jcem-56-6-1120; SHAABAN MM, 1987, J STEROID BIOCHEM, V21, P1043; SOWERS M, 1991, OBSTET GYNECOL, V77, P841; SOWERS MF, 1985, PREV MED, V14, P585, DOI 10.1016/0091-7435(85)90079-9; SPENCER GR, 1979, AM J PATHOL, V95, P277; Termine J.D., 1990, PRIMER METABOLIC BON, P16; WARDLAW GM, 1986, AM J CLIN NUTR, V44, P283, DOI 10.1093/ajcn/44.2.283; ZARATE A, 1987, J STEROID BIOCHEM, V27, P1023, DOI 10.1016/0022-4731(87)90185-3	54	286	288	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3130	3135		10.1001/jama.269.24.3130	http://dx.doi.org/10.1001/jama.269.24.3130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505816				2022-12-28	WOS:A1993LH14500027
J	HAYNES, BF				HAYNES, BF			SCIENTIFIC AND SOCIAL-ISSUES OF HUMAN-IMMUNODEFICIENCY-VIRUS VACCINE DEVELOPMENT	SCIENCE			English	Article							NEUTRALIZING ANTIBODIES; SYNTHETIC PEPTIDES; ANTI-HIV; ENVELOPE GLYCOPROTEINS; INFECTED INDIVIDUALS; AIDS VACCINES; ACID SEQUENCE; HIGH TITERS; T-CELL; GP120	Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.	DUKE CTR AIDS RES, DURHAM, NC 27710 USA	Duke University	HAYNES, BF (corresponding author), DUKE UNIV, MED CTR, DURHAM, NC 27710 USA.				NCI NIH HHS [P0-1 CA 43447] Funding Source: Medline; NIAID NIH HHS [AI28662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA043447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADA G, 1992, NATURE, V359, P572, DOI 10.1038/359572a0; ADA G, 1989, NATURE, V339, P331, DOI 10.1038/339331a0; ADA G, 1992, AIDS RES HUM RETROV, V8, P1317, DOI 10.1089/aid.1992.8.1317; ADA G, 1992, AIDS RES HUM RETROV, V8, P758; ADA GL, 1992, VACCINE RES, V1, P17; AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; AIRHIHENBUWA CO, 1992, AIDS EDUC PREV, V4, P267; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERZOFSKY JA, 1991, J ACQ IMMUN DEF SYND, V4, P451; BERZOFSKY JA, 1991, FASEB J, V5, P2412, DOI 10.1096/fasebj.5.10.1712327; BOLOGNESI DP, 1989, AIDS, V3, pS111, DOI 10.1097/00002030-198901001-00016; BOLOGNESI DP, 1989, JAMA-J AM MED ASSOC, V261, P3007, DOI 10.1001/jama.261.20.3007; BURKE DS, 1992, PERSPECT BIOL MED, V35, P511; BURKE DS, 1992, AIDS RES HUM RETROV, V8, P1531, DOI 10.1089/aid.1992.8.1531; BURKE DS, 1992, INT ETHICAL GUIDELIN; CHEN I, 1991, JUL WORKSH UND HIV P; CHESNEY M, 1992, DEC I MED ROUNDT DEV; CHESNEY M, COMMUNICATION; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; CHRISTAKIS NA, 1988, HASTINGS CENT REP, V18, P31, DOI 10.2307/3562201; CIANCIOLO G, 1990, J IMMUNOL, V124, P2950; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEMENTS ML, 1992, DEC I MED ROUNDT DEV; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COHEN J, 1992, SCIENCE, V258, P1729; COHEN J, 1993, SCIENCE, V259, P1690, DOI 10.1126/science.8456293; COHEN J, 1992, SCIENCE, V258, P211, DOI 10.1126/science.1411518; COHEN J, 1992, SCIENCE, V258, P1568, DOI 10.1126/science.1455241; CORDIALI P, 1992, AIDS RES HUM RETROV, V8, P1561, DOI 10.1089/aid.1992.8.1561; COWELL S, 1988, J ASS COMMUNITY HLTH, V33, P253; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; DAAR ES, 1993, SCIENCE, V259, P1749; DALTON HL, 1989, DAEDALUS-US, V118, P205; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DANIEL MD, 1989, AIDS, V3, pS131, DOI 10.1097/00002030-198901001-00019; DIXON DO, IN PRESS J ACQUIRED; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; DREESMAN G, 1988, J INFECT DIS, V151, P761; Edelman R, 1990, Int Rev Immunol, V7, P51, DOI 10.3109/08830189009061764; EMINI EA, 1992, VACCINES NEW APPROAC, P309; Enel Patricia, 1992, AIDS Public Policy J, V7, P50; FAHEY JL, 1992, CLIN EXP IMMUNOL, V88, P1; FAST PE, IN PRESS AIDS; FAUCI AS, 1989, ANN INTERN MED, V110, P373, DOI 10.7326/0003-4819-110-5-373; FAUCI AS, 1989, ACAD MED, V64, P115, DOI 10.1097/00001888-198903000-00002; Fortin Alfred J, 1991, AIDS Public Policy J, V6, P15; FRANCIS DP, 1989, EPIDEMIOLOGY AIDS EX, P309; FRANCIS DP, 1990, MOL BIOL MED, V7, P1; FRANCIS DP, 1990, J ACQ IMMUN DEF SYND, V3, P390; FULTZ P, 1991, VACCINE, V9, P783, DOI 10.1016/0264-410X(91)90212-O; Gardner M B, 1990, Int Rev Immunol, V7, P31, DOI 10.3109/08830189009061763; GARDNER MB, 1989, J MED PRIMATOL, V18, P321; GARRISON L, 1989, Comprehensive Therapy, V15, P47; GIRARD M, 1991, VACCINE, V9, P781, DOI 10.1016/0264-410X(91)90211-N; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; Graham B S, 1990, Infect Dis Clin North Am, V4, P223; GRASSI F, 1991, J EXP MED, V174, P53, DOI 10.1084/jem.174.1.53; HAIGWOOD NL, 1992, J VIROL, V66, P172, DOI 10.1128/JVI.66.1.172-182.1992; HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201; HARRINGTON M, 1992, AIDS RES HUM RETROV, V8, P1431, DOI 10.1089/aid.1992.8.1431; HART MK, 1990, J IMMUNOL, V145, P2677; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HAYNES BF, 1993, J EXP MED, V177, P717, DOI 10.1084/jem.177.3.717; HAYNES BF, 1993, CLIN RES, V41, pA261; HAYNES BF, 1992, AIDS ETIOLOGY DIAGNO, P77; HAYNES BF, IN PRESS LYMPHOPOIES; Hilleman M R, 1989, Immunol Ser, V44, P605; HILLEMAN MR, 1992, PROG MED VIROL, V39, P1; HILLEMAN MR, 1992, AIDS RES HUM RETROV, V8, P1743, DOI 10.1089/aid.1992.8.1743; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HOGH D, 1992, DEC I MED ROUNDT DEV; JAVAHERIAN K, 1992, P NATL ACAD SCI USA, V89, P1418, DOI 10.1073/pnas.89.4.1418; KARPATKIN S, 1992, J CLIN INVEST, V89, P356, DOI 10.1172/JCI115593; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; KION TA, 1991, SCIENCE, V253, P1138, DOI 10.1126/science.1909456; KOENIG S, 1992, 8 INT C AIDS AMST; KOFF WC, 1992, AIDS RES HUM RETROV, V8, P1313, DOI 10.1089/aid.1992.8.1313; KOFF WC, 1989, AIDS, V3, pS125, DOI 10.1097/00002030-198901001-00018; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; KORBER B, 1992, AUG NAT COOP VACC DE; KOUP R, 1991, OCT INT C ADV AIDS V; KURTH R, 1991, AIDS RES HUM RETROV, V7, P425, DOI 10.1089/aid.1991.7.425; LASARTE JJ, 1992, CELL IMMUNOL, V141, P211, DOI 10.1016/0008-8749(92)90140-K; LAWRENCE D, 1991, AUG JOINT STAT M ATL; LEITMAN P, 1990, J ACQUIRED IMMUNE S2, V3, pS27; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LIU MA, IN PRESS VACCINES 93; MACQUEEN KM, 1991, AM J PUBLIC HEALTH, V81, P1557; MARINER WK, 1989, AM J PUBLIC HEALTH, V79, P86, DOI 10.2105/AJPH.79.1.86; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCGUIRE TC, 1986, AM J VET RES, V47, P537; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MYERS G, 1991, HUMAN RETROVIRUSES A; NATHANSON N, 1981, J COMP PATHOL, V91, P185, DOI 10.1016/0021-9975(81)90023-2; NEURATH AR, 1990, AIDS RES HUM RETROV, V6, P1183, DOI 10.1089/aid.1990.6.1183; NORLEY S, 1992, IMMUNOBIOLOGY, V184, P193, DOI 10.1016/S0171-2985(11)80475-4; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NZILA N, 1992, AIDS RES HUM RETROV, V8, P1423, DOI 10.1089/aid.1992.8.1423; OSBORN J, 1992, CHALLENGE HIV AIDS C; OSBORN JE, 1990, CLEV CLIN J MED, V57, P709, DOI 10.3949/ccjm.57.8.709; OSBORN JE, 1988, NEW ENGL J MED, V318, P444, DOI 10.1056/NEJM198802183180710; OSBORN JE, 1992, 8 INT C AIDS AMST; OSTROW DG, 1989, DAEDALUS-US, V118, P229; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PETRICCIANI JC, 1992, AIDS RES HUM RETROV, V8, P1527, DOI 10.1089/aid.1992.8.1527; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; REDFIELD RR, 1992, AIDS RES HUM RETROV, V8, P1051, DOI 10.1089/aid.1992.8.1051; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; RIMSKYCLARKE LT, 1992, AUG ANN M LAB TUM CE; ROBERTSON R, 1990, THEOR CULT SOC, V7, P15; ROBINSON HL, IN PRESS VACCINES 93; ROBINSON WE, 1990, J VIROL, V64, P5301, DOI 10.1128/JVI.64.11.5301-5305.1990; ROGERS DE, 1991, NEW ENGL J MED, V325, P806, DOI 10.1056/NEJM199109123251111; ROPER WL, 1991, PUBLIC HEALTH REP, V106, P111; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; RUEGG CL, 1991, CELL IMMUNOL, V137, P1, DOI 10.1016/0008-8749(91)90051-C; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SABIN AB, 1992, P NATL ACAD SCI USA, V89, P8852, DOI 10.1073/pnas.89.18.8852; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SASTRY KJ, 1992, VIROLOGY, V188, P502, DOI 10.1016/0042-6822(92)90504-I; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; Schultz A M, 1990, Semin Immunol, V2, P351; SCHULTZ AM, IN PRESS AIDS; SHERIDAN K, 1989, HEALTH PSYCHOL, V8, P761, DOI 10.1037/0278-6133.8.6.761; SHIBATA R, 1991, J VIROL, V65, P3514, DOI 10.1128/JVI.65.7.3514-3520.1991; Sonigo P, 1989, Immunodefic Rev, V1, P349; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; STEIN RE, 1992, VACCINE RES DEV, V1, P223; TACKET CO, 1990, J INFECT DIS, V161, P356, DOI 10.1093/infdis/161.2.356; TORRES G, 1992, DEC I MED ROUNDT DEV; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VERMUND SH, 1992, 8 INT C AIDS AMST; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WARE RE, 1989, J IMMUNOL, V143, P3632; WEBER D, COMMUNICATION; WEINHOLD K, IN PRESS AIDS RES HU; WEISS R, 1990, J CONSULT CLIN PSYCH, V58, P70, DOI 10.1037/h0092559; WIGZELL H, 1991, FASEB J, V5, P2406, DOI 10.1096/fasebj.5.10.2065889; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YASUTOMI Y, UNPUB; YOUNG JAT, 1988, NATURE, V333, P215, DOI 10.1038/333215c0; ZAGURY D, 1991, LANCET, V338, P694, DOI 10.1016/0140-6736(91)91269-Z; 1993, NIHNIAIDDAIDS9321; 1992, DEC I MED ROUNDT DEV; 1993, RESSF1921 WHO GLOB P, P1; 1992, 1991 AD HOC HIV ADV; 1992, NIAID COUNCIL NEWS, V1, P3	158	108	206	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1279	1286		10.1126/science.8493572	http://dx.doi.org/10.1126/science.8493572			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493572				2022-12-28	WOS:A1993LE02500034
J	DOHENY, KF; SORGER, PK; HYMAN, AA; TUGENDREICH, S; SPENCER, F; HIETER, P				DOHENY, KF; SORGER, PK; HYMAN, AA; TUGENDREICH, S; SPENCER, F; HIETER, P			IDENTIFICATION OF ESSENTIAL COMPONENTS OF THE SACCHAROMYCES-CEREVISIAE KINETOCHORE	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; YEAST SACCHAROMYCES-CEREVISIAE; CENTROMERE DNA; MUTANTS; PROTEIN; SEGREGATION; MOVEMENT; SEQUENCE; COMPLEX; MINICHROMOSOMES	We have designed and utilized two in vivo assays of kinetochore integrity in S. cerevisiae. One assay detects relaxation of a transcription block formed at centromeres; the other detects an increase in the mitotic stability of a dicentric test chromosome. ctf13-30 and ctf14-42 were identified as putative kinetochore mutants by both assays. CTF14 is identical to NDC10/CBF2, a recently identified essential gene that encodes a 110 kd kinetochore component. CTF13 is an essential gene that encodes a predicted 478 amino acid protein with no homology to known proteins. ctf13 mutants missegregate chromosomes at permissive temperature and transiently arrest at nonpermissive temperature as large-budded cells with a G2 DNA content and a short spindle. Antibodies recognizing epitope-tagged CTF13 protein decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro. Together, the genetic and biochemical data indicate that CTF13 is an essential kinetochore protein.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	DOHENY, KF (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838	NATIONAL CANCER INSTITUTE [P01CA016519, T32CA009139] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09139, CA16519] Funding Source: Medline; NIGMS NIH HHS [P32GM07814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BLOOM KS, 1984, J CELL BIOL, V99, P1559, DOI 10.1083/jcb.99.5.1559; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARBON J, 1990, New Biologist, V2, P10; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CELLINI A, 1986, MOL CELL BIOL, V6, P1571, DOI 10.1128/MCB.6.5.1571; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COTTAREL G, 1989, MOL CELL BIOL, V9, P3342, DOI 10.1128/MCB.9.8.3342; DENSMORE L, 1991, MOL CELL BIOL, V11, P154, DOI 10.1128/MCB.11.1.154; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; GERRING S, 1990, METHOD ENZYMOL, V194, P57; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GOH PY, 1993, IN PRESS J CELL BIOL; HABER JE, 1984, GENETICS, V106, P207; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; JIANG W, 1993, IN PRESS J CELL BIOL; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAINE GT, 1984, GENETICS, V106, P365; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MCCLEOD M, 1986, MOL CELL BIOL, V6, P3357; MEEKSWAGNER D, 1986, CELL, V44, P53, DOI 10.1016/0092-8674(86)90484-8; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; PALMER RE, 1989, J CELL BIOL, V109, P3355, DOI 10.1083/jcb.109.6.3355; PERIER F, 1992, GENETICS, V132, P39; PETERSON JB, 1976, J CELL SCI, V22, P219; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SHERO JH, 1991, METHOD ENZYMOL, V194, P749; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; SPENCER F, 1990, GENETICS, V124, P237; SPENCER F, 1988, CANCER CELL, V6, P441; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841; [No title captured]	69	190	193	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					761	774		10.1016/0092-8674(93)90255-O	http://dx.doi.org/10.1016/0092-8674(93)90255-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500169	Green Published, hybrid			2022-12-28	WOS:A1993LD83000014
J	HEIDEMANN, SR				HEIDEMANN, SR			A NEW TWIST ON INTEGRINS AND THE CYTOSKELETON	SCIENCE			English	Editorial Material							EXTRACELLULAR-MATRIX; ELONGATION; INVITRO; TENSION; GROWTH		MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824	Michigan State University	HEIDEMANN, SR (corresponding author), MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824, USA.							BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUXBAUM RE, 1992, J THEOR BIOL, V144, P409; CRICK FHC, 1950, EXP CELL RES, V2, P37; DANOWSKI BA, 1989, J CELL SCI, V93, P255; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INGBER DE, 1993, J CELL SCI, V104, P613; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KORNBERG L, 1992, TRENDS PHARMACOL SCI, V13, P93, DOI 10.1016/0165-6147(92)90034-4; MADREPERLA SA, 1989, DEV BIOL, V131, P149, DOI 10.1016/S0012-1606(89)80046-6; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; PIENTA KJ, 1992, J CELL BIOCHEM, V49, P357, DOI 10.1002/jcb.240490406; PIENTA KJ, 1991, MED HYPOTHESES, V34, P88, DOI 10.1016/0306-9877(91)90072-7; SACHS F, 1988, CRC CRIT R BIOMED EN, V16, P41; TOMASEK JJ, 1984, J CELL BIOL, V99, P536, DOI 10.1083/jcb.99.2.536; VANDENBURGH HH, 1991, FASEB J, V5, P2860, DOI 10.1096/fasebj.5.13.1916108; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; ZHENG J, 1991, J NEUROSCI, V11, P1117	26	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1080	1081						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493551				2022-12-28	WOS:A1993LC94200017
J	LIAN, JP; FERRONOVICK, S				LIAN, JP; FERRONOVICK, S			BOS1P, AN INTEGRAL MEMBRANE-PROTEIN OF THE ENDOPLASMIC-RETICULUM TO GOLGI TRANSPORT VESICLES, IS REQUIRED FOR THEIR FUSION COMPETENCE	CELL			English	Article							YEAST SECRETORY PATHWAY; BINDING YPT1 PROTEIN; ESCHERICHIA-COLI; COMPLEX; ER; RECONSTITUTION; IDENTIFICATION; MUTANTS	BOS1 encodes an integral endoplasmic reticulum (ER) membrane protein and genetically interacts with three other yeast genes (BET1, SEC22, and YPT1) whose products are required for membrane traffic between the ER and the Golgi apparatus. Using an assay that reconstitutes transport at this stage of the pathway, we find that anti-Bos1p antibody blocks protein export after vesicles bud from the ER but prior to fusion with the Golgi. Additionally, the depletion of Bos1p from the ER leads to the formation of transport-incompetent vesicles. Carrier vesicles, immunoisolated with anti-Bos1p antibody, are approximately 50 nm in size. These vesicles contain Bos1p, Sec22p, and Ypt1p, but not Bet1p. The functional interactions of Bos1p with Ypt1p and Sec22p may be necessary for the fusion competence of the ER to Golgi transport vesicles.			LIAN, JP (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.				NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46128] Funding Source: Medline; NIGMS NIH HHS [1 RO1 GM45431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GROESCH ME, 1992, METHOD ENZYMOL, V219, P137; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, BIOESSAYS, V12, P485, DOI 10.1002/bies.950121006; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	33	137	139	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					735	745		10.1016/0092-8674(93)90253-M	http://dx.doi.org/10.1016/0092-8674(93)90253-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500167	hybrid			2022-12-28	WOS:A1993LD83000012
J	YAMADA, T; PFAFF, SL; EDLUND, T; JESSELL, TM				YAMADA, T; PFAFF, SL; EDLUND, T; JESSELL, TM			CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - MOTOR-NEURON INDUCTION BY DIFFUSIBLE FACTORS FROM NOTOCHORD AND FLOOR PLATE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; CHICK-EMBRYO; SPINAL-CORD; MONOCLONAL-ANTIBODIES; CREST CELLS; EXPRESSION; MOUSE; DIFFERENTIATION; MOTONEURONS; GUIDANCE	The identity of cell types generated along the dorsoventral axis of the neural tube depends on inductive signals that derive from both mesodermal and neural cells. To define the nature of these signals, we have analyzed the differentiation of cells in neural plate explants. Motor neurons and neural crest cells differentiate in vitro from appropriate regions of the neural plate, indicating that the specification of cell fate along the dorsoventral axis of the neural tube begins at the neural plate stage. Motor neuron differentiation can be induced by a diffusible factor that derives initially from the notochord and later from floor plate cells. By contrast, floor plate induction requires contact with the notochord. Thus, the identity and patterning of neural cell types appear to involve distinct contact-mediated and diffusible signals from the notochord and floor plate.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University	YAMADA, T (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.							ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BERND P, 1985, DEV BIOL, V112, P145, DOI 10.1016/0012-1606(85)90128-9; BERNHARDT RR, 1992, J COMP NEUROL, V326, P263, DOI 10.1002/cne.903260208; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DELANNET M, 1992, DEVELOPMENT, V116, P275; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSELL TM, 1992, HARVEY LECT, V86, P87; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1990, J NEUROSCI, V10, P2451; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MAXWELL GD, 1988, NEURON, V1, P557, DOI 10.1016/0896-6273(88)90105-5; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; SECHRIST J, 1991, NEURON, V7, P947, DOI 10.1016/0896-6273(91)90340-6; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STOCKER KM, 1991, DEVELOPMENT, V111, P635; TANAKA H, 1989, DEV BIOL, V132, P419, DOI 10.1016/0012-1606(89)90238-8; TANAKA H, 1990, DEVELOPMENT, V110, P565; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TOUSSAINT JL, 1992, GENOMICS, V12, P412, DOI 10.1016/0888-7543(92)90395-9; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	49	442	452	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					673	686		10.1016/0092-8674(93)90248-O	http://dx.doi.org/10.1016/0092-8674(93)90248-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500163	hybrid			2022-12-28	WOS:A1993LD83000007
J	MARTIN, RD				MARTIN, RD			PRIMATE ORIGINS - PLUGGING THE GAPS	NATURE			English	Review							CRANIAL MORPHOLOGY; ADAPIS-PARISIENSIS; LATE EOCENE; ANTHROPOID ORIGINS; SEXUAL DIMORPHISM; FOSSIL RECORD; PHYLOGENY; EVOLUTION; DISCOVERY; ADAPTATIONS	Recent discoveries of fossil primate specimens have produced several surprises and challenged prevailing views of early primate evolution. Plesiadapiforms, long regarded as 'archaic primates', may perhaps be linked to the peculiar colugos instead. Inferred relationships of the earliest known undoubted primates (adapids and omomyids) are in turmoil. Both groups have been proposed as sources for the simian primates. Although the origin of the simian primates is obscure, new fossil evidence could push it further back by at least 10 million years. Such uncertainties reflect the low sampling level of the primate fossil record, which can potentially also lead to underestimation of times of origin within the primate tree.	UNIV ZURICH IRCHEL MUSEUM,CH-8057 ZURICH,SWITZERLAND		MARTIN, RD (corresponding author), UNIV ZURICH IRCHEL,INST ANTHROPOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.							ADKINS RM, 1991, P NATL ACAD SCI USA, V88, P10317, DOI 10.1073/pnas.88.22.10317; Aiello L.C., 1986, P47; BAILEY WJ, 1992, SCIENCE, V256, P86, DOI 10.1126/science.1301735; BAKER RJ, 1991, SYST ZOOL, V40, P216, DOI 10.2307/2992259; Beard K. C., 1989, J VERTEBR PALEONTOL, V9, p13A; BEARD KC, 1990, NATURE, V345, P340, DOI 10.1038/345340a0; BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BEARD KC, 1991, BIPEDIE CHEZ HOMINID, P79; BEARD KC, IN PRESS MAMMAL PHYL, V2, P129; BEARD KC, 1989, POSTCRANIAL ANATOMY; BEECHER RM, 1983, INT J PRIMATOL, V4, P99, DOI 10.1007/BF02739362; BEECHER RM, 1979, AM J PHYS ANTHROPOL, V50, P418; Butler P.M., 1972, P253; Cartmill M., 1980, P243; CIOCHON RL, 1985, SCIENCE, V229, P756, DOI 10.1126/science.229.4715.756; Cronin J.E., 1980, P293; DAGOSTO M, 1983, FOLIA PRIMATOL, V41, P49, DOI 10.1159/000156119; DAGOSTO M, 1992, INT J PRIMATOL, V13, P307, DOI 10.1007/BF02547818; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; DUCROCQ S, 1982, PALAEONTOLOGY, V35, P373; FLEAGLE JG, 1986, SCIENCE, V234, P1247, DOI 10.1126/science.234.4781.1247; FLEAGLE JG, 1978, PALEOBIOLOGY, V4, P67, DOI 10.1017/S0094837300005698; Franzen J.L., 1987, Courier Forschungsinstitut Senckenberg, V91, P151; Franzen J.L., 1986, Modern Geology, V10, P159; FRANZEN JL, 1988, COUR FORSCH I SENCKE, V107, P263; FRANZEN JL, 1991, INT C MONUMENT GRUBE; Gazin C. L., 1958, Smithsonian Miscellaneous Collections, V136, P1; GEBO DL, 1991, AM J PHYS ANTHROPOL, V86, P51, DOI 10.1002/ajpa.1330860105; Gidley J. W., 1923, Proceedings of the United States National Museum, V63, P1; Gingerich P.D., 1980, P123; Gingerich P. D., 1977, Geobios Lyon Memoire Special, VNo. 1, P165; GINGERICH PD, 1981, AM J PHYS ANTHROPOL, V56, P235, DOI 10.1002/ajpa.1330560304; GINGERICH PD, 1984, YEARB PHYS ANTHROPOL, V27, P57; GINGERICH PD, 1977, J HUM EVOL, V6, P483, DOI 10.1016/S0047-2484(77)80059-6; GINGERICH PD, 1977, FOLIA PRIMATOL, V28, P60, DOI 10.1159/000155799; GINGERICH PD, 1981, AM J PHYS ANTHROPOL, V56, P217, DOI 10.1002/ajpa.1330560303; Gingerich PD., 1976, U MICHIGAN PAPERS PA, V15, P1; GINSBURG L, 1986, CR ACAD SCI II-MEC P, V304, P1213; GODINOT M, 1992, CR ACAD SCI II, V314, P237; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot M., 1992, Human Evolution, V6, P307, DOI 10.1007/BF02437255; GOODMAN M, 1985, Cladistics, V1, P171, DOI 10.1111/j.1096-0031.1985.tb00420.x; Gregory W. K., 1920, Memoirs from the American Museum of Natural History New York NS, V3, P49; Gregory W. K., 1910, B AM MUS NAT HIST, V27, P1, DOI DOI 10.1007/S13364-013-0165-6; Gunnell GF., 1989, U MICH PAP PALEONT, V27, P1; HERSHKOVITZ P, 1974, FOLIA PRIMATOL, V21, P1, DOI 10.1159/000155594; HOFFSTET.R, 1974, J HUM EVOL, V3, P327, DOI 10.1016/0047-2484(74)90028-1; Hoffstetter R., 1980, P103; HOFFSTETTER RC, 1986, R ACAD SCI PARIS 2, V302, P43; HUNT RM, 1980, J MORPHOL, V164, P167, DOI 10.1002/jmor.1051640206; JONES FW, 1923, ANCESTRY MAN, P1; Jouffroy F.-K., 1984, P167; KAPPELMAN J, 1992, J HUM EVOL, V6, P495; KAY RF, 1992, AM J PHYS ANTHROPOL, V89, P477, DOI 10.1002/ajpa.1330890409; KAY RF, 1990, NATURE, V345, P342, DOI 10.1038/345342a0; Koenigswald W. v, 1979, PALAEONTOL Z, V53, P63, DOI DOI 10.1007/BF02987788; KRAUSE DW, 1991, J HUM EVOL, V21, P177, DOI 10.1016/0047-2484(91)90060-9; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; KRISHTALKA L, 1990, P NATL ACAD SCI USA, V87, P5223, DOI 10.1073/pnas.87.13.5223; Laneque L., 1992, Human Evolution, V7, P1, DOI 10.1007/BF02437449; LANEQUE L, 1992, CR ACAD SCI II, V314, P1387; Lekagul B., 1977, MAMMALS THAILAND, P1; MacPhee R.D.E., 1986, P219; MacPhee R.D.E., 1989, Journal of Vertebrate Paleontology, V9, P329; MACPHEE RDE, 1983, NATURE, V301, P509, DOI 10.1038/301509a0; Martin R.D., 1986, P1; Martin R.D., 1979, P45; Martin R.D., 1990, PRIMATE ORIGINS EVOL; MARTIN RD, 1991, NATURE, V349, P19, DOI 10.1038/349019a0; MARTIN RD, 1972, PHILOS T ROY SOC B, V264, P295, DOI 10.1098/rstb.1972.0013; MARTIN RD, 1990, NATURE, V345, P291, DOI 10.1038/345291a0; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; McKenna M. C., 1975, PHYLOGENY PRIMATES, P21, DOI DOI 10.1007/978-1-4684-2166-8_2; NOVACEK M J, 1986, Cladistics, V2, P257, DOI 10.1111/j.1096-0031.1986.tb00463.x; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, P99; PETTIGREW JD, 1989, PHILOS T ROY SOC B, V325, P489, DOI 10.1098/rstb.1989.0102; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; PETTIGREW JD, 1991, AM J PHYS ANTHR S, V18, P3; PIRLOT P, 1982, CAN J ZOOL, V60, P565, DOI 10.1139/z82-084; RASMUSSEN DT, 1986, J HUM EVOL, V15, P1, DOI 10.1016/S0047-2484(86)80060-4; RASMUSSEN DT, 1990, AM J PRIMATOL, V22, P263, DOI 10.1002/ajp.1350220406; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P439, DOI 10.1007/BF02196131; RASMUSSEN DT, 1992, INT J PRIMATOL, V13, P477, DOI 10.1007/BF02547829; RASMUSSEN DT, 1989, FOLIA PRIMATOL, V51, P182; ROSE K D, 1977, Contributions from the Museum of Paleontology University of Michigan, V24, P221; Rosenberger A.L., 1980, P139; ROSENBERGER AL, 1985, FOLIA PRIMATOL, V45, P179, DOI 10.1159/000156227; ROSENBERGER AL, 1985, FOLIA PRIMATOL, V44, P15, DOI 10.1159/000156195; ROSENBERGER AL, 1992, TOPICS PRIMATOLOGY, V3, P37; RUSSELL DE, 1982, PALAEOVERTEBRATA MEM, P1; SCHMID P, 1979, FOLIA PRIMATOL, V31, P301, DOI 10.1159/000155893; SCHMID P, 1983, FOLIA PRIMATOL, V40, P1, DOI 10.1159/000156088; Schmid P., 1982, SYSTEMATISCHE REVISI; SCHMID P, 1981, PRIMATE EVOLUTIONARY, P6; SHOSHANI J, 1986, MOL BIOL EVOL, V3, P222; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; Simons E.L., 1972, PRIMATE EVOLUTION; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1989, AM J PHYS ANTHROPOL, V79, P1, DOI 10.1002/ajpa.1330790103; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; SOLA SM, IN PRESS FOLIA PRIMA; Stehlin H. G, 1912, ABH SCHWEIZ PALAONT, V38, P1165; Suteethorn V., 1988, N JB GEOL PALAONT MH, V9, P563; Szalay F.S., 1980, P133; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Thalmann U., 1989, Palaeovertebrata (Montpellier), V19, P115; THIELE A, 1991, J COMP NEUROL, V314, P671, DOI 10.1002/cne.903140404; THOMAS H, 1988, CR ACAD SCI II, V306, P823; VANCOUVERING JA, 1991, J HUM EVOL, V21, P241, DOI 10.1016/0047-2484(91)90106-6; VONKOENIGSWALD W, 1985, CAROLINEA, V42, P145; Wortman JL, 1904, AM J SCI, V17, P203; WYSS AR, 1987, MOL BIOL EVOL, V4, P99; [No title captured]	117	215	218	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					223	234		10.1038/363223a0	http://dx.doi.org/10.1038/363223a0			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LC866	8487862				2022-12-28	WOS:A1993LC86600041
J	BULGER, RJ				BULGER, RJ			USING ACADEMIC HEALTH CENTERS TO HELP AVOID HEALTH CARES NEXT CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BULGER, RJ (corresponding author), ASSOC ACAD HLTH CTR,OFF PRESIDENT,1400 16TH ST NW,SUITE 410,WASHINGTON,DC 20036, USA.							1992, AVOIDING NEXT CRISIS	1	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2548	2549		10.1001/jama.269.19.2548	http://dx.doi.org/10.1001/jama.269.19.2548			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487421				2022-12-28	WOS:A1993LB45000037
J	CRANDALL, SJS; VOLK, RJ; LOEMKER, V				CRANDALL, SJS; VOLK, RJ; LOEMKER, V			MEDICAL-STUDENTS ATTITUDES TOWARD PROVIDING CARE FOR THE UNDERSERVED - ARE WE TRAINING SOCIALLY RESPONSIBLE PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECIALTY CHOICE; PAYMENT REFORM; HEALTH; PROFESSION; AMERICANS; CONFLICT; SOCIETY; SYSTEM; OREGON; GENDER	Objective.-To investigate the association between attitudes toward caring for the medically indigent and years of medical training. Design.-Questionnaire comparing attitudes of first-year medical students (MS-Is) and fourth-year medical students (MS-IVs). Setting.-Southwest medical school. Participants.-A total of 83 (67%) male and 41 (33%) female MS-I and 65 (73%) male and 24 (27%) female MS-IV volunteers. Main Outcome Measure.-Self-report, attitudinal scale developed for this study that provided a measure of overall attitudes, perceived societal expectations, physician/student responsibility, personal efficacy, and provision of basic services and expensive procedures. Results.-Overall attitudes were significantly less favorable for MS-IVs (95% confidence interval [CI], 99.6 to 106.2) than MS-Is (95% CI, 109.5 to 114.3, P<.0001). Except for basic services (P=.46), MS-IVs had worse attitudes on all attitudes subscales. Male MS-IVs reported significantly less favorable attitudes than male MS-Is in the areas of general attitudes (P=.03) and physician/student responsibility (P=.01). Female medical students showed no significant differences across classes (P>.05). Except for physician/student responsibility, female medical students' attitudes were more favorable than those of males, regardless of class. Conclusions.-The MS-IVs are less favorably inclined toward caring for the medically indigent than MS-Is, though these differences are apparent only for males. Further research is needed to explore why females appear to be more resistant to attitude changes, and what educational interventions are necessary to better train physicians to respond to national health care issues.	UNIV TEXAS,MED BRANCH,DEPT FAMILY MED,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	CRANDALL, SJS (corresponding author), UNIV OKLAHOMA HLTH SCI CTR,DEPT FAM,OKLAHOMA CITY,OK 73104, USA.		Crandall, Sonia/A-1613-2019	Volk, Robert/0000-0001-8811-5854				BERGQUIST SR, 1985, J MED EDUC, V60, P379; BLUMENTHAL D, 1991, NEW ENGL J MED, V325, P198, DOI 10.1056/NEJM199107183250309; COHEN J, 1977, STATISTICAL POWER AN; COTTON P, 1991, JAMA-J AM MED ASSOC, V266, P2802, DOI 10.1001/jama.266.20.2802; CRANDALL SJS, 1990, 20TH P ANN STAND C U, P184; Crane M, 1992, Med Econ, V69, P62; CRANE M, 1992, MED ECON, V69, P71; CRANE M, 1992, MED ECON, V69, P68; CRANE M, 1992, MED ECON, V69, P67; CRANE M, 1992, MED ECON, V69, P75; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P2399, DOI 10.1001/jama.265.18.2399; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1449; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1169; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1165; Eddy DM, 1991, JAMA-J AM MED ASSOC, V265, P2405; EISENBERG C, 1989, NEW ENGL J MED, V321, P1542, DOI 10.1056/NEJM198911303212210; FRIBOURG S, 1991, JAMA-J AM MED ASSOC, V266, P1215, DOI 10.1001/jama.1991.03470090049016; Gilligan C., 1988, MAPPING MORAL DOMAIN, P245; Gilligan C., 1982, DIFFERENT VOICE; Goldberg J H, 1992, Med Econ, V69, P76; GOLDBERG JH, 1992, MED ECON, V69, P82; GOLDBERG JH, 1992, MED ECON, V69, P91; GOLDBERG JH, 1992, MED ECON, V69, P88; GOLDBERG JH, 1992, MED ECON, V69, P87; GRANT L, 1986, SEX ROLES, V15, P95, DOI 10.1007/BF00287534; HARKIN T, 1991, JAMA-J AM MED ASSOC, V266, P1692; HEINS M, 1979, AM J PUBLIC HEALTH, V69, P1132, DOI 10.2105/AJPH.69.11.1132; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; IGLEHART JK, 1991, NEW ENGL J MED, V325, P823, DOI 10.1056/NEJM199109123251126; Jack D., 1988, MAPPING MORAL DOMAIN, P263; JOFFE M, 1989, COMMUNITY MED, V11, P35; LEE PR, 1991, JAMA-J AM MED ASSOC, V266, P1562, DOI 10.1001/jama.266.11.1562; LUMPKIN JR, 1985, PSYCHOL REP, V57, P655, DOI 10.2466/pr0.1985.57.2.655; MCGRATH E, 1977, J MED EDUC, V52, P293; MCGRATH E, 1977, J AM MED WOMEN ASSOC, V32, P361; MILES SH, 1992, JAMA-J AM MED ASSOC, V268, P2561, DOI 10.1001/jama.268.18.2561; MORFESIS FA, 1991, JAMA-J AM MED ASSOC, V266, P1647, DOI 10.1001/jama.1991.03470120049020; MULL JD, 1984, FAM MED, V16, P126; Murray D, 1992, Med Econ, V69, P44; MURRAY D, 1992, MED ECON, V69, P53; MURRAY D, 1992, MED ECON, V69, P61; MURRAY D, 1992, MED ECON, V69, P56; MURRAY D, 1992, MED ECON, V69, P58; MURRAY D, 1992, MED ECON, V69, P49; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1989, NEW ENGL J MED, V321, P1540, DOI 10.1056/NEJM198911303212209; REZLER AG, 1974, J MED EDUC, V49, P1023; RING JJ, 1991, JAMA-J AM MED ASSOC, V266, P1694, DOI 10.1001/jama.266.12.1694; ROGERS DE, 1989, CLIN ED DOCTOR TOMOR, P109; SCHRAMM CJ, 1991, JAMA-J AM MED ASSOC, V265, P3296, DOI 10.1001/jama.265.24.3296; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; TODD JS, 1991, JAMA-J AM MED ASSOC, V266, P1566, DOI 10.1001/jama.266.11.1566; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1991, 1990 MED STUDENT GRA; 1990, 1989 MATRICULATING S	63	123	128	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2519	2523						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB450	8487415				2022-12-28	WOS:A1993LB45000031
J	LEWIS, J; BRAGANZA, J; WILLIAMS, T				LEWIS, J; BRAGANZA, J; WILLIAMS, T			PSYCHOMOTOR RETARDATION AND SEMISTUPOROUS STATE WITH PAROXETINE	BRITISH MEDICAL JOURNAL			English	Letter											LEWIS, J (corresponding author), ST TYDFILS HOSP,MERTHYR TYDFIL,WALES.							BOYER WF, 1992, J CLIN PSYCHIAT, V53, P61	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1169	1169		10.1136/bmj.306.6886.1169-b	http://dx.doi.org/10.1136/bmj.306.6886.1169-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499822	Green Published, Bronze			2022-12-28	WOS:A1993LA68500025
J	HUROWITZ, JC				HUROWITZ, JC			TOWARD A SOCIAL-POLICY FOR HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INEQUALITIES											Berkman LF, 1983, HLTH WAYS LIVING ALA; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; NELSON MD, 1992, AM J PUBLIC HEALTH, V82, P1131, DOI 10.2105/AJPH.82.8.1131; ROGERS RG, 1992, DEMOGRAPHY, V29, P287, DOI 10.2307/2061732; ROGOT E, 1992, NIH923297 PUBL; SMITH GD, 1992, AM J PUBLIC HEALTH, V82, P1079, DOI 10.2105/AJPH.82.8.1079; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; TOWNSEND P, 1990, INT J HEALTH SERV, V20, P373, DOI 10.2190/9Q6H-2KE7-X6FN-3DK8; TOWNSEND P, 1990, INT J HEALTH SERV, V20, P363, DOI 10.2190/DBH3-9HYL-TQY5-Y734; WILKINSON RG, 1992, AM J PUBLIC HEALTH, V82, P1082, DOI 10.2105/AJPH.82.8.1082; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; 1992, DHHS PHS921232 DEP H, P266	14	40	41	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					130	133		10.1056/NEJM199307083290213	http://dx.doi.org/10.1056/NEJM199307083290213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL196	8510691				2022-12-28	WOS:A1993LL19600013
J	RINGDEN, O; HOROWITZ, MM; GALE, RP; BIGGS, JC; GAJEWSKI, J; RIMM, AA; SPECK, B; VEUMSTONE, JA; DEWITTE, T; BORTIN, MM				RINGDEN, O; HOROWITZ, MM; GALE, RP; BIGGS, JC; GAJEWSKI, J; RIMM, AA; SPECK, B; VEUMSTONE, JA; DEWITTE, T; BORTIN, MM			OUTCOME AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR LEUKEMIA IN OLDER ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERSUS-HOST DISEASE; SEVERE APLASTIC-ANEMIA; RISK-FACTORS; MYELOGENOUS LEUKEMIA; RELAPSE; AGE	Objective.-To determine whether age over 40 years is associated with adverse outcome after allogeneic bone marrow transplantation for leukemia. Design.-A retrospective analysis of outcome after bone marrow transplants for leukemia reported to the International Bone Marrow Transplant Registry (IBMTR) among recipients 30 through 39 years, 40 through 44 years, 45 through 49 years, and 50 years of age and older. Setting.-Transplantations performed in 138 institutions worldwide and reported to the IBMTR. Patients.-A total of 2180 recipients of HLA-identical sibling bone marrow transplants for leukemia, divided into four cohorts based on age: 30 through 39 years (n=1282), 40 through 44 years (n=527), 45 through 49 years (n=291), and 50 years and older (n=80). Main Outcome Measures and Results.-Incidence of leukemia-free survival, graft-vs-host disease, and relapse was comparable among the four age cohorts. Patients with advanced leukemia aged 45 years or older hard a slightly higher risk of treatment-related mortality, and the 45- through 49-year-old cohort had a higher risk of interstitial pneumonia. Conclusions.-These data indicate that among leukemia patients over 30 years of age at the time of allogeneic bone marrow transplantation, increasing age into the fifth decade does not adversely affect outcome after transplants from HLA-identical siblings.	MED COLL WISCONSIN, INST HLTH POLICY, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA; HUDDINGE HOSP, S-14186 HUDDINGE, SWEDEN; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA USA; ST VINCENTS HOSP, DARLINGHURST, NSW 2010, AUSTRALIA; KANTONSSPITAL, CH-4004 BASEL, SWITZERLAND; CATHOLIC UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS	Medical College of Wisconsin; University of California System; University of California Los Angeles; St Vincents Hospital Sydney; Kantonsspital Aarau AG (KSA); University of Basel; Radboud University Nijmegen			de Witte, T.J.M./L-4762-2015; horowitz, Mary/ABH-2173-2021		NCI NIH HHS [P0L-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON K, 1990, BLOOD, V75, P2459; BAR BMAM, 1990, BRIT J HAEMATOL, V74, P53, DOI 10.1111/j.1365-2141.1990.tb02537.x; BARRETT AJ, 1989, BLOOD, V74, P862; BORTIN MM, 1981, JAMA-J AM MED ASSOC, V245, P1132, DOI 10.1001/jama.245.11.1132; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; COX DR, 1972, J R STAT SOC B, V34, P187; ELFENBEIN G, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P235; GALE RP, 1989, LANCET, V1, P1119; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; KLINGEMANN HG, 1986, BLOOD, V67, P770; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; RINGDEN O, 1987, TRANSPLANT P, V19, P2600; RINGDEN O, 1985, TRANSPLANTATION, V40, P39; STORB R, 1983, ANN INTERN MED, V98, P461, DOI 10.7326/0003-4819-98-4-461; WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168; WEINER RS, 1989, BRIT J HAEMATOL, V71, P535, DOI 10.1111/j.1365-2141.1989.tb06314.x	17	127	127	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					57	60		10.1001/jama.270.1.57	http://dx.doi.org/10.1001/jama.270.1.57			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510297				2022-12-28	WOS:A1993LK36600023
J	BRIDGES, AJ; CONLEY, C; WANG, G; BURNS, DE; VASEY, FB				BRIDGES, AJ; CONLEY, C; WANG, G; BURNS, DE; VASEY, FB			A CLINICAL AND IMMUNOLOGICAL EVALUATION OF WOMEN WITH SILICONE BREAST IMPLANTS AND SYMPTOMS OF RHEUMATIC DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						SILICONE ELASTOMERS; IMPLANTS, ARTIFICIAL; CONNECTIVE TISSUE DISEASES; RHEUMATIC DISEASES; MAMMAPALSTY	SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; REVISED CRITERIA; SCLERODERMA; ANTIBODIES; SCLEROSIS; CLASSIFICATION; ASSOCIATION	Objective: To describe the clinical and serologic features of women with silicone breast implants who were referred for symptoms of rheumatic disease. Design: A case series. Setting: University and private rheumatology practices. Patients: A total of 156 women with silicone breast implants and rheumatic disease complaints. Controls for the serologic studies included women with silicone implants and no rheumatic symptoms (n = 12) and women with fibromyalgia without silicone implants (n = 174). Measurements: Complete physical examination and testing for immunoglobulins; complement; C-reactive protein; rheumatoid factor; and autoantibodies by indirect immunofluorescence, immunodiffusion, and Western blot. Results: Three subgroups of patients were defined based on clinical and laboratory findings: joint and muscle pain (n = 95), joint swelling (n = 32), and connective tissue disease (n = 29). Most women had normal immunologic studies. The patients with joint swelling had mild, asymmetric, rheumatoid-factor-negative synovitis that did not meet American College of Rheumatology criteria for rheumatoid arthritis. Fourteen patients had a scleroderma-like illness and anti-centromere or anti-PM-Scl antibodies by Western blot. Ten patients had a positive Western blot for BB' polypeptide, a small nuclear ribonucleoprotein (snRNP), but did not meet criteria for systemic lupus erythematosus. No autoantibodies to known disease-related polypeptides were detected on Western blot in the control groups. Conclusion: Most women with silicone implants and rheumatic complaints had normal results of serologic tests and nonspecific symptoms, suggesting no serious connective tissue disease. However, a subset of women had clinical signs and serologic tests that were unusual even for referred patients. These observations suggest, but cannot establish, that some women with silicone breast implants may develop atypical immunologic reactions.	UNIV S FLORIDA, DIV RHEUMATOL, TAMPA, FL 33612 USA; JAMES A HAILEY VET ADM HOSP, TAMPA, FL USA	State University System of Florida; University of South Florida	BRIDGES, AJ (corresponding author), UNIV WISCONSIN HOSP, H6-367 CLIN SCI CTR, 600 HIGHLAND AVE, MADISON, WI 53792 USA.							ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BARNETT AJ, 1988, J RHEUMATOL, V15, P276; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BRIDGES AJ, 1992, ANN RHEUM DIS, V51, P793, DOI 10.1136/ard.51.6.793; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOX RI, 1984, SEMIN ARTHRITIS RHEU, V14, P77, DOI 10.1016/0049-0172(84)90001-5; GIORDANO M, 1986, J RHEUMATOL, V13, P911; GULDNER HH, 1986, CLIN IMMUNOL IMMUNOP, V40, P532, DOI 10.1016/0090-1229(86)90198-4; GUTIERREZ FJ, 1990, AM J MED, V89, P390; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LEROY EC, 1988, J RHEUMATOL, V15, P202; LIFSHITZ MS, 1988, LAB MED, V19, P510, DOI 10.1093/labmed/19.8.510; MASI AT, 1980, ARTHRITIS RHEUM-US, V23, P875; MCGRATH MH, 1984, PLAST RECONSTR SURG, V74, P550, DOI 10.1097/00006534-198410000-00019; PETTERSSON I, 1986, ARTHRITIS RHEUM, V29, P986, DOI 10.1002/art.1780290807; PORTER JF, 1988, ARTHRITIS RHEUM, V31, P219, DOI 10.1002/art.1780310210; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; REICHLIN M, 1984, ARTHRITIS RHEUM, V27, P1150, DOI 10.1002/art.1780271011; ROKEACH LA, 1990, J IMMUNOL, V144, P1015; SAHN EE, 1990, ARCH DERMATOL, V126, P1198, DOI 10.1001/archderm.126.9.1198; SHARP GC, 1976, NEW ENGL J MED, V295, P1149, DOI 10.1056/NEJM197611182952101; SILMAN AJ, 1991, ANN RHEUM DIS, V50, P846, DOI 10.1136/ard.50.Suppl_4.846; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAN EM, 1980, ARTHRITIS RHEUM, V23, P617, DOI 10.1002/art.1780230602; TERBORG EJ, 1988, ARTHRITIS RHEUM, V31, P1563, DOI 10.1002/art.1780311215; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VARGA J, 1990, ARCH DERMATOL, V126, P1220, DOI 10.1001/archderm.126.9.1220; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WALSH FW, 1989, ARCH INTERN MED, V149, P1194, DOI 10.1001/archinte.149.5.1194; WEINER SR, 1986, PLAST RECONSTR SURG, V77, P185, DOI 10.1097/00006534-198602000-00001; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; 1982, DICT RHEUMATIC DISEA, P74	39	184	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					929	936		10.7326/0003-4819-118-12-199306150-00003	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489106				2022-12-28	WOS:A1993LF93700003
J	DRMANAC, R; DRMANAC, S; STREZOSKA, Z; PAUNESKU, T; LABAT, I; ZEREMSKI, M; SNODDY, J; FUNKHOUSER, WK; KOOP, B; HOOD, L; CRKVENJAKOV, R				DRMANAC, R; DRMANAC, S; STREZOSKA, Z; PAUNESKU, T; LABAT, I; ZEREMSKI, M; SNODDY, J; FUNKHOUSER, WK; KOOP, B; HOOD, L; CRKVENJAKOV, R			DNA-SEQUENCE DETERMINATION BY HYBRIDIZATION - A STRATEGY FOR EFFICIENT LARGE-SCALE SEQUENCING	SCIENCE			English	Article								The concept of sequencing by hybridization (SBH) makes use of an array of all possible n-nucleotide oligomers (n-mers) to identify n-mers present in an unknown DNA sequence. Computational approaches can then be used to assemble the complete sequence. As a validation of this concept, the sequences of three DNA fragments, 343 base pairs in length, were determined with octamer oligonucleotides. Possible applications of SBH include physical mapping (ordering) of overlapping DNA clones, sequence checking, DNA fingerprinting comparisons of normal and disease-causing genes, and the identification of DNA fragments with particular sequence motifs in complementary DNA and genomic libraries. The SBH techniques may accelerate the mapping and sequencing phases of the human genome project.	ARGONNE NATL LAB, DIV BIOL & MED RES, ARGONNE, IL 60439 USA; CALTECH, DEPT BIOL, PASADENA, CA 91125 USA; INST MOLEC GENET & GENET ENGN, YU-11000 BELGRADE, YUGOSLAVIA	United States Department of Energy (DOE); Argonne National Laboratory; California Institute of Technology			Paunesku, Tatjana/AAF-8529-2021; Koop, Ben F./A-8151-2008; Paunesku, Tatjana/A-3488-2017	Paunesku, Tatjana/0000-0001-8698-2938; Koop, Ben F./0000-0003-0045-5200; Paunesku, Tatjana/0000-0001-8698-2938				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; DRMANAC R, 1990, DNA CELL BIOL, V9, P527, DOI 10.1089/dna.1990.9.527; DRMANAC R, 1992, INT J GENOME RES, V1, P59; DRMANAC R, 1991, J BIOMOL STRUCT DYN, V8, P1085, DOI 10.1080/07391102.1991.10507867; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1992, ELECTROPHORESIS, V13, P566, DOI 10.1002/elps.11501301115; DRMANAC R, 1987, Patent No. 57087; DRMANAC R, 1991, ELECTROPHORESES SUPE, P60; DRMANAC R, 1992, GENOME MAPPING SEQUE, P318; DRMANAC R, 1990, SCI YUGOSL, V16, P97; EGGERS M, 1992, GENOME MAPPING SEQUE, P111; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; KHRAPKO KR, 1991, J DNA SEQUENCING MAP, V1, P375; KOOP BF, IN PRESS BIOTECHNIQU; LABAT I, UNPUB; LEHRACH H., 1990, GENOME ANAL, P39; LINDSAY SM, 1991, GENET ANAL-BIOMOL E, V8, P8, DOI 10.1016/1050-3862(91)90003-A; LYSOV IP, 1988, DOKL AKAD NAUK SSSR+, V303, P1508; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; PAUNESKU T, UNPUB; PEVZNER PA, 1991, J BIOMOL STRUCT DYN, V9, P399, DOI 10.1080/07391102.1991.10507920; POUSTKA A, 1986, COLD SPRING HARB SYM, V51, P131, DOI 10.1101/SQB.1986.051.01.016; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; SOUTHERN EM, 1988, Patent No. 8810400; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; WILSON RK, 1992, GENOMICS, V13, P1198, DOI 10.1016/0888-7543(92)90038-T	31	165	312	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1649	1653		10.1126/science.8503011	http://dx.doi.org/10.1126/science.8503011			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503011				2022-12-28	WOS:A1993LG17600030
J	CASAVILLA, FA; GORDON, R; WRIGHT, HI; GAVALER, JS; STARZL, TE; VANTHIEL, DH				CASAVILLA, FA; GORDON, R; WRIGHT, HI; GAVALER, JS; STARZL, TE; VANTHIEL, DH			CLINICAL COURSE AFTER LIVER-TRANSPLANTATION IN PATIENTS WITH SARCOIDOSIS	ANNALS OF INTERNAL MEDICINE			English	Note						LIVER TRANSPLANTATION; SARCOIDOSIS; CYCLOSPORINE; FK-506; LIVER DISEASES	PULMONARY SARCOIDOSIS; CYCLOSPORINE	The effects of liver transplantation and the obligate use of cyclosporine on the subsequent clinical course of nine patients with sarcoidosis were examined. Two comparison groups, each consisting of 18 patients without sarcoidosis, were also studied. The liver allograft recipients received either cyclosporine or FK 506 as their primary immunosuppressive agent. Patient and graft survival were assessed for all three groups. In patients with sarcoidosis before transplantation, evidence for continued disease activity after transplantation was also assessed. Patient and allograft survival were excellent. No clinical evidence of continued disease activity was noted. Thus, the presence of sarcoidosis is not a contraindication for liver transplantation in otherwise appropriate candidates for the procedure.	UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIDDK NIH HHS [R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELORY L, 1988, TRANSPLANT P, V20, P144; CUNNAH D, 1988, AM J MED, V85, P580; DUFFELL GM, 1992, MED PRACTICING PHYSI, P962; GUPTA AK, 1990, ARCH DERMATOL, V126, P339, DOI 10.1001/archderm.126.3.339; HAMMOND JMJ, 1990, RESP MED, V84, P77, DOI 10.1016/S0954-6111(08)80099-6; LEE ET, 1980, STATISTICAL METHODS, P122; MARTINET Y, 1988, AM REV RESPIR DIS, V138, P1242, DOI 10.1164/ajrccm/138.5.1242; PEREIRALIMA J, 1987, AM J MED, V83, P144, DOI 10.1016/0002-9343(87)90510-9; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V221, P600; YORK EL, 1990, CHEST, V98, P1026, DOI 10.1378/chest.98.4.1026	11	59	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					865	866		10.7326/0003-4819-118-11-199306010-00007	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	8480961	Green Accepted			2022-12-28	WOS:A1993LD25200007
J	LOHOF, AM; IP, NY; POO, MM				LOHOF, AM; IP, NY; POO, MM			POTENTIATION OF DEVELOPING NEUROMUSCULAR SYNAPSES BY THE NEUROTROPHINS NT-3 AND BDNF	NATURE			English	Article							NERVE GROWTH-FACTOR; NEURONS; EXPRESSION; NGF; RECEPTOR; CULTURE; INDUCTION; PATTERNS; INVITRO	THE neurotrophins are a family of neurotrophic factors that promote survival and differentiation of various neuronal populations1,2. Although the long-term effects of neurotrophins on neuronal survival and differentiation have been intensively studied, nothing is known about their effects on synaptic function. Here we report that acute exposure to neurotrophin-3 (NT-3)3,4 or brain-derived neurotrophic factor (BDNF)5, but not nerve growth factor (NGF)6, rapidly potentiates the spontaneous and impulse-evoked synaptic activity of developing neuromuscular synapses in culture. The effect appears to be presynaptic in origin and to be mediated by the Trk family of receptor tyrosine kinases7. These results provide evidence for the regulation of the function of developing synapses by neurotrophins.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Columbia University; Regeneron				Lohof, Ann/0000-0002-0994-7706; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BERG MM, 1992, J BIOL CHEM, V267, P13; BIXBY JL, 1984, J PHYSIOL-LONDON, V353, P143, DOI 10.1113/jphysiol.1984.sp015328; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOHN A, 1990, NATURE, V344, P39; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Lo D C, 1992, Curr Opin Neurobiol, V2, P336, DOI 10.1016/0959-4388(92)90125-5; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Tabti N., 1991, CULTURING NERVE CELL, P137; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	35	687	701	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					350	353		10.1038/363350a0	http://dx.doi.org/10.1038/363350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497318				2022-12-28	WOS:A1993LD91700053
J	MAFEE, MF				MAFEE, MF			IMAGING METHODS FOR SINUSITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SURGERY				MAFEE, MF (corresponding author), UNIV ILLINOIS,CHAMPAIGN,IL 61820, USA.							BABBEL R, 1991, AM J NEURORADIOL, V12, P849; CHOW JM, 1989, OTOLARYNG CLIN N AM, V22, P691; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; Mettler FA, 1985, MED EFFECTS IONIZING; POZNANSKY AK, 1989, JAMA-J AM MED ASSOC, V262, P3058; UPTON AC, 1982, SCI AM, V246, P41, DOI 10.1038/scientificamerican0282-41; WAGNER LK, 1991, RADIOLOGY, V178, P622, DOI 10.1148/radiology.178.3.1994387; 1989, EXPOSURE US POPULATI	8	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1993	269	20					2608	2608						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC865	8487429				2022-12-28	WOS:A1993LC86500002
J	BLOOM, K				BLOOM, K			THE CENTROMERE FRONTIER - KINETOCHORE COMPONENTS, MICROTUBULE-BASED MOTILITY, AND THE CEN-VALUE PARADOX	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; DICENTRIC CHROMOSOME; YEAST PROTEIN; BUDDING YEAST; MITOSIS; ANTIBODIES; MOVEMENT; BINDING; COMPLEX; ENCODES				BLOOM, K (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Bloom, Kerry/AAE-5336-2019	Bloom, Kerry/0000-0002-3457-004X				BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1991, CELL, V66, P1229, DOI 10.1016/0092-8674(91)90045-Z; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DOHENY KF, 1993, CELL, V73, P621; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1989, MECHANISMS CHROMOSOM, P9; FUNAKABI H, 1993, IN PRESS J CELL BIOL, V121; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HILL A, 1989, MOL CELL BIOL, V9, P1368, DOI 10.1128/MCB.9.3.1368; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MATSUMOTO H, 1989, J CELL BIOL, V109, P1963; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; NICKLAS RB, 1992, J CELL SCI, V102, P681; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; RAIKOV IB, 1982, CELL BIOL MONOGR, V9, P72; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHULMAN IG, 1993, IN PRESS MOL CELL BI, V13; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; SPENCER F, 1990, GENETICS, V124, P237; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; UZAWA S, 1992, J CELL SCI, V101, P267; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	40	66	76	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					621	624		10.1016/0092-8674(93)90242-I	http://dx.doi.org/10.1016/0092-8674(93)90242-I			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500159				2022-12-28	WOS:A1993LD83000001
J	GOSTIN, LO; WIDISS, AI				GOSTIN, LO; WIDISS, AI			WHATS WRONG WITH THE ERISA VACUUM - EMPLOYERS FREEDOM TO LIMIT HEALTH-CARE COVERAGE PROVIDED BY RISK RETENTION PLANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSURANCE; AIDS		UNIV IOWA HOSP & CLIN,COLL LAW,IOWA CITY,IA 52242	University of Iowa	GOSTIN, LO (corresponding author), AMER SOC LAW MED & ETH,OFF EXECUT DIRECTOR,765 COMMONWEALTH AVE,16TH FLOOR,BOSTON,MA 02215, USA.							ACKOUREY KA, 1991, EMORY LJ, V40, P1183; [Anonymous], 1991, AM DISABILITIES ACT; BARTLETT L, 1990, AIDS HLTH CARE SYSTE, P211; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; CLIFFORD KA, 1987, HARVARD LAW REV, V100, P1806, DOI 10.2307/1341233; CLINTON W, 1992, NEW ENGL J MED, V327, P804; CORLIN R, 1992, COMMUNICATION   0728; ENTHOVEN AC, 1992, NEW ENGL J MED, V327, P807, DOI 10.1056/NEJM199209103271113; FADEN RR, 1988, AM J PUBLIC HEALTH, V78, P437, DOI 10.2105/AJPH.78.4.437; FOX DM, 1989, J HEALTH POLIT POLIC, V14, P239, DOI 10.1215/03616878-14-2-239; FOX DM, 1990, AIDS HLTH CARE SYSTE, P197; FREUDENHEIM M, 1992, NY TIMES        0329, P26; GILBERT E, 1992, SPECIAL REPORT EMPLO, P15; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GOSTIN L, 1991, AM J LAW MED, V17, P109; GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; GREANEY TL, 1992, NATL LAW J, V15, P26; GREENE MR, 1981, RISK INSURANCE, P11; HUGHES WJ, 1992, C RECORD        1005, pE3049; KEETON RE, 1988, INSURANCE LAW; LAMEL L, 1978, INSUR LAW J, V665, P336; MCCORMICK B, 1992, AM MED NEWS     1102, P46; PEAR R, 1992, NY TIMES        0422, pA18; PEAR R, 1992, NY TIMES        0225, pA1; PEAR R, 1992, NY TIMES        0422, pA12; PEAR R, 1992, NY TIMES        1110, pA9; PHILLIPS CG, 1992, COMMUNICATION   0810; REINHARDT UE, 1992, NEW ENGL J MED, V327, P809, DOI 10.1056/NEJM199209103271114; RUMELD MD, 1992, NATL LAW J, V15, P26; SCANDLEN G, 1987, EMPLOYEE BENEFIT JUN, P6; SCHATZ B, 1987, HARVARD LAW REV, V100, P1782, DOI 10.2307/1341232; SCHERZER M, 1988, AIDS PRACTICE MANUAL, P5; SCHERZER M, 1992, AIDS PUBLIC POLICY J, V7, P96; SHAY E, 1992, AIDS PUBLIC POLICY J, V7, P92; SOHLGREN EC, 1991, LOY LA L REV, V24, P1247; STARR P, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.suppl_1.7; STODDARD TB, 1992, NY TIMES        0523, P1; STODDARD TB, 1992, NY TIMES        0523, P2; SULLIVAN LW, 1992, NEW ENGL J MED, V327, P801, DOI 10.1056/NEJM199209103271111; TURNER R, 1992, AIDS PUBLIC POLICY J, V7, P89; WORTHAM L, 1986, OHIO ST LJ, V47, P835; 1990, STATISTICAL ABSTRACT, P413; 1990, 1990 LIFE INSURANCE; 1992, MEDICARE AM HLTH CAR; 1992, PENSION REP, V19, P824; 1992, DAILY LABOR REP, V214, pA8; [No title captured]; 1992, ANN INTERN MED, V117, P511; 1988, MED TESTING HLTH INS, P114	49	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2527	2532						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB450	8487417				2022-12-28	WOS:A1993LB45000033
J	REINHARDT, UE				REINHARDT, UE			GRADING CLINTON HEALTH PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											REINHARDT, UE (corresponding author), PRINCETON UNIV,DEPT ECON,PRINCETON,NJ 08544, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1993	269	19					2553	2553						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB450	8487423				2022-12-28	WOS:A1993LB45000039
J	BRADLEY, TD; SHAPIRO, CM				BRADLEY, TD; SHAPIRO, CM			ABC OF SLEEP DISORDERS - UNEXPECTED PRESENTATIONS OF SLEEP-APNEA - USE OF CPAP IN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	BRADLEY, TD (corresponding author), MINIST HLTH ONTARIO,TORONTO,ON,CANADA.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1260	1262		10.1136/bmj.306.6887.1260	http://dx.doi.org/10.1136/bmj.306.6887.1260			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499860	Bronze, Green Published			2022-12-28	WOS:A1993LB80400025
J	GUPTA, JM; NAIDOO, D				GUPTA, JM; NAIDOO, D			ORAL VERSUS INTRAMUSCULAR VITAMIN-K IN NEWBORN-INFANTS	BRITISH MEDICAL JOURNAL			English	Letter									UNIV NEW S WALES,SCH PATHOL,KENSINGTON,NSW 2033,AUSTRALIA	University of New South Wales Sydney	GUPTA, JM (corresponding author), UNIV NEW S WALES,ROYAL HOSP WOMEN,SCH PAEDIAT,PADDINGTON,NSW 2021,AUSTRALIA.							GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105	2	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1272	1273		10.1136/bmj.306.6887.1272-c	http://dx.doi.org/10.1136/bmj.306.6887.1272-c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499871	Green Published			2022-12-28	WOS:A1993LB80400057
J	CATTERALL, JR; SHAPIRO, CM				CATTERALL, JR; SHAPIRO, CM			ABC OF SLEEP DISORDERS - NOCTURNAL ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	CATTERALL, JR (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND.							BEASLEY R, 1989, THORAX, V44, P220; Floyer J., 1698, TREATISE ASTHMA	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1189	1192		10.1136/bmj.306.6886.1189	http://dx.doi.org/10.1136/bmj.306.6886.1189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499828	Bronze, Green Published			2022-12-28	WOS:A1993LA68500033
J	LEVI, S; FOSTER, C; HODGSON, HJF; WARD, KN; SO, A; GARSON, JA; WAXMAN, J; SWIRSKY, D				LEVI, S; FOSTER, C; HODGSON, HJF; WARD, KN; SO, A; GARSON, JA; WAXMAN, J; SWIRSKY, D			HAMMERSMITH STAFF ROUNDS - CHRONIC LIVER-DISEASE DUE TO HEPATITIS-C	BRITISH MEDICAL JOURNAL			English	Discussion							NON-A	The low concentration of hepatitis C virus in the blood of infected patients has made it difficult to detect. Infected patients can now be identified by using more sensitive immunoassays and amplification of viral RNA by the polymerase chain reaction. Nevertheless, the virus remains difficult to eliminate. We present the case of a woman with a history of autoimmune haemolytic anaemia, thrombocytopenia, and common variable immunodeficiency who developed chronic hepatitis.	UNIV LONDON UNIV COLL,SCH MED,LONDON WC1E 6BT,ENGLAND	University of London; University College London; UCL Medical School	LEVI, S (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND.		Garson, Jeremy A/C-5357-2008	Garson, Jeremy/0000-0003-0553-0126				CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467	3	11	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1054	1056		10.1136/bmj.306.6884.1054	http://dx.doi.org/10.1136/bmj.306.6884.1054			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490506	Green Published, Bronze			2022-12-28	WOS:A1993KY44800030
J	RENNICK, G; SHANN, F; DECAMPO, J				RENNICK, G; SHANN, F; DECAMPO, J			CEREBRAL HERNIATION DURING BACTERIAL-MENINGITIS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							LUMBAR PUNCTURE; CHILDHOOD	Objective-To see whether the incidence of cerebral herniation is increased immediately after lumbar puncture in children with bacterial meningitis and whether any children with herniation have normal results on cranial computed tomography. Design-Retrospective review of case notes; computed tomograms were read again. Setting-Large paediatric teaching hospital. Subjects-445 children over 30 days old admitted to hospital with bacterial meningitis. Main outcome measures-Timing of herniation in relation to lumbar puncture; findings on computed tomography in children with herniation. Results-Cerebral herniation was detected in 19 (4.3%) of the 445 children (21 episodes; herniation occurred twice in two children). Herniation occurred in 14 (45%) of the 31 children who died. Nineteen episodes of herniation occurred in the 17 children who had a lumbar puncture; 12 of the episodes occurred in the first 12 hours after the lumbar puncture and seven over six other 12 hour periods (odds ratio 32.6 (95% confidence interval 8.5 to 11 7.3); p < 0.001). The results of cranial computed tomography were normal in five (36%) of the 14 episodes of herniation in which scanning was performed at about the time of herniation. Conclusions-The temporal relation between lumbar puncture and herniation strongly suggests that a lumbar puncture may cause herniation in some patients, and normal results on computed tomography do not mean that it is safe to do a lumbar puncture in a child with bacterial meningitis.	ROYAL CHILDRENS HOSP,INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT RADIOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne			Shann, Frank/C-9510-2011					ARMITAGE P, 1987, STATISTICAL METHODS, P479; BENJAMIN CM, 1988, BRIT MED J, V296, P20, DOI 10.1136/bmj.296.6614.20; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; FENICHEL GM, 1988, CLIN PEDIATRIC NEURO, P109; GLOVER D, 1987, PEDIATRIC INTENSIVE, P291; GOWER DJ, 1987, J NEUROL NEUROSUR PS, V50, P1071, DOI 10.1136/jnnp.50.8.1071; HARPER JR, 1985, BRIT MED J, V291, P651, DOI 10.1136/bmj.291.6496.651; HART IK, 1988, BRIT MED J, V296, P51, DOI 10.1136/bmj.296.6614.51; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; KLEIN JO, 1986, PEDIATRICS S, V78, P959; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; ROSENBERG DI, 1989, INTRACRANIAL PRESSUR, V7, P770	12	122	122	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					953	955		10.1136/bmj.306.6883.953	http://dx.doi.org/10.1136/bmj.306.6883.953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490469	Green Published, Bronze			2022-12-28	WOS:A1993KX43600013
J	YOKOYAMA, T; COPELAND, NG; JENKINS, NA; MONTGOMERY, CA; ELDER, FFB; OVERBEEK, PA				YOKOYAMA, T; COPELAND, NG; JENKINS, NA; MONTGOMERY, CA; ELDER, FFB; OVERBEEK, PA			REVERSAL OF LEFT-RIGHT ASYMMETRY - A SITUS-INVERSUS MUTATION	SCIENCE			English	Article							GENETIC-LINKAGE MAP; MOUSE; DNA	A recessive mutation was identified in a family of transgenic mice that resulted in a reversal of left-right polarity (situs inversus) in 100 percent of the homozygous transgenic mice tested. Sequences that flanked the transgenic integration site were cloned and mapped to mouse chromosome 4, between the Tsha and Hxb loci. During early embryonic development, the direction of postimplantation turning, one of the earliest manifestations of left-right asymmetry, was reversed in homozygous transgenic embryos. This insertional mutation identifies a gene that controls embryonic turning and visceral left-right polarity.	BAYLOR COLL MED, INST MOLEC GENET, DEPT CELL BIOL, HOUSTON, TX 77030 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; BAYLOR COLL MED, INST MOLEC GENET, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CTR COMPARAT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL & LAB MED, HOUSTON, TX 77225 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; University of Texas Health Science Center Houston				Overbeek, Paul/0000-0001-9784-2084	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NICHD NIH HHS [HD25340] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AFZELIUS B A, 1976, Science (Washington D C), V193, P317; BRINKLEY W, COMMUNICATION; BROWN NA, 1990, DEVELOPMENT, V109, P1; BROWN NA, 1989, BIOL ASYMMETRY HANDE, P182; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Green EL, 1981, GENETICS PROBABILITY, P77; HSIEH C, 1991, MAMM GENOME S, V1, pS522; HUMMEL KP, 1959, J HERED, V50, P10; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kartagener H, 1935, SCHWEIZ MED WSCHR, V65, P782; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LAYTON WM, 1980, ETIOLOGY MORPHOGENES, P109; LONGMIRE JL, 1987, NUCLEIC ACIDS RES, V15, P859, DOI 10.1093/nar/15.2.859; MORGAN MJ, 1978, BEHAV BRAIN SCI, V1, P270, DOI 10.1017/S0140525X00074483; MORGAN MJ, 1991, CIBA F SYMP, V162, P234; SELDON RF, 1987, CURRENT PROTOCOLS MO; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; TORGERSEN J, 1949, ARCH PATHOL, V47, P566; WEIS JH, 1987, CURRENT PROTOCOLS MO; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; YOKOYAMA T, UNPUB; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0	25	431	438	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1993	260	5108					679	682		10.1126/science.8480178	http://dx.doi.org/10.1126/science.8480178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ641	8480178				2022-12-28	WOS:A1993KZ64100034
